"Rank","NCT Number","Title","Acronym","Recruitment","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","Last Verified","First Submitted","First Posted","Results First Submitted","Results First Posted","Last Update Submitted","Last Update Posted","Locations","URL"
1,"NCT02367196","A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers","null","Recruiting","No Results Available","Hematologic Neoplasms","Drug: CC-90002|Drug: Rituximab","Dose‐Limiting Toxicity (DLT)|Non-Tolerated Dose (NTD) - Part A|Maximum Tolerated Dose (MTD) - Part A|Non-Tolerated Dose (NTD) - Part B|Maximum Tolerated Dose (MTD) - Part B|Antitumor efficacy|Pharmacokinetics ‐ Cmax|Pharmacokinetics - AUC|Pharmacokinetics - tmax|Pharmacokinetics ‐ T1/2|Pharmacokinetics - CL|Pharmacokinetics - Vmax|Anti-Drug Antibodies (ADAs)|Overall Survival - Part B|Progression-free survival- Part B","Celgene","All","18 Years and older   (Adult, Senior)","Phase 1","65","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90002-ST-001|2015-000101-39","March 12, 2015","June 13, 2019","June 13, 2019","September 2017","February 13, 2015","February 20, 2015","null","null","September 28, 2017","October 2, 2017","Scottsdale Healthcare Research Institute, Scottsdale, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|University of California San Francisco, San Francisco, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Hospital Universitari Germans Trias i Pujol Can Ruti, Badalona (Barcelona), Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain","https://ClinicalTrials.gov/show/NCT02367196"
2,"NCT01613066","Intra-bone Cord Blood Transplantation in Patients With Haematological Malignancies","null","Unknown status","No Results Available","High Risk Haematological Malignancies|Advanced Haematological Malignancies","Procedure: Intrabone Allogeneic Transplant","Time to neutrophil recovery|Incidence of platelet engraftment|Acute graft versus host disease|Chronic Graft Versus Host Disease|Overall Survival","Ospedale Santa Croce-Carle Cuneo","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Emato68","November 2008","November 2012","May 2013","June 2012","June 4, 2012","June 6, 2012","null","null","June 5, 2012","June 6, 2012","Azienda Ospedaliera S Croce e Carle, Cuneo, Italy","https://ClinicalTrials.gov/show/NCT01613066"
3,"NCT01080664","A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies","null","Terminated","No Results Available","Haematological Malignancies","Drug: AS703569","Dose-Limiting Toxicity (DLT)|Preliminary anti-tumour activity|Treatment-emergent adverse events (TEAE)","EMD Serono","All","18 Years and older   (Adult, Senior)","Phase 1","124","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","27335","December 2006","March 2010","August 2011","October 2013","March 2, 2010","March 4, 2010","null","null","October 21, 2013","October 22, 2013","CTRC at the UT Health Science Center at San Antonio, San Antonio, Texas, United States|Haematologie UZ Gasthuisberg, Leuven, Belgium|Mont-Godinne University Hospital (UCL), Yvoir, Belgium|Universitatsklinik Frankfurt, Frankfurt am Main, Germany|Technische Universitat Munchen, Munchen, Germany|Medizinische Universitatsklinik, Ulm, Germany|Policlinico Sant'Orsola Malpighi, Bologna, Italy|Kantonsspital Basel, Basel, Switzerland|Hospitaux Universitaires, Geneva, Switzerland|Kantonsspital St Gallen, St Gallen, Switzerland","https://ClinicalTrials.gov/show/NCT01080664"
4,"NCT03146468","Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation","NIVALLO","Recruiting","No Results Available","Haematological Malignancy","Drug: Nivolumab Injection","Graft versus host disease|Overall response rate","Melbourne Health","All","18 Years and older   (Adult, Senior)","Phase 2","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RMH 2016.281","May 8, 2017","June 1, 2020","June 1, 2020","May 2017","May 7, 2017","May 10, 2017","null","null","May 7, 2017","May 10, 2017","Royal Melbourne Hospital, Parkville, Victoria, Australia","https://ClinicalTrials.gov/show/NCT03146468"
5,"NCT02745743","Phase I Trial of BAY1251152 for Advanced Blood Cancers","null","Recruiting","No Results Available","Hematologic Neoplasms","Drug: BAY1251152","Maximum tolerated dose(MTD)|Recommended Phase 2 dose (RP2D)|Number of adverse events (AE)|Pharmacokinetics (PK) is determined by maximum concentration (Cmax)|Pharmacokinetics (PK) is determined by Area Under concentration versus time Curve (AUC)|Response assessment of BAY 1251152 in hematological malignancies based on the internationally accepted criteria for the specific hematological malignancy which patient is suffering from","Bayer","All","18 Years and older   (Adult, Senior)","Phase 1","74","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18117|2015-005122-18","June 17, 2016","February 14, 2019","February 14, 2019","December 2017","April 18, 2016","April 20, 2016","null","null","December 21, 2017","December 22, 2017","Bronx, New York, United States|New York, New York, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Dresden, Sachsen, Germany|Madrid, Spain|Madrid, Spain|Cardiff, United Kingdom","https://ClinicalTrials.gov/show/NCT02745743"
6,"NCT01488591","Biomarker Research for Personalized Medicine","null","Unknown status","No Results Available","Hematologic Neoplasms","","","Inje University","All","Child, Adult, Senior","","1000","Other","Observational","Time Perspective: Prospective","09-029","April 2009","null","null","May 2013","December 6, 2011","December 8, 2011","null","null","May 30, 2013","May 31, 2013","Inje University, Busan, Korea, Republic of","https://ClinicalTrials.gov/show/NCT01488591"
7,"NCT00389428","Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.","null","Completed","No Results Available","Hematologic Neoplasms","Drug: CPX-351 (Cytarabine:Daunorubicin) Liposome Injection","To determine the maximum tolerated dose (MTD) for use in phase 2|To evaluate the safety and dose-limiting toxicities (DLT) of CPX-351.|To determine the pharmacokinetic parameters of CPX-351 administered in this schedule.|To assess preliminary efficacy information of CPX-351 administered in this schedule in patients with advanced leukemias.","Jazz Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 1","48","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLTR0305-101","September 2006","December 2008","December 2009","May 2012","October 16, 2006","October 18, 2006","null","null","May 16, 2012","May 17, 2012","Georgetown University Medical Center, Washington, District of Columbia, United States|H. Lee Moffit Cancer Center & Research Institute at the University of S. Florida, Tampa, Florida, United States|North Shore University Hospital, Manhasset, New York, United States|New York Presbyterian Hospital Weill Medical College of Cornell University, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00389428"
8,"NCT00838890","A Study of BMS-863233 in Patients With Hematologic Cancer","null","Terminated","No Results Available","Refractory Hematologic Cancer","Drug: Cdc7-inhibitor (BMS-863233)","To determine maximum tolerated dose and anti-tumor activity of BMS-863233/XL413 when administered to subjects with refractory Hematologic Cancer|To determine the safety of BMS-863233/XL413 when administered to subjects with refractory Hematologic Cancer|To determine the pharmacokinetics of BMS-863233/XL413 when administered to subjects with refractory Hematologic Cancer|To determine the anti-tumor activity of BMS-863233/XL413 when administered to subjects with refractory Hematologic Cancer","Bristol-Myers Squibb|Exelixis","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","11","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA198-001","March 2009","January 2010","January 2010","September 2015","February 6, 2009","February 9, 2009","null","null","September 23, 2015","October 12, 2015","University Of Miami, Miami, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Roswell Park, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT00838890"
9,"NCT00623870","A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.","null","Completed","No Results Available","Hematologic Neoplasms","Drug: RO5045337","Maximum tolerated dose/Dose-limiting toxicities|Safety: Incidence of adverse events|Comparison of daily versus twice daily dosing: Incidence of adverse events|Pharmacokinetics: Blood/Urine concentrations|Pharmacodynamics: Blood leukemia cells/MIC-1 protein level/CD33+CD34 markers|Clinical response: Clinical/hematologic malignancy assessments","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 1","116","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NO21279","May 2008","November 2012","November 2012","November 2016","February 18, 2008","February 26, 2008","null","null","November 1, 2016","November 2, 2016","Duarte, California, United States|New Brunswick, New Jersey, United States|New York, New York, United States|Houston, Texas, United States|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Bologna, Emilia-Romagna, Italy|Roma, Lazio, Italy|Glasgow, United Kingdom|Leeds, United Kingdom|Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT00623870"
10,"NCT01802879","Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator","null","Active, not recruiting","No Results Available","Hematologic Neoplasms","Drug: Panobinostat","Number of patients receiving single agent panobinostat|Number fo patients experiencing Serious Adverse Events (SAEs)","Novartis Pharmaceuticals|Novartis","All","Child, Adult, Senior","Phase 2","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLBH589B2402B|2012-005252-41","June 24, 2013","November 9, 2018","November 9, 2018","February 2017","February 26, 2013","March 4, 2013","null","null","February 7, 2017","February 8, 2017","City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(1), Duarte, California, United States|Georgia Regents University SC-2, Augusta, Georgia, United States|Dana Farber Cancer Institute Reg. Ped, Boston, Massachusetts, United States|University of Utah / Huntsman Cancer Institute SC-2, Salt Lake City, Utah, United States|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Salamanca, Castilla y Leon, Spain","https://ClinicalTrials.gov/show/NCT01802879"
11,"NCT00005785","Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer","null","Completed","No Results Available","Hematologic Neoplasm|HIV Infection","Drug: GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV","","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1","30","NIH","Interventional","Primary Purpose: Treatment","990167|99-DK-0167","September 1999","null","November 2001","November 2001","June 3, 2000","June 5, 2000","null","null","March 3, 2008","March 4, 2008","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00005785"
12,"NCT02329847","A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies","null","Active, not recruiting","No Results Available","Hematologic Neoplasms","Drug: Ibrutinib|Drug: Nivolumab","Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Overall Response Rate (ORR)|Duration of Stable Disease|Duration of response|Progression-Free Survival (PFS)|Overall survival|1-year Progression-Free Survival (PFS) Rate|Plasma and serum concentration of Ibrutinib and nivolumab","Janssen Research & Development, LLC|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","141","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR106681|PCI-32765LYM1002|2014-005191-28","March 11, 2015","July 15, 2019","July 31, 2019","December 2017","December 30, 2014","January 1, 2015","null","null","December 20, 2017","December 21, 2017","New York, New York, United States|Bedford Park, Australia|Darlinghurst, Australia|Woolloongabba, Australia|Haifa, Israel|Jeursalem, Israel|Ramat Gan, Israel|Tel Aviv, Israel|Chorzow, Poland|Gdansk, Poland|Krakow, Poland|Wroclaw, Poland|Barcelona, Spain|Madrid, Spain|Salamanca, Spain|Ankara, Turkey|Istanbul, Turkey|İzmir, Turkey","https://ClinicalTrials.gov/show/NCT02329847"
13,"NCT00185640","Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies","null","Completed","Has Results","Blood Cancer|Leukemia","Drug: Cyclosporine|Drug: Anti-Thymocyte Globulin|Drug: mycophenolate mofetil|Drug: Granulocyte-Colony Stimulating Factor|Radiation: Total Lymphoid Irradiation","Acute Graft vs Host Disease (GvHD)|Acute Graft vs Host Disease (GvHD), All Evaluable|Incidence of Relapse|Overall Survival (OS)|Event-free Survival (EFS)|Transplant-related Mortality","Stanford University","All","50 Years to 70 Years   (Adult, Senior)","Phase 2","303","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-11960|78998|BMT153","March 2003","April 2014","January 2016","February 2015","September 12, 2005","September 16, 2005","December 1, 2016","October 3, 2017","September 4, 2017","October 3, 2017","Stanford University School of Medicine, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT00185640"
14,"NCT01374841","Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors","null","Recruiting","No Results Available","Hematologic Neoplasms","Drug: Cyclophosphamide|Other: Hematopoietic Stem Cell Transplantation,","Donor engraftment|Incidence and severity of graft versus host disease|Non-relapse-related mortality","European Institute of Oncology","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IEO S513/110|2009-018083-94","August 2010","August 2019","December 2019","August 2016","June 15, 2011","June 16, 2011","null","null","August 9, 2016","August 10, 2016","European Institute of Oncology, Milan, Italy","https://ClinicalTrials.gov/show/NCT01374841"
15,"NCT00186225","Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors","null","Completed","No Results Available","Blood Cancer|Blood and Marrow Transplant (BMT)","Procedure: ablative allogeneic hematopoietic cell transplantation","oxicity and efficacy of TBI and cyclophosphamide as preparation for hematopoietic cell transplantation from partially matched and unrelated donors.|Overall Survival|Event Free Survival","Stanford University","All","up to 50 Years   (Child, Adult)","","250","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BMT22|75268","November 1989","June 2007","May 2010","July 2010","September 13, 2005","September 16, 2005","null","null","July 23, 2010","July 27, 2010","Stanford University School of Medicine, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT00186225"
16,"NCT03262220","Total Marrow Irradiation With Volumetric Arc Therapy for Patients Unfit for a 12 Gy TBI","null","Recruiting","No Results Available","Haematological Malignancy","Radiation: Volumetric Arc Therapy (VMAT)","Grade II and III toxicity|Cumulative incidence of Transplant Related Mortality(TRM)|Cumulative incidence of Grade II Organ toxicity","Thomas Zilli|University Hospital, Geneva","All","40 Years to 80 Years   (Adult, Senior)","","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-00066","April 11, 2017","April 2019","April 2020","August 2017","August 23, 2017","August 25, 2017","null","null","August 23, 2017","August 25, 2017","University Hospital of Geneva, Genève, Switzerland","https://ClinicalTrials.gov/show/NCT03262220"
17,"NCT00900614","Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer","null","Completed","No Results Available","Hematologic Neoplasms|Prostatic Neoplasms","Drug: APR-246","Dose-Limiting Toxicity (DLT) is reached and HFD is defined accordingly, OR the dose, which is expected to result in maximum plasma concentration close to, but not exceeding 35 μg/ml in any single patient without showing signs of DLT.|Determination of the toxicity and safety profile of APR-246 based on safety parameters from the entire study period.|Determination of the PK profile for up to 22 hours after the last APR-246 infusion. Cmax (maximal plasma concentration), AUC (area under the curve), t1/2 (half-life) and clearance will be determined.","Aprea Therapeutics AB","All","18 Years and older   (Adult, Senior)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","APR-246-01","May 2009","October 2010","October 2010","June 2011","May 11, 2009","May 13, 2009","null","null","June 22, 2011","June 23, 2011","Section of Haematology and Coagulation, Sahlgrenska University Hospital, Göteborg, Sweden|Hematology Centre, M54, Karolinska Institute, Karolinska University Hospital, Huddinge, Stockholm, Sweden|Clinical Research and Development Unit, Department of Oncology, Akademiska Hospital, Uppsala, Sweden|Department of Haematology, Akademiska Hospital, Uppsala, Sweden|Department of Hematology, University Hospital, Örebro, Sweden|Urology clinic, University Hospital, Örebro, Sweden","https://ClinicalTrials.gov/show/NCT00900614"
18,"NCT00934557","Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation","ATG FRES","Unknown status","No Results Available","Paediatric Patients Affected by Haematological Malignancies and Eligible to Undergo HSCT From an Unrelated Volunteer","Drug: ATG Fresenius","incidence and severity of acute GVHD|• incidence of chronic GVHD •relapse rate •TRM •EFS •incidence of infection","IRCCS Policlinico S. Matteo|Italian Association for Pediatric Hematology Oncology","All","1 Year to 19 Years   (Child, Adult)","Phase 3","42","Other","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Prevention","ProfGVHD1","March 2008","null","null","July 2009","July 7, 2009","July 8, 2009","null","null","July 7, 2009","July 8, 2009","Franco Locatelli, Pavia, Italy","https://ClinicalTrials.gov/show/NCT00934557"
19,"NCT01957579","A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies","null","Completed","Has Results","Blood Cancer|Advanced B Cell Malignancies","Drug: MEDI-551","Number of Participants With Adverse Events|Number of Participants With Dose Limiting Toxicities|Maximum Tolerated Dose|MEDI-551 Trough Concentration Levels at Day 0 (Pre-dose)|MEDI-551 Trough Concentration Levels at Day 7|MEDI-551 Trough Concentration Levels at Day 28|MEDI-551 Trough Concentration Levels at Day 56|MEDI-551 Trough Concentration Levels at Day84|MEDI-551 Trough Concentration Levels at Day 112|MEDI-551 Trough Concentration Levels at Day 140|MEDI-551 Trough Concentration Levels at Day 168|Anti-MEDI-551 Antibodies|Number of Participants With Tumour Response in FL Patients|Number of Participants With Tumour Response in DLBCL Patients|Number of Participants With Tumour Response in CLL Patients|Number of Participants With Tumour Response in MM Patients","AstraZeneca|MedImmune LLC","All","20 Years to 130 Years   (Adult, Senior)","Phase 1","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D2850C00001","May 25, 2011","September 15, 2015","September 15, 2015","May 2017","October 1, 2013","October 8, 2013","February 27, 2017","April 10, 2017","May 8, 2017","June 12, 2017","Research Site, Fukuoka-shi, Japan|Research Site, Isehara-shi, Japan|Research Site, Nagoya-shi, Japan","https://ClinicalTrials.gov/show/NCT01957579"
20,"NCT02504047","Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units","null","Recruiting","No Results Available","Hematologic Neoplasms","Procedure: T-Cell replete haplo-transplant","Six month survival, free from relapse, graft failure and grade III/IV acute GVHD|Incidence of Grade III/IV Acute Graft Versus Host Disease|Incidence of Chronic Extensive Graft Versus Host Disease|Cumulative incidence of non-relapse mortality at 1 year|Graft failure rate (ANC < 0.5 and low donor chimerism)|Overall and Disease Free Survival|Relapse Rate|Patients remaining on immune suppression at 1 year|Incidence of CMV and EBV reactivation requiring treatment","University of Calgary|The Canadian Blood and Marrow Transplant Group","All","Child, Adult, Senior","","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","26110","February 2014","July 2018","July 2019","August 2016","July 17, 2015","July 21, 2015","null","null","August 31, 2016","September 2, 2016","Foothills Medical Center / Tom Baker Cancer Center, Calgary, Alberta, Canada|Health Sciences Center, Winnipeg, Manitoba, Canada|Ottawa General Hospital, Ottawa, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada","https://ClinicalTrials.gov/show/NCT02504047"
21,"NCT03349372","Impact of Pulmonary Follow-up After Stem Cell Graft","null","Completed","No Results Available","Hematologic Neoplasms","Procedure: Hematopoietic stem cell transplantation","Medical complications","Hospices Civils de Lyon","All","18 Years and older   (Adult, Senior)","","227","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CRC_GHN_2017_007","November 1, 2016","October 31, 2017","October 31, 2017","November 2017","November 17, 2017","November 21, 2017","null","null","November 17, 2017","November 21, 2017","Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France","https://ClinicalTrials.gov/show/NCT03349372"
22,"NCT03320915","Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT","null","Recruiting","No Results Available","Hematologic Neoplasms","Drug: Cholecalciferol","Chronic GVHD|Acute GVHD|Vitamin D deficiency|25(OH)D3","Seoul National University Hospital|Seoul National University","All","18 Years and older   (Adult, Senior)","Phase 2","88","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H-1702-040-830","October 1, 2017","December 2018","December 2019","October 2017","October 22, 2017","October 25, 2017","null","null","October 22, 2017","October 25, 2017","Seoul National University Hospital, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT03320915"
23,"NCT03083327","Prophylactic Early PN in HPT/BMT","null","Not yet recruiting","No Results Available","Hematologic Neoplasms","Dietary Supplement: Parenteral nutrition.|Other: Pragmatic standard care.","Disease free survival time","University of Sydney|Australasian Bone Marrow Transplant Recipient Registry|University of Roma La Sapienza|Northern Clinical School Intensive Care Research Unit, University of Sydney","All","18 Years and older   (Adult, Senior)","","408","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","NHMRC APP1108301|ACTRN12615001329550|U1111-1194-5952","July 30, 2017","May 1, 2021","May 1, 2022","May 2017","March 8, 2017","March 20, 2017","null","null","May 8, 2017","May 10, 2017","","https://ClinicalTrials.gov/show/NCT03083327"
24,"NCT02895529","A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy","null","Recruiting","No Results Available","Hematologic Neoplasms","Drug: Itraconazole|Drug: Caspofungin","Response Rate Measured by the Percentage of Participants That Achieve all of the Following 5 Composite Endpoints|Percentage of Participants With Survival for 7 Days After Completion of Treatment|Percentage of Participants With Absence of Breakthrough Invasive Fungal Infection|Percentage of Participants With Successful Treatment of Baseline Fungal Infection|Percentage of Participants With Defervescence During the Period of Neutropenia|Percentage of Participants With No Premature Withdrawal From the Study due to Drug-related Toxicity or Lack of Efficacy|Response Rate Measured by the Percentage of Participants That Achieve all of the Following 5 Composite Endpoints With Oral Administration of Itraconazole","Xian-Janssen Pharmaceutical Ltd.","All","18 Years and older   (Adult, Senior)","Phase 4","408","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR108202|R051211FUN4057","November 30, 2016","March 5, 2018","December 31, 2018","December 2017","September 6, 2016","September 9, 2016","null","null","December 21, 2017","December 22, 2017","The General Hospital of the People's Liberation Army(PLAGH), Beijign, China|Beijing Chaoyang Hospital, Beijing, China|Peking University, Beijing, China|Navy General Hopital PLA China, Beijing, China|Peking Union Medical College Hospital, Beijing, China|The first Affiliated Hospital of Jilin University, Changchun, China|The First People's Hospital Of Changzhou, Changzhou, China|Chongqing Medical University, Chongqing, China|Xinqiao Hospital of the Third Military Medical University, Chongqing, China|Fujian Meidical University Union Hospital, Fuzhou, China|Guangzhou First Municipal People's Hospital, Guangzhou, China|Nanfang Hospital, Guangzhou, China|The Affiliated Hospital of Guizhou Medical University, Guiyang, China|Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China|the 1st affiliated hospital of Anhui Medical University, Hefei, China|Shandong Provincial Hospital, Jinan, China|First Affiliated Hospital of Kunming Medical Unversity, Kunming City, China|Jiangsu Province Hospital, Nanjing, China|Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China|Huashan Hospital Fudan University, Shanghai, China|Shanghai Tongji Hospital, Shanghai, China|Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China|ShangHai Changhai Hospital, Shanghai, China|The first hospital of China medical university, Shenyang, China|The Second People's Hospital of Shenzhen, Shenzhen, China|First Affiliated Hospital, SooChow University, Suzhou, China|The Second Hospital Of Shanxi Medical University, Taiyuan, China|Blood Disease Hospital of Chinese Academy of Medical Sciences, Tianjin, China|Tianjin Medical University General Hospital, Tianjin, China|Henan Cancer Hospital, Zhengzhou, China","https://ClinicalTrials.gov/show/NCT02895529"
25,"NCT02650791","Platelet Transfusion Requirements in Hematopoietic Transplantation","PATH","Recruiting","No Results Available","Hematologic Neoplasms","Drug: Tranexamic Acid","Enrolment, as measured by the number of patients screened per month at each site|Number of off-protocol platelet transfusions, with a target of < 10% off-protocol transfusions in each treatment arm|Total number of platelet transfusions/group, with a target of 25% reduction in the tranexamic acid arm|Adherence to tranexamic acid use, defined as excellent (greater than or equal to 90% use), acceptable (75-90% use), poor (< 75% use)|WHO (World Health Organization) Bleeding events of Grade 2 or higher|Time from randomization to bleeding of WHO bleeding events Grade 2 or higher|Number of days with bleeding of WHO bleeding events Grade 2 or higher|Bleeding Severity Measurement Scale for bleeding events Grade 2 or higher|Number of platelet and/or red cell transfusions|Time to platelet recovery|Number of days with platelet count < 10 x 10^9/L|LOS (Length of hospital stay)|Adverse transfusion reactions|Bearman Toxicity Score|Infections at Day 30|Quality of Life measurements, as determined by a battery of QoL instruments","Ottawa Hospital Research Institute","All","18 Years to 90 Years   (Adult, Senior)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","20150629-01H","October 2016","January 2018","June 2018","August 2017","January 6, 2016","January 8, 2016","null","null","August 28, 2017","August 29, 2017","Tom Baker Cancer Centre, Calgary, Alberta, Canada|Hamilton Health Sciences - Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada|London Health Sciences Center, London, Ontario, Canada|Ottawa Hospital, Ottawa, Ontario, Canada","https://ClinicalTrials.gov/show/NCT02650791"
26,"NCT02623309","Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients","null","Recruiting","No Results Available","Hematologic Neoplasms","Procedure: Allogeneic (Allo) hematopoietic stem cell transplantation","Event-free survival with death, relapse or occurrence of severe cGVHD as event whatever occurs first|Engraftment: time to reach 0.5 x 109/l ANC, 20 x 109/l platelets and full donor lymphoid chimerism|Acute and chronic GVHD cumulative incidences|Non-relapse mortality cumulative incidence|Relapse incidence|Probabilities of overall survival and progression-free survival|Evaluation of HRQL including patients who relapse|Evaluation of procedure costs from beginning of search until death or two-year follow-up","Institut Paoli-Calmettes","All","55 Years to 70 Years   (Adult, Senior)","Phase 3","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HAPLOMUDELDERLY-IPC 2015-004","February 2016","February 2019","February 2021","March 2017","November 30, 2015","December 7, 2015","null","null","March 27, 2017","March 28, 2017","CHU Amiens, Amiens, France|CHU Besançon, Besançon, France|CHU Estaing/Clermont-ferrand, Clermont-ferrand, France|CHU Albert Michallon, Grenoble, France|CHU Limoges, Limoges, France|Institut Paoli Calmettes, Marseille, France|CHRU Montpellier, Montpellier, France|CHU Nantes, Nantes, France|Hôpital Necker, Paris, France|Hôpital Saint Antoine, Paris, France|Hôpital Saint Louis, Paris, France|Hôpital Haut Leveque, Pessac, France|Institut de Cancérologie Lucien Neuwirth, Saint Priest en Jarez, France|IUCT, Toulouse, France","https://ClinicalTrials.gov/show/NCT02623309"
27,"NCT02477878","Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant","null","Recruiting","No Results Available","Hematologic Neoplasms","Biological: BPX-501|Drug: AP1903","Adverse events","Bellicum Pharmaceuticals","All","18 Years to 65 Years   (Adult)","Phase 1","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BP-008","July 2016","December 2019","December 2020","June 2017","May 18, 2015","June 23, 2015","null","null","December 7, 2017","December 11, 2017","BMT Program at Northside Hospital, Atlanta, Georgia, United States|University of Kansas, Westwood, Kansas, United States|Roswell Park, Buffalo, New York, United States|Weill Cornell Medical College, New York, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|Vanderbilt University, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT02477878"
28,"NCT01332006","Intra-bone Cord Blood Transplantation","null","Unknown status","No Results Available","Hematologic Neoplasms","Procedure: Intrabone injection|Biological: Intra-bone cord blood hematopoietic stem cell transplantation","Proportion of transplanted patients with successful engraftment at day +30|Clinical response with the analysis of global survival, survival without relapse, relapse incidence|Infections' Incidence|Chimerism monitoring on selected cell populations|Immunological reconstitution|Acute an Chronic GVHD","Università degli Studi di Brescia","All","18 Years to 65 Years   (Adult)","Phase 2","17","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBMCB - BS study","November 2009","April 2016","June 2016","December 2015","April 6, 2011","April 8, 2011","null","null","December 31, 2015","January 1, 2016","USD TMO Adulti, Piazzale Spedali Civili, Brescia, Italy","https://ClinicalTrials.gov/show/NCT01332006"
29,"NCT02061761","Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies","null","Recruiting","No Results Available","Hematologic Neoplasms","Biological: BMS-986016|Biological: BMS-936558","Proportion of subjects with Adverse Events (AEs)|Proportion of subjects with Serious Adverse Events (SAEs)|Proportion of Deaths|Proportion of subjects with clinical laboratory test abnormalities|Objective response rate (ORR)|Duration of Response (DOR)|Maximum observed serum concentration (Cmax) of BMS-986016 administered alone and in combination with Nivolumab|Time of maximum observed serum concentration (Tmax) of BMS-986016 administered both alone and in combination with Nivolumab|Trough observed serum concentration (Ctrough) of BMS-986016 administered both alone and in combination with Nivolumab|Concentration at the end of a dosing interval (Ctau) of BMS-986016 administered both alone and in combination with Nivolumab|Average concentration over a dosing interval [AUC(TAU)/tau] (Css,avg) of BMS-986016 administered both alone and in combination with Nivolumab|Area under the concentration-time curve in one dosing interval (AUC(TAU)) of BMS-986016 administered both alone and in combination with Nivolumab|Total body clearance (CLT) of BMS-986016 administered both alone alone and in combination with Nivolumab|Volume of distribution at steady state (Vss) of BMS-986016 administered both alone and in combination with Nivolumab|Effective elimination half-life that explains the degree of AUC administered alone accumulation observed (T-HALFeff AUC) of BMS-986016 administered both alone and in combination with Nivolumab|Effective elimination half-life that explains the degree of Cmax administered alone accumulation observed (T-HALFeff Cmax) of BMS-986016 administered both alone and in combination with Nivolumab|Accumulation index; ration of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986016 administered both alone and in combination with Nivolumab|Cmax accumulation index; ratio of Cmax at steady state to Cmax after the first dose (AI_Cmax) of BMS-986016 administered both alone and in combination with Nivolumab|Ctau accumulation index; ratio of Ctau at steady state to Ctau after the first dose (AI_Ctau) of BMS-986016 administered both alone and in combination with Nivolumab|Degree of fluctuation or fluctuation index ([Cmax - Ctau]/Css,avg) (DF) of BMS-986016 administered both alone and in combination with Nivolumab|Incidence of ADA to nivolumab and BMS-986016|Summary of AEs of special interest by","Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","132","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA224-022","February 25, 2014","June 28, 2018","January 15, 2020","December 2017","February 12, 2014","February 13, 2014","null","null","December 11, 2017","December 13, 2017","The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Weill Cornell Medical College, New York, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Washington, Seattle, Washington, United States|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT02061761"
30,"NCT01869218","Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy","null","Active, not recruiting","No Results Available","Hematologic Neoplasms","","Molecularly characterizing pre-treatment tumor biopsies|Rate of obtaining adequate post-treatment tumor biopsies and blood samples","University of Colorado, Denver","All","18 Years and older   (Adult, Senior)","","40","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","12-1025.cc","April 2, 2013","August 3, 2015","November 2017","August 2017","May 28, 2013","June 5, 2013","null","null","August 18, 2017","August 22, 2017","University of Colorado Cancer Center, Aurora, Colorado, United States","https://ClinicalTrials.gov/show/NCT01869218"
31,"NCT01362179","National Marrow Donor Program Long-Term Donor Follow-Up","LTDFU","Active, not recruiting","No Results Available","Hematologic Neoplasms","","Incidence of malignant myeloid hematologic disorders","Center for International Blood and Marrow Transplant Research|National Marrow Donor Program","All","18 Years to 60 Years   (Adult)","","21932","Other","Observational","Observational Model: Cohort|Time Perspective: Other","LTDFU","October 2010","September 30, 2020","September 30, 2020","October 2016","May 26, 2011","May 30, 2011","null","null","June 13, 2017","June 14, 2017","City of Hope, Duarte, California, United States|National Marrow Donor Program Northern California & Northwest District, Oakland, California, United States|National Marrow Donor Program Southern California & Southwest District, Santa Ana, California, United States|Colorado Marrow Donor Program, Denver, Colorado, United States|Community Blood Centers of Florida, Inc., Lauderhill, Florida, United States|Hawaii Bone Marrow Donor Registry, Honolulu, Hawaii, United States|LifeSource, Glenview, Illinois, United States|Rock River Valley Blood Center, Rockford, Illinois, United States|Indiana Blood Center, Indianapolis, Indiana, United States|National Marrow Donor Program Southcentral District, Heart of America, Leawood, Kansas, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|NIH Marrow Donor Center, Rockville, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Michigan Blood, Grand Rapids, Michigan, United States|The HLA Registry, Oradell, New Jersey, United States|New York Blood Center, Brooklyn, New York, United States|DKMS Americas, New York, New York, United States|National Marrow Donor Program Southeast District, Charlotte, North Carolina, United States|National Marrow Donor Program Northcentral District, Cleveland, Ohio, United States|Oklahoma Blood Institute, Oklahoma City, Oklahoma, United States|National Marrow Donor Program Northeast District, Philadelphia, Pennsylvania, United States|Rhode Island Blood Center, Providence, Rhode Island, United States|Blood Assurance, Inc., Chattanooga, Tennessee, United States|Cooperative Appalachian Marrow Program Medic Regional Blood Center, Knoxville, Tennessee, United States|Baylor Research Institute, Dallas, Texas, United States|Cook Children's, El Paso, Texas, United States|Gulf Coast Regional Blood Center, Houston, Texas, United States|South Texas Blood and Tissue Center, San Antonio, Texas, United States|Scott & White Clinic, Temple, Texas, United States|Puget Sound Blood Center, Seattle, Washington, United States|Community Blood Center, Inc., Appleton, Wisconsin, United States|National Marrow Donor Program at Puerto Rico, Guaynabo, Puerto Rico","https://ClinicalTrials.gov/show/NCT01362179"
32,"NCT00410696","Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy","null","Completed","No Results Available","Hematological Neoplasms|Tumors","Drug: Filgrastim|Drug: Pegfilgrastim","Duration of aplasia period|Immunological reconstitution","Armando Santoro, MD|Istituto Clinico Humanitas","All","18 Years and older   (Adult, Senior)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ONC-2006-001|EUDRACT 2006-001409-27","September 2006","November 2008","November 2008","June 2013","December 12, 2006","December 13, 2006","null","null","June 28, 2013","July 1, 2013","Istituto Clinico Humanitas, Rozzano, Milan, Italy","https://ClinicalTrials.gov/show/NCT00410696"
33,"NCT01827579","Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)","ICAT","Recruiting","No Results Available","Haematological Malignancies","Biological: CD25/71 allodepleted donor T-cells","Circulating CD3+ve T cell count at 4 months post-SCT|Incidence of grade II-IV acute and chronic GVHD|Time to recovery of normal T-cell (>700/uL) and CD4 (>300/uL) counts and normal TCR diversity as assessed by Vb spectratyping|In vitro anti-viral responses of circulating PBMC|Transplant related mortality at 1 year post-SCT|Disease-free survival at 1 year post-SCT","University College, London|Medical Research Council","All","16 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UCL/11/0519|2013-000872-14|MR/K007491/1","July 2014","January 2018","July 2018","May 2017","April 4, 2013","April 9, 2013","null","null","May 9, 2017","May 10, 2017","University College London Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01827579"
34,"NCT01275534","Symptom Experience and Self-management After Haematopoietic Stem Cell Transplantation","PROVIVO","Completed","No Results Available","Hematologic Neoplasms","","Symptom experience|Perception of late effects|Self-management behaviors|Self-management in view of medical and health tasks, emotional and role tasks|Objective late effects","University Hospital, Basel, Switzerland|University of Basel|University Hospital, Zürich","All","18 Years and older   (Adult, Senior)","","375","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","EKBB 264-10","November 2010","November 2012","November 2012","January 2013","January 3, 2011","January 12, 2011","null","null","January 16, 2013","January 17, 2013","University Hospital Basel, Basel, Switzerland|University Hospital Zürich, Zürich, Switzerland","https://ClinicalTrials.gov/show/NCT01275534"
35,"NCT01244906","Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant","null","Completed","Has Results","Hematologic Neoplasms","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation","Incidence of GVHD|Incidence of Absolute Neutrophil Count (ANC)/Platelet Engraftment|Number of Participants With Non-Relapse Mortality|Number of Patients With Disease Free Survival at 2 Years|Number of Patients to Achieve Full Donor Chimerism|Number of Patients With Overall Survival at 2 Years.","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSH 911","December 2010","April 2014","December 2014","January 2015","November 18, 2010","November 19, 2010","January 29, 2015","March 17, 2015","April 9, 2015","May 1, 2015","Northside Hospital, Atlanta, Georgia, United States","https://ClinicalTrials.gov/show/NCT01244906"
36,"NCT00312429","Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer","null","Completed","No Results Available","Hematologic Neoplasms","Procedure: Stem Cell Transplantation","Survival Rates","Duke University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","34","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2166|R01HL062095-06","January 2002","May 2008","May 2008","April 2012","April 6, 2006","April 10, 2006","null","null","April 2, 2012","April 3, 2012","Duke University, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00312429"
37,"NCT00914849","Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies","null","Completed","Has Results","Hematologic Neoplasms","Drug: AMD3100|Procedure: Leukopheresis|Procedure: Stem cell transplant","Number of Donors Treated With IV AMD3100 Who Required a Second Collection to Obtain the Minimum CD34/kg (2 X 106) Necessary for Allogeneic Stem Cell Transplant|Number of Donors Who Experience Grade 3-4 Infusional Toxicity|Number of Recipients Who Have Neutrophil Engraftment|Pharmacokinetics of IV AMD3100 as Measured by the Mean Maximum Plasma Concentration (Cmax)|Pharmacokinetics of IV AMD3100 as Measured by Half Life|Pharmacokinetics of IV AMD3100 as Measured by Mean Area Under Curve (AUC)|Rate of Acute GVHD (Grade II-IV) in Recipients|Rate of Acute GVHD (Grade III-IV) in Recipients|Time to Neutrophil Engraftment for Recipients|Time to Platelet Engraftment for Recipients|Transplant Related Mortality Rate for Recipients|Grade 3-4 Toxicity for Recipients|Rate of Chronic GVHD in Recipients|Number of Donors Who Experience Grade 3-4 Mobilization Toxicity Due to Pheresis Procedure","Washington University School of Medicine","All","18 Years to 65 Years   (Adult)","Phase 2","68","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-0713 / 201103429","August 2009","January 2011","February 2012","April 2017","June 1, 2009","June 5, 2009","July 14, 2016","August 24, 2016","April 6, 2017","May 17, 2017","Washington University School of Medicine, St. Louis, Missouri, United States","https://ClinicalTrials.gov/show/NCT00914849"
38,"NCT00051311","Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers","null","Completed","No Results Available","Hematologic Neoplasms","Procedure: Stem cell transplantation","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","62","NIH","Interventional","Primary Purpose: Treatment","030077|03-C-0077","January 3, 2003","September 25, 2014","September 25, 2014","September 25, 2014","January 8, 2003","January 8, 2003","null","null","October 5, 2017","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00051311"
39,"NCT00044759","Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma","null","Completed","No Results Available","Hematologic Neoplasms","Drug: Piperacillin/Tazobactam (Tazocin)","","Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Senior)","Phase 3","null","Industry","Interventional","Primary Purpose: Treatment","0910B1-308","null","null","January 2003","October 2007","September 4, 2002","September 6, 2002","null","null","October 8, 2007","October 10, 2007","Little Rock, Arkansas, United States|Los Angeles, California, United States|Denver, Colorado, United States|Gainesville, Florida, United States|North Miami, Florida, United States|Ocala, Florida, United States|St. Petersburg, Florida, United States|Thomasville, Georgia, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Louisville, Kentucky, United States|Camden, New Jersey, United States|Hackensack, New Jersey, United States|Bronx, New York, United States|Buffalo, New York, United States|New York, New York, United States|Rochester, New York, United States|Rochester, New York, United States|Valhalla, New York, United States|Tulsa, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Sayre, Pennsylvania, United States|Upland, Pennsylvania, United States|West Reading, Pennsylvania, United States|Providence, Rhode Island, United States|Columbia, South Carolina, United States|Houston, Texas, United States|Morgantown, West Virginia, United States|Milwaukee, Wisconsin, United States|Hamilton, Canada|Montreal, Canada|Ottawa, Canada|Saskatoon, Canada|Winnepeg, Canada","https://ClinicalTrials.gov/show/NCT00044759"
40,"NCT03094026","Cognitive Training Intervention and Attitudes Towards Genetics","cTAG","Recruiting","No Results Available","Cognitive Impairment|Hematologic Neoplasms|Hematopoietic Cell Transplant","Behavioral: Lumosity|Behavioral: Lumosity (waitlist control)","Number of HCT patients completing the 2-arm wait-listed randomized trial of cognitive training intervention for a period of 3 months|Change in cognitive function between intervention and wait list control arms from baseline to 12 weeks.|16-item survey to measure genetic factual knowledge at baseline|Effect size of associations of key predictors with genetic factual knowledge at baseline|5 Likert scale survey questionnaire to measure importance of receiving genetic risk information|5 Likert scale survey questionnaire to measure impact of receiving genetic risk information on intervention uptake|5 Likert scale survey questionnaire to measure impact of receiving genetic risk information on intervention adherence","University of Alabama at Birmingham","All","21 Years and older   (Adult, Senior)","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","X161221006","August 21, 2017","December 2018","December 2018","September 2017","March 17, 2017","March 29, 2017","null","null","September 12, 2017","September 13, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States","https://ClinicalTrials.gov/show/NCT03094026"
41,"NCT01915498","Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation","null","Active, not recruiting","No Results Available","Hematologic Neoplasms","Drug: AG-221","Adverse Events (AEs)|Maximum Tolerated Dose|Clinical Activity of AG-221 for subjects with relapsed or refractory acute myelogenous leukemia (AML) with Isocitrate dehydrogenase protein 2 (IDH2) mutation|Dose Limiting Toxicities|Pharmacokinetic Cmax|Pharmacokinetic Tmax|Clinical Activity pf AG-221 in subjects with hematologic malignancies|Pharmacokinetic AUC|Pharmacokinetic Elimination half-life|Pharmacodynamics Analyses Plasma|Pharmacodynamics Analyses Urine|Pharmacodynamics Analyses Bone Marrow (2-HG)|Clinical Activity of AG-221 in subjects with Relapse/Refractory AML with an IDH2 mutation","Celgene|Agios Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","357","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AG-221-C-001","August 27, 2013","May 31, 2018","May 31, 2019","November 2017","July 31, 2013","August 5, 2013","null","null","November 28, 2017","November 30, 2017","City of Hope, Duarte, California, United States|Stanford Cancer Center, Stanford, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|University of Miami Sylvester Cancer Center, Miami, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Cornell University Weill Medical College, New York, New York, United States|Memorial Sloan-Kettering Cancer Center - NYC, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Gahanna, Ohio, United States|Oregon Health and Science University OHSU, Portland, Oregon, United States|Sarah Cannon Research Institute Drug Development Unit, Nashville, Tennessee, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Institut Bergonie Department Oncologie, Bordeaux, France|Hospital Saint Louis, Paris, France|Hospital haut leveque, Pessac, France|CHU Purpan, Toulouse, France|Institut Gustave Roussy, Villejuif, France","https://ClinicalTrials.gov/show/NCT01915498"
42,"NCT01719341","Study of Non-Myeloablative Haplo-identical Haematopoietic Stem Cell Transplantation in Patients With Haematological Malignancies or Acquired Aplastic Anaemia","null","Unknown status","No Results Available","Haematological Malignancies|Acquired Aplastic Anaemia","","1 year overall survival after HLA-Haploidentical transplantation|Progression free survival one and 2 years post-transplantation|Cumulative incidence of relapse/progression at one and 2 years post-transplant","National University Hospital, Singapore","All","18 Years to 70 Years   (Adult, Senior)","","21","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2012/00465","September 2012","June 2014","null","December 2013","October 30, 2012","November 1, 2012","null","null","December 10, 2013","December 11, 2013","National University Hospital, Singapore, Singapore","https://ClinicalTrials.gov/show/NCT01719341"
43,"NCT00185614","Mixed Chimera Allo Transplantation in Multiple Myeloma","null","Completed","No Results Available","Blood Cancer|Multiple Myeloma","Procedure: autologous then nonmyeloablative allogeneic transplant|Drug: cyclophosphamide|Drug: Melphalan|Drug: cyclosporin|Drug: Mycophenolate mofetil","Survival, event-free survival and relapse rate with an intent-to-treat analysis. Results will be compared to allogeneic HCT reported results.|Development of Graft Versus Host Disease (GVHD) in vaccinated patients|Development of GVHD in concurrent myeloma patients receiving allogeneic HCT at our institution who are not candidates for vaccination.","Stanford University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BMT109|75190","August 2000","April 2009","April 2010","April 2011","September 12, 2005","September 16, 2005","null","null","April 18, 2011","April 19, 2011","Stanford University School of Medicine, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT00185614"
44,"NCT03031106","Multidisciplinary Follow-up of Patients Treated for Malignant Hematological Disease","null","Recruiting","No Results Available","Malignant Hematologic Neoplasm","","Health-Related Quality of Life (HRQoL) - General|Health-Related Quality of Life (HRQoL) - Disease specific|Symptoms of depression and anxiety","Aalborg Universitetshospital","All","18 Years and older   (Adult, Senior)","","300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","TVO","January 2017","July 2018","null","May 2017","January 12, 2017","January 25, 2017","null","null","May 3, 2017","May 5, 2017","Aalborg University Hospital, Department of Hematology, Aalborg, Denmark","https://ClinicalTrials.gov/show/NCT03031106"
45,"NCT00595686","Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies","null","Completed","No Results Available","Hematologic Neoplasms","Drug: SNX-5422","adverse events and other safety assessments|disease response specific to the hematological malignancy","Esanex Inc.|Serenex, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1311002|SNX-5422-CLN1-002","January 2008","May 2010","May 2010","May 2012","January 7, 2008","January 16, 2008","null","null","May 15, 2012","May 17, 2012","Pfizer Investigational Site, Augusta, Georgia, United States|Pfizer Investigational Site, Chapel Hill, North Carolina, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT00595686"
46,"NCT01915992","Natural Killer Cells Functions, Tumoral Escape to Immune System and Regulation of Natural Cytotoxixity Receptors in Haematological Malignancies","null","Unknown status","No Results Available","Leukemia","Other: blood samples","blood sample","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Senior)","","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","2012-A01412-41|2012-34","February 2013","August 2014","January 2015","August 2014","February 20, 2013","August 5, 2013","null","null","August 29, 2014","September 1, 2014","Assistance Publique Hopitaux de Marseille, Marseille, France","https://ClinicalTrials.gov/show/NCT01915992"
47,"NCT01212796","Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH","null","Unknown status","No Results Available","Allogeneic Stem Cell Transplantation","","","Grupo Espanol de trasplantes hematopoyeticos y terapia celular","All","Child, Adult, Senior","","350","Other","Observational","Time Perspective: Retrospective","GET-ALO-2010-01|get-alo-2010-01","September 2010","March 2011","June 2011","September 2010","September 30, 2010","October 1, 2010","null","null","September 30, 2010","October 1, 2010","","https://ClinicalTrials.gov/show/NCT01212796"
48,"NCT00975975","Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer","null","Completed","Has Results","Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Myelodysplasia|Non-Hodgkin's Lymphoma|Hodgkin's Disease|Multiple Myeloma|Myelofibrosis|Anemia, Aplastic|Hemoglobinuria, Paroxysmal","Drug: Basiliximab","Grade 3-4 Acute GVHD Rate|Time to Neutrophil Engraftment|Time to Platelet Engraftment","Indiana University School of Medicine|Indiana University","All","18 Years and older   (Adult, Senior)","Phase 2","17","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0908-04; IUCRO-0256","September 2009","October 2012","November 2013","January 2016","September 11, 2009","September 14, 2009","January 28, 2016","February 26, 2016","January 28, 2016","February 26, 2016","Indiana University Cancer Center, Indianapolis, Indiana, United States","https://ClinicalTrials.gov/show/NCT00975975"
49,"NCT01775072","Genomic Profiling in Cancer Patients","null","Recruiting","No Results Available","Solid Tumors|Hematologic Cancers","Genetic: molecular profiling of tumors|Genetic: Clinical Germline Analysis","frequency of ""actionable"" oncogenic mutations|To determine the impact of molecular profiling results performed in the CLIA-setting on the treatment of patients.|interrogate the mechanisms|To explore the genetic mechanisms of tumorigenesis","Memorial Sloan Kettering Cancer Center","All","Child, Adult, Senior","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","12-245","January 2013","January 2018","January 2018","December 2017","January 21, 2013","January 24, 2013","null","null","December 18, 2017","December 20, 2017","Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States|Miami Cancer Institute Baptist Health South Florida, Miami, Florida, United States|Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Kings County Hopsital Center, Brooklyn, New York, United States|Coney Island Hospital, Brooklyn, New York, United States|Memorial Sloan Kettering Cancer Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Queens Cancer Center of Queens Hospital, Jamaica, New York, United States|Ralph Lauren Center for Cancer Care and Prevention, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT01775072"
50,"NCT00742560","A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma","null","Completed","No Results Available","Hematologic Cancer","Biological: elotuzumab (HuLuc63)|Drug: lenalidomide|Drug: dexamethasone","Phase 1 Portion: Maximum tolerated dose|Phase 2 portion: Objective response according to the International Myeloma Working group Uniform Response Criteria|Safety profile of elotuzumab|Pharmacokinetic profile of elotuzumab|Immunogenicity of elotuzumab|Anti tumor activity of elotuzumab|Phase 1 portion: Objective response according to the International Myeloma Working group Uniform Response Criteria","AbbVie (prior sponsor, Abbott)|Bristol-Myers Squibb|AbbVie","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","101","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HuLuc63-1703|2007-006677-83","August 2008","October 2016","October 2016","April 2017","August 25, 2008","August 27, 2008","null","null","April 26, 2017","April 27, 2017","Site Reference ID/Investigator# 63587, Atlanta, Georgia, United States|Site Reference ID/Investigator# 63591, Boston, Massachusetts, United States|Site Reference ID/Investigator# 63588, Boston, Massachusetts, United States|Site Reference ID/Investigator# 63586, Ann Arbor, Michigan, United States|Site Reference ID/Investigator# 63592, Detroit, Michigan, United States|Site Reference ID/Investigator# 63589, Saint Louis, Missouri, United States|Site Reference ID/Investigator# 63585, New York, New York, United States|Site Reference ID/Investigator# 63582, Calgary, Canada|Site Reference ID/Investigator# 63584, Halifax, Canada|Site Reference ID/Investigator# 63583, Toronto, Canada|Site Reference ID/Investigator# 63562, Lille Cedex, France|Site Reference ID/Investigator# 63564, Lyon, Cedex 8, France|Site Reference ID/Investigator# 63567, Montpellier Cedex 5, France|Site Reference ID/Investigator# 63565, Nantes, France|Site Reference ID/Investigator# 63502, Tours Cedex, France|Site Reference ID/Investigator# 63570, Heidelberg, Germany|Site Reference ID/Investigator# 63569, Kiel, Germany","https://ClinicalTrials.gov/show/NCT00742560"
51,"NCT02966457","A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM)","DEHAM","Completed","No Results Available","Hematological Infection","Drug: Colistimethate Sodium","Rate of eradication of ESBL-producing or carbapenem-resistant Enterobacteriaceae, carbapenem-resistant A. baumannii or P. aeruginosa at day 21 post-treatment|Rate of resistance of isolated on day 21 post-treatment Enterobacteriaceae, A. baumannii, P. aeruginosa to polymyxin antibiotics","Minsk State Clinical Hospital No 9|Belarusian state medical university","All","18 Years and older   (Adult, Senior)","Phase 4","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","HEM-3_1","January 2017","December 2017","December 2017","December 2017","November 15, 2016","November 17, 2016","null","null","December 26, 2017","December 28, 2017","Republican Center of Hematology and Bone Marrow Transplantation, Minsk, Belarus","https://ClinicalTrials.gov/show/NCT02966457"
52,"NCT03136445","TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia","TREATT","Recruiting","No Results Available","Hematologic Neoplasms|Hemorrhage|Hematopoietic Stem Cell Transplantation","Drug: Tranexamic acid (TXA).|Drug: Placebo","Estimated proportion of patients who died or had bleeding of WHO grade 2 or above during the first 30 days of the trial.|Proportion of days with bleeding (WHO grade 2 or above).|Time to first episode of bleeding of WHO grade 2 or greater for those patients who bled.|Highest grade of bleeding a patient experiences.|Number of platelet transfusions per patient.|Number of red cell transfusions per patient.|Estimated proportion of patients surviving at least 30 days without a platelet transfusion.|Estimated proportion of patients surviving at least 30 days without a red cell transfusion.|Number of thrombotic events from first administration of trial treatment up to and including 120 days after the first dose of trial treatment is administered, per day at risk.|Number of patients developing Veno-occlusive Disease (VOD; Sinusoidal obstructive syndrome, SOS) within 60 days of first administration of trial treatment.|All-cause mortality during the first 30 days and the first 120 days after the first dose of trial treatment is administered. All-cause mortality during the first 30 days and the first 120 days after the first dose of trial treatment is administered|Death due to thrombosis during the first 120 days after the first dose of trial treatment is administered.|Death due to bleeding during the first 30 days after the first dose of trial treatment is administered.|Number of serious adverse events (SAE) from first administration of trial treatment until 60 days after the first dose of trial treatment is administered.","NHS Blood and Transplant|National Health and Medical Research Council, Australia|Monash University","All","18 Years and older   (Adult, Senior)","Phase 3","616","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","12-01-CSU|2014-001513-35|ISRCTN73545489","June 2015","June 2020","September 2020","September 2017","February 21, 2017","May 2, 2017","null","null","September 26, 2017","September 27, 2017","Royal Adelaide Hospital, Adelaide, Australia|Andrew Love Cancer Centre, Geelong, Australia|Alfred Hospital, Melbourne, Australia|St Vincent's Hospital, Melbourne, Australia|Victorian Comprehensive Cancer Centre, Melbourne, Australia|Royal North Shore Hospital, St Leonards, Australia|Westmead Hospital, Westmead, Australia|Royal United Hospital, Bath, United Kingdom|Belfast City Hospital, Belfast, United Kingdom|Heartlands Hospital, Birmingham, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Royal Devon and Exeter Hospital, Exeter, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|St James's Hospital, Leeds, United Kingdom|Lincoln County Hospital, Lincoln, United Kingdom|King's College Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Freeman Hospital, Newcastle, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Salisbury District Hospital, Salisbury, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT03136445"
53,"NCT02583035","Telephone OncoGériatric Followed in the Management of Elderly Patients Treated for Cancer or Haematological Malignancy","TelOG","Recruiting","No Results Available","Cancer|Hematologic Malignancy","Other: Nurse telephone contact","Memory on the Mini Mental Scale|Falls on the number of falls|Pain on the EVS (verbal scale) scale|Autonomy on the ADL (activities of daily living) score|Pain on the EN (numericale scale) scale|Autonomy on the IADL (The Lawton Instrumental Activities of Daily Living Scale ) score","Centre Francois Baclesse","All","70 Years and older   (Senior)","","131","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TelOG","February 2015","February 2018","December 2018","January 2018","September 17, 2015","October 21, 2015","null","null","January 3, 2018","January 4, 2018","Centre Hospitalier, Bayeux, France|CHU, Caen, France|Centre François Baclesse, Caen, France|Centre Hospitalier, Dieppe, France|Centre Hospitalier du Havre, Le Havre, France","https://ClinicalTrials.gov/show/NCT02583035"
54,"NCT02635984","Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens","FOND-O","Recruiting","No Results Available","Complications of Bone Marrow Transplant|Hematologic Neoplasms","Drug: Olanzapine|Drug: Placebo","Overall percentage of patients who had a complete response|Number of emetic episodes per patient|Number of rescue medications doses administered per patient|Percent of patients with no significant nausea|Percent of patients achieving complete protection|Rate of discontinuation of study drug","Augusta University|University of Georgia","All","18 Years and older   (Adult, Senior)","Phase 3","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","818888","November 2015","December 2017","December 2017","March 2017","December 15, 2015","December 21, 2015","null","null","March 25, 2017","March 28, 2017","Augusta University Medical Center, Augusta, Georgia, United States","https://ClinicalTrials.gov/show/NCT02635984"
55,"NCT02634294","Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT","null","Recruiting","No Results Available","Hematological Neoplasms|Recurrence","Drug: Peg interferon alfa-2b","response rate of Peg interferon alpha-2b|overall survival after relapsing|disease prognostic factors of overall survival after alloHSCT relapse|disease free survival after relapsing","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","All","14 Years to 60 Years   (Child, Adult)","Phase 4","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Shanghai1st","August 2015","December 2017","December 2018","October 2016","December 5, 2015","December 18, 2015","null","null","October 15, 2016","October 18, 2016","Shanghai Jiao Tong University Affilated First People's Hospital, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT02634294"
56,"NCT00987987","Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion","ILD-Treg","Completed","No Results Available","Hematologic Neoplasms|Relapse","Procedure: donor lymphocyte infusion","Incidence of ""severe"" GHVD (grade >II) following dDLI should be inferior to 40%.|The incidence of GVHD of any grade after dDLI|The anti-tumoral efficiency of dDLI to treat the relapse of the hematological malignancy|The survival and the survival without disease after dDLI","Assistance Publique - Hôpitaux de Paris|Université Paris XII|Pierre and Marie Curie University","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P040441","December 2005","December 2009","December 2009","September 2009","September 30, 2009","October 1, 2009","null","null","January 21, 2011","January 24, 2011","Hopital Henri Mondor, Créteil, France","https://ClinicalTrials.gov/show/NCT00987987"
57,"NCT00067730","A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation","null","Completed","No Results Available","Sepsis|Hematologic Neoplasms|Hematopoietic Stem Cell Transplantation|Infection","Drug: Drotrecogin Alfa (activated)","Safety|Mortality|Bleeding incidence","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 4","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6416|F1K-US-EVCE","March 2003","null","October 2003","December 2007","August 25, 2003","August 27, 2003","null","null","December 3, 2007","December 7, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iowa City, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manhassaet, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00067730"
58,"NCT01334060","WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation","WIN","Suspended","No Results Available","Leukaemia (Acute)|Leukaemia (Chronic)|Leukaemia (Acute Myeloid)|Leukaemia (Acute Lymphoblastic)|Leukaemia (Acute Promyelocytic)","Biological: p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine","Molecular response following p.DOM-epitope DNA vaccination in patients with CML (BCR-ABL, WT1) and AML (WT1)|CML-Time to disease progression, next treatment and survival|AML-2 year survival, overall survival","University Hospital Southampton NHS Foundation Trust|Imperial College Healthcare NHS Trust|Royal Devon and Exeter NHS Foundation Trust|Inovio Pharmaceuticals|Efficacy and Mechanism Evaluation ( EME ) programme|Leukemia Research Fund","All","18 Years and older   (Adult, Senior)","Phase 2","184","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RHMCAN0700|2009-017340-14|ISRCTN62678383","February 2010","April 2013","null","October 2016","April 11, 2011","April 12, 2011","null","null","October 12, 2016","October 13, 2016","Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom|Imperial College NHS Trust, London, United Kingdom|Southampton University Hospitals NHS Trust, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01334060"
59,"NCT00750126","Allogeneic Hematopoietic Stem Cell Transplantation","RICE","Unknown status","No Results Available","Solid Tumors|Hematologic Neoplasms","Drug: Fludarabine, Busulfan, Thymoglobulin","Primary criterion - Hematological reconstitution and chimerism post-transplantation|Secondary criteria - Adverse effects, graft-related mortality at D90 and at 12 months, incidence and severity of acute and/or chronic GVH reactions","University Hospital, Clermont-Ferrand","All","up to 20 Years   (Child, Adult)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHU-0039","April 2007","April 2009","April 2009","January 2011","September 9, 2008","September 10, 2008","null","null","January 18, 2011","January 19, 2011","Paillard Catherine, Clermont-Ferrand, France","https://ClinicalTrials.gov/show/NCT00750126"
60,"NCT02955966","PET/CT Guided Antifungal Stewardship in Invasive Pulmonary Aspergillosis","OPTIFIL","Recruiting","No Results Available","Aspergillosis and Haematological Malignancy","Device: imaging 18F-FDG-PET/CT|Biological: Blood collection","Response rate according to 18F-FDG-PET/CT (PET/CT response)|Response rate according to EORTC/MSG criteria (Segal response).|Response rate according to PET/CT|Number of patients for whom 18F-FDG-PET/CT has evidenced extra pulmonary attributable lesions|Number of patients for whom 18F-FDG-PET/CT has evidenced extra pulmonary attributable lesions in initial work-up|Patient mortality rate","Assistance Publique - Hôpitaux de Paris|Institut Pasteur, Paris France","All","18 Years and older   (Adult, Senior)","","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","P150916|2016-A00408-43","June 2, 2017","August 2019","February 2021","July 2017","November 3, 2016","November 4, 2016","null","null","July 31, 2017","August 1, 2017","Department of Infectious Diseases and Tropical Medicine, Necker enfants malades hospital, Paris, France","https://ClinicalTrials.gov/show/NCT02955966"
61,"NCT03023202","UWCCC Molecular Tumor Board Registry","null","Recruiting","No Results Available","Hematologic Neoplasms|Solid Neoplasm","Other: PMMTB (Precision Medicine Molecular Tumor Board)","Frequency of acceptance of molecular tumor board recommendations|Benefit from PMMTB recommended treatment|Correlation of mutations with protein overexpression|Correlations of mutations with circulating tumor DNA|Correlations of mutations with spheroid culture investigations","University of Wisconsin, Madison|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","500","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","UW15068|2015-1370|P30CA014520","March 2016","March 2021","null","January 2017","January 13, 2017","January 18, 2017","null","null","January 13, 2017","January 18, 2017","University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT03023202"
62,"NCT03263637","Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies","null","Recruiting","No Results Available","Relapsed or Refractory Haematological Malignancies Including|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|High Risk Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Richter's Syndrome|B-cell Non-Hodgkin Lymphoma|T-cell Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma|Multiple Myeloma","Drug: AZD4573","Incidence of adverse events|Dose limiting toxicities|maximum tolerated dose|Maximum observed plasma concentration of AZD4573|Area under the concentration-time curve for plasma concentrations of AZD4573|Volume of distribution (Vd).|Clearance (CL).|Urine PK for AZD4573|Antitumor activity of AZD4573 in patients by assessing overall response rate (ORR).|Duration of response (DOR)|Antitumor activity of AZD4573 in patients by assessing overall survival (OS).|Minimal Residual Disease (MRD)|Progression free survival (PFS)","AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 1","42","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D8230C00001","October 24, 2017","October 31, 2019","October 31, 2019","December 2017","August 11, 2017","August 28, 2017","null","null","December 8, 2017","December 11, 2017","Research Site, Aachen, Germany|Research Site, Bonn, Germany|Research Site, Heidelberg, Germany|Research Site, Ulm, Germany|Research Site, Amsterdam, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Cardiff, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT03263637"
63,"NCT03052777","Using Telephone Counselling to Improve Exercise Participation in Hematologic Cancer Survivors","null","Completed","No Results Available","Leukemia|Lymphoma|Lymphoma, Non-Hodgkin|Behavior, Health","Behavioral: Telephone counselling","Change from baseline in Exercise Levels|Change from baseline in Exercise Motivation|Change from baseline in Quality of life|Change from baseline in Fatigue","University of Alberta","All","18 Years to 80 Years   (Adult, Senior)","","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HREBA.CC-16-0775","February 21, 2017","August 1, 2017","August 1, 2017","October 2017","January 31, 2017","February 14, 2017","null","null","October 2, 2017","October 3, 2017","University of Alberta, Edmonton, Alberta, Canada","https://ClinicalTrials.gov/show/NCT03052777"
64,"NCT02988258","Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT","CMV_TCR-001","Recruiting","No Results Available","Haematological Malignancies|CMV Infection","Genetic: CMV-TCR transduced donor-derived T cells","Determination of the frequency of transduced donor-derived cells expressing the CMV-specific TCR by flow cytometry.|Evaluation of treatment toxicity according to the NCI Common Toxicity Criteria Scale (v4.03).|Documentation of anti-CMV responses post CMV-TCR transduced cell infusion using quantitative PCR to determine viral copy numbers in peripheral blood.|Evaluation of GvHD post CMV-TCR transduced cell infusion following allo-HSCT using standardised international criteria.|Evaluation of immune reconstitution post CMV-TCR transduced cell infusion following allo-HSCT.|Assessment of the number of CMV-TCR transduced cells that are able to persist post-infusion using quantitative real-time PCR.|Phenotypic characterisation of CMV-TCR transduced cells by flow cytometry in terms of relative expression of markers associated with cell differentiation, proliferation and intracellular cytokine production.","University College, London","All","18 Years to 65 Years   (Adult)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCL 08/0214|2008-006649-18|G0701703|08/0214","July 2013","April 2018","August 2019","February 2017","July 12, 2012","December 9, 2016","null","null","February 20, 2017","February 23, 2017","University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom|University College London Hospital, London, United Kingdom|Nottingham University Hospital, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT02988258"
65,"NCT02193880","Safety and Efficacy Trial for Alpha-Beta Depleted T-Cell Infusions Post Haplo Transplant","ABD","Active, not recruiting","No Results Available","Hematologic Neoplasms|Graft-Versus-Host Disease","Device: Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.","One-year progression-free survival.|Incidence of acute graft-versus-host disease.|Incidence of chronic graft-versus-host disease.|Incidence of relapse.|Incidence of overall survival.","Ayman Saad|University of Alabama at Birmingham","All","19 Years to 65 Years   (Adult)","","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UAB 1397","October 2014","January 2018","January 2019","November 2017","July 14, 2014","July 18, 2014","null","null","November 1, 2017","November 6, 2017","UAB Medical Center (University of Alabama at Birmingham), Birmingham, Alabama, United States","https://ClinicalTrials.gov/show/NCT02193880"
66,"NCT02860598","Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy","EPREX/LAM-ALLO","Recruiting","No Results Available","Anemia|Acute Myeloid Leukemia","","Change in the Haemoglobin level from the inclusion to the final visit|Change in Fact-An questionnaire score|Change in Fact-An subscales|Change in Fact-G questionnaire score|Change in Fact-Anemia questionnaire score|Change in the Number of red blood cell transfusions|Change in the Number of platelet transfusions","Hospices Civils de Lyon","All","18 Years and older   (Adult, Senior)","","104","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL16_0419","December 2011","December 2018","June 2019","June 2016","July 20, 2016","August 9, 2016","null","null","August 4, 2016","August 9, 2016","Jeremy MONFRAY, Pierre Bénite, France","https://ClinicalTrials.gov/show/NCT02860598"
67,"NCT02805075","Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant","null","Active, not recruiting","No Results Available","Hematopoietic and Lymphoid Cell Neoplasm|Recurrent Hematologic Malignancy","Other: Fructooligosaccharide|Other: Laboratory Biomarker Analysis","Maximum tolerated dose defined as the ability to take 80% of all doses over 21 days","Stanford University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","BMT303|NCI-2016-00847|37379|P30CA124435","June 2016","June 2018","null","November 2017","June 15, 2016","June 17, 2016","null","null","November 9, 2017","November 14, 2017","Stanford University, School of Medicine, Palo Alto, California, United States","https://ClinicalTrials.gov/show/NCT02805075"
68,"NCT00071045","Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members","null","Recruiting","No Results Available","Neoplasms|Hematologic Neoplasms","","","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","2 Years and older   (Child, Adult, Senior)","","9999","NIH","Observational","Time Perspective: Other","040012|04-H-0012","October 8, 2003","null","null","December 18, 2017","October 9, 2003","October 10, 2003","null","null","December 27, 2017","December 28, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00071045"
69,"NCT00582894","Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases","null","Completed","Has Results","Hematological Neoplasms|Hematopoietic Stem Cell Transplantation","Drug: Busulfex, Fludarabine, ALemtuzumab","Number of Participants Experiencing Transplant Related Mortality (TRM)|Number of Participants Experiencing Engraftment Donor Chimerism (EDC)|Number of Participants Relapse-Free|Number of Participants Overall Survival as a Function of Time.","University of Oklahoma","All","18 Years to 75 Years   (Adult, Senior)","","17","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Reduced-Intensity|IRB #11835","February 2005","March 2008","March 2008","March 2011","December 19, 2007","December 28, 2007","January 10, 2011","April 22, 2011","March 23, 2011","April 22, 2011","University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States","https://ClinicalTrials.gov/show/NCT00582894"
70,"NCT00473577","Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients","null","Completed","No Results Available","Hematologic Neoplasms|Neoplasms","Drug: CRA-24781","","Pharmacyclics LLC.","All","18 Years and older   (Adult, Senior)","Phase 1","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PCYC 0401","August 2005","November 2007","December 2007","August 2010","May 11, 2007","May 15, 2007","null","null","August 24, 2010","August 25, 2010","University of Chicago, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT00473577"
71,"NCT00423124","Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies","null","Completed","No Results Available","Hematological Malignancies","Genetic: HSV-TK","Evaluation of clinical activity in terms of immune-reconstitution, provided by the add- back of the transduced T-cells after haplo-HCT|Evaluation of the ""in vivo"" control of GvHD after administration of ganciclovir in patients treated with HSV-TK transduced T-cells|Evaluation of GvL effect|Time to relapse, time to death (evaluated by disease free survival and overall survival)|Incidence of infectious events (measured by number of infectious events)|Acute and long term toxicity related to the infusions (measured by incidence of adverse events)","MolMed S.p.A.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","57","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TK007|2005-003587-34","July 2002","December 2011","November 2013","May 2014","January 16, 2007","January 17, 2007","null","null","May 29, 2014","May 30, 2014","Medizinische Hoschule Hannover, Hannover, Germany|G. Papanicolau, Thessaloniki, Greece|Hadassah University Hospital, Jerusalem, Israel|Fondazione San Raffaele, Milan, Italy|Istituto Clinico Humanitas, Milan, Italy|Policlinico Monteluce, Perugia, Italy|Ospedale Civile, Pescara, Italy|Hammersmith Hospital, London, United Kingdom","https://ClinicalTrials.gov/show/NCT00423124"
72,"NCT01606033","Study of Stress and Life Quality of Patients Participating in Clinical Trials Versus Patients Non Participating","IPSY","Completed","No Results Available","Metastatic Neoplasm|Recurrent Hematologic Cancer","Other: questionnaires|Other: questionnaire","assess and compare stress and life quality of patients participating to a clinical trial vs patients treated a standard way|evaluate links between using adjustment therapy and emotional regulation, and emotional and psychological experience of patients facing one or another situation|measure and compare variation in time of psychological and emotional consequences during treatment|measure the level of knowledge on the implications of participating in a clinical trial (case)","Centre Oscar Lambret","All","18 Years and older   (Adult, Senior)","","125","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IPSY 0905","March 2011","January 2014","February 2014","July 2016","May 23, 2012","May 25, 2012","null","null","July 27, 2016","July 28, 2016","Oscar Lambret Center, Lille, Nord Pas de Calais, France|Paul PAPIN Center, Angers, France|François Baclesse Center, Caen, France|CHOLET Hospital, Cholet, France|Georges-François LECLERC Center, Dijon, France|Léon BERARD Center, Lyon, France|Val D'AURELLE Center, Montpellier, France|Jean GODINOT Institut, Reims, France","https://ClinicalTrials.gov/show/NCT01606033"
73,"NCT00460694","Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies","alloCIK","Completed","No Results Available","Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia|Non Hodgkin's Lymphoma|Hodgkin's Disease|Myelodysplastic Syndrome|Multiple Myeloma","Biological: infusion of allogeneic CIK cells","Feasibility of expansion of frozen donor mononuclear cells into CIK|Toxicity including GVHD and marrow aplasia|Efficacy in terms of disease response as compared to previous treatment modality ie unmanipulated DLI","Singapore General Hospital|National Medical Research Council (NMRC), Singapore","All","12 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIK#2/2007|NMRC/1097/2006","August 2006","December 2012","December 2012","February 2017","April 12, 2007","April 16, 2007","null","null","February 9, 2017","February 10, 2017","Singapore General Hospital, Singapore, Singapore","https://ClinicalTrials.gov/show/NCT00460694"
74,"NCT01908387","Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms","null","Terminated","No Results Available","Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia|Multiple Myeloma|Non-Hodgkin Lymphoma|Hodgkin Lymphoma","Drug: Oral azacitidine","Dose limiting toxicities|Number of participants with adverse events.|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - AUCt|Pharmacokinetics - AUC Zero to Infinity|Pharmacokinetics - AUCext%|Pharmacokinetics - Terminal Phase|Pharmacokinetics - Terminal Half-Life|Pharmacokinetics - Total Clearance|Pharmacokinetics - Volume of distribution|Pharmacokinetics - Aet|Pharmacokinetics - fet|Pharmacokinetics - Renal Clearance|Investigator's response assessment","Celgene Corporation|Celgene","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","2","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-486-MDS-001","July 2013","July 2015","July 2015","July 2015","July 23, 2013","July 25, 2013","null","null","July 24, 2015","July 28, 2015","National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan","https://ClinicalTrials.gov/show/NCT01908387"
75,"NCT00001872","Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease","null","Recruiting","No Results Available","Graft vs Host Disease|Hematologic Neoplasm","","","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult)","","40","NIH","Observational","Time Perspective: Prospective","990037|99-H-0037","February 2, 1999","null","null","November 27, 2017","November 3, 1999","November 4, 1999","null","null","November 28, 2017","November 29, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00001872"
76,"NCT00592046","A Phase I Trial of ZIO-101 in Hematologic Cancers","null","Completed","No Results Available","Acute Leukemia|Chronic Myeloproliferative Disease|Chronic Lymphoproliferative Disease|Multiple Myeloma|Lymphoma|Poor-risk Myelodysplasia (MDS)","Drug: ZIO-101 (Darinaparsin)","Response Rate|The RECIST criteria will be used for patients with all leukemias and myelodysplastic syndromes.|Patients with lymphoma or myeloma will be assessed by the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas.|EBMT, IBMTR and ABMTR criteria for definition of response, relapse and progression in patients with multiple myeloma .","Ziopharm","All","18 Years and older   (Adult, Senior)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGL1001","May 2005","June 2008","June 2008","July 2012","December 26, 2007","January 11, 2008","null","null","July 18, 2012","July 19, 2012","Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00592046"
77,"NCT02678338","CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies","null","Recruiting","No Results Available","Acute Myeloid Leukemia|Myelodysplastic Syndrome","Drug: Hu5F9-G4","Maximum tolerated dose (MTD) of Hu5F9‐G4, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Part A)","Forty Seven, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCI-CD47-002|2015-000720-29","November 2015","March 2018","August 2018","August 2017","January 27, 2016","February 9, 2016","null","null","August 10, 2017","August 11, 2017","University Hospital of Wales, Cardiff, United Kingdom|St. James University Hospital, Leeds, United Kingdom|The Royal Liverpool University Hospital, Liverpool, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Churchill Hospital, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT02678338"
78,"NCT02494258","A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.","null","Recruiting","No Results Available","Hematologic Neoplasm|Neoplasms","Drug: CC-486","Adverse Events (AEs)|Overall Survival","Celgene","All","18 Years and older   (Adult, Senior)","Phase 2","125","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-486-GEN-001","October 22, 2015","November 30, 2020","December 31, 2020","October 2017","July 8, 2015","July 10, 2015","null","null","October 27, 2017","October 31, 2017","University of Florida College of Med, Gainesville, Florida, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|MD Anderson Cancer Center, Houston, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States","https://ClinicalTrials.gov/show/NCT02494258"
79,"NCT00440765","VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands","null","Completed","No Results Available","Multiple Myeloma|Hematological Neoplasms","Drug: bortezomib","Response to treatment; determination of response, duration of response, determination of relapse/progression|bortezomib treatment schedule used|combination therapies for multiple myeloma|adverse events|overall survival","Janssen-Cilag B.V.","All","18 Years and older   (Adult, Senior)","Phase 4","331","Industry","Observational","Observational Model: Case-Only","CR003469|26866138MMY4001","November 2004","January 2012","January 2012","January 2014","February 26, 2007","February 27, 2007","null","null","January 13, 2014","January 14, 2014","'S-Hertogenbosch, Netherlands|Alkmaar, Netherlands|Amersfoort, Netherlands|Amstelveen, Netherlands|Amsterdam Zuidoost, Netherlands|Apeldoorn, Netherlands|Bergen Op Zoom, Netherlands|Blaricum, Netherlands|Breda, Netherlands|Capelle Aan Den Ijss, Netherlands|Delfzijl, Netherlands|Den Haag, Netherlands|Deventer, Netherlands|Dirksland, Netherlands|Doetinchem, Netherlands|Dordrecht, Netherlands|Drachten, Netherlands|Ede Gld, Netherlands|Eindhoven, Netherlands|Geldrop, Netherlands|Goes, Netherlands|Gouda, Netherlands|Groningen, Netherlands|Hardenberg, Netherlands|Heerenveen, Netherlands|Hoofddorp, Netherlands|Hoogeveen, Netherlands|Leiden, Netherlands|Maastricht, Netherlands|Nieuwegein, Netherlands|Nijmegen, Netherlands|Oss, Netherlands|Roosendaal, Netherlands|Rotterdam, Netherlands|Schiedam, Netherlands|Terneuzen, Netherlands|Tilburg, Netherlands|Utrecht, Netherlands|Veghel, Netherlands|Veldhoven, Netherlands|Vlissingen, Netherlands|Woerden, Netherlands|Zaandam, Netherlands|Zutphen, Netherlands","https://ClinicalTrials.gov/show/NCT00440765"
80,"NCT00440479","ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.","null","Completed","No Results Available","Multiple Myeloma|Hematological Neoplasms","Drug: Bortezomib","Response to treatment|bortezomib treatment schedule, dosing and timing|combination therapies for multiple myeloma|adverse events|overall survival","Janssen-Cilag B.V.","All","18 Years and older   (Adult, Senior)","Phase 4","11","Industry","Observational","Observational Model: Case-Only","CR012361|26866138MMY4013","September 2006","January 2011","January 2011","April 2015","February 26, 2007","February 27, 2007","null","null","April 15, 2015","April 16, 2015","Bergen Op Zoom, Netherlands|Breda, Netherlands|Ede Gld, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Terneuzen, Netherlands|Tilburg, Netherlands|Utrecht, Netherlands|Vlissingen, Netherlands","https://ClinicalTrials.gov/show/NCT00440479"
81,"NCT03219268","A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms","null","Recruiting","No Results Available","Advanced Solid Tumors|Hematologic Neoplasms","Biological: MGD013","Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03|Maximum Tolerated Dose|Area Under the Plasma Concentration versus Time Curve (AUC) of MGD013|Maximum Plasma Concentration (Cmax) of MGD013|Time to reach maximum (peak) plasma concentration (Tmax) of MGD013|Trough plasma concentration (Ctrough) of MGD013|Total body clearance of the drug from plasma (CL) of MGD013|Apparent volume of distribution at steady state (Vss) of MGD013|Terminal half-life (t1/2) of MGD013|Percent of patients with anti-drug antibody|Efficacy: Preliminary anti-tumor activity of MGD013","MacroGenics","All","18 Years and older   (Adult, Senior)","Phase 1","131","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CP-MGD013-01","August 23, 2017","February 2020","August 2022","December 2017","July 12, 2017","July 17, 2017","null","null","December 7, 2017","December 11, 2017","UCLA Hematology & Oncology Clinic, Los Angeles, California, United States|Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States|University of Chicago Medicine, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT03219268"
82,"NCT01855698","PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism","null","Recruiting","No Results Available","Hematologic Neoplasm|Acute Leukemia|Myelodysplastic Syndrome|Lymphoma|Multiple Myeloma","Other: Observation","Number of patients with progression of thrombosis.|Type of management strategy (including observation).|Dosage of the antithrombotic drugs.|Number of different types of hematologica neoplasms.|Number of types of arterial or venous thrombosis.|Level of platelet count.","Gruppo Italiano Malattie EMatologiche dell'Adulto","All","18 Years and older   (Adult, Senior)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","EMATO0213","June 2013","December 2017","December 2017","October 2017","May 14, 2013","May 16, 2013","null","null","October 16, 2017","October 17, 2017","S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI, Ancona, Italy|Divisione di Immunoematologia e Medicina Trasfusionale & Centro Trombosi - A.O. Papa Giovanni XXIII, Bergamo, Italy|US Dipartimentale - Centro per le malattie del sangue - Ospedale Civile - S.Giacomo, Castelfranco Veneto, Italy|Unità Operativa Complessa) - Medicina Generale - Sezione di Ematologia - Ospedale Versilia USL 12 Toscana, Lido di Camaiore, Italy|Azienda Ospedaliera Universitaria - Policlinico G. Martino Dipartimento di Medicina Interna - U.O. Messina, Messina, Italy|N. Osp. divisione di Ematologia ""S.Gerardo dei Tintori!"", Monza, Italy|Ospedale San Gennaro - ASL Napoli 1, Napoli, Italy|U.O. di Ematologia con trapianto - Centro di Riferimento Regionale per le coagulopatie rare nel bambino e nell'adulto Dipart. Biomedico di Medicina Interna - A.U. Policlinico ""Paolo Giaccone"", Palermo, Italy|Cattedra di Ematologia CTMO Università degli Studi di Parma, Parma, Italy|Med. Int. ed Oncologia Medica IRCCS Policlinico S. Matteo, Pavia, Italy|Università di Pisa - Azienda Ospedaliera Pisana - Dipartimento di Oncologia, dei Trapianti e delle nuove Tecnologie in Medicina - Divisione di Ematologia, Pisa, Italy|Ematologia - Ospedale San Carlo, Potenza, Italy|Az. Ospedaliera ""Sant' Andrea""-Università la Sapienza Seconda Facoltà di Medicina e Chirurgia, Roma, Italy|Divisione Ematologia - Università Campus Bio-Medico, Roma, Italy|Padiglione Cesalpino - I piano - Divisione di Ematologia - Ospedale S. Camillo, Roma, Italy|Università Cattolica del Sacro Cuore - Policlinico A. Gemelli, Roma, Italy|Università Cattolica di Roma, Roma, Italy|Università degli Studi ""Sapienza"" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia, Roma, Italy|Università degli Studi - Policlinico di Tor Vergata, Roma, Italy|UOC Medicina Trasfusionale e Cellule Staminali Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Divisione di Ematologia dell' Università degli Studi di Torino - ""Città della Salute e della Scienza di Torino"", Torino, Italy|ULSS N. 6 Osp. S. Bortolo, Vicenza, Italy","https://ClinicalTrials.gov/show/NCT01855698"
83,"NCT02842229","A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms","null","Completed","No Results Available","Myelodysplastic Syndromes|Leukemia Myeloid Acute|Multiple Myeloma|Leukemia, Lymphocytic, Chronic, B-Cell","","Assessment of the tolerability of the treatment administered|The score of number of drugs on the Geriatric Assessment in Haematology (GAH) scale|The time of gait velocity on the Geriatric Assessment in Haematology (GAH) scale|The score of activities of daily living on th Geriatric Assessment in Haematology (GAH) scale|The score of subjective health status on the Geriatric Assessment in Haematology (GAH) scale|The score of nutrition on the Geriatric Assessment in Haematology (GAH) scale|The score of mental State on the Geriatric Assessment in Haematology (GAH) scale|The score of comorbidity on the Geriatric Assessment in Haematology (GAH) scale|Therapeutic approach according to clinical judgment|Discontinuation of the planned treatment due to toxicity|Modification of the planned treatment regimen due to toxicity|Percentage of patients with toxicity|Number of participants visit to hospital as a result of toxicity","Celgene","All","65 Years and older   (Adult, Senior)","","117","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","CEL-GAH-2016-01","July 20, 2016","February 2, 2017","February 2, 2017","July 2017","June 21, 2016","July 22, 2016","null","null","July 24, 2017","July 26, 2017","Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Durán I Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Parc Taulí, Sabadell, Barcelona, Spain|C. H. Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Canarias, San Cristóbal de la Laguna, Tenerife, Spain|Hospital Ntra. Sra. La Candelaria, Santa Cruz de Tenerife, Tenerife, Spain|Hospital La Ribera, Alzira, Valencia, Spain|Hospital Vall d' Hebrón, Barcelona, Spain|C.H. Universitario A Coruña, La Coruña, Spain|Hospital U. Gregorio Marañón, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital de Segovia, Segovia, Spain|Hospital La Fe, Valencia, Spain|Hospital Txagorritxu, Vitoria, Álava, Spain","https://ClinicalTrials.gov/show/NCT02842229"
84,"NCT00526045","Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients","null","Completed","No Results Available","Breast Cancer|Hematologic Neoplasms","Drug: AUY922","The safe dose of AUY922 when administered once a week|Efficacy of AUY922 administered once a week|Pharmacokinetics of AUY922 and Pharmacodynamics by PET response, blood and tumor biomarkers at baseline and post-AUY922","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","117","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAUY922A2101|2006-002766-20","July 2007","April 2012","April 2012","May 2013","September 5, 2007","September 6, 2007","null","null","May 10, 2013","May 14, 2013","UCLA/ University of California Los Angeles UCLA, Los Angeles, California, United States|Georgia Health Sciences University Med College of GA, Augusta, Georgia, United States|Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101, Boston, Massachusetts, United States|Washington University School Of Medicine-Siteman Cancer Ctr Dept. of Siteman Cancer Ctr., St. Louis, Missouri, United States|Nevada Cancer Institute Clinical Trials Office, Las Vegas, Nevada, United States|MD Anderson Cancer Center/University of Texas Thoractic Head/Neck Med.Onc(2), Houston, Texas, United States|Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3), San Antonio, Texas, United States|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Bellinzona, Switzerland|Novartis Investigative Site, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT00526045"
85,"NCT01166009","Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries","null","Recruiting","No Results Available","Autologous Stem Cell Transplantation|Allogeneic Stem Cell Transplantation|Solid Tumors|Blood Cancers","","A Comprehensive Source of Observational Data to assess Stem Cell Transplant|A Comprehensive Source of Data for Marrow Toxic Injuries","Center for International Blood and Marrow Transplant Research","All","Child, Adult, Senior","","99999999","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NMDP IRB-1999-0021","July 2002","July 2020","July 2020","October 2016","July 16, 2010","July 20, 2010","null","null","June 13, 2017","June 14, 2017","Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT01166009"
86,"NCT02240537","Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer","BBMPI03","Active, not recruiting","No Results Available","Acute Myelogenous Leukemia (AML)|Multiple Myeloma (MM)|Myelodysplastic Syndrome (MDS)|Smoldering Multiple Myeloma (sMM)","Drug: Sargramostim|Drug: BB-MPI-03|Drug: Montanide","Determine the safety, dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and optimal biologic dose (OBD) of BB-MPI-03 and adjuvants in subjects with hematologic cancers who are off treatment and with stable disease (SD) or better.|Determine the in vivo cellular immune response profile of BB-MPI-03 and adjuvants in subjects who receive 5 and 6 intradermal (ID) injections over a 6- month period.|Evaluate any anti-tumor activity of BB-MPI-03 and adjuvants as assessed by disease reduction and lack of disease progression during and after treatment.","Benovus Bio, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","4","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BBMPI03-Hem-01","January 2015","December 2016","June 2017","April 2016","September 9, 2014","September 15, 2014","null","null","April 18, 2016","April 19, 2016","University of Chicago, Chicago, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States","https://ClinicalTrials.gov/show/NCT02240537"
87,"NCT00003395","Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm","Drug: arsenic trioxide","","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","17 Years and older   (Child, Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","98-023|CDR0000066395|NCI-G98-1449","April 1998","March 2000","March 2000","June 2013","November 1, 1999","August 16, 2004","null","null","June 24, 2013","June 25, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00003395"
88,"NCT02333058","Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies","null","Active, not recruiting","No Results Available","Acute Lymphoblastic Leukaemias (ALL)|Acute Myeloid Leukaemias (AML)|Myelodysplastic Syndromes (MDS)|Juvenile Myelomonocytic Leukaemias (JMML)","Drug: Treosulfan","Freedom from transplant (treatment)-related mortality (TRM)|Engraftment after HSCT|Safety including early toxicity until day +100 after HSCT, serious adverse reactions (SARs) until the end of the longer-term follow-up phase|Hepatic sinusoidal obstruction syndrome (HSOS), lung toxicity (CTCAE term pulmonary fibrosis), hepatic toxicity and infections of any CTCAE grade (non-serious and serious)|Donor-type chimerism|Non relapse mortality (NRM), transplant related mortality (TRM), graft failure rate, incidence of relapse/progression, relapse-free/progression-free survival (RFS/PFS) and overall survival (OS)|Incidence and severity of acute (until day +100) and chronic (until 12 months after HSCT) graft versus host disease (aGvHD/cGvHD)|Use of rescue therapies including donor-lymphocyte infusions (DLIs) and further conditioning regimens|PK parameters of Treosulfan and its epoxides","medac GmbH|Celerion|INC Research","All","up to 17 Years   (Child)","Phase 2","70","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC-FludT.17/M","July 2014","September 2017","September 2019","January 2017","December 22, 2014","January 7, 2015","null","null","January 20, 2017","January 23, 2017","St. Anna Children Hospital, Vienna, Austria|University Hospital Motol, Charles University, Prague, Prague, Czech Republic|University Clinic Düsseldorf, Düsseldorf, Germany|University Clinic Erlangen-Nürnberg, Erlangen, Germany|University Hospital Johann Wolfgang Goethe, Frankfurt, Germany|University Clinic Hamburg-Eppendorf, Hamburg, Germany|Medical University Hannover, Hannover, Germany|University Clinic Heidelberg, Heidelberg, Germany|University Clinic Jena, Jena, Germany|University Clinic München, München, Germany|Univercity Clinic Münster, Münster, Germany|University Clinic Regensburg, Regensburg, Germany|University Clinic Ulm, Ulm, Germany|University Clinic Würzburg, Würzburg, Germany|Ospedale Bambino Gesu Roma, Rome, Italy|Ospedale Infantile Regina Margherita Torino, Turin, Italy|Bydgoszcz Medical University, Bydgoszcz, Poland|Kraków Medical University, Kraków, Poland|Lublin Medical University, Lublin, Poland|Wroclaw Medical University, Wroclaw, Poland|Birmingham Children's Hospital, Birmingham, United Kingdom|Central Manchester University Hospital, Manchester, United Kingdom|Sheffield Children's Hospital, Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT02333058"
89,"NCT00230321","A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)","null","Completed","No Results Available","Blood Cancer|Myelodysplastic Syndromes|Myelodysplastic Syndromes (MDS)","Drug: Darbepoetin alfa","hemoglobin and/or red blood cell (RBC) transfusion-dependence.|To assess erythroid responses to DARBEPOETIN ALFA, as determined by changes in|To assess bone marrow progenitor BFU-E growth before and after treatment|DARBEPOETIN ALFA","Peter L Greenberg|Amgen|Stanford University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","21","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HEMMDS0001|13536","February 2002","November 2007","January 2008","January 2013","September 28, 2005","September 30, 2005","null","null","January 31, 2013","February 4, 2013","Stanford University School of Medicine, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT00230321"
90,"NCT02443831","CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies","null","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Burkitt Lymphoma","Procedure: Leukapheresis|Drug: Lymphodepletion with fludarabine|Drug: Lymphodepletion with cyclophosphamide|Biological: CD19 CAR T-cells","Toxicity evaluation following CD19CAR T-cell infusion|Molecular remission|Long term molecular remission|Frequency of circulating CD19 CAR T-cells|Incidence of hypogammaglobulinaemia|Relapse rate|Overall Survival","University College, London","All","up to 24 Years   (Child, Adult)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCL 14/0529","April 2016","April 2018","December 2028","September 2016","April 29, 2015","May 14, 2015","null","null","September 1, 2016","September 2, 2016","Great Ormond Street Hospital, London, United Kingdom|University College Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT02443831"
91,"NCT00001873","The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers","null","Completed","No Results Available","Chronic Lymphocytic Leukemia|Graft vs Host Disease|Hematologic Neoplasm|Multiple Myeloma|Myelodysplastic Syndrome","Device: Isolex 300i plus MoAbs","The proportion of patients with clinically significant acute GHVD (Grade II or higher) following the T depleted PBPC transplant (and before D45 add-back).","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","10 Years to 55 Years   (Child, Adult)","Phase 2","102","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","990046|99-H-0046","February 22, 1999","December 28, 2007","June 13, 2017","June 13, 2017","November 3, 1999","November 4, 1999","null","null","October 5, 2017","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00001873"
92,"NCT01021683","The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants","null","Completed","Has Results","Hematologic Neoplasms|Neutropenia|Fever","Drug: Itraconazole","Percentage of Participants Achieving Plasma Level of Itraconazole at 1000 Nanogram Per Milliliter (ng/mL) or Higher After Administration of Study Treatment|Percentage of Participants With Deferevescence After Administration of Study Treatment|Mean Time to Defervescence in Participants Who Received the Study Treatment|Duration of Neutropenia|Absolute Neutrophil Count (ANC)|Percentage of Participants With Defervescence by Plasma Level of Itraconazole|Plasma Concentration of Itraconazole by Overall Success Rate (OSR) in Participants Who Received the Study Treatment|Percentage of Participants With Baseline Fungal Infection|Plasma Concentration of Itraconazole by Breakthrough Fungal Infection","Janssen Korea, Ltd., Korea","All","20 Years and older   (Adult, Senior)","Phase 4","203","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CR016597|ITR-KOR-5085|ITRFUN4049","July 2009","July 2010","July 2010","July 2013","November 25, 2009","November 30, 2009","April 15, 2013","July 3, 2013","July 24, 2013","August 12, 2013","","https://ClinicalTrials.gov/show/NCT01021683"
93,"NCT02773342","An Evaluation of Sequential Computed Tomography of the Chest in Management of Invasive Pulmonal Aspergillosis in Neutropenic Patients With Haematological Malignancies","null","Not yet recruiting","No Results Available","Invasive Aspergillosis","","Overall survival (%)","University Hospital of Cologne","All","18 Years and older   (Adult, Senior)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CT_IPA_NEUT","June 2013","April 2016","null","May 2016","May 6, 2013","May 16, 2016","null","null","May 13, 2016","May 16, 2016","University Hospital of Cologne, Cologne, North Rhine-Westphalia, Germany","https://ClinicalTrials.gov/show/NCT02773342"
94,"NCT02034981","Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1","AcSé","Recruiting","No Results Available","Hematologic Cancers|Solid Tumors|Metastatic Cancer","Drug: Crizotinib","The efficacy of crizotinib as a single agent across diverse type of tumors guided by the presence of identified activating molecular alterations in the crizotinib target genes, per cohort, per pathology, and per target.|The safety profile of crizotinib.|Disease control rate|response duration|Progression-free survival|Overall survival","UNICANCER|National Cancer Institute, France|Fondation ARC|Pfizer","All","1 Year and older   (Child, Adult, Senior)","Phase 2","488","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UC-0105/1303|2013-000885-13","August 2013","December 2016","July 2019","February 2016","October 16, 2013","January 14, 2014","null","null","February 16, 2016","February 17, 2016","Gustave Roussy, Villejuif, Ile de France, France","https://ClinicalTrials.gov/show/NCT02034981"
95,"NCT02304809","Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations","AcSé","Recruiting","No Results Available","Solid Tumors|Hematologic Cancers|Metastatic Cancers","Drug: Vemurafenib","The objective response rate (ORR) will be defined as the proportion of patients with a complete response (CR) or a partial response (PR) as best overall response during the study|Safety profile of Vemurafenib (frequency of adverse events coded using the common toxicity criteria (CTC-V4.0) grade)","UNICANCER|National Cancer Institute, France|Fondation ARC|Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","500","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UC-0105/1401|2014 001225 33","July 2014","February 2016","February 2022","February 2016","November 26, 2014","December 2, 2014","null","null","February 15, 2016","February 17, 2016","Tredaniel, Paris, France","https://ClinicalTrials.gov/show/NCT02304809"
96,"NCT00185796","TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD","null","Completed","No Results Available","Myeloproliferative Disorders|Blood Cancer|Myelodysplastic Syndromes","Procedure: Total Lymphoid Irradiation (TLI)|Procedure: Anti-Thymocyte Globulin as Conditioning (ATG)","To improve survival outcome for selected patients with advanced stages of MDS and MPD with non-myeloablative allogeneic HCT from related and unrelated donors.|To evaluate the feasibility and safety of TLI/ATG conditioning for allogeneic HCT for elderly patients or those with co-morbid conditions that preclude myeloablative transplantation for advanced stage MDS and MPD.|To evaluate myeloid and platelet engraftment.|To evaluate the incidence of acute and chronic GVHD.|To evaluate the rate of primary and secondary graft failure.|To evaluate the rate of relapse, survival and event-free survival.|To evaluate if DLI can be used safely in patients with mixed chimerism.","Stanford University|National Institutes of Health (NIH)","All","49 Years to 75 Years   (Adult, Senior)","Phase 2","77","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BMT168|95130|13680","July 2004","April 2014","February 2015","March 2015","September 12, 2005","September 16, 2005","null","null","March 16, 2015","March 18, 2015","Stanford University School of Medicine, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT00185796"
97,"NCT01336478","CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation","null","Withdrawn","No Results Available","Haematological Malignancies|Allogeneic Stem Cell Transplant|CD56+CD3- NK Cells","Procedure: Infusion of donor derived ex-vivo selected NK cells to patients after transplant|Procedure: Haematology / Blood chemistry sampling","Safety and toxicity donor CD56+CD3- NK cells|Donor neutrophil and platelet engraftment|Rates of acute GVHD (grade 2-4)|Relapse rate","Imperial College London","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JROHH0203","April 2011","June 2014","June 2014","March 2012","March 22, 2011","April 18, 2011","null","null","June 3, 2015","June 8, 2015","Hammersmith Hospital, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01336478"
98,"NCT01772771","Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program","null","Recruiting","No Results Available","Invasive Cancer|Sarcoma|Hematologic Cancer","","Database of Somatic Mutations and Clinical Characteristics","M.D. Anderson Cancer Center","All","Child, Adult, Senior","","8000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PA11-0852","March 2012","March 2032","March 2032","August 2017","January 14, 2013","January 21, 2013","null","null","August 25, 2017","August 28, 2017","University of Texas MD Anderson Cancer Center/Regional Cancer Centers, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT01772771"
99,"NCT00957580","Trial of Pimasertib in Hematological Malignancies","null","Terminated","Has Results","Leukemia, Myeloid, Acute|Hematologic Neoplasms","Drug: Pimasertib","Part 1: Number of Subjects With Dose Limiting Toxicities (DLTs)|Part 2: Percentage of Subjects With Best Overall Response|Part 1: Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Permanent Treatment Discontinuation|Part 1: Maximum Plasma Concentration (Cmax) of Pimasertib Single Dose|Part 1: Maximum Plasma Concentration (Cmax) of Pimasertib Multiple Dose|Part 1: Time to Reach Maximum Plasma Concentration (Tmax): Single Dose|Part 1: Time to Reach Maximum Plasma Concentration (Tmax): Multiple Dose|Part 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Single Dose|Part 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Multiple Dose|Part 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Single Dose|Part 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Multiple Dose|Part 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Single Dose|Part 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Multiple Dose|Part 1: Apparent Oral Clearance (CL/f) of Pimasertib: Single Dose|Part 1: Apparent Oral Clearance (CL/f) of Pimasertib for Pimasertib 75 mg Reporting Arm: Single Dose|Part 1: Apparent Oral Clearance (CL/f) of Pimasertib: Multiple Dose|Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib:Single Dose|Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib for Pimasertib 75 mg Reporting Arm:Single Dose|Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib: Multiple Dose|Part 1: Percentage of Subjects With Best Overall Response|Part 2: Number of Subjects With TEAEs, Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Permanent Treatment Discontinuation","EMD Serono","All","18 Years and older   (Adult, Senior)","Phase 2","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EMR200066_002|2009-010866-49","September 30, 2009","December 31, 2012","December 31, 2012","July 2017","August 11, 2009","August 12, 2009","July 4, 2016","March 29, 2017","July 19, 2017","August 21, 2017","Northwestern University, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Hospital Hotel Dieu, Service D'Hematologie, Nantes, Cedex, France|Hospital Edouard Herriot, Service d'Hematologie Clinique, Lyon Cedex, France|Hospital Saint Louis, Service des Maladies du Sang, Paris, France|CHU du Haut-Leveque, Service des Maladies du Sang Unite de Recherche Clinique, Pessac, France","https://ClinicalTrials.gov/show/NCT00957580"
100,"NCT03288441","Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia","MATTER","Not yet recruiting","No Results Available","Hematologic Neoplasms|Thrombocytopenia|Anticoagulants|Platelet Aggregation Inhibitors","Drug: Hold|Drug: Prophylactic dose antithrombotic|Drug: Change antithrombotic Drug|Biological: Change platelet transfusion threshold|Drug: Full dose antithrombotics|Device: Mechanical measures|Drug: Intermediate dose antithrombotic","Composite of major bleeding or thrombosis|Platelet transfusion related adverse effects|Clinically Relevant non-Major Bleeding|Number of platelet tranfusions|Number of RBC tranfusions|Death|Change in antithrombotic management","Maastricht University Medical Center","All","18 Years and older   (Adult, Senior)","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","METC 17-4-061","December 2017","December 2018","April 2020","November 2017","September 7, 2017","September 20, 2017","null","null","November 13, 2017","November 14, 2017","Seattle Cancer Care Alliance, Seattle, Washington, United States|Rabin Medical Center, Petaẖ Tiqwa, Israel|A.O. Papa Giovanni XXIII - S.I.M.T., Bergamo, Italy|Maastricht University Medical Center (MUMC+), Maastricht, Netherlands|HagaZiekenhuis, The Hague, Netherlands","https://ClinicalTrials.gov/show/NCT03288441"
101,"NCT00387153","Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer","null","Terminated","Has Results","Cancer","Drug: MPC-2130","Number of Subjects With Dose Limiting Toxicities and Grade 3/4 Adverse Events. As a General Guideline, a Severe Adverse Event is Considered Grade 3, and a Life Threatening or Disabling Adverse Event is Considered Grade 4.|Pharmacokinetics|Antiproliferative Activity","Myriad Therapeutics, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","8","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MPC-2130-04-002","August 2005","October 2006","October 2006","October 2009","October 10, 2006","October 12, 2006","June 23, 2009","October 22, 2009","October 27, 2009","November 3, 2009","MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00387153"
102,"NCT00348959","An Evaluation of the Effect of 'Open Window' on Psychological Well-being and Experience of Stem Cell Transplantation","null","Completed","No Results Available","Hematological Malignancies","Behavioral: 'Open Window' Project","The primary outcome measures are Anxiety, Depression and Distress. Measures will be taken on 7 occasions over a six month period.|Patient expectations in relation to the experience of having a stem cell transplant.","St. James's Hospital, Ireland|Irish Cancer Society","All","16 Years and older   (Child, Adult, Senior)","","198","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","PSY04MCC","August 2006","January 2010","January 2010","June 2012","July 5, 2006","July 6, 2006","null","null","June 12, 2012","June 13, 2012","St. James's Hospital, Dublin, Ireland","https://ClinicalTrials.gov/show/NCT00348959"
103,"NCT00968630","Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer","null","Completed","No Results Available","Hematopoietic and Lymphoid Cell Neoplasm|HIV Infection","Other: Laboratory Biomarker Analysis|Procedure: Leukapheresis","Quantification of donor-derived HIV-1-specific immune responses following HCT|Quantification of latently infected CD4+ cells in HIV+ patients","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Institute of Allergy and Infectious Diseases (NIAID)","All","Child, Adult, Senior","Phase 2","9","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2212.00|NCI-2009-01244|2212|P01CA018029|P30CA015704|U19AI096111","December 17, 2009","March 17, 2017","March 17, 2017","May 2017","August 28, 2009","August 31, 2009","null","null","May 22, 2017","May 24, 2017","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00968630"
104,"NCT01790568","Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant","null","Active, not recruiting","Has Results","Graft vs Host Disease|Hematologic Neoplasms|Non-Neoplastic Hematologic and Lymphocytic Disorder","Drug: Vorinostat|Drug: Tacrolimus|Drug: Methotrexate","Percentage of Patients That Experience Grade 2-4 GVHD Within 100 Days of Transplant|Percentage of Patients Alive at 1 Year|Non-Relapse Mortality Incidence","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UMCC 2012.047|HUM00070080","December 2014","January 1, 2017","July 2018","December 2017","October 2, 2012","February 13, 2013","November 17, 2017","January 1, 2018","December 28, 2017","January 1, 2018","University of Michigan Cancer Center, Ann Arbor, Michigan, United States","https://ClinicalTrials.gov/show/NCT01790568"
105,"NCT00001397","Evaluation, Treatment, and Training for Patients With Blood Disorders","null","Recruiting","No Results Available","Hematologic Disease|Hematologic Neoplasm|Pancytopenia","","","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","2 Years and older   (Child, Adult, Senior)","","99999999","NIH","Observational","","940010|94-H-0010","October 20, 1993","null","null","November 27, 2017","November 3, 1999","November 4, 1999","null","null","November 28, 2017","November 29, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00001397"
106,"NCT01597219","Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers","UK-Haplo","Recruiting","No Results Available","Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Acute Myeloid Leukaemia|Acute Lymphoblastic Leukaemia|Myelodysplastic Syndrome|Chronic Myeloid Leukaemia|Chronic Lymphocytic Leukaemia|Acquired Bone Marrow Failure Syndromes|Other Haematological Malignancies; Unrelated HSCT Indicated","Procedure: Reduced intensity haplodentical stem cell transplant|Procedure: Myeloablative haploidentical stem cell transplant","Overall survival","University College, London|Bloodwise","All","16 Years to 70 Years   (Child, Adult, Senior)","Phase 2","78","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCL/10/0411","March 2013","March 2018","March 2020","April 2017","May 10, 2012","May 11, 2012","null","null","April 26, 2017","April 27, 2017","Birmingham Heartlands, Birmingham, United Kingdom|Bristol Royal Infirmary, Bristol, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Beatson Hospital, Glasgow, United Kingdom|St James' University Hospital, Leeds, United Kingdom|Royal Liverpool Hospital, Liverpool, United Kingdom|King's College Hospital, London, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|University College Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Freeman Hospital, Newcastle, United Kingdom|Royal Hallamshire, Sheffield & Weston Park, Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT01597219"
107,"NCT03087227","Shared Health Information System for Febrile Neutropenia","NEUTROSIS","Recruiting","No Results Available","Febrile Neutropenia|Solid Tumor|Hematologic Neoplasms","Device: NEUTROSIS","average length of hospital stay for febrile neutropenia|hospitalisation rate|healthcare use rate|Use rate","Marie-Helene METZGER|Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|University of Paris 13","All","18 Years and older   (Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","16-009","February 22, 2017","November 30, 2018","February 28, 2019","September 2017","February 20, 2017","March 22, 2017","null","null","September 7, 2017","September 8, 2017","Hôpital Antoine Béclère, Clamart, France|Hôpital BICETRE, Le Kremlin-Bicêtre, France","https://ClinicalTrials.gov/show/NCT03087227"
108,"NCT02033928","Comprehensive Frailty Assessment","null","Active, not recruiting","No Results Available","Myeloma, Multiple|Paraproteinemias|Hematologic Neoplasms","","Change in Comprehensive Frailty Assessment|Time to progression","Ohio State University Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","","111","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","OSU-13135","April 2014","June 2017","null","September 2016","December 18, 2013","January 13, 2014","null","null","September 21, 2016","September 22, 2016","The Ohio State University Hospital East, Columbus, Ohio, United States|The Ohio State University, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT02033928"
109,"NCT00001432","The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies","null","Completed","No Results Available","Chronic Myeloid Leukemia|Healthy|Hematologic Neoplasm|Lymphoma","","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","","75","NIH","Observational","","950086|95-C-0086","March 1995","null","November 2003","November 2003","November 3, 1999","November 4, 1999","null","null","March 3, 2008","March 4, 2008","National Cancer Institute (NCI), Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00001432"
110,"NCT03333486","Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer","null","Recruiting","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Leukemia in Remission|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia With FLT3/ITD Mutation|Acute Myeloid Leukemia With Gene Mutations|Aplastic Anemia|B-Cell Non-Hodgkin Lymphoma|CD40 Ligand Deficiency|Chronic Granulomatous Disease|Chronic Leukemia in Remission|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Congenital Amegakaryocytic Thrombocytopenia|Congenital Neutropenia|Congenital Pure Red Cell Aplasia|Glanzmann Thrombasthenia|Immunodeficiency Syndrome|Myelodysplastic Syndrome|Myelofibrosis|Myeloproliferative Neoplasm|Paroxysmal Nocturnal Hemoglobinuria|Plasma Cell Myeloma|Polycythemia Vera|Recurrent Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome|Severe Aplastic Anemia|Shwachman-Diamond Syndrome|Sickle Cell Disease|T-Cell Non-Hodgkin Lymphoma|Thalassemia|Waldenstrom Macroglobulinemia|Wiskott-Aldrich Syndrome","Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Procedure: Peripheral Blood Stem Cell Transplantation|Radiation: Total-Body Irradiation","Relapse rate|Engraftment rate|Incidence of acute graft versus host disease (GVHD)|Incidence of chronic GVHD|Overall survival|Progression free survival|Transplant related mortality","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","1 Year to 75 Years   (Child, Adult, Senior)","Phase 2","58","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 40916|NCI-2017-01949|P30CA016056","December 7, 2017","September 6, 2021","September 6, 2022","December 2017","November 2, 2017","November 7, 2017","null","null","December 7, 2017","December 11, 2017","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT03333486"
111,"NCT02130492","A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)","null","Recruiting","No Results Available","Radiosensitive Stage IV Solid and Hematological Tumors With High FDG Uptake Not Responding to Standard of Care|Lung Cancer, Head and Neck Cancer, Breast Cancer, Gastric Cancer, Pancreatic Cancer, Colon Cancer, Lymphomas, Sarcomas, Etc","Radiation: FDG","Number of Participants with Serious and Non-Serious Adverse Events and Type of Serious and Non-Serious Adverse Events|Efficacy Outcome Measure","Northwell Health","All","21 Years and older   (Adult, Senior)","Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB# 13-382A","May 2014","July 2019","July 2019","September 2017","May 1, 2014","May 5, 2014","null","null","September 8, 2017","September 11, 2017","North Shore LIJ Cancer Institute, Lake Success, New York, United States|NSLIJ Monter Cancer Institute, Lake Success, New York, United States","https://ClinicalTrials.gov/show/NCT02130492"
112,"NCT01251575","Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant","null","Recruiting","No Results Available","Adult Acute Lymphoblastic Leukemia|Adult Acute Myeloid Leukemia|Adult Diffuse Large B-Cell Lymphoma|Adult Myelodysplastic Syndrome|Adult Non-Hodgkin Lymphoma|Aggressive Non-Hodgkin Lymphoma|Childhood Acute Lymphoblastic Leukemia|Childhood Acute Myeloid Leukemia|Childhood Diffuse Large B-Cell Lymphoma|Childhood Myelodysplastic Syndrome|Childhood Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia in Remission|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid Cell Neoplasm|Mantle Cell Lymphoma|Plasma Cell Myeloma|Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|T-Cell Prolymphocytic Leukemia|Waldenstrom Macroglobulinemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Hodgkin Lymphoma","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclosporine|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Sirolimus|Radiation: Total-Body Irradiation","Rate of grade II-IV acute graft versus host disease (GVHD) in human leukocyte antigen (HLA) class I or II mismatched nonmyeloablative transplants|Rate of grade III-IV acute GVHD","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","80","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2206.00|NCI-2010-02222|P01CA018029|P30CA015704","December 1, 2010","November 30, 2018","null","October 2017","November 29, 2010","December 2, 2010","null","null","October 30, 2017","November 1, 2017","Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|VA Puget Sound Health Care System, Seattle, Washington, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States|Rigshospitalet University Hospital, Copenhagen, Denmark","https://ClinicalTrials.gov/show/NCT01251575"
113,"NCT00421213","Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers","null","Completed","No Results Available","Hematologic Neoplasms|Bone Marrow Neoplasms|Non-Hodgkin's Lymphoma","Drug: Darinaparsin","Response Rate|toxicities","Ziopharm","All","18 Years and older   (Adult, Senior)","Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SGL2003","December 2006","April 2012","April 2012","July 2012","January 10, 2007","January 11, 2007","null","null","July 18, 2012","July 19, 2012","Miami, Florida, United States|Chicago, Illinois, United States|Bethesda, Maryland, United States|Fargo, North Dakota, United States|Sioux Falls, South Dakota, United States|Morgantown, West Virginia, United States","https://ClinicalTrials.gov/show/NCT00421213"
114,"NCT01326728","Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation","null","Terminated","No Results Available","Chronic Myelogenous Leukemia|Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia|Hodgkins Lymphoma|Non-Hodgkins Lymphoma","","Provide a mechanism for systematic, comprehensive evaluation of individuals with relapsed hematologic malignancy after allotransplant","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","","56","NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","110125|11-C-0125","March 30, 2011","null","October 19, 2017","October 19, 2017","March 30, 2011","March 31, 2011","null","null","October 20, 2017","October 23, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT01326728"
115,"NCT02260414","Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer","METRO B","Completed","No Results Available","Lymphoma|Multiple Myeloma","Drug: Tinzaparin|Other: Blood sample","Endogenous Thrombin Potential (ETP, nM.min) for all patients with de novo myeloma with high thrombotic risk|Endogenous Thrombin Potential (ETP, nM.min) for all patients with aggressive lymphoma treated with chemotherapy|Endogenous Thrombin Potential (ETP, nM.min) for all patients with over 40 years hospitalized for heart or respiratory failure|Differences of Endogenous Thrombin Potential (ETP, nM.min) between group 1 and group 2 et 3","Centre Hospitalier Universitaire de Saint Etienne|LEO Pharma","All","18 Years and older   (Adult, Senior)","Phase 2","19","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","1408049|2014-000946-31","April 14, 2015","May 9, 2017","May 9, 2017","May 2017","October 2, 2014","October 9, 2014","null","null","May 10, 2017","May 11, 2017","CHU de Saint-Etienne, Saint-Etienne, France","https://ClinicalTrials.gov/show/NCT02260414"
116,"NCT02066259","OctavaColon Cancer Blood Tests OctavaGold and OctavaSilver - Blood Tests for the Help in Diagnosis of Colon Cancer Clinical Study Protocol","null","Recruiting","No Results Available","Colon Cancer","","Number of participants in each of the clinicaly defined groups (0,1 and 2).","Eventus Diagnostics Ltd","All","18 Years and older   (Adult, Senior)","","1080","Industry","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","OctavaColon_001","August 2014","March 2016","March 2018","August 2014","February 9, 2014","February 19, 2014","null","null","August 4, 2014","August 5, 2014","Soroka Medical Center, Beer Sheva, Israel|""Carmel"" Medical Center, Haifa, Israel|Sheba Tel hashomer, Ramat gan, Israel","https://ClinicalTrials.gov/show/NCT02066259"
117,"NCT03195010","Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia","null","Enrolling by invitation","No Results Available","Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|B-Cell Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematologic and Lymphocytic Disorder|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome|Primary Myelofibrosis|Secondary Myelofibrosis|T-Cell Non-Hodgkin Lymphoma|Thrombocytopenia|Venous Thromboembolism","Biological: Platelet Transfusion","Number of eligible patients approached for the study|Number of patients consenting to enrollment|Number of patients eligible|Number of patients successfully following protocol|Number of patients screened and deemed ineligible|Number of patients approached for but refusing consent|Incidence of hemorrhagic events (World Health Organization grade 2 or greater)|Major bleeds (World Health Organization grade 3 or 4)|Number of platelet transfusions per patient during the study period|Percent of days on which subjects are transfused (or transfusion are not given)|Platelet transfusion related complications|Progressive or new arterial thromboembolism|Progressive or new venous thromboembolic","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","12","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","9799|NCI-2017-00864|P30CA015704","June 9, 2017","October 5, 2018","October 5, 2018","June 2017","June 13, 2017","June 22, 2017","null","null","June 21, 2017","June 23, 2017","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT03195010"
118,"NCT01953692","A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)","null","Active, not recruiting","No Results Available","Myelodysplastic Syndrome|Multiple Myeloma|Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Primary Mediastinal B-Cell Lymphoma","Biological: Pembrolizumab|Drug: Lenalidomide","Number of Participants Experiencing Adverse Events (AEs)|Number of Participants Discontinuing Treatment due to an AE|Cohort 1: Objective Response Rate (ORR) Based on International Working Group (IWG) Criteria for MDS|Cohort 2: ORR based on International Myeloma Working Group (IMWG) criteria|Cohort 3: Complete Remission Rate (CRR) Based on Revised Response Criteria for Malignant Lymphoma|Cohort 4: ORR Based on Revised Response Criteria for Malignant Lymphoma|Cohort 5: ORR Based on Revised Response Criteria for Malignant Lymphoma","Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 1","207","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3475-013|2013-001603-37|MK-3475-013","November 22, 2013","June 10, 2022","June 10, 2022","December 2017","September 26, 2013","October 1, 2013","null","null","December 15, 2017","December 19, 2017","","https://ClinicalTrials.gov/show/NCT01953692"
119,"NCT00539656","Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers","Cord Blood","Terminated","No Results Available","Acute Myeloid Leukemia|Leukemia, Lymphoblastic, Acute|Leukemia, Bilineage, Acute|Leukemia, Myeloid, Chronic","Device: Ex vivo expansion of cord blood","Toxicities related to Infusion of Expanded Cord Blood Products|Neutrophil Engraftment within 21 days|Non-relapse mortality","Sidney Kimmel Comprehensive Cancer Center","All","6 Months to 55 Years   (Child, Adult)","Phase 1|Phase 2","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J0606|NA00001903","October 2007","December 2010","null","October 2013","October 2, 2007","October 4, 2007","null","null","October 24, 2013","October 28, 2013","Johns Hopkins Hospital, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00539656"
120,"NCT01792882","Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples","GBCPRT0008","Enrolling by invitation","No Results Available","Breast Cancer|Colorectal Cancer|Lung Cancer|Prostate Cancer|Hematologic Cancer","","Tumor genetic sequence variation|Transcription profile","Global BioClinical","All","18 Years to 90 Years   (Adult, Senior)","","100","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","GBC PRT0008","February 2013","December 2018","December 2018","December 2017","February 6, 2013","February 15, 2013","null","null","December 4, 2017","December 6, 2017","GBC, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT01792882"
121,"NCT00038376","Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies","null","Terminated","No Results Available","Lymphoma, T-Cell|Mycosis Fungoides|Hematologic Neoplasms","Drug: Isotretinoin (Accutane)|Drug: Interferon Alpha","To determine if the drug combination of alpha-interferon and isotretinoin is effective in controlling T-cell malignancies.","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DM90-007","May 1990","June 2005","June 2005","July 2012","May 30, 2002","May 31, 2002","null","null","July 27, 2012","July 31, 2012","M. D. Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00038376"
122,"NCT01499303","Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer","null","Completed","Has Results","Diffuse Large B-Cell Lymphoma","Drug: Fostamatinib","Objective Response Rate","AstraZeneca","All","18 Years and older   (Adult, Senior)","Phase 2","101","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D4302C00001","December 2011","October 2013","October 2013","August 2014","December 19, 2011","December 26, 2011","June 17, 2014","August 22, 2014","August 8, 2014","August 22, 2014","Research Site, Huntsville, Alabama, United States|Research Site, Denver, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Sarasota, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Iowa City, Iowa, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Rochester, Minnesota, United States|Research Site, St. Louis, Missouri, United States|Research Site, Hackensack, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Columbus, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, London, United Kingdom|Research Site, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01499303"
123,"NCT02999854","Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer","HATCY","Recruiting","No Results Available","Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome","Biological: ATIR101|Drug: Cyclophosphamide|Procedure: T-cell depleted HSCT from a related, haploidentical donor|Procedure: T-cell replete HSCT from a related, haploidentical donor","Graft-versus-host disease-free, relapse-free survival (GRFS)|Overall survival (OS)|Progression-free survival (PFS)|Relapse-related mortality (RRM)|Transplant-related mortality (TRM)","Kiadis Pharma","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","195","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CR-AIR-009|2016-004672-21","November 29, 2017","May 2020","May 2020","December 2017","December 19, 2016","December 21, 2016","null","null","December 20, 2017","December 21, 2017","Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium|Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium|Institut Jules Bordet, Brussels, Belgium|Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada|University Hospital Frankfurt, Goethe University, Frankfurt, Germany|University Medical Center Mainz, Mainz, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal|University Hospital Barcelona Vall d' Hebron, Barcelona, Spain|Hospital Puerta de Hierro Majadahonda, Madrid, Spain|Servicio de Hematología Hospital, Universitari I politècnic La Fe, Valencia, Spain|Heartlands Hospital, Birmingham, United Kingdom|St James University Hospital, Leeds, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|Hammersmith Hospital, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT02999854"
124,"NCT00089596","Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers","null","Completed","No Results Available","Acute Lymphocytic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Non-Hodgkin Lymphoma|Chronic Myelogenous Leukemia","Procedure: Expansion of umbilical cord stem cells","","ViaCell","All","12 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CB001","March 2004","null","October 2006","April 2007","August 6, 2004","August 10, 2004","null","null","April 11, 2007","April 12, 2007","Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT00089596"
125,"NCT00861965","Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match Alternative to Allogeneic Transplant for Blood Cancers","null","Withdrawn","No Results Available","Advanced or Refractory Leukemia, Lymphoma, Multiple Myeloma","Biological: AlloStim-8","To evaluate the safety of administration of an intravenous AlloStim-9 infusion and to define any drug-related toxicity and reversibility of such toxicity|evaluate the safety of administration of up to three consecutive daily intravenous AlloStim-8 booster infusions in patients that previously received a infusion of AlloStim-9 and to define any drug-related toxicity and reversibility of such toxicity|evaluate the anti-tumor effect of AlloStim infusions by evaluating the objective response rates","Immunovative Therapies, Ltd.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ITL-001-HM","January 2010","November 2012","null","April 2015","March 12, 2009","March 16, 2009","null","null","April 1, 2015","April 3, 2015","Immunovative Clinical Research, Inc, Carlsbad, California, United States","https://ClinicalTrials.gov/show/NCT00861965"
126,"NCT00849147","Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)","null","Completed","Has Results","Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Myeloid, Acute|Burkitt Lymphoma|Lymphoma, B-Cell|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse","Biological: Haploidentical Bone Marrow Transplantation|Biological: GVHD prophylaxis","Overall Survival at 180 Days From the Time of Transplant|Neutrophil Recovery|Primary Graft Failure|Secondary Graft Failure|Platelet Recovery|Donor Cell Engraftment|Acute Graft-versus-host Disease (GVHD)|Chronic GVHD|Progression-free Survival|Treatment-related Mortality (TRM)|Infections","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program","All","1 Year to 70 Years   (Child, Adult, Senior)","Phase 2","55","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BMTCTN0603|U01HL069294|5U24CA076518","October 2008","June 2011","November 2013","August 2016","February 20, 2009","February 23, 2009","May 20, 2015","September 7, 2015","November 28, 2017","December 22, 2017","City of Hope National Medical Center, Duarte, California, United States|University of California San Diego Medical Center, La Jolla, California, United States|University of Florida College of Medicine (Shands), Gainesville, Florida, United States|Bone Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, Georgia, United States|Kapi'olani Medical Center for Women and Children, University of Hawaii, Honolulu, Hawaii, United States|University of Maryland, Greenbaum Cancer Center, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center (SKCCC), Baltimore, Maryland, United States|DFCI, Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Children's Hospital of Michigan, Detroit, Michigan, United States|Washington University, Barnes Jewish Hospital, Saint Louis, Missouri, United States|Oregon Health & Science University, Portland, Oregon, United States|Fox Chase, Temple University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|Texas Transplant Institute, San Antonio, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00849147"
127,"NCT01767467","Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers","null","Completed","Has Results","Herpes Zoster","Biological: Herpes zoster vaccine (GSK 1437173A)|Drug: Placebo","Vaccine Response Rates (VRR) for Anti-gE Antibody ELISA Concentrations|Adjusted Geometric Mean Concentration of Anti-gE Antibodies|Number of Subjects With Any and Grade 3 Solicited Local Symptoms.|Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.|Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs).|Number of Subjects With Serious Adverse Events (SAEs).|Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)|Number of Days With Solicited Local Symptoms|Number of Days With Solicited General Symptoms|Occurrence of Confirmed HZ Cases|Number of Subjects With Antibody Titer Equal to or Above Cut-off|Anti-gE Antibody Concentration|Concentrations of Anti-gE Antibodies|Frequency of gE -Specific Cluster of Differentiation 4+ T Cells (CD4+) Expressing at Least 2 Activation Markers|Vaccine Response Rates (VRR) for gE-specific CD4 [2+] T-cells, Expressing at Least 2 Activation Markers.|Anti-gE Humoral Immunogenicity in Subjects With Confirmed HZ and Matched Controls|Number of Subjects With Serious Adverse Events (SAEs)","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 3","568","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","116428|2012-003438-18","March 1, 2013","January 7, 2016","January 6, 2017","March 2017","January 10, 2013","January 14, 2013","January 5, 2017","May 25, 2017","April 21, 2017","May 25, 2017","GSK Investigational Site, Inverness, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Elkhart, Indiana, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Marshfield, Wisconsin, United States|GSK Investigational Site, Darlinghurst, New South Wales, Australia|GSK Investigational Site, Hobart, Tasmania, Australia|GSK Investigational Site, Coburg, Victoria, Australia|GSK Investigational Site, Wodonga, Victoria, Australia|GSK Investigational Site, Antwerpen, Belgium|GSK Investigational Site, Brugge, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Hasselt, Belgium|GSK Investigational Site, Jette, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Saint John, New Brunswick, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Oshawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Praha 2, Czechia|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Tampere, Finland|GSK Investigational Site, Montpellier cedex 5, France|GSK Investigational Site, Mulhouse, France|GSK Investigational Site, Nantes cedex 1, France|GSK Investigational Site, Pessac cedex, France|GSK Investigational Site, Périgueux cedex, France|GSK Investigational Site, Rouen cedex 1, France|GSK Investigational Site, Hong Kong, Hong Kong|GSK Investigational Site, Meldola (FC), Emilia-Romagna, Italy|GSK Investigational Site, Udine, Friuli-Venezia-Giulia, Italy|GSK Investigational Site, Novara, Piemonte, Italy|GSK Investigational Site, Busan, Korea, Republic of|GSK Investigational Site, Daegu, Korea, Republic of|GSK Investigational Site, Incheon, Korea, Republic of|GSK Investigational Site, Jellanamdo, Korea, Republic of|GSK Investigational Site, Jeonju, Korea, Republic of|GSK Investigational Site, Kyunggi-do, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Christchurch, New Zealand|GSK Investigational Site, Hamilton, New Zealand|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Multan, Pakistan|GSK Investigational Site, Panama, Panama|GSK Investigational Site, Chorzow, Poland|GSK Investigational Site, Opole, Poland|GSK Investigational Site, Slupsk, Poland|GSK Investigational Site, Ekaterinburg, Russian Federation|GSK Investigational Site, Nizhniy Novgorod, Russian Federation|GSK Investigational Site, Petrozavodsk, Russian Federation|GSK Investigational Site, St'Petersburg, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Móstoles, Madrid, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, Pozuelo de Alarcón/Madrid, Spain|GSK Investigational Site, Santander, Spain|GSK Investigational Site, Eskilstuna, Sweden|GSK Investigational Site, Karlskrona, Sweden|GSK Investigational Site, Malmö, Sweden|GSK Investigational Site, Uppsala, Sweden|GSK Investigational Site, Kaohsiung, Taiwan|GSK Investigational Site, Taichung, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taoyuan Hsien, Taiwan|GSK Investigational Site, Ankara, Turkey|GSK Investigational Site, Ankara, Turkey|GSK Investigational Site, Orpington, Kent, United Kingdom|GSK Investigational Site, Airdrie, Lanarkshire, United Kingdom|GSK Investigational Site, Swindon, Wiltshire, United Kingdom|GSK Investigational Site, Bournemouth, United Kingdom|GSK Investigational Site, Headington, Oxford, United Kingdom|GSK Investigational Site, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01767467"
128,"NCT00001637","Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults","null","Completed","No Results Available","Chronic Lymphocytic Leukemia|Graft vs Host Disease|Leukemia|Myelodysplastic Syndrome|Myeloid Leukemia","Procedure: Blood cell transplantation","The proportion of patients with clinically significant acute GHVD (Grade II or higher) following the T depleted PBPC transplant.","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","55 Years to 71 Years   (Adult, Senior)","Phase 2","28","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","970202|97-H-0202","September 29, 1997","July 28, 2008","December 28, 2016","December 28, 2016","November 3, 1999","November 4, 1999","null","null","October 5, 2017","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00001637"
129,"NCT02806791","Efficacy of Biosimilar Filgrastim on the Mobilization of Hematopoietic Stem Cell CD34+ (Cluster of Differentiation 34) and on the Kinetic Engraftment","null","Active, not recruiting","No Results Available","Blood Diseases","Drug: FILGRASTIM","Collection of autologous stem cells (time the median of achieving> 20 CD34 + / ul circulating)|Trend in blood counts after discharge values|Collection of autologous stem cells (total hematopoietic stem cells CD34 + * 10 ^ 6 / kg collected)|Collection of autologous stem cells (the median time from the first day of chemotherapy mobilizing)|Collection of autologous stem cells (the median number of leukapheresis performed)|Collection of autologous stem cells (median number of white blood cells)|Collection of autologous stem cells ( with the aid of Plerixafor)|Engraftment after autologous transplantation (granulocyte and platelet engraftment)|Engraftment after autologous transplantation ( median time to achieve neutrophils> 500)|Engraftment after autologous transplantation (the median number of days of G-CSF administration)|Engraftment after autologous transplantation (median number of days of aplasia)|Engraftment after autologous transplantation (median length of stay)|Engraftment after autologous transplantation (number of transfusions)|transplant-related mortality|Overall survival (overall survival, OS)","Azienda Ospedaliera San Giovanni Battista","All","Child, Adult, Senior","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","BIO-AUTO 06-15","May 2016","May 2016","null","June 2016","May 31, 2016","June 21, 2016","null","null","June 20, 2016","June 21, 2016","Aou Citta' Della Salute E Della Scienza Di Torino, Divisione Di Ematologia, Sscvd Trapianto Allogenico, Torino, Italy","https://ClinicalTrials.gov/show/NCT02806791"
130,"NCT00962494","Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors","null","Completed","No Results Available","Blood Cancer|Breast Cancer|Prostatic Neoplasms|Colorectal Neoplasms|Neoplasms","Behavioral: Cancer: Thriving and Surviving Online Workshop","Document patterns of health care utilization|Quality of Life|Outcome Measure: Better Interactions with Oncologists|Health Behaviors|Satisfaction with intervention","Stanford University|University of Hawaii Cancer Research Center","All","19 Years and older   (Adult, Senior)","Phase 2","585","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","VAR0044|SU-07292009-3460","July 2009","August 2011","December 2011","February 2013","August 18, 2009","August 20, 2009","null","null","February 5, 2013","February 7, 2013","Stanford University School of Medicine, Stanford, California, United States|Macmillan Cancer Support, London, UK, United Kingdom","https://ClinicalTrials.gov/show/NCT00962494"
131,"NCT00618969","Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors","null","Completed","No Results Available","Hematologic Neoplasms|Anemia, Aplastic|Hemoglobinuria, Paroxysmal|Multiple Myeloma","Other: haploidentical allogeneic PBSC transp","The primary efficacy endpoint is the presence of donor lymphohematopoietic chimerism (defined as at least 50% donor cells in the peripheral blood)in peripheral blood by day +100.|To determine the safety of haploidentical related allogeneic PBSCT using a preparative regimen of busulfan, melphalan and alemtuzumab.","University of Arizona","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIO 07-122","February 2008","December 2013","February 2016","March 2016","February 8, 2008","February 20, 2008","null","null","March 1, 2016","March 3, 2016","Arizona Cancer Center/University Medical Center, Tucson, Arizona, United States","https://ClinicalTrials.gov/show/NCT00618969"
132,"NCT01553461","Transplants With Unlicensed Preserved Cord Blood","null","Recruiting","No Results Available","Myelodysplastic Syndrome (MDS)|Hematologic Neoplasms|Hematologic Diseases|Severe Aplastic Anemia","Procedure: Cord Blood Transplant","To examine the incidence of neutrophil recovery of greater than or equal to 500/mm (3) after unlicensed CBU transplant.|Assess incidence of graft rejection, transmission of infection, serious infusion reactions.|Determine 1 year survival.|Assess cumulative incidence of acute GVHD (grades II to IV), (grades III to IV), and incidence of chronic GVHD.","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","up to 99 Years   (Child, Adult, Senior)","Phase 1|Phase 2","500","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","120064|12-H-0064","February 2, 2012","October 20, 2036","October 20, 2036","November 24, 2017","March 13, 2012","March 14, 2012","null","null","November 25, 2017","November 28, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT01553461"
133,"NCT00075478","Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer","null","Completed","Has Results","Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia in Remission|Aggressive Non-Hodgkin Lymphoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Diffuse Large B-Cell Lymphoma|Hematopoietic and Lymphoid Cell Neoplasm|Indolent Non-Hodgkin Lymphoma|Mantle Cell Lymphoma|Myelodysplastic/Myeloproliferative Neoplasm|Plasma Cell Myeloma|Refractory Chronic Lymphocytic Leukemia|Refractory Hodgkin Lymphoma|Waldenstrom Macroglobulinemia","Procedure: Total-Body Irradiation|Drug: Fludarabine Phosphate|Drug: Mycophenolate Mofetil|Drug: Cyclosporine|Procedure: Peripheral Blood Stem Cell Transplantation","Overall Survival|Incidence of Non-relapse Mortality|Incidence of Relapse/Progression|Incidence of Relapse-related Mortality|Incidence of Grades II-IV Acute GVHD|Incidence of Chronic Extensive GVHD|Incidence of Graft Rejection|Progression-free Survival","Fred Hutchinson Cancer Research Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)","All","up to 75 Years   (Child, Adult, Senior)","Phase 3","87","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1813.00|NCI-2009-01532|P30CA015704|P01CA078902","October 2003","February 2014","February 2, 2014","April 2017","January 9, 2004","January 12, 2004","April 16, 2014","May 19, 2014","April 7, 2017","May 15, 2017","OHSU Cancer Institute-Southern Region, Medford, Oregon, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|VA Puget Sound Health Care System, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Medizinische Univ Klinik Koln, Koln, Germany|Universitaet Leipzig, Leipzig, Germany|University of Tuebingen-Germany, Tuebingen, Germany|University of Torino, Torino, Italy","https://ClinicalTrials.gov/show/NCT00075478"
134,"NCT00089011","Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer","null","Active, not recruiting","Has Results","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage I Small Lymphocytic Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage IIA Mycosis Fungoides/Sezary Syndrome|Stage IIB Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Small Lymphocytic Lymphoma|Stage IIIA Mycosis Fungoides/Sezary Syndrome|Stage IIIB Mycosis Fungoides/Sezary Syndrome|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Stage IVA Mycosis Fungoides/Sezary Syndrome|Stage IVB Mycosis Fungoides/Sezary Syndrome|Testicular Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies|Waldenström Macroglobulinemia","Drug: fludarabine phosphate|Radiation: total-body irradiation|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: peripheral blood stem cell transplantation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Other: laboratory biomarker analysis","Incidence of Grade III/IV GVHD|Incidence of Chronic Extensive GVHD|Incidences of Graft Rejection|Overall Survival|Incidences of Grades II-IV Acute GVHD|Rates of Disease Progression|Rates of Relapse-related Mortality|Rate and Duration of Steroid Use for the Treatment of Chronic GVHD","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 74 Years   (Child, Adult, Senior)","Phase 2","150","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1898.00|NCI-2010-00267|P01CA078902|P30CA015704","April 2004","March 2014","October 1, 2018","December 2017","August 4, 2004","August 5, 2004","April 14, 2017","May 22, 2017","December 5, 2017","January 1, 2018","Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|VA Puget Sound Health Care System, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States|University of Torino, Torino, Italy","https://ClinicalTrials.gov/show/NCT00089011"
135,"NCT00028418","Clofarabine in Chronic Lymphocytic Leukemia","null","Completed","No Results Available","Hematologic Neoplasms|Lymphoproliferative Disorders|Leukemia|Leukemia, Lymphocytic, Chronic","Drug: Clofarabine","","M.D. Anderson Cancer Center|FDA Office of Orphan Products Development","All","18 Years and older   (Adult, Senior)","Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","FD-R-1972-01|DM93-036; FD-R-001972-01","February 1999","null","March 2004","November 2001","January 4, 2002","January 9, 2002","null","null","March 24, 2015","March 25, 2015","University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00028418"
136,"NCT00923442","Biology Studies of Hematologic Cancers","null","Enrolling by invitation","No Results Available","Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome (MDS)|Non-Hodgkins Lymphoma|Acute Myelogenous Leukemia|Hodgkins Lymphoma","","Tissue acquisition for lab investigations","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","up to 75 Years   (Child, Adult, Senior)","","178","NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","040102|04-C-0102","January 22, 2004","null","null","September 28, 2017","June 17, 2009","June 18, 2009","null","null","October 11, 2017","October 12, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00923442"
137,"NCT00898508","Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease","null","Active, not recruiting","No Results Available","Breast Cancer","Genetic: gene expression analysis|Genetic: mutation analysis|Genetic: proteomic profiling|Genetic: reverse transcriptase-polymerase chain reaction|Other: fluorescent antibody technique|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: liquid chromatography|Other: mass spectrometry|Other: medical chart review|Procedure: quality-of-life assessment","Establishment of a specimen bank|Ability of the quantitative real-time reverse-transcriptase PCR (qRT-PCR) to distinguish between biopsy benign and malignant results|Ability of the qRT-PCR to predict treatment response|Ability of the qRT-PCR to predict relapse|Ability of the qRT-PCR to perform as an independent prognostic factor","City of Hope Medical Center|National Cancer Institute (NCI)","Female","20 Years and older   (Adult, Senior)","","910","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","04125|P30CA033572|CHNMC-04125|CDR0000628766","August 2005","November 2020","November 2020","December 2017","May 9, 2009","May 12, 2009","null","null","December 13, 2017","December 15, 2017","Tower Cancer Research Foundation, Beverly Hills, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|City of Hope Medical Group, Pasadena, California, United States","https://ClinicalTrials.gov/show/NCT00898508"
138,"NCT03377010","UF-BMT-HSCT-001: A Non-Interventional Study Evaluating Diet in HSCT Survivors","null","Not yet recruiting","No Results Available","Hematopoietic Neoplasm","Other: Dietary intake -Food Frequency Questionnaire|Other: Receptivity to Participating in Diet Interventions","Diet intake","University of Florida","All","18 Years to 99 Years   (Adult, Senior)","","300","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","IRB201702189|UF-BMT-HSCT-001","January 2018","January 2021","January 2022","December 2017","December 13, 2017","December 19, 2017","null","null","December 18, 2017","December 20, 2017","UF Health Cancer Center, Gainesville, Florida, United States","https://ClinicalTrials.gov/show/NCT03377010"
139,"NCT03032783","A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity","null","Recruiting","No Results Available","Hematopoietic and Lymphoid Cell Neoplasm","Radiation: Total-Body Irradiation|Procedure: Donor Lymphocyte Infusion|Drug: Cyclophosphamide|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation","Overall Survival (OS)|Incidence of graft failure|Incidence of non-relapse mortality","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 2","42","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16D.606","January 31, 2017","July 24, 2020","July 24, 2020","November 2017","January 24, 2017","January 26, 2017","null","null","November 17, 2017","November 21, 2017","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT03032783"
140,"NCT02310997","Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)","MAC UCBT","Terminated","No Results Available","Leukaemia|Lymphoma|Other Haematological Diseases","Other: Umbilical Cord Blood Transplant|Drug: Cyclophosphamide|Radiation: Total body irradiation|Drug: Busulfan|Drug: Melphalan|Drug: Fludarabine","Non-relapse mortality at 100 days post transplant|Overall survival at 1 year|Time course of mixed chimerism established by the donor graft|Recovery from neutropenia and cytopenia|Incidence of acute and chronic GVHD|Incidence of relapse","University College, London|Cancer Research UK","All","up to 45 Years   (Child, Adult)","Phase 2","11","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCL/09/0128|2009-011818-21","July 2011","May 2015","May 2015","May 2015","September 18, 2014","December 8, 2014","null","null","May 26, 2015","May 27, 2015","University College London Hospital, London, Greater London, United Kingdom|University Hospital Birmingham, Birmingham, United Kingdom|Bristol Haematology & Oncology Centre, Bristol, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|St James' University Hospital, Leeds, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|Great Ormond Street Hospital for Children, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT02310997"
141,"NCT00723099","Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer","null","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Aggressive Non-Hodgkin Lymphoma|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Indolent Non-Hodgkin Lymphoma|Lymphoma|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Recurrent Chronic Lymphocytic Leukemia|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Follicular Lymphoma|Refractory Hodgkin Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Small Lymphocytic Lymphoma|T-Cell Non-Hodgkin Lymphoma","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Cyclosporine|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Radiation: Total-Body Irradiation|Procedure: Umbilical Cord Blood Transplantation","Overall survival|Incidence of chronic GVHD for each arm|Incidence of clinically significant infections|Incidence of grade II-IV and III-IV acute GVHD for each arm|Incidence of graft failure/rejection|Incidence of neutrophil engraftment|Incidence of non-relapse mortality|Incidence of platelet engraftment|Incidence of relapse or disease progression|Progression-free survival","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 69 Years   (Child, Adult, Senior)","Phase 2","76","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2239.00|NCI-2009-01551|2239|P30CA015704","June 25, 2008","November 13, 2018","November 13, 2019","December 2017","July 25, 2008","July 28, 2008","null","null","December 12, 2017","December 14, 2017","University of Colorado Hospital, Aurora, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|LDS Hospital, Salt Lake City, Utah, United States|VA Puget Sound Health Care System, Seattle, Washington, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT00723099"
142,"NCT00918658","Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer","null","Terminated","No Results Available","Leukemia|Multiple Myeloma and Plasma Cell Neoplasm","Other: biologic sample preservation procedure|Other: immunologic technique|Other: laboratory biomarker analysis","Collection of normal and malignant cells to use as target cells in cytotoxicity assays","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","","34","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","CASE2Z08|P30CA043703|CASE-2Z08-CC502","April 2008","March 2011","March 2011","October 2015","June 10, 2009","June 11, 2009","null","null","October 8, 2015","October 9, 2015","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT00918658"
143,"NCT02071888","Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors","null","Completed","No Results Available","Non-Hodgkin's Lymphoma (NHL)|Multiple Myeloma|Waldenstrom's Macroglobulinemia (WM)|Diffuse Large B-cell Lymphoma (DLBCL),|Other B-cell NHL Subtypes, Including WM|T-cell NHL","Drug: CB-839|Drug: CB-839 and low dose dexamethasone|Drug: CB-839, pomalidomide, and low dose dexamethasone","Safety and tolerability of CB-839: Incidence of adverse events|Pharmacokinetics: Area under the Curve (AUC) of CB-839 concentration in blood|Pharmacodynamics: % inhibition of glutaminase in blood|Clinical activity: Change in tumor size from baseline","Calithera Biosciences, Inc","All","18 Years and older   (Adult, Senior)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CX-839-002","February 2014","April 2016","April 2016","April 2016","February 14, 2014","February 26, 2014","null","null","April 29, 2016","May 3, 2016","Mayo Clinic, Scottsdale, Arizona, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Winship Cancer Institute of Emory School of Medicine, Atlanta, Georgia, United States|John Theruer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT02071888"
144,"NCT00304018","Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Biological: sargramostim|Drug: busulfan|Drug: etoposide|Drug: fludarabine phosphate|Drug: prednisone|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation","Determine the safety and feasibility of performing donor umbilical cord blood transplantation (UCBT) in patients with advanced hematologic malignancies","University of California, San Francisco|National Cancer Institute (NCI)","All","18 Years to 55 Years   (Adult)","Phase 1","5","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000463370|UCSF-02253|UCSF-H24045-21269-04|UCSF-2207","October 2002","March 2009","March 2009","August 2013","March 15, 2006","March 17, 2006","null","null","August 13, 2013","August 14, 2013","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT00304018"
145,"NCT00423826","Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease","null","No longer available","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Secondary Myelofibrosis","Drug: Busulfan|Drug: Cytarabine|Drug: Fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation","","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","up to 69 Years   (Child, Adult, Senior)","","null","Other|NIH","Expanded Access","","CDR0000518230|P30CA022453|WSU-2006-059|WSU-112506MP2F","January 2007","January 2015","January 2015","February 2016","January 16, 2007","January 18, 2007","null","null","February 26, 2016","February 29, 2016","Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States","https://ClinicalTrials.gov/show/NCT00423826"
146,"NCT01137643","Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer","null","Recruiting","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Nonmalignant Neoplasm","Other: biologic sample preservation procedure|Other: cytology specimen collection procedure","Tissue, blood, and body fluid samples collection for ongoing diagnostic, prognostic, or immune-monitoring studies|Development of a centralized, quality-controlled, quality-assured facility for the procurement, processing, storage, and distribution of normal and malignant tissue specimens and corresponding blood specimens","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","","15000","Other|NIH","Observational","Observational Model: Other|Time Perspective: Prospective","LCCC 0824|P30CA016086|CDR0000674072","July 2009","July 2040","July 2040","September 2017","June 3, 2010","June 4, 2010","null","null","September 20, 2017","September 21, 2017","Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States","https://ClinicalTrials.gov/show/NCT01137643"
147,"NCT02976558","The Influence of TaKeTiNa Music Therapy, Traditional Chinese Acupuncture and Clown Theatrical Performance on Quality of Life and the Therapeutic Process of Patients Undergoing Allogenic Stem Cell Transplantation","TriCAM","Recruiting","No Results Available","Hematological Neoplasm|Graft-Versus-Host Disease|Depression|Stem Cell Transplant Complications|Quality of Life|Leukemia","Behavioral: Clown theatrical Performance|Procedure: Acupuncture|Behavioral: Music Therapy TaKeTiNa","Difference in the Quality of Life of the intervention group compared to the control group|Difference in development of GvHD of the intervention group compared to the control group|Difference in development of fungal infections of the intervention group compared to the control group|Difference in development of bacterial infections of the intervention group compared to the control group|Difference in development of viral infections including CMV and EBV of the intervention group compared to the control group|Difference in Depression of the intervention group compared to the control group|Impact of the diagnosis and therapy according to traditional chinese medicine on the difference in development of Infections of the intervention group compared to the control group|Impact of the diagnosis and therapy according to traditional chinese medicine on the difference in development of GvHD of the intervention group compared to the control group","University of Erlangen-Nürnberg Medical School","All","18 Years and older   (Adult, Senior)","","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCS Erlangen 0383","December 2016","November 2019","July 2020","December 2016","November 21, 2016","November 29, 2016","null","null","December 3, 2016","December 6, 2016","University of Erlangen Nuermberg Medical School, Erlangen, Bavaria, Germany","https://ClinicalTrials.gov/show/NCT02976558"
148,"NCT00008216","Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer","null","Terminated","No Results Available","Adult Langerhans Cell Histiocytosis|Childhood Langerhans Cell Histiocytosis|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Procedure: Peripheral Blood Stem Cell Transplantation","Toxicity|Time to engraftment|Clinical response|Survival rate|Number of participants with Graft-versus-host disease|Time to treatment failure and relapse","Columbia University|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","48","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","AAAA5571|CPMC-IRB-AAAA5571|CPMC-CAMP-016|NCI-G00-1891","July 1996","January 2009","January 2009","June 2014","January 6, 2001","January 27, 2003","null","null","June 5, 2014","June 6, 2014","Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00008216"
149,"NCT00290628","Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer","null","Terminated","No Results Available","Chronic Myeloproliferative Disorders|Diamond-blackfan Anemia|Fanconi Anemia|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Drug: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: filgrastim|Drug: melphalan|Drug: methylprednisolone|Drug: mycophenolate mofetil|Procedure: radiation therapy|Procedure: umbilical cord blood transplantation","","Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI)","All","up to 45 Years   (Child, Adult)","","43","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","2000LS017|UMN-MT1999-28","October 1999","April 2007","April 2007","November 2017","February 9, 2006","February 13, 2006","null","null","November 27, 2017","November 29, 2017","University of Minnesota Cancer Center, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00290628"
150,"NCT01521611","Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy","null","Recruiting","No Results Available","Acute Leukaemia|Chronic Leukaemia|Myeloma|Lymphoma","Radiation: Targeted radiotherapy","Toxicities related to radiolabelled antibody.|Dosimetry model","University Hospital Southampton NHS Foundation Trust|Royal Free and University College Medical School","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","55","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RHMCAN0227","March 2002","December 2017","December 2018","October 2016","January 26, 2012","January 30, 2012","null","null","October 14, 2016","October 17, 2016","Southampton University Hospitals NHS Trust, Southampton, Hampshire, United Kingdom|Royal Free Hospital and University College London, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01521611"
151,"NCT00827099","Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer","null","Terminated","Has Results","Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Drug: fludarabine phosphate|Drug: Melphalan|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: umbilical cord blood transplantation","Number of Participants With 100 Day Transplant-related Mortality (TRM)|Number of Patients That Engrafted Blood Counts by 30 Days After Transplant|Percentage of Donor and Host Chimerism of Each Cord Blood Unit|Number of Patients Who Experience Acute and Chronic Graft-vs-host Disease After Transplant.|Number of Patients Who Experience Disease Relapse Post-transplant|Number of Patients Who Survive Following Treatment on This Protocol","Northside Hospital, Inc.","All","18 Years to 65 Years   (Adult)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000632453|BMTGG-NSH-801","June 2006","November 2009","November 2009","March 2012","January 21, 2009","January 22, 2009","July 28, 2011","August 3, 2011","March 19, 2012","March 23, 2012","Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States","https://ClinicalTrials.gov/show/NCT00827099"
152,"NCT00602693","T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma|Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: umbilical cord blood transplantation|Drug: Allopurinol|Drug: fludarabine phosphate|Drug: Cyclophosphamide|Radiation: Total body irradiation|Biological: Treg infusion|Drug: Sirolimus","Maximum tolerated dose|Number of patients with detectable Treg cells|Number of Patients with grade II-IV and grade III-IV acute graft versus host disease (GVHD)|Number of patients with sustained donor engraftment|Number of patients with double chimerism|Incidence of neutrophil recovery after umbilical cord blood (UCB) transplantation|Number of Patients with Chronic Graft Versus Host Disease (GVHD)|Number of Patients with disease-free survival|Number of Patients with Fungal and Viral Infections|Incidence of platelet recovery after umbilical cord blood (UCB)|Number of Patients with Disease Relapse|Percent of Patients with Immune Cell Recovery","Masonic Cancer Center, University of Minnesota","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007LS022|MT2006-01|0701M00303","July 23, 2007","September 25, 2014","April 16, 2015","November 2017","January 10, 2008","January 28, 2008","null","null","November 29, 2017","December 1, 2017","Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00602693"
153,"NCT00919425","S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Other: biologic sample preservation procedure","Maintenance and expansion of tissue repositories of highly characterized samples from patients with ALL, CLL, AML, CML, or myelodysplastic syndromes","Southwest Oncology Group|National Cancer Institute (NCI)","All","Child, Adult, Senior","","1294","Other|NIH","Observational","","S9910|U10CA032102","April 1999","January 2012","January 2012","March 2015","June 11, 2009","June 12, 2009","null","null","March 5, 2015","March 6, 2015","Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Ft. Smith, Arkansas, United States|Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States|Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center, Burbank, California, United States|Peninsula Medical Center, Burlingame, California, United States|North Bay Cancer Center, Fairfield, California, United States|Sutter Health - Western Division Cancer Research Group, Novato, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|California Pacific Medical Center - California Campus, San Francisco, California, United States|Stanford Cancer Center, Stanford, California, United States|Sutter Solano Medical Center, Vallejo, California, United States|University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, United States|Memorial Hospital Cancer Center - Colorado Springs, Colorado Springs, Colorado, United States|Veterans Affairs Medical Center - Denver, Denver, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Front Range Cancer Specialists, Fort Collins, Colorado, United States|St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center, Grand Junction, Colorado, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|M.D. Anderson Cancer Center at Orlando, Orlando, Florida, United States|Phoebe Cancer Center at Phoebe Putney Memorial Hospital, Albany, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Northside Hospital Cancer Center, Atlanta, Georgia, United States|Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|WellStar Cobb Hospital, Austell, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|Kennestone Cancer Center at Wellstar Kennestone Hospital, Marietta, Georgia, United States|Southern Regional Medical Center, Riverdale, Georgia, United States|Harbin Clinic Cancer Center - Medical Oncology, Rome, Georgia, United States|Kapiolani Medical Center at Pali Momi, Aiea, Hawaii, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|OnCare Hawaii, Incorporated - Lusitana, Honolulu, Hawaii, United States|Queen's Cancer Institute at Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Incorporated, Honolulu, Hawaii, United States|Hawaii Medical Center - East, Honolulu, Hawaii, United States|OnCare Hawaii, Incorporated - Kuakini, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Castle Medical Center, Kailua, Hawaii, United States|Kauai Medical Clinic, Lihue, Hawaii, United States|Maui Memorial Medical Center, Wailuku, Hawaii, United States|Pacific Cancer Institute - Maui, Wailuku, Hawaii, United States|Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Mountain States Tumor Institute at St. Luke's Regional Medical Center, Boise, Idaho, United States|Saint Anthony's Hospital at Saint Anthony's Health Center, Alton, Illinois, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States|Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Regional Cancer Center at Memorial Medical Center, Springfield, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|St. Francis Hospital and Health Centers - Beech Grove Campus, Beech Grove, Indiana, United States|Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States|Reid Hospital & Health Care Services, Richmond, Indiana, United States|McFarland Clinic, PC, Ames, Iowa, United States|Medical Oncology and Hematology Associates - West Des Moines, Clive, Iowa, United States|Genesis Regional Cancer Center at Genesis Medical Center, Davenport, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas, PA - Liberal, Liberal, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's Hospital - South, Overland Park, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|CCOP - Kansas City, Prairie Village, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Tammy Walker Cancer Center at Salina Regional Health Center, Salina, Kansas, United States|Cotton-O'Neil Cancer Center, Topeka, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Lucille P. Markey Cancer Center at University of Kentucky, Lexington, Kentucky, United States|Tulane Cancer Center Office of Clinical Research, Alexandria, Louisiana, United States|Louisiana State University Health Sciences Center - Monroe, Monroe, Louisiana, United States|Feist-Weiller Cancer Center at Louisiana State University Health Sciences, Shreveport, Louisiana, United States|Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Battle Creek Health System Cancer Care Center, Battle Creek, Michigan, United States|Mecosta County Medical Center, Big Rapids, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Green Bay Oncology, Limited - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center, Grand Blanc, Michigan, United States|Butterworth Hospital at Spectrum Health, Grand Rapids, Michigan, United States|CCOP - Grand Rapids, Grand Rapids, Michigan, United States|Lacks Cancer Center at Saint Mary's Health Care, Grand Rapids, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Dickinson County Healthcare System, Iron Mountain, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|Mercy General Health Partners, Muskegon, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|University of Mississippi Cancer Clinic, Jackson, Mississippi, United States|Regional Cancer Center at Singing River Hospital, Pascagoula, Mississippi, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Truman Medical Center - Hospital Hill, Kansas City, Missouri, United States|Saint Luke's Cancer Institute at Saint Luke's Hospital, Kansas City, Missouri, United States|St. Joseph Medical Center, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Parvin Radiation Oncology, Kansas City, Missouri, United States|Heartland Hematology Oncology Associates, Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Hospital, Liberty, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Joseph Oncology, Incorporated, Saint Joseph, Missouri, United States|Midwest Hematology Oncology Group, Incorporated, Saint Louis, Missouri, United States|Saint Louis University Cancer Center, Saint Louis, Missouri, United States|CCOP - St. Louis-Cape Girardeau, Saint Louis, Missouri, United States|David C. Pratt Cancer Center at St. John's Mercy, Saint Louis, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Big Sky Oncology, Great Falls, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Methodist Estabrook Cancer Center, Omaha, Nebraska, United States|CCOP - Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States|Presbyterian Cancer Center at Presbyterian Hospital, Charlotte, North Carolina, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States|Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Kinston Medical Specialists, Kinston, North Carolina, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Iredell Memorial Hospital, Statesville, North Carolina, United States|McDowell Cancer Center at Akron General Medical Center, Akron, Ohio, United States|Mary Rutan Hospital, Bellefontaine, Ohio, United States|Mercy Cancer Center at Mercy Medical Center, Canton, Ohio, United States|Aultman Cancer Center at Aultman Hospital, Canton, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Charles M. Barrett Cancer Center at University Hospital, Cincinnati, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Medical Center Cancer Care, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital, Dayton, Ohio, United States|David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Cancer Care Center, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Blanchard Valley Medical Associates, Findlay, Ohio, United States|Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|St. Rita's Medical Center, Lima, Ohio, United States|MedCentral - Mansfield Hospital, Mansfield, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|Southern Ohio Medical Center Cancer Center, Portsmouth, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States|Mount Carmel St. Ann's Cancer Center, Westerville, Ohio, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Willamette Falls Hospital, Oregon City, Oregon, United States|Legacy Good Samaritan Hospital & Comprehensive Cancer Center, Portland, Oregon, United States|Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, United States|CCOP - Columbia River Oncology Program, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center and Children's Hospital, Portland, Oregon, United States|Northwest Cancer Specialists at Rose Quarter Cancer Center, Portland, Oregon, United States|Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|AnMed Cancer Center, Anderson, South Carolina, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|McLeod Regional Medical Center, Florence, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Medical X-Ray Center, PC, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|U.T. Medical Center Cancer Institute, Knoxville, Tennessee, United States|Baylor University Medical Center - Dallas, Dallas, Texas, United States|Baylor University Medical Center - Houston, Houston, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital, Houston, Texas, United States|Veterans Affairs Medical Center - Houston, Houston, Texas, United States|Veterans Affairs Medical Center - San Antonio (Murphy), San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University Hospital - San Antonio, San Antonio, Texas, United States|Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States|Danville Regional Medical Center, Danville, Virginia, United States|Island Hospital Cancer Care Center at Island Hospital, Anacortes, Washington, United States|St. Joseph Cancer Center, Bellingham, Washington, United States|Olympic Hematology and Oncology, Bremerton, Washington, United States|Highline Medical Center Cancer Center, Burien, Washington, United States|Providence Centralia Hospital, Centralia, Washington, United States|St. Francis Hospital, Federal Way, Washington, United States|Columbia Basin Hematology, Kennewick, Washington, United States|Skagit Valley Hospital Cancer Care Center, Mount Vernon, Washington, United States|Providence St. Peter Hospital Regional Cancer Center, Olympia, Washington, United States|Harrison Poulsbo Hematology and Onocology, Poulsbo, Washington, United States|Good Samaritan Cancer Center, Puyallup, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Minor and James Medical, PLLC, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Group Health Central Hospital, Seattle, Washington, United States|Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle, Washington, United States|University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States|North Puget Oncology at United General Hospital, Sedro-Woolley, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|Evergreen Hematology and Oncology, PS, Spokane, Washington, United States|Franciscan Cancer Center at St. Joseph Medical Center, Tacoma, Washington, United States|Allenmore Hospital, Tacoma, Washington, United States|CCOP - Northwest, Tacoma, Washington, United States|MultiCare Regional Cancer Center at Tacoma General Hospital, Tacoma, Washington, United States|Madigan Army Medical Center - Tacoma, Tacoma, Washington, United States|St. Clare Hospital, Tacoma, Washington, United States|Southwest Washington Medical Center Cancer Center, Vancouver, Washington, United States|Legacy Salmon Creek Medical Center, Vancouver, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Marshfield Clinic - Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Clinic Cancer Care at Regional Cancer Center, Eau Claire, Wisconsin, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States|Saint Joseph's Hospital, Marshfield, Wisconsin, United States|Marshfield Clinic - Lakeland Center, Minocqua, Wisconsin, United States|Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States|Ministry Medical Group at Saint Mary's Hospital, Rhinelander, Wisconsin, United States|Marshfield Clinic - Indianhead Center, Rice Lake, Wisconsin, United States|Marshfield Clinic at Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Marshfield Clinic - Wausau Center, Wausau, Wisconsin, United States|Diagnostic and Treatment Center, Weston, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Marshfield Clinic - Wisconsin Rapids Center, Wisconsin Rapids, Wisconsin, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States","https://ClinicalTrials.gov/show/NCT00919425"
154,"NCT00296023","Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Biological: filgrastim|Biological: therapeutic allogeneic lymphocytes|Drug: busulfan|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Toxicity and survival","University of California, San Francisco|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","","25","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000463724|UCSF-98251|UCSF-9805|UCSF-H9996-15837-06","January 1999","June 2007","June 2008","October 2012","February 23, 2006","February 24, 2006","null","null","October 2, 2012","October 4, 2012","Alta Bates Comprehensive Cancer Center, Berkeley, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT00296023"
155,"NCT00881946","Repeat Dose Safety Study for Compound to Treat Hematologic Cancer","null","Completed","No Results Available","Hematologic Malignancies","Drug: GSK21110183","Physical exam|Electrocardiogram (ECG)|Vital signs|Transthoracic Echocardiogram (TTE)/Multiple Gated Acquisition (MUGA) Scans|Clinical Laboratory assessments|ECOG Peformance Status|PK - Maximum observed plasma concentraion (Cmax)|PK - time to Cmax [tmax] (Maximum observed plasma concentration)|PK - Area under the plasma concentration-time curve (AUC(0-t))|PK - Apparent terminal phase elimination rate constant|PK - Apparent terminal phase half-life (t1/2)|PK - oral clearance (CL/F)|Metabolite Profiling","Accenture","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","73","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PKB112835","July 2009","March 2012","March 2012","April 2012","March 20, 2009","April 15, 2009","null","null","April 3, 2012","April 4, 2012","Prince of Wales Hospital, Sydney, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Princess Margaret Hospital, Toronto, Ontario, Canada|Seoul National University Hospital, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT00881946"
156,"NCT00004132","Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer","null","Completed","No Results Available","Drug/Agent Toxicity by Tissue/Organ|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Oral Complications|Radiation Toxicity","Biological: filgrastim|Biological: palifermin|Drug: cyclophosphamide|Drug: etoposide|Drug: ifosfamide|Procedure: quality-of-life assessment|Radiation: radiation therapy","","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","12 Years to 65 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Supportive Care","AMGEN-KGF-980231-03|UCLA-9812041|CDR0000067362|NCI-G99-1609","January 2000","null","May 2004","June 2007","December 10, 1999","May 20, 2004","null","null","June 25, 2013","June 26, 2013","Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT00004132"
157,"NCT00725062","Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant","null","Terminated","No Results Available","Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: CD4+CD25+ regulatory T cells|Procedure: allogeneic hematopoietic stem cell transplantation","Maximum tolerated dose of CD4+CD25+ cells/kg (phase I)|Incidence of grade 3-5 infusional toxicity (phase II)|Cumulative incidence of grade II-IV acute graft-versus-host-disease (GVHD)|Incidence of chronic graft-versus-host disease (GVHD)|Incidence of Relapse|Overall Survival|Disease-free survival","Masonic Cancer Center, University of Minnesota","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004LS034|MT2004-03","June 2008","April 2010","April 2010","November 2017","July 29, 2008","July 30, 2008","null","null","November 27, 2017","November 29, 2017","Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00725062"
158,"NCT00003270","Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methylprednisolone|Procedure: bone marrow ablation with stem cell support|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","To determine the safety, efficacy and toxicity of using cord blood as a source for stem cell transplantation in patients with hematologic malignancies.","Roswell Park Cancer Institute","All","5 Years to 50 Years   (Child, Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DS 97-26","September 4, 1997","October 16, 2017","October 16, 2017","October 2017","November 1, 1999","April 27, 2004","null","null","October 24, 2017","October 26, 2017","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT00003270"
159,"NCT02240719","Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer","null","Recruiting","No Results Available","Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Multiple Myeloma","Drug: everolimus|Drug: bendamustine hydrochloride","MTD of everolimus, defined as the dose that produces dose-limiting toxicity (DLT) in =< 1/6 patients, determined by incidence of DLT graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Incidence and severity of adverse events as defined by the NCI CTCAE version 4.03|Response rates (complete response, partial response, stable disease)","University of California, Davis|Novartis","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCDCC#245|NCI-2014-01934|CRAD001NUS235T","October 2014","December 2017","December 2018","January 2017","September 12, 2014","September 16, 2014","null","null","January 19, 2017","January 20, 2017","University of California Davis, Sacramento, California, United States","https://ClinicalTrials.gov/show/NCT02240719"
160,"NCT00006098","PS-341 in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: bortezomib","","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","00-031|CDR0000068105|NCI-G00-1827","April 2000","October 2001","October 2001","June 2013","August 3, 2000","March 17, 2004","null","null","June 17, 2013","June 18, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00006098"
161,"NCT00003335","Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer","null","Completed","No Results Available","Graft Versus Host Disease|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclosporine|Drug: melphalan|Drug: methylprednisolone|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","rates of durable engraftment in patients|Event-free survival by clinical and pathological disease assessment|incidence of recurrent disease in patients post UCB transplant","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 54 Years   (Child, Adult)","Phase 2","44","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CWRU4Y97|P30CA043703|NCI-G98-1429","January 1998","November 2007","January 2012","March 2012","November 1, 1999","January 27, 2003","null","null","March 14, 2012","March 15, 2012","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT00003335"
162,"NCT00281879","Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","null","Terminated","Has Results","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Unusual Cancers of Childhood","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: busulfan|Drug: carmustine|Drug: cyclophosphamide|Drug: cyclosporine|Drug: cytarabine|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Drug: methotrexate|Drug: methylprednisolone|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: peripheral blood stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","Number of Participants With Disease Free Survival (DFS).","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","up to 60 Years   (Child, Adult)","Phase 2","200","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000452794|P30CA016058|OHSU-TPI-9695-L|OHSU-540","February 2006","February 2008","March 2008","September 2017","January 24, 2006","January 25, 2006","May 17, 2012","June 19, 2012","September 25, 2017","September 27, 2017","OHSU Knight Cancer Institute, Portland, Oregon, United States","https://ClinicalTrials.gov/show/NCT00281879"
163,"NCT00015925","MS-275 in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Drug: entinostat","","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068574, J0253|U01CA069854|P30CA006973|JHOC-J0253|MSGCC-0050|NCI-2791","February 2001","null","null","March 2010","May 6, 2001","January 27, 2003","null","null","March 9, 2010","March 10, 2010","Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00015925"
164,"NCT00544115","Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","null","Active, not recruiting","No Results Available","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Precancerous/Nonmalignant Condition","Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Drug: methotrexate|Drug: mycophenolate mofetil|Drug: sirolimus|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation","Neutrophil and platelet engraftment|Incidence of acute and chronic graft-versus-host disease (GVHD)|Impact of HLA class I and class II allele-matching on the incidence of GVHD and on the survival outcome|Overall survival|Disease-free survival|Relapse","City of Hope Medical Center|National Cancer Institute (NCI)","All","up to 120 Years   (Child, Adult, Senior)","Phase 2","260","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01089|P30CA033572|CHNMC-01089|CDR0000566376","September 2001","September 2018","September 2018","September 2017","October 13, 2007","October 16, 2007","null","null","September 26, 2017","September 27, 2017","","https://ClinicalTrials.gov/show/NCT00544115"
165,"NCT00003396","Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Biological: graft-versus-tumor induction therapy|Drug: cyclophosphamide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","","University of Maryland|University of Maryland Greenebaum Cancer Center","All","Child, Adult, Senior","Phase 2","42","Other","Interventional","Primary Purpose: Treatment","CDR0000066397|MSGCC-9805|NCI-V98-1430","September 1998","December 2002","December 2002","September 2009","November 1, 1999","June 3, 2004","null","null","September 23, 2009","September 24, 2009","Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00003396"
166,"NCT00886522","Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies","IBCB","Completed","No Results Available","Hematological Malignancies","Procedure: Intrabone cord blood infusion","Proportion of transplanted patients with successful engraftment at day +42|Clinical response with the analysis of global survival, survival without relapse, relapse incidence|Acute and chronic GVHD incidence|Infection incidence|Chimerism study on selected populations (myeloid, lymphoid, NK)|Studies on immunological reconstitution","St. Orsola Hospital","All","18 Years to 65 Years   (Adult)","Phase 2","23","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","152/2008/U/Sper","April 2009","May 2012","May 2013","April 2016","April 22, 2009","April 23, 2009","null","null","April 14, 2016","April 15, 2016","Hematology Institute ""L. and A. Seràgnoli"", S. Orsola-Malpighi University Hospital, Bologna, Italy","https://ClinicalTrials.gov/show/NCT00886522"
167,"NCT00301951","Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Biological: sargramostim|Drug: busulfan|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: umbilical cord blood transplantation","Safety and Feasibility of donor cord blood transplant","University of California, San Francisco|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","7","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000465362|UCSF-04253|UCSF-2407|UCSF-H24045-25271-02","September 2004","July 2009","July 2009","October 2017","March 9, 2006","March 13, 2006","null","null","October 10, 2017","October 12, 2017","UCSF Comprehensive Cancer Center, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT00301951"
168,"NCT00963872","Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer","null","Terminated","Has Results","Leukemia|Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes","Drug: cyclophosphamide|Drug: fludarabine phosphate|Radiation: Total body irradiation|Biological: Umbilical cord blood unit with C3a fragment|Biological: Unmanipulated UCB Unit","Number of Patients With the Complement 3a (C3a) Unit Predominating|Neutrophil Engraftment|Donor Chimerism in Blood|Incidence of Grades II-IV Graft-vs-host Disease|Non-Relapse Mortality|Overall Survival|Bone Marrow Chimerism|Chronic Graft-Versus-Host Disease|Relapse of Disease|Disease Progression|Platelet Recovery|Incidence of Grades III-IV Graft-vs-host Disease|Non-relapse Mortality|Overall Survival at Day 720|Donor Chimerism","Masonic Cancer Center, University of Minnesota|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","31","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008UC097|MT2008-15|0809M46361|RC1HL099447","March 2010","August 2012","August 2013","December 2017","August 21, 2009","August 24, 2009","April 22, 2015","November 10, 2015","December 3, 2017","December 28, 2017","University of Minnesota Medical Center - Fairview, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00963872"
169,"NCT01460134","A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers","null","Active, not recruiting","No Results Available","CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Marginal Zone B Cell Lymphoma)|Any T-cell Malignancy|Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma|Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer|Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)|Burkett's Lymphoma|Primary Lymphoma of the Central Nervous System","Drug: CDX-1127","Characterize the adverse events associated with CDX-1127 administration|Levels of anti-CD27 antibodies in circulating blood.|Levels of CDX-1127 in circulating blood.|Activity Evaluations|Immune system effects (eg: lymphoid cell populations and serum cytokine levels)","Celldex Therapeutics","All","18 Years and older   (Adult, Senior)","Phase 1","90","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDX1127-01","October 2011","December 2015","December 2017","August 2017","October 12, 2011","October 26, 2011","null","null","August 11, 2017","August 14, 2017","Mayo Clinic Arizona - Cancer Clinical Research Unit, Scottsdale, Arizona, United States|Stanford Cancer Center - Stanford University, Stanford, California, United States|Mayo Clinic, Rochester, Minnesota, United States|Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine, New York, New York, United States|The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States","https://ClinicalTrials.gov/show/NCT01460134"
170,"NCT00003661","Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Graft Versus Host Disease|Leukemia|Lymphoma|Myelodysplastic Syndromes|Neuroblastoma","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclosporine|Drug: melphalan|Drug: methylprednisolone|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","","Roswell Park Cancer Institute","All","up to 54 Years   (Child, Adult)","Phase 2","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000066754|RPCI-RP-9801","June 1998","November 1999","March 2006","March 2011","November 1, 1999","August 4, 2004","null","null","March 3, 2011","March 7, 2011","University of Florida Health Science Center, Gainesville, Florida, United States|Division of Pediatric Surgery, Jacksonville, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Children's Hospital of New Orleans, New Orleans, Louisiana, United States|Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|North Shore University Hospital, Manhasset, New York, United States|New York Blood Center, New York, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of South Carolina School of Medicine, Columbia, South Carolina, United States","https://ClinicalTrials.gov/show/NCT00003661"
171,"NCT00818961","Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer","null","Terminated","Has Results","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: alemtuzumab|Biological: graft-versus-tumor induction therapy|Biological: rituximab|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation","Survival at Day 100|Overall Survival at 1 Year|Non-relapse Mortality at Day 100|Non-relapse Mortality at 1 Year Post-transplant|Complete Donor Chimerism|Neutrophil Recovery|Platelet Engraftment|Number of Patients Requiring the Use of Donor Leukocyte Infusion (DLI) for Early Mixed T-cell Chimerism|Number of Patients Experiencing Grade 2-4 Acute Graft-versus-host Disease Post-transplant|Number of Patients Experiencing Chronic Graft Versus Host Disease|Number of Patients Experiencing Veno-occlusive Disease (VOD) Post-transplant","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","40 Years to 72 Years   (Adult, Senior)","Phase 2","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000630617|BMTGG-NSH-756","May 2005","March 2011","March 2012","October 2013","January 7, 2009","January 8, 2009","March 22, 2013","December 18, 2013","October 28, 2013","December 18, 2013","Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States","https://ClinicalTrials.gov/show/NCT00818961"
172,"NCT00993694","Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Methemoglobinemia|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Nonmalignant Neoplasm","Drug: chemotherapy|Drug: dapsone|Other: medical chart review|Procedure: assessment of therapy complications","Incidence of methemoglobinemia in patients with hematologic malignancy or aplastic anemia who received dapsone prophylaxis through a retrospective chart review encompassing the last 15 years|Major risk factors for developing methemoglobinemia","Vanderbilt University|National Cancer Institute (NCI)|Vanderbilt University Medical Center","All","up to 18 Years   (Child, Adult)","","41","Other|NIH","Observational","","CDR0000652603|P30CA068485|VU-VICC-PED-0916|IRB# 090009","January 2009","December 2009","December 2009","April 2017","October 9, 2009","October 12, 2009","null","null","April 13, 2017","April 17, 2017","Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT00993694"
173,"NCT00387608","ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific","Drug: veliparib|Other: pharmacological study|Procedure: biopsy","Change in tumor poly (ADP-ribose) (PAR) levels from baseline to 3-6 hours after ABT-888 administration|Pharmacokinetics|Safety of administering 1 dose of ABT-888|Changes in PAR levels in peripheral blood mononuclear cells from baseline to after ABT-888 administration","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","23","NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","060172|06-C-0172|NCI-P6890|CDR0000487701","June 2006","February 2008","April 2009","March 2012","October 12, 2006","October 13, 2006","null","null","March 14, 2012","March 15, 2012","Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00387608"
174,"NCT00024180","FR901228 in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma","Drug: romidepsin","","Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068898|OSU-00H0350|NCI-27","January 2002","null","August 2006","November 2002","September 13, 2001","January 27, 2003","null","null","January 30, 2013","January 31, 2013","Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT00024180"
175,"NCT01254578","Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers","null","Completed","No Results Available","Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A|Adult Acute Promyelocytic Leukemia With PML-RARA|Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-Cell Lymphoma|Alkylating Agent-Related Acute Myeloid Leukemia|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Hepatosplenic T-Cell Lymphoma|Intraocular Lymphoma|Lymphomatous Involvement of Non-Cutaneous Extranodal Site|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Post-Transplant Lymphoproliferative Disorder|Primary Cutaneous B-Cell Non-Hodgkin Lymphoma|Prolymphocytic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Richter Syndrome|Small Intestinal Lymphoma|Splenic Marginal Zone Lymphoma|T-Cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenstrom Macroglobulinemia","Other: Laboratory Biomarker Analysis|Drug: Lenalidomide|Other: Pharmacological Study","MTD of lenalidomide after allogeneic hematopoietic stem cell transplantation graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0|Overall response in patients treated with lenalidomide according to the International Working Group (IWG) criteria","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","17","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2011-02551|OSU 10079|OSU-10079|CDR0000688918|2010C0069|OSU-2010C0069|8305|P30CA016058|U01CA076576","November 24, 2010","November 9, 2012","November 9, 2012","September 2017","December 3, 2010","December 6, 2010","null","null","September 22, 2017","September 25, 2017","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT01254578"
176,"NCT00095797","XK469R in Treating Patients With Refractory Hematologic Cancer","null","Completed","No Results Available","Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Refractory Chronic Lymphocytic Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia|Untreated Adult Acute Myeloid Leukemia","Drug: R(+)XK469|Other: pharmacological study|Other: laboratory biomarker analysis","MTD as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0|Dose-limiting toxicity (DLT) defined as a clinically significant adverse event or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications using CTCAE version 3.0|Pharmacokinetic profile of XK496R|Candidate genes for XK469R using PCR assay","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","60","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02633|MDA-2004-0154|U10CA62461|CDR0000393836","October 2004","March 2007","null","February 2013","November 9, 2004","November 9, 2004","null","null","February 7, 2013","February 8, 2013","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00095797"
177,"NCT00004047","Chemotherapy in Treating Patients Who Have Hematologic Cancer","null","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes","Drug: exatecan mesylate","","Daiichi Sankyo, Inc.","All","Child, Adult, Senior","Phase 1","null","Industry","Interventional","Primary Purpose: Treatment","CDR0000067149|DAIICHI-8951A-PRT014|MDA-ID-99013|NCI-V99-1556","June 1999","April 2005","April 2005","May 2012","December 10, 1999","July 19, 2004","null","null","May 15, 2012","May 16, 2012","University of Texas - MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00004047"
178,"NCT00054327","Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer","null","Completed","Has Results","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Drug: busulfan|Drug: cyclophosphamide|Drug: cytarabine|Radiation: radiation therapy|Drug: Etoposide|Procedure: Stem Cell Transfusion","Rates of Durable Engraftment|Graft-versus-host Disease (GVHD)|Incidence of Recurrent Disease|Toxicity as Measured by CTC v2.0","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 55 Years   (Child, Adult)","Phase 2","34","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CWRU1Y00|P30CA043703|CASE-CWRU-1Y00","November 2000","September 2011","September 2011","June 2013","February 5, 2003","February 6, 2003","April 30, 2013","July 24, 2013","June 19, 2013","July 24, 2013","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT00054327"
179,"NCT00008164","Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia","null","Unknown status","No Results Available","Childhood Langerhans Cell Histiocytosis|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Procedure: umbilical cord blood transplantation","Response rate|Toxicity|Survival|Incidence of graft-versus-host disease","Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 60 Years   (Child, Adult)","Phase 2","30","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068384|CPMC-IRB-7934|CPMC-CAMP-021|NCI-G00-1899","January 1997","null","null","January 2007","January 6, 2001","January 27, 2003","null","null","December 17, 2013","December 18, 2013","Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00008164"
180,"NCT00053989","Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic Anemia","null","Active, not recruiting","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Biological: graft-versus-tumor induction therapy|Biological: sargramostim|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methylprednisolone|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: umbilical cord blood transplantation","Safety|Toxicity|Clinical response|Overall outcome|Incidence of graft-vs-tumor effect, graft-vs-host disease, and chimerism","Roswell Park Cancer Institute","All","5 Years to 75 Years   (Child, Adult, Senior)","Phase 2","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000269673|RP01-05","January 29, 2002","May 1, 2018","May 1, 2018","May 2017","February 5, 2003","February 6, 2003","null","null","May 16, 2017","May 17, 2017","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT00053989"
181,"NCT00004232","Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition","Biological: filgrastim|Drug: cyclosporine|Drug: methylprednisolone|Drug: prednisone|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","","Northwestern University|National Cancer Institute (NCI)","All","10 Years to 65 Years   (Child, Adult)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Supportive Care","NU FDA96H4|NU-96H4|NCI-G99-1660","October 1999","October 2002","October 2002","May 2012","January 28, 2000","May 9, 2003","null","null","May 31, 2012","June 1, 2012","Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT00004232"
182,"NCT00295880","Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer","null","Terminated","Has Results","Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes","Procedure: umbilical cord blood transplantation","Median Number of Days to Neutrophil Engraftment|Number of Patients Achieving Neutrophil Recovery|Number of Patients With Evidence of Engraftment.|Number of Patients With Acute Graft-versus-host Disease (GVHD)|Number of Patients With Transplant-related Mortality (TRM)|Number of Patients Surviving at Day 100 and 1 Year.|Number of Patients With Grade III-IV Acute Graft-versus-host Disease (GVHD)|Number of Patients With Chronic Graft-versus-host Disease (GVHD).","Masonic Cancer Center, University of Minnesota","All","12 Years to 45 Years   (Child, Adult)","Phase 1|Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004LS072|UMN-MT2004-26|UMN-0412M65789","June 2005","August 2008","August 2008","December 2017","February 23, 2006","February 24, 2006","March 25, 2009","September 3, 2009","December 3, 2017","December 28, 2017","","https://ClinicalTrials.gov/show/NCT00295880"
183,"NCT01164709","Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Mature T-cell and Nk-cell Neoplasms|Multiple Myeloma and Plasma Cell Neoplasm","Drug: bortezomib|Drug: nelfinavir mesylate","Dose limiting toxicity|Objective response|Adverse events according to NCI CTCAE v.4.0","Swiss Group for Clinical Cancer Research","All","18 Years and older   (Adult, Senior)","Phase 1","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SAKK 65/08|SWS-SAKK-65/08|EU-21051|SWS-SAKK-JC26866138LYM1005|CDR0000681442","July 2010","July 2012","November 2013","January 2014","July 16, 2010","July 19, 2010","null","null","January 31, 2014","February 3, 2014","Inselspital Bern, Bern, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kantonsspital - St. Gallen, St. Gallen, Switzerland","https://ClinicalTrials.gov/show/NCT01164709"
184,"NCT00005967","Tipifarnib in Treating Patients With Advanced Hematologic Cancer","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: tipifarnib","","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","36","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02342|UCCRC-10294|NCI-42|CDR0000067950","August 2000","April 2004","null","October 2004","July 5, 2000","January 27, 2003","null","null","February 8, 2013","February 11, 2013","University of Chicago Cancer Research Center, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT00005967"
185,"NCT00002970","506U78 in Treating Patients With Refractory Hematologic Cancer","null","Completed","No Results Available","Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Lymphoblastic Lymphoma|T-cell Childhood Acute Lymphoblastic Leukemia","Drug: nelarabine|Drug: methotrexate|Drug: cytarabine|Drug: therapeutic hydrocortisone","Early marrow CR plus PR rate at day 21|Remission duration|6 month cumulative event-free survival","National Cancer Institute (NCI)|Children's Cancer Group","All","up to 21 Years   (Child, Adult)","Phase 2","148","NIH|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-01836|P9673|CCG-P9673|POG-9673|CDR0000065478|U10CA098543","June 1997","January 2005","null","July 2013","November 1, 1999","August 11, 2003","null","null","July 1, 2013","July 2, 2013","Children's Oncology Group, Arcadia, California, United States","https://ClinicalTrials.gov/show/NCT00002970"
186,"NCT00004904","Stem Cell Transplantation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Small Intestine Cancer","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: cladribine|Drug: cyclophosphamide|Drug: etoposide|Drug: methylprednisolone|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation","","Northwestern University|National Cancer Institute (NCI)","All","up to 45 Years   (Child, Adult)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU FDA97H1|NU-97H1|NCI-G00-1691","October 1999","July 2000","July 2000","May 2012","March 7, 2000","March 3, 2004","null","null","May 31, 2012","June 4, 2012","Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT00004904"
187,"NCT00005854","Bone Marrow Transplantation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: allogeneic bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation|Radiation: radiation therapy","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","1457.00|FHCRC-1457.00|NCI-H00-0059|CDR0000067879","December 1999","null","October 2000","November 2011","June 2, 2000","June 28, 2004","null","null","November 28, 2011","November 30, 2011","Johns Hopkins Oncology Center, Baltimore, Maryland, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|University of South Carolina School of Medicine, Columbia, South Carolina, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00005854"
188,"NCT00031980","Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer","null","Completed","No Results Available","Anemia|Leukemia|Neutropenia|Thrombocytopenia","Drug: cyclosporine","Frequency of cytopemic response","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CALGB-10003|CDR0000069246","March 2002","May 2005","May 2005","July 2016","March 8, 2002","January 27, 2003","null","null","July 1, 2016","July 6, 2016","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT00031980"
189,"NCT00453206","Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases","null","Completed","Has Results","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Treatment-related Mortality Within the First 6 Months After Transplantation|Complete Response|Overall Survival|Disease-free Survival|Graft-versus-host Disease|Iron Status at the Time of Transplantation|Quality of Life at the Time of Transplantation|Treatment-related Mortality at 100 Days After Transplantation","Wake Forest University Health Sciences","All","up to 70 Years   (Child, Adult, Senior)","","66","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000538185|CCCWFU-29506|IRB00001366","February 2007","February 2014","August 2014","February 2017","March 27, 2007","March 28, 2007","May 28, 2014","July 2, 2014","July 31, 2017","August 30, 2017","Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00453206"
190,"NCT00104923","Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm","Drug: fenretinide","To determine the maximum tolerated dose of fenretinide|To describe the toxicities of fenretinide","California Cancer Consortium|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1","29","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000413887|P30CA033572|CCC-PHI-42|NCI-6528|LAC-USC-0C-04-3|NCI-06-C-0227|NCI-P6820","February 2005","April 2017","April 2017","July 2017","March 3, 2005","March 4, 2005","null","null","July 18, 2017","July 19, 2017","USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States","https://ClinicalTrials.gov/show/NCT00104923"
191,"NCT00003398","Bone Marrow Transplantation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Anemia|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: cyclophosphamide|Drug: thiotepa|Procedure: allogeneic bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Radiation: radiation therapy","","University of Maryland|University of Maryland Greenebaum Cancer Center","All","up to 50 Years   (Child, Adult)","Phase 4","45","Other","Interventional","Primary Purpose: Treatment","CDR0000066400|MSGCC-9739|NCI-V98-1433","September 1998","May 2000","May 2000","September 2009","November 1, 1999","April 27, 2004","null","null","September 23, 2009","September 24, 2009","Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00003398"
192,"NCT00064090","3-AP and Cytarabine in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Drug: cytarabine|Drug: triapine","","Vion Pharmaceuticals|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Industry","Interventional","Primary Purpose: Treatment","VION-CLI-032|CDR0000306465|MDA-DM-030096","March 2003","September 2004","January 2008","August 2008","July 8, 2003","July 9, 2003","null","null","July 17, 2013","July 18, 2013","University of Texas - MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00064090"
193,"NCT00005797","Bone Marrow Transplant in Treating Patients With Hematologic Cancers","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Multiple Myeloma and Malignant Plasma Cell Neoplasms|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Drug: busulfan|Drug: Cyclophosphamide|Drug: VP-16|Radiation: Fractionated Total Body Irradiation (FTBI)","Relapse-free survival","H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)","All","15 Years to 55 Years   (Child, Adult)","Phase 2","125","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-11281|MCC-IRB-4188|NCI-G00-1759","March 1993","July 2007","July 2007","October 2012","June 2, 2000","January 27, 2003","null","null","October 24, 2012","October 25, 2012","H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States","https://ClinicalTrials.gov/show/NCT00005797"
194,"NCT00005804","Bone Marrow Transplantation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Small Intestine Cancer","Drug: cyclophosphamide|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","1467.00|FHCRC-1467.00|NCI-H00-0054|CDR0000067780","October 1999","August 2002","August 2002","March 2010","June 2, 2000","August 28, 2003","null","null","March 31, 2010","April 2, 2010","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00005804"
195,"NCT00365287","Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer","null","Completed","No Results Available","Breast Cancer|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: radiation therapy|Procedure: umbilical cord blood transplantation","Safety as assessed by a non-relapse mortality < 30% within day 100|Hematopoietic recovery and the degree of chimerism at days 21, 60, 100, 180, and 360 after study completion","Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI)","All","up to 69 Years   (Child, Adult, Senior)","Phase 1|Phase 2","148","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","2000LS039|MT2000-15","June 2000","December 2005","December 2005","November 2017","August 16, 2006","August 17, 2006","null","null","November 27, 2017","November 29, 2017","","https://ClinicalTrials.gov/show/NCT00365287"
196,"NCT00003107","Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors","null","Completed","No Results Available","Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor","Biological: recombinant interleukin-12","","Indiana University School of Medicine|National Cancer Institute (NCI)|Indiana University","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","9708-05; T97-0027|IUMC-9708-05|NCI-T97-0027","October 1997","null","null","September 2014","November 1, 1999","April 6, 2004","null","null","September 9, 2014","September 10, 2014","Indiana University Cancer Center, Indianapolis, Indiana, United States","https://ClinicalTrials.gov/show/NCT00003107"
197,"NCT00003116","High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Hematopoietic reconstitution measured daily during transplant","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","4 Years to 55 Years   (Child, Adult)","Phase 2","66","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CWRU1995T|P30CA043703|CASE-CWRU-1995|NCI-G97-1354|CASE1995T","May 1997","March 2006","June 2009","June 2010","November 1, 1999","January 27, 2003","null","null","June 9, 2010","June 11, 2010","Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT00003116"
198,"NCT00003960","Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: busulfan|Drug: cyclophosphamide|Drug: methylprednisolone|Procedure: allogeneic bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation","","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","19 Years to 55 Years   (Adult)","Phase 2","36","Other|NIH","Interventional","Primary Purpose: Treatment","J9828 CDR0000067159|P30CA006973|JHOC-98032006|JHOC-J9828|NCI-G99-1543","April 1998","September 2001","September 2001","May 2014","November 1, 1999","April 28, 2004","null","null","May 1, 2014","May 2, 2014","Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Center for Cancer Treatment and Research, Columbia, South Carolina, United States","https://ClinicalTrials.gov/show/NCT00003960"
199,"NCT00003435","Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer","null","Withdrawn","No Results Available","Leukemia|Lymphoma","Biological: anti-thymocyte globulin|Drug: melphalan|Procedure: antiviral therapy|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","","Duke University|National Cancer Institute (NCI)","All","18 Years to 55 Years   (Adult)","Phase 1","0","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066461|DUMC-97028|NCI-G98-1458","May 1998","null","null","December 2000","November 1, 1999","June 9, 2004","null","null","March 6, 2013","March 7, 2013","Duke Comprehensive Cancer Center, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00003435"
200,"NCT00813501","Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases","null","Terminated","No Results Available","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic-Myeloproliferative Diseases|Neuroblastoma|Therapy-related Toxicity","Biological: immunosuppressive therapy|Other: immunological diagnostic method|Procedure: allogeneic hematopoietic stem cell transplantation","Acute graft-versus-host disease (GVHD)|Grade of acute GVHD|Response criteria for treatment of acute GVHD|Chronic GVHD|Grade of chronic GVHD|Response criteria for treatment of chronic GVHD|Infections (i.e., bacterial, fungal, or viral)","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","","60","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","07200|P30CA033572|CHNMC-07200|CDR0000628793","June 2008","June 2010","June 2010","March 2011","December 20, 2008","December 23, 2008","null","null","March 3, 2011","March 7, 2011","City of Hope Comprehensive Cancer Center, Duarte, California, United States","https://ClinicalTrials.gov/show/NCT00813501"
201,"NCT00536601","High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","null","Active, not recruiting","No Results Available","Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Plasma Cell Neoplasm|Primary Systemic Amyloidosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Neuroblastoma|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Regional Neuroblastoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia","Drug: etoposide|Drug: cyclophosphamide|Drug: carmustine|Drug: melphalan|Drug: busulfan|Drug: carboplatin|Drug: thiotepa|Radiation: total-body irradiation|Procedure: autologous hematopoietic stem cell transplantation|Procedure: autologous-autologous tandem hematopoietic stem cell transplantation","Progression-free survival distribution of patients with HL, NHL, and MM for each disease-specific high-dose therapy regimen|Progression-free survival distribution of patients with amyloidosis, acute leukemia, and selected solid tumors for each disease-specific high-dose therapy regimen|Regimen-related toxicity|Response rate|Overall survival","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","4 Years and older   (Child, Adult, Senior)","","174","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 72806|NCI-2011-00131|P30CA016056","June 29, 2006","April 18, 2018","April 18, 2018","March 2017","September 27, 2007","September 28, 2007","null","null","March 30, 2017","March 31, 2017","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT00536601"
202,"NCT00003805","Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count","null","Completed","No Results Available","Bone Marrow Suppression|Fever, Sweats, and Hot Flashes|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific","Drug: piperacillin sodium|Drug: piperacillin-tazobactam|Drug: tazobactam sodium|Drug: vancomycin","","European Organisation for Research and Treatment of Cancer - EORTC","All","2 Years and older   (Child, Adult, Senior)","Phase 3","859","Other","Interventional","Allocation: Randomized|Primary Purpose: Supportive Care","EORTC-46971","November 1997","June 2000","null","September 2012","November 1, 1999","July 16, 2004","null","null","September 20, 2012","September 24, 2012","Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Algemeen Ziekenhuis Middelheim, Antwerp, Belgium|Institut Jules Bordet, Brussels (Bruxelles), Belgium|Cliniques Universitaires Saint-Luc, Brussels (Bruxelles), Belgium|Hopital Universitaire Erasme, Brussels, Belgium|Kingston General Hospital, Kingston, Ontario, Canada|Ottawa Regional Cancer Center - General Division, Ottawa, Ontario, Canada|Masaryk University Hospital, Brno, Czech Republic|Turku University Central Hospital, Turku, Finland|CHR de Besancon - Hopital Saint-Jacques, Besancon, France|Klinikum der Universitaet Ulm, Ulm, Germany|Hellenic Institute for Cancer-Saint Savas Hospital, Athens, Greece|Athens University-Laikon General Hospital, Athens, Greece|Metaxa's Memorial Cancer Hospital, Piraeus, Greece|University of Patras Medical School, Rio Patras, Greece|Wolfson Medical Center, Holon, Israel|Hadassah University Hospital, Jerusalem, Israel|Chaim Sheba Medical Center, Ramat-Gan, Israel|National Cancer Institute - Bratislava, Bratislava, Slovakia|St. Elizabeth Cancer Institute Hospital, Bratislava, Slovakia|Ospedale San Giovanni, Bellinzona, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Universitaetsspital, Zurich, Switzerland|Ibn-i Sina Hospital, Ankara Univeristy, Ankara, Turkey|Section of Infectious Diseases, Ankara, Turkey|Marmara University Hospital, Istanbul, Turkey|Royal Marsden Hospital, Sutton, England, United Kingdom","https://ClinicalTrials.gov/show/NCT00003805"
203,"NCT00003243","Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: aldesleukin|Biological: filgrastim|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: etoposide|Drug: pegylated liposomal doxorubicin hydrochloride","","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066119, J9743|P30CA006973|JHOC-97112101|NCI-V98-1387","January 1998","null","null","March 2010","November 1, 1999","January 27, 2003","null","null","March 9, 2010","March 10, 2010","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00003243"
204,"NCT00003662","Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases","null","Completed","No Results Available","Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes|Thymic Carcinoma","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: melphalan|Drug: methylprednisolone|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","90","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066755|P30CA016056|RPCI-RP-9803|NCI-G98-1486","August 1998","January 2001","January 2001","March 2011","November 1, 1999","August 4, 2004","null","null","March 3, 2011","March 7, 2011","University of Florida Health Science Center, Gainesville, Florida, United States|Division of Pediatric Surgery, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Children's Hospital of New Orleans, New Orleans, Louisiana, United States|Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|New York Blood Center, New York, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of South Carolina School of Medicine, Columbia, South Carolina, United States","https://ClinicalTrials.gov/show/NCT00003662"
205,"NCT00004145","Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation","Hematopoetic recovery and toxicities of non-myeloablative allogenic stem cell transplantation Hematopoetic recovery and toxicities of non-myeloablative allogenic stem cell transplantation","University of Chicago|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","16","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9581|UCCRC-9581|UCCRC-CTRC-9852|NCI-G99-1618","November 1998","November 2003","August 2011","March 2014","December 10, 1999","February 16, 2004","null","null","March 6, 2014","March 7, 2014","University of Chicago Cancer Research Center, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT00004145"
206,"NCT00619645","Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers","null","Completed","Has Results","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: busulfan|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Number of Patients With Day 100 Transplant-related Mortality|Number of Patients Without Progression After Day 100 Transplant|Number of Patients Alive 24 Months Post Day 100 Transplant","University of California, Davis","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCDCC#196|UCD-196","June 2007","October 2013","November 2013","March 2017","February 20, 2008","February 21, 2008","January 13, 2017","May 8, 2017","March 27, 2017","May 8, 2017","University of California Davis Cancer Center, Sacramento, California, United States","https://ClinicalTrials.gov/show/NCT00619645"
207,"NCT00547196","Study of Four Different Chemotherapy Regimens With or Without Total-Body Irradiation Followed by Umbilical Cord Blood Transplant in Treating Patients With Relapsed or Refractory Hematologic Cancer","null","Active, not recruiting","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes","Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Drug: mycophenolate mofetil|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation","Survival at day 100 after allogeneic hematopoietic stem cell transplantation (HSCT) from umbilical cord blood (UCB)|Incidence and timing of neutrophil engraftment|Incidence and timing of platelet engraftment|Incidence and severity of acute and chronic graft-versus-host-disease|Survival at day 180 after HSCT from UCB transplantation|Disease-free survival|Incidence of primary and secondary engraftment failure|Incidence of transplantation-related complications (e.g., infection, veno-occlusive disease of the liver, or organ toxicity)|Incidence of post-transplantation-related lymphoproliferative disease, secondary myelodysplastic syndromes, and other secondary malignancies|Incidence of relapse|Post-transplantation chimerism|Immune reconstitution","City of Hope Medical Center|National Cancer Institute (NCI)","All","up to 120 Years   (Child, Adult, Senior)","","10","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","02165|P30CA033572|CHNMC-02165|CDR0000570249","August 9, 2005","September 2018","September 2018","August 2017","October 19, 2007","October 22, 2007","null","null","August 9, 2017","August 11, 2017","Banner Good Samaritan Medical Center, Phoenix, Arizona, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States","https://ClinicalTrials.gov/show/NCT00547196"
208,"NCT00004239","506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment","null","Terminated","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: Compound 506U78","Maximum tolerated dose","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CALGB-69803|U10CA031946|CLB-69803|CDR0000067483","December 1999","January 2002","January 2002","July 2016","January 28, 2000","January 29, 2004","null","null","July 1, 2016","July 4, 2016","University of Chicago Cancer Research Center, Chicago, Illinois, United States|Holden Comprehensive Cancer Center at The University of Iowa, Iowa City, Iowa, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00004239"
209,"NCT00782379","Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer","null","Completed","Has Results","Leukemia|Lymphoma|Myelodysplastic Syndromes","Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Incidence of Graft Rejection for Patients at Day 100|Number of Patients Who Experienced Severe Graft-versus-host Disease (GVHD)(Grade 3 or 4)|Overall Survival at Day 100|Non-relapse Mortality at 1 Year After Peripheral Blood Stem Cell Transplantation (PBSCT)|Achievement of >90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 30 Post-transplantation|Non-relapse Mortality at Day 100 After Peripheral Blood Stem Cell Transplantation (PBSCT)|Achievement of >90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 60 Post-transplantation|Achievement of >90% (Full) Donor Chimerism in the T-Cell Lineage as Measured by PCR at Day 90 Post-transplantation|Overall Survival at 12 Months|Disease Free Survival at 12 Months|Disease Free Survival at Day 100","Northside Hospital, Inc.","All","18 Years to 60 Years   (Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000617648|BMTGG-NSH-864","October 2008","April 2011","April 2012","March 2013","October 29, 2008","October 31, 2008","March 18, 2013","May 3, 2013","October 28, 2013","November 21, 2013","Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States","https://ClinicalTrials.gov/show/NCT00782379"
210,"NCT00290641","Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes","Biological: filgrastim|Biological: graft-versus-tumor induction therapy|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","Engraftment as measured by an absolute neutrophil count of donor origin > 0.5 x 109 /L for 3 days by day 42|Incidence and severity of acute or chronic graft-versus-host-disease, relapse, or mortality at day 100|Survival and event-free survival by Kaplan-Meier estimation at 1 and 2 years after umbilical cord blood (UCB) transplant","Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI)","All","up to 45 Years   (Child, Adult)","","68","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","2000LS068|MT2000-25","April 2001","January 2006","January 2006","November 2017","February 9, 2006","February 13, 2006","null","null","November 27, 2017","November 29, 2017","University of Minnesota Cancer Center, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00290641"
211,"NCT00376480","Laboratory-Treated Peripheral Blood Cell Infusion After Donor Stem Cell Transplant in Treating Patients With Hematologic Cancers or Other Diseases","null","Unknown status","No Results Available","Leukemia|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Biological: peripheral blood lymphocyte therapy|Drug: fludarabine phosphate|Drug: methylprednisolone|Drug: thiotepa|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation|Radiation: total-body irradiation","Feasibility|Safety|Alloreactivity|Rate of acute graft-versus-host disease|Hyporesponsiveness by donor T cells|Immune cell function|Pathogen-specific immunity|Rate of recovery|Opportunistic infection patterns","Dana-Farber Cancer Institute|National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","Phase 1","40","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000491633|DFCI-05030|MDA-2005-0695","March 2005","June 2010","null","July 2009","September 13, 2006","September 15, 2006","null","null","November 10, 2009","November 11, 2009","Childrens Hospital Los Angeles, Los Angeles, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00376480"
212,"NCT00354172","Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.","null","Terminated","Has Results","Leukemia|Myelodysplastic Syndromes","Biological: aldesleukin|Biological: filgrastim|Biological: natural killer cell (NK) therapy|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: methylprednisolone|Drug: mycophenolate mofetil|Procedure: Umbilical Cord Blood Transplantation (UCBT)|Radiation: Total body irradiation (TBI)","Number of Participants (Patients) Who Were Disease-free and Alive at 6 Months|Number of Participants (Patients) Who Were Disease-free and Alive at 12 Months|Number of Patients Who Were Disease-free and Alive at 24 Months|Number of Participants (Patients) Who Died Due to Transplant.|Number of Participants (Patients) Who Attained Neutrophil Engraftment|Number of Participants (Patients) Who Attained Platelet Engraftment|Number of Participants (Patients) With Acute Graft-versus-host Disease (GVHD) Grade II-IV|Number of Participants (Patients) With Acute Graft-versus-Host Disease at Grade III-IV|Number of Participants (Patients) With Chronic Graft-Versus-Host Disease|Number of Participants (Patients) Who Died by 12 Months|Number of Participants (Patients) Who Died by 24 Months|Number of Participants (Patients) Who Experienced Relapse by 12 Months|Number of Participants (Patients) Who Experienced Relapse by 24 Months|Number of Participants (Patients) With Successful Natural Killer Cell Expansion|Chimerism After Double Umbilical Cord Blood Transplant (UCBT)","Masonic Cancer Center, University of Minnesota","All","up to 45 Years   (Child, Adult)","Phase 2","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMN-2005LS058|MT2005-18|0509M73449","February 2006","August 2008","August 2008","December 2017","July 19, 2006","July 20, 2006","November 30, 2009","December 31, 2009","December 3, 2017","December 28, 2017","Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00354172"
213,"NCT01135329","Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers","null","Terminated","No Results Available","Lymphoma|Leukemia|Myelodysplastic Syndrome","Drug: Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus,","Estimate the proportion of patients achieving full donor chimerism|Graft-versus-host disease (GVHD)","Sidney Kimmel Comprehensive Cancer Center","All","6 Months to 75 Years   (Child, Adult, Senior)","Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J1046|NA_00039363","August 2010","May 2012","May 2012","April 2014","June 1, 2010","June 2, 2010","null","null","April 16, 2014","April 17, 2014","The Sydney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT01135329"
214,"NCT00075816","Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)","null","Completed","Has Results","Leukemia|Myeloproliferative Disorders|Myelodysplastic-Myeloproliferative Diseases","Biological: Allogeneic bone marrow transplantation|Biological: Peripheral blood stem cell transplantation","Two-year Overall Survival|Neutrophil Engraftment|Platelet Engraftment|Graft Failure|Extensive Chronic Graft-versus-host Disease (GVHD)|Chronic GVHD|Relapse|Infections|Grades III-V Unexpected Adverse Events|Acute GVHD Grade II-IV|Acute GVHD Grade III-IV|Current Immunosuppressive (IS) Free Survival|Immune Reconstitution|Donor Recovery of Baseline Complete Blood Count (CBC) and White Blood Cell Count (WBC) Differential|Donor Recovery to Baseline Toxicity Scores|Donor Quality of Life|Patient Quality of Life","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program","All","up to 66 Years   (Child, Adult, Senior)","Phase 3","551","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BMTCTN0201|U01HL069294-05|BMT CTN 0201|5U24CA076518","January 2004","April 2013","April 2014","August 2016","January 9, 2004","January 13, 2004","January 22, 2015","February 1, 2016","October 24, 2017","November 28, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|City of Hope National Medical Center, Duarte, California, United States|UCSD Cancer Center, La Jolla, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|University of Florida College of Medicine (Shands), Gainesville, Florida, United States|Emory University, Atlanta, Georgia, United States|Loyola University, Maywood, Illinois, United States|IBMT (Indiana Blood and Marrow Transplant) at St Francis Franciscan Health, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Hospital, Kansas City, Kansas, United States|University of Maryland, Baltimore, Maryland, United States|DFCI/Brigham & Women's, Boston, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Washington University/Barnes Jewish Hospital, Saint Louis, Missouri, United States|Washington University/St. Louis Children's Hospital, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center Cancer Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Cohen Children's Hospital, New Hyde Park, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Ohio State/Arthur G. James Cancer Hospital, Columbus, Ohio, United States|University of Oklahoma Medical Center, Oklahoma City, Oklahoma, United States|Oregon Health & Science University (Peds), Portland, Oregon, United States|Oregon Health Sciences University, Portland, Oregon, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|Baylor College of Medicine/The Methodist Hospital, Houston, Texas, United States|University of Texas/MD Anderson CRC, Houston, Texas, United States|Texas Transplant Institute, San Antonio, Texas, United States|Utah BMT/Primary Children's Medical Center, Salt Lake City, Utah, United States|Utah BMT/University of Utah Medical School, Salt Lake City, Utah, United States|Virginia Commonwealth University MCV Hospitals, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Tom Baker Cancer Centre, Calgary, Calgary, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Hamilton Health Sciences - McMaster Site, Hamilton, Ontario, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada|Queen Elizabeth II Health Sciences Centre - Halifax, Halifax, Canada","https://ClinicalTrials.gov/show/NCT00075816"
215,"NCT00003816","Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer","null","Active, not recruiting","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Nonmalignant Neoplasm|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Drug: thiotepa|Radiation: total-body irradiation","Activity of allogeneic stem cell transplant|Influence of donor histocompatibility on outcome","Roswell Park Cancer Institute","All","4 Years to 70 Years   (Child, Adult, Senior)","Phase 2|Phase 3","362","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000066968|RP 98-15","October 19, 1998","December 29, 2017","December 1, 2018","December 2017","November 1, 1999","January 27, 2003","null","null","December 6, 2017","December 8, 2017","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT00003816"
216,"NCT00010192","Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","B-cell Adult Acute Lymphoblastic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma","Biological: rituximab|Biological: aldesleukin|Other: laboratory biomarker analysis|Other: pharmacological study","MTD defined as the dose preceding that at which at least 2 of 6 patients experience DLT using NCI CTC version 2.0","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","30","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-01404|0037|CDR0000068454|OSU-0037|NCI-130|OSU-00H0223|U01CA076576","December 2000","January 2003","null","June 2013","February 2, 2001","January 27, 2003","null","null","June 5, 2013","June 6, 2013","Ohio State University Medical Center, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT00010192"
217,"NCT00006239","Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Drug: sodium phenylbutyrate|Drug: tretinoin","","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","J9879 CDR0000068164|R01CA067803|P30CA006973|JHOC-J9879|JHOC-99072306|NCI-T98-0068","December 2000","February 2005","March 2005","September 2017","September 11, 2000","January 27, 2003","null","null","September 27, 2017","September 29, 2017","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00006239"
218,"NCT00003913","Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease","null","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: busulfan|Drug: cyclophosphamide|Drug: methylprednisolone|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)","All","up to 18 Years   (Child, Adult)","Phase 2","390","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","1330.00|FHCRC-1330.00|UMN-MT-9817|NCI-G99-1523|CDR0000067092","December 1998","August 2005","August 2005","March 2010","November 1, 1999","January 27, 2003","null","null","March 31, 2010","April 2, 2010","City of Hope Comprehensive Cancer Center, Duarte, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Children's Hospital of New Orleans, New Orleans, Louisiana, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States|Warren Grant Magnuson Clinical Center, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Spectrum Health and DeVos Children's Hospital, Grand Rapids, Michigan, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States|Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|North Shore University Hospital, Manhasset, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical City Dallas Hospital, Dallas, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00003913"
219,"NCT00301860","Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer","null","Terminated","No Results Available","Leukemia|Lymphoma","Biological: anti-thymocyte globulin|Biological: filgrastim|Biological: therapeutic allogeneic lymphocytes|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Drug: methotrexate|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","","University of California, San Francisco|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","","8","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000462439|UCSF-02164|UCSF-H10216-21819-03","January 2003","March 2007","November 2007","July 2013","March 9, 2006","March 13, 2006","null","null","July 11, 2013","July 15, 2013","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT00301860"
220,"NCT01233921","Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer","null","Completed","Has Results","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Graft Versus Host Disease|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma","Biological: palifermin|Other: flow cytometry|Other: laboratory biomarker analysis|Other: pharmacological study","Changes in the Number of Recent Thymic Emigrants (RTE) Cluster of Differentiation (CD)4 T Cells in the Blood|Changes in the Number of Naive CD4 T Cells in the Blood","Martin, Paul|National Cancer Institute (NCI)|Fred Hutchinson Cancer Research Center","All","18 Years and older   (Adult, Senior)","","6","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2437.00|NCI-2010-01711","September 2010","July 2012","null","February 2014","November 2, 2010","November 3, 2010","December 20, 2013","April 2, 2014","February 19, 2014","April 2, 2014","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT01233921"
221,"NCT00053196","Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma|Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myeloproliferative Neoplasms","Biological: anti-thymocyte globulin|Biological: G-CSF|Drug: busulfan|Drug: fludarabine phosphate|Drug: methotrexate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic cell transplantation|Drug: allopurinol","Treatment-related mortality|Per cent donor chimerism|Disease-free survival|Graft-versus-host disease incidence|Response Rates","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","up to 69 Years   (Child, Adult, Senior)","Phase 2","82","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CALGB-100002|U10CA031946|CDR0000269301","December 2002","November 2006","August 2010","June 2016","January 27, 2003","January 28, 2003","null","null","June 30, 2016","July 1, 2016","Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|Beebe Medical Center, Lewes, Delaware, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|St. Francis Hospital, Wilmington, Delaware, United States|Union Hospital Cancer Center at Union Hospital, Elkton MD, Maryland, United States|Siteman Cancer Center at Barnes-Jewish Hospital, St Louis, Missouri, United States|Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees, Voorhees, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States|Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Massey Cancer Center at Virginia Commonwealth University, Richmond, Virginia, United States","https://ClinicalTrials.gov/show/NCT00053196"
222,"NCT01044745","Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","null","Active, not recruiting","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Graft Versus Host Disease|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage I Small Lymphocytic Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Waldenström Macroglobulinemia","Drug: rituximab|Drug: mycophenolate mofetil|Drug: tacrolimus|Drug: anti-thymocyte globulin|Procedure: allogeneic hematopoietic stem cell transplantation|Other: laboratory biomarker analysis|Biological: graft versus host disease prophylaxis/therapy|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: busulfan|Radiation: total-body irradiation|Biological: graft-versus-tumor induction therapy|Biological: immunosuppressive therapy","Incidence of grades II-IV acute GVHD|Event-free survival|Overall survival|Transplant-related mortality (TRM) defined as any mortality after transplantation except mortality from relapsed disease","University of Nebraska|National Cancer Institute (NCI)","All","19 Years to 75 Years   (Adult, Senior)","Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","083-09|NCI-2009-01552|P30CA036727","December 2009","December 2017","March 2018","September 2017","January 7, 2010","January 8, 2010","null","null","September 29, 2017","October 2, 2017","University of Nebraska Medical Center, Omaha, Nebraska, United States","https://ClinicalTrials.gov/show/NCT01044745"
223,"NCT00438958","Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Myelodysplastic Syndromes|Secondary Myelofibrosis","Biological: filgrastim|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Time to treatment failure (extensive chronic graft-versus-host disease [GVHD], relapse, death)|Time to neutrophil recovery|Primary graft failure|Overall survival|Quality of life|Time to acute GVHD|Time to chronic GVHD|Chronic GVHD details|Cost|Detailed donor and patient self-reported outcomes","The Canadian Blood and Marrow Transplant Group|National Cancer Institute (NCI)","All","16 Years to 65 Years   (Child, Adult)","Phase 3","230","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000528289|CBMTG-0601","March 2007","null","null","July 2009","February 20, 2007","February 22, 2007","null","null","March 4, 2014","March 5, 2014","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Vancouver Hospital and Health Science Center, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Cancer Care Nova Scotia, Halifax, Nova Scotia, Canada|McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada|London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada|Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada|Royal Victoria Hospital - Montreal, Montreal, Quebec, Canada|Hopital de L'Enfant Jesus, Quebec City, Quebec, Canada|Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada|Auckland City Hospital, Auckland, New Zealand|King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia","https://ClinicalTrials.gov/show/NCT00438958"
224,"NCT00054236","Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: umbilical cord blood transplantation|Drug: methylprednisolone","Event-free survival by disease assessment|Umbilical cord blood donor engraftment by chimerism and complete blood count (CBC)","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 1","55","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CWRU6Y01|P30CA043703|12-01-32J","May 2002","March 2011","March 2011","September 2012","February 5, 2003","February 6, 2003","null","null","September 11, 2012","September 12, 2012","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT00054236"
225,"NCT00064285","Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia","Drug: alvocidib|Drug: imatinib mesylate","","Virginia Commonwealth University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","22","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000310175|U01CA062502|MCV-NCI-6013|MCV-VCU-1902|NCI-6013|CWRU-030323","June 2003","null","null","April 2010","July 8, 2003","July 9, 2003","null","null","April 30, 2010","May 3, 2010","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Massey Cancer Center at Virginia Commonwealth University, Richmond, Virginia, United States","https://ClinicalTrials.gov/show/NCT00064285"
226,"NCT00351975","Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases","null","Completed","No Results Available","Accelerated Phase of Disease|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndrome|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Previously Treated Myelodysplastic Syndrome|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Disease|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome","Drug: Belinostat|Drug: Azacitidine|Other: Laboratory Biomarker Analysis","Maximum tolerated dose of belinostat in combination with azacitidine|Changes in pharmacodynamic variables (target gene expression, apoptosis)|Association of methylation status, categorized as positive or negative, with changes in target gene expression|Clinical activity (complete remission, partial remission, stable disease, hematologic improvement)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","56","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-00146|UCCRC-14510A|NCI-7285|CDR0000486418|14510A|7285|U01CA069852|U01CA132123|P30CA014599|U01CA062491","June 2006","March 2013","March 2013","October 2013","July 13, 2006","July 14, 2006","null","null","December 22, 2014","December 23, 2014","University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada|Princess Margaret Hospital, Cashmere, Canterbury, New Zealand","https://ClinicalTrials.gov/show/NCT00351975"
227,"NCT00301912","Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer","null","Withdrawn","No Results Available","Anemia|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: filgrastim|Drug: busulfan|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Treatment-related mortality in the first 100 days post-transplant|Overall survival at 1 year post-transplant|Incidence and severity of organ-specific toxicity|Engraftment including neutrophil and platelet recovery and donor chimerism at 3 and 12 months post-transplant|Rate of acute graft-vs-host disease (GVHD)|Rate of chronic GVHD","University of California, San Francisco|National Cancer Institute (NCI)","All","16 Years to 60 Years   (Child, Adult)","Phase 2","0","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000463168|UCSF-02257|UCSF-2214|UCSF-H24045-22163-04","January 2002","November 2007","null","October 2012","March 9, 2006","March 13, 2006","null","null","October 1, 2012","October 2, 2012","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT00301912"
228,"NCT00039676","Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer","null","Recruiting","No Results Available","Waldenstrom Macroglobulinemia|Chronic Lymphocytic Leukemia|Hodgkin Disease|NonHodgkin Lymphoma|Mixed Lymphoproliferative Disease","","To define the clinical spectrum and natural history of familial blood and lymph node malignancies and susceptibility states over time.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","1 Year to 100 Years   (Child, Adult, Senior)","","3000","NIH","Observational","Observational Model: Family-Based|Time Perspective: Other","020210|02-C-0210","June 19, 2002","null","null","June 9, 2017","June 6, 2002","June 7, 2002","null","null","October 5, 2017","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00039676"
229,"NCT02333162","Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant","null","Recruiting","No Results Available","Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Hematologic Malignancy","Drug: Fludarabine Phosphate|Drug: Melphalan|Radiation: Intensity-Modulated Radiation Therapy|Radiation: Total Marrow Irradiation|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Peripheral Blood Stem Cell Transplantation|Procedure: Allogeneic Bone Marrow Transplantation|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Other: Laboratory Biomarker Analysis","MTD of conditioning regimen defined as any grade III or higher dose-limiting toxicity, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Overall incidence of adverse events, graded according to the NCI CTCAE version 4.0|Transplant related mortality|Time to neutrophil engraftment|Time to platelet engraftment|overall survival (OS)|event-free-survival (EFS)","University of Chicago|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB14-0709|NCI-2014-02469|P30CA014599","December 5, 2014","April 2018","April 2018","July 2017","January 5, 2015","January 7, 2015","null","null","July 24, 2017","July 26, 2017","University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT02333162"
230,"NCT00003962","Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm","Biological: aldesleukin","","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","J9825 CDR0000067162|P01CA015396|JHOC-98040902|JHOC-J9825|NCI-H99-0033","April 1998","June 2000","June 2000","May 2014","November 1, 1999","August 27, 2004","null","null","May 1, 2014","May 2, 2014","Johns Hopkins Oncology Center, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00003962"
231,"NCT00005946","Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: filgrastim|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: etoposide","","University of Maryland","All","up to 120 Years   (Child, Adult, Senior)","Phase 1","null","Other","Interventional","Primary Purpose: Treatment","MSGCC-9951|CDR0000067863|NCI-V00-1588","October 2000","June 2002","June 2002","March 2017","July 5, 2000","March 5, 2004","null","null","March 28, 2017","March 30, 2017","Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00005946"
232,"NCT00946283","Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome","null","Terminated","No Results Available","Breast Cancer|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor","Dietary Supplement: Lactobacillus rhamnosus GG","Safety as indicated by the lack of infection attributable to probiotic organisms","Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey","All","18 Years to 120 Years   (Adult, Senior)","","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","060802|P30CA072720|CDR0000649274|0220090096|NCI-2012-00597","March 2010","May 2013","October 14, 2015","February 2017","July 23, 2009","July 24, 2009","null","null","February 2, 2017","February 3, 2017","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States","https://ClinicalTrials.gov/show/NCT00946283"
233,"NCT00019656","Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Unspecified Adult Solid Tumor, Protocol Specific","Drug: perifosine","","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","NIH","Interventional","Primary Purpose: Treatment","CDR0000066960|NCI-99-C-0043|NCI-T98-0065","August 1999","null","null","August 2004","July 11, 2001","January 27, 2003","null","null","April 28, 2015","April 29, 2015","Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States|NCI - Center for Cancer Research, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00019656"
234,"NCT00002742","Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: amphotericin B deoxycholate|Drug: nystatin","","Aronex Pharmaceuticals|National Cancer Institute (NCI)","All","2 Years and older   (Child, Adult, Senior)","Phase 3","null","Industry","Interventional","Allocation: Randomized|Primary Purpose: Supportive Care","CDR0000064660|AR-95-41.356-006|NCI-V96-0845","January 1996","null","September 2007","July 2007","November 1, 1999","August 24, 2004","null","null","March 25, 2013","March 26, 2013","Veterans Affairs Medical Center - Phoenix (Hayden), Phoenix, Arizona, United States|Holt-Krock Clinic, Fort Smith, Arkansas, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Office of Rosalda Rodriguez, M.D., Chula Vista, California, United States|Beckman Research Institute, City of Hope, Duarte, California, United States|Eisenhower Medical Center, Rancho Mirage, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|New Britain General Hospital, New Britain, Connecticut, United States|Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States|Sylvester Cancer Center, University of Miami, Miami, Florida, United States|Tampa Children's Hospital, Tampa, Florida, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|St. John's Pavilion - Springfield Clinic Research Department, Springfield, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Lake Charles Medical and Surgical Clinic, Lake Charles, Louisiana, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Boston University School of Medicine, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|United Hospital, Saint Paul, Minnesota, United States|Columbia Comprehensive Cancer Care Clinic, Columbia, Missouri, United States|University of Missouri-Columbia Hospital and Clinics, Columbia, Missouri, United States|Children's Mercy Hospital - Kansas City, Kansas City, Missouri, United States|Veterans Affairs Medical Center - Kansas City, Kansas City, Missouri, United States|Antibiotic Research Associates, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Jersey Shore Cancer Center, Neptune, New Jersey, United States|Riverview Medical Center, Red Bank, New Jersey, United States|Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States|Brooklyn Hospital Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|St. Vincent's Medical Center of Richmond, Staten Island, New York, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Brookview Research, Inc., Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Summa Health System, Akron, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center, Cleveland, Ohio, United States|Office of Ian Baird & Mark Herbert, Columbus, Ohio, United States|Infectious Disease Associates of N.W. Ohio, Toledo, Ohio, United States|Northeast Ohio Infectious Disease Associates, Inc., Youngstown, Ohio, United States|Medical Specialists, Inc., Zanesville, Ohio, United States|University of Oklahoma - Department of Pharmacy Practice, Oklahoma City, Oklahoma, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|University of Tennessee Medical Center at Knoxville, Knoxville, Tennessee, United States|Baptist Clinical Research Services, Memphis, Tennessee, United States|Texas Cancer Center at Brackenridge Hospital, Austin, Texas, United States|University of Texas Southwestern Medical School, Dallas, Texas, United States|Infectious Disease Associates of Houston, Houston, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Wilford Hall - 59th Medical Wing, Lackland Air Force Base, Texas, United States|South Texas Oncology and Hematology, San Antonio, Texas, United States|Scott and White Clinic, Temple, Texas, United States|Infections Limited, P.S., Tacoma, Washington, United States","https://ClinicalTrials.gov/show/NCT00002742"
235,"NCT00534118","Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant","null","Active, not recruiting","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: donor lymphocytes","Determine if response rate exceeds 10%|Estimate the complete Response rate|Duration of response|Assess toxicity of cellular therapy","Roswell Park Cancer Institute","All","up to 76 Years   (Child, Adult, Senior)","","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000564827|RPCI-I-00703","October 1, 2003","February 28, 2018","April 30, 2018","January 2018","September 20, 2007","September 24, 2007","null","null","January 2, 2018","January 4, 2018","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT00534118"
236,"NCT00009984","Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer","null","Terminated","No Results Available","Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia","Drug: fludarabine phosphate|Drug: thalidomide","Toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0|Incidence of complete and partial remission","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","70","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02393|NYWCCC-MTS-00-0535ME|CDR0000068429|NCI-639|N01CM62204","March 2002","November 2006","null","June 2013","February 2, 2001","January 27, 2003","null","null","June 5, 2013","June 6, 2013","Montefiore Medical Center, Bronx, New York, United States","https://ClinicalTrials.gov/show/NCT00009984"
237,"NCT00295997","Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia","null","Unknown status","No Results Available","Chronic Myeloproliferative Disorders|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: anti-thymocyte globulin|Biological: filgrastim|Biological: graft-versus-tumor induction therapy|Biological: therapeutic allogeneic lymphocytes|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methotrexate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","","University of California, San Francisco|National Cancer Institute (NCI)","All","up to 74 Years   (Child, Adult, Senior)","","35","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000463522|UCSF-01251|UCSF-H5010-19585-05|UCSF-2101","May 2005","null","null","April 2007","February 23, 2006","February 24, 2006","null","null","January 3, 2014","January 6, 2014","UCSF Comprehensive Cancer Center, San Francisco, California, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00295997"
238,"NCT00006225","Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer","null","Completed","No Results Available","Breast Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic/Myeloproliferative Diseases","Biological: filgrastim|Biological: recombinant flt3 ligand|Biological: recombinant human thrombopoietin|Biological: recombinant interleukin-3|Procedure: in vitro-treated peripheral blood stem cell transplantation","","Northwestern University","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","NU 97B2|NU-97B2|NCI-V00-1611","November 1999","January 2004","January 2004","May 2012","September 11, 2000","May 7, 2003","null","null","May 31, 2012","June 6, 2012","Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT00006225"
239,"NCT00006042","Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 70 Years   (Child, Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068057, J9966|P30CA006973|JHOC-J9966|JHOC-99110501|NCI-G00-1816","December 1999","null","null","March 2010","July 5, 2000","January 27, 2003","null","null","March 9, 2010","March 10, 2010","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00006042"
240,"NCT00015951","Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers","null","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes","Biological: bevacizumab|Drug: cytarabine|Drug: mitoxantrone hydrochloride","","University of Maryland|National Cancer Institute (NCI)|University of Maryland Greenebaum Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068576|MSGCC-0076|NCI-2490","April 2001","April 2003","March 2004","September 2009","May 6, 2001","January 27, 2003","null","null","September 23, 2009","September 24, 2009","Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States|Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00015951"
241,"NCT00376922","Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Pain|Precancerous Condition|Psychosocial Effects of Cancer and Its Treatment","Procedure: music therapy","State anxiety as measured by the State-Trait Anxiety Inventory (STAI) questionnaire|Perceived pain level as measured by the Visual Analogue Scale|Patient satisfaction as measured by a post-procedure questionnaire","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","","65","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CDR0000495315|CCCWFU-98306|CCCWFU-IRB00000468","June 2006","May 2007","May 2010","July 2012","September 13, 2006","September 15, 2006","null","null","May 25, 2017","May 30, 2017","Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00376922"
242,"NCT00450450","Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases","null","Terminated","Has Results","Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Juvenile Myelomonocytic Leukemia|Previously Treated Myelodysplastic Syndromes|Recurrent Childhood Acute Lymphoblastic Leukemia|Secondary Myelodysplastic Syndromes","Procedure: allogeneic bone marrow transplantation|Other: laboratory biomarker analysis|Biological: filgrastim","Estimated Two-year Event-free Survival (EFS)|Estimated Graft Failure Rate|Estimated Incidence of Grade III-IV Acute Graft-versus-host Disease (aGVHD)|Estimated 100-day Transplant Related Mortality (TRM) Percentage|Estimated Percentage of Chronic Graft-versus-host Disease (cGVHD)|Estimated Median Time to Neutrophil Engraftment|Estimated Median Length of Initial Hospitalization","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","27","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASCT0631|NCI-2009-01069|COG-ASCT0631|COG-PBMTC-STC051|CDR0000532926|U10CA098543","December 2007","June 2013","June 2013","February 2017","March 20, 2007","March 22, 2007","November 10, 2016","May 9, 2017","March 29, 2017","May 9, 2017","Children's Oncology Group, Arcadia, California, United States|University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Childrens Memorial Hospital, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|The Childrens Mercy Hospital, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|New York Medical College, Valhalla, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT00450450"
243,"NCT00049504","Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer","null","Completed","Has Results","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hematopoietic/Lymphoid Cancer|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage II Multiple Myeloma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Childhood Hodgkin Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia","Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: tacrolimus|Drug: mycophenolate mofetil|Genetic: polymerase chain reaction|Genetic: fluorescence in situ hybridization|Genetic: polymorphism analysis|Genetic: gene expression analysis|Radiation: total-body irradiation|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation","Donor Engraftment (Chimerism)|Incidence of Grades III-IV Acute GVHD|Non-relapse-related Mortality","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","53","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1667.00|NCI-2010-00166","January 2002","March 2011","February 2014","April 2017","November 12, 2002","January 27, 2003","April 10, 2017","May 17, 2017","April 10, 2017","May 17, 2017","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00049504"
244,"NCT00611351","Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Secondary Myelofibrosis","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: mycophenolate mofetil|Drug: tacrolimus|Genetic: polymerase chain reaction|Genetic: polymorphism analysis|Other: flow cytometry|Other: laboratory biomarker analysis|Other: pharmacogenomic studies|Other: pharmacological study|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Transplantation-related mortality at 100 days post-transplantation|Incidence of grade II-IV acute graft-versus-host-disease (GVHD)|Incidence of chronic GVHD|Event-free survival|Overall survival","University of Nebraska|National Cancer Institute (NCI)","All","19 Years to 65 Years   (Adult)","Phase 2","5","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","122-05|P30CA036727|UNMC-12205","June 2005","February 2008","September 2008","February 2011","February 7, 2008","February 8, 2008","null","null","February 3, 2011","February 7, 2011","","https://ClinicalTrials.gov/show/NCT00611351"
245,"NCT00255684","Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer","null","Terminated","Has Results","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: graft-versus-tumor induction therapy|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Radiation: radiation therapy","Number of Participants Who Survived 100 Days or Longer|Number of Participants Who Developed Acute Graft Versus Host Disease","University of Rochester","All","up to 75 Years   (Child, Adult, Senior)","","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000448637|URCC-U19403|URCC-RSRB-10063","December 2003","March 2013","June 2016","September 2016","November 18, 2005","November 21, 2005","May 18, 2016","June 27, 2016","September 28, 2016","November 3, 2016","James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States","https://ClinicalTrials.gov/show/NCT00255684"
246,"NCT00555048","Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer","null","Terminated","Has Results","Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: alemtuzumab|Drug: busulfan|Drug: cyclophosphamide|Drug: methotrexate|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Lowest Dose of Alemtuzumab Associated With Transplant-related Mortality|Life-threatening Infection|Grades III-IV Acute Graft-vs-host Disease (GVHD)|Overall Survival|Disease Relapse|Extensive Chronic GVHD|Graft Failure","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","Phase 1|Phase 2","1","Other|NIH","Interventional","Primary Purpose: Treatment","1981.00|P30CA015704|FHCRC-1981.00|CDR0000574145","September 2007","October 2010","null","April 2017","November 6, 2007","November 7, 2007","April 17, 2017","May 24, 2017","April 17, 2017","May 24, 2017","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00555048"
247,"NCT00004065","Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer","null","Completed","No Results Available","Bladder Cancer|Breast Cancer|Colorectal Cancer|Gastric Cancer|Head and Neck Cancer|Kidney Cancer|Leukemia|Lung Cancer|Melanoma (Skin)|Ovarian Cancer|Prostate Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: tanespimycin","","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","99-037|CDR0000067267|NCI-T99-0035|UCLA-0206019","July 1999","March 2005","March 2005","June 2013","December 10, 1999","January 27, 2003","null","null","June 20, 2013","June 24, 2013","Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00004065"
248,"NCT00004061","Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Oral Complications","Biological: filgrastim|Biological: palifermin|Drug: cyclophosphamide|Drug: etoposide|Drug: ifosfamide|Procedure: peripheral blood stem cell transplantation|Procedure: quality-of-life assessment|Radiation: radiation therapy","","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","111","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Supportive Care","AMGEN-KGF-980231-04|MSKCC-99029|CDR0000067261|NCI-G99-1574","May 1999","May 2003","December 2009","December 2009","December 10, 1999","May 25, 2004","null","null","June 25, 2013","June 26, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00004061"
249,"NCT00002553","Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma","Drug: cyclophosphamide|Procedure: allogeneic bone marrow transplantation|Radiation: low-LET cobalt-60 gamma ray therapy","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 55 Years   (Child, Adult)","Phase 2","50","Other|NIH","Interventional","Primary Purpose: Treatment","160.06|CDR0000063397|NCI-H94-0372","August 1990","null","June 2003","November 2011","November 1, 1999","April 26, 2004","null","null","November 28, 2011","November 30, 2011","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00002553"
250,"NCT00060255","High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors","null","Completed","No Results Available","Breast Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Testicular Germ Cell Tumor|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific","Drug: busulfan|Drug: carboplatin|Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Drug: melphalan|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Morbidity|Mortality|Overall outcome|Response rate|Toxicity|Disease-free survival|Overall survival","Roswell Park Cancer Institute","All","4 Years and older   (Child, Adult, Senior)","Phase 2","451","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000301587|RPCI-DS-9115","December 1991","August 2006","February 2013","May 2013","May 6, 2003","May 7, 2003","null","null","May 7, 2013","May 9, 2013","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT00060255"
251,"NCT00003269","Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors","null","Completed","No Results Available","Breast Cancer|Drug/Agent Toxicity by Tissue/Organ|Lung Cancer|Lymphoma|Ovarian Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Biological: sargramostim|Drug: amifostine trihydrate|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide","duration of neutropenia|incidence of nephrotoxicity|incidence of ototoxicity","Scripps Health","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CDR0000066165|SCRF-98014|ALZA-97-49-ii|NCI-V98-1396","February 1998","January 2001","January 2001","January 2011","November 1, 1999","May 24, 2004","null","null","January 6, 2011","January 10, 2011","Scripps Clinic, La Jolla, California, United States","https://ClinicalTrials.gov/show/NCT00003269"
252,"NCT00513474","Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant","null","Completed","Has Results","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporin-A|Drug: etoposide|Drug: methotrexate|Drug: rasburicase|Drug: sirolimus|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation|Drug: fludarabine|Drug: allopurinol","Percentage of Participants With Grades II to IV Acute Graft-Versus-Host Disease (aGVHD)|Uric Acid Levels|Number of Participant With Adverse Events (AE)|Graft-versus-host and Host-versus-graft Immune Responses","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult)","Phase 1","46","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CDR0000558480|MGH-07-071|DFCI-07-071","January 2008","February 12, 2013","February 12, 2013","April 2017","August 6, 2007","August 8, 2007","February 27, 2017","April 11, 2017","April 20, 2017","May 25, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT00513474"
253,"NCT00004058","12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder","null","Terminated","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Precancerous/Nonmalignant Condition","Drug: tetradecanoylphorbol acetate","","University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","5986; CDR0000067255|P30CA072720|CINJ-059806|UMDNJ-2716|NCI-G99-1573","December 1998","November 2004","November 2004","January 2010","December 10, 1999","January 27, 2003","null","null","January 25, 2010","January 26, 2010","Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States","https://ClinicalTrials.gov/show/NCT00004058"
254,"NCT00112567","Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","null","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes","Drug: fludarabine phosphate|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Safety|Risk of severe graft-versus-host disease|Kinetics of immune reconstitution|Risk of life-threatening infections","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 20 Years   (Child, Adult)","Phase 1|Phase 2","20","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","1629.00|FHCRC-1629.00|CDR0000430650","April 2003","null","July 2007","September 2010","June 2, 2005","June 3, 2005","null","null","September 17, 2010","September 21, 2010","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00112567"
255,"NCT00161187","Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor","null","Completed","No Results Available","Cancer","Biological: therapeutic allogeneic lymphocytes","Toxicity|Response|Presence of disease or antigen-specific lymphocytes","University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey","All","Child, Adult, Senior","Phase 1","37","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","010101|P30CA072720|0220003330|CDR0000540298","May 2001","October 2010","October 2011","September 2013","September 8, 2005","September 12, 2005","null","null","November 5, 2015","November 6, 2015","Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States","https://ClinicalTrials.gov/show/NCT00161187"
256,"NCT00489203","Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","null","Completed","No Results Available","Hematopoietic/Lymphoid Cancer|Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extramedullary Plasmacytoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Graft Versus Host Disease|Isolated Plasmacytoma of Bone|Juvenile Myelomonocytic Leukemia|Meningeal Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Disease, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma","Drug: beclomethasone dipropionate|Drug: placebo|Drug: tacrolimus|Drug: methotrexate|Procedure: allogeneic hematopoietic stem cell transplantation","Development of acute graft-versus-host disease (GVHD) with severity sufficient to require systemic immunosuppressive treatment|Cumulative glucocorticoid dose (measured as prednisone equivalents) per kg body weight|Peak and average skin, liver and gut morbidity stages and overall grades|Modified average acute GVHD index score|Cumulative incidence of systemic immunosuppressive treatment for acute GVHD|Cumulative incidence of topical therapy for acute GVHD, including psoralen and UV irradiation, hydrocortisone cream, topical tacrolimus, oral BDP, or oral swish and spit dexamethasone|Cumulative incidence of biopsy-proven gastrointestinal GVHD|Proportion of patients with grade IIa GVHD|Proportions of patients with grades IIa and IIb - IV GVHD|Cumulative incidence of chronic GVHD requiring systemic immunosuppressive treatment|Number of days in the hospital|Non-relapse mortality|Overall survival|Survival|Safety|Feasibility|Survival without recurrent malignancy","Fred Hutchinson Cancer Research Center","All","Child, Adult, Senior","Phase 2","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","2079.00|NCI-2009-01544","April 2007","November 2010","null","March 2015","June 20, 2007","June 21, 2007","null","null","March 5, 2015","March 26, 2015","Hackensack University Medical Center, Hackensack, New Jersey, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00489203"
257,"NCT00856388","Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","null","Active, not recruiting","Has Results","Accelerated Phase Chronic Myelogenous Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Aplastic Anemia|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Fanconi Anemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Paroxysmal Nocturnal Hemoglobinuria|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Waldenström Macroglobulinemia","Drug: fludarabine phosphate|Drug: melphalan|Radiation: total-body irradiation|Procedure: allogeneic hematopoietic stem cell transplantation|Biological: anti-thymocyte globulin","Day 100 TRM|Median Time to ANC Engraftment|Median Time to Platelet Engraftment|Rate of Complete Donor Chimerism - Blood|Acute GVHD Grade III-IV|1 yr Extenstive Chronic GVHD|3 yr Overall Survival","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","3 Years to 75 Years   (Child, Adult, Senior)","","62","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 118807|NCI-2009-01508","January 14, 2009","August 9, 2012","August 15, 2019","November 2017","March 4, 2009","March 5, 2009","May 5, 2016","June 13, 2016","November 29, 2017","December 25, 2017","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT00856388"
258,"NCT00103272","17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer","null","Terminated","No Results Available","Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia","Drug: tanespimycin|Drug: bortezomib","Maximum tolerated dose (MTD) of bortezomib) in combination with 17-AAG)","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","74","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-01463|OSU 0448|NCI-6520|CDR0000409584|OSU-2004C0084|OSU-0448|U01CA076576","April 2005","April 2008","null","June 2013","February 7, 2005","February 8, 2005","null","null","June 3, 2013","June 4, 2013","Ohio State University Medical Center, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT00103272"
259,"NCT00357708","Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases","null","Completed","No Results Available","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Chronic Myelomonocytic Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Philadelphia Chromosome Negative Chronic Myelogenous Leukemia|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia","Drug: decitabine|Drug: vorinostat|Other: laboratory biomarker analysis|Other: pharmacological study","Maximum tolerated dose and dose-limiting toxicity of vorinostat and decitabine","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","50","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-03088|2005-0723|U01CA062461","June 2006","October 2009","null","January 2013","July 26, 2006","July 27, 2006","null","null","January 4, 2013","January 7, 2013","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00357708"
260,"NCT00265837","Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer","null","Completed","No Results Available","Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: graft versus host disease prophylaxis/therapy|Procedure: allogeneic bone marrow transplantation|Procedure: in vitro-treated bone marrow transplantation","Incidence of graft-vs-host disease or graft failure","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 3","72","Other|NIH","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","J0165 CDR0000454926|P01CA015396|P30CA006973|JHOC-J0165|JHOC-WIRB-1908|JHOC-WIRB-20020342","December 2002","August 2007","August 2007","April 2014","December 14, 2005","December 15, 2005","null","null","April 16, 2014","April 17, 2014","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00265837"
261,"NCT00589602","T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases","null","Terminated","Has Results","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Malignant Plasma Cell Neoplasms|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Secondary Myelofibrosis","Procedure: peripheral blood lymphocyte therapy|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation (TBI)","Treatment-related Mortality (TRM)|The Rate of Acute Graft Versus Host Disease (GVHD)|Number of Participants With Duration of Absolute Neutropenia|Number of Participants Able to Receive T-cell Add Backs|Number of Participants With Relapse-free Survival","The Cleveland Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","13","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCF-6501|P30CA043703","January 2004","August 2009","December 2014","April 2017","January 1, 2008","January 9, 2008","September 20, 2016","May 30, 2017","April 18, 2017","May 30, 2017","Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT00589602"
262,"NCT00004114","Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer","null","Withdrawn","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes","Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation","","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067340|P30CA016042|UCLA-9902026|NCI-G99-1603","null","null","null","July 2012","December 10, 1999","February 16, 2004","null","null","September 30, 2015","October 2, 2015","","https://ClinicalTrials.gov/show/NCT00004114"
263,"NCT00005092","Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: Cyclophosphamide|Drug: Psoralen|Drug: Thiotepa|Procedure: Allogeneic bone marrow transplantation|Procedure: In vitro-treated peripheral blood stem cell transplantation (PBSCT)|Radiation: Radiation Therapy (RT)","Maximum Tolerated Dose (MTD) of T-cells photochemically treated with psoralen and ultraviolet A","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","up to 49 Years   (Child, Adult)","Phase 1","7","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DM98-283|P30CA016672|MDA-DM-98283|NCI-G00-1742|CDR0000067734","March 1999","August 2002","August 2002","July 2012","April 6, 2000","April 23, 2004","null","null","July 27, 2012","July 31, 2012","University of Illinois at Chicago, Chicago, Illinois, United States|Washington University Barnard Cancer Center, Saint Louis, Missouri, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00005092"
264,"NCT00462657","Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease","null","Unknown status","No Results Available","Graft Versus Host Disease|Infection|Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Genetic: polymerase chain reaction|Other: bronchoalveolar lavage|Other: immunoenzyme technique|Other: laboratory biomarker analysis|Procedure: bronchoscopy|Procedure: management of therapy complications","Sensitivity and specificity of galactomannan (GM) ELISA and real time PCR in detecting invasive aspergillosis (IA)|Diagnostic value of IA screening by GM ELISA and real time PCR, in terms of positive and negative predicative values","St. Bartholomew's Hospital|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","200","Other","Interventional","Primary Purpose: Diagnostic","CDR0000539539|BARTS-PECT2005|EU-20719|PFIZER-BARTS-PECT2005|SPRI-BARTS-PECT2005|GILEAD-BARTS-PECT2005|BARTS-05/Q0603/68","July 2005","null","null","September 2007","April 18, 2007","April 19, 2007","null","null","August 23, 2013","August 26, 2013","Saint Bartholomew's Hospital, London, England, United Kingdom|Royal Brompton Hospital, London, England, United Kingdom","https://ClinicalTrials.gov/show/NCT00462657"
265,"NCT00105001","Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer","null","Active, not recruiting","Has Results","Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Previously Treated Myelodysplastic Syndrome|Refractory Chronic Lymphocytic Leukemia|Refractory Plasma Cell Myeloma|Waldenstrom Macroglobulinemia|Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Lymphoma|Childhood Myelodysplastic Syndrome|Stage II Contiguous Adult Burkitt Lymphoma|Stage II Contiguous Adult Diffuse Large Cell Lymphoma|Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma|Stage II Contiguous Adult Diffuse Small Cleaved Cell Lymphoma|Stage II Adult Contiguous Immunoblastic Lymphoma|Stage II Contiguous Adult Lymphoblastic Lymphoma|Stage II Grade 1 Contiguous Follicular Lymphoma|Stage II Grade 2 Contiguous Follicular Lymphoma|Stage II Grade 3 Contiguous Follicular Lymphoma|Stage II Contiguous Mantle Cell Lymphoma|Stage II Non-Contiguous Adult Burkitt Lymphoma|Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma|Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma|Stage II Non-Contiguous Adult Diffuse Small Cleaved Cell Lymphoma|Stage II Adult Non-Contiguous Immunoblastic Lymphoma|Stage II Non-Contiguous Adult Lymphoblastic Lymphoma|Stage II Grade 1 Non-Contiguous Follicular Lymphoma|Stage II Grade 2 Non-Contiguous Follicular Lymphoma|Stage II Grade 3 Non-Contiguous Follicular Lymphoma|Stage II Non-Contiguous Mantle Cell Lymphoma|Stage II Small Lymphocytic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Burkitt Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Recurrent Childhood Hodgkin Lymphoma|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Secondary Myelodysplastic Syndrome|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Immunoblastic Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Childhood Burkitt Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage II Childhood Burkitt Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Childhood Burkitt Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Childhood Burkitt Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma","Drug: Fludarabine Phosphate|Radiation: Total-Body Irradiation|Procedure: Peripheral Blood Stem Cell Transplantation|Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Tacrolimus|Drug: Mycophenolate Mofetil|Drug: Sirolimus","Incidence of Grades II-IV Acute GVHD|Incidence of Non-relapse Mortality|Incidence of High-dose Corticosteroid Utilization.|Overall Survival|Progression-free Survival","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","210","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1938.00|NCI-2010-00268|P30CA015704|P01CA018029","November 2004","May 2011","null","November 2016","March 3, 2005","March 4, 2005","August 13, 2015","September 15, 2015","November 23, 2016","November 25, 2016","Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|Veterans Administration Center-Seattle, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Rigshospitalet University Hospital, Copenhagen, Denmark|Medizinische Univ Klinik Koln, Koln, Germany|Universitaet Leipzig, Leipzig, Germany|University of Tuebingen-Germany, Tuebingen, Germany","https://ClinicalTrials.gov/show/NCT00105001"
266,"NCT00521430","Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Nonmalignant Neoplasm|Unspecified Adult Solid Tumor, Protocol Specific","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: methotrexate|Drug: methylprednisolone|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Engraftment (neutrophil, platelet, and red blood cells)|Frequency and kinetics of mixed chimerism as assessed by polymerase chain reaction|Frequency and severity of regimen-related toxicities|Frequency of acute and chronic graft-versus-host disease|Immune reconstitution|Tumor response rate|Duration of tumor response|Survival","Asan Medical Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","","30","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000561542|AMC-UUCM-2004-0029","April 2004","May 2008","September 2008","October 2007","August 24, 2007","August 27, 2007","null","null","March 25, 2013","March 26, 2013","Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT00521430"
267,"NCT00732316","Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome","null","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes","Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","tumor response|Donor cell engraftment (neutrophil, platelet, and red blood cells)|Acute and chronic graft-versus-host disease","Asan Medical Center|Pusan National University Hospital","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","54","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000600347|AMC-UUCM-2008-0037","April 2008","December 2009","May 2011","July 2012","August 8, 2008","August 11, 2008","null","null","July 16, 2012","July 17, 2012","Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT00732316"
268,"NCT00245037","Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","Bu Flu TBI","Completed","Has Results","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Precancerous Condition","Biological: therapeutic allogeneic lymphocytes|Drug: busulfan|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: peripheral blood stem cell transplantation|Radiation: Total Body Irradiation (TBI)|Drug: Granulocyte colony-stimulating factor (G-CSF)|Drug: Phenytoin|Drug: Methotrexate","Regimen-Related Toxicities|Non-relapse Mortality|Overall Survival|Progression-Free Survival|Relapse Mortality|Acute Graft-Versus-Host Disease (aGVHD) Outcome|Chronic Graft-Versus-Host Disease (cGVHD) Outcome","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","147","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00000210|P30CA016058|OHSU-HEM-05011-L|OHSU-210","June 2005","August 2015","August 2015","September 2017","October 25, 2005","October 27, 2005","April 20, 2017","July 2, 2017","September 25, 2017","September 27, 2017","Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States","https://ClinicalTrials.gov/show/NCT00245037"
269,"NCT00006220","Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy","null","Terminated","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: arsenic trioxide|Drug: tretinoin","Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT)|Likelihood of complete (CR) or partial (PR) response following therapy|Explore the pharmacokinetics of arsenic trioxide alone and in combination with ATRA|Evaluate acute and chronic toxicities of arsenic trioxide alone and in combination with ATRA.|Determine the effects of arsenic trioxide alone and combined with ATRA on bcl-2, pml, and class I antigen expression and on apoptosis. Determine the effects of arsenic trioxide on T and B cell number and function","Washington University School of Medicine|National Cancer Institute (NCI)","All","15 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","5","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","CDR0000068108|WU-99-0236|NCI-V00-1608","June 1999","November 2000","February 2002","February 2013","September 11, 2000","May 20, 2004","null","null","February 4, 2013","February 6, 2013","Washington University Barnard Cancer Center, Saint Louis, Missouri, United States","https://ClinicalTrials.gov/show/NCT00006220"
270,"NCT00005942","Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy","null","Completed","No Results Available","Chronic Myelomonocytic Leukemia|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation","Drug: liposomal daunorubicin citrate|Drug: semaxanib|Other: laboratory biomarker analysis","MTD of semaxanib defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicities|Achievement of CR, defined as normalization of the peripheral blood and bone marrow with 5% or less blasts, normo-or hypercellular marrow, a granulocyte count of 1x 10^9 L or above, and a platelet count of 100 x 10^9 L or above","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","37","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02329|ID99-341|CDR0000067822","March 2000","December 2000","null","January 2013","July 5, 2000","May 26, 2004","null","null","January 22, 2013","January 23, 2013","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00005942"
271,"NCT00691015","Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant","null","Completed","Has Results","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: rituximab|Drug: busulfan|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: etoposide|Drug: fludarabine phosphate|Drug: melphalan|Radiation: total body irradiation (TBI)|Drug: anti-thymocyte globulin IV","Incidence of Acute Graft-versus-host Disease (GVHD)|Severity of Acute Graft-versus-host Disease (GVHD)|Safety, as Defined by Serious Adverse Events and Adverse Events Related to Study Treatment.|Incidence of Chronic GVHD.|Time to Engraftment (i.e., Absolute Neutrophil Recovery [ANC > 500/mm³] )|Overall Survival.|Incidence of Infections, Including Bacterial, Fungal, and Viral Infections (i.e., CMV and EBV Reactivation, Including Post-transplant Lymphoproliferative Disorders)|Karnofsky Performance Status Performance Status","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","48","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2007-127|P30CA022453|GENZ-WSU-2007-127","May 2008","April 2014","April 2014","May 2017","June 4, 2008","June 5, 2008","December 9, 2015","June 28, 2017","May 26, 2017","June 28, 2017","Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States","https://ClinicalTrials.gov/show/NCT00691015"
272,"NCT00534430","Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer","null","Active, not recruiting","No Results Available","Leukemia|Myelodysplastic Syndromes","Drug: busulfan|Drug: cyclosporine|Drug: etoposide|Drug: mycophenolate mofetil|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation","Efficacy as determined by disease free survival|Disease-free survival at 2 years and 5 years|Prognostic factors for relapse, disease-free survival, and overall survival evaluated by cytogenetics, WBC at presentation, targeted busulfan dose, and number of courses of induction therapy to achieve remission|Early and late toxicities","City of Hope Medical Center|National Cancer Institute (NCI)","All","16 Years to 50 Years   (Child, Adult)","Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","99041|P30CA033572|CHNMC-99041|CDR0000564777","January 2000","January 2018","January 2018","January 2017","September 20, 2007","September 24, 2007","null","null","January 31, 2017","February 1, 2017","","https://ClinicalTrials.gov/show/NCT00534430"
273,"NCT00062140","Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Drug: cyclophosphamide|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 1","null","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","1797.00|FHCRC-1797.00|CDR0000304522","April 2003","null","July 2004","September 2010","June 5, 2003","June 6, 2003","null","null","September 20, 2010","September 21, 2010","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00062140"
274,"NCT00053157","Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: sargramostim","","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","5 Years to 60 Years   (Child, Adult)","","10","Other|NIH","Interventional","Primary Purpose: Supportive Care","RPC 02-01|RPCI-RPC-0201","June 2002","August 2004","null","January 2013","January 27, 2003","January 28, 2003","null","null","January 30, 2013","January 31, 2013","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT00053157"
275,"NCT00044954","Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","null","Unknown status","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: therapeutic allogeneic lymphocytes|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","","Simmons Cancer Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000069461|UTSMC-0799296|AMGEN-UTSMC-0799296|IBMTR-SC-00-03.1|ROCHE-UTSMC-0799296|SPRI-UTSMC-0799296|NCI-V02-1705","November 2001","null","null","February 2005","September 6, 2002","January 27, 2003","null","null","February 6, 2009","February 9, 2009","Rocky Mountain Cancer Centers - Denver Midtown, Denver, Colorado, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States|Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States|Kansas City Cancer Centers - Central, Kansas City, Missouri, United States|Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States|Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center, Nashville, Tennessee, United States|Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States|Texas Transplant Institute, San Antonio, Texas, United States|Massey Cancer Center at Virginia Commonwealth University, Richmond, Virginia, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT00044954"
276,"NCT00002809","Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Biological: filgrastim|Biological: sargramostim|Biological: therapeutic immune globulin|Drug: cyclophosphamide|Drug: methotrexate|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","","Temple University","All","17 Years to 60 Years   (Child, Adult)","Phase 2","10","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000064937|TUHSC-2803|NCI-V96-0950","August 1996","December 2003","December 2003","September 2010","November 1, 1999","January 27, 2003","null","null","September 30, 2010","October 1, 2010","Fox Chase-Temple Cancer Center, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00002809"
277,"NCT00134004","Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer","null","Completed","Has Results","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","Transplant-related Mortality|Relapse Rate|Progression-free Survival|Graft Failure Rate|Hematologic and Non-hematologic Toxicities as Measured by NCI Common Toxicity Criteria for Adverse Events, v 3.0 Weekly Until 1 Year After Transplantation","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","6 Months to 74 Years   (Child, Adult, Senior)","Phase 2","210","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J0457 CDR0000440990|P01CA015396|P30CA006973|JHOC-J0457|JHOC-04072704","October 2004","January 2015","January 2015","September 2015","August 22, 2005","August 24, 2005","June 26, 2015","August 24, 2015","September 2, 2015","October 6, 2015","Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Hahnemann University Hospital, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00134004"
278,"NCT00916045","Pilot Study of Unrelated Cord Blood Transplantation","null","Terminated","No Results Available","Leukemia, Myeloid, Acute|Myelodysplastic Syndromes|Leukemia, Lymphoblastic, Acute|Lymphoma, Non-Hodgkin|Hodgkin Disease|Chronic Lymphocytic Leukemia","Drug: Thiotepa|Drug: Fludarabine|Drug: Intravenous busulphan|Drug: Thymoglobulin|Drug: Ciclosporin|Drug: Mycophenolate mofetil (MMF)|Drug: Cyclophosphamide|Radiation: Radiotherapy|Drug: Melphalan","Treatment related mortality at day 100|Disease free survival at one year post-transplant for each cohort|Chimerism|Incidence of neutrophil engraftment by day 42|Incidence of platelet engraftment by 6 months|Incidence of grade II-IV and III-IV acute GVHD|Incidence of chronic GVHD during the first year|One year overall survival for each treatment cohort|Incidence of systemic infections|Incidence of CMV, adenovirus and EBV activation|Immune reconstitution|Dynamics of EBV infection and immunity following cord blood transplantation|The development (if any) of transplant associated post transplant lymphoproliferative disease (PTLD)|Identify any possible predictive markers for patients most at risk of PTLD development|Quality of life|Incidence of one year relapse or disease progression for each treatment cohort","King's College Hospital NHS Trust","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07CC12|REC - 07/H0808/193|EudraCT - 2007-001657-26","September 2009","March 2012","March 2012","March 2012","June 5, 2009","June 8, 2009","null","null","February 10, 2015","February 11, 2015","King's College Hosptial NHS Foundation Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT00916045"
279,"NCT00027560","Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer","null","Completed","Has Results","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: alemtuzumab|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Overall Survival|Acute Graft-versus-Host Disease Matched Related Patients|Acute Graft-versus-Host Disease Unrelated and Mismatched Related Patients|Extensive Chronic Graft-versus-Host Disease Matched Related Patients|Extensive Chronic Graft-versus-Host Disease Unrelated and Mismatched Related Patients","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","51","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01-092|MSKCC-01092|NCI-G01-2028","July 2001","April 2009","April 2009","December 2012","December 7, 2001","January 27, 2003","November 27, 2012","January 7, 2013","December 3, 2012","January 7, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00027560"
280,"NCT00006350","Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: daclizumab|Biological: therapeutic allogeneic lymphocytes|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: peripheral blood stem cell transplantation","","University of Maryland","All","18 Years to 120 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Primary Purpose: Treatment","MSGCC-0012|CDR0000068212|NCI-V00-1624","January 2000","November 2001","November 2001","March 2017","October 4, 2000","March 8, 2004","null","null","March 28, 2017","March 30, 2017","Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00006350"
281,"NCT00110045","Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant","null","Completed","No Results Available","Cancer","Drug: caspofungin acetate","Response rate as assessed by standard criteria after completion of study treatment|Response rate as assessed by standard and alternative criteria at 84 days and after completion of study treatment|Survival rate at 84 days|Safety","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 2","171","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Supportive Care","EORTC-65041|EUDRACT-2004-002944-90","February 2005","March 2008","null","September 2012","May 3, 2005","May 4, 2005","null","null","September 20, 2012","September 24, 2012","CHU Liege - Domaine Universitaire du Sart Tilman, Liege, Belgium|Centre Hospitalier Universitaire Henri Mondor, Creteil, France|Hopital Edouard Herriot - Lyon, Lyon, France|Hopital Saint-Louis, Paris, France|Hopital Universitaire Hautepierre, Strasbourg, France|Medizinische Poliklinik, Universitaet Wuerzburg, Wuerzburg, Germany|Ospedale Santa Croce, Cuneo, Italy|Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Ospedale San Martino, Genoa, Italy|Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore, Rome, Italy|National Cancer Institute - Bratislava, Bratislava, Slovakia|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Hacettepe University - Faculty of Medicine, Ankara, Turkey","https://ClinicalTrials.gov/show/NCT00110045"
282,"NCT00755040","Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder","null","Completed","Has Results","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Drug: cyclosporine ophthalmic emulsion|Other: placebo","Number of Patients That Develop Ocular GVHD While on Study in the Two Arms (Ocular Cyclosporine (Restasis) vs. Placebo)|Numerical Score of Ocular Surface Disease Index (OSDI) and Development or Lack of Ocular GVHD (by Ophthalmologic Examination) as Measured by Odds Ratio in a Linear Regression Model.","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","164","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","VICC BMT 0766|P30CA068485|VU-VICC-BMT-0766|VU-080786","October 2008","December 2014","May 2016","January 2017","September 17, 2008","September 18, 2008","October 14, 2016","December 8, 2016","January 24, 2017","March 7, 2017","Stanford University, Palo Alto, California, United States|Norwestern Memorial Hospital, Chicago, Illinois, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|M. D. Anderson Cancer Center, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00755040"
283,"NCT00014469","Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer","null","Completed","No Results Available","Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Drug: busulfan|Drug: melphalan|Drug: methotrexate|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation","","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","00-126|P30CA008748|P01CA023766|MSKCC-00126|NCI-H01-0070","December 2000","May 2007","May 2007","March 2013","April 10, 2001","January 27, 2003","null","null","March 6, 2013","March 7, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00014469"
284,"NCT00237627","Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer","null","Completed","No Results Available","Breast Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Ovarian Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: PS-341|Drug: Doxil|Drug: Velcade","Maximum tolerated dose (MTD) of PS-341 in combination with Doxil (Phase I)|Response rate of the combination of Velcade and Doxil in patients with metastatic breast cancer","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","107","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 2020|UNC-LCCC-2020|CDR0000368767","May 2001","December 2006","January 2010","May 2012","October 7, 2005","October 12, 2005","null","null","May 16, 2012","May 18, 2012","Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00237627"
285,"NCT00001620","Screening for Hematology Branch Protocols","null","Recruiting","No Results Available","Anemia|Hematologic Neoplasm|Neutropenia|Pancytopenia|Thrombocytopenia","","Determine patient eligibility","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","2 Years and older   (Child, Adult, Senior)","","9999","NIH","Observational","Observational Model: Other|Time Perspective: Other","970041|97-H-0041","December 10, 1996","null","null","November 27, 2017","November 3, 1999","November 4, 1999","null","null","November 28, 2017","November 29, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00001620"
286,"NCT00003572","Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: peripheral blood lymphocyte therapy|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","20","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066639, J9845|R01CA067782|P30CA006973|JHOC-98070603|JHOC-9845|NCI-H98-0023","August 1998","April 2002","April 2002","May 2014","November 1, 1999","February 20, 2004","null","null","May 1, 2014","May 2, 2014","Johns Hopkins Oncology Center, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00003572"
287,"NCT00134017","Combination Chemotherapy, Tacrolimus, and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant For Hematologic Cancer","null","Active, not recruiting","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Drug: busulfan|Drug: cyclophosphamide|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: bone marrow ablation with stem cell support","Dose Finding|Immune reconstitution and disease control","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","92","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J0373 CDR0000440164|P01CA015396|P30CA006973|JHOC-03121504|JHOC-J0373","May 2004","April 2017","null","October 2016","August 22, 2005","August 24, 2005","null","null","October 17, 2016","October 18, 2016","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00134017"
288,"NCT00317785","Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases","null","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes","Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Drug: mycophenolate mofetil|Drug: sirolimus|Drug: tacrolimus|Other: pharmacological study|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation","Non-relapse mortality (NRM) at 200 days|Overall survival|Relapse rate|Sinusoidal obstruction syndrome (SOS)|Acute renal failure|Respiratory failure|Cause of death","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","50","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","1998.00|FHCRC-1998.00|CDR0000471840","May 2005","November 2007","null","May 2010","April 24, 2006","April 25, 2006","null","null","May 5, 2010","May 7, 2010","Seattle Cancer Care Alliance, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00317785"
289,"NCT00423514","Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease","null","Active, not recruiting","No Results Available","Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes","Biological: filgrastim|Drug: clofarabine|Drug: melphalan|Drug: mycophenolate mofetil|Drug: tacrolimus|Drug: thiotepa|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Relapse of leukemia|Overall and disease-free survival|Early post-transplant regimen-related severe morbidity (grade III to IV nonhematologic toxicity) and mortality as measured by the NCI Cancer Therapy Evaluation Program CTCAE v 3.0","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","up to 54 Years   (Child, Adult)","Phase 1|Phase 2","42","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-125|MSKCC-06125","November 2006","November 2018","November 2018","May 2017","January 16, 2007","January 18, 2007","null","null","May 2, 2017","May 3, 2017","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00423514"
290,"NCT00126477","Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes|Quality of Life","Procedure: cognitive assessment|Procedure: management of therapy complications|Procedure: psychosocial assessment and care|Procedure: quality-of-life assessment","Neuroendocrine status of disease-free childhood transplant patients at 5 years after transplant and ≥ age 18|Cognitive capability of disease-free childhood transplant patients at 5 years after transplant and ≥ age 18|Physical capability of disease-free childhood transplant patients at 5 years after transplant and ≥ age 18|Psychosocial status of disease-free childhood transplant patients at 5 years after transplant and ≥ age 18","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","750","Other|NIH","Observational","","1098.00|FHCRC-1098.00|CDR0000434793","March 1996","April 2007","March 2010","April 2013","August 2, 2005","August 4, 2005","null","null","April 29, 2013","May 1, 2013","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00126477"
291,"NCT00448201","Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease","null","Completed","Has Results","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Biological: sargramostim|Biological: therapeutic allogeneic lymphocytes|Drug: busulfan|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Treatment-related Mortality|Complete Response at 6 and 12 Months Post-transplant|Complete or Mixed Donor Chimerism at 30, 60, and 90 Days Post-transplant|5-year Disease-free Survival|Graft-vs-host Disease at 6 Months Post-transplant","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","All","10 Years and older   (Child, Adult, Senior)","Phase 2","71","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 0306|P30CA016086","January 7, 2011","January 11, 2011","May 23, 2012","May 2017","March 14, 2007","March 16, 2007","April 17, 2017","May 30, 2017","May 23, 2017","May 30, 2017","Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00448201"
292,"NCT00028730","Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: thiotepa|Procedure: allogeneic bone marrow transplantation|Radiation: radiation therapy","Minimal transplantation related mortality|High disease-free survival at 2 years","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","Phase 2","25","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","01-105|P30CA008748|P01CA033049|P01CA023766|MSKCC-01105|NCI-H01-0083","August 2001","July 2006","June 2008","December 2015","January 4, 2002","January 27, 2003","null","null","December 21, 2015","December 22, 2015","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00028730"
293,"NCT02658201","Ultrafast MRI Imaging to Exclude Constipation","FIESTA","Completed","No Results Available","Constipation","Device: MRI","Correlation between constipation scores for abdominal radiographs and FIESTA MRI|Inter-rater correlation of constipation scores|Observed, clinically relevant, additional findings on MRI compared to abdominal radiographs as assessed by the scoring radiologist at the time of review","Sheffield Children's NHS Foundation Trust","All","6 Years to 18 Years   (Child, Adult)","","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCH/12/026","September 2012","April 2014","July 2017","July 2017","April 23, 2015","January 18, 2016","null","null","October 12, 2017","October 13, 2017","Sheffield Children's NHS Foundation Trust, Sheffield, Sheffield (South Yorkshire district), United Kingdom","https://ClinicalTrials.gov/show/NCT02658201"
294,"NCT00104975","Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: alemtuzumab|Biological: therapeutic allogeneic lymphocytes|Drug: fludarabine phosphate|Drug: melphalan|Drug: tacrolimus|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation","","Yale University|National Cancer Institute (NCI)","All","18 Years to 55 Years   (Adult)","Phase 1","20","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000413698|YALE-25971|NCI-6765","February 2005","May 2008","May 2008","December 2016","March 3, 2005","March 4, 2005","null","null","December 13, 2016","December 15, 2016","Yale Cancer Center, New Haven, Connecticut, United States","https://ClinicalTrials.gov/show/NCT00104975"
295,"NCT00005988","Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy","null","Completed","No Results Available","Graft Versus Host Disease|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myeloma","Drug: cyclophosphamide|Drug: cyclosporine|Drug: leucovorin calcium|Drug: methotrexate|Drug: methylprednisolone|Procedure: in vitro-treated bone marrow transplantation|Radiation: radiation therapy","Incidence of primary graft failure|Incidence of hyperacute GVHD|Incidence of Grade D acute GVHD|Incidence of adverse events","Dana-Farber Cancer Institute|National Cancer Institute (NCI)","All","up to 40 Years   (Child, Adult)","Phase 1","5","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","99-205|P30CA006516|GENE-C9909-38|NCI-G00-1801|CDR0000067977","February 2000","June 16, 2001","March 8, 2002","March 2017","July 5, 2000","May 3, 2004","null","null","March 30, 2017","April 4, 2017","Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00005988"
296,"NCT02758080","Matching Patients With Hematologic Malignancy to Adequate Clinical Trials","null","Recruiting","No Results Available","Hematologic Malignancies","Other: Matching on the basis of molecular analysis|Other: Matching on the basis of physician's choice","Response rate|Types of identified molecular profile|Overall survival|Progression-free survival|Toxicity profile|Frequencies of identified molecular profile","Seoul National University Hospital|The Korea Health Technology R&D Project through the Korea Health Industry Development Institute|The Ministry of Health & Welfare, Republic of Korea","All","18 Years and older   (Adult, Senior)","","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-1690","January 2016","June 2019","June 2019","October 2017","April 15, 2016","May 2, 2016","null","null","October 24, 2017","October 26, 2017","Seoul National University Hospital, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT02758080"
297,"NCT01658241","Panobinostat Biological Correlates Study","VEG VCA1","Active, not recruiting","No Results Available","Nodal Lymphoma|Lymphoma With Cutaneous Involvement|Lymphoma in Leukemic Phase|Marrow Involvement With Lymphoma|Multiple Myeloma","Drug: panobinostat","Change in gene expression profile of tumor samples taken before and after treatement with panobinostat|Overall response (OR): this is a composite clinical endpoint including those who have achieved a complete remission (CR) or partial remission (PR) by conventional disease-appropriate criteria. (i.e. OR=CR+PR)|Clinical benefit: a composite endpoint including those with complete remission, partial remission, marginal response and those with otherwise stable disease that has been maintained for at least 2 cycles of therapy|Time to response: the time from first drug dose to best confirmed response|Time to progression: the time from initial observation of response to confirmed disease progression, or the time from first drug dose to confirmed disease progression|Progression-free survival: time from trial registration to disease progression or death from any cause|Disease-specific biological improvement - as defined in the protocol|Sustained disease-specific biological improvement - as defined in the protocol","Peter MacCallum Cancer Centre, Australia","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","12/18","July 2012","July 2016","July 2018","September 2017","July 20, 2012","August 6, 2012","null","null","September 18, 2017","September 20, 2017","Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia","https://ClinicalTrials.gov/show/NCT01658241"
298,"NCT00014482","Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation","null","Completed","No Results Available","Anxiety Disorder|Chronic Myeloproliferative Disorders|Depression|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Pain","Procedure: pain therapy|Procedure: psychosocial assessment and care","","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","null","Other|NIH","Interventional","Allocation: Randomized","00-134|CDR0000068547|NCI-G01-1934","December 2000","March 2003","March 2003","June 2013","April 10, 2001","January 27, 2003","null","null","June 17, 2013","June 18, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00014482"
299,"NCT00255710","Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: filgrastim|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Post-transplant immunosuppression regimen with ≤ 20% incidence of a grade II-IV graft-versus-host-disease (GVHD) and < 10% incidence of nonengraftment (< 5% donor chimerism) at day 60 following transplant|Incidence and severity of acute GVHD at day 60 following transplant|Frequency of mixed chimerism defined as any detectable donor cells at day 60 following transplant","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","60","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Supportive Care","CDR0000449652|P01CA015396|P30CA006973|JHOC-J0169|WIRB-20020304","July 2002","null","null","March 2010","November 18, 2005","November 21, 2005","null","null","March 16, 2010","March 17, 2010","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00255710"
300,"NCT00789776","Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer","null","Active, not recruiting","No Results Available","Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Aggressive Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Previously Treated Myelodysplastic Syndrome|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Indolent Adult Non-Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Small Lymphocytic Lymphoma|Waldenstrom Macroglobulinemia","Procedure: Allogeneic Bone Marrow Transplantation|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Biological: Natural Killer Cell Therapy|Drug: Tacrolimus|Radiation: Total-Body Irradiation","Dose-limiting toxicity (Phase I)|Relapse (Phase II)|Acute GvHD (Phase II)|Chronic extensive GvHD (Phase II)|Contribution of KIR ligand alloreactivity to relapse (Phase II)|Engraftment (Phase II)|Evaluation of rejection (Phase II)|NK cell infusion on post-transplant immune reconstitution (Phase II)|Non-relapse mortality (Phase II)|Overall survival (Phase II)|Progression (Phase II)","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|The Wayne D. Kuni and Joan E. Kuni Foundation","All","Child, Adult, Senior","Phase 1|Phase 2","42","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2230.00|NCI-2010-00106|P01CA078902|P30CA015704","October 13, 2008","May 18, 2017","May 18, 2021","November 2017","November 12, 2008","November 13, 2008","null","null","November 8, 2017","November 13, 2017","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT00789776"
301,"NCT00089037","Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Drug: methotrexate|Drug: sirolimus|Drug: tacrolimus","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 1|Phase 2","null","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Supportive Care","1811.00|FHCRC-1811.00|CDR0000378004","June 2003","April 2005","April 2005","July 2011","August 4, 2004","August 5, 2004","null","null","July 13, 2011","July 15, 2011","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00089037"
302,"NCT00096096","Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Drug: mycophenolate mofetil|Drug: tacrolimus","Efficacy|Safety|Area under the curve of plasma mycophenolic acid","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Supportive Care","1893.00|FHCRC-1893.00|CDR0000391026","August 2004","May 2006","null","May 2010","November 9, 2004","November 9, 2004","null","null","May 12, 2010","May 13, 2010","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00096096"
303,"NCT00008307","Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders","null","Unknown status","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Drug: methylprednisolone|Drug: mycophenolate mofetil|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Procedure: syngeneic bone marrow transplantation","Hematopoietic recovery|Incidence of graft-versus-host disease|Chemotherapeutic toxicity|Relapse and survival","Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)","All","1 Year to 80 Years   (Child, Adult, Senior)","Phase 2","52","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000068396|CPMC-IRB-8462|CPMC-IRB-CAMP-25|NCI-G00-1897","April 1998","null","null","April 2006","January 6, 2001","January 27, 2003","null","null","January 3, 2014","January 6, 2014","Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00008307"
304,"NCT00118352","Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer","null","Completed","Has Results","Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Juvenile Myelomonocytic Leukemia|Mast Cell Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia","Biological: alemtuzumab|Radiation: total-body irradiation|Drug: fludarabine phosphate|Drug: cyclosporine|Drug: mycophenolate mofetil|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Biological: graft versus host disease prophylaxis/therapy|Other: laboratory biomarker analysis","Incidence of Grade III-IV Acute GVHD|Incidence of Graft Rejection|Incidence of High-dose Corticosteroid Utilization.|Incidence of Non-relapse Mortality|Incidence of Infection|Immune Reconstitution|Disease Progression/Relapse","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 74 Years   (Child, Adult, Senior)","Phase 2","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1959.00|NCI-2009-01496|P01CA018029|P30CA015704","March 2005","July 2010","May 26, 2015","April 2017","July 8, 2005","July 11, 2005","January 12, 2017","May 30, 2017","April 25, 2017","May 30, 2017","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States|University of Torino, Torino, Italy","https://ClinicalTrials.gov/show/NCT00118352"
305,"NCT02143635","Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt","null","Recruiting","No Results Available","Advanced Solid and Hematological TP53wt Tumors","Drug: HDM201|Drug: ancillary treatment","Incidence of dose limiting toxicities (DLTs)|Number of patients with adverse events (AEs)|Pharmacokinetics (PK) parameters of HDM201|Changes from baseline of Pharmacodynamics markers|Tumor response","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 1","225","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHDM201X2101","July 7, 2014","June 20, 2017","July 14, 2018","September 2017","May 19, 2014","May 21, 2014","null","null","September 12, 2017","September 14, 2017","Dana Farber Cancer Institute SC-6, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center Onc. Dep, New York, New York, United States|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Würzburg, Germany|Novartis Investigative Site, Kobe-city, Hyogo, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, Japan|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Taipei, Taiwan ROC, Taiwan","https://ClinicalTrials.gov/show/NCT02143635"
306,"NCT00085449","Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: alemtuzumab|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Drug: mycophenolate mofetil|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Engraftment rate|Risk of graft-vs-host disease|Progression-free survival (PFS)","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","56","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CALGB-100102|CDR0000370797","May 2006","January 2007","January 2007","July 2016","June 10, 2004","June 11, 2004","null","null","July 1, 2016","July 6, 2016","Moores UCSD Cancer Center, La Jolla, California, United States|Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States|UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States|St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Don Monti Comprehensive Cancer Center at North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, United States|Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States","https://ClinicalTrials.gov/show/NCT00085449"
307,"NCT00042822","FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma","null","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Drug: romidepsin","","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000069473|MSKCC-00116|NCI-1715","May 2002","March 2005","null","December 2009","August 5, 2002","January 27, 2003","null","null","May 14, 2011","May 17, 2011","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00042822"
308,"NCT02459743","Molecular Disease Profile of Hematological Malignancies","RELab1","Recruiting","No Results Available","Hematological Malignancies","","Cumulative incidence of gene mutations in principal clone and subclones in each hematological malignancy|Genotype-phenotype correlations between clinical characteristics and mutational status|Overall survival and disease-free survival according to clinical and biological risk factors at diagnosis and during disease evolution","University of Pavia|IRCCS Policlinico S. Matteo|Fondazione Salvatore Maugeri","All","18 Years and older   (Adult, Senior)","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PDS20140005575","February 2015","January 2017","December 2018","June 2015","February 25, 2015","June 2, 2015","null","null","June 4, 2015","June 8, 2015","Department of Hematology Oncology, IRCCS Policlinico San Matteo & University of Pavia, Italy, Pavia, Italy","https://ClinicalTrials.gov/show/NCT02459743"
309,"NCT00598624","Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)","AlloTreo","Unknown status","No Results Available","Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Diffuse Large Cell Lymphoma|Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Multiple Myeloma","Drug: Treosulfan IV","Efficacy: Evaluation of engraftment|Safety: Evaluation of the incidence of CTC grade 3 and 4 adverse events|Efficacy: Evaluation of disease free survival (DFS)|Efficacy: Evaluation of overall survival (OS)|Efficacy: Evaluation of relapse incidence (RI)|Efficacy: Documentation of donor chimerism|Safety: Evaluation of incidence of non-relapse mortality (NRM)|Safety: cumulative incidence of NRM|Safety: Evaluation of cumulative incidence and severity of acute and chronic graft vs. host disease (GvHD)|Safety: EBV reactivation","IRCCS San Raffaele","All","18 Years to 69 Years   (Adult, Senior)","Phase 2","175","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005-005182-11","September 2005","December 2009","December 2010","August 2009","January 10, 2008","January 22, 2008","null","null","August 10, 2009","August 11, 2009","Ematologia, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy|IRCCS San Raffaele; Unità Operativa di Ematologia, Milano, MI, Italy|USC Ematologia, Ospedali Riuniti, Bergamo, Italy|Ospedale centrale di Bolzano - Reparto di Ematologia, Bolzano, Italy|PO ""R.Binaghi"" - CTMO, Cagliari, Italy|AO ""Santa Croce"" e Carle - Reparto di Ematologia, Cuneo, Italy|Istituto Europeo di Oncologia - Divisione di Ematologia, Milano, Italy|Ospedale Civile - UTI ematologia per il trapianto emopoietico, Pescara, Italy|Arcispedale Santa Maria Nuova - SC di Ematologia, Reggio Emilia, Italy|Dipartimento Biotecnologie Cellulari ed Ematologia; Azienda Policlinico Umberto I, Roma, Italy|AO San Camillo Forlanini - UOC ematologia e trapianto, Roma, Italy|AOU Santa Maria della Misericordia - Clinica Ematologica, Udine, Italy","https://ClinicalTrials.gov/show/NCT00598624"
310,"NCT02562105","Prognosis of Hematological Cancer Patient Underwent Mechanical Ventillation","null","Completed","No Results Available","Hematological Malignancy|Acute Respiratory Failure|Mechanical Ventilation","Procedure: Mechanical ventilation","Survival|Sequential Organ Failure Assessment score|Simplified Acute Physiology Score II|Mode of mechanical ventilation|lowest Pa02/FiO2|Reason for need of ventilatory support","Mansoura University","All","18 Years to 75 Years   (Adult, Senior)","","50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","15.05.42","January 2015","August 2015","September 2015","September 2015","September 23, 2015","September 29, 2015","null","null","September 27, 2015","September 29, 2015","Mansoura Cancer Therapy Center, Mansoura, Dakahlia, Egypt","https://ClinicalTrials.gov/show/NCT02562105"
311,"NCT00323518","A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis","null","Completed","No Results Available","Oral Mucositis|Stomatitis","Drug: velafermin|Drug: placebo","the incidence of grade 3/4 oral mucositis using WHO grading system","CuraGen Corporation|Celldex Therapeutics","All","18 Years and older   (Adult, Senior)","Phase 2","390","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CG53135-CLN-12","May 2006","August 2008","August 2008","March 2016","May 8, 2006","May 9, 2006","null","null","March 14, 2016","April 13, 2016","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Alta Bates Comprehensive Cancer Center, Berkley, California, United States|Research Facility, La Jolla, California, United States|Scripps Green Medical Center, La Jolla, California, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|Rocky Mountain Blood and Marrow Transplant Program, Denver, Colorado, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|St. Francis Hospital and Health Centers, Beech Grove, Indiana, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Louisiana State University Health Science Center, Shreveport, Louisiana, United States|Wayne State University, Detroit, Michigan, United States|MAYO Clinic, Rochester, Minnesota, United States|Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Biomedical Research Alliance of New York, Bronx, New York, United States|Cornell Medical Center, New York, New York, United States|Biomedical Research Alliance of New York, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Legacy Good Samaritan Hospital and Cancer Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Fox Chase-Temple Bone Marrow Transplant Program, Philadelphia, Pennsylvania, United States|Roger Williams Medical Center, Providence, Rhode Island, United States|Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Texas Health Science Center, San Antonio, Texas, United States|Medical College of Wisonsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT00323518"
312,"NCT00185692","Allogeneic Transplantation From Related Haploidentical Donors","null","Completed","Has Results","Blood Cancer|Leukemia|Graft Versus Host Disease|Malignancy|CLL|NHL|Hodgkin's Disease|MDS","Procedure: non-myeloablative hematopoietic cell transplantation|Drug: Anti-Thymocyte Globulin|Drug: Cyclosporine|Drug: Mycophenolate Mofetil|Drug: G-CSF|Drug: Solumedrol|Drug: Acetaminophen|Drug: Diphenydramine|Drug: Hydrocortisone","Engraftment of Haploidentical CD34+ Selected Blood Stem Cells in Older Patients or Those With Medical Co-morbidities Following Total Lymphoid Irradiation and Antithymocyte Globulin Transplant Conditioning|Acute Graft-versus-Host Disease (GVHD) Grade 2-4 Risk From Time of Transplant Until Day 90 Post-transplant","Stanford University","All","12 Months and older   (Child, Adult, Senior)","Phase 2","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-13371|75117|BMT 124","August 2000","December 2010","December 2010","January 2015","September 12, 2005","September 16, 2005","December 1, 2016","January 26, 2017","December 1, 2016","January 26, 2017","Stanford University School of Medicine, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT00185692"
313,"NCT03187756","Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft","null","Recruiting","No Results Available","Hematopoietic Malignancies","Drug: Cyclophosphamide","Relapse free survival (EFS) rate|Progression free survival (EFS) rate|Death free survival (EFS) rate","New York University School of Medicine","All","18 Years to 90 Years   (Adult, Senior)","Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-00042","June 2, 2017","December 2017","January 2018","August 2017","June 2, 2017","June 15, 2017","null","null","August 8, 2017","August 10, 2017","New York University School of Medicine, New York, New York, United States","https://ClinicalTrials.gov/show/NCT03187756"
314,"NCT01288378","Empirical Versus Preemptive Antifungal Therapy","null","Active, not recruiting","No Results Available","Fungal Infection|Leukemia|Myelodysplastic Syndromes","Drug: caspofungin acetate","Overall survival at 42 days after randomization|Overall survival at 84 days after randomization|Development of proven or probable invasive fungal disease (IFD) during the 42 and 84 days following randomization|Proper management according to allocated treatment arm (i.e., appropriate administration of caspofungin acetate in compliance to protocol, and compliance to the treatment strategy) during the 42 and 84 days after randomization|Survival-free of fungal infection during the 42 and 84 days following randomization|Safety (adverse event [AE] and serious adverse event [SAE]) as assessed by CTCAE criteria v4.0|Number of days under caspofungin treatment or under another antifungal treatment administered after caspofungin (evaluation will be done at day 42 and day 84 after randomization)|Costs related to the strategy for initiating and monitoring antifungal treatment during the 42 and 84 days following randomization","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 3","556","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","EORTC-65091-06093|2010-020814-27|MK-0991-070","March 2012","July 2018","July 2018","December 2017","February 1, 2011","February 2, 2011","null","null","December 12, 2017","December 13, 2017","A.Z. St. Jan, Brugge, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels, Belgium|U.Z. Gasthuisberg, Leuven, Belgium|C.H.U. Sart-Tilman, Liège, Belgium|Masaryk University, Brno, Czechia|CHU de Caen - Hopital Cote de Nacre, Caen, France|C.H.U. Henri Mondor AP-HP, Créteil, France|CHRU de Lille - Hopital Hurie, Lille, France|CHU de Limoges - Hopital Dupuytren, Limoges, France|Hopital Universitaire Hautepierre, Strasbourg, France|Institut Gustave Roussy, Villejuif, France|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitaetsklinikum Wuerzburg - Medizinische Klinik und Poliklinik II, Wuerzburg, Germany|Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands|National Cancer Institute, Bratislava, Slovakia","https://ClinicalTrials.gov/show/NCT01288378"
315,"NCT01328496","Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen","null","Completed","Has Results","Hematologic Malignancies|Disorder Related to Transplantation|Hematopoietic Malignancy","Drug: Preparative Regimen","Event Free Survival (EFS) for Research Participants|Number of Observational Arm Participants Engrafted|Number of Observational Arm Patients Who Relapsed|Number of Deaths of Observational Arm Patients|Number of Observational Arm Patients With Transplant-related Mortality (TRM)|Number of Participants With Acute GVHD|Number of Participants With Chronic GVHD|Time to Engraftment of Research Arm Participants|Incidence of Transplant-related Mortality (TRM)|The Number of Participants With Transplant-related Morbidity","St. Jude Children's Research Hospital|The Hartwell Foundation|Assisi Foundation","All","up to 21 Years   (Child, Adult)","Phase 2","14","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCBT01|NCI-2011-03700","June 15, 2011","October 31, 2016","October 31, 2016","March 2017","March 31, 2011","April 4, 2011","March 23, 2017","May 5, 2017","May 4, 2017","June 5, 2017","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","https://ClinicalTrials.gov/show/NCT01328496"
316,"NCT02944045","Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients","PIC","Recruiting","No Results Available","Pneumocystis|Steroids|Immunocompromised Patient|Hematologic Neoplasms|Immunosuppressive Agents|Neoplasms","Drug: Methylprednisolone|Drug: Placebo","Mortality|Hospital mortality|ICU mortality|Acute respiratory failure|Duration of mechanical ventilation|Occurrence of septic shock|acute kidney injury|Hospital acquired infectious disease|Hospital length of stay|ICU length of stay|Duration of Insulin treatment","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Senior)","Phase 3","222","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P150961|2016-002275-10","February 15, 2017","October 2019","October 2020","October 2016","October 17, 2016","October 25, 2016","null","null","February 27, 2017","March 1, 2017","Medical ICU, Paris, France","https://ClinicalTrials.gov/show/NCT02944045"
317,"NCT01451502","Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units","null","Recruiting","No Results Available","Lymphatic Diseases|Hematopoietic Malignancy","Biological: Umbilical Cord Blood (UCB)","Incidence of Blood Borne Pathogen Transmission from Unlicensed UCB Units.|Incidence of Serious Infusion Reactions of Minimally Manipulated Unlicensed UCB Units|Number of the Desired Lineage Specific Cells in Minimally Manipulated Unlicensed UCB Units|Incidence of Mislabeled UCB Units|Comparison of Specific Cord Blood Banks (CBBs)","Masonic Cancer Center, University of Minnesota","All","Child, Adult, Senior","","250","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2011LS079|MT2011-13R","October 20, 2011","December 2017","December 2017","December 2017","October 11, 2011","October 13, 2011","null","null","December 3, 2017","December 5, 2017","Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT01451502"
318,"NCT00001748","HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies","null","Completed","No Results Available","Graft vs Host Disease|Hematologic Neoplasms|Lymphoma|Myelodysplastic Syndromes|Myeloid Leukemia","Procedure: Peripheral blood progenitor cell transplant","","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1","35","NIH","Interventional","Primary Purpose: Treatment","980122|98-H-0122","June 1998","null","May 2000","August 1999","November 3, 1999","December 10, 2002","null","null","March 3, 2008","March 4, 2008","National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00001748"
319,"NCT02862275","Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer","null","Recruiting","No Results Available","Hematopoietic and Lymphoid Cell Neoplasm|Metastatic Malignant Solid Neoplasm|Unresectable Solid Neoplasm","Drug: Atezolizumab|Other: Laboratory Biomarker Analysis","Incidence of adverse events according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.0|Anti-tumor activity|Biomarker analysis|Expansion of engrafted T cells following atezolizumab administration in the peripheral blood and within the tumor microenvironment|Phenotype and function of engrafted T cells following atezolizumab administration|Progression free survival using immune related Response Criteria (irRC) and Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1, or other tumor-specific criteria|Survival outcomes using immune related Response Criteria (irRC) and Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1, or other tumor-specific criteria|The response rate using immune related Response Criteria (irRC) and Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1, or other tumor-specific criteria","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","40","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2016-01232|PJC-024|PJC-023|10014|UM1CA186644","February 23, 2017","November 21, 2020","November 21, 2020","November 2017","August 9, 2016","August 11, 2016","null","null","November 6, 2017","November 7, 2017","Moffitt Cancer Center, Tampa, Florida, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University Health Network Princess Margaret Cancer Center LAO, Toronto, Ontario, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT02862275"
320,"NCT02791737","Exercise Prehab in Older Adults With Hematologic Malignancies","null","Recruiting","No Results Available","Hematopoietic and Lymphoid Cell Neoplasm","Behavioral: Exercise Intervention|Other: Laboratory Biomarker Analysis|Procedure: Physical Therapy|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Incidence of adverse events (AE), graded according to Common Terminology Criteria for Adverse Events version 4.0|Percentage of eligible of participants completing the OEP|Change in biomarker expression levels|Change in GA measured using the CARG GA for patients undergoing transplant|Change in geriatric assessment (GA) measured using the CARG GA|Change in HRQL measured using the PROMIS|Change in HRQL measured using the PROMIS for patients undergoing transplant|Change in number of falls|Change in physical performance measured using the SPPB|Change in physical performance measured using the SPPB for patients undergoing transplant|Hospital readmission rate for patients undergoing transplant|Length of inpatient stays for patients undergoing transplant|Number of inpatient falls for patients undergoing transplant","Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI)","All","60 Years and older   (Adult, Senior)","","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","OSU-16016|NCI-2016-00446|P30CA016058","July 2016","December 2018","null","September 2016","June 1, 2016","June 7, 2016","null","null","September 21, 2016","September 23, 2016","The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT02791737"
321,"NCT00997386","Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States","ALBUM","Completed","No Results Available","Hematologic Neoplasms|Multiple Myeloma|Anemia, Aplastic|Hemoglobinuria, Paroxysmal|Myelofibrosis","Drug: busulfan, and melphalan, and alemtuzumab","The primary efficacy endpoint is the presence of donor lymphohematopoietic chimerism (defined as at least 50% donor cells in the peripheral blood) in peripheral blood by day +100 (i.e., 100 days after allogeneic PBSCT).|Analyses of relapse-free survival, event-free survival and overall survival will be performed","University of Arizona","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-0679-04","September 2009","April 2014","January 2016","December 2015","October 15, 2009","October 19, 2009","null","null","March 30, 2016","April 1, 2016","University Medical Center and UMC-North Clinic, Tucson, Arizona, United States","https://ClinicalTrials.gov/show/NCT00997386"
322,"NCT02203903","Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies","null","Recruiting","No Results Available","Relapsed/Refractory Hematopoietic Malignancies","Biological: Tumor associated antigen lymphocytes (TAA-CTL)","Safety|Tumor associated antigen lymphocytes (TAA-CTL) responses","Catherine Bollard|Children's Research Institute|Johns Hopkins University","All","6 Months to 80 Years   (Child, Adult, Senior)","Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RESOLVE","January 2015","October 2018","December 2018","October 2017","July 25, 2014","July 30, 2014","null","null","October 30, 2017","November 1, 2017","Childrens National Medical Center, Washington, D.C., District of Columbia, United States|Shannon R. McCurdy, MD, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT02203903"
323,"NCT01523171","Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib","JAKARTA2","Completed","No Results Available","Hematopoietic Neoplasm","Drug: SAR302503","Response Rate (RR), defined as the proportion of subjects who have a ≥35% reduction from baseline in volume of spleen at the end of Cycle 6 as measured by Magnetic Resonance Imaging (MRI) (or CT scan in subjects with contraindications for MRI)|Symptom Response Rate (SRR): Proportion of subjects with a ≥50% reduction from baseline to the end of Cycle 6 in the total symptom score using the modified MFSAF|Duration of spleen response, measured by MRI (or CT scan in subjects with contraindications for MRI)|Proportion of subjects with a ≥50% reduction in length of spleen by palpation from baseline at the end of Cycle 6|Response Rate at the end of Cycle 3, defined as the proportion of subjects who have a ≥35% reduction from baseline in volume of spleen at the end of Cycle 3 as measured by MRI (or CT scan in subjects with contraindications for MRI)|Percent change of spleen volume at the end of Cycles 3 and 6 from baseline as measured by MRI (or CT scan in subjects with contraindications for MRI)|Safety, as assessed by clinical, laboratory, ECG, and vital sign events; graded by the NCI CTCAE v4.03|Plasma concentrations of SAR302503|The effect of SAR302503 on the JAK2V617F allele burden","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","97","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD12181|2011-005226-21|U1111-1124-0967","April 2012","April 2014","April 2014","February 2016","January 27, 2012","February 1, 2012","null","null","February 17, 2016","March 17, 2016","Investigational Site Number 840007, Phoenix, Arizona, United States|Investigational Site Number 840003, San Francisco, California, United States|Investigational Site Number 840004, San Francisco, California, United States|Investigational Site Number 840005, Atlanta, Georgia, United States|Investigational Site Number 840014, Chicago, Illinois, United States|Investigational Site Number 840001, Kansas City, Kansas, United States|Investigational Site Number 840017, Baltimore, Maryland, United States|Investigational Site Number 840013, Baltimore, Maryland, United States|Investigational Site Number 840010, Ann Arbor, Michigan, United States|Investigational Site Number 840009, New York, New York, United States|Investigational Site Number 840018, New York, New York, United States|Investigational Site Number 840022, Cleveland, Ohio, United States|Investigational Site Number 840019, Middletown, Ohio, United States|Investigational Site Number 840024, Charleston, South Carolina, United States|Investigational Site Number 840002, Houston, Texas, United States|Investigational Site Number 840015, Salt Lake City, Utah, United States|Investigational Site Number 040002, Salzburg, Austria|Investigational Site Number 040001, Wien, Austria|Investigational Site Number 056002, Antwerpen, Belgium|Investigational Site Number 056003, Leuven, Belgium|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 250001, Marseille, France|Investigational Site Number 250003, Nimes Cedex 9, France|Investigational Site Number 250002, Paris Cedex 10, France|Investigational Site Number 250006, Paris Cedex 12, France|Investigational Site Number 250004, Toulouse, France|Investigational Site Number 276003, Frankfurt Am Main, Germany|Investigational Site Number 276007, Leipzig, Germany|Investigational Site Number 276006, Magdeburg, Germany|Investigational Site Number 276001, Mannheim, Germany|Investigational Site Number 276005, Ulm, Germany|Investigational Site Number 380004, Firenze, Italy|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 380002, Roma, Italy|Investigational Site Number 380003, Varese, Italy|Investigational Site Number 528002, Amsterdam, Netherlands|Investigational Site Number 528003, Maastricht, Netherlands|Investigational Site Number 528001, Nijmegen, Netherlands|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724003, Majadahonda, Spain|Investigational Site Number 724002, Salamanca, Spain|Investigational Site Number 826001, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01523171"
324,"NCT01437787","Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis","JAKARTA","Completed","No Results Available","Hematopoietic Neoplasm","Drug: SAR302503|Drug: Placebo","Response Rate (RR), defined as the proportion of patients who have a ≥35% reduction in volume of spleen size at the end of Cycle 6, and confirmed 4 weeks thereafter|Symptom Response Rate (SRR): Proportion of patients with ≥50% reduction from baseline to the end of Cycle 6 in the total symptom score.|OS (overall survival) of either 400 mg/day or 500 mg/day of IMP as compared to placebo.|PFS (progression free survival) of either 400 mg/day or 500 mg/day of IMP as compared to placebo.|Proportion of patients who have ≥25% reduction in volume of spleen size at end of Cycle 6, and confirmed 4 weeks thereafter.|Duration of spleen response, measured by MRI (or CT scan in patients with contraindications for MRI.|Clinical and laboratory events graded by the NCI CTCAE v4.03.","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 3","289","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC12153|2011-001897-25|U1111-1121-7170","December 2011","June 2014","June 2014","December 2015","September 16, 2011","September 21, 2011","null","null","December 8, 2015","January 8, 2016","Investigational Site Number 840014, Scottsdale, Arizona, United States|Investigational Site Number 840001, La Jolla, California, United States|Investigational Site Number 840012, La Jolla, California, United States|Investigational Site Number 840006, Los Angeles, California, United States|Investigational Site Number 840013, Baton Rouge, Louisiana, United States|Investigational Site Number 840008, Rochester, Minnesota, United States|Investigational Site Number 840009, Newark, New Jersey, United States|Investigational Site Number 840002, Canton, Ohio, United States|Investigational Site Number 840004, Houston, Texas, United States|Investigational Site Number 036001, Box Hill, Australia|Investigational Site Number 036005, Herston, Australia|Investigational Site Number 036003, Randwick, Australia|Investigational Site Number 036004, Tweed Heads, Australia|Investigational Site Number 036002, Wodonga, Australia|Investigational Site Number 040001, Wien, Austria|Investigational Site Number 056003, Antwerpen, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 076002, Jau, Brazil|Investigational Site Number 076004, Porto Alegre, Brazil|Investigational Site Number 076001, Rio De Janeiro, Brazil|Investigational Site Number 124001, Montreal, Canada|Investigational Site Number 124003, Montreal, Canada|Investigational Site Number 124002, Saint John, Canada|Investigational Site Number 250006, Marseille, France|Investigational Site Number 250005, Nantes Cedex 01, France|Investigational Site Number 250004, Nimes, France|Investigational Site Number 250002, Pierre Benite Cedex, France|Investigational Site Number 250007, Poitiers, France|Investigational Site Number 250003, Toulouse, France|Investigational Site Number 250001, Villejuif Cedex, France|Investigational Site Number 276006, Aachen, Germany|Investigational Site Number 276007, Bonn, Germany|Investigational Site Number 276008, Dresden, Germany|Investigational Site Number 276001, Mannheim, Germany|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348001, Debrecen, Hungary|Investigational Site Number 348007, Györ, Hungary|Investigational Site Number 348006, Kecskemét, Hungary|Investigational Site Number 348003, Miskolc, Hungary|Investigational Site Number 372002, Dublin, Ireland|Investigational Site Number 372001, Galway, Ireland|Investigational Site Number 376003, Haifa, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380002, Bergamo, Italy|Investigational Site Number 380007, Bologna, Italy|Investigational Site Number 380004, Firenze, Italy|Investigational Site Number 380001, Pavia, Italy|Investigational Site Number 380006, Pavia, Italy|Investigational Site Number 380003, Varese, Italy|Investigational Site Number 410002, Bundang-Gu, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 410005, Seoul, Korea, Republic of|Investigational Site Number 410006, Seoul, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 440001, Kaunas, Lithuania|Investigational Site Number 440002, Klaipeda, Lithuania|Investigational Site Number 484001, Queretaro, Mexico|Investigational Site Number 616005, Brzozow, Poland|Investigational Site Number 616002, Gdansk, Poland|Investigational Site Number 616006, Lodz, Poland|Investigational Site Number 616010, Warszawa, Poland|Investigational Site Number 616003, Wroclaw, Poland|Investigational Site Number 620005, Coimbra, Portugal|Investigational Site Number 620004, Lisboa, Portugal|Investigational Site Number 620001, Lisboa, Portugal|Investigational Site Number 620003, Porto, Portugal|Investigational Site Number 642003, Brasov, Romania|Investigational Site Number 642004, Bucharest, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642006, Bucuresti, Romania|Investigational Site Number 642001, Timisoara, Romania|Investigational Site Number 643009, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643010, Nizhny Novgorod, Russian Federation|Investigational Site Number 643008, Petrozavodsk, Russian Federation|Investigational Site Number 643004, St-Petersburg, Russian Federation|Investigational Site Number 643005, St.-Petersburg, Russian Federation|Investigational Site Number 643007, Volgograd, Russian Federation|Investigational Site Number 702002, Singapore, Singapore|Investigational Site Number 702001, Singapore, Singapore|Investigational Site Number 710003, Johannesburg, South Africa|Investigational Site Number 710002, Parktown, South Africa|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 752001, Stockholm, Sweden|Investigational Site Number 752002, Uddevalla, Sweden|Investigational Site Number 158002, Changhua, Taiwan|Investigational Site Number 158003, Kaohsiung, Taiwan|Investigational Site Number 158001, Taipei, Taiwan|Investigational Site Number 826006, Belfast, United Kingdom|Investigational Site Number 826003, Birmingham, United Kingdom|Investigational Site Number 826002, Glasgow, United Kingdom|Investigational Site Number 826004, Leeds, United Kingdom|Investigational Site Number 826001, London, United Kingdom|Investigational Site Number 826005, London, United Kingdom|Investigational Site Number 826007, Manchester, United Kingdom|Investigational Site Number 826008, Newcastle Upon Tyne, United Kingdom|Investigational Site Number 826009, Oxford, United Kingdom|Investigational Site Number 826010, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01437787"
325,"NCT01420770","Phase 2 Study of SAR302503 in Patients With Myelofibrosis","null","Completed","No Results Available","Hematopoietic Neoplasm","Drug: SAR302503","The percent change in spleen volume based on MRI at the end of Cycle 3 relative to baseline|The proportion of patients who achieve ≥35% reduction in spleen volume from baseline, to Cycle 6 end of cycle (EOC)|The percent change in spleen volume based on MRI at Cycle 6 EOC compared to baseline|Duration of maintenance of ≥35% reduction in spleen volume relative to baseline, as measured at Cycle 3 EOC, at Cycle 6 EOC, after a year, after 18 months and after two years and at end of treatment (EOT).|Characterization of the safety profile of SAR302503, including the frequency, duration, and severity of adverse events (AEs) 2 years|Area under the plasma concentration versus time curve (AUC) of SAR302503|Peak plasma concentration (CMax) of SAR302503|In patients with the JAK2V617F mutation, change in peripheral blood granulocyte JAK2V617F allele burden from baseline to Cycle 3 EOC, to Cycle 6 EOC and at the end of every third cycle thereafter until Cycle 12 EOC and EOT","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD11936|U1111-1119-2965","August 2011","April 2014","April 2014","February 2016","August 11, 2011","August 22, 2011","null","null","February 17, 2016","March 16, 2016","Investigational Site Number 840001, San Francisco, California, United States|Investigational Site Number 840003, Ann Arbor, Michigan, United States|Investigational Site Number 840006, Rochester, Minnesota, United States|Investigational Site Number 840007, Canton, Ohio, United States","https://ClinicalTrials.gov/show/NCT01420770"
326,"NCT01039155","Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy","null","Completed","No Results Available","Adult Solid Neoplasm|Hematopoietic and Lymphoid Cell Neoplasm","Drug: Azacitidine|Other: Laboratory Biomarker Analysis|Drug: Oxaliplatin|Other: Pharmacological Study","MTD graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Changes in concentration of oxaliplatin|Changes in DNA methylation|Changes in the CTR1 score|Pharmacokinetic parameters of azacitidine and oxaliplatin","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","41","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02909|662917|2008-0277|8321|P30CA016672|U01CA062461","December 2009","September 2012","July 2015","May 2015","December 23, 2009","December 24, 2009","null","null","October 5, 2015","October 6, 2015","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT01039155"
327,"NCT00001623","Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia","null","Completed","No Results Available","Graft vs Host Disease|Hematologic Neoplasm|Leukemia|Multiple Myeloma|Myelodysplastic Syndrome","Procedure: Allogeneic Bone Marrow Transplant","To evaluate the feasibility of using G-CSF mobilized donor blood to transplant a predetermined dose of stem cells and T lymphocytes to recipients with hematologic malignacies.","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","10 Years to 55 Years   (Child, Adult)","","41","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","970099|97-H-0099","March 27, 1997","January 31, 2008","August 3, 2017","August 3, 2017","November 3, 1999","November 4, 1999","null","null","October 5, 2017","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00001623"
328,"NCT03222258","Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients","null","Recruiting","No Results Available","Stage IV Breast Cancer|Stage IV Pancreatic Cancer|Stage IV Colon Cancer|Stage IV Gastric Cancer|Stage IV Lung Cancer|Stage IV Liver Cancer|Malignant Hematologic Neoplasm|Biliary Cancer Metastatic|Pediatric Leukemia|Pediatric Lymphoma|Pediatric Brain Tumor|Pediatric Solid Tumor","Behavioral: Early palliative care|Behavioral: Routine hospice care","Quality of Life Questionnaire - Core 15 items|Mcgill Quality of Life|Pediatric Quality of Life Inventory|Patients survival and Physicians Orders for Life Sustaining Treatment (POLST) documentation|Depression|Level of decision conflict|Understanding the illness|Recognition of health status|Crisis overcoming capability|Daily functional skills in elderly|Medical cost in KRW/person/month|Utilization of healthcare services|Preference of Advance care and Palliative care|M.D. Anderson Symptom Inventory","Seoul National University Hospital|Seoul National University Bundang Hospital|National Cancer Center, Korea|Kyunghee University Medical Center|Severance Hospital|Gyeongsang National University Hospital|Chungnam National University Hospital|Chonbuk National University Hospital|Ewha Womans University Mokdong Hospital|Daegu Fatima Hospital, South Korea|Chonnam National University Hospital|Keimyung University Dongsan Medical Center|Hallym University Medical Center|Asan Medical Center|National Evidence-Based Healthcare Collaborating Agency|National Institute of Health, Korea|National Clinical Research Coordination Center, Seoul, Korea|Ulsan University Hospital","All","Child, Adult, Senior","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HC15C1391-2","December 17, 2016","June 30, 2019","June 30, 2019","September 2017","June 5, 2017","July 19, 2017","null","null","September 5, 2017","September 8, 2017","National Cancer Center, Korea, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Gyeongsang National University Hospital, Jinju-si, Gyeongsangnam-do, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Korea, Republic of|Daegu Fatima Hospital, Daegu, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Kyunghee University Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of","https://ClinicalTrials.gov/show/NCT03222258"
329,"NCT02223052","Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies","null","Recruiting","No Results Available","Hematological Neoplasms|Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|Lymphoma|Multiple Myeloma|Acute Myeloid Leukemia|Leukemia|Myelodysplastic Syndromes|Neoplasms|Melanoma|Breast Cancer|Metastatic Breast Cancer|Non-Small Cell Lung Cancer|Small Cell Lung Cancer|Renal Cell Carcinoma|Glioblastoma Multiforme|Osteosarcoma|Sarcoma|Thyroid Cancer|Genitourinary","Drug: CC-486|Drug: Vidaza","Pharmacokinetics Cmax - Stage I (Bioequivalence)|Pharmacokinetics Tmax - Stage I (Bioequivalence)|Pharmacokinetics AUC-t - Stage I (Bioequivalence)|Pharmacokinetics AUC-infinity - Stage I (Bioequivalence)|Pharmacokinetics λz (Terminal Rate) - Stage I (Bioequivalence)|Pharmacokinetics Terminal Half-Life (t½) - Stage I (Bioequivalence)|Pharmacokinetics Apparent total clearance (CL/F) - Stage I (Bioequivalence)|Pharmacokinetics Apparent volume of distribution (Vd/F) - Stage I (Bioequivalence)|Pharmacokinetics Cmax - Stage II (Food Effect Bioavailability)|Pharmacokinetics Tmax - Stage II (Food Effect Bioavailability)|Pharmacokinetics AUC-t - Stage II (Food Effect Bioavailability)|Pharmacokinetics AUC-infinity - Stage II (Food Effect Bioavailability)|Pharmacokinetics λz (Terminal Rate) - Stage II (Food Effect Bioavailability)|Pharmacokinetics Terminal Half-Life (t½) - Stage II (Food Effect Bioavailability)|Pharmacokinetics Apparent total clearance (CL/F) - Stage II (Food Effect Bioavailability)|Pharmacokinetics Apparent volume of distribution (Vd/F) - Stage II (Food Effect Bioavailability)|Adverse Events (AEs)","Celgene","All","18 Years and older   (Adult, Senior)","Phase 1","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-486-CAGEN-001","October 27, 2014","August 18, 2018","September 5, 2018","September 2017","August 20, 2014","August 22, 2014","null","null","September 28, 2017","September 29, 2017","Scottsdale Healthcare Research Institute, Scottsdale, Arizona, United States|Mayo Clinic - Arizona, Scottsdale, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|University of Iowa, Iowa City, Iowa, United States|Henry Ford Health System, Detroit, Michigan, United States|Veteran Affairs Medical Center, Research #517, Kansas City, Missouri, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Greenville Hospital System, Greenville, South Carolina, United States|Vanderbilt- Ingram Cancer Center, Nashville, Tennessee, United States|The Methodist Hospital Research Institute l, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT02223052"
330,"NCT00698685","Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation","null","Terminated","Has Results","Leukemia|Lymphoma|Hodgkin's Disease|Hematologic Neoplasms|Multiple Myeloma|Carcinoma, Renal Cell","Drug: Pentostatin|Biological: Alemtuzumab|Procedure: Allogeneic hematopoietic stem cell transplantation","Actuarial Probability of Donor Hematopoietic Engraftment (Defined as at Least 50% Donor DNA in Bone Marrow at Day 100).|Non-relapse Mortality at or Before Day 100","University of Arizona|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","14","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05-0624-04|R21CA106177|05110|UARIZ-05-0624-01|UARIZ-SRC17920","January 23, 2006","April 13, 2009","April 26, 2011","March 2017","June 14, 2008","June 17, 2008","December 28, 2010","January 12, 2011","March 23, 2017","March 31, 2017","Arizona Cancer Center at UMC North/University Medical Center, Tucson, Arizona, United States|Arizona Cancer Center at UMC North, Tucson, Arizona, United States","https://ClinicalTrials.gov/show/NCT00698685"
331,"NCT01602211","INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant","INSPIRE","Completed","No Results Available","Cancer Survivor|Depression|Hematopoietic and Lymphoid Cell Neoplasm|Myelodysplastic Syndrome","Other: Internet-Based Intervention|Other: Medical Chart Review|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Cancer and treatment distress (CTXD) score as reported on the PCA using binary outcomes|PHQ-8 depression score as reported on the PCA, using binary outcomes|Proportion of adherence to recommended survivorship preventive care and barriers to PCA|Health behaviors|Physical function, as assessed by the Patient Reported Outcomes Measurement Information System scale|Total minutes per week of moderate to vigorous intensity exercise as assessed by the Godin Leisure Time Exercise Questionnaire","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","1600","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","2605.00|NCI-2012-00743|P30CA015704|R01CA160684","May 14, 2013","November 28, 2016","November 28, 2016","September 2017","May 15, 2012","May 18, 2012","null","null","September 1, 2017","September 6, 2017","Moffitt Cancer Center, Tampa, Florida, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT01602211"
332,"NCT01594723","A Study of LY2784544 in Participants With Myeloproliferative Neoplasms","null","Active, not recruiting","No Results Available","Neoplasms, Hematologic","Drug: 120 mg LY2784544","Percentage of Participants with an Objective Response (Objective Response Rate)|Percentage of Participants with a Molecular Response (Molecular Response Rate)|Percentage of Participants with Hematological Improvement (Hematological Improvement Rate)|Change in Spleen Size|Change in Bone Marrow Fibrosis Grade|Change in Number of Thrombotic or Hemorrhagic Events|Change in Number of Phlebotomies and Transfusions|Duration of Response|Time to Best Response|Change in Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)|Time to Treatment Failure|Time to Disease Progression|Progression Free Survival (PFS)|Change in Activities of Daily Living (ADL)/ Instrumental Activities of Daily Living (IADL)|Change in EuroQol - 5 dimensions (EQ-5D) Index Score|Change in International Prognosis Scoring System Scales (IPSS)|Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2784544|PK: Time of Maximal Concentration (Tmax) of LY2784544|Change in Liver Size|Change in 6-item Physician Symptom Assessment","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 2","110","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13861|I3X-MC-JHTB","May 2012","March 2015","August 2018","May 2017","May 1, 2012","May 9, 2012","null","null","May 18, 2017","May 23, 2017","Highlands Oncology Group, Fayetteville, Arkansas, United States|Providence St. Joseph's Medical Center, Burbank, California, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Palm Beach Cancer Institue, West Palm Beach, Florida, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Indiana Blood & Marrow Transplantation (IBMT), Indianapolis, Indiana, United States|Cancer Center of Kansas, P.A., Wichita, Kansas, United States|University of Maryland- Biological Sciences, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University Medical Center, Saint Louis, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Weill Cornell Medical College, New York, New York, United States|Albert Einstein College of Medicine, The Bronx, New York, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Mid Ohio Oncology Hematology, Columbus, Ohio, United States|The Jones Clinic, Germantown, Tennessee, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Joe Arrington Cancer Center, Lubbock, Texas, United States|Swedish Medical Center, Seattle, Washington, United States|Dean Medical Center, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Garran, Australian Capital Territory, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wodonga, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jena, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bologna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Firenze, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uddevalla, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden","https://ClinicalTrials.gov/show/NCT01594723"
333,"NCT03091933","Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)","GLIDE","Recruiting","No Results Available","Hematologic Cancer|Relapse Leukemia|Relapsed Adult ALL|Relapsed Adult AML|Relapsed CLL|Relapsed Non Hodgkin Lymphoma|Relapsed Hodgkin's Lymphoma|Relapsed Myelodysplastic Syndromes|Relapsed Multiple Myeloma","Biological: GLIDE","Non-hematologic toxicity related to GLIDE post injection|Response of hematologic malignancy (acute leukemia (ALL, AML, biphenotypic), CLL, HL, NHL, MM or MDS) post-injection|Incidence and severity of acute and chronic graft versus host disease (GvHD)|Persistence of GLIDE in the host and homing to peripheral blood, bone marrow and other tissues|Non-Relapse mortality (NRM)|Relapse-incidence (RI)|Overall survival (OS)|Progression-free survival (PFS)","Ciusss de L'Est de l'Île de Montréal","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR-MIHA-001","February 6, 2017","March 31, 2018","March 31, 2019","December 2017","March 21, 2017","March 27, 2017","null","null","December 4, 2017","December 6, 2017","CIUSSS d l'Est-de-l'Île-de-Montréal, Montreal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT03091933"
334,"NCT03301493","Genomic Testing and Resulting Medical Decisions","null","Recruiting","No Results Available","Cancer of Unknown Origin|Cancer Refractory|Cancer of Stomach|Cancer Head Neck|Cancer of Skin|Cancer, Lung|Cancer Colorectal|Cancer of Esophagus|Cancer, Bladder|Cancer, Uterus|Cancer Cervix|Cancer Liver|Cancer, Kidney|Cancer, Breast|Hematologic Neoplasms","Other: Genomic testing","Types of:molecular profiling methods|Types of cancer, for which comprehensive molecular profiling is used|Timing of molecular profiling|Number of patients with mutations identified|Quality standards|Treatment decisions|Outcome of treatment","Arbeitsgemeinschaft medikamentoese Tumortherapie|Roche Pharma AG","All","18 Years and older   (Adult, Senior)","","500","Other|Industry","Observational","Observational Model: Other|Time Perspective: Other","AGMT_NGS-Registry","March 30, 2017","December 2019","December 2019","October 2017","September 22, 2017","October 4, 2017","null","null","October 3, 2017","October 4, 2017","Innere Medizin II, LKH Feldkirch, Feldkirch, Austria|Universitätsklinikum Krems, Krems an der Donau, Austria|IIIrd Medical Department, Private Medical University Hospital Salzburg, Salzburg, Austria","https://ClinicalTrials.gov/show/NCT03301493"
335,"NCT02900248","CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice","N1","Recruiting","No Results Available","Neoplasms|Lung Neoplasms|Colon Neoplasms|Breast Neoplasms|Pancreatic Neoplasms|Prostate Neoplasms|Kidney Neoplasms|Liver Neoplasms|Rectal Neoplasms|Hematologic Neoplasms|Multiple Myeloma|Myelodysplastic Syndromes|Ovarian Neoplasms|Bladder Neoplasms|Testicular Neoplasms|Endometrial Neoplasms|Brain Neoplasms|Biliary Tract Neoplasms|Head and Neck Neoplasms|Uterine Cervical Neoplasms|Skin Neoplasms|Melanoma|Gastric Neoplasms|Anal Neoplasms|Sarcoma","Other: Provider determined","Best Overall Response|Time to Treatment Progression|Overall Survival|Establish stable estimates of biomarker prevalence in patients with advanced malignancies in a large population.|To determine rate of enrollment into existing and future therapeutic clinical trials.","CureOne","All","18 Years and older   (Adult, Senior)","","100000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","N1OR","October 2, 2017","October 2021","October 2024","October 2017","June 18, 2015","September 14, 2016","null","null","October 2, 2017","October 4, 2017","Teton Cancer Institute, Idaho Falls, Idaho, United States","https://ClinicalTrials.gov/show/NCT02900248"
336,"NCT02544230","Granulocyte Transfusions in Hematological Patients With Febrile Neutropenia","null","Completed","No Results Available","Neutropenia|Fever|Bacterial Infection|Fungal Infection|Fever of Unknown Origin|Hematological Neoplasms|Sepsis","","Infection-related mortality","Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne","All","18 Years and older   (Adult, Senior)","","101","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GTX.01","January 2004","December 2011","December 2011","September 2015","September 4, 2015","September 9, 2015","null","null","September 5, 2015","September 9, 2015","Catholic University of Sacred Heart, Rome, Italy","https://ClinicalTrials.gov/show/NCT02544230"
337,"NCT01435200","Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy","null","Completed","No Results Available","Gynecologic Cancer","Drug: Intravenous iron","Red blood cell (RBC) transfusion rate|total number of red blood transfusion units and number of cycles requiring blood transfusion|Number of participants with adverse events","Chulalongkorn University","Female","20 Years to 70 Years   (Adult, Senior)","Phase 3","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IV iron 2","June 2011","October 2012","November 2012","January 2017","September 14, 2011","September 16, 2011","null","null","January 31, 2017","February 1, 2017","Chulalongkorn Hospital, Bangkok, Thailand","https://ClinicalTrials.gov/show/NCT01435200"
338,"NCT02843074","Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients","null","Recruiting","No Results Available","Multiple Myeloma","Drug: elotuzumab|Drug: Lenalidomide|Drug: Dexamethasone|Procedure: autologous stem cell transplantation","Induction Feasibility Rate (IFR)|Complete Response Rate (CRR)|Overall Response Rate (ORR)|Progression-free survival (PFS)|Overall survival (OS)|The number of treatment-emergent adverse events, serious adverse events, deaths as a measure of safety","SCRI Development Innovations, LLC|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 2","53","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI MM61","September 21, 2016","July 2021","March 2022","May 2017","July 20, 2016","July 25, 2016","null","null","May 16, 2017","May 17, 2017","Colorado Blood Cancer Institute, Denver, Colorado, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|HCA Midwest Health/Research Medical Center, Kansas City, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Tennessee Oncology, Chattanooga, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT02843074"
339,"NCT00904787","Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies","null","Completed","No Results Available","Relapsed or Refractory Hematological Malignancies","Drug: ENMD-2076","Define the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of oral daily ENMD 2076 by evaluation of adverse events|Safety and toxicity of repeated oral dosing of ENMD 2076|Describe any preliminary evidence of anti-cancer effects of ENMD-2076 in patients with hematological malignancies","CASI Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","27","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2076-CL-003","April 2009","December 2010","May 2011","August 2011","May 19, 2009","May 20, 2009","null","null","August 3, 2011","August 4, 2011","Princess Margaret Hospital, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT00904787"
340,"NCT02066025","Blood Test for Breast Cancer Associated Auto Antibodies - Improvement of Octava Blood Test","null","Not yet recruiting","No Results Available","Breast Cancer","","Number of participants in each of the clinicaly defined groups (0,1 and 2).","Eventus Diagnostics Ltd","Female","18 Years and older   (Adult, Senior)","","1425","Industry","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","OctavaBreast_1","March 2014","March 2016","March 2018","February 2014","February 9, 2014","February 19, 2014","null","null","February 17, 2014","February 19, 2014","""Carmel"" Medical Center, Haifa, Israel","https://ClinicalTrials.gov/show/NCT02066025"
341,"NCT03128879","Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL)","null","Recruiting","No Results Available","Primary Lymphoid Haematopoietic Neoplasms|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma","Drug: Venetoclax|Drug: Ibrutinib|Drug: Allopurinol","Overall Response (OR)","M.D. Anderson Cancer Center|AbbVie","All","18 Years and older   (Adult, Senior)","Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0785","June 16, 2017","June 2022","June 2022","December 2017","April 21, 2017","April 25, 2017","null","null","December 6, 2017","December 8, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03128879"
342,"NCT02209389","OctavaPink for Women With Dense Breast After Negative Mammography","null","Unknown status","No Results Available","Breast Cancer","Device: MRI","Positive MRI as an approval for a positive OctavaPink test","Eventus Diagnostics Ltd","Female","30 Years to 79 Years   (Adult, Senior)","","1750","Industry","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","OctavaPink for Dense Breast","August 2014","August 2015","August 2017","August 2014","July 29, 2014","August 5, 2014","null","null","August 18, 2014","August 19, 2014","Detroit Clinical Research Center, Detroit, Michigan, United States|MD Anderson cancer center, Houston, Texas, United States|Shaarey Tzedek, Jerusalem, Israel|Shiba, Ramat Gan, Israel|Kaplan medical center, Rehovot, Israel|Sourasky medical center, Tel Aviv, Israel|Fondazione Carlo ferri, Rome, Italy","https://ClinicalTrials.gov/show/NCT02209389"
343,"NCT03207854","Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers","null","Recruiting","No Results Available","Healthy Subject|Hematologic and Lymphocytic Disorder|Hematopoietic and Lymphoid Cell Neoplasm|Immune System Disorder|Malignant Neoplasm","Procedure: Biospecimen Collection|Other: Laboratory Biomarker Analysis|Other: Questionnaire Administration","Sample collection for immunology studies from patients with cancer or blood disorders, and healthy volunteers","University of Southern California|National Cancer Institute (NCI)","All","19 Years and older   (Adult, Senior)","","500","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","0S-15-16|NCI-2017-00625|P30CA014089","April 12, 2017","April 12, 2022","April 12, 2023","September 2017","June 2, 2017","July 5, 2017","null","null","September 12, 2017","September 14, 2017","USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT03207854"
344,"NCT01755000","Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings","null","Completed","No Results Available","Leukemia|Lymphoma|Paraproteinemias|Multiple Myeloma|Myelodysplastic Syndromes","Procedure: USCOM scan|Procedure: Fluid Bolus","What is the inter-rater agreement between multiple independent USCOM users measuring stroke volume (SV) and peak velocity (Vpk) whose systolic blood pressures (SBPs) and mean arterial pressures (MAPs) are stable (SBP above 95 mmHg and MAP above 65 mmHg)?|What is the inter-rater agreement between multiple independent USCOM users measuring SV and Vpk in hematopoietic malignancy patients whose SBPs drop below 95mmHg or MAPs drop below 65mmHg?|In what percentage of patients is fluid bolus administration successful as measured by the current standard of care (MAP) and what is the level of agreement between the standard measure and USCOM readings in determining return to hemodynamic stability?","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","","69","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","201206070","December 2012","April 2013","April 2013","August 2013","December 18, 2012","December 21, 2012","null","null","August 30, 2013","September 2, 2013","Washington University School of Medicine, St. Louis, Missouri, United States","https://ClinicalTrials.gov/show/NCT01755000"
345,"NCT01420783","Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia","null","Completed","No Results Available","Hematopoietic Neoplasm","Drug: SAR302503","Dose Ranging Phase: Proportion of PV patients with absence of phlebotomy and hematocrit below 45% and proportion of ET patients with a platelet count ≤ 400 x 10x9/L for a minimum of 3 months during the first 8 cycles of therapy.|PV Dose Expansion Phase: Proportion of PV patients with absence of phlebotomy eligibility beginning at Day 1 of Cycle 4 visit and continuing through Day 1 of Cycle 6 visit.|ET Dose Ranging Phase (only 600 mg dose group): Proportion of ET patients with a platelet count ≤400 x 10x9/L beginning at Day 1 of Cycle 4 visit and continuing through Day 1 of Cycle 6 visit.|Proportion of PV patients with absence of phlebotomy eligibility beginning at Day 1 of Cycle 4 visit through Cycle 8 (for PV dose expansion phase only).|Proportion of ET patients with platelet count ≤400 x 10x9/L beginning at Day 1 of Cycle 4 visit and continuing through Cycle 8.|Characterization of clinicohematologic response (CR, PR, and no Response) defined by European LeukemiaNet beginning at Day 1 of Cycle 6 visit through Cycle 8.|Percent change in spleen volume (per Magnetic Resonance Imaging (MRI)) at the end of Cycles 4 and 8 or end of treatment (EOT) relative to baseline.|Proportion of patients with a ≥ 35% reduction in spleen volume (per Magnetic Resonance Imaging (MRI)) at the end of Cycles 4 and 8 or end of treatment (EOT) relative to baseline.|Number of participants who have changes in histological, cytogenetic, and molecular responses in bone marrow.|Response (defined as either a 2-point improvement in or resolution of a symptom present at baseline) at the end of Cycles 1, 4, and 8 or end of treatment (EOT), as measured by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF).|Cumulative Distribution Function of responses between treatment groups at the end of Cycles 1, 4, and 8 or EOT on the MPN-SAF.|For each MPN-associated symptom present at baseline on the MPN-SAF, proportion of patients with resolution of that symptom at the end of Cycles 1, 4, and 8.|To measure generic health-related quality of life and utility values using the EQ-5D questionnaire after completion of 8 cycles of therapy.|Characterization of the safety profile of SAR302503, including the frequency, duration, and severity of adverse events graded using the National Cancer Institute (NCI) - CTCAE version 4.03, clinical laboratory parameters, ECG, and vital signs.","Sanofi","All","18 Years and older   (Adult, Senior)","Phase 2","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD12042|2011-001847-58|U1111-1121-4203","October 2011","November 2012","May 2014","February 2016","August 11, 2011","August 22, 2011","null","null","February 17, 2016","March 17, 2016","Investigational Site Number 840008, Scottsdale, Arizona, United States|Investigational Site Number 840004, La Jolla, California, United States|Investigational Site Number 840005, Los Angeles, California, United States|Investigational Site Number 840011, Palo Alto, California, United States|Investigational Site Number 840010, Ann Arbor, Michigan, United States|Investigational Site Number 840007, Rochester, Minnesota, United States|Investigational Site Number 840003, St Louis, Missouri, United States|Investigational Site Number 840001, Houston, Texas, United States|Investigational Site Number 036001, Clayton, Australia|Investigational Site Number 036002, Kingswood, Australia|Investigational Site Number 036004, Kogarah, Australia|Investigational Site Number 036003, Randwick, Australia|Investigational Site Number 124002, Montreal, Canada|Investigational Site Number 124003, Toronto, Canada|Investigational Site Number 124001, Vancouver, Canada|Investigational Site Number 250004, Brest, France|Investigational Site Number 250003, Marseille, France|Investigational Site Number 250001, Paris Cedex 10, France|Investigational Site Number 276004, Frankfurt Am Main, Germany|Investigational Site Number 276003, Mannheim, Germany|Investigational Site Number 380003, Bologna, Italy|Investigational Site Number 380001, Firenze, Italy|Investigational Site Number 380004, Orbassano, Italy|Investigational Site Number 410001, Seongnam, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 724004, Badalona, Spain|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724002, Valencia, Spain|Investigational Site Number 826001, Belfast, United Kingdom|Investigational Site Number 826006, Birmingham, United Kingdom|Investigational Site Number 826003, London, United Kingdom|Investigational Site Number 826004, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01420783"
346,"NCT02164071","Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies","GAH","Completed","No Results Available","Myelodysplastic Syndromes|Leukemia Myeloid Acute|Multiple Myeloma|Leuklemia, Lymphocytic, Chronic","Other: Geriatric Assessment of Health Status Scale administration","Geriatric Health Assessment (GHA) Questionnaire","Celgene Corporation","All","65 Years and older   (Adult, Senior)","","363","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CEL-GAH-2011-01","April 2012","December 2013","July 2015","March 2016","June 12, 2014","June 16, 2014","null","null","March 30, 2016","March 31, 2016","Hospital Txagorritxu, Vitoria, Alava, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Sant Joan de Deu, Espluges de Llobregat, Barcelona, Spain|Hospital Duran I Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Parc Tauli, Sabadell, Barcelona, Spain|Hospital de Donostia, San Sebastian, Guipuzcoa, Spain|Hospital U. Puerta de Hierro, Majadahonda, Madrid, Spain|C.H. Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Canarias, San Cristobal de la Laguna, Tenerife, Spain|Hospital Ntra. Sra. La Candelaria, Santa Cruz de Tenerife, Tenerife, Spain|Hospital La Ribera, Alzira, Valencia, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital Virgen de las Nieves, Granada, Spain|C.H. Universitario A Coruna, La Coruna, Spain|Arnau de Vilanova, Lerida, Spain|Hospital U. Gregorio Maranon, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital de Segovia, Segovia, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital La Fe, Valencia, Spain","https://ClinicalTrials.gov/show/NCT02164071"
347,"NCT02848001","A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia","null","Recruiting","No Results Available","Leukemia, Myeloid, Acute","Drug: CC-90009","Dose- limiting toxicity (DLT)|Non-tolerated dose (NTD)|Maximum tolerated dose (MTD)|Pharmacokinetics-Cmax|Pharmacokinetics - AUC|Pharmacokinetics - tmax|Pharmacokinetics - t 1/2|Pharmacokinetics - CL|Pharmacokinetics - Vmax|Preliminary efficacy of CC-90009","Celgene","All","18 Years and older   (Adult, Senior)","Phase 1","78","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90009-AML-001","November 14, 2016","August 5, 2019","June 21, 2021","August 2017","June 22, 2016","July 28, 2016","null","null","August 29, 2017","August 31, 2017","Yale Cancer Center, New Haven, Connecticut, United States|Northwestern Memorial, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University Siteman Cancer Center, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada|Institut Paoli Calmettes, Marseille Cedex 9, France|Institut Gustave Roussy Faculte de Medecine Paris Sud Service de pneumologie, Villejuif, France|Spedali Civili Di Brescia, Brescia, Italy|A.O. Ospedale Ca Granda - Niguarda, Milano, Italy|Beatson West of Scotland Cancer Centre, Glasgow Scotland, United Kingdom|The Churchill Hospital, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT02848001"
348,"NCT00129155","MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies","null","Unknown status","No Results Available","Hematological Malignancies|Allogeneic Transplantation","Drug: treosulfan","Overall survival at 1 year|Engraftment evaluation|Acute and chronic graft-versus-host disease incidence and severity|Response rate and survival without progression|Evaluation of conditioning and transplant toxicity|Chimerism evaluation","Hospices Civils de Lyon","All","18 Years to 65 Years   (Adult)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2003.332","February 2005","null","null","October 2007","August 9, 2005","August 11, 2005","null","null","October 3, 2007","October 4, 2007","Hôpital Edouard Herriot, Lyon, France","https://ClinicalTrials.gov/show/NCT00129155"
349,"NCT01010217","Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide","null","Completed","No Results Available","Blood Stem Cell Transplant Failure|Leukemia|Hematologic Malignancies","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Melphalan|Drug: Mesna|Drug: Rituximab|Procedure: Stem Cell Transplantation|Drug: Thiotepa|Drug: Tacrolimus|Drug: Mycofenolate mofetil|Drug: G-CSF","100-Day Non-relapse Mortality (NRM)","M.D. Anderson Cancer Center","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","177","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-0266|NCI-2011-03144","November 5, 2009","October 5, 2017","October 5, 2017","October 2017","November 6, 2009","November 9, 2009","null","null","October 6, 2017","October 9, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT01010217"
350,"NCT00513318","Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients Wtih Advanced Hematopoietic Malignancies","null","Terminated","No Results Available","Acute Myeloid Leukemia|Myelodysplasia|Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Multiple Myeloma|Lymphomas|Low-grade NHL and Chronic Lymphocytic Leukemia","","","University of California, San Francisco","All","18 Years to 70 Years   (Adult, Senior)","","15","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","UC2407","August 2004","June 2009","June 2009","August 2013","August 7, 2007","August 8, 2007","null","null","August 1, 2013","August 2, 2013","University of California San Francisco, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT00513318"
351,"NCT00514722","Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies","null","Terminated","No Results Available","Acute Myeloid Leukemia|Myelodysplasia|Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Multiple Myeloma|Lymphoma, Large-Cell, Diffuse|Lymphoma, Mantle-Cell|Lymphoma, T-Cell, Peripheral|T-NK Cell Lymphoma|Hodgkin Disease","Other: umbilical cord stem cells","efficacy|safety of umbilical cord transplant|safety of umbilical cord stem cell transplant","University of California, San Francisco","All","18 Years to 55 Years   (Adult)","","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UC2207","October 2002","March 2009","March 2009","August 2013","August 8, 2007","August 10, 2007","null","null","August 13, 2013","August 14, 2013","University of California, San Francisco, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT00514722"
352,"NCT00559065","A Case-Cohort Study of Hematopoietic Malignancies and Related Disorders and Lung Cancer in Benzene-Exposed Workers in China","null","Completed","No Results Available","Lung Cancer|Lymphoma|Acute Non-Lymphocytic Leukemia|Benzene Poisoning|Leukemia","","Benzene poisoning, Hemapoietic Malignancies and relateddisorders, Lung cancer","National Cancer Institute (NCI)|China for Disease Control (CDC)|Netherlands: Ministry of Health, Welfare and Sports|National Institutes of Health Clinical Center (CC)","All","21 Years to 90 Years   (Adult, Senior)","","3260","NIH|Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","999906205|06-C-N205","July 11, 2006","null","null","October 18, 2017","November 15, 2007","November 16, 2007","null","null","October 26, 2017","October 27, 2017","China Center for Disease Control (CDC), Beijing, China","https://ClinicalTrials.gov/show/NCT00559065"
353,"NCT01231412","Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant","null","Completed","Has Results","Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Aggressive Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Diffuse Large B-Cell Lymphoma|Hematopoietic and Lymphoid Cell Neoplasm|Indolent Non-Hodgkin Lymphoma|Mantle Cell Lymphoma|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Plasma Cell Myeloma|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Hodgkin Lymphoma|Small Lymphocytic Lymphoma|T-Cell Chronic Lymphocytic Leukemia|Waldenstrom Macroglobulinemia","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclosporine|Drug: Fludarabine Phosphate|Drug: Mycophenolate Mofetil|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Sirolimus|Radiation: Total-Body Irradiation","Rate of Acute Grade II-IV GVHD, Exclusive of GVHD That Occurs as a Result of Alterations to Immunosuppressive Therapy in Response to Relapse or Progression|Chronic Extensive GVHD|Grade III-IV Acute GVHD|Non-relapse Mortality|Overall Survival|Relapse/Progression","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 3","174","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2448.00|NCI-2010-02035|P01CA018029|P30CA015704","November 2010","October 8, 2016","June 30, 2017","November 2017","October 28, 2010","November 1, 2010","November 1, 2017","December 4, 2017","November 1, 2017","December 4, 2017","University of Colorado, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|VA Puget Sound Health Care System, Seattle, Washington, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States|Aarhus University Hospital, Arhus, Denmark|Rigshospitalet University Hospital, Copenhagen, Denmark|Medizinische Univ Klinik Koln, Koln, Germany|Universitaet Leipzig, Leipzig, Germany|University of Tuebingen-Germany, Tuebingen, Germany","https://ClinicalTrials.gov/show/NCT01231412"
354,"NCT00519090","Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)","ENEST","Terminated","Has Results","Myelogenous Leukemia","Drug: Imatinib|Drug: Nilotinib (AMN107)","Complete Cytogenetic Response Rate(CCyR) in Patients Who Had a Suboptimal Cytogenetic Response on Imatinib|Durable Complete Cytogenetic Response Rate","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 3","6","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAMN107A2302","October 2007","October 2008","October 2008","November 2011","August 17, 2007","August 21, 2007","November 11, 2010","May 10, 2011","November 4, 2011","November 7, 2011","Arizona Cancer Center, Tucson, Arizona, United States|Southern California Permanente Medical Group, Anaheim, California, United States|Southern California Permanente Medical Group, Baldwin Park, California, United States|Southern California Permanente Medical Group, Fontana, California, United States|Kaiser Permanente Medical Group/Hayward Medical Center, Hayward, California, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|Kaiser Permanente Medical Group/Oakland Medical Center, Oakland, California, United States|Southern California Permanente Medical Group, Panorama City, California, United States|Southern California Permanente Medical Group, Riverside, California, United States|Kaiser Permanente Medical Group/South San Francisco Medical Center, S. San Francisco, California, United States|Kaiser Permanente Medical Group/Sacramento Medical Center, Sacramento, California, United States|Southern California Permanente Medical Group, San Diego, California, United States|Kaiser Permanente Medical Group, San Francisco, California, United States|Kaiser Permanente Medical Group, San Jose, California, United States|Kaiser Permanente Medical Group/Santa Clara Medical Office, Santa Clara, California, United States|Kaiser Permanente Medical Group/Vallejo Medical Center, Vallejo, California, United States|Kaiser Permanente Medical Group/Walnut Creek Medical Center, Walnut Creek, California, United States|Southen California Permanente Medical Group, Woodland Hills, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|Indiana Blood and Marrow Transplantation, Beech Grove, Indiana, United States|Holden Cancer Center, Iowa City, Iowa, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|Methodist Cancer Center, Omaha, Nebraska, United States|The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Duke University Hospital, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Oregon Health Sciences University, Portland, Oregon, United States|St. Luke's Hospital and Health Network, Bethlehem, Pennsylvania, United States|Jones Cancer Center, Germantown, Tennessee, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas/MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Novartis Investigative Site, Darlinghurst, Australia|Novartis Investigative Site, Herston, Australia|Novartis Investigative Site, Liverpool, Australia|Novartis Investigative Site, Perth, Australia|Novartis Investigative Site, Prahran, Australia|Novartis Investigative Site, South Brisbane, Australia|Novartis Investigative Site, St. Leonards, Australia|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Mannheim, Brazil|Novartis Investigative Site, Porto Alegre, Brazil|Novartis Investigative Site, Sao Paulo, Brazil|Novartis Investigative Site, Olomouc, Czech Republic|Novartis Investigative Site, Praha, Czech Republic|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Eisensach, Germany|Novartis Investigative Site, Firenze, Germany|Novartis Investigative Site, Griefswald, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Leipzeg, Germany|Novartis Investigative Site, Postsdam, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Weiden, Germany|Novartis Investigative Site, Bologna, Italy|Novartis Investigative Site, Milano, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Orbassano, Italy|Novartis Investigative Site, Reggio Calabra, Italy|Novartis Investigative Site, Roma, Italy|Novartis Investigative Site, Nagoya, Japan|Novartis Investigative Site, Oaska, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Hwasun-Gun, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Salamanca, Spain|Novartis Investigative Site, Santiago de Compostela, Spain|Novartis Investigative Site, Valencia, Spain","https://ClinicalTrials.gov/show/NCT00519090"
355,"NCT00471497","A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)","ENESTnd","Active, not recruiting","Has Results","Myelogenous Leukemia, Chronic","Drug: nilotinib|Drug: imatinib","Molecular Response Rate (MMR) at 12 Months|Rate of Durable MMR at 24 Months.|Rate Reduction in BCR-ABL Transcript Levels in Nilotinib Treatment Arms With Imatinib at 12 Months|Rate of Complete Cytogenetic Response (CCyR) in Nilotinib Treatment Arms With Imatinib at 12 Months","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 3","852","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAMN107A2303|2007-000208-34","July 31, 2007","September 2, 2009","October 15, 2018","October 2017","May 7, 2007","May 10, 2007","April 10, 2013","June 17, 2013","October 30, 2017","December 5, 2017","University of California at Los Angeles Dept. of Hematology Clinic, Los Angeles, California, United States|Kaiser Permanente - California Southern Dept of Kaiser South 3, San Diego, California, United States|Kaiser Permanente - California Southern Dept of Kaiser South 9, San Diego, California, United States|Kaiser Permanente - California Southern San Diego Zion Avenue, San Diego, California, United States|Kaiser Permanente - California Northern Kaiser Med, Vallejo, California, United States|Kaiser Permanente - California Northern Vallejo Med Center/Med Offices, Vallejo, California, United States|Rocky Mountain Cancer Centers RMCC - Colorado Springs, Greenwood Village, Colorado, United States|Florida Cancer Specialists Dept. FloridaCancerSpecialists, Fort Myers, Florida, United States|Advanced Medical Specialties Research Dept., Miami, Florida, United States|Cancer Centers of Florida PA Cancer Centers of FL, Ocoee, Florida, United States|Florida Cancer Institute Flordia Cancer Affilates, Orlando, Florida, United States|University of Chicago Medical Center Section of Hematology/Oncology, Chicago, Illinois, United States|Indiana Blood and Marrow Institute Dept. of Indiana Blood&Marrow, Beech Grove, Indiana, United States|University of Iowa Hospitals and Clinics Dept.of U of Iowa Hosp&Clinics, Iowa City, Iowa, United States|Kansas City Cancer Center KCCC Business Office, Overland Park, Kansas, United States|LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center, New Orleans, Louisiana, United States|Michigan State University / Breslin Cancer Center Breslin Cancer Center, Lansing, Michigan, United States|Missouri Cancer Associates Dept. of Boone Hospital Center, Columbia, Missouri, United States|Hematology Oncology Consultants, Inc. Deptof Hem. Onc.Consunsultants, Saint Louis, Missouri, United States|Hackensack University Medical Center Department of Research, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center Clinical Trials Office, New York, New York, United States|University of North Carolina UNC Lineberger Cancer Center, Chapel Hill, North Carolina, United States|Cancer Centers of North Carolina Cancer Centers of NC-Raleigh, Raleigh, North Carolina, United States|Wake Forest University Health Sciences Dept. of Industry Research, Winston-Salem, North Carolina, United States|University of Cincinnati / Barrett Cancer Center Dept.of Internal Med., Cincinnati, Ohio, United States|Cleveland Clinic Foundation CCF, Cleveland, Ohio, United States|Northwest Cancer Specialists Compass Oncology -BKM, Portland, Oregon, United States|Cancer Centers of the Carolinas CC of C -Eastside, Greenville, South Carolina, United States|Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology, Chattanooga, Tennessee, United States|Tennessee Oncology Dept. of Centennial Medical, Nashville, Tennessee, United States|Texas Cancer Center ( Medical City Dallas Hospital), Dallas, Texas, United States|Cancer Care Centers of South Texas / HOAST CCC of So.TX- Medical Center, San Antonio, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Brasilia, DF, Brazil|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Jaú, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Québec, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Bogotá, Cundinamarca, Colombia|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Praha 2, Czech Republic, Czechia|Novartis Investigative Site, Olomouc, CZE, Czechia|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, HUS Helsinki, Finland|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Paris Cedex 10, Cedex 10, France|Novartis Investigative Site, Caen, Cedex, France|Novartis Investigative Site, Saint Priest en Jarez, Loire, France|Novartis Investigative Site, Angers Cedex 1, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Créteil, France|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Nantes, France|Novartis Investigative Site, Nice Cedex, France|Novartis Investigative Site, Pierre-Benite Cedex, France|Novartis Investigative Site, Poitiers, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Vandoeuvre les Nancy, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Eisenach, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Alessandria, AL, Italy|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Pescara, PE, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Udine, UD, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Perugia, Italy|Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Maebashi-city, Gunma, Japan|Novartis Investigative Site, Maebashi, Gunma, Japan|Novartis Investigative Site, Hiroshima city, Hiroshima, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, Japan|Novartis Investigative Site, Sapporo, Hokkaido, Japan|Novartis Investigative Site, Nishinomiya-city, Hyogo, Japan|Novartis Investigative Site, Tsukuba-city, Ibaraki, Japan|Novartis Investigative Site, Kanazawa-city, Ishikawa, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, Japan|Novartis Investigative Site, Tsu-city, Mie, Japan|Novartis Investigative Site, Nagasaki-city, Nagasaki, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Sayama, Osaka, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Hidaka-city, Saitama, Japan|Novartis Investigative Site, Saitama-city, Saitama, Japan|Novartis Investigative Site, Hamamatsu-city, Shizuoka, Japan|Novartis Investigative Site, Shimotsuke-city, Tochigi, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, Japan|Novartis Investigative Site, Shinagawa-ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Akita, Japan|Novartis Investigative Site, Chiba, Japan|Novartis Investigative Site, Niigata, Japan|Novartis Investigative Site, Hwasun-gun, Jeollanam-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Taegu, Korea, Republic of|Novartis Investigative Site, Selangor, Malaysia|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Trondheim, Norway|Novartis Investigative Site, Katowice, Poland|Novartis Investigative Site, Lublin, Poland|Novartis Investigative Site, Rzeszow, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bratislava, Slovak Republic, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bloemfontein, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Elche, Alicante, Spain|Novartis Investigative Site, Granada, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Santander, Cantabria, Spain|Novartis Investigative Site, Salamanca, Castilla y Leon, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Bilbao, Pais Vasco, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, La Laguna, Santa Cruz de Tenerife, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Göteborg, Sweden|Novartis Investigative Site, Huddinge, Sweden|Novartis Investigative Site, Lulea, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Sundsvall, Sweden|Novartis Investigative Site, Umeå, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Örebro, Sweden|Novartis Investigative Site, Genève, Switzerland|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Lin-Kou, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Glasgow - Scotland, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Caracas, Distrito Capital, Venezuela","https://ClinicalTrials.gov/show/NCT00471497"
356,"NCT02464696","Early Non Invasive Ventilation and Hematological Malignancies","null","Recruiting","No Results Available","Hematological Malignancies|Chronic Hypoxemic Respiratory Failure","Other: Non-Invasive Positive Pressure Ventilation (NIPPV)|Other: High Flow Nasal Cannula Oxygen Therapy","Percentage of Participants Who Meet Criteria for Intubation","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Senior)","","366","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2015-0165|NCI-2015-01514","October 2015","October 2019","null","December 2016","June 3, 2015","June 8, 2015","null","null","December 27, 2016","December 28, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT02464696"
357,"NCT03301168","Safety Study of Gene Modified Donor T-cells Following TCR + Alpha Beta Depleted Stem Cell Transplant","null","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Leukemia, Acute Myeloid (AML), Child|Lymphoma, Non-Hodgkin|Myelodysplastic Syndromes|Immunologic Deficiency Syndromes","Biological: BPX-501 T cells and AP1903|Drug: AP1903","Adverse events","Bellicum Pharmaceuticals","All","1 Month to 18 Years   (Child, Adult)","Phase 1|Phase 2","120","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BP-U-004","April 2014","December 2018","December 2019","December 2017","September 29, 2017","October 4, 2017","null","null","December 7, 2017","December 11, 2017","Children's Hospital Los Angeles, Los Angeles, California, United States|Stanford University; Division of Pediatric Stem Cell Transplant & Regenerative Medicine, Palo Alto, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States|Children's Hospital at Montefiore, Bronx, New York, United States|Oregon Health Sciences University - Doernbecher Children's Hospital, Portland, Oregon, United States|University of Texas Southwestern-Children's Medical Center, Dallas, Texas, United States|Baylor College of Medicine/ Texas Children's Hospital, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT03301168"
358,"NCT02065869","Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant","null","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Leukemia, Acute Myeloid (AML), Child|Lymphoma, Non-Hodgkin|Myelodysplastic Syndrome|Immunologic Deficiency Syndromes","Biological: BPX-501 T cells and AP1903|Drug: AP1903","Event-Free -Survival|TRM (non-malignant) or NRM (malignant)|Cumulative incidence and severity of acute (grade 2-4) and chronic GvHD at 180 days|Time to resolution of acute GvHD after administration of rimiducid|Immune reconstitution","Bellicum Pharmaceuticals","All","1 Month to 18 Years   (Child, Adult)","Phase 1|Phase 2","175","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BP-004","April 2014","December 2018","December 2019","December 2017","February 13, 2014","February 19, 2014","null","null","December 1, 2017","December 5, 2017","IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy|Unidad de Trasplante Hematopoyético, Hospital Niño Jesús, Madrid, Spain|Institute of Child Health & Great Ormond Street Hospital, London, United Kingdom|Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom","https://ClinicalTrials.gov/show/NCT02065869"
359,"NCT03086252","Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study","null","Recruiting","No Results Available","Anemia|Aplastic Anemia|Bone Marrow Failure|Hematopoietic and Lymphoid Cell Neoplasm|Leukemia|Myelodysplastic Syndrome","Procedure: Red Blood Cell Transfusions (RBCT)","Incidence of laboratory and clinical adverse events (AEs) assessed by the Common Terminology Criteria for Adverse Events version 4.03.|Frequency of RBC units transfused|Hemoglobin concentration at the time subject requests RBCT|Number of RBC units transfused|QoL scores from the Functional Assessment of Cancer Therapy - Anemia/Fatigue (FACT-An) questionnaire at the time hemoglobin is 8 +/- 0.5 g/dL|QoL scores from the Functional Assessment of Cancer Therapy - Anemia/Fatigue (FACT-An) questionnaire at the time subjects request RBCT","Emory University","All","19 Years and older   (Adult, Senior)","","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB00090306|NCI-2016-01059|Winship3145-16","July 24, 2017","July 2020","July 2021","July 2017","March 17, 2017","March 22, 2017","null","null","July 26, 2017","July 28, 2017","Emory University/Winship Cancer Institute, Atlanta, Georgia, United States","https://ClinicalTrials.gov/show/NCT03086252"
360,"NCT02396134","Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant","null","Active, not recruiting","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Hodgkin Lymphoma|Adult Non-Hodgkin Lymphoma|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Cytomegaloviral Infection|Hematopoietic and Lymphoid Cell Neoplasm|HLA-A*0201 Positive Cells Present|Myelodysplastic Syndrome|Adult Lymphoblastic Lymphoma|Chronic Lymphocytic Leukemia|Myelofibrosis|Myeloproliferative Neoplasm","Biological: CMVpp65-A*0201 peptide vaccine|Other: Placebo|Other: Laboratory Biomarker Analysis","CMV events encompassing any CMV reactivation defined as >= 500 CMV gc/mL or CMV disease|non-relapse mortality (NRM)|Severe (grade 3-4) aGVHD probably or definitely related to the vaccination|Grade 3-4 AEs graded by CTCAE version 4.0 probably or definitely related to the vaccination|Time to viremia|Duration of viremia|Incidence of late CMV viremia|Use of antiviral drugs triggered by clinically significant viremia >= 1,500 CMV gc/mL|Cumulative number of CMV specific antiviral treatment days|Time to engraftment|Incidence of aGVHD|Incidence of cGVHD|Incidence of relapse|All-cause mortality|Incidence of infections|PD-1 expression|NK phenotype assessed by change in cytotoxicity|NK function assessed by change in cytokine production|Levels of CD8+ T cells binding to A2-CMV-dextramers","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","96","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","13494|NCI-2015-00283|R01CA181045","May 21, 2015","May 2019","May 2019","December 2017","March 12, 2015","March 24, 2015","null","null","December 15, 2017","December 19, 2017","City of Hope Medical Center, Duarte, California, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT02396134"
361,"NCT00588991","Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders","null","Active, not recruiting","No Results Available","Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A|Adult Acute Myeloid Leukemia Without Maturation|Adult Acute Myelomonocytic Leukemia|Adult Erythroleukemia|Adult Pure Erythroid Leukemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndrome|Essential Thrombocythemia|Hematopoietic and Lymphoid Cell Neoplasm|Myelodysplastic Syndrome|Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Polycythemia Vera|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Disease|Secondary Myelodysplastic Syndrome","Drug: Carboplatin|Other: Laboratory Biomarker Analysis|Drug: Topotecan Hydrochloride|Drug: Veliparib","Clinical response (CR, CRi, PR)|Maximum tolerated dose of veliparib, determined as the highest dose level where 0/3 or 1/6 experience DLT, measured according to NCI-CTCAE 4.0|Pharmacokinetics and pharmacodynamics of veliparib","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","12","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-00259|CDR0000579626|J0783|7968|P30CA006973|U01CA062491|U01CA069912|U01CA070095","November 28, 2007","February 1, 2014","null","October 2017","December 20, 2007","January 9, 2008","null","null","December 11, 2017","December 12, 2017","Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00588991"
362,"NCT00013533","Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies","null","Completed","No Results Available","Hodgkin Lymphoma|Lymphocytic Leukemia|Mixed Cell Leukemia|Myelodysplastic Syndrome|Non Hodgkin's Lymphoma|CML|ALL|AML|Lymphoma","Procedure: Stem cell transplantation","To determine the efficacy and safety of this chemotherapy regimen in facilitating donor engraftment after allogeneic bone marrow transplantation (BMT).|Safety/Efficacy|Toxicity of regimen|To determine the toxicity of this non-myelablative allogeneic BMT regimen.|fludarabine-based induction reducing T-cells|immune suppression|IL-7 levels|cytokine profiles|response rates and DFS|incidence and severity of GVHD|response rates, DFS rates, and incidence and severity ofGVHD following withdrawal of immunosuppression and donorlymphocyte infusions (DLI) for patients who developprogressive disease after day +28 post-transplant","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","4 Years to 20 Years   (Child, Adult)","Early Phase 1","30","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","010125|01-C-0125","March 14, 2001","March 1, 2008","May 7, 2015","May 7, 2015","March 20, 2001","March 21, 2001","null","null","October 5, 2017","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00013533"
363,"NCT00113893","SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.","null","Completed","No Results Available","Bone Marrow Diseases|Myelodysplastic Syndromes|Hematologic Diseases|Bone Marrow Neoplasms","Drug: SCIO-469","Percentage of Participants With Major or Minor Erythroid Response (Hematological Improvement - Erythroid [HI-E])|Percentage of Participants Achieving Major or Minor Neutrophil Response (HI-N)|Percentage of Participants Achieving Major or Minor Platelet Response (HI-P)|Percentage of Participants Achieving Complete or Partial Bone Marrow (BM) Response|Percentage of Participants Achieving Major or Minor Cytogenetic Response","Scios, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR005179","May 2005","December 2007","December 2007","October 2013","June 10, 2005","June 13, 2005","null","null","October 15, 2013","November 7, 2013","","https://ClinicalTrials.gov/show/NCT00113893"
364,"NCT02556931","Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies","null","Recruiting","No Results Available","Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Small Lymphocytic Lymphoma|Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Chronic Myeloid Leukemia|Chronic Myeloproliferative Disorders|Multiple Myeloma|Plasma Cell Neoplasm|Plasma Cell Dyscrasia|Myelofibrosis|Polycythemia Vera|Essential Thrombocythemia|Plasma Cell Leukemia","Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total body irradiation|Drug: Tacrolimus|Drug: Mycophenolate mofetil","Percentage of participants who are able to stop prophylactic tacrolimus (D90 cohort)|Percentage of participants who are able to stop prophylactic tacrolimus (D60 cohort)|Incidence of grades III-IV acute GVHD, Days 90-180 (D90)|Incidence of grades III-IV acute GVHD, Days 60-180 (D60)|Incidence of chronic GVHD, Days 90-180 (D90)|Incidence of chronic GVHD, Days 60-180 (D60)|Incidence of graft failure, Days 90-180 (D90)|Incidence of graft failure, Days 60-180 (D60)|Incidence of relapse, Days 90-180 (D90)|Incidence of relapse, Days 60-180 (D60)|Incidence of non-relapse mortality, Days 90-180 (D90)|Incidence of non-relapse mortality, Days 60-180 (D60)|Incidence of grades III-IV acute GVHD, Day 360 (D90)|Incidence of grades III-IV acute GVHD, Day 360 (D60)|Incidence of chronic GVHD, Day 360 (D90)|Incidence of chronic GVHD, Day 360 (D60)|Incidence of graft failure, Day 360 (D90)|Incidence of graft failure, Day 360 (D60)|Incidence of relapse, Day 360 (D90)|Incidence of relapse, Day 360 (D60)|Incidence of non-relapse mortality, Day 360 (D90)|Incidence of non-relapse mortality, Day 360 (D60)","Sidney Kimmel Comprehensive Cancer Center","All","Child, Adult, Senior","Phase 2","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J15165|IRB00080399","December 2015","March 2019","December 2019","July 2017","September 21, 2015","September 22, 2015","null","null","July 12, 2017","July 17, 2017","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT02556931"
365,"NCT01529827","Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","null","Active, not recruiting","Has Results","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Aplastic Anemia|Burkitt Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Congenital Amegakaryocytic Thrombocytopenia|Diamond-Blackfan Anemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Juvenile Myelomonocytic Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Paroxysmal Nocturnal Hemoglobinuria|Peripheral T-cell Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Secondary Myelofibrosis|Severe Combined Immunodeficiency|Severe Congenital Neutropenia|Shwachman-Diamond Syndrome|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Waldenstrom Macroglobulinemia|Wiskott-Aldrich Syndrome","Drug: fludarabine phosphate|Drug: melphalan|Radiation: total-body irradiation|Drug: tacrolimus|Drug: mycophenolate mofetil|Drug: methotrexate|Other: laboratory biomarker analysis|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Transplant Related Mortality (TRM)|Clinical Response|Progression Free Survival (PFS) at One Year|Median Time to Neutrophil Engraftment","Roswell Park Cancer Institute","All","3 Years to 75 Years   (Child, Adult, Senior)","Phase 2","94","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 177110|NCI-2011-03563","February 28, 2012","May 28, 2015","May 1, 2018","September 2017","February 6, 2012","February 9, 2012","June 30, 2017","July 2, 2017","September 8, 2017","September 12, 2017","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT01529827"
366,"NCT00824993","Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients","null","Completed","No Results Available","Hematological Malignancies","Drug: Ibandronate|Drug: Vitamin Supplements","Percent Reduction in Bone Mineral Density (BMD) of the lumbar spine, femoral neck, and total hip","M.D. Anderson Cancer Center|Roche Pharma AG","All","18 Years and older   (Adult, Senior)","Phase 3","78","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-0960|NCI-2010-01024","December 9, 2008","April 7, 2017","April 7, 2017","April 2017","January 15, 2009","January 19, 2009","null","null","April 10, 2017","April 12, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00824993"
367,"NCT01520623","Complement and Graft-versus-host Disease","null","Completed","No Results Available","Allografted With Myeloablative Conditioning","Other: Serum concentration /Serum inflammatory","Activation of the complement system and the development of acute gut GvHD|Overall survival|Overall survival without relapse","Assistance Publique - Hôpitaux de Paris|Clinical haematology and BMT unit,Necker Hospital, Paris|Clinical haematology and BMT unit,Saint Antoine Hospital, Paris|Clinical haematology and BMT unit,Saint Louis Hospital,Paris|European Georges Pompidou Hospital","All","18 Years to 65 Years   (Adult)","","70","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CRC 08025","April 2010","February 2013","July 2013","April 2015","December 26, 2011","January 30, 2012","null","null","April 9, 2015","April 10, 2015","Saint Louis Hospital, Paris, France|Saint Antoine Hospital, Paris, France|Necker Hospital, Paris, France","https://ClinicalTrials.gov/show/NCT01520623"
368,"NCT00750737","Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)","null","Completed","Has Results","Invasive Fungal Infections|Hematologic Malignancies","Drug: Posaconazole|Drug: ABLC","Incidence of Invasive Fungal Infection (IFI)|Efficacy Outcome Measured as Success or Failure","M.D. Anderson Cancer Center|Enzon Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 3","46","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-0020","June 2008","June 2012","June 2012","January 2016","September 10, 2008","September 11, 2008","December 1, 2015","January 6, 2016","August 22, 2016","September 29, 2016","UT MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00750737"
369,"NCT02823184","Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms","PhiNESS","Recruiting","No Results Available","Polycythemia Vera|Essential Thrombocythemia","Biological: RNA sample of total leukocytes before start of treatment","To correlate endoplasmic reticulum stress (defined as splicing of XBP1 above 30%) to the rate of complete response after 6 months according to the 2009 ELN criteria","University Hospital, Bordeaux","All","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CHUBX 2014/27","April 27, 2017","September 2019","September 2019","July 2017","June 24, 2016","July 6, 2016","null","null","July 25, 2017","July 27, 2017","Ch de La Cöte Basque, Bayonne, France|Chu de Bordeaux, Bordeaux, France|Crlcc Bergonie, Bordeaux, France|Ch de Libourne, Libourne, France|Chu de Limoges, Limoges, France|Chu de Nimes, Nimes, France|Chu de Toulouse, Toulouse, France","https://ClinicalTrials.gov/show/NCT02823184"
370,"NCT01345019","Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma","null","Active, not recruiting","No Results Available","Cancer|Hematologic Malignancies|Multiple Myeloma|Oncology|Bone Metastases|Multiple Myeloma Bone Lesions","Drug: Denosumab|Drug: Zoledronic acid|Other: Placebo SC|Other: Placebo IV","Time to the first on-study skeletal related event (SRE) (non-inferiority test)|Time to the first-and-subsequent SRE (superiority test, using multiple event analysis)|Time to the first on-study SRE (superiority test)","Amgen|Daiichi Sankyo, Inc.","All","18 Years and older   (Adult, Senior)","Phase 3","1718","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","20090482","May 17, 2012","July 19, 2016","February 1, 2019","December 2017","April 28, 2011","April 29, 2011","null","null","December 20, 2017","December 22, 2017","Research Site, Tucson, Arizona, United States|Research Site, Fayetteville, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Campbell, California, United States|Research Site, Encinitas, California, United States|Research Site, Fresno, California, United States|Research Site, Pleasant Hill, California, United States|Research Site, Santa Barbara, California, United States|Research Site, Santa Maria, California, United States|Research Site, Stamford, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Columbus, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Joliet, Illinois, United States|Research Site, Maywood, Illinois, United States|Research Site, Niles, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Ames, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Paducah, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Scarborough, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Westminster, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Danvers, Massachusetts, United States|Research Site, Fairhaven, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Jackson, Mississippi, United States|Research Site, Springfield, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, North Las Vegas, Nevada, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Lake Success, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Fayetteville, North Carolina, United States|Research Site, Goldsboro, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, West Reading, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Aberdeen, South Dakota, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Watertown, South Dakota, United States|Research Site, Memphis, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Christiansburg, Virginia, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Minocqua, Wisconsin, United States|Research Site, Wauwatosa, Wisconsin, United States|Research Site, Liverpool, New South Wales, Australia|Research Site, Tweed Heads, New South Wales, Australia|Research Site, Douglas, Queensland, Australia|Research Site, South Brisbane, Queensland, Australia|Research Site, Hobart, Tasmania, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Epping, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Krems an der Donau, Austria|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Burnaby, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, St. Johns, Newfoundland and Labrador, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Sault Ste. Marie, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Trois-Rivières, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Amiens Cedex 1, France|Research Site, Avignon Cedex 9, France|Research Site, Creteil, France|Research Site, Le Kremlin Bicetre, France|Research Site, Le Mans Cedex 9, France|Research Site, Le Mans, France|Research Site, Lille, France|Research Site, Lyon Cédex 3, France|Research Site, Marseille cedex 5, France|Research Site, Marseille Cedex 9, France|Research Site, Nantes Cedex 1, France|Research Site, Nice Cedex 3, France|Research Site, Paris Cedex 12, France|Research Site, Paris Cedex 14, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pessac Cedex, France|Research Site, Pierre-Benite cedex, France|Research Site, Pontoise Cedex, France|Research Site, Reims Cedex, France|Research Site, Rouen cedex, France|Research Site, Saint Quentin, France|Research Site, Strasbourg, France|Research Site, Villefranche Sur Saone Cedex, France|Research Site, Bonn, Germany|Research Site, Chemnitz, Germany|Research Site, Essen, Germany|Research Site, Hamburg, Germany|Research Site, Kassel, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Münster, Germany|Research Site, Regensburg, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Patra, Greece|Research Site, Piraeus, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyor, Hungary|Research Site, Gyula, Hungary|Research Site, Kaposvar, Hungary|Research Site, Szeged, Hungary|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Limerick, Ireland|Research Site, Tullamore, Ireland|Research Site, Ancona, Italy|Research Site, Bari, Italy|Research Site, Brescia, Italy|Research Site, Busto Arsizio, Italy|Research Site, Catania, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Messina, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Napoli, Italy|Research Site, Novara, Italy|Research Site, Palermo, Italy|Research Site, Pescara, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Rozzano MI, Italy|Research Site, Torino, Italy|Research Site, Udine, Italy|Research Site, Vimercate MB, Italy|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Akita-shi, Akita, Japan|Research Site, Kamogawa-shi, Chiba, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Gifu-shi, Gifu, Japan|Research Site, Ogaki-shi, Gifu, Japan|Research Site, Maebashi-shi, Gunma, Japan|Research Site, Shibukawa-shi, Gunma, Japan|Research Site, Fukuyama-shi, Hiroshima, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Kawagoe-shi, Saitama, Japan|Research Site, Tokushima-shi, Tokushima, Japan|Research Site, Shibuya-ku, Tokyo, Japan|Research Site, Shinjuku-ku, Tokyo, Japan|Research Site, Toyama-shi, Toyama, Japan|Research Site, Anyang, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kaunas, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Ipoh, Perak, Malaysia|Research Site, Georgetown, Pinang, Malaysia|Research Site, Kuching, Sarawak, Malaysia|Research Site, Ampang, Malaysia|Research Site, Christchurch, New Zealand|Research Site, Grafton, Auckland, New Zealand|Research Site, Legnica, Poland|Research Site, Lublin, Poland|Research Site, Slupsk, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Braga, Portugal|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Matosinhos, Portugal|Research Site, Porto, Portugal|Research Site, Dzerzhinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Bratislava, Slovakia|Research Site, Nitra, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Sevilla, Andalucía, Spain|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, Salamanca, Castilla León, Spain|Research Site, Badalona, Cataluña, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Ourense, Galicia, Spain|Research Site, San Sebastian, País Vasco, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Chur, Switzerland|Research Site, Zurich, Switzerland|Research Site, Zurich, Switzerland|Research Site, Changhua, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Cherkasy, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Khmelnitskiy, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Harrow, United Kingdom|Research Site, Inverness, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT01345019"
371,"NCT02311569","Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation","null","Completed","No Results Available","Myeloproliferative Neoplasm|Primary Myelofibrosis|Essential Thrombocythemia|Polycythemia Vera","Drug: Mirabegron","Reduction in the burden of mutated alleles of ≥50% at 24 weeks.|Reduction in the burden of mutated alleles of ≥50%|Reduction in the burden of mutated alleles of ≥25%","Swiss Group for Clinical Cancer Research","All","18 Years and older   (Adult, Senior)","Phase 2","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SAKK 33/14","April 2015","December 2016","December 2016","December 2016","December 4, 2014","December 8, 2014","null","null","December 28, 2016","December 29, 2016","Kantonsspital Aarau, Aarau, Switzerland|Universitaetsspital-Basel, Basel, Switzerland|Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Hopitaux Universitaires de Geneve, Genève 14, Switzerland|Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland|Kantonsspital Liestal, Liestal, Switzerland|Kantonsspital Luzern, Luzern, Switzerland|Kantonsspital Münsterlingen, Münsterlingen, Switzerland|Universitätsspital Zürich, Zurich, Switzerland|Stadtspital Triemli, Zürich, Switzerland","https://ClinicalTrials.gov/show/NCT02311569"
372,"NCT03121599","18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms","null","Recruiting","No Results Available","Essential Thrombocythemia|Primary Myelofibrosis, Fibrotic Stage|Primary Myelofibrosis, Prefibrotic Stage|Polycythemia Vera","Device: Diagnostic (18F-FLT PET/CT)","Evaluate the uptake of 3'-deoxy-3'-[18F] fluorothymidine (FLT) positron emission tomography/computed tomography (PET) in children with MPNs|Number of patients who have similar diagnosis and pattern between FLT and Bone Marrow","Hamad Medical Corporation","All","14 Years to 18 Years   (Child, Adult)","","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","16294/16","June 11, 2017","May 1, 2018","June 1, 2018","July 2017","April 17, 2017","April 20, 2017","null","null","July 24, 2017","July 26, 2017","National Center for Cancer Care & Research (NCCCR), Doha, Qatar","https://ClinicalTrials.gov/show/NCT03121599"
373,"NCT03065400","PD-1 Inhibition in Advanced Myeloproliferative Neoplasms","null","Recruiting","No Results Available","Chronic Phase Myelofibrosis|Primary Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis|Polycythemia Vera","Drug: Pembrolizumab","European Leukemia Net -International Working Group (ELN-IWG) criteria|Acute Myeloid Leukemia Response Criteria","John Mascarenhas|Massachusetts General Hospital|Montefiore Medical Center|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Senior)","Phase 2","34","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 16-2350","June 14, 2017","April 30, 2019","April 30, 2020","June 2017","February 22, 2017","February 27, 2017","null","null","June 27, 2017","June 29, 2017","Harvard Medical School Massachusetts General Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Montefiore Medical Center Division of Hematology, Department of Oncology, The Bronx, New York, United States","https://ClinicalTrials.gov/show/NCT03065400"
374,"NCT02760238","Myeloproliferative Neoplasms (MPNs) Patient Registry","null","Recruiting","No Results Available","Primary Myelofibrosis|Polycythemia Vera|Essential Thrombocythemia|Mastocytosis|Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative|Leukemia, Myelomonocytic, Juvenile|Chronic Eosinophilic Leukemia-not Otherwise Specified|Myelodysplastic-Myeloproliferative Diseases|Neoplasms|Leukemia, Myelomonocytic, Chronic","Other: Observational","Survival|General patient characteristics will be captured from the Hematologic Malignacy tissue bank|Disease risk score|Quality of life|Co-morbidities|Physical symptoms of MPN|MPN treatment type received|Transfusion dependence status|Current Blood Work|Identifying MPN driver mutations by using next generation sequencing.|Bone marrow transplant details (if received)|Bone marrow transplant complications (if received)|Portal hypertension|Pulmonary hypertension|Thrombosis|Family history of MPN will be obtained from the patient record.|Disease progression","University Health Network, Toronto","All","Child, Adult, Senior","","5000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","UHN REB 15-9814 CE","April 2016","October 2025","October 2025","October 2017","March 24, 2016","May 3, 2016","null","null","October 27, 2017","October 31, 2017","Princess Margaret Cancer Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT02760238"
375,"NCT01520220","Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms","null","Completed","No Results Available","Myeloproliferative Neoplasms of|Polycythemia Vera|Essential Thrombocythemia|Myelofibrosis","Drug: LY2784544","Number of participants with LY2784544 dose limiting toxicities (DLT)|Recommended dose range and regimen for Phase 2 studies|Pharmacokinetics of LY2784544: Maximum concentration (Cmax)|Pharmacokinetics of LY2784544: Area under the concentration-time curve (AUC)|International Working Group (IWG) response|Dynamic International Prognostic Scoring System (DIPSS) Plus|Change in symptom burden as assessed by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)|Change in Myeloproliferative Neoplasm (MPN) Physician Symptom Assessment","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 1","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14539|I3X-MC-JHTC","June 11, 2012","June 26, 2015","February 24, 2017","April 2017","January 10, 2012","January 27, 2012","null","null","April 10, 2017","April 12, 2017","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scottsdale, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fayetteville, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Washington, District of Columbia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT01520220"
376,"NCT01816022","Myeloproliferative Neoplasms and Bone Structure","null","Unknown status","No Results Available","Polycythemia Vera|Thrombocythemia, Essential|Primary Myelofibrosis","","Bone Mineral Density (BMD)|Evaluation of Geometry, Strength and Micro-Structure of the bone.","University of Southern Denmark","All","18 Years and older   (Adult, Senior)","","125","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","HFEX 11.15","March 2012","March 2014","March 2015","March 2013","September 18, 2012","March 21, 2013","null","null","March 20, 2013","March 21, 2013","Faculty of Health Sciences, Institute of Clinical Research, Odense, Region Syddanmark, Denmark","https://ClinicalTrials.gov/show/NCT01816022"
377,"NCT01831635","Myeloproliferative Neoplasms: an In-depth Case-control Study","MOSAICC","Unknown status","No Results Available","Polycythemia Vera|Essential Thrombocythemia|Primary Myelofibrosis","Other: Methodological pens|Other: Methodological compensation|Other: Methodological trolley tokens","Influence of pre- and post- incentives on participation rates.|Residence|Occupational history using FINJEM|Occupational history using OccIDEAS|Medical history|Demographics|Tobacco use|Alcohol|Gardening and household exposures","Queen's University, Belfast|University Hospital Southampton NHS Foundation Trust|University of Manchester|Western Australian Institute for Medical Research|Mayo Clinic","All","18 Years and older   (Adult, Senior)","","300","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","B12/24|MPDVOICE001","April 2013","July 2014","June 2015","April 2013","March 27, 2013","April 15, 2013","null","null","April 23, 2013","April 24, 2013","University Hospitals Southampton NHS Foundation Trust, Southampton, England, United Kingdom|Belfast Health And Social Care Trust, Belfast, Northern Ireland, United Kingdom|Queen's University Belfast, Belfast, Northern Ireland, United Kingdom","https://ClinicalTrials.gov/show/NCT01831635"
378,"NCT01970930","Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients","null","Completed","No Results Available","Polycythemia Vera|Essential Thrombocythemia","Procedure: Blood specimen","Stem cell function|CD34+ cells assays","Icahn School of Medicine at Mount Sinai|The Leukemia and Lymphoma Society","All","Child, Adult, Senior","","571","Other","Observational","Observational Model: Other|Time Perspective: Prospective","GCO 12-0481","August 2012","September 28, 2016","September 28, 2016","January 2018","August 20, 2013","October 28, 2013","null","null","January 2, 2018","January 4, 2018","Icahn School of Medicine at Mount Sinai, New York, New York, United States","https://ClinicalTrials.gov/show/NCT01970930"
379,"NCT03287245","A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera","null","Recruiting","No Results Available","Polycythemia Vera","Drug: Idasanutlin","Composite Response at Week 32 for Participants With Splenomegaly at Baseline|Hematocrit (Hct) Control Without Phlebotomy at Week 32 for Participants Without Splenomegaly at Baseline|Response per Modified European Leukemia Net (ELN) Criteria at Week 32 for Ruxolitinib-Naïve Participants and All Participants Irrespective of Prior Ruxolitinib Exposure|Duration of Response, Including Percentage of Participants With Durable Response Lasting at Least 12 Weeks|Composite Response at Week 32 for Participants With Splenomegaly at Baseline Irrespective of Prior Ruxolitinib Exposure|Hematocrit (Hct) Control in Participants Without Splenomegaly at Baseline Irrespective of Prior Ruxolitinib Exposure|Percentage of Participants With Abnormal Clinical Laboratory Findings|Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Eastern Cooperative Oncology Group (ECOG) Performance Status|Percentage of Participants With Abnormal Electrocardiogram (ECG) Findings, Vital Signs, and Physical Findings|Percentage of Participants With Concomitant Medications|Maximum Serum Concentration Observed (Cmax)|Trough Concentration (Ctrough)|Time of Maximum Concentration Observed (tmax)|Clearance (CL)|Apparent clearance (CL/F)|Volume or Apparent Volume of Distribution (Vdss/F)|Area under the curve (AUC)|Half-life (t1/2)|Baseline and Mean Change from Baseline Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)|Baseline and Mean Change from Baseline European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)|Baseline and Mean Change from Baseline Patient Global Impression of Change (PGIC)","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NP39761|2017-000861-58","December 21, 2017","January 10, 2019","July 15, 2020","December 2017","September 8, 2017","September 19, 2017","null","null","December 7, 2017","December 11, 2017","Mayo Clinic - Arizona, Phoenix, Arizona, United States|University of Kansas Cancer Center; Westwood Cancer Center/BMT Output Clinic, Kansas City, Kansas, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia Univ Med Ctr, New York, New York, United States|MSKCC, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Wake Forest University School of Medicine; Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Cancer Center, Independence, Ohio, United States|University of Texas Health Sciences Center in San Antonio, San Antonio, Texas, United States|Peter MacCallum Cancer Centre; Department of Haematology, Melbourne, Victoria, Australia|Princess Margaret Hospital; Department of Med Oncology, Toronto, Ontario, Canada|ASST PAPA GIOVANNI XXIII; Ematologia, Bergamo, Lombardia, Italy|Ospedale Di Circolo E Fondazione Macchi; Ematologia, Varese, Lombardia, Italy|Az. Ospedaliero-Universitaria Careggi; CRIMM, Firenze, Toscana, Italy","https://ClinicalTrials.gov/show/NCT03287245"
380,"NCT02912884","Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure","MPNClot","Recruiting","No Results Available","Polycythemia Vera|Thrombocythemia, Essential","Drug: No cytoreductive vs cytoreductive drugs","Fibrin polymerization; lag-time (in seconds)|Fibrin polymerization; maximal absorbance|Clot lysis time (in minutes)|Clot permeation; permeation coefficient|Quantitative parameters of thrombin generation test (TGT); endogenous thrombin potential (nM*minutes)|Quantitative parameters of thrombin generation test (TGT); peak (nM)|Quantitative parameters of thrombin generation test (TGT); time to peak (minutes)|Fibrin density by laser scanner confocal microscopy (number per 100 μm)","Dr Yan Beauverd|University Hospital, Geneva","All","18 Years and older   (Adult, Senior)","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CCER 2016-00950","September 2016","December 2019","December 2019","November 2017","September 10, 2016","September 23, 2016","null","null","November 7, 2017","November 8, 2017","Geneva University Hospitals, Geneva, Switzerland|Guy's Hospital, London, United Kingdom","https://ClinicalTrials.gov/show/NCT02912884"
381,"NCT02893410","Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients","OUEST","Completed","No Results Available","Polycythemia Vera|Essential Thrombocythemia","","Rate of adherence to drug prescription","University Hospital, Brest","All","18 Years and older   (Adult, Senior)","","286","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","OUEST (RB14.115)","December 2014","December 2015","December 2015","September 2016","August 26, 2016","September 8, 2016","null","null","September 2, 2016","September 8, 2016","CHRU de Brest, Brest, France","https://ClinicalTrials.gov/show/NCT02893410"
382,"NCT01668173","HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET","null","Terminated","Has Results","Myeloproliferative Neoplasms","Drug: AUY922","Overall Objective Response","Memorial Sloan Kettering Cancer Center|Novartis","All","18 Years and older   (Adult, Senior)","Phase 2","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-076","August 2012","May 2015","May 2015","April 2016","August 13, 2012","August 17, 2012","January 4, 2016","May 23, 2016","April 11, 2016","May 23, 2016","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT01668173"
383,"NCT01131247","PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab","null","Withdrawn","No Results Available","Chronic Lymphocytic Leukemia (CLL)","Drug: ofatumumab + bendamustine","Overall Response Rate/ Efficacy|Safety Evaluation|Response Rate|Correlative Analysis","Nevada Cancer Institute|Cephalon|GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","37","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NVCI 09-15|18083/6265","null","null","null","July 2011","May 25, 2010","May 26, 2010","null","null","July 19, 2011","July 20, 2011","Mayo Clinic, PHoenix/Scottsdale, Arizona, United States","https://ClinicalTrials.gov/show/NCT01131247"
384,"NCT01125787","Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab","null","Terminated","No Results Available","Chronic Lymphocytic Leukemia (CLL)","Drug: ofatumumab + bendamustine","Overall Response Rate (Efficacy)|Safety Evaluation|Response Rate Evaluation|Correlative Analysis","Nevada Cancer Institute|GlaxoSmithKline|Cephalon","All","18 Years and older   (Adult, Senior)","Phase 2","1","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NVCI 09-14|C18083/6264","May 2010","August 2010","April 2011","July 2011","May 14, 2010","May 18, 2010","null","null","July 19, 2011","July 20, 2011","University of Florida, Gainesville, Florida, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States","https://ClinicalTrials.gov/show/NCT01125787"
385,"NCT03003325","The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV","Low-PV","Recruiting","No Results Available","Polycythemia Vera","Drug: AOP2014|Procedure: Phlebotomies|Drug: ASA","Number of patients who maintains the median value of HCT< 45%, along 12 months, on number of patients randomized in each arm, per cent|Median number of phlebotomies performed|Number of patients achieving hematological response (as defined below in 'Description') on number of patients randomized in each arm, per cent,|Proportion (rate per cent) of patients with not palpable spleen|Janus kinase-2 allele burden reduction or complete molecular remission|Bone marrow histological remission|Incidence and frequence of thrombotic and hemorrhagic events occurred|Number of adverse events occurred","Fondazione per la Ricerca Ospedale Maggiore|AOP Orphan Pharmaceuticals AG","All","18 Years to 60 Years   (Adult)","Phase 2","150","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Low-PV","February 2, 2017","December 2018","December 2019","August 2017","November 3, 2016","December 28, 2016","null","null","August 9, 2017","August 10, 2017","U.O. Ematologia, Ospedale Casa Sollievo della Sofferenza Istituto di Ricovero e Cura a Carattere Scientifico, San Giovanni Rotondo, (FG) Puglia, Italy|Azienda Ospedaliera Universitaria Federico II di Napoli, Napoli, Campania, Italy|Divisione Ematologia Policlinico S. Orsola - Malpighi, Bologna, Emilia Romagna, Italy|Clinica Ematologica, Azienda Ospedaliero-Universitaria ""Santa Maria della Misericordia"", Udine, Friuli Venezia Giulia, Italy|UCSC Ematologia, Fondazione Policlinico Universitario ""Agostino Gemelli""Università Cattolica del Sacro Cuore, Roma, Lazio, Italy|USC Ematologia, ASST Papa Giovanni XXIII, Bergamo, Lombardia, Italy|Divisione Oncoematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Lombardia, Italy|Divisione Ematologia ASST, Grande Ospedale Metropolitano Niguarda, Milano, Lombardia, Italy|Divisione Ematologia, ASST di MONZA - Ospedale San Gerardo di Monza, Monza, Lombardia, Italy|Divisione Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy|U.O. Ematologia, Ospedale di Circolo e Fondazione Macchi Varese, Varese, Lombardia, Italy|S.C. Ematologia Azienda Ospedaliera S. Croce e Carle Cuneo, Cuneo, Piemonte, Italy|SCDU Ematologia, A.O.U. Maggiore della Carità, Novara, Piemonte, Italy|S.C. Ematologia, AOU- Presidio Ospedaliero Molinette, Torino, Piemonte, Italy|U.O. Ematologia con Trapianto, Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari, Bari, Puglia, Italy|Unità Operativa Complessa di Emostasi Azienda Ospedaliero-Universitario ""Policlinico Vittorio-Emanuele - Presidio Ospedaliero Ferrarotto, Catania, Sicilia, Italy|UOC Ematologia, Azienda Ospedaliera Universitaria Policlinico ""G. Martino"", Messina, Sicilia, Italy|Divisione Ematologia Azienda Ospedaliera Universitaria Policlinico ""Paolo Giaccone"" Palermo, Palermo, Sicilia, Italy|SOD Ematologia AUOC Azienda Ospedaliero-Universitaria ""Careggi"", Firenze, Toscana, Italy|Clinica Medica I Azienda Ospedaliera di Padova, Padova, Veneto, Italy|Divisione Ematologia, Ospedale Borgo Roma, Verona, Veneto, Italy|Divisione Ematologia, Ospedale San Bortolo, Vicenza, Veneto, Italy","https://ClinicalTrials.gov/show/NCT03003325"
386,"NCT02577926","The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia","Ruxo-BEAT","Recruiting","No Results Available","Polycythemia Vera (PV)|Essential Thrombocythemia (ET)","Drug: Ruxolitinib|Drug: BAT","The rate of complete clinicohematologic response rate (CHR) as defined by Barosi et al Blood 2009|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|The complete response rate (CR) at month 6 as defined by Barosi et al Blood 2013 (revised ELN response criteria)|The rate of complete responses (CHR) at month 12 as defined by Barosi et al Blood 2009|The efficacy as assessed by the absence of phlebotomy (Hct <45%)|The efficacy as assessed by the reduction in spleen size (palpable spleen that is reduced by > 50% from baseline measured by palpation and ultrasound) OR platelet count < 600 x 10^9/l (ET)|Proportion of subjects achieving both durable absence of phlebotomy eligibility AND durable spleen volume reduction measured by palpation and ultrasound (PV) OR durable platelet count <600 x 10^9/l (ET) (durable defined as >3 months) {Barosi et al 2013)|The rate of overall clinicohematologic remissions (CR + PR) according to both guidelines (Barosi et al 2009 and 2013)","RWTH Aachen University|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","380","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-181","October 2015","December 2020","December 2022","January 2018","October 1, 2015","October 16, 2015","null","null","January 2, 2018","January 4, 2018","Universitätsmedizin Mannheim III. Medizinische Klinik Hämatologie und Internistische Onkologie, Mannheim, Baden-Württemberg, Germany|Universitätsklinikum Ulm Klinik für Innere Medizin III, Ulm, Baden-Württemberg, Germany|Rems-Murr Klinikum Winnenden, Winnenden, Baden-Württemberg, Germany|Studienzentrum Aschaffenburg, Aschaffenburg, Bayern, Germany|III. Medizinischen Klinik des Klinikums rechts der Isar der TU München, Müchen, Bayern, Germany|Klinikum Nürnberg Nord Medizinische Klinik 5, Nürnberg, Bayern, Germany|Universitätsmedizin Mainz III. Medizinische Klinik und Poliklinik, Mainz, Hessen, Germany|Universitätsklinikum Bonn Medizinische Klinik und Poliklinik III, Bonn, Nordrhein-Westfalen, Germany|Johanniter-Krankenhaus Rheinhausen GmbH Hämatologie / Internistische Onkologie / Tagesklinik, Duisburg, Nordrhein-Westfalen, Germany|Universitätsklinikum Düsseldorf Klinik für Hämatologie, Onkologie und Klinische Immunologie, Düsseldorf, Nordrhein-Westfalen, Germany|Universitätsklinikum Essen Klinik für Hämatologie, Essen, Nordrhein-Westfalen, Germany|Mühlenkreiskliniken Johannes Wesling Klinikum Minden Klinik für Hämatologie, Onkologie und Palliativmedizin, Minden, Nordrhein-Westfalen, Germany|Zentralklinikum Medizinische Klinik A Hämatologie, Hämostaseologie, Onkologie und Pneumologie, Münster, Nordrhein-Westfalen, Germany|Uniklinik RWTH Aachen, Aachen, NRW, Germany|Universitätsklinikum Magdeburg, Magdeburg, Sachesen-Anhalt, Germany|Universitätsklinikum Halle (Saale), Halle (Saale), Sachsen-Anhalt, Germany|Klinikum Chemnitz gGmbH Klinik für Innere Medizin III, Chemnitz, Sachsen, Germany|Universitätsklinikum Dresden Medizinische Klinik und Poliklinik I, Dresden, Sachsen, Germany|Charité Universitätsmedizin Berlin Med. Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany|Universitätsklinikum Freiburg - Klinik für Innere Medizin I, Freiburg, Germany|Universitätsklinikum Hamburg Eppendorf Klinik und Poliklinik für Onkologie, Hämatologie und KMT mit Sektion Pneumologie, Hamburg, Germany|Universitätsklinik Jena - Klinik für Innere Medizin II, Jena, Germany","https://ClinicalTrials.gov/show/NCT02577926"
387,"NCT01816256","Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms","null","Recruiting","No Results Available","Myeloproliferative Neoplasms (MPN)|Polycythemia Vera (PV)|Essential Thrombocythemia (ET)|Myelofibrosis (MF)","Procedure: Upper gastrointestinal endoscopy and Doppler ultrasound","Incidence of asymptomatic portal vein thrombosis (PVT) and/or portal hypertension (PHTN) in patients with Philadelphia negative myeloproliferative neoplasms (MPNs)|Comparison of baseline characteristics in patients with or without asymptomatic PVT/PHTN|Comparison of survival and number of patients with leukemic transformation in patients with or without asymptomatic PVT/PHTN","University Health Network, Toronto|Novartis Pharmaceuticals","All","Child, Adult, Senior","","100","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","MPN 12-01","May 2013","January 2018","January 2018","September 2017","January 14, 2013","March 22, 2013","null","null","September 27, 2017","September 28, 2017","Princess Margaret Cancer Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT01816256"
388,"NCT00726232","Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia","null","Active, not recruiting","Has Results","MPN (Myeloproliferative Neoplasms)","Drug: Ruxolitinib","Percentage of Polycythemia Vera Participants With a Confirmed Clinical Partial Response (PR) or Complete Response (CR)|Percentage of Essential Thrombocythemia (ET) Participants With a Confirmed Clinical Partial Response (PR) or Complete Response (CR)|Percentage of Polycythemia Vera Participants Who Achieved Individual Components of Clinical Response at 12 Weeks|Percentage of Polycythemia Vera Participants Who Achieved Individual Components of Clinical Response at 24 Weeks|Percentage of Polycythemia Vera Participants Who Achieved Individual Components of Clinical Response at 36 Weeks|Percentage of Essential Thrombocythemia Participants Who Achieved Individual Components of Clinical Response at 4 Weeks|Percentage of Essential Thrombocythemia Participants Who Achieved Individual Components of Clinical Response at 24 Weeks|Percentage of Essential Thrombocythemia Participants Who Achieved Individual Components of Clinical Response at 36 Weeks|Change From Baseline to Week 4 in Polycythemia Vera Symptoms|Change From Baseline to Week 4 in Essential Thrombocythemia Symptoms|Change From Baseline to Week 4 in Health-related Quality of Life","Incyte Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","73","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCB 18424-256","July 2008","June 2010","July 2018","December 2017","July 29, 2008","July 31, 2008","January 20, 2012","February 24, 2012","December 7, 2017","January 1, 2018","Houston, Texas, United States|Bergamo, Italy|Firenze, Italy|Pavia, Italy","https://ClinicalTrials.gov/show/NCT00726232"
389,"NCT02897297","Myeloproliferative Neoplastic Diseases Observatory From Brest","OBENE","Recruiting","No Results Available","Polycythemia Vera|Essential Thrombocythemia|Primary Myelofibrosis","","Overall Survival","University Hospital, Brest","All","Child, Adult, Senior","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","OBENE","September 2015","September 2025","September 2025","September 2016","August 26, 2016","September 13, 2016","null","null","September 7, 2016","September 13, 2016","CHRU de Brest, Brest, France","https://ClinicalTrials.gov/show/NCT02897297"
390,"NCT02407080","Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia","null","Recruiting","No Results Available","Polycythemia Vera|Essential Thrombocythemia","Drug: RG7388|Drug: Pegasys","The dose limiting toxicity of RG7388|The dose limiting toxicity of combination of RG7388 and Pegasys|Hematologic response of PR + CR by modified ELN response criteria|Molecular response by percent reduction in baseline JAK2V617F allele burden|Changes in bone marrow histopathologic abnormalities|Reduction in baseline reticulin/collagen fibrosis|Incidence of venous and arterial thrombosis|Changes in MPN related symptoms as measured by the MPN-SAF","John Mascarenhas|Roche Pharma AG|The Leukemia and Lymphoma Society|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 12-0481-1001|MPD-RC 115|GCO 14-1919","April 2015","April 2017","April 2018","January 2017","March 24, 2015","April 2, 2015","null","null","January 16, 2017","January 18, 2017","Mayo Clinic, Scottsdale, Arizona, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT02407080"
391,"NCT00890747","Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy","null","Completed","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Grade III Lymphomatoid Granulomatosis|Adult Langerhans Cell Histiocytosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Aggressive NK-cell Leukemia|AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Malignancies|AIDS-related Small Noncleaved Cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Clear Cell Renal Cell Carcinoma|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extramedullary Plasmacytoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|HIV Infection|HIV-associated Hodgkin Lymphoma|Intraocular Lymphoma|Isolated Plasmacytoma of Bone|Light Chain Deposition Disease|Mast Cell Leukemia|Myelodysplastic Syndrome With Isolated Del(5q)|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myeloid/NK-cell Acute Leukemia|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Osteolytic Lesions of Multiple Myeloma|Peripheral T-cell Lymphoma|Plasma Cell Neoplasm|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Primary Systemic Amyloidosis|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Renal Cell Cancer|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Stage IV Renal Cell Cancer|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia","Drug: sunitinib malate|Other: pharmacological study|Other: laboratory biomarker analysis","Grades 3, 4, and 5, treatment-related adverse events, graded according to the National Cancer Institute (NCI) CTCAE version 3.0|Dose-limiting toxicity (DLT) defined as an adverse event that is possibly related to the study medication, graded according to the NCI CTCAE version 3.0|Evaluation of response|Antiretroviral drug pharmacokinetics due to sunitinib malate|Alterations in immune parameters, including total leukocyte count, CD4, and viral load","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","42","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02208|AMC-061|U01CA121947","August 2009","May 2011","null","September 2013","April 29, 2009","April 30, 2009","null","null","March 14, 2014","March 17, 2014","Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|Northwestern University, Chicago, Illinois, United States|AIDS - Associated Malignancies Clinical Trials Consortium, Rockville, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Washington University - Jewish, Saint Loius, Missouri, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States|Virginia Mason Medical Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00890747"
392,"NCT02523638","Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients","PEN-PV","Completed","No Results Available","Polycythemia Vera","Drug: Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen","To evaluate ease of self-administration of AOP2014|Adverse Event|number of phlebotomies|Disease response|blood parameters|spleen size|disease related symptoms|protocol-specific adverse events of special interest","AOP Orphan Pharmaceuticals AG|PharmaEssentia Corporation (Co-Sponsor for USA)","All","18 Years to 99 Years   (Adult, Senior)","Phase 3","30","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PEN-PV|2014-001356-31","July 2015","December 2015","December 2015","February 2016","June 12, 2015","August 14, 2015","null","null","February 16, 2016","February 17, 2016","LKH Graz, Graz, Austria|University Hospital Innsbruck, Innsbruck, Austria|Elisabethinen Hospital Linz, Linz, Austria|Salzburg Regional Hospital, Salzburg, Austria|Hanusch Hospital, Vienna, Austria|Medical University Vienna, Vienna, Austria|Hospital Wels-Grieskirchen, Wels, Austria|Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment - Hristo Botev, Vratsa, First Department of Internal Medicine, Vratsa, Bulgaria|University Hospital Brno, Brno, Czech Republic|University Hospital Hradec Kralove, Hradec Kralove, Czech Republic|Institute of Hematology and Blood Transfusion, Prague, Czech Republic|University Hospital Kralovske Vinohrady, Prague, Czech Republic|University Hospital Motol, Prague, Czech Republic|Institute Paoli-Calmettes, Marseilles, France|Hospital Saint-Louis, Paris, France|Clinical Research Center CIC, Poitiers, France|St Istvan and St Laszlo Hospital of Budapest, Budapest, Hungary|University of Debrecen, Debrecen, Hungary|Bekes County Pandy Kalman Hospital, 1st Department of Medicine, Hematology, Gyula, Hungary|Kaposi Mor County Teaching Hospital, Kaposvar, Hungary|University of Szeged, Albert Szent-Gyorgyi Clinical Center, Koranyi fasor 6, Szeged, Hungary|Andrzej Mielecki Independent Public Clinical Hospital of Medical University of Silesia in Katowice, Katowice, Poland|University Hospital in Cracow, Krakow, Poland|Independent Public Teaching Hospital No.1 in Lublin, Lublin, Poland|Fryderyk Chopin Provincial Specialized Hospital, Rzeszow, Poland|Nicolaus Copernicus Municipal Specialist Hospital, Torun, Poland|Institute of Hematology and Transfusion Medicine, Warsaw, Poland|University Hospital with Outpatient Clinic F.D. Roosevelt, Banska Bystrica, Slovakia|Saint Cyril and Metod University Hospital Bratislava, Bratislava, Slovakia|Cherkasy Regional Oncology Center, Regional Treatment and Diagnostics Hematology Center, Cherkasy, Ukraine|Dnipropetrovsk City Multispecialty Clinical Hospital #4, Dnipropetrovsk, Ukraine|National Research Center for Radiation Medicine, Institute of Clinical Radiology, Kiev, Ukraine|Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine|O.F. Herbachevskyi Regional Clinical Hospital, Zhytomyr, Ukraine","https://ClinicalTrials.gov/show/NCT02523638"
393,"NCT02129101","Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies","null","Active, not recruiting","No Results Available","Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndrome|Essential Thrombocythemia|Myelodysplastic Syndrome|Myelodysplastic/Myeloproliferative Neoplasm|Polycythemia Vera|Previously Treated Myelodysplastic Syndrome|Primary Myelofibrosis|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia","Drug: Azacitidine|Drug: Decitabine|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Drug: Sonidegib","Best overall response (complete response [CR] or complete response with incomplete recovery [CRi]) in untreated AML, CMML, MDS, or MDS/MPN Overlap patients (Phase IB [Dose Expansion])|Best overall response (CR or CRi) in myelofibrosis patients (Phase IB [Dose Expansion])|Best overall response (CR or CRi) in relapsed/refractory AML, CMML, MDS, or MDS/MPN Overlap patients (Phase IB [Dose Expansion])|MTD defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients) (Phase I)|Duration of response|Incidence of adverse events graded using the NCI CTCAE version 4.0 (Phase IB [dose expansion])|Overall survival|Time to AML|Time to death|Time to progression","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","78","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC1389|NCI-2014-00866|Mod13-009003-08|P30CA015083","May 2014","April 2018","April 2018","January 2017","April 30, 2014","May 2, 2014","null","null","January 20, 2017","January 23, 2017","Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT02129101"
394,"NCT01998828","Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia","null","Terminated","No Results Available","Polycythemia Vera|Essential Thrombocythemia","Drug: Momelotinib","Overall response rate|Confirmed overall response rate|Proportion of participants with hematocrit < 45% in the absence of phlebotomy that lasts at least 4 weeks|Proportion of participants with WBC < 10 x 10^9/L that lasts at least 4 weeks|Proportion of participants with platelet count ≤ 400 x 10^9/L that lasts at least 4 weeks|Proportion of participants with resolution of palpable splenomegaly that lasts at least 4 weeks|Proportion of participants with ≥ 10 point decrease in modified Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPNSAF TSS) compared to baseline that lasts at least 12 weeks","Gilead Sciences","All","18 Years and older   (Adult, Senior)","Phase 2","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-354-0101|2013-004105-11","February 2014","March 2015","May 2015","April 2016","November 25, 2013","December 2, 2013","null","null","April 26, 2016","May 25, 2016","Scottsdale, Arizona, United States|Whittier, California, United States|Tupelo, Mississippi, United States|Saint Louis, Missouri, United States|Houston, Texas, United States|Frankston, Victoria, Australia|Parkville, Victoria, Australia|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Vancouver, Canada|La Tronche, France|Nantes Cedex 1, France|Paris, France|Dresden, Germany|Minden, Germany","https://ClinicalTrials.gov/show/NCT01998828"
395,"NCT01053494","Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer","null","Active, not recruiting","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase Chronic Myelogenous Leukemia|Burkitt Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Mantle Cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Essential Thrombocythemia|Extramedullary Plasmacytoma|Intraocular Lymphoma|Isolated Plasmacytoma of Bone|Juvenile Myelomonocytic Leukemia|Mast Cell Leukemia|Meningeal Chronic Myelogenous Leukemia|Noncontiguous Stage II Mantle Cell Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Primary Myelofibrosis|Primary Systemic Amyloidosis|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Stage 0 Chronic Lymphocytic Leukemia|Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Multiple Myeloma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Childhood Hodgkin Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Hodgkin Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|T-cell Large Granular Lymphocyte Leukemia|Unspecified Childhood Solid Tumor, Protocol Specific","Procedure: massage therapy|Other: questionnaire administration|Procedure: quality-of-life assessment|Other: intervention by caregiver|Procedure: standard follow-up care","Feasibility and acceptability of conducting a massage intervention with childhood cancer patients and their primary caregivers|Effectiveness of caregiver massage to reduce child and caregiver distress and promote child health-related quality of life","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","3 Years to 17 Years   (Child)","","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CCCWFU 97709|NCI-2009-01456","April 2010","February 2012","null","May 2017","January 20, 2010","January 21, 2010","null","null","May 30, 2017","June 1, 2017","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States","https://ClinicalTrials.gov/show/NCT01053494"
396,"NCT02292446","Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available.","null","Recruiting","No Results Available","Polycythemia Vera","Drug: Ruxolitinib","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Change in hematocrit|Change in spleen|Change in MPN-SAF","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 3","200","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CINC424B2001X","November 23, 2014","January 2, 2018","January 2, 2018","December 2017","November 5, 2014","November 17, 2014","null","null","December 1, 2017","December 5, 2017","Novartis Investigative Site, A-1090 Vienna, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Rankweil, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Wels, Austria|Novartis Investigative Site, Antwerp, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Viña del Mar, Vina Del Mar, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Bayonne, Bayonne Cedex, France|Novartis Investigative Site, Angers Cedex 1, France|Novartis Investigative Site, Avignon cedex 9, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Chambéry Cedex, France|Novartis Investigative Site, Dunkerque, France|Novartis Investigative Site, Le Mans Cedex 09, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Meaux cedex, France|Novartis Investigative Site, Metz, France|Novartis Investigative Site, Mulhouse cedex, France|Novartis Investigative Site, Nice Cedex, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Perpignan, France|Novartis Investigative Site, Pierre-Benite Cedex, France|Novartis Investigative Site, Pringy cedex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Vandoeuvre Les Nancy, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Mannheim, Baden-Württemberg, Germany|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Bad Soden, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bottrop, Germany|Novartis Investigative Site, Eisenach, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Friedrichshafen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamm, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Heilbronn, Germany|Novartis Investigative Site, Koblenz, Germany|Novartis Investigative Site, Mutlangen, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Monterrey, Nuevo Léon, Mexico|Novartis Investigative Site, Fredrikstad, Norway|Novartis Investigative Site, Tromso, Norway|Novartis Investigative Site, Braga, Portugal|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Lulea, Sweden|Novartis Investigative Site, Uddevalla, Sweden|Novartis Investigative Site, Khon Kaen, THA, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand","https://ClinicalTrials.gov/show/NCT02292446"
397,"NCT01387763","A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms","DALIAH","Active, not recruiting","No Results Available","Polycythemia Vera|Essential Thrombocythemia|Primary Myelofibrosis","Drug: PegIntron|Drug: Pegasys|Drug: Hydrea","molecular response (changes from baseline)|toxicity (discontinuation of therapy due to intolerability)|Quality of life (changes from baseline)|Histopathological response (changes from baseline)|Sustained molecular response (changes from level at time of discontinuation of therapy)|Neutralizing antibodies against PegIntron and Pegasys|hematological response","Thomas Stauffer Larsen|Odense University Hospital","All","18 Years and older   (Adult, Senior)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","daliah2011","January 2012","January 2020","January 2020","April 2017","June 23, 2011","July 6, 2011","null","null","April 4, 2017","April 5, 2017","Dept of Hematology, Aalborg hospital, Aalborg, Denmark|Dept. of Hematology, Aarhus University Hospital, Aarhus, Denmark|Dept of Hematology, Esbjerg Hospital, Esbjerg, Denmark|Dept of Hematology, Herlev Hospital, Herlev, Denmark|Dept of Hematology, Holstebro Hospital, Holstebro, Denmark|Dept of Hematology, Rigshospitalet, København, Denmark|Dept of hematology, Odense University Hospital, Odense, Denmark|Dept. of Hematology, Roskilde Hospital, Roskilde, Denmark","https://ClinicalTrials.gov/show/NCT01387763"
398,"NCT02252159","Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)","null","Active, not recruiting","No Results Available","Polycythemia Vera","","Description of patterns of the disease Polycythemia Vera (PV), and associations of such patterns with patients' exposures or treatments|Incidence (frequency) of disease progression|Incidence (frequency) of healthcare resources utilization|Incidence (frequency) of complications due to PV|Incidence (frequency) and description of PV-related symptoms|Incidence (frequency) of adverse events (for those patients on active therapies, including PHL)|Patient-reported outcomes as assessed by Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) for assessment of the severity of symptoms|Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) score for assessment of work productivity and activity impairment|European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) for Health Related Quality of Life (HRQoL)|Caregiver burden|Burden of phlebotomy (PHL)","Incyte Corporation","All","18 Years and older   (Adult, Senior)","","2544","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","INCB-MA-PV-401","July 2014","August 2018","October 2018","September 2017","September 23, 2014","September 30, 2014","null","null","September 26, 2017","September 27, 2017","Green Valley, Arizona, United States|Safford, Arizona, United States|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Yuma, Arizona, United States|Jonesboro, Arkansas, United States|Little Rock, Arkansas, United States|North Little Rock, Arkansas, United States|Stuttgart, Arkansas, United States|Berkeley, California, United States|Burbank, California, United States|Corona, California, United States|Fountain Valley, California, United States|Highland, California, United States|Laguna Hills, California, United States|Los Alamitos, California, United States|Oceanside, California, United States|Orange, California, United States|Pismo Beach, California, United States|Rancho Mirage, California, United States|Riverside, California, United States|Santa Maria, California, United States|Santa Rosa, California, United States|Tarzana, California, United States|Torrance, California, United States|Vallejo, California, United States|West Hills, California, United States|Whittier, California, United States|Aurora, Colorado, United States|Colorado Springs, Colorado, United States|Fort Collins, Colorado, United States|Pueblo, Colorado, United States|Middletown, Connecticut, United States|Norwich, Connecticut, United States|Stamford, Connecticut, United States|Washington, D.C., District of Columbia, United States|Aventura, Florida, United States|Boynton Beach, Florida, United States|Deerfield Beach, Florida, United States|Fort Lauderdale, Florida, United States|Hialeah, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Miami Lakes, Florida, United States|Ocala, Florida, United States|Pembroke Pines, Florida, United States|Pensacola, Florida, United States|Santa Rosa Beach, Florida, United States|Winter Haven, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Austell, Georgia, United States|Cartersville, Georgia, United States|Columbus, Georgia, United States|Douglasville, Georgia, United States|Gainesville, Georgia, United States|Marietta, Georgia, United States|Rome, Georgia, United States|Savannah, Georgia, United States|Thomasville, Georgia, United States|Boise, Idaho, United States|Post Falls, Idaho, United States|Berwyn, Illinois, United States|Chicago, Illinois, United States|Danville, Illinois, United States|Decatur, Illinois, United States|Effingham, Illinois, United States|Evanston, Illinois, United States|Harvey, Illinois, United States|Joliet, Illinois, United States|Kewanee, Illinois, United States|Macomb, Illinois, United States|Maywood, Illinois, United States|Morris, Illinois, United States|New Lenox, Illinois, United States|Normal, Illinois, United States|Ottawa, Illinois, United States|Park Ridge, Illinois, United States|Pekin, Illinois, United States|Peoria, Illinois, United States|Peru, Illinois, United States|Princeton, Illinois, United States|Skokie, Illinois, United States|Springfield, Illinois, United States|Urbana, Illinois, United States|Anderson, Indiana, United States|Columbus, Indiana, United States|Crown Point, Indiana, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Lafayette, Indiana, United States|Marion, Indiana, United States|Mooresville, Indiana, United States|New Albany, Indiana, United States|Newburgh, Indiana, United States|Terre Haute, Indiana, United States|Cedar Rapids, Iowa, United States|Iowa City, Iowa, United States|Mason City, Iowa, United States|Sioux City, Iowa, United States|Topeka, Kansas, United States|Wichita, Kansas, United States|Ashland, Kentucky, United States|Danville, Kentucky, United States|Hazard, Kentucky, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Mount Sterling, Kentucky, United States|Paducah, Kentucky, United States|Richmond, Kentucky, United States|Alexandria, Louisiana, United States|Baton Rouge, Louisiana, United States|Marrero, Louisiana, United States|Shreveport, Louisiana, United States|Rockport, Maine, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|Clinton, Maryland, United States|Cumberland, Maryland, United States|Hagerstown, Maryland, United States|Boston, Massachusetts, United States|Fairhaven, Massachusetts, United States|Lawrence, Massachusetts, United States|Pittsfield, Massachusetts, United States|Worcester, Massachusetts, United States|Ann Arbor, Michigan, United States|Battle Creek, Michigan, United States|Brighton, Michigan, United States|Canton, Michigan, United States|Chelsea, Michigan, United States|Dearborn, Michigan, United States|Detroit, Michigan, United States|Flint, Michigan, United States|Grand Rapids, Michigan, United States|Jackson, Michigan, United States|Kalamazoo, Michigan, United States|Lansing, Michigan, United States|Marquette, Michigan, United States|Pontiac, Michigan, United States|Saginaw, Michigan, United States|Edina, Minnesota, United States|Minneapolis, Minnesota, United States|Saint Cloud, Minnesota, United States|Saint Louis Park, Minnesota, United States|Saint Paul, Minnesota, United States|Bolivar, Missouri, United States|Cape Girardeau, Missouri, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Billings, Montana, United States|Kalispell, Montana, United States|Henderson, Nevada, United States|Las Vegas, Nevada, United States|Dover, New Hampshire, United States|Portsmouth, New Hampshire, United States|Bricktown, New Jersey, United States|East Orange, New Jersey, United States|Edison, New Jersey, United States|Flemington, New Jersey, United States|Hackettstown, New Jersey, United States|Paramus, New Jersey, United States|Somerville, New Jersey, United States|Sparta, New Jersey, United States|Vineland, New Jersey, United States|Farmington, New Mexico, United States|Albany, New York, United States|Binghamton, New York, United States|Brooklyn, New York, United States|Cooperstown, New York, United States|Corning, New York, United States|East Setauket, New York, United States|Elmira, New York, United States|Herkimer, New York, United States|Ithaca, New York, United States|Johnson City, New York, United States|New York, New York, United States|Oneonta, New York, United States|Poughkeepsie, New York, United States|Rochester, New York, United States|Staten Island, New York, United States|The Bronx, New York, United States|Utica, New York, United States|Albemarle, North Carolina, United States|Boone, North Carolina, United States|Charlotte, North Carolina, United States|Clayton, North Carolina, United States|Durham, North Carolina, United States|Greenville, North Carolina, United States|Hendersonville, North Carolina, United States|Henderson, North Carolina, United States|Hickory, North Carolina, United States|Lincolnton, North Carolina, United States|Shelby, North Carolina, United States|Smithfield, North Carolina, United States|Winston-Salem, North Carolina, United States|Bismarck, North Dakota, United States|Canton, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Dover, Ohio, United States|Huber Heights, Ohio, United States|Massillon, Ohio, United States|Mount Vernon, Ohio, United States|Oregon, Ohio, United States|Toledo, Ohio, United States|West Chester, Ohio, United States|Oklahoma City, Oklahoma, United States|Beaverton, Oregon, United States|Corvallis, Oregon, United States|Portland, Oregon, United States|Salem, Oregon, United States|Allentown, Pennsylvania, United States|Bethlehem, Pennsylvania, United States|Broomall, Pennsylvania, United States|Drexel Hill, Pennsylvania, United States|Easton, Pennsylvania, United States|Gettysburg, Pennsylvania, United States|Hanover, Pennsylvania, United States|Hershey, Pennsylvania, United States|Kittanning, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Quakertown, Pennsylvania, United States|Sayre, Pennsylvania, United States|Upland, Pennsylvania, United States|Wellsboro, Pennsylvania, United States|Willow Grove, Pennsylvania, United States|York, Pennsylvania, United States|Pawtucket, Rhode Island, United States|Charleston, South Carolina, United States|Hilton Head Island, South Carolina, United States|Murrells Inlet, South Carolina, United States|Rock Hill, South Carolina, United States|Rapid City, South Dakota, United States|Sioux Falls, South Dakota, United States|Watertown, South Dakota, United States|Germantown, Tennessee, United States|Jackson, Tennessee, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Athens, Texas, United States|Bryan, Texas, United States|Corpus Christi, Texas, United States|Galveston, Texas, United States|Houston, Texas, United States|Jacksonville, Texas, United States|Plano, Texas, United States|Richardson, Texas, United States|Tyler, Texas, United States|Ogden, Utah, United States|Salt Lake City, Utah, United States|Bristol, Virginia, United States|Chesapeake, Virginia, United States|Falls Church, Virginia, United States|Portsmouth, Virginia, United States|Suffolk, Virginia, United States|Bellingham, Washington, United States|Everett, Washington, United States|Puyallup, Washington, United States|Seattle, Washington, United States|Martinsburg, West Virginia, United States|Green Bay, Wisconsin, United States|Milwaukee, Wisconsin, United States|Weston, Wisconsin, United States|Bayamon, Puerto Rico|Ponce, Puerto Rico","https://ClinicalTrials.gov/show/NCT02252159"
399,"NCT02218047","AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.","CONTI-PV","Active, not recruiting","No Results Available","Polycythemia Vera","Drug: Pegylated-Proline-interferon alpha-2b|Drug: Best available therapy (BAT)","Disease response at quarterly assessment visits","AOP Orphan Pharmaceuticals AG|PharmaEssentia (Co-Sponsor for USA)","All","18 Years and older   (Adult, Senior)","Phase 3","170","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","CONTINUATION-PV|2014-001357-17","November 2014","June 2019","June 2019","November 2016","August 14, 2014","August 15, 2014","null","null","November 22, 2016","November 23, 2016","LKH Graz, Graz, Austria|University Hospital Innsbruck, Innsbruck, Austria|Elisabethinen Hospital Linz, Linz, Austria|Salzburg Regional Hospital, Salzburg, Austria|Hanusch Hospital, Vienna, Austria|Medical University Vienna, Vienna, Austria|Hospital Wels-Grieskirchen, Wels, Austria|University Multiprofile Hospital for Active Treatment ""Sveti Georgi"", Plovdiv, Plovdiv, Bulgaria|Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment ""Sveta Marina"", Varna, Varna, Bulgaria|Multiprofile Hospital for Active Treatment - Hristo Botev, Vratsa, First Department of Internal Medicine, Vratsa, Bulgaria|University Hospital Brno, Brno, Czech Republic|University Hospital Hradec Kralove, Hradec Kralove, Czech Republic|University Hospital Kralovske Vinohrady, Prague, Czech Republic|University Hospital Motol, Prague, Czech Republic|Institute Paoli-Calmettes, Marseilles, France|Hospital Saint-Louis, Paris, France|Clinical Research Center CIC, Poitiers, France|Aachen University Hospital, Medical Clinic IV, Aachen, Germany|University Hospital Bonn, Center for Internal Medicine, Medical Clinic and Outpatient Clinic III, Bonn, Germany|University Hospital Carl Gustav Carus, Medical Clinic and Polyclinic I, Dresden, Germany|St Istvan and St Laszlo Hospital of Budapest, Budapest, Hungary|University of Debrecen, Debrecen, Hungary|Bekes County Pandy Kalman Hospital, 1st Department of Medicine, Hematology, Gyula, Hungary|Kaposi Mor County Teaching Hospital, Kaposvar, Hungary|University of Szeged, Albert Szent-Gyorgyi Clinical Center, Koranyi fasor 6, Szeged, Hungary|University Hospital in Cracow, Krakow, Poland|Independent Public Teaching Hospital No.1 in Lublin, Lublin, Poland|Fryderyk Chopin Provincial Specialized Hospital, Rzeszow, Poland|Nicolaus Copernicus Municipal Specialist Hospital, Torun, Poland|Institute of Hematology and Transfusion Medicine, Warsaw, Poland|Emergency Clinical County Hospital Brasov, Brasov, Romania|Bucharest University Emergency Hospital, Bucharest, Romania|Coltea Clinical Hospital, Bucharest, Romania|Baranov Republican Hospital, Petrozavodsk, Russian Federation|Samara Kalinin Regional Clinical Hospital, Samara, Russian Federation|Komi Republican Oncology Center, Syktyvkar, Russian Federation|Tula Regional Clinical Hospital, Tula, Russian Federation|Yaroslavl Regional Clinical Hospital, Yaroslavl, Russian Federation|University Hospital with Outpatient Clinic F.D. Roosevelt, Banska Bystrica, Slovakia|Saint Cyril and Metod University Hospital Bratislava, Bratislava, Slovakia|Hospital del Mar, Barcelona, Spain|Cherkasy Regional Oncology Center, Regional Treatment and Diagnostics Hematology Center, Cherkasy, Ukraine|Dnipropetrovsk City Multispecialty Clinical Hospital #4, Dnipropetrovsk, Ukraine|National Research Center for Radiation Medicine, Institute of Clinical Radiology, Kiev, Ukraine|Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine|O.F. Herbachevskyi Regional Clinical Hospital, Zhytomyr, Ukraine","https://ClinicalTrials.gov/show/NCT02218047"
400,"NCT02038036","Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.","RESPONSE-2","Active, not recruiting","No Results Available","Polycythemia Vera","Drug: Best Available Therapy|Drug: ruxolitinib","Efficacy of ruxolitinib to Best Available Therapy (BAT) as assessed by Hct control at Week 28|Efficacy of ruxolitinib to BAT as assessed by peripheral blood count remission at Week 28.|Efficacy of ruxolitinib to BAT as assessed by durable Hct control at Week 52|Efficacy of ruxolitinib to BAT as assessed by durable peripheral blood count remission at Week 52.|Change in ECOG status|Change in spleen length|Efficacy of ruxolitinib to BAT as assessed by partial remission based on the ELN and IWG-MRT criteria at Week 28|Efficacy of ruxolitinib to BAT as assessed by durable partial remission based on the ELN and IWG-MRT criteria at Week 52.|Efficacy of BAT patients after they cross over to ruxolitinib|Changes in MPN-SAF TSS|Resolution of disease related symptoms in MPN-SAF TSS at Week 28.|Changes in patient reported outcomes|Safety of ruxolitinib and Best Available Therapy|Safety of BAT patients after they crossover","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 3","149","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CINC424B2401","March 25, 2014","April 20, 2020","April 20, 2020","October 2017","January 14, 2014","January 16, 2014","null","null","October 3, 2017","October 4, 2017","Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Bayonne, Bayonne cedex, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Brest, France|Novartis Investigative Site, Lille cedex, France|Novartis Investigative Site, Nice Cedex, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Strasbourg cedex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Mannheim, Baden-Württemberg, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Minden, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Nahariya, Israel|Novartis Investigative Site, Netanya, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Varese, VA, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Salamanca, Castilla y Leon, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Las Palmas de Gran Canaria, Las Palmas de G.C, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Talas / Kayseri, Turkey","https://ClinicalTrials.gov/show/NCT02038036"
401,"NCT01760655","Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies","null","Recruiting","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Juvenile Myelomonocytic Leukemia|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Refractory Cytopenia With Multilineage Dysplasia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia","Drug: Fludarabine phosphate|Drug: Thiotepa|Radiation: Total body irradiation|Biological: Therapeutic allogeneic lymphocytes|Drug: Cyclophosphamide|Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT)|Procedure: Peripheral blood stem cell transplantation|Drug: Tacrolimus|Drug: Mycophenolate mofetil","Disease-free survival (DFS)|Overall survival|Incidence of Regimen Related Toxicity|Immune reconstitution|Incidence and degree of GVHD|Engraftment rates","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12D.501|2012-67","December 24, 2012","December 2019","January 2020","November 2017","January 2, 2013","January 4, 2013","null","null","November 8, 2017","November 13, 2017","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT01760655"
402,"NCT01949805","Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera","PROUD-PV","Completed","No Results Available","Polycythemia Vera","Drug: Peg-P-IFN-alpha-2b (AOP2014)|Drug: Hydroxyurea","Disease response rate|Disease response|JAK2 allelic burden changes|time to response|duration of response|number of phlebotomies|blood parameters|spleen size|disease related symptoms|adverse events|protocol-specific adverse events of special interest","AOP Orphan Pharmaceuticals AG|PharmaEssentia (Co-Sponsor for USA)","All","18 Years and older   (Adult, Senior)","Phase 3","257","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PROUD-PV|2012-005259-18","September 2013","July 2016","July 2016","November 2016","September 6, 2013","September 25, 2013","null","null","November 24, 2016","November 28, 2016","LKH Graz, Graz, Austria|University Hospital Innsbruck, Innsbruck, Austria|Elisabethinen Hospital Linz, Linz, Austria|Salzburg Regional Hospital, Salzburg, Austria|Hanusch Hospital, Vienna, Austria|Medical University Vienna, Vienna, Austria|Hospital Wels-Grieskirchen, Wels, Austria|Centre du Cancer et D'hematologie, Brussels, Belgium|UZA, Antwerp University Hospital, Edegem, Belgium|UZ Leuven, Leuven, Belgium|Haematolgy, University of Liège, Liège, Belgium|University Multiprofile Hospital for Active Treatment ""Sveti Georgi"", Plovdiv, Bulgaria|Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment ""Sveta Marina"", Varna, Bulgaria|Multiprofile Hospital for Active Treatment - Hristo Botev, Vratsa, First Department of Internal Medicine, Vratsa, Bulgaria|University Hospital Brno, Brno, Czech Republic|University Hospital Hradec Kralove, Hradec Kralove, Czech Republic|Institute of Hematology and Blood Transfusion, Prague, Czech Republic|University Hospital Kralovske Vinohrady, Prague, Czech Republic|University Hospital Motol, Prague, Czech Republic|Institute Paoli-Calmettes, Marseilles, France|Hospital Saint-Louis, Paris, France|Clinical Research Center CIC, Poitiers, France|Aachen University Hospital, Medical Clinic IV, Aachen, Germany|University Hospital Bonn, Center for Internal Medicine, Medical Clinic and Outpatient Clinic III, Bonn, Germany|University Hospital Carl Gustav Carus, Medical Clinic and Polyclinic I, Dresden, Germany|St Istvan and St Laszlo Hospital of Budapest, Budapest, Hungary|University of Debrecen, Debrecen, Hungary|Bekes County Pandy Kalman Hospital, 1st Department of Medicine, Hematology, Gyula, Hungary|Kaposi Mor County Teaching Hospital, Kaposvar, Hungary|University of Szeged, Albert Szent-Gyorgyi Clinical Center, Koranyi fasor 6, Szeged, Hungary|Careggi University Hospital, Florence, Italy|Foundation IRCCS Policlinico San Matteo, Pavia, Italy|Andrzej Mielecki Independent Public Clinical Hospital of Medical University of Silesia in Katowice, Katowice, Poland|University Hospital in Cracow, Krakow, Poland|Independent Public Teaching Hospital No.1 in Lublin, Lublin, Poland|Fryderyk Chopin Provincial Specialized Hospital, Rzeszow, Poland|Nicolaus Copernicus Municipal Specialist Hospital, Torun, Poland|Institute of Hematology and Transfusion Medicine, Warsaw, Poland|Emergency Clinical County Hospital Brasov, Brasov, Romania|Bucharest University Emergency Hospital, Bucharest, Romania|Coltea Clinical Hospital, Bucharest, Romania|""Prof. Dr. Ion Chiricuta"" Institute of Oncology, Cluj-Napoca, Romania|Baranov Republican Hospital, Petrozavodsk, Russian Federation|Samara Kalinin Regional Clinical Hospital, Samara, Russian Federation|First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation|Komi Republican Oncology Center, Syktyvkar, Russian Federation|Tula Regional Clinical Hospital, Tula, Russian Federation|Yaroslavl Regional Clinical Hospital, Yaroslavl, Russian Federation|University Hospital with Outpatient Clinic F.D. Roosevelt, Banska Bystrica, Slovakia|Saint Cyril and Metod University Hospital Bratislava, Bratislava, Slovakia|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Cherkasy Regional Oncology Center, Regional Treatment and Diagnostics Hematology Center, Cherkasy, Ukraine|Dnipropetrovsk City Multispecialty Clinical Hospital #4, Dnipropetrovsk, Ukraine|National Research Center for Radiation Medicine, Institute of Clinical Radiology, Kiev, Ukraine|Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine|O.F. Herbachevskyi Regional Clinical Hospital, Zhytomyr, Ukraine","https://ClinicalTrials.gov/show/NCT01949805"
403,"NCT01901432","A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera","null","Active, not recruiting","No Results Available","Polycythemia Vera","Drug: Givinostat","Part A: Maximum Tolerated Dose|Part B: Preliminary efficacy after 3 cycles of treatment|Part A: Safety and tolerability|Part B: Safety and tolerability after 3 cycles of treatment|Part A: characterization of pharmacokinetic|Part B: characterization of pharmacokinetic|Part A: preliminary efficacy after 3 and 6 cycles of treatment|Part B: preliminary efficacy of Givinostat at the Maximum Tolerated Dose after 6 cycles.|Part B: safety and tolerability after 6 cycles","Italfarmaco","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","48","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DSC/12/2357/45|2013-000860-27","October 2013","September 2017","June 2018","March 2017","July 10, 2013","July 17, 2013","null","null","September 28, 2017","September 29, 2017","CHU Amiens - Hôpital Sud, Amiens Cedex 1, France|Hôpital Morvan - CHRU de Brest, Brest Cedex, France|Hopital Saint Vincent de Paul - GHICL Lille, Lille cedex, France|Hôpital Saint-Louis (AP-HP), Centre Investigations Cliniques, Paris Cedex 10, France|Charite Research Organisation GmbH, Berlin, Germany|Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitaetsklinikum Koeln, Koeln, Germany|Azienda ospedaliero universitaria Consorziale Policlinico di Bari, Bari, BA, Italy|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, BG, Italy|Azienda Ospedaliero-Universitaria Careggi, Florence, Florence, FI, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, PV, Italy|Istituto Tumori Giovanni Paolo II - IRCCS Ospedale Oncologico di Bari, Bari, Italy|Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano, Italy|Università degli Studi di Napoli Federico II, Facoltà di Medicina e Chirurgia, Napoli, Italy|Ospedale Civile dello Spirito Santo, Pescara, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Azienda Ospedaliera ""Bianchi-Melacrino-Morelli"", Reggio Calabria, Italy|Università Campus Bio-Medico di Roma, Rome, Italy|Ospedale San Bortolo di Vicenza, Vicenza, Italy|SP ZOZ Zespol Szpitali Miejskich w Chorzowie, Chorzow, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Belfast City Hospital, Belfast, United Kingdom|Royal London Hospital, London, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom","https://ClinicalTrials.gov/show/NCT01901432"
404,"NCT01384513","A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies","null","Recruiting","No Results Available","Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Aplastic Anemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Myelodysplastic Syndromes|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Essential Thrombocythemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Juvenile Myelomonocytic Leukemia|Mastocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Anemia|Refractory Anemia With Ringed Sideroblasts|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Waldenström Macroglobulinemia","Drug: Fludarabine|Drug: Busulfan|Radiation: Total Body Irradiation (TBI)|Biological: Donor Lymphocyte Infusion (DLI)|Drug: Cyclophosphamide (CY)|Drug: Tacrolimus|Drug: Mycophenolate mofetil|Device: Allogeneic hematopoietic stem cell transplantation|Procedure: Peripheral blood stem cell transplantation (PBSCT)","Overall Survival (OS) in patients with haploidentical family donors with hematological malignancies in morphological or radiographic remission or with chemosensitive, indolent diseases|Treatment Related Mortality (TRM)|Incidence and severity of GVHD, graded according to standard criteria|Relapse Rate|Engraftment Rates|Incidence of Treatment Related Mortality (TRM)|Relapse Related Mortality|Lymphoid Reconstitution","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11D.247|2011-31","August 4, 2011","December 1, 2019","July 2020","December 2017","June 27, 2011","June 29, 2011","null","null","December 4, 2017","December 6, 2017","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT01384513"
405,"NCT03373877","Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis","null","Recruiting","No Results Available","Myelofibrosis|Primary Myelofibrosis|Post-polycythemia Vera Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis","Drug: PU-H71|Drug: Ruxolitinib","Incidence of adverse events|Maximum Tolerated Dose of PU-H71 (MTD)|Recommended Phase 2 Dose of PU-H71 (RP2D)|Pharmacokinetic profile of PU-H71: Area under the plasma concentration versus time curve (AUC)|Pharmacokinetic profile of PU-H71: Trough plasma concentration (Cmin)|Pharmacokinetic profile of PU-H71: Peak plasma concentration (Cmax)|Pharmacokinetic profile of PU-H71: Time to maximum plasma concentration (Tmax)|Pharmacokinetic profile of PU-H71: Plasma half-life (T1/2)|Treatment Response|Symptom Burden Assessment|Biological Markers","Samus Therapeutics, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PU-H71-01-002","December 2017","October 2019","December 2019","December 2017","November 29, 2017","December 14, 2017","null","null","December 11, 2017","December 14, 2017","Ochsner Clinic Foundation, New Orleans, Louisiana, United States","https://ClinicalTrials.gov/show/NCT03373877"
406,"NCT02421354","Study of Nivolumab in Patients With Myelofibrosis","null","Active, not recruiting","No Results Available","Myeloproliferative Diseases","Drug: Nivolumab|Behavioral: Questionnaire|Behavioral: Phone Call","Objective Response Rate (ORR)","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 2","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0962|NCI-2015-00836","May 14, 2015","May 2020","May 2020","November 2017","April 10, 2015","April 20, 2015","null","null","November 10, 2017","November 14, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT02421354"
407,"NCT01645124","Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)","CYTO-PV","Terminated","No Results Available","Polycythemia Vera","Drug: Hydroxyurea|Procedure: Phlebotomy","Reduction of PEP (Primary End Point)defined as CV deaths plus thrombotic events|PEP plus minor thrombosis, hospitalization and malignancy","Consorzio Mario Negri Sud|Agenzia Italiana del Farmaco|A.O. Ospedale Papa Giovanni XXIII","All","18 Years and older   (Adult, Senior)","Phase 3","365","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FARM6YNXAN","May 2008","June 2012","July 2012","May 2012","July 17, 2012","July 20, 2012","null","null","July 19, 2012","July 20, 2012","IRCCS Ospedale Casa Sollievo della Sofferenza di San Giovanni Rotondo, San Giovanni Rotondo, Foggia, Italy|IRCCS Centro di Riferimento Oncologico di Basilicata (CROB), Rionero in Vulture, Potenza, Italy|Azienda Ospedaliero-Universitaria San Luigi Gonzaga di Orbassano, Orbassano, Torino, Italy|Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Ospedaliera Universitaria Ospedale Consorziale Policlinico di Bari, Bari, Italy|Azienda Ospedali Riuniti di Bergamo, Bergamo, Italy|Azienda Unità Sanitaria Locale di Brindisi BR/1- Ospedale ""Di Summa - Perrino"", Brindisi, Italy|Ospedale Armando Businco, Cagliari, Italy|Azienda Ospedaliera Universitaria-'Policlinico- Vittorio Emanuele'-Ospedale Ferrarotto Alessi di Catania, Catania, Italy|Azienda Ospedaliera S. Croce e Carle di Cuneo, Cuneo, Italy|Azienda Ospedaliera Universitaria Careggi di Firenze, Firenze, Italy|Azienda Ospedaliera Universitaria Policlinico Martino di Messina, Messina, Italy|Fondazione IRCSS Cà Granda- Ospedale Maggiore Policlinico, Milano, Italy|Ospedale S.Raffaele, Milano, Italy|Ospedale S.Gerardo di Monza, Monza, Italy|Azienda Ospedaliera Universitaria'Maggiore della Carità' di Novara, Novara, Italy|Università di Padova, Padova, Italy|Azienda Ospedaliero-Universitaria Policlinico Giaccone di Palermo, Palermo, Italy|IRCCS Policlinico S. Matteo di Pavia, Pavia, Italy|Azienda Ospedaliera S. Salvatore, Presidio San Salvatore Muraglia, Pesaro, Italy|AUSL 4 Prato, Ospedale ""Misericordia e Dolce"" di Prato, Prato, Italy|Ospedale di S.Maria Nuova, Reggio Emilia, Italy|IRCCS Istituto Regina Elena (IFO), Roma, Italy|Università degli Studi di Roma ""La Sapienza"", Roma, Italy|Policlinico Universitario Gemelli di Roma, Roma, Italy|Ospedale San Bortolo di Vicenza, Vicenza, Italy","https://ClinicalTrials.gov/show/NCT01645124"
408,"NCT01632904","Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study","null","Completed","Has Results","Polycythemia Vera","Drug: Ruxolitinib|Drug: Hydroxyurea (HU)|Drug: HU-placebo|Drug: Ruxolitinib-placebo","Percentage of Subjects Achieving a ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine (TSS-C) at Week 16, as Measured by the Modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Diary|Percentage of Subjects Achieving ≥ 50% Improvement From Baseline in the Individual Symptom Scores for TSS-C at Week 16|Proportion of Subjects Randomized to Ruxolitinib Who Achieved ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine and the Individual Symptom Scores at Week 16 That Were Maintained at Week 48","Incyte Corporation","All","18 Years and older   (Adult, Senior)","Phase 3","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","18424-357","June 2012","March 2014","May 2016","October 2017","June 29, 2012","July 3, 2012","March 26, 2015","April 7, 2015","October 12, 2017","November 14, 2017","Scottsdale, Arizona, United States|Fayetteville, Arkansas, United States|Burbank, California, United States|Glendale, California, United States|La Jolla, California, United States|Los Angeles, California, United States|San Diego, California, United States|Aurora, Colorado, United States|Stamford, Connecticut, United States|Washington, D.C., District of Columbia, United States|Boynton Beach, Florida, United States|Orlando, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Niles, Illinois, United States|Springfield, Illinois, United States|Ames, Iowa, United States|Westwood, Kansas, United States|Alexandria, Louisiana, United States|Baltimore, Maryland, United States|Southfield, Michigan, United States|Minneapolis, Minnesota, United States|Columbia, Missouri, United States|Saint Louis, Missouri, United States|Henderson, Nevada, United States|Las Vegas, Nevada, United States|East Orange, New Jersey, United States|Morristown, New Jersey, United States|Somerville, New Jersey, United States|Albany, New York, United States|Armonk, New York, United States|Mineola, New York, United States|New York, New York, United States|Canton, Ohio, United States|Bethlehem, Pennsylvania, United States|Charleston, South Carolina, United States|Chattanooga, Tennessee, United States|Amarillo, Texas, United States|Bedford, Texas, United States|Dallas, Texas, United States|Garland, Texas, United States|Houston, Texas, United States|Longview, Texas, United States|Midland, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Tyler, Texas, United States|Salt Lake City, Utah, United States|Alexandria, Virginia, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States|Antwerpen, Belgium|Brugge, Belgium|Aachen, Germany|Berlin, Germany|Freiburg, Germany|Hamburg, Germany|Stuttgart, Germany|Ulm, Germany|Galway, Ireland|Firenze, Italy|Reggio Calabria, Italy|Varese, Italy|Barcelona, Spain|Pamplona, Spain|Salamanca, Spain|Boston, United Kingdom|Leicester, United Kingdom|Nottingham, United Kingdom|West Bromwich, United Kingdom","https://ClinicalTrials.gov/show/NCT01632904"
409,"NCT03136185","IMG-7289 in Patients With Myelofibrosis","null","Recruiting","No Results Available","Myelofibrosis|Post-polycythemia Vera Myelofibrosis (PPV-MF)|Post-essential Thrombocythemia Myelofibrosis (PET-MF)|Primary Myelofibrosis (PMF)","Drug: IMG-7289","Incidence of treatment-emergent adverse events, and changes in physical examination, vital signs and laboratory parameters [safety and tolerability]|Drug Concentration|Spleen Volume","Imago BioSciences,Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMG-7289-CTP-102","July 1, 2017","February 2018","December 2018","September 2017","April 18, 2017","May 2, 2017","null","null","September 21, 2017","September 25, 2017","Royal Adelaide Hospital, Adelaide, South Australia, Australia","https://ClinicalTrials.gov/show/NCT03136185"
410,"NCT01259856","Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)","null","Active, not recruiting","No Results Available","High Risk Polycythemia Vera|High Risk Essential Thrombocythemia","Drug: PEGASYS|Drug: Hydroxyurea|Drug: Aspirin","To compare hematologic response rates in patients randomized to treatment with Pegylated Interferon Alfa-2a vs Hydroxyurea in two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET).|To compare the toxicity, safety and tolerability of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) in the study populations by recording the adverse events that occur during the study using the CTC 4.0 as the guide.|To compare the hematologic partial response rates on therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea).|To compare specific pre-defined toxicity and tolerance of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) and validate the utility of sequential structured symptom assessment package of patient reported outcome instruments.|To compare the impact of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) on key biomarkers of the disease(s) by measuring the JAK2 allele burden.|To compare the impact of therapy on JAK2-V617F (JAK2), CALR, hematopoietic cell clonality in platelets and granulocytes in females, bone marrow histopathology, and cytogenetic abnormalities.|To estimate survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea).|To estimate incidence of major cardiovascular events after therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea).","Ronald Hoffman|Myeloproliferative Disorders-Research Consortium|National Cancer Institute (NCI)|Roche Pharma AG|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Senior)","Phase 3","168","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 09-1300-00002|P01CA108671|MPD-RC 112","September 2011","June 2017","June 2017","January 2017","December 7, 2010","December 14, 2010","null","null","January 10, 2017","January 11, 2017","Mayo Clinic, Scottsdale, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|The Palo Alto Clinic, Palo Alto, California, United States|Stanford University School of Medicine, Stanford, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Emory Hospital, Atlanta, Georgia, United States|John H. Stroger Hospital of Cook County, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Geisinger Cancer Center, Danville, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States|Hopitaux de Paris, Paris, France|Belfast City Hospital, Belfast, Ireland|Ospedale Riuniti de Bergamo, Bergamo, Italy|University Of Florence, Florence, Italy|Ospedale San Maartino Genova, Genova, Italy|San Matteo Hospital, Pavia, Italy|Universita Cattolica del Sacro Cuore, Rome, Italy|Heart of England NHS Foundation Trust, Birmingham, United Kingdom|Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01259856"
411,"NCT01259817","Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)","null","Completed","No Results Available","High Risk Polycythemia Vera|High Risk Essential Thrombocythemia","Drug: PEGASYS|Drug: Aspirin","Evaluate the ability of Pegylated Interferon Alfa-2a to achieve Complete Response or Partial Response in patients with (1) high risk polycythemia vera or (2) high risk essential thrombocythemia or (3) splanchnic vein thrombosis|To evaluate the toxicity and tolerability of therapy Pegylated Interferon Alfa-2a in each of the 3 strata by recording the number of adverse events that occur during the study by using CTC 4.0 as the guide.|To measure the impact of Pegylated Interferon Alfa-2a on key biomarkers of the disease(s)by measuring the JAK2 allele burden.|To evaluate specific pre-defined toxicity and tolerance of Pegylated Interferon Alfa-2a through a sequential structured symptom assessment package of patient reported outcome instruments.|To estimate survival, and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation during therapy Pegylated Interferon Alfa-2a.|Estimate the observed incidence of major cardiovascular events during therapy Pegylated Interferon Alfa-2a.|To measure the impact of Pegylated Interferon Alfa-2a on JAK2-V617F, CALR, hematopoietic cell clonality in platelets and granulocytes in females, bone marrow histopathology, and cytogenetic abnormalities.","Ronald Hoffman|Myeloproliferative Disorders-Research Consortium|National Cancer Institute (NCI)|Roche Pharma AG|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Senior)","Phase 2","135","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 09-1300 001|P01CA108671|MPD-RC 111","September 2011","December 2016","December 2016","January 2017","December 6, 2010","December 14, 2010","null","null","January 10, 2017","January 11, 2017","Mayo Clinic, Scottsdale, Arizona, United States|The Palo Alto Clinic, Palo Alto, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Emory Hospital, Atlanta, Georgia, United States|John H. Stroger Hospital of Cook County, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|University of Maryland, Baltimore, Maryland, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Geisinger Cancer Center, Danville, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States|Ospedale Riuniti de Bergamo, Bergamo, Italy|University Of Florence, Florence, Italy|Ospedale San Maartino Genova, Genova, Italy|San Matteo Hospital, Pavia, Italy|Universita Cattolica del Sacro Cuore, Rome, Italy","https://ClinicalTrials.gov/show/NCT01259817"
412,"NCT01243073","Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera","ET/PV","Completed","No Results Available","Essential Thrombocythemia|Polycythemia Vera","Drug: Imetelstat","Hematologic Response|Safety and tolerability: Number of Patients with Hematological Toxicities, Non-Heme Grade 3 and 4 AEs, and Hemorrhagic Events","Geron Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CP14B015","December 2010","October 2013","April 2015","December 2015","November 11, 2010","November 18, 2010","null","null","December 22, 2015","January 26, 2016","City of Hope, Duarte, California, United States|MDACC - Orlando, Orlando, Florida, United States|University of Chicago, Chicago, Illinois, United States|Johns Hopkins University - Bunting Blaustein Cancer Research Building, Baltimore, Maryland, United States|Saint Francis Hospital, Greenville, South Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|University Hospital of Essen - West German Cancer Center, Essen, Germany|Medizinische Klinik II, Abt. Hämatologie und Onkologie - Johann Wolfgang Goethe Universität, Frankfurt, Germany|SLK-Kliniken GmbH, Heilbronn, Germany|Hematology Oncology Center - Ludwig-Maximilians, University Munich Medical School, Munich, Germany|University Hospital Regensburg - Uniklinik Regensburg, Regensburg, Germany|INSELSPITAL, University Hospital Bern, Bern, Switzerland","https://ClinicalTrials.gov/show/NCT01243073"
413,"NCT02966353","Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.","REALISE","Recruiting","No Results Available","Primary Myelofibrosis|Post-Polycythemia Vera-Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis","Drug: ruxolitinib","Spleen length response rate|Percent change from baseline on spleen length|Effect of ruxolitinib on symptoms - MFSAF|Effect of ruxolitinib on Patient Global Impression of Change (PGIC).|Effect of ruxolitinib on transfusion requirements.|Effect of ruxolitinib on symptoms - MF-7|Effect of ruxolitinib on transfusion requirements","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 2","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CINC424A2411","April 2, 2017","December 23, 2018","December 23, 2018","October 2017","October 18, 2016","November 17, 2016","null","null","October 3, 2017","October 4, 2017","Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Halle/S., Germany|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Kocaeli, Turkey","https://ClinicalTrials.gov/show/NCT02966353"
414,"NCT02871323","Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis","null","Active, not recruiting","No Results Available","Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase|Primary Myelofibrosis","Biological: Durvalumab|Other: Laboratory Biomarker Analysis","Incidence of Adverse Events|Changes in MF symptom burden|Changes in spleen size|Response to anti-PDL1 treatment in blood|Response to anti-PDL1 treatment in bone marrow","Northwestern University|Celgene|The Leukemia and Lymphoma Society|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","10","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 16H05|STU00202833|P30CA060553|NCI-2016-01024","September 2016","November 2018","July 2020","July 2017","August 9, 2016","August 18, 2016","null","null","July 10, 2017","July 13, 2017","Northwestern University, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT02871323"
415,"NCT03289910","Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia","null","Not yet recruiting","No Results Available","Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Myelodysplastic/Myeloproliferative Neoplasm|Myelofibrosis|Polycythemia Vera|Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia","Drug: Carboplatin|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Placebo|Drug: Topotecan Hydrochloride|Drug: Veliparib","Overall response defined as complete response/complete response with incomplete recovery|Distribution of mutations in deoxyribonucleic acid (DNA) repair defects via assessment in Leukemia mutation panel|frequency of patients with functional impairment of DNA damage response via assessment with RAD51 assay|Incidence of toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Pharmacokinetic sampling studies measured using a validated liquid chromatography/tandem mass spectrometric method in plasma and bone marrow","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","60","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","NCI-2017-01715|10147|UM1CA186691","May 18, 2018","June 30, 2019","June 30, 2019","September 2017","September 20, 2017","September 21, 2017","null","null","December 11, 2017","December 12, 2017","","https://ClinicalTrials.gov/show/NCT03289910"
416,"NCT01284712","Natural Killer Cells and Polycythemia Vera (Vaquez's Disease)","null","Unknown status","No Results Available","Polycythemia Vera","Biological: blood sample","To describe immunologic anomalies in polycythemia vera","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Senior)","","27","Other","Observational","Time Perspective: Prospective","2009/16|2009-A00395-52","July 2009","July 2013","null","September 2015","August 3, 2009","January 27, 2011","null","null","September 29, 2015","October 1, 2015","Assistance Publique - Hopitaux de Marseille, Marseille, France","https://ClinicalTrials.gov/show/NCT01284712"
417,"NCT01199562","Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant","null","Completed","No Results Available","Hematopoietic/Lymphoid Cancer|Accelerated Phase Chronic Myelogenous Leukemia|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Aplastic Anemia|Atypical Chronic Myeloid Leukemia, BCR-ABL Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Cytomegalovirus Infection|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extramedullary Plasmacytoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Isolated Plasmacytoma of Bone|Mast Cell Leukemia|Meningeal Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Primary Systemic Amyloidosis|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Secondary Myelofibrosis|Splenic Marginal Zone Lymphoma|Stage 0 Chronic Lymphocytic Leukemia|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Waldenstrom Macroglobulinemia","Procedure: infection prophylaxis and management|Other: laboratory biomarker analysis|Other: flow cytometry|Genetic: DNA analysis|Genetic: RNA analysis|Procedure: management of therapy complications|Drug: ganciclovir|Drug: valganciclovir|Drug: foscarnet sodium|Procedure: antiviral therapy|Genetic: polymerase chain reaction|Genetic: protein expression analysis","Initiation of anti-CMV therapy|Diagnosis of CMV pneumonia|CMV reactivation-free survival, monitored using a real time PCR assay for CMV DNA in plasma|Percent cytotoxicity and ex vivo percent CD56+/CD107B+ cells","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","153","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","09038|NCI-2010-01932","December 2010","December 2013","December 2013","June 2015","September 8, 2010","September 13, 2010","null","null","June 3, 2015","June 8, 2015","City of Hope Medical Center, Duarte, California, United States","https://ClinicalTrials.gov/show/NCT01199562"
418,"NCT01243944","Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)","null","Active, not recruiting","Has Results","Polycythemia Vera","Drug: ruxolitinib tablets|Other: Best Available Therapy (BAT)","The Percentage of Subjects Achieving a Primary Response at Week 32|The Percentage of Subjects Achieving a Durable Primary Response at Week 48|The Percentage of Subjects Achieving Complete Hematological Remission at Week 32|The Percentage of Subjects Who Achieved a Durable Complete Hematological Remission at Week 48|The Percentage of Subjects Who Achieved a Durable Hematocrit Control at Week 48|The Percentage of Subjects Who Achieved Durable Spleen Volume Reduction at Week 48|Estimated Duration of the Primary Response|The Percentage of Subjects Who Achieved Overall Clinicohematologic Response at Week 32|The Percentage of Subjects Achieving a Durable Complete or Partial Clinicohematologic Response at Week 48|Estimated Duration of the Complete Hematological Remission","Incyte Corporation|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 3","222","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CINC424B2301","October 2010","January 2014","March 2018","December 2017","November 17, 2010","November 19, 2010","December 22, 2014","March 6, 2015","December 7, 2017","January 1, 2018","Birmingham, Alabama, United States|Scottsdale, Arizona, United States|Pomona, California, United States|Sacramento, California, United States|San Diego, California, United States|Bridgeport, Connecticut, United States|New Haven, Connecticut, United States|Boynton Beach, Florida, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Winter Park, Florida, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Lafayette, Louisiana, United States|Scarborough, Maine, United States|Baltimore, Maryland, United States|Columbia, Maryland, United States|Southfield, Michigan, United States|Jefferson City, Missouri, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Morristown, New Jersey, United States|Somerville, New Jersey, United States|Charleston, South Carolina, United States|Greenville, South Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Seattle, Washington, United States|Buenos Aires, Argentina|Brisbane, Australia|Parkville, Australia|Tweed Heads, Australia|Antwerp, Belgium|Brugge, Belgium|Bruxelles, Belgium|Leuven, Belgium|Hamilton, Canada|Montreal, Canada|Toronto, Canada|Beijing, China|Hangzhou, China|Avignon, France|Bayonne, France|Brest, France|Lille, France|Nantes, France|Paris, France|Vandœuvre-lès-Nancy, France|Aachen, Germany|Berlin, Germany|Bonn, Germany|Freiburg, Germany|Hamburg, Germany|Jena, Germany|Magdeburg, Germany|Mannheim, Germany|Minden, Germany|Munchen, Germany|Ulm, Germany|Budapest, Hungary|Kecskemet, Hungary|Szeged, Hungary|Szombathely, Hungary|Bari, Italy|Bergamo, Italy|Bologna, Italy|Firenze, Italy|Milano, Italy|Napoli, Italy|Orbassano, Italy|Pavia, Italy|Reggio Calabria, Italy|Roma, Italy|Varese, Italy|Vicenza, Italy|Chiba, Japan|Chuo-city Yamanashi, Japan|Maebashi, Japan|Nagoya-city Aichi, Japan|Osaka, Japan|Tokyo, Japan|Seoul, Korea, Republic of|Enschede, Netherlands|Rotterdam, Netherlands|Moscow, Russian Federation|St. Petersburg, Russian Federation|Barcelona, Spain|Coruña, Spain|Las Palmas de Gran Canaria, Spain|Madrid, Spain|Majadahonda, Spain|Malaga, Spain|Pamplona, Spain|Salamanca, Spain|Valencia, Spain|Bangkok, Thailand|Ankara, Turkey|Istanbul, Turkey|Izmir, Turkey|Bournemouth, United Kingdom|Cardiff, United Kingdom|London, United Kingdom","https://ClinicalTrials.gov/show/NCT01243944"
419,"NCT03165734","Dose-Finding Study of Pacritinib in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib","null","Recruiting","No Results Available","Primary Myelofibrosis|Post-polycythemia Vera Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis","Drug: Pacritinib","Spleen volume|Percentage of patients with CTCAE grade ≥3 cardiac AEs, CTCAE grade ≥3 hemorrhage AEs, CTCAE grade ≥4 thrombocytopenia toxicity, or CTCAE grade ≥4 anemia toxicity","CTI BioPharma|Covance","All","18 Years and older   (Adult, Senior)","Phase 2","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PAC203","June 26, 2017","December 1, 2018","March 1, 2019","December 2017","May 17, 2017","May 24, 2017","null","null","December 22, 2017","December 27, 2017","City of Hope, Duarte, California, United States|UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Stanford Cancer Center, Palo Alto, Stanford, California, United States|George Washington University-Medical Faculty Associates, Washington, District of Columbia, United States|Florida Cancer Specialists & Research Institute, Fort Myers, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States|Saint Agnes Hospital, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Washington University School of Medicine-Siteman Cancer Center, Saint Louis, Missouri, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Sarah Cannon Research Institute-Tennessee Oncology, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Center at San Antonio School of Medicine, San Antonio, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT03165734"
420,"NCT01193699","Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera","PEGINVERA","Active, not recruiting","No Results Available","Polycythemia Vera","Drug: PEG-P-INF alpha-2b (P1101)","Maximum tolerated dose (MTD)","AOP Orphan Pharmaceuticals AG","All","18 Years to 90 Years   (Adult, Senior)","Phase 1|Phase 2","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P11012010","August 2010","December 2017","December 2017","December 2016","September 1, 2010","September 2, 2010","null","null","December 22, 2016","December 23, 2016","Innsbruck, Tirol, Austria|Wels, Upper Austria, Austria|Salzburg, Austria|Vienna, Austria|Vienna, Austria|Vienna, Austria","https://ClinicalTrials.gov/show/NCT01193699"
421,"NCT02584777","A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis","null","Withdrawn","No Results Available","Primary Myelofibrosis","Biological: Pacritinib","Proportion of participants achieving a ≥35% reduction in spleen volume|Proportion of participants with ≥50% reduction in total symptom score (TSS)|Proportion of participants with baseline platelet count <100,000/μL achieving ≥35% reduction in spleen volume|Proportion of participants with baseline platelet count <100,000/μL achieving ≥50% reduction in total symptom score (TSS)|Proportion of participants with baseline platelet count <50,000/μL achieving ≥35% reduction in spleen volume|Proportion of participants with baseline platelet count <50,000/μL achieving ≥50% reduction in total symptom score (TSS)|Clinically significant adverse events (AEs)|Clinically significant changes in laboratory results|Clinically significant changes in vital signs|Clinically significant changes in electrocardiograms (ECGs)|Pacritinib pharmacokinetic (PK) parameter: maximum observed concentration (Cmax)|Pacritinib pharmacokinetic (PK) parameter: Time of maximum observed concentration (Tmax)|Pacritinib pharmacokinetic (PK) parameter: minimum observed concentration (Cmin)|Pacritinib pharmacokinetic (PK) parameter: area under the concentration curve (AUC)|Pacritinib pharmacokinetic (PK) parameter: apparent volume of distribution (V/F)|Pharmacodynamic parameter: Maximum observed effect (Emax)|Pharmacodynamic parameter: time of maximum observed effect (tEmax)|Pharmacodynamic parameter: area under the effect curve (AUEC)","Baxalta now part of Shire|CTI BioPharma|Shire","All","18 Years and older   (Adult, Senior)","Phase 2","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","381401","November 2015","September 2017","August 2020","July 2016","October 21, 2015","October 23, 2015","null","null","October 19, 2017","October 23, 2017","","https://ClinicalTrials.gov/show/NCT02584777"
422,"NCT01588015","Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant","null","Active, not recruiting","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Promyelocytic Leukemia (M3)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma|B-cell Adult Acute Lymphoblastic Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cytomegalovirus Infection|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extramedullary Plasmacytoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Isolated Plasmacytoma of Bone|Monoclonal Gammopathy of Undetermined Significance|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Peripheral T-cell Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Central Nervous System Hodgkin Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Primary Myelofibrosis|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Multiple Myeloma|Stage I Small Lymphocytic Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage IIA Mycosis Fungoides/Sezary Syndrome|Stage IIB Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Multiple Myeloma|Stage III Small Lymphocytic Lymphoma|Stage IIIA Mycosis Fungoides/Sezary Syndrome|Stage IIIB Mycosis Fungoides/Sezary Syndrome|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Small Lymphocytic Lymphoma|Stage IVA Mycosis Fungoides/Sezary Syndrome|Stage IVB Mycosis Fungoides/Sezary Syndrome|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Large Granular Lymphocyte Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Hairy Cell Leukemia|Waldenström Macroglobulinemia","Biological: tetanus-CMV fusion peptide vaccine|Other: laboratory biomarker analysis","Safety based on assessment of GVHD, graded according to the Keystone Consensus system and adverse events (AEs) based on National Cancer Institute (NCI) CTCAE version 4.03|Immunogenicity evaluated by monitoring CMV-specific CD8+ T cells by multi color flow cytometric analyses","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","36","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","12022|NCI-2012-00589","August 2012","October 2018","October 2018","November 2017","April 26, 2012","April 30, 2012","null","null","November 17, 2017","November 21, 2017","City of Hope Medical Center, Duarte, California, United States","https://ClinicalTrials.gov/show/NCT01588015"
423,"NCT02515630","Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)","null","Completed","No Results Available","Primary Myelofibrosis (PMF)|Post-polycythemia Vera (Post-PV) Myelofibrosis|Postessential Thrombocythemia (Post-ET) Myelofibrosis","Drug: MMB","Transfusion independence response rate by Week 24|Transfusion response rate by Week 24|Baseline and change in marker of anemia|Change in pharmacodynamics biomarker|Splenic response rate at Week 24|Response rate in total symptom score (TSS) at Week 24|Maximum observed plasma concentration (Cmax) of MMB|Last observable concentration (Clast) of MMB|Observed drug concentration at the end of the dosing interval (Ctau) for MMB|Area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUClast) for MMB|Change in circulating cytokine and inflammatory markers","Gilead Sciences","All","18 Years and older   (Adult, Senior)","Phase 2","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-352-1672","January 29, 2016","July 18, 2017","August 15, 2017","August 2017","August 3, 2015","August 5, 2015","null","null","August 22, 2017","August 23, 2017","Phoenix, Arizona, United States|Los Angeles, California, United States|Orange, California, United States|Jacksonville, Florida, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Saint Louis, Missouri, United States|New York, New York, United States|The Bronx, New York, United States|Durham, North Carolina, United States|Cleveland, Ohio, United States|Houston, Texas, United States|Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT02515630"
424,"NCT01120821","Treatment of Polycythemia Vera With Gleevec","null","Completed","No Results Available","Polycythemia Vera","Drug: Gleevec","Stabilization of hematocrit|Platelet count maintenance a therapeutic range.|Splenomegaly (if existent)|Quality of life, performance status, side effects and complications during treatment.","Weill Medical College of Cornell University","All","18 Years and older   (Adult, Senior)","Phase 2","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0702-375|CSTI571AUS41","August 2002","January 2007","June 2007","May 2010","May 7, 2010","May 11, 2010","null","null","May 14, 2010","May 17, 2010","Weill Cornell Medical College, New York, New York, United States","https://ClinicalTrials.gov/show/NCT01120821"
425,"NCT01499147","Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies","null","Completed","Has Results","Acute Myeloid Leukemia|Acute Leukemia|Chronic Myelogenous Leukemia|Malignant Lymphoma|Hodgkin's Disease|Multiple Myeloma|Lymphocytic Leukemia|Myeloproliferative Disorder|Polycythemia Vera|Myelofibrosis|Aplastic Anemia","Drug: fludarabine/busulfan|Drug: fludarabine/ melphalan|Drug: ATG","Number of Participants With Engraftment.|Participants With 100 Day Transplant-related Mortality.|Time to ANC and Platelet Engraftment|Number of Participants With Moderate to Severe (Grade 2-4) Acute Graft Versus Host Disease (GVHD).","University of Illinois at Chicago","All","10 Years to 65 Years   (Child, Adult)","","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000-0117","February 2000","May 2013","May 2013","May 2017","November 23, 2011","December 26, 2011","June 19, 2015","June 14, 2017","October 25, 2017","December 1, 2017","University of Illinois at Chicago Medical Center, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT01499147"
426,"NCT00790036","Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy","PILLAR2","Completed","Has Results","Diffuse Large B-cell Lymphoma","Drug: Everolimus|Drug: Everolimus Placebo","Disease-free Survival (DFS)|Overall Survival (OS)|Lymphoma-specific Survival (LSS)","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 3","742","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","CRAD001N2301|2008-000498-40","July 24, 2009","June 15, 2016","June 15, 2016","June 2017","November 11, 2008","November 13, 2008","June 14, 2017","July 12, 2017","June 14, 2017","July 12, 2017","Ironwood Cancer and Research Centers SC, Chandler, Arizona, United States|Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States|University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (3), La Jolla, California, United States|USC/Kenneth Norris Comprehensive Cancer Center Dept.ofNorrisMedicalCenter(4), Los Angeles, California, United States|University of Colorado Health, Colorado Springs, Colorado, United States|Denver Health & Hospital Authority CACZ885M2301, Denver, Colorado, United States|Rocky Mountain Cancer Centers RMCC, Greenwood Village, Colorado, United States|University Cancer Institute, Boynton Beach, Florida, United States|University Cancer & Blood Center, LLC, Athens, Georgia, United States|Columbus Regional, Columbus, Georgia, United States|Rush University Medical Center Div. of Hematology & Oncology, Chicago, Illinois, United States|Indiana University Hospital IU Cancer Center, Indianapolis, Indiana, United States|Tulane University Health Sciences Center Office of Clinical Research, New Orleans, Louisiana, United States|Lahey Clinic Dept of Lahey Clinic (3), Burlington, Massachusetts, United States|Mayo Clinic - Rochester Dept. of MayoClinic-Rochester, Rochester, Minnesota, United States|Washington University School of Medicine Div. of Medical Oncology, Saint Louis, Missouri, United States|Dartmouth Hitchcock Medical Center Dartmouth, Lebanon, New Hampshire, United States|Levine Cancer Institute Oncology, Charlotte, North Carolina, United States|Wake Forest University Baptist Medical Center Dept. of WFUHS, Winston-Salem, North Carolina, United States|University of Pittsburgh Medical Center SC-3, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina -Hollings Cancer Center MUSC/HCC (2), Charleston, South Carolina, United States|Cancer Centers of the Carolinas Cancer Centers of Carolinas (3, Greenville, South Carolina, United States|University of Tennessee Cancer Institute SC-2, Memphis, Tennessee, United States|The West Clinic, Memphis, Tennessee, United States|The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD, Fort Worth, Texas, United States|University of Texas/MD Anderson Cancer Center Dept of MD Anderson (18), Houston, Texas, United States|Baylor College of Medicine Dept.of Baylor College of Med., Houston, Texas, United States|South Texas Oncology and Hematology, PA South Texas Oncology (2), San Antonio, Texas, United States|Texas A&M HealthSciencesCtr-Scott & White Memorial Hospital CenterForCancerPrevention&Care, Temple, Texas, United States|University of Vermont Office of Clinical Trials Res., Burlington, Vermont, United States|University of Virginia Health Systems SC-2, Charlottesville, Virginia, United States|Blue Ridge Research Center at Roanoke Neurological Center SC, Roanoke, Virginia, United States|Dean Health System, Madison, Wisconsin, United States|Waukesha Memorial Hospital Cancer Center Dept.ofWaukeshaMemorialHosp., Waukesha, Wisconsin, United States|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Douglas, Queensland, Australia|Novartis Investigative Site, Greenslopes, Queensland, Australia|Novartis Investigative Site, Clayton, Victoria, Australia|Novartis Investigative Site, Geelong, Victoria, Australia|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Leoben, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Brampton, Ontario, Canada|Novartis Investigative Site, Cambridge, Ontario, Canada|Novartis Investigative Site, Mississauga, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Québec, Quebec, Canada|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Guangzhou, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Bogotá, Cundinamarca, Colombia|Novartis Investigative Site, Bucaramanga, Colombia|Novartis Investigative Site, Medellín, Colombia|Novartis Investigative Site, Brno - Bohunice, Czech Republic, Czechia|Novartis Investigative Site, Hradec Kralove, CZE, Czechia|Novartis Investigative Site, Olomouc, CZE, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Alexandria, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Mansoura, Egypt|Novartis Investigative Site, Amiens cedex1, France|Novartis Investigative Site, Brest, France|Novartis Investigative Site, La Roche sur Yon cedex 9, France|Novartis Investigative Site, Limoges cedex, France|Novartis Investigative Site, Pessac, France|Novartis Investigative Site, Saint Priest en Jarez Cedex, France|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Bad Saarow, Germany|Novartis Investigative Site, Bamberg, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Ioannina, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Heraklion Crete, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Gyor, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Brindisi, BR, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, San Giovanni Rotondo, FG, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Lecce, LE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Piacenza, PC, Italy|Novartis Investigative Site, Pescara, PE, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Potenza, PZ, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Reggio Emilia, RE, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Venezia, VE, Italy|Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Matsuyama-city, Ehime, Japan|Novartis Investigative Site, Kure, Hiroshima, Japan|Novartis Investigative Site, Kanazawa-city, Ishikawa, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Sunto-gun, Shizuoka, Japan|Novartis Investigative Site, Chuo-ku, Tokyo, Japan|Novartis Investigative Site, Koto, Tokyo, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Shinjuku-ku, Japan|Novartis Investigative Site, Gyeonggi-do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Grafton, Auckland, New Zealand|Novartis Investigative Site, Wellington, New Zealand|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Jesus Maria, Lima, Peru|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Lublin, Lubelskie, Poland|Novartis Investigative Site, Bydgoszcz, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Warsaw, Poland|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, N. Novgorod, Russian Federation|Novartis Investigative Site, Petrozavodsk, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Dammam, Saudi Arabia|Novartis Investigative Site, Jeddah, Saudi Arabia|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Cadiz, Andalucía, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Santander, Cantabria, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Majadahonda, Madrid, Spain|Novartis Investigative Site, Pozuelo de Alarcon, Madrid, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Zürich, CH, Switzerland|Novartis Investigative Site, Bellinzona, Switzerland|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Talas / Kayseri, Turkey|Novartis Investigative Site, Caracas, Distrito Capital, Venezuela|Novartis Investigative Site, Caracas, Distrito Capital, Venezuela","https://ClinicalTrials.gov/show/NCT00790036"
427,"NCT02436135","Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease","Madison","Completed","No Results Available","Myelofibrosis","Drug: Idelalisib|Drug: Ruxolitinib","Adverse events (AEs), abnormal laboratory tests, and drug discontinuations due to AEs and serious AEs|Plasma pharmacokinetics (PK) profiles of ruxolitinib (and metabolite[s], as applicable) and idelalisib and/or its primary metabolite, GS-563117: Cmax, Tmax, AUC, and Ctrough|AEs, abnormal laboratory tests, and drug discontinuations due to AEs and serious AEs|Rate of overall response","Gilead Sciences","All","18 Years and older   (Adult, Senior)","Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-397-1245","June 5, 2015","November 20, 2017","November 20, 2017","November 2017","May 1, 2015","May 6, 2015","null","null","November 30, 2017","December 4, 2017","Stanford Hospital and Clinics, Stanford, California, United States|University of Michigan Health System, Ann Arbor, Michigan, United States","https://ClinicalTrials.gov/show/NCT02436135"
428,"NCT00866762","A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia","null","Unknown status","No Results Available","Polycythemia Vera|Essential Thrombocythemia","Drug: HDAC inhibitor (MK-0683)","To evaluate the efficacy of study drug (MK-0683) in the treatment of patients with PV and ET.|To study changes in bone marrow morphology before and after treatment with study drug.","Copenhagen University Hospital at Herlev","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MK-0683/092-0","February 2009","August 2012","December 2012","December 2011","March 17, 2009","March 20, 2009","null","null","December 9, 2011","December 12, 2011","Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark|Esberg Hospital, Esbjerg, Denmark|Herlev Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark|Roskilde Hospital, Roskilde, Denmark|Regional Hospital Viborg, Viborg, Denmark|VU University Medical Centre, Amsterdam, Netherlands|University Hospital Orebro, Orebro, Sweden|Stockholm South General Hospital (Sodersjukhuset), Stockholm, Sweden|Karolinska University Hospital Huddinge, Stockholm, Sweden|Sahlgrenska University Hospital & Uddevalla Hospital, Uddevalla, Sweden|Uppsala University Hospital, Uppsala, Sweden|Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom|Cardiff University, Cardiff, United Kingdom|Russell's Hall Hospital, Dudley, United Kingdom|St Thomas' Hospital, London, United Kingdom","https://ClinicalTrials.gov/show/NCT00866762"
429,"NCT01038856","Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera","null","Terminated","No Results Available","Polycythemia Vera","Drug: Erlotinib","Overall response rate to include Complete Hematological response, Complete molecular response, partial hematological response, and minimal hematological response|Toxicity, improvement in splenomegaly size, and a decrease of mutant JAK2V617F allele burden, measured by PCR","University of Oklahoma|OSI Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","6","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSI-TAR-766","December 2009","December 2012","February 2014","May 2014","December 22, 2009","December 24, 2009","null","null","May 19, 2014","May 20, 2014","University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States","https://ClinicalTrials.gov/show/NCT01038856"
430,"NCT02124746","Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia","null","Active, not recruiting","No Results Available","Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis|Polycythemia Vera|Essential Thrombocythemia","Drug: Momelotinib","Adverse event profile of momelotinib as measured by incidence and severity of adverse events|Laboratory abnormality profile of momelotinib as measured by incidence and severity of clinical laboratory abnormalities|Overall survival|Progression-free survival|Leukemia-free survival|Rate of RBC transfusion|Duration of splenic response (Cohorts 1 and 2 only)|Duration of transfusion independence response (Cohorts 1 and 2 only)|Duration of anemia response (Cohorts 1 and 2 only)|Transfusion response rate (Cohort 4 only)","Gilead Sciences","All","18 Years and older   (Adult, Senior)","Phase 2","105","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-352-1154|2013-004476-36","April 30, 2014","June 2018","June 2018","December 2017","April 24, 2014","April 28, 2014","null","null","December 4, 2017","December 6, 2017","Scottsdale, Arizona, United States|Orange, California, United States|Stanford, California, United States|Jacksonville, Florida, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|New York, New York, United States|Cleveland, Ohio, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Frankston, Victoria, Australia|Parkville, Victoria, Australia|Toronto, Ontario, Canada|Montreal, Quebec, Canada|La Tronche, France|Paris, France|Dresden, Germany|Minden, Germany","https://ClinicalTrials.gov/show/NCT02124746"
431,"NCT00940784","Clopidogrel and Aspirin for the Treatment of Polycythemia Vera","ISCLAP","Withdrawn","No Results Available","Polycythemia Vera","Drug: Clopidogrel (Plavix)|Drug: Placebo|Drug: Aspirin","To determine the safety and efficacy of using Clopidogrel plus aspirin on Polycythemia Vera patients","Ronald Hoffman|Myeloproliferative Disorders-Research Consortium|National Cancer Institute (NCI)|Icahn School of Medicine at Mount Sinai","All","18 Years to 81 Years   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GCO 07-0548-00108|P01CA108671-01A2|MPD-RC 108","June 2009","January 2011","January 2011","November 2014","July 14, 2009","July 16, 2009","null","null","November 24, 2014","November 26, 2014","","https://ClinicalTrials.gov/show/NCT00940784"
432,"NCT00928707","Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera","PV","Completed","No Results Available","Polycythemia Vera","Drug: GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea|Drug: GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea","To evaluate the efficacy of GIVINOSTAT (ITF2357) in combination with hydroxyurea in patients with JAK2V617F positive Polycythemia Vera non-responders to the maximum tolerated dose of hydroxyurea monotherapy.|To evaluate the safety and tolerability of GIVINOSTAT-HU combination in patients with JAK2V617F positive PV NR to the MTD of HU monotherapy; to evaluate the molecular response.","Italfarmaco","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DSC/08/2357/38","June 2009","July 2011","October 2011","September 2012","June 25, 2009","June 26, 2009","null","null","September 17, 2012","September 18, 2012","Azienda Ospedaliero-Universitaria Policlinico Consorziale di Bari, Bari, BA, Italy|Azienda Ospedaliera Santa Croce e Carle di Cuneo, Cuneo, CN, Italy|Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi di Catania, Catania, CT, Italy|Fondazione I. R. C. C. S. - Casa sollievo della sofferenza di San Giovanni Rotondo, San Giovanni Rotondo, FG, Italy|Azienda Ospedaliero-Universitaria Careggi di Firenze, Florence, FI, Italy|Azienda Ospedaliera San Gerardo di Monza, Monza, MB, Italy|Azienda Ospedaliera Universitaria Policlinico ""Gaetano Martino"" di Messina, Messina, ME, Italy|Azienda Ospedaliera Ospedali Riuniti ""Villa Sofia - Cervello"" di Palermo, Palermo, PA, Italy|Azienda Unità Sanitaria Locale di Pescara, Presidio Ospedaliero ""Spirito Santo"", Pescara, PE, Italy|Azienda Ospedaliera Santa Maria della Misericordia di Perugia, Perugia, PG, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, PI, Italy|Azienda Ospedaliera Ospedale San Carlo di Potenza, Potenza, PT, Italy|Fondazione I.R.C.C.S.-Policlinico San Matteo, Pavia, Pavia, PV, Italy|Azienda Ospedaliera ""Bianchi-Melacrino-Morelli"", Reggio di Calabria, RC, Italy|Azienda Ospedaliera Universitaria S. Luigi Gonzaga di Orbassano, Orbassano, TO, Italy|Azienda Ospedaliero-Universitaria San Giovanni Battista(""Le Molinette"") di Torino, Torino, TO, Italy|Ospedale Mauriziano Umberto I, Torino, TO, Italy|Ospedale San Bortolo di Vicenza, Vicenza, VI, Italy|Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy|Azienda Ospedaliera Universitaria Università degli Studi di Napoli Federico II, Napoli, Italy|Università ""Campus Bio-Medico"", Rome, Rome, Italy|Policlinico Universitario Agostino Gemelli di Roma, Rome, Italy","https://ClinicalTrials.gov/show/NCT00928707"
433,"NCT02226172","Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib","null","Recruiting","No Results Available","Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis","Drug: Glasdegib (PF-04449913)|Drug: Placebo","Proportion of patients achieving spleen volume reduction =>35% from baseline to Week 24 as measured by MRI/CT.|Proportion of patients achieving =>50% reduction in total symptom score from baseline through Week 24, as measured by the Myeloproliferative neoplasm symptom assessment diary.|Proportion of patients with improvement in peripheral blood counts, as defined by the Revised IWG-MRT Response Criteria.","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 2","222","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B1371013|SMOI|2014-000933-21|2014-001048-40","October 2014","December 2016","December 2017","October 2017","August 25, 2014","August 27, 2014","null","null","October 27, 2017","October 31, 2017","Mayo Clinic Building, Phoenix, Phoenix, Arizona, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|Mayo Clinic Building - Phoenix, Phoenix, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|UC San Diego Moores Cancer Center - Investigational Drug Services, La Jolla, California, United States|UCSD Medical Center Clinical Laboratory - La Jolla, La Jolla, California, United States|University of California San Diego (UCSD) Moores Cancer Center, La Jolla, California, United States|UC San Diego Medical Center- Hillcrest, San Diego, California, United States|University of Michigan, Ann Arbor, Michigan, United States|Weill Cornell Medical College - New York-Presbyterian Hospital, New York, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Herbert Irving Comprehensive Cancer Center-Columbia University Medical Center, New York, New York, United States|New York - Presbyterian Hospital, New York, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States|Huntsman Cancer Institute-University of Utah, Salt Lake City, Utah, United States|University of Utah, Huntsman Cancer Hospital, Salt Lake City, Utah, United States|Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Kobe University Hospital, Kobe, Hyogo, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Osaka University Hospital, Osaka, Japan|Tokyo Medical University Hospital, Tokyo, Japan","https://ClinicalTrials.gov/show/NCT02226172"
434,"NCT02493530","TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea","null","Recruiting","No Results Available","Myelofibrosis|Polycythemia Vera","Drug: TGR-1202|Drug: ruxolitinib","Safety of TGR1202 in combination with ruxolitinib|Overall response|Total symptom score (MPN-TSS)|Blood levels of TGR1202 in combination with ruxolitinib (Pharmacokinetics)","Vanderbilt-Ingram Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VICC HEM 1538","July 2015","December 2018","July 2019","July 2017","July 1, 2015","July 9, 2015","null","null","July 18, 2017","July 19, 2017","Mayo Clinic - Arizona, Phoenix, Arizona, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT02493530"
435,"NCT02805868","Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis","null","Withdrawn","No Results Available","Myelofibrosis|Polycythemia Vera|Primary Myelofibrosis|Thrombocytopenia","Procedure: Bone Marrow Aspiration and Biopsy|Other: Laboratory Biomarker Analysis|Biological: Siltuximab","Incidence of Adverse Events|Clinical Improvement (CI): changes in symptoms|Clinical Improvement (CI): splenomegaly|Clinical Improvement (CI): Anemia response|Overall Response Rate (ORR)","Northwestern University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Early Phase 1","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 16H01|STU00202680|P30CA060553|NCI-2016-00685","June 2016","February 2019","null","October 2016","June 10, 2016","June 20, 2016","null","null","October 21, 2016","October 24, 2016","","https://ClinicalTrials.gov/show/NCT02805868"
436,"NCT01773187","Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis","null","Terminated","No Results Available","Primary Myelofibrosis|Post-polycythemia Vera Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis","Drug: Pacritinib|Drug: Best Available Therapy","Efficacy|Symptomatic Efficacy","CTI BioPharma","All","18 Years and older   (Adult, Senior)","Phase 3","327","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PERSIST-1 (PAC325)","December 2012","January 2015","June 2016","December 2016","January 18, 2013","January 23, 2013","null","null","December 15, 2016","December 16, 2016","CTI Investigational Site 10002, Scottsdale, Arizona, United States|CTI Investigational Site 10004, Omaha, Nebraska, United States|CTI Investigational Site 10001, Morristown, New Jersey, United States|CTI Investigational Site 10003, Greenville, South Carolina, United States|CTI Investigational Site 61006, Box Hill, Australia|CTI Investigational Site 61001, Coffs Harbour, Australia|CTI Investigational Site 61005, Geelong, Australia|CTI Investigational Site 61004, Hobart, Australia|CTI Investigational Site 61002, Milton, Australia|CTI Investigational Site 61003, North Gosford, Australia|CTI Investigational Site 32002, Antwerp, Belgium|CTI Investigational Site 32003, Antwerp, Belgium|CTI Investigational Site 32001, Brugge, Belgium|CTI Investigational Site 32005, Bruxelles, Belgium|CTI Investigational Site 32004, La Louviere, Belgium|CTI Investigational Site 42003, Brno, Czech Republic|CTI Investigational Site 42001, Olomouc, Czech Republic|CTI Investigational Site 42002, Plzen, Czech Republic|CTI Investigational Site 42004, Prague, Czech Republic|CTI Investigational Site 33005, Amiens, France|CTI Investigational Site 33006, Caen, France|CTI Investigational Site 33011, Grenoble, France|CTI Investigational Site 33012, Lens, France|CTI Investigational Site 33007, Lille, France|CTI Investigational Site 33001, Nimes Cedex, France|CTI Investigational Site 33004, Paris, France|CTI Investigational Site 33008, Paris, France|CTI Investigational Site 33009, Pessac, France|CTI Investigational Site 33010, Pierre Benite, France|CTI Investigational Site 33003, Strasbourg, France|CTI Investigational Site 33002, Toulouse, France|CTI Investigational Site 49006, Berlin, Germany|CTI Investigational Site 49007, Berlin, Germany|CTI Investigational Site 49003, Dresden, Germany|CTI Investigational Site 49008, Essen, Germany|CTI Investigational Site 49002, Freiburg, Germany|CTI Investigational Site 49001, Koln, Germany|CTI Investigational Site 49005, Mainz, Germany|CTI Investigational Site 49004, Munchen, Germany|CTI Investigational Site 49009, Munster, Germany|CTI Investigational Site 36002, Budapest, Hungary|CTI Investigational Site 36005, Debrecen, Hungary|CTI Investigational Site 36006, Gyula, Hungary|CTI Investigational Site 36003, Kaposvar, Hungary|CTI Investigational Site 36004, Kecskemet, Hungary|CTI Investigational Site 36001, Szeged, Hungary|CTI Investigational Site 36008, Szolnok, Hungary|CTI Investigational Site 36007, Szombathely, Hungary|CTI Investigational Site 39003, Bologna, Italy|CTI Investigational Site 39001, Firenze, Italy|CTI Investigational Site 39005, Milano, Italy|CTI Investigational Site 39004, Monza, Italy|CTI Investigational Site 39002, Padova, Italy|CTI Investigational Site 39008, Reggio Emilia, Italy|CTI Investigational Site 39006, Rimini, Italy|CTI Investigational Site 31001, Amsterdam, Netherlands|CTI Investigational Site 31002, Maastricht, Netherlands|CTI Investigational Site 31003, Rotterdam, Netherlands|CTI Investigational Site 31004, Utrecht, Netherlands|CTI Investigational Site 64001, Christchurch, New Zealand|CTI Investigational Site 64004, Dunedin, New Zealand|CTI Investigational Site 64002, Hamilton, New Zealand|CTI Investigational Site 64003, Takapuna, New Zealand|CTI Investigational Site 70011, Izhevsk, Russian Federation|CTI Investigational Site 70008, Moscow, Russian Federation|CTI Investigational Site 70009, Moscow, Russian Federation|CTI Investigational Site 70002, Petrozavodski, Russian Federation|CTI Investigational Site 70005, Samara, Russian Federation|CTI Investigational Site 70006, Sochi, Russian Federation|CTI Investigational Site 70001, St. Petersburg, Russian Federation|CTI Investigational Site 70004, St. Petersburg, Russian Federation|CTI Investigational Site 70010, St. Petersburg, Russian Federation|CTI Investigational Site 70007, Volgograd, Russian Federation|CTI Investigational Site 44004, Birmingham, United Kingdom|CTI Investigational Site 44008, Bournemouth, United Kingdom|CTI Investigational Site 44002, Cambridge, United Kingdom|CTI Investigational Site 44003, Cardiff, United Kingdom|CTI Investigational Site 44001, London, United Kingdom|CTI Investigational Site 44007, London, United Kingdom|CTI Investigational Site 44006, Manchester, United Kingdom|CTI Investigational Site 44005, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT01773187"
437,"NCT02101268","Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF","Simplify 2","Active, not recruiting","No Results Available","Primary Myelofibrosis (PMF)|Post-polycythemia Vera (Post-PV)|Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)","Drug: Momelotinib|Drug: Best Available Therapy (BAT)","Splenic response rate at Week 24|Response rate in total symptom score at Week 24|Rate of red blood cell (RBC) transfusion through Week 24|RBC transfusion independence rate at Week 24|RBC transfusion dependence rate at Week 24","Gilead Sciences","All","18 Years and older   (Adult, Senior)","Phase 3","156","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-352-1214|2013-005007-13","June 19, 2014","July 28, 2016","June 2018","August 2017","March 28, 2014","April 2, 2014","null","null","August 23, 2017","August 24, 2017","Los Angeles, California, United States|Gainesville, Florida, United States|Atlanta, Georgia, United States|Kansas City, Kansas, United States|Baltimore, Maryland, United States|Saint Louis, Missouri, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Durham, North Carolina, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Edmonton, Alberta, Canada|Montreal, Canada|Toronto, Canada|Lille cedex, France|Marseille, France|Nantes, France|Paris, France|Pierre Benite Cedex, France|Toulouse, France|Villejuif Cedex, France|Dresden, Germany|Hamburg, Germany|Koln, Germany|Mannheim, Germany|Ashkelon, Israel|Haifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Tel-Aviv, Israel|Bologna, Italy|Firenze, Italy|Genova, Italy|Milano, Italy|Novara, Italy|Roma, Italy|Varese, Italy|Badalona, Spain|Barcelona, Spain|Madrid, Spain|Salamanca, Spain|Valencia, Spain|Zaragoza, Spain|Birmingham, England, United Kingdom|Leeds, England, United Kingdom|Leicester, England, United Kingdom|London, England, United Kingdom|London, United Kingdom","https://ClinicalTrials.gov/show/NCT02101268"
438,"NCT02098161","Phase 2 LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)","null","Recruiting","No Results Available","Leukemia","Drug: LCL-161|Behavioral: Questionnaires|Other: Phone Calls","Objective Response (OR) of LCL-161|Time to Response","M.D. Anderson Cancer Center|Novartis","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-0612|NCI-2014-01241","December 2014","December 2019","December 2019","December 2017","March 21, 2014","March 27, 2014","null","null","December 27, 2017","December 29, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT02098161"
439,"NCT02087059","A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis","null","Completed","Has Results","Primary Myelofibrosis (MF)","Drug: Ruxolitinib","Number of Participants With Adverse Events as a Measure of Safety and Tolerability|Charge in Spleen Size From Baseline at Specified Week|Charge in Spleen Size From Baseline up to the Specified Week|Summary of Total Symptom Score as Measured by Seven-day Modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 by Time|Summary of Summary of EORTC QLQ-C30 Responses by Time","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 3","51","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CINC424AJP01","April 2014","March 2015","April 2015","May 2016","March 12, 2014","March 14, 2014","April 11, 2016","July 11, 2016","May 26, 2016","July 11, 2016","Novartis Investigative Site, Nagoya-city, Aichi, Japan|Novartis Investigative Site, Matsuyama, Ehime, Japan|Novartis Investigative Site, Toon-city, Ehime, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Kurume-city, Fukuoka, Japan|Novartis Investigative Site, Maebashi-city, Gunma, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, Japan|Novartis Investigative Site, Kobe-city, Hyogo, Japan|Novartis Investigative Site, Kobe-city, Hyogo, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Tsu-city, Mie, Japan|Novartis Investigative Site, Sendai-city, Miyagi, Japan|Novartis Investigative Site, Miyazaki-city, Miyazaki, Japan|Novartis Investigative Site, Okayama-city, Okayama, Japan|Novartis Investigative Site, Hirakata-city, Osaka, Japan|Novartis Investigative Site, OsakaSayama, Osaka, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Shimotsuke-city, Tochigi, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Chuo-city, Yamanashi, Japan|Novartis Investigative Site, Akita, Japan|Novartis Investigative Site, Gifu, Japan","https://ClinicalTrials.gov/show/NCT02087059"
440,"NCT00586651","Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis","null","Completed","No Results Available","Polycythemia Vera|Essential Thrombocytosis","Drug: lestaurtinib","Determine whether a specific reduction in the JAK2 V617F allele has been indicated in this study.|- improvements in hemoglobin values, neutrophil count, and platelet count. - reduction in dose of hydroxyurea - reduction in splenic enlargement - rate of phlebotomy","Cephalon|Teva Pharmaceutical Industries","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","39","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C0701/2030/ON/US","December 2007","October 2009","September 2010","September 2015","December 21, 2007","January 4, 2008","null","null","September 22, 2015","October 8, 2015","Johns Hopkins University, Baltimore, Maryland, United States|NY Presbyterian-Cornell, New York City, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00586651"
441,"NCT01981850","A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis","null","Active, not recruiting","No Results Available","Primary Myelofibrosis|Polycythemia Vera|Post-Essential Thrombocythemia Myelofibrosis","Biological: PRM-151","Bone marrow response rate, defined as the percent of subjects with a reduction in bone marrow fibrosis score by at least one grade according to WHO criteria at any time during the study.|Comparison of primary and secondary efficacy parameters between doses|Incidence of adverse events (AEs), serious adverse events (SAEs), and changes in laboratory test results|Bone marrow improvement: Bone marrow response rate at weeks 12, 24, and 36; Duration of bone marrow response|Hemoglobin improvement|Platelet improvement|Hematologic improvement|Symptom improvement|Percent of subjects with complete response, partial response, clinical improvement, stable disease, and progressive disease according to IWG-MRT criteria","Promedior, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","98","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PRM-151G-101","October 2013","April 2017","April 2019","December 2016","October 29, 2013","November 13, 2013","null","null","December 7, 2016","December 8, 2016","Mayo Clinic Cancer Center, Phoenix, Arizona, United States|Stanford Cancer Institute, Palo Alto, California, United States|Emory Hospital, Atlanta, Georgia, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mount Sinai Medical Center, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Providence Health Care, Vancouver, British Columbia, Canada|The Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hospital Saint-Louis, Paris, France|University Medical Center RWTH Aachen, Aachen, Germany|Johannes Wesling Academic Medical Center, Minden, Germany|Hadassah Medical Centre, Jerusalem, Israel|Meir Medical Centre, Kfar Saba, Israel|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Marche Nord Hospital, Pesaro, Italy|Erasmus Medical Center, Rotterdam, Zuid Holland, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Guy's and St. Thomas' Hospital, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01981850"
442,"NCT01969838","Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis","Simplify 1","Active, not recruiting","No Results Available","Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis","Drug: Momelotinib|Drug: Ruxolitinib|Drug: Placebo to match momelotinib|Drug: Placebo to match ruxolitinib","Splenic response rate at Week 24|Response rate in total symptom score at Week 24|Rate of red blood cell (RBC) transfusion through Week 24|RBC transfusion independence rate at Week 24|RBC transfusion dependence rate at Week 24","Gilead Sciences","All","18 Years and older   (Adult, Senior)","Phase 3","432","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GS-US-352-0101|2013-002707-33","December 6, 2013","September 12, 2016","June 2018","May 2017","October 22, 2013","October 25, 2013","null","null","August 23, 2017","August 24, 2017","Phoenix, Arizona, United States|Escondido, California, United States|Stanford, California, United States|Jacksonville, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Saint Louis, Missouri, United States|Durham, North Carolina, United States|Seattle, Washington, United States|Darlinghurst, New South Wales, Australia|Parkville, New South Wales, Australia|Saint Leonards, New South Wales, Australia|Brisbane, Queensland, Australia|Herston, Queensland, Australia|Adelaide, South Australia, Australia|Bedford Park, South Australia, Australia|Frankston, Victoria, Australia|Melbourne, Victoria, Australia|Perth, Western Australia, Australia|Wien, Vienna, Austria|Charleroi, Hainaut, Belgium|Antwerp, Belgium|Leuven, Belgium|Liege, Belgium|Pleven, Bulgaria|Plovdiv, Bulgaria|Ruse, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Hradec Kralove, Vychodocesky Kraj, Czechia|Brno, Czechia|Ostrava, Czechia|Aalborg, Denmark|Herlev, Denmark|Toulouse cedex 9, Midi-pyrenees, France|Pierre Bénite Cedex, Rhone-alpes, France|Le Kremlin Bicetre Cedex, France|Lens, France|Lille Cedex, France|Marseille Cedex 9, France|Nantes cedex 1, France|Paris, France|Pessac Cedex, France|Villejuif Cedex, France|München, Bayern, Germany|Leipzig, Sachsen, Germany|Dresden, Germany|Dusseldorf, Germany|Freiburg, Germany|Hamburg, Germany|Mainz, Germany|Mannheim, Germany|Budapest, Hungary|Debrecen, Hungary|Kaposvár, Hungary|Afula, Israel|Ashkelon, Israel|Haifa, Israel|Jerusalem, Israel|Tel Aviv, Israel|Ogaki City, Gifu, Japan|Kitaku Sapporo, Hokkaido, Japan|Osaka Sayama, Osaka, Japan|Osaka-City, Osaka, Japan|Bunkyo-ku, Tokyo, Japan|Fukushima City, Japan|Kumamoto City, Japan|Matsuyama, Japan|Okayama, Japan|Seoul, Korea, Republic of|Maastricht, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Lodz, Lodzkie, Poland|Lublin, Lubelskie, Poland|Kraków, Malopolskie, Poland|Warszawa, Mazowiekie, Poland|Gdansk, Pomorskie, Poland|Poznan, Wielkopolskie, Poland|Bialystok, Poland|Brzozow, Poland|Chorzow, Poland|Arad, Romania|Brasov, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Iasi, Romania|Singapore, Singapore|Majadahonda, Madrid, Spain|Pamplona, Navarra, Spain|Badalona, Spain|Barcelona, Spain|Valencia, Spain|Zaragoza, Spain|Lund, Skane, Sweden|Stockholm, Sweden|Uddevalla, Sweden|Örebro, Sweden|Kaohsiung, Taiwan|Leicester, England, United Kingdom|London, England, United Kingdom|Manchester, England, United Kingdom|Newcastle Upon Tyne, England, United Kingdom|Oxford, England, United Kingdom|Cardiff, Wales, United Kingdom|Northern Ireland, United Kingdom|Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT01969838"
443,"NCT02055781","Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia","PAC326","Terminated","No Results Available","Primary Myelofibrosis|Post-polycythemia Vera Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis","Drug: Pacritinib|Drug: Best Available Therapy","Efficacy","CTI BioPharma","All","18 Years and older   (Adult, Senior)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PERSIST-2 (PAC326)","December 2013","August 2016","November 2016","December 2016","February 3, 2014","February 5, 2014","null","null","December 15, 2016","December 16, 2016","Mayo Clinic Arizona, Scottsdale, Arizona, United States|Arizona Clinical Research Center, Tucson, Arizona, United States|City of Hope, Duarte, California, United States|Moores Cancer Centre, La Jolla, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|Rocky Mountain Cancer Center, Boulder, Colorado, United States|George Washington University- Medical Faculty Associates, Washington, District of Columbia, United States|SCRI- Florida Cancer Specialists South Region, Fort Myers, Florida, United States|SCRI - Florida Cancer Specialists North Region, St. Petersburg, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Indiana University Goshen Cancer Centre, Goshen, Indiana, United States|Investigative Clinical Research of Indiana, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Siouxland Hematology-Oncology Associates, L.L.P (SHOA), Sioux City, Iowa, United States|Norton Cancer Institute, Suburban, Louisville, Kentucky, United States|St Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Providence Cancer Institute, Southfield, Michigan, United States|Washington University School of Medicine Division of Oncology, St. Louis, Missouri, United States|Nebraska Hematology-Oncology, P.C., Lincoln, Nebraska, United States|Hackensack University, Hackensack, New Jersey, United States|Hematology-Oncology Associates of Northern Jersey, Morristown, New Jersey, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|SCRI-Oncology Hematology Care, Cincinnati, Ohio, United States|Cleveland Clinic-Taussig Cancer Center, Cleveland, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Upstate Oncology Associates, Greenville, South Carolina, United States|Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States|Texas Onocolgy-Baylor Sammons Cancer Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|UTMB Galveston, Galveston, Texas, United States|Houston Methodist, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Huntsman Cancer Hospital, Salt Lake City, Utah, United States|Virginia Cancer Specialists, Leesburg, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Green Bay Oncology, Green Bay, Wisconsin, United States|Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|St George Hospital, Kogarah, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Monash Health - Monash Medical Centre, Clayton, Victoria, Australia|Perth Blood Institute, Nedlands, Western Australia, Australia|Haematology and Oncology Clinics of Australia, Chermside, Australia|Prince of Wales Hospital, Randwick, Australia|Centre Hospitalier de Jolimont-Lobbes, Haine-Saint-Paul, Hainaut, Belgium|ZNA - Stuivenberg, Antwerpen, Belgium|AZ Sint Jan Brugge-Oostende AV, Brugge, Belgium|Hopital Brugmann, Brussels, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|St Augustinus, Wilrizk, Belgium|UC Louvain, Yvoir, Belgium|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Fakultní nemocnice Brno, Brno, NAP, Czech Republic|Faculty Hospital Olomouc, Olomouc, NAP, Czech Republic|Fakultní nemocnice Plzeň, Plzeň, NAP, Czech Republic|University Hospital Hradec Kralove, Kralove, Czech Republic|Chu d'Amiens Hopital Sud, Amiens, Cedex 1, France|Hôpital Caremeau, Nimes, Cedex 9, France|CHU Rennes, Rennes, Cedex 9, France|CHU Purpan, Toulouse, Cedex 9, France|CH de Mulhouse, Mulhouse, Cedex, France|CHU de CAEN, Caen, France|Centre Hospitalier de Lens, Lens, France|Hopital l'Archet, CHU de Nice, Nice, France|Saint Antoine Hospital, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|CHU de Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif Cedex, France|Charite-Medical University, Berlin, Germany|Gemeinschaftspraxis Hämatologie/Onkologie, Dresden, Germany|University Hospital Essen, Essen, Germany|Uniklinik Freiburg, Freiburg, Germany|Universitatsklinikum Halle (Saale), Halle (Saale), Germany|Klinik I fur Innere Medizin, Universitat Koln, Koln, Germany|University Hospital Leipzig, Leipzig, Germany|Städtisches Klinikum München GmbH, Munchen, Germany|University of Munster, Munster, Germany|University Hospital Ulm, Ulm, Germany|Semmelweis Egyetem AOK, Budapest, Hungary|University of Debrecen, Belgyogyaszati Intezet, Debrecen, Hungary|Bekes Megyei Pandy Kalman Korhaz, Gyula, Hungary|Kaposi Mór Oktató Kórház, Kaposvár, Hungary|SZTE II. sz Belgyogyoszati Klinika es Kardiologiai Kozpont, Szeged, Hungary|Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Rendelőint, Szolnok, Hungary|University Hospital Maastricht, Maastricht, Netherlands|Erasmus MC, Rotterdam, Netherlands|Auckland District Health Board, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Canterbury District Health Board, Christchurch, New Zealand|North Shore Hospital, Takapuna, New Zealand|CCDHB - Wellington Hospital, Wellington, New Zealand|Bashkir State Medical University, Ufa, Republic of Bashkortostan, Russian Federation|Saratov State Medical University, Saratov, Saratov Region, Russian Federation|National Haematology Research Center, Moscow, Russian Federation|Republican Hopsital n.a. V.A. Baranov, Petrozavodsk, Russian Federation|Ryazan Regional Clinical Hospital, Ryazan, Russian Federation|Russian Research Institute of Hematology and Transfusiology, St. Petersburg, Russian Federation|Military Medical Academy n.a. S.M. Kirov, St. Petersburg, Russian Federation|Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom|Belfast Health and Social Care Trust, Belfast, N. Ireland, United Kingdom|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Guy's Hospital, London, United Kingdom|Hammersmith Hosp - ICH NHS Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Oxford University Hospitals NHS Trust, Oxford, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT02055781"
444,"NCT00436059","The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)","null","Completed","No Results Available","Multiple Myeloma","Drug: bortezomib","Changes in bone markers during treatment|Changes in osteolysis during treatment","Vejle Hospital|Odense University Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006/175","February 2007","July 2009","July 2009","July 2009","February 15, 2007","February 16, 2007","null","null","July 7, 2009","July 8, 2009","University Hospital Odense, Odense, Denmark|Vejle Hospital, Vejle, Denmark","https://ClinicalTrials.gov/show/NCT00436059"
445,"NCT02663648","Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders","null","Withdrawn","No Results Available","Myeloproliferative Disorders|Polycythemia Vera|Essential Thrombocythemia|Myelofibrosis|Chronic Myeloid Leukemia","","quantified the level of CDK, CCP, PLK by real time PCR and westen blot|age of MPN patients and volunteers|gender of MPN patients and volunteers|count of peripheral blood cells","Shandong University","All","18 Years to 80 Years   (Adult, Senior)","","0","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","Cell cycle regulatory gene-MPD","June 2016","June 2018","June 2020","January 2016","December 21, 2015","January 26, 2016","null","null","April 18, 2016","April 20, 2016","Qilu Hospital, Shandong University, Jinan, Shandong, China","https://ClinicalTrials.gov/show/NCT02663648"
446,"NCT01200498","Study of SB939 in Subjects With Myelofibrosis","null","Completed","Has Results","Myeloproliferative Disorders","Drug: SB939","Participants With an Objective Response","M.D. Anderson Cancer Center|S*BIO","All","18 Years and older   (Adult, Senior)","Phase 2","23","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-0319","November 2010","November 2012","November 2012","December 2013","September 9, 2010","September 13, 2010","December 13, 2013","January 30, 2014","December 13, 2013","January 30, 2014","UT MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT01200498"
447,"NCT00025415","Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction","null","Completed","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Acute Undifferentiated Leukemia|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Primary CNS Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Eosinophilic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extramedullary Plasmacytoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Gastrointestinal Stromal Tumor|Intraocular Lymphoma|Isolated Plasmacytoma of Bone|Meningeal Chronic Myelogenous Leukemia|Monoclonal Gammopathy of Undetermined Significance|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Primary Central Nervous System Non-Hodgkin Lymphoma|Primary Myelofibrosis|Primary Systemic Amyloidosis|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Unspecified Adult Solid Tumor, Protocol Specific|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Hairy Cell Leukemia|Waldenström Macroglobulinemia","Drug: imatinib mesylate|Other: pharmacological study","MTD defined based on the toxicities observed during the first cycle of treatment|Toxicity evaluation graded according to the NCI common toxicity criteria and relationship to the study drug|Pharmacokinetic data|Responses|Child-Pugh Classification","National Cancer Institute (NCI)","All","15 Years and older   (Child, Adult, Senior)","Phase 1","60","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02418|01-028|U01CA099168|U01CA062505|U01CA062491|U01CA062502|U01CA062487|CDR0000068959","August 2001","January 2005","null","February 2013","October 11, 2001","January 27, 2003","null","null","February 6, 2013","February 7, 2013","University of Pittsburgh, Pittsburgh, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00025415"
448,"NCT00595829","A Phase 1 Study of XL019 in Adults With Polycythemia Vera","null","Terminated","No Results Available","Polycythemia Vera","Drug: XL019","Safety and tolerability of XL019 as a single agent when orally administered in adults with Polycythemia Vera (PV)|Determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) for XL019|Evaluate pharmacokinetic and pharmacodynamic parameters of XL019 in adults with PV|Evaluate preliminary efficacy of XL019","Exelixis","All","18 Years and older   (Adult, Senior)","Phase 1","3","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XL019-002","December 2007","February 2009","February 2009","August 2015","January 7, 2008","January 16, 2008","null","null","August 19, 2015","August 21, 2015","UCLA School of Medicine, Center for Health Sciences, Los Angeles, California, United States|UCSF - Division of Hematology/Oncology, San Francisco, California, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Weill Cornell Medical College, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00595829"
449,"NCT01790295","Ruxolitinib Prior to Transplant in Patients With Myelofibrosis","null","Active, not recruiting","No Results Available","Primary Myelofibrosis|Post Polycythemia Vera Myelofibrosis|Post Essential Thrombocythemia Myelofibrosis","Drug: Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)","Assessment of 100-day survival without graft failure|Neutrophil recovery|platelet recovery|Non-relapse mortality (NRM)|Acute and chronic GvHD|Chimerism studies|Remission status according to IWG-MRT criteria|Relapse/progression (defined as per IWG-MRT criteria)|Progression-free survival|Overall Survival|Impact of allogeneic stem cell transplant on myelofibrosis associated symptoms and overall quality of life|Expression profiling and measurements of cytokines prior to start of Ruxolitinib, prior to start of chemotherapy for conditioning|Association of cytokines levels with acute and chronic GvHD","John Mascarenhas|Myeloproliferative Disorders-Research Consortium|National Cancer Institute (NCI)|Incyte Corporation|Novartis|Icahn School of Medicine at Mount Sinai","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","21","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 12-1809|MPD-RC 114","February 2013","December 2017","February 2021","January 2017","February 8, 2013","February 13, 2013","null","null","January 16, 2017","January 18, 2017","Emory Hospital, Atlanta, Georgia, United States|Northwestern University, Robert h. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|University of Kansas Cancer Center, Westood, Kansas, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada|University of Oxford, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT01790295"
450,"NCT02809274","Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features","null","Not yet recruiting","No Results Available","Polycythemia Vera","Other: questionnaires","Incidence of iron deficiency in patients with PV|Association between iron deficiency and other clinical features|Influence of therapy (phlebotomies, hydroxyurea, other therapies) on iron parameters|Influence of iron parameters on Patient-reported symptoms|Influence of iron deficiency on arterial and venous thrombosis rate","Rambam Health Care Campus|Meir Medical Center","All","18 Years to 100 Years   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0186-16 CTIL","July 2016","July 2018","August 2018","June 2016","June 18, 2016","June 22, 2016","null","null","June 21, 2016","June 22, 2016","Emek Medical center, Afula, Israel|Soroka medical center, Beer Sheva, Israel|Hillel Yaffe Medical Center, Hadera, Israel|Bnei Zion medical center, Haifa, Israel|Rambam Medical center, Haifa, Israel|Meir Medical center, Kfar Saba, Israel|Sheba medical center, Ramat Gan, Israel|Kaplan medical center, Rehovot, Israel|Maccabi, Tel Aviv, Israel|Tel Aviv Sourasky, Tel Aviv, Israel|Ziv Medical center, Zefat, Israel|Assaf Harofeh Medical Center, Zerifin, Israel","https://ClinicalTrials.gov/show/NCT02809274"
451,"NCT00538980","Dasatinib in Polycythemia Vera","null","Terminated","Has Results","Polycythemia Vera","Drug: Dasatinib","Effect of Dasatinib on the Platelet Count and the Stabilization of Hematocrit When Restored by Phlebotomy to Normal Range|Change in Performance Status and Development of Side Effects and Complications|Changes in Marrow Cellularity, Reticulin and Fibrous Content|Change in Cytogenetics|Change in JAK2 Allele Burden","Weill Medical College of Cornell University|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 2","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0701008940|CA180-104","April 30, 2007","August 25, 2010","August 27, 2010","May 2017","October 2, 2007","October 3, 2007","May 23, 2017","June 20, 2017","May 23, 2017","June 20, 2017","Emory Winship Cancer Institute, Atlanta, Georgia, United States|Hematology/Oncology Associates of Rockland, New City, New York, United States|Weill Cornell Medical College - New York Presbyterian Hospital, New York, New York, United States|The Jones Clinic, Germantown, Tennessee, United States","https://ClinicalTrials.gov/show/NCT00538980"
452,"NCT01692366","Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly","null","Completed","No Results Available","Myelofibrosis","Drug: SAR302503","Response Rate (RR), defined as the proportion of subjects who have a ≥35% reduction as measured by MRI (or CT scan in subjects with contraindications for MRI). - Time Frame:|Number of patients with Serious Adverse events using NCI CTCAE v4.03, clinical parameters and vital signs|Measurements of SAR302503 pharmacokinetic endpoints including Cmax, Tmax, and AUC0-24|Symptom Response Rate (SRR): Proportion of subjects with a ≥50% reduction in the total symptom score using the modified MFSAF|Duration of maintenance of ≥35% reduction in spleen volume|Percent change from baseline in spleen volume measured by MRI|Percent change from baseline in spleen size measured by palpation|Proportion of patients with any grade reduction in reticulin fibrosis","Sanofi","All","20 Years and older   (Adult, Senior)","Phase 2","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD12888|U1111-1130-3710","November 2012","March 2014","March 2014","September 2014","September 10, 2012","September 25, 2012","null","null","September 19, 2014","September 22, 2014","Investigational Site Number 392010, Akita-Shi, Japan|Investigational Site Number 392002, Bunkyo-Ku, Japan|Investigational Site Number 392006, Bunkyo-Ku, Japan|Investigational Site Number 392004, Sendai-Shi, Japan|Investigational Site Number 392008, Shinjuku-Ku, Japan|Investigational Site Number 392009, Shinjuku-Ku, Japan|Investigational Site Number 392003, Suita-Shi, Japan","https://ClinicalTrials.gov/show/NCT01692366"
453,"NCT00430066","Effects of Imatinib Mesylate in Polycythemia Vera","null","Completed","No Results Available","Polycythemia Vera","Drug: Imatinib Mesylate","Reduction of Haematocrit to less than 45%.|Response duration|Safety profile|Reduction in platelet count and spleen size|Reduction of incidence phlebotomies.|Symptoms improvement in patients.","Niguarda Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSTI571POLIVERA","February 2007","November 2009","September 2012","October 2014","January 31, 2007","February 1, 2007","null","null","October 7, 2014","October 8, 2014","","https://ClinicalTrials.gov/show/NCT00430066"
454,"NCT01423851","Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF","null","Active, not recruiting","No Results Available","Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis","Drug: NS-018","To evaluate safety and tolerability of NS-018 assessed by the type, frequency, seriousness and intensity of adverse events|To establish maximum tolerated dose of NS-018|To evaluate response to NS-018 treatment using the International Working Group-Myeloproliferative Neoplasms Research and treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus, change in spleen size and bone marrow assessment|To determine the pharmacokinetic parameters of NS-018 (Cmax, Tmax, AUC, t1/2 and accumulation ratio)|To evaluate pharmacodynamic correlates of NS-018|To evaluate quality of life assessments using Myelofibrosis Symptom Assessment Form (MF-SAF) for Phase 1 and the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) for Phase 2.","NS Pharma, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","77","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NS-018-101","June 2011","December 2017","October 2019","September 2017","August 15, 2011","August 26, 2011","null","null","September 26, 2017","September 28, 2017","Mayo Clinic Scottsdale Recruiting, Scottsdale, Arizona, United States|UC San Diego Moores Cancer Center, San Diego, California, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Weill Cornell Medical College, New York, New York, United States|MD Anderson Cancer Center, Department of Leukemia, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT01423851"
455,"NCT01369498","Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis","null","Completed","No Results Available","Myelofibrosis","Drug: Simtuzumab|Drug: Ruxolitinib","Rate of clinical response as defined by reduction in bone marrow fibrosis score|Rate of clinical response as defined by improvement in hemoglobin, platelet, or absolute neutrophil count|Incidence of adverse events|Change in Myelofibrosis Symptoms Assessment Score|Changes in cytokine levels|Anti-simtuzumab antibody formation","Gilead Sciences","All","18 Years and older   (Adult, Senior)","Phase 2","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AB0024-102","June 2011","June 2014","September 2014","October 2015","June 6, 2011","June 9, 2011","null","null","October 22, 2015","November 13, 2015","Mayo Clinic, Scottsdale, Arizona, United States|University of California San Diego, San Diego, California, United States|Stanford University Medical center, Stanford, California, United States|Washington University in St. Louis, St. Louis, Missouri, United States|Oncology Hematology Care Clinical Trials, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Tennessee Oncology, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Utah University, Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT01369498"
456,"NCT00910728","Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases","null","Completed","Has Results","Primary Myelofibrosis (PMF)|Post-Polycythaemia Vera|Essential Thrombocythaemia Myelofibrosis","Drug: AZD1480","Pharmacokinetic Parameters Following Single Dosing: AUC0-12|Pharmacokinetic Parameters Following Single Dosing: AUC0-24|Pharmacokinetic Parameters Following Single Dosing:AUC0-inf|Pharmacokinetic Parameters Following Multiple Dosing: Cmax,ss|Pharmacokinetic Parameters Following Multiple Dosing: Cmin,ss|Pharmacokinetic Parameters Following Single Dosing: Cmax|Pharmacokinetic Parameters Following Single Dosing: Vz/F|Pharmacokinetic Parameters Following Single Dosing: CL/F|Pharmacokinetic Parameters Following Multiple Dosing: CLss/F|Pharamcokinetic Parameters Following Single Dosing: Tmax|Pharamcokinetic Parameters Following Multiple Dosing: Tmax,ss|Inhibition of PSTAT3 (Count)","AstraZeneca|University of Texas|New York City Hoffman Center|Gustave Roussy, Cancer Campus, Grand Paris","All","25 Years to 99 Years   (Adult, Senior)","Phase 1","65","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","D1060C00001","May 2009","March 2012","August 2014","March 2017","May 28, 2009","June 1, 2009","August 18, 2015","April 24, 2017","March 13, 2017","April 24, 2017","Research Site, New York, New York, United States|Research Site, Houston, Texas, United States|Research Site, Villejuif Cedex, France","https://ClinicalTrials.gov/show/NCT00910728"
457,"NCT00112593","Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer","null","Completed","Has Results","Accelerated Phase Chronic Myelogenous Leukemia|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Aggressive NK-cell Leukemia|AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Primary CNS Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Essential Thrombocythemia|Extramedullary Plasmacytoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|HIV Infection|HIV-associated Hodgkin Lymphoma|Intraocular Lymphoma|Isolated Plasmacytoma of Bone|Juvenile Myelomonocytic Leukemia|Mast Cell Leukemia|Meningeal Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myeloid/NK-cell Acute Leukemia|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Central Nervous System Lymphoma|Primary Myelofibrosis|Primary Systemic Amyloidosis|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage 0 Chronic Lymphocytic Leukemia|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage I Small Lymphocytic Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Childhood Hodgkin Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage IIA Mycosis Fungoides/Sezary Syndrome|Stage IIB Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Small Lymphocytic Lymphoma|Stage IIIA Mycosis Fungoides/Sezary Syndrome|Stage IIIB Mycosis Fungoides/Sezary Syndrome|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Hodgkin Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Stage IVA Mycosis Fungoides/Sezary Syndrome|Stage IVB Mycosis Fungoides/Sezary Syndrome|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia","Drug: fludarabine phosphate|Radiation: total-body irradiation|Procedure: peripheral blood stem cell transplantation|Drug: cyclosporine|Drug: mycophenolate mofetil|Other: laboratory biomarker analysis","Death From Regimen Toxicity or Opportunistic Infection|Death From GVHD|Successful Induction of Mixed Hematopoietic Chimerism as Assessed by the Percentage of Peripheral Blood T Cells That Are of Donor Origin|Overall Survival|Progression of HIV|Reconstitution of HIV-specific Immunity","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 75 Years   (Child, Adult, Senior)","","5","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1410.00|NCI-2010-00802|P30CA015704|P01CA018029","November 1999","November 2014","null","April 2017","June 2, 2005","June 3, 2005","April 17, 2017","May 24, 2017","April 17, 2017","May 24, 2017","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00112593"
458,"NCT01445769","Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis","null","Completed","Has Results","Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis","Drug: Ruxolitinib","Mean Percentage Change From Baseline in Spleen Volume at Week 24|Median Percent Change From Baseline in Spleen Volume at Week 24|Mean Percentage Change From Baseline in the Total Symptom Score at Week 24|Median Percent Change From Baseline in the Total Symptom Score at Week 24|Percentage of Participants With a ≥ 35% Reduction From Baseline in Spleen Volume at Week 24|Percentage of Participants With a ≥ 10% Reduction From Baseline in Spleen Volume at Week 24|Percentage of Participants With a ≥ 50% Improvement From Baseline in Total Symptom Score at Week 24|Mean Percentage Change From Baseline in Palpable Spleen Length at Week 24|Median Percent Change From Baseline in Palpable Spleen Length at Week 24|Percentage of Participants With a ≥ 50% Improvement From Baseline in Their Transfusion Status or With New Transfusion Independence Status for Those Participants Who Were Transfusion Dependent at Baseline|Percentage of Participants With Clinically Notable Anemia|Mean Percentage Change in Abdominal Symptom Scores at Week 24.|Median Percentage Change in Abdominal Symptom Scores at Week 24.|Number of Participants With Grade 3 or Grade 4 Adverse Events","Incyte Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","45","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18424-261","September 2011","March 2013","April 2013","September 2014","September 23, 2011","October 4, 2011","March 31, 2014","September 19, 2014","September 16, 2014","September 19, 2014","Highland, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Jacksonville, Florida, United States|Orange City, Florida, United States|Winter Park, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Southfield, Michigan, United States|Morristown, New Jersey, United States|Armonk, New York, United States|Hickory, North Carolina, United States|Canton, Ohio, United States|Hazelton, Pennsylvania, United States|Hershey, Pennsylvania, United States|Charleston, South Carolina, United States|Sioux Falls, South Dakota, United States|San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT01445769"
459,"NCT01433445","Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis","null","Active, not recruiting","No Results Available","Idiopathic Myelofibrosis|Post Essential Thrombocythemia Myelofibrosis|Post Polycythemia-Vera Myelofibrosis","Drug: panobinostat|Drug: ruxolitinib","Rate of dose limiting toxicities at the different dose levels|Percentage of Responders achieving at least a 35% reduction in splenic volume (compared to baseline) at Week 12, or end of study, whichever comes first as determined by MRI/CT|Percentage of responders as measured by improvement in bone marrow fibrosis as graded according to the International Working Group consensus criteria for treatment response as compared to baseline|Percentage of Responders as measured by Summary statistics in absolute values at each visit and absolute and percentage change from baseline at each visit for change in JAK2V617F allele burden and cytokine measurement|Proportion of patients who are transfusion dependent, as well as, the proportion of patients whose transfusion status (dependent or independent) changed (from dependent to independent or vice versa) at each cycle as compared to baseline|Percentage of Responders as measured by a change in spleen length of at least 50% reduction as determined by manual palpation from Baseline to Week 12 and maintained until Week 24|Rate of adverse events, serious adverse events, notable laboratory, vital signs and ECG results by dose level|AUC and Cmax of ruxolitinib and panobinostat at various dose levels","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 1","61","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLBH589X2106|2011-000861-10","November 1, 2011","December 12, 2018","December 12, 2018","November 2017","June 27, 2011","September 14, 2011","null","null","November 9, 2017","November 14, 2017","Novartis Investigative Site, Paris, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Varese, VA, Italy|Novartis Investigative Site, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01433445"
460,"NCT01423058","Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis","null","Completed","No Results Available","Primary Myelofibrosis|Post-Polycythemia Vera|Post-Essential Thrombocythemia Myelofibrosis","Drug: Momelotinib","To determine the safety of momelotinib by characterization and relationship of adverse events, affects on vital signs and laboratory parameters, and QTc intervals as measured by electrocardiogram (ECG)|To determine maximum tolerated dose of momelotinib by characterization of Dose Limiting Toxicities|To confirm the half-life of momelotinib by pharmacokinetic analyses|To determine the efficacy of momelotinib by evaluation of spleen and liver size, disease related constitutional symptoms, transfusion dependence and anemia response.|To determine the effect of momelotinib on JAK2V617F mutant allele burden via Polymerase Chain Reaction (PCR) analyses|To determine the effect of momelotinib on plasma levels of inflammatory, fibrogenic and angiogenic cytokines via Enzyme-Linked Immunosorbent Assay (ELISA)|To determine the effect of momelotinib on bone marrow or peripheral blood cytogenetic findings","Gilead Sciences","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","61","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","YM387-II-02","August 2011","June 2014","June 2014","January 2015","July 7, 2011","August 25, 2011","null","null","January 16, 2015","January 28, 2015","Mayo Clinic, Scottsdale, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|MD Anderson Cancer Center, The University of Texas, Houston, Texas, United States|Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States|Princess Margaret Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT01423058"
461,"NCT01392443","Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF","null","Active, not recruiting","No Results Available","Primary Myelofibrosis (MF)|Post-Polycythemia Vera (PV) MF|Post-Essential Thrombocythemia (ET) MF","Drug: Ruxolitinib","Efficacy by reduction in spleen volume|Safety/tolerability of INC424|patient reported outcomes|Duration of response","Novartis Pharmaceuticals|Novartis","All","18 Years to 65 Years   (Adult)","Phase 2","120","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CINC424A2202","August 1, 2011","November 9, 2017","November 9, 2017","October 2017","July 11, 2011","July 12, 2011","null","null","October 12, 2017","October 16, 2017","Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Suzhou, Jiangsu, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Tianjin, Tianjin, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Jinan, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Maebashi-city, Gunma, Japan|Novartis Investigative Site, Kanazawa-city, Ishikawa, Japan|Novartis Investigative Site, Tsu-city, Mie, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan","https://ClinicalTrials.gov/show/NCT01392443"
462,"NCT00665067","Correlative Biomarker Study in Patients With Myeloproliferative Disorders","null","Recruiting","No Results Available","Myeloproliferative Disease|Myelofibrosis|Idiopathic Myelofibrosis|Essential Thrombocythemia|Polycythemia Vera","","To collect and store tissue samples from patients with myeloproliferative disorders (PV,IM,and ET). Tissue samples will be used to perform a variety of biomarker studies to monitor the effects of a particular therapeutic intervention.","Icahn School of Medicine at Mount Sinai|Myeloproliferative Disorders-Research Consortium|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","860","Other|NIH","Observational","Observational Model: Other|Time Perspective: Other","GCO 07-0548-00107|P01CA108671-05|MPD-RC 107","April 2007","June 2019","June 2019","October 2017","April 21, 2008","April 23, 2008","null","null","October 4, 2017","October 5, 2017","Mayo Clinic, Scottsdale, Arizona, United States|The Palo Alto Clinic, Palo Alto, California, United States|Georgetown University, Washington, D.C., District of Columbia, United States|Emory Hospital, Atlanta, Georgia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Maryland, Baltimore, Maryland, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|New York Blood Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Geisinger Cancer Center, Hazleton, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Ospedali Riuniti di Bergamo, Bergamo, Italy|University of Florence, Florence, Italy|Ospedale San Martino Genova, Genova, Italy|San Matteo Hospital, Pavia, Italy|Universita Cattolica del Sacro Cuore, Rome, Italy|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT00665067"
463,"NCT01348490","Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis","null","Recruiting","No Results Available","Primary Myelofibrosis|Post Essential Thrombocythemia-myelofibrosis|Post Polycythemia Vera-myelofibrosis","Drug: Ruxolitinib (INCB018424)","Measure spleen volume changes in patients with PMF, PPV-MF and PET-MF|Establish adequate dose of INCB018424 in patients with low platelets","Incyte Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","150","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCB18424-258","June 2011","February 2018","September 2020","May 2017","May 4, 2011","May 5, 2011","null","null","May 12, 2017","May 16, 2017","Birmingham, Alabama, United States|Beverly Hills, California, United States|Burbank, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Pomona, California, United States|San Diego, California, United States|New Haven, Connecticut, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Orange City, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Southfield, Michigan, United States|Saint Louis, Missouri, United States|Hackensack, New Jersey, United States|Morristown, New Jersey, United States|Somerville, New Jersey, United States|New York, New York, United States|Durham, North Carolina, United States|Hickory, North Carolina, United States|Canton, Ohio, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Danville, Pennsylvania, United States|Hershey, Pennsylvania, United States|Charleston, South Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States","https://ClinicalTrials.gov/show/NCT01348490"
464,"NCT00745550","A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis","null","Completed","No Results Available","Myelofibrosis|Myeloproliferative Disorders|Polycythemia Vera|Essential Thrombocythemia","Drug: SB1518","Phase 1: to establish the maximum tolerated dose of SB1518 as a single agent when administered orally daily|Phase 2: to assess the clinical benefit rate in subjects with CIMF who are treated with SB1518 at the recommended dose|Assess the safety and tolerability of SB1518, administered orally once daily in subjects with CIMF|Assess the pharmacokinetic profile of SB1518|Assess the pharmacodynamic profile of SB1518","S*BIO","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","55","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SB1518-2008-003","August 2008","January 2012","January 2012","April 2012","September 2, 2008","September 3, 2008","null","null","April 19, 2012","April 20, 2012","Mayo Clinic, Scottsdale, Arizona, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Royal Adelaide Hospital, Adelaide, Australia","https://ClinicalTrials.gov/show/NCT00745550"
465,"NCT01298934","LBH589 (Panobinostat) for the Treatment of Myelofibrosis","null","Unknown status","No Results Available","Primary Myelofibrosis|Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase|Post-Essential Thrombocythemia Related Myelofibrosis","Drug: LBH589","To assess the safety and tolerability of oral LBH589 in patients with PMF, post-PV/ET MF|Evaluation of treatment response by International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)|Assess changes in biomarkers","Ronald Hoffman|Novartis|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 08-0572|LBH589-JM","September 2009","July 2015","July 2015","March 2015","February 16, 2011","February 18, 2011","null","null","March 5, 2015","March 6, 2015","Icahn School of Medicine at Mount Sinai, New York, New York, United States","https://ClinicalTrials.gov/show/NCT01298934"
466,"NCT01291784","Anti-TGF-beta Therapy in Patients With Myelofibrosis","null","Terminated","Has Results","Myelofibrosis|Primary Myelofibrosis|Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase|Post-essential Thrombocythemia Related Myelofibrosis","Biological: monoclonal antibody to TGF-beta","Safety and Tolerability|Bauermeister Scale|European Consensus Fibrosis Grade|Peripheral Blood CD34+|JAK2V617F Allele Burden","John Mascarenhas|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Senior)","Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 10-1450|GC1008-JM","February 2011","January 2013","January 2013","November 2014","February 7, 2011","February 8, 2011","July 31, 2013","August 28, 2014","November 21, 2014","December 8, 2014","Icahn School of Medicine at Mount Sinai, New York, New York, United States","https://ClinicalTrials.gov/show/NCT01291784"
467,"NCT00241241","Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera","null","Completed","No Results Available","Polycythemia Vera","Drug: pegylated interferon-alfa 2a","response rate after one year of treatment|safety|molecular response","PV-Nord","All","18 Years to 65 Years   (Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PVN1","September 2004","October 2006","January 2008","October 2015","October 17, 2005","October 18, 2005","null","null","October 20, 2015","October 21, 2015","Hopital Avicenne, Bobigny, France|Hopital Huriez, Lille, France|Hopital Dupuytren, Limoges, France|Hopital Lariboisiere, Paris, France|Hopital Saint-Louis, Paris, France","https://ClinicalTrials.gov/show/NCT00241241"
468,"NCT00669578","CC-4047 in Treating Patients With Myelofibrosis","null","Completed","Has Results","Chronic Myeloproliferative Disorders|Secondary Myelofibrosis","Drug: CC-4047","Determine the Maximum Tolerated Dose of CC-4047|Best Overall Response Over the First 6 Cycles of Treatment|Number of Participants With Treatment Related Adverse Events.|Duration of Response Time|Time to Response","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1|Phase 2","77","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MC078B|P30CA015083|NCI-2009-01331|07-005317|PO-MMM-PI-0007","May 2008","July 2010","May 2014","October 2015","April 29, 2008","April 30, 2008","November 7, 2012","May 9, 2014","October 29, 2015","November 25, 2015","Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00669578"
469,"NCT00666289","Familial Myeloproliferative Disorders","null","Completed","No Results Available","Polycythemia Vera|Essential Thrombocythemia|Idiopathic Myelofibrosis","","To determine a linkage from the DNA analyzed to find a gene that will allow for genetic evaluation of families with MPDs.","Icahn School of Medicine at Mount Sinai|Myeloproliferative Disorders-Research Consortium|National Cancer Institute (NCI)","All","7 Years and older   (Child, Adult, Senior)","","17","Other|NIH","Observational","Observational Model: Family-Based|Time Perspective: Other","GCO 07-0548-00105|P01CA108671-01A2|MPD-RC 105","March 2008","January 20, 2015","June 20, 2015","September 2017","April 22, 2008","April 24, 2008","null","null","September 1, 2017","September 5, 2017","Georgetown University, Washington, D.C., District of Columbia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Mount Sinai School of Medicine, New York, New York, United States|Weill Cornell, New York, New York, United States|University of Utah, Salt Lake City, Utah, United States|University of Florence, Florence, Italy","https://ClinicalTrials.gov/show/NCT00666289"
470,"NCT01236638","Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)","null","Completed","No Results Available","Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis","Drug: Momelotinib","To determine the long term safety and tolerability of orally-administered CYT387 in patients with PMF or post-ET/PV MF following completion of core study CCL09101|To obtain information on the long term effectiveness of orally-administered CYT387 in patients with PMF or post-ET/PV MF","Gilead Sciences","All","18 Years and older   (Adult, Senior)","Phase 2","120","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCL09101E","November 2010","June 2014","June 2014","July 2014","November 5, 2010","November 8, 2010","null","null","July 11, 2014","July 15, 2014","Stanford Cancer Center, Stanford, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|The Royal Melbourne Hospital, Parkville, Victoria, Australia|Princess Margaret Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT01236638"
471,"NCT01633372","An Open Label Study of INCB039110 Administered Orally in Patients With Myelofibrosis","null","Active, not recruiting","No Results Available","Primary Myelofibrosis|Post Polycythemia Vera Fibrosis|Post Essential Thrombocythemia Myelofibrosis","Drug: itacitinib","Proportion of subjects with >/= 50% reduction in total symptom score in each dose group, as measured by the modified The Myelofibrosis Symptom Assessment Form (MFSAF) v3.0 diary|Proportion of subjects with >/= 35% reduction in spleen volume, and mean percent change in spleen volume|Proportion of transfusion dependent subjects who exhibit changes in transfusion frequency over any 12 week period on study and proportion of transfusion independent subjects who exhibit changes in hemoglobin level|Safety and tolerability of itacitinib (INCB039110) as measured by adverse events.","Incyte Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCB 39110-230","April 2012","December 2013","January 2018","August 2017","June 26, 2012","July 4, 2012","null","null","August 10, 2017","August 14, 2017","Birmingham, Alabama, United States|Scottsdale, Arizona, United States|Los Angeles, California, United States|Atlanta, Georgia, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|New York, New York, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Columbia, South Carolina, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Darlinghurst, New South Wales, Australia|Kogarah, New South Wales, Australia|Box Hill, Victoria, Australia|Frankston, Victoria, Australia|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT01633372"
472,"NCT02020928","Laser Therapy Prevents Mucositis Oral in Chemotherapy for Bone Marrow Transplantation?","lasertherapy","Unknown status","No Results Available","Oral Mucositis|Effects of Chemotherapy|Malignant Neoplasm of Bone Marrow","Device: Low level laser therapy","Incidence of Oral Mucositis|Degree of mucositis","Instituto Materno Infantil Prof. Fernando Figueira","All","18 Years to 60 Years   (Adult)","Phase 3","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","3547-13","January 2015","July 2015","August 2015","September 2013","December 19, 2013","December 25, 2013","null","null","December 19, 2013","December 25, 2013","Instituto de Medicina Integral Prof. Fernando Figueira, Recife, Pernambuco, Brazil","https://ClinicalTrials.gov/show/NCT02020928"
473,"NCT01134120","A Study in Myeloproliferative Disorders","null","Active, not recruiting","No Results Available","Myeloproliferative Disorders|Thrombocythemia, Essential|Polycythemia Vera|Primary Myelofibrosis","Drug: LY2784544","Determination of a recommended Phase 2 dosing regimen|Number of participants with clinical significant effects|Preliminary pharmacokinetics of LY2784544 (Cmax)|Preliminary pharmacokinetics of LY2784544 (AUC)|Malignant clone burden","Eli Lilly and Company","All","18 Years and older   (Adult, Senior)","Phase 1","80","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13201|I3X-MC-JHTA","April 2010","April 2014","August 2018","May 2017","May 27, 2010","May 31, 2010","null","null","May 18, 2017","May 19, 2017","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT01134120"
474,"NCT00522574","A Safety Study of XL019 in Adults With Myelofibrosis","null","Terminated","No Results Available","Myeloproliferative Disorders|Myelofibrosis|Polycythemia Vera|Thrombocythemia, Essential","Drug: XL019","To evaluate the safety, tolerability, maximum tolerated dose, and dose-limiting toxicities of XL019 as a single agent when orally administered in subjects with PMF, post-PV MF, or post-ET MF.|Determine plasma pharmacokinetics, evaluate pharmacodynamic correlates, and estimate renal elimination of XL019|Evaluate preliminary efficacy of XL019 as a single agent when administered orally","Exelixis","All","18 Years and older   (Adult, Senior)","Phase 1","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XL019-001","August 2007","null","null","April 2011","August 27, 2007","August 29, 2007","null","null","April 4, 2011","April 5, 2011","UCSF - Division of Hematology/Oncology, San Francisco, California, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mt. Sinai School of Medicine, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00522574"
475,"NCT01014546","Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis","null","Terminated","No Results Available","Essential Thrombocythemia|Polycythemia Vera|Primary Myelofibrosis","Drug: Arsenic Trioxide|Dietary Supplement: Ascorbic Acid|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study","Adverse events, and their attribution throughout the study|Dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 3.0 (Stage 1)|Maximum tolerated dose (MTD), defined as the dose level at which 0 or 1 of 6 subjects experience DLT, and 2 of 3 or 2 of 6 experience DLT at the next higher dose level, assessed by the NCI CTC version 3.0 (Stage 1)|Change in absolute number of circulating CD34+ cells in the peripheral blood (Stage 2 only)|Change in JAK2/MPL (Stage 2 only)|Change in plasma levels of chemokines as measured by ELISA (Stage 2)|Change in plasma levels of cytokines as measured by ELISA (Stage 2)|Change in plasma levels of proteases as measured by enzyme-linked immunosorbent assay (ELISA) (Stage 2)|Disease response assessed using the IWG-MRT response criteria","Roswell Park Cancer Institute|National Cancer Institute (NCI)|Cephalon","All","19 Years and older   (Adult, Senior)","Phase 1","5","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 154609|NCI-2009-01660|P30CA016056","April 2010","February 2015","null","July 2016","November 16, 2009","November 17, 2009","null","null","July 25, 2016","July 26, 2016","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT01014546"
476,"NCT00952289","COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial","null","Completed","Has Results","Myelofibrosis","Drug: Ruxolitinib|Drug: Placebo","Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24|Maintenance of a ≥ 35% Reduction From Baseline in Spleen Volume Among Patients Initially Randomized to Receive Ruxolitinib|Duration of Maintenance of a ≥ 35% Reduction From Baseline in Spleen Volume Among Patients Initially Randomized to Receive Ruxolitinib|Number of Participants With a ≥ 50% Reduction in Total Symptom Score From Baseline to Week 24|Change From Baseline to Week 24 in Total Symptom Score|Overall Survival|Overall Survival Time|Overall Survival - Extended Data|Overall Survival Time - Extended Data|Overall Survival at Week 144|Overall Survival Time at Week 144","Incyte Corporation","All","18 Years and older   (Adult, Senior)","Phase 3","309","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","INCB 18424-351","August 2009","November 2010","October 2015","June 2016","August 4, 2009","August 6, 2009","December 16, 2011","January 24, 2012","June 29, 2016","July 28, 2016","Birmingham, Alabama, United States|Scottsdale, Arizona, United States|Baldwin Park, California, United States|Bellflower, California, United States|Beverly Hills, California, United States|Corona, California, United States|Fullerton, California, United States|Highland, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Orange, California, United States|Palo Alto, California, United States|Panorama City, California, United States|Rancho Cucamonga, California, United States|Riverside, California, United States|Sacramento, California, United States|San Diego, California, United States|West Covina, California, United States|Aurora, Colorado, United States|Denver, Colorado, United States|Fort Collins, Colorado, United States|Norwalk, Connecticut, United States|Washington, District of Columbia, United States|Boynton Beach, Florida, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|West Palm Beach, Florida, United States|Winter Park, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Honolulu, Hawaii, United States|Boise, Idaho, United States|Meridian, Idaho, United States|Twin Falls, Idaho, United States|Chicago, Illinois, United States|Beech Grove, Indiana, United States|Indianapolis, Indiana, United States|Ames, Iowa, United States|Iowa City, Iowa, United States|Sioux City, Iowa, United States|Waterloo, Iowa, United States|Louisville, Kentucky, United States|Alexandria, Louisiana, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Novi, Michigan, United States|Southfield, Michigan, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|St. Louis Park, Minnesota, United States|New Albany, Mississippi, United States|St. Louis, Missouri, United States|Billings, Montana, United States|Denville, New Jersey, United States|Hackensack, New Jersey, United States|Morristown, New Jersey, United States|Somerville, New Jersey, United States|Albuquerque, New Mexico, United States|East Setauket, New York, United States|New York, New York, United States|Valhalla, New York, United States|Durham, North Carolina, United States|Hickory, North Carolina, United States|Winston-Salem, North Carolina, United States|Bismarck, North Dakota, United States|Akron, Ohio, United States|Canton, Ohio, United States|Cleveland, Ohio, United States|Dayton, Ohio, United States|Dover, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Germantown, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|New Braunfels, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States|Everett, Washington, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States|Darlinghurst, New South Wales, Australia|Kogarah, New South Wales, Australia|Randwick, New South Wales, Australia|St Leonards, New South Wales, Australia|Brisbane, Queensland, Australia|Douglas, Queensland, Australia|Herston, Queensland, Australia|Milton, Queensland, Australia|Woolloongabba, Queensland, Australia|Bedford Park, South Australia, Australia|Box Hill, Victoria, Australia|Clayton, Victoria, Australia|Frankston, Victoria, Australia|Ringwood East, Victoria, Australia|Fremantle, Western Australia, Australia|Perth, Western Australia, Australia|Vancouver, British Columbia, Canada|St. John's, Newfoundland and Labrador, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Levis, Quebec, Canada|Montreal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT00952289"
477,"NCT00946270","Pomalidomide for Myelofibrosis Patients","null","Active, not recruiting","No Results Available","Polycythemia Vera|Thrombocythemia","Drug: CC-4047|Drug: Prednisone","Best Overall Response","M.D. Anderson Cancer Center|Celgene","All","18 Years and older   (Adult, Senior)","Phase 2","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-0199|NCI-2012-00360","July 2009","August 2018","null","November 2016","July 23, 2009","July 24, 2009","null","null","November 14, 2016","November 15, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00946270"
478,"NCT00935987","Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)","null","Completed","No Results Available","Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis","Drug: CYT387","Safety and tolerability, dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of orally-administered CYT387 in patients with PMF or post-ET/PV MF.|Objective Response Rate (ORR), as measured by complete response (CR) rate, partial response (PR) rate and clinical improvement (CI) rate according to International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) consensus criteria|Pharmacokinetics of CYT387 in patients with PMF or post-ET/PV MF|Effect of CYT387 on bone marrow or peripheral blood cytogenetic findings in patients with PMF or post-ET/PV MF.|Effect of CYT387 on peripheral blood granulocyte JAK2V617F allele burden in patients with PMF or post-ET/PV MF.|Effect of CYT387 on peripheral blood endogenous myeloid colony formation in patients with PMF or post-ET/PV MF.|Effect of CYT387 on plasma levels of inflammatory, fibrogenic and angiogenic cytokines in patients with PMF or post-ET/PV MF|Pharmacodynamic correlates of CYT387 activity in patients with PMF or post-ET/PV MF who are receiving treatment with CYT387.","Gilead Sciences","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","166","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCL09101","November 2009","April 2012","April 2012","November 2013","July 7, 2009","July 9, 2009","null","null","November 8, 2013","December 4, 2013","Stanford Cancer Center, Stanford, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|The Royal Melbourne Hospital, Parkville, Victoria, Australia|Princess Margaret Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT00935987"
479,"NCT00934544","Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial","null","Completed","Has Results","Myelofibrosis","Drug: INC424/INCB018424|Drug: Best Available Therapy (BAT)","Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 48|Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 24|Duration of Maintenance of at Least 35% Reduction in Spleen Volume (DoMSR) From Baseline|Time to First at Least 35% Reduction in Spleen Volume From Baseline by Treatment|Progression Free Survival (PFS) by Treatment|Leukemia-free Survival (LFS)|Overall Survival (OS) by Treatment|Percentage of Participants With Bone Marrow Histomorphology at Week 48","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 3","219","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CINC424A2352|CINCB 18424-352","July 2009","March 2015","March 2015","February 2016","July 6, 2009","July 8, 2009","December 15, 2011","May 30, 2012","March 17, 2016","April 15, 2016","Novartis Investigative Site, Innsbruck, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Antwerp, Belgium|Novartis Investigative Site, Antwerp, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Kortrijk, Belgium|Novartis Investigative Site, La Louvière, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Roeselare, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Amiens cedex 1, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, Lens Cedex, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Nimes, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pessac, France|Novartis Investigative Site, Poitiers Cedex, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse Cedex, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Frankfurt/M, Germany|Novartis Investigative Site, Köln, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Tuebingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Pavia, (pv), Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Florence, Italy|Novartis Investigative Site, Orbassano, Italy|Novartis Investigative Site, Pavia, Italy|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Majadahonda, Madrid, Spain|Novartis Investigative Site, Göteborg, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Belfast, United Kingdom|Novartis Investigative Site, Cambridge, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT00934544"
480,"NCT00715247","Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes","null","Recruiting","No Results Available","Polycythemia Vera|Essential Thrombocythemia|Myelofibrosis","","Identify genes whose mutations cause Polycythemia Vera, Essential Thrombocythemia and Primary Myelofibrosis.|To determine if there are proteins expressed by cells from patients that might be targets for the immune response.","University of Utah|Myeloproliferative Disorders-Research Consortium|National Cancer Institute (NCI)","All","Child, Adult, Senior","","700","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","17793|1P01CA10867101A2","July 2006","July 2020","July 2020","November 2017","July 11, 2008","July 15, 2008","null","null","November 1, 2017","November 6, 2017","University of Utah, Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT00715247"
481,"NCT00668421","CEP-701 (Lestaurtinib) in Myelofibrosis","null","Unknown status","No Results Available","Myelofibrosis|Essential Thrombocythemia|Polycythemia Vera","Drug: CEP-701 (Lestaurtinib)","To determine the safety and maximum tolerated dose of a novel kinase inhibitor in subjects with myelofibrosis.|To estimate the efficacy of a novel kinase inhibitor in subjects with myelofibrosis, as determined by a reduction in JAK2 V617F allele frequency in peripheral blood neutrophils.|To estimate the incidence, severity, and attribution of treatment-emergent adverse events.|To estimate the rate of complete or major clinical-hematological response from treatment with Lestaurtinib (CEP-701) in this subject population as measured by the EUMNET response criteria.","Ronald Hoffman|Myeloproliferative Disorders-Research Consortium|National Cancer Institute (NCI)|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 07-0548-00104|P01CA108671-01A2|MPD-RC 104","April 2008","September 2013","January 2015","November 2014","April 25, 2008","April 29, 2008","null","null","November 24, 2014","November 26, 2014","Palo Alto Medical Facilities, Palo Alto, California, United States|Georgetown University Medicine Center, Washington, District of Columbia, United States|University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States|Weill Cornell, Ithaca, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT00668421"
482,"NCT00666549","Research Tissue Bank","null","Recruiting","No Results Available","Myelofibrosis|Idiopathic Myelofibrosis|Essential Thrombocythemia|Polycythemia Vera","","To collect and store tissue specimens from patients with MPDs including PV, IM, ET. The samples will be used to conduct laboratory investigations to help define mechanisms involved in the pathophysiology and treatment of these disorders.","Icahn School of Medicine at Mount Sinai|Myeloproliferative Disorders-Research Consortium|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","400","Other|NIH","Observational","Observational Model: Other|Time Perspective: Other","GCO 07-0548-00106|P01CA108671-01A2|MPD-RC 106","September 2007","June 2019","June 2019","October 2017","April 23, 2008","April 25, 2008","null","null","October 4, 2017","October 5, 2017","Palo Alto Medical Foundation Research Institute, Palo Alto, California, United States|Weill Cornell University, Washington, D.C., District of Columbia, United States|University of Georgetown, Washington, D.C., District of Columbia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Johns Hopkins, Baltimore, Maryland, United States|Roswell Park, Buffalo, New York, United States|Mount Sinai Medical Center, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States|Ospedali Riuniti di Bergamo, Bergamo, IL, Italy|University of Florence, Florence, IL, Italy","https://ClinicalTrials.gov/show/NCT00666549"
483,"NCT00631462","A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis","null","Completed","No Results Available","Myelofibrosis","Drug: TG101348","Safety (i.e., adverse events; effects on laboratory parameters, vital signs, and ECGs; dose-limiting toxicities), tolerability, and MTD|Pharmacokinetics and pharmacodynamics","TargeGen","All","18 Years and older   (Adult, Senior)","Phase 1","59","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MF-TG101348-001","January 2008","October 2009","October 2009","October 2009","January 29, 2008","March 7, 2008","null","null","October 22, 2009","October 26, 2009","UCSD Moores Cancer Center, San Diego, California, United States|Stanford Comprehensive Cancer Center, Stanford, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00631462"
484,"NCT00931762","Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis","null","Completed","No Results Available","Primary Myelofibrosis|Post-Polycythemia Vera|Post-Essential Thrombocytopenia","Drug: Panobinostat","To evaluate the overall response (CR, PR, and clinical improvement) to oral panobinostat as a single agent at 40 mg daily every Monday, Wednesday and Friday in patients with myelofibrosis.|To compare the response to panobinostat in patients with the JAK2 V617F mutation to those without the JAK2 V617F mutation|To evaluate the symptomatic improvement of myelofibrosis patients treated with panobinostat using the Myelofibrosis Symptom Assessment Form (MF-SAF) at baseline and after 2 and 4 months of treatment|To assess compliance to panobinostat treatment as assessed by monthly capsule counts","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 2","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLBH589BUS58","July 2009","August 2011","August 2011","November 2016","July 1, 2009","July 2, 2009","null","null","November 16, 2016","November 18, 2016","Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States|City of Hope National Medical Center, Duate, California, United States|Stanford Comprehensive Cancer Center, Stanford, California, United States|Medical College of Georgia, Augusta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|New York Prebyterian Hospital - Weill Cornell Medical College, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00931762"
485,"NCT00509899","Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis","null","Completed","Has Results","Myelofibrosis|Polycythemia Vera|Thrombocytosis","Drug: Ruxolitinib","Number of Participants With Adverse Events (AEs)|Percentage of Participants With Clinical Improvement (CI) Over Time|Percentage of Participants Achieving ≥ 50% Reduction From Baseline in Spleen Palpation Length Over Time|Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume Over Time|Change From Baseline in Myelofibrosis Total Symptom Score at Week 24|Change From Baseline to Week 24 in Health-Related Quality of Life|Change From Baseline in Body Weight Over Time|Change From Baseline to Week 24 in Eastern Cooperative Oncology Group (ECOG) Performance Status","Incyte Corporation","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","154","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCB 18424-251","June 2007","December 2007","February 2017","March 2017","July 30, 2007","August 1, 2007","December 15, 2011","August 2, 2012","March 2, 2017","March 31, 2017","Rochester, Minnesota, United States|Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00509899"
486,"NCT00433862","Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders","null","Completed","No Results Available","Polycythemia Vera|Essential Thrombocytosis|Idiopathic Myelofibrosis|Neutrophils|Chronic Myeloproliferative Disorders","","","National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","","8","NIH","Observational","Time Perspective: Prospective","070090|07-CC-0090","February 6, 2007","null","May 19, 2010","May 19, 2010","February 9, 2007","February 12, 2007","null","null","June 30, 2017","July 2, 2017","VA Medical Center, Washington D.C., Washington, D.C., District of Columbia, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00433862"
487,"NCT00445744","Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome","null","Completed","Has Results","Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Childhood Acute Myeloid Leukemia in Remission|Childhood Myelodysplastic Syndromes|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Myelodysplastic Syndrome With Isolated Del(5q)|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Secondary Myelofibrosis|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies","Drug: cyclophosphamide|Drug: busulfan|Drug: tacrolimus|Drug: methotrexate|Genetic: cytogenetic analysis|Other: flow cytometry|Other: pharmacological study|Other: pharmacogenomic studies|Procedure: peripheral blood stem cell transplantation|Procedure: allogeneic hematopoietic stem cell transplantation","Effectiveness of Cyclophosphamide/Busulfan Regimen in Reducing Regimen-related Liver Toxicity|Non-relapse Mortality (NRM) (Patients With AML/MDS)","Fred Hutchinson Cancer Research Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","","52","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2130.00|NCI-2010-00270|P01HL036444","December 2006","June 2011","June 2013","December 2017","March 7, 2007","March 9, 2007","April 5, 2017","January 1, 2018","December 1, 2017","January 1, 2018","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00445744"
488,"NCT00357305","Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders","null","Completed","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes","Drug: vorinostat|Drug: cytarabine|Drug: etoposide|Other: pharmacological study|Other: laboratory biomarker analysis","Maximum tolerated dose (MTD) of vorinostat (SAHA) in combination with cytarabine and etoposide|Response rate|Progression-free survival|Disease-specific survival|One-year survival|Overall survival|Degree of upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-death receptors and proteins associated with apoptosis|Alterations in cell cycle phase|Expression of MDR proteins at MTD of SAHA","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","25","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-00088|GCC 0447|NCI-6829|CDR0000487484","May 2006","November 2011","null","May 2013","July 26, 2006","July 27, 2006","null","null","May 1, 2013","May 3, 2013","University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00357305"
489,"NCT00227591","Lenalidomide and Prednisone in Treating Patients With Myelofibrosis","null","Completed","Has Results","Essential Thrombocythemia|Polycythemia Vera|Primary Myelofibrosis","Drug: lenalidomide|Drug: prednisone|Other: laboratory biomarker analysis","Overall Response Rate","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","48","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02976|ECOG-E4903|E4903|U10CA021115","December 2005","December 2010","December 2010","December 2012","September 26, 2005","September 28, 2005","October 11, 2012","September 26, 2013","May 2, 2014","May 21, 2014","Eastern Cooperative Oncology Group, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT00227591"
490,"NCT00397813","Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders","null","Active, not recruiting","No Results Available","Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndrome|Essential Thrombocythemia|Myeloproliferative Neoplasm|Paroxysmal Nocturnal Hemoglobinuria|Polycythemia Vera|Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase|Primary Myelofibrosis|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Ring Sideroblasts|Refractory Cytopenia With Multilineage Dysplasia|Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts","Drug: Cyclosporine|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Peripheral Blood Stem Cell Transplantation|Radiation: Total-Body Irradiation","Decrease of incidence of HCT failure to less than 20%|Incidence of infections|Kinetics of donor engraftment in peripheral blood and whole bone marrow|Probability of progression-free survival in patients with MPD or MDS-RA and those with CMML or MDS-RAEB|Rate of relapse/progression in patients with MPD or MDS-RA and those with CMML or MDS-RAEB","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)","All","Child, Adult, Senior","Phase 2","77","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2056.00|NCI-2010-00237|P01CA018029|P30CA015704","January 2006","September 18, 2017","September 2022","October 2017","November 9, 2006","November 10, 2006","null","null","October 23, 2017","October 25, 2017","LDS Hospital, Salt Lake City, Utah, United States|Veterans Administration Center-Seattle, Seattle, Washington, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00397813"
491,"NCT00353483","Effect of Chemotherapy Administered Before Surgery on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells","null","Recruiting","No Results Available","Breast Neoplasms","Procedure: Peripheral blood draw|Procedure: Breast tissue collection|Procedure: Bone marrow biopsy","Characterize tumor markers expressed by DTC which are present after chemotherapy.|Compare the expression of these markers to that on DTC detected prior to chemotherapy.|Correlate expression of the defined tumor markers on DTC with clinical outcome of breast cancer patients to identify those markers that are predictive of disease recurrence.|Compare the tumor markers present on DTC before and after chemotherapy with the tumor marker expression of the primary tumor and post-treatment tumor.|To xenograft tumor cells into mice for further genetic and phenotypic characterization.","Washington University School of Medicine","All","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","05-0648 / 201101961","September 14, 2005","August 31, 2021","August 31, 2021","December 2017","July 17, 2006","July 18, 2006","null","null","December 14, 2017","December 18, 2017","Washington University School of Medicine, Saint Louis, Missouri, United States","https://ClinicalTrials.gov/show/NCT00353483"
492,"NCT00381550","3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia","null","Completed","Has Results","Accelerated Phase Chronic Myelogenous Leukemia|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Philadelphia Chromosome Negative Chronic Myelogenous Leukemia|Polycythemia Vera|Primary Myelofibrosis|Relapsing Chronic Myelogenous Leukemia","Drug: fludarabine phosphate|Drug: triapine|Procedure: laboratory biomarker analysis","Response Rate Including Complete Response, Partial Response, and Hematological Improvement Assessed by Blood Cell Counts, Number of Blasts in Bone Marrow, and Clinical Evaluation|Incidence of Grade 3 or 4 Drug-related Non-hematologic Toxicity as Assessed by NCI CTCAE v3.0","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","35","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-00209|J0638|7704|P30CA006973|U01CA070095","August 2006","March 2011","March 2011","June 2014","September 26, 2006","September 28, 2006","April 23, 2014","May 21, 2014","December 16, 2014","January 6, 2015","Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00381550"
493,"NCT00047190","Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia","null","Completed","No Results Available","Essential Thrombocythemia|Polycythemia Vera|Primary Myelofibrosis","Drug: tipifarnib|Other: laboratory biomarker analysis","Confirmed response defined as the objective status of complete response (CR) or partial response (PR) on 2 consecutive evaluations at least 4 weeks apart|Overall survival|Time to progression|Duration of response","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","35","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02804|MC0184|N01CM17104","August 2002","April 2007","null","June 2013","October 3, 2002","January 27, 2003","null","null","June 3, 2013","June 4, 2013","Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00047190"
494,"NCT00255346","Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)","null","Completed","No Results Available","Acute Myeloid Leukemia|Myelodysplastic Syndromes|Agnogenic Myeloid Metaplasia|Myelofibrosis|Hypereosinophilic Syndrome|Polycythemia Vera|Mastocytosis|Leukemia, Myelomonocytic, Chronic","Drug: Dasatinib (BMS-354825)","Participant Response Rate|Duration of Response (Survival)","M.D. Anderson Cancer Center|Bristol-Myers Squibb","All","18 Years and older   (Adult, Senior)","Phase 2","68","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004-0817|NCI-2012-01353","November 15, 2005","March 3, 2017","March 3, 2017","March 2017","November 16, 2005","November 18, 2005","null","null","March 7, 2017","March 9, 2017","The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00255346"
495,"NCT00052520","Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation","null","Completed","No Results Available","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia","Biological: therapeutic allogeneic lymphocytes|Biological: aldesleukin|Procedure: peripheral blood stem cell transplantation|Procedure: allogeneic bone marrow transplantation|Other: laboratory biomarker analysis|Genetic: gene expression analysis|Other: immunologic technique|Other: flow cytometry|Genetic: polymerase chain reaction|Genetic: cytogenetic analysis|Other: staining method","Toxicity rate associated with infusing donor CD8+ CTL clones specific for WT1 in patients at high risk for post transplant relapse of CML, AML, or ALL|Relapse of disease","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 1|Phase 2","37","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1655.00|NCI-2009-01471|P01CA018029","September 2002","April 2011","June 2013","July 2013","January 24, 2003","January 27, 2003","null","null","March 27, 2017","March 29, 2017","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00052520"
496,"NCT00039416","Imatinib Mesylate in Treating Patients With Myelofibrosis","null","Completed","No Results Available","Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Polycythemia Vera|Primary Myelofibrosis","Drug: imatinib mesylate|Other: laboratory biomarker analysis","Clinical responses in terms of improvement in anemia and splenomegaly as previously published for myelofibrosis|Frequency of adverse events graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0|Progression-free survival|Bone marrow response","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","18","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-02895|CDR0000069381|11498A|5669|N01CM62201|P30CA014599","April 2002","August 2007","null","December 2012","June 6, 2002","January 27, 2003","null","null","February 24, 2014","February 25, 2014","University of Chicago, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT00039416"
497,"NCT00038675","Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate","null","Completed","No Results Available","Chronic Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Polycythemia Vera|Hypereosinophilic Syndrome|Mastocytosis","Drug: Imatinib Mesylate (Gleevec)","Objective response rate|Duration of response and survival","M.D. Anderson Cancer Center|Novartis Pharmaceuticals","All","Child, Adult, Senior","","125","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID01-167","June 2001","November 2013","November 2013","December 2013","June 4, 2002","June 5, 2002","null","null","December 10, 2013","December 12, 2013","UT MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00038675"
498,"NCT00113204","Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma","IPi-504-01","Completed","No Results Available","Multiple Myeloma","Drug: IPI-504","To determine the safety and maximum tolerated dose of IPI-504|Recommend a dose for subsequent studies of IPI-504|To examine the pharmacokinetic parameters of IPI-504|To evaluate the potential anti-tumor activity with standard markers of disease progression|To examine pharmacodynamic markers of biologic activity of IPI-504","Infinity Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IPI-504-01","June 2005","March 2007","March 2007","May 2008","June 6, 2005","June 7, 2005","null","null","May 15, 2008","May 20, 2008","Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Hackensack University Medical Center The David Jurist Research Center, Hackensack, New Jersey, United States|St. Vincent's Comprehensive Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00113204"
499,"NCT02641002","A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)","null","Recruiting","No Results Available","Leukemia, Myeloid, Acute|Myelodysplastic Syndromes","Drug: CC-90002","Dose-limiting Toxicity (DLT)|Non-tolerated Dose (NTD)|Maximum tolerated dose (MTD)|Preliminary Efficacy of CC-90002|Pharmacokinetics-Cmax|Pharmacokinetics-AUC|Pharmacokinetics-Tmax|Pharmacokinetics-T 1/2|Pharmacokinetics- CL|Pharmacokinetics- Vss|Anti-Drug Antibodies (ADAs)","Celgene","All","18 Years and older   (Adult, Senior)","Phase 1","71","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CC-90002-AML-001","March 1, 2016","July 10, 2019","July 10, 2019","August 2017","November 12, 2015","December 29, 2015","null","null","August 30, 2017","September 1, 2017","Mayo Clinic Phoenix, Phoenix, Arizona, United States|UCLA Division of Hematology Oncology, Los Angeles, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|University of Chicago, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT02641002"
500,"NCT00458250","Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H","null","Completed","No Results Available","Leukemia, Myeloid, Acute|Leukemia, Lymphoblastic, Acute","Procedure: Haploidentical hematopoietic stem cell transplantation|Drug: Busulfan|Drug: Cyclophosphamide|Drug: CAMPATH-1H|Drug: Cyclosporin A|Drug: Methotrexate","Engraftment one month after transplantation|six months survival","Tehran University of Medical Sciences","All","2 Years to 50 Years   (Child, Adult)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","418-A-1954","September 2006","null","February 2008","November 2008","April 7, 2007","April 10, 2007","null","null","November 15, 2008","November 18, 2008","Hematology-Oncology & BMT Research Center, Tehran, Iran, Islamic Republic of","https://ClinicalTrials.gov/show/NCT00458250"
501,"NCT00964873","A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia","null","Completed","No Results Available","Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Blast-phase Chronic Myelogenous Leukemia|AML|ALL|CML","Drug: STA-9090 (ganetespib)","To assess efficacy in subjects with AML, ALL and blast-phase CML based on standard response criteria|To characterize the safety and tolerability of once-weekly STA-9090 (ganetespib) in subjects with AML, ALL and blast-phase CML","Synta Pharmaceuticals Corp.","All","18 Years and older   (Adult, Senior)","Phase 1","29","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9090-04","August 2009","December 2010","August 2011","September 2014","August 24, 2009","August 25, 2009","null","null","September 17, 2014","September 18, 2014","Tampa, Florida, United States|Baltimore, Maryland, United States|Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00964873"
502,"NCT03218319","Study of the Variations of the Blood Pressure After Nephrectomy for Renal Cancer (VAPANCR)","VAPANCR","Not yet recruiting","No Results Available","Renal Cancer|Nephrectomy|Blood Pressure","Biological: Renin measurement","Blood pressure change|Renal function|Cardiovascular risk","University Hospital, Angers","All","18 Years and older   (Adult, Senior)","","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","49RC17_0004","July 2017","December 2018","December 2018","July 2017","July 11, 2017","July 14, 2017","null","null","July 12, 2017","July 14, 2017","","https://ClinicalTrials.gov/show/NCT03218319"
503,"NCT01247688","Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies","UCALL","Withdrawn","No Results Available","Lymphoid Hematological Malignancies|Umbilical Cord Blood Transplant","Drug: Cytoxan|Drug: Fludarabine|Radiation: Total Body Irradiation (TBI)|Procedure: Cord Blood Stem Cell Infusion","Overall Survival at 1 year after UCB transplant in pediatric patients|Assessment of Platelet Count Recovery|Number of participants with severe acute GVHD grade III-IV as an assessment of safety|Number of participants with chronic GvHD as an assessment of safety|Assess relapse rate after transplant|Assessment of neutrophil count recovery|To evaluate cell recovery and function|Assess leukemia free survival","Baylor College of Medicine|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine","All","Child, Adult, Senior","","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","26336-UCALL","November 2010","December 2013","December 2013","December 2013","November 17, 2010","November 24, 2010","null","null","December 11, 2013","December 12, 2013","","https://ClinicalTrials.gov/show/NCT01247688"
504,"NCT01334437","Blood Test for Ovarian Cancer Associated Auto Antibodies","null","Unknown status","No Results Available","Ovarian Cancer","","Number of participants in each of the clinicaly defined groups (OC, suspected and control).","Eventus Diagnostics Ltd","Female","18 Years and older   (Adult, Senior)","","250","Industry","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","EventusDx_ovary_2011ver2","June 2012","January 2015","January 2015","February 2014","April 12, 2011","April 13, 2011","null","null","February 19, 2014","February 20, 2014","""Carmel"" Medical Center, Haifa, Israel","https://ClinicalTrials.gov/show/NCT01334437"
505,"NCT00923221","Collection of Blood From Patients With Prostate Cancer","null","Recruiting","No Results Available","Prostatic Neoplasms","","Acquisition and longitudinal analysis of genomic DNA from patients with prostate cancer to aid in understanding the mechanisms of prostate carcinogenesis and progression","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Male","18 Years to 100 Years   (Adult, Senior)","","1000","NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","070100|07-C-0100","March 1, 2007","null","null","September 27, 2017","June 17, 2009","June 18, 2009","null","null","October 18, 2017","October 19, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00923221"
506,"NCT02186236","Detection of Oncogenic Tumor Mutations in the Urine and Blood of Lung and Colorectal Cancer Patients","null","Completed","No Results Available","Lung Cancer|Colorectal Cancer","","EGFR detection in urinary cell free DNA [cfDNA]|To validate the Trovagene urine assay|EGFR detection in plasma circulating tumor cells [CTC] and plasma cfDNA)","Memorial Sloan Kettering Cancer Center|Trovagene, Inc.","All","18 Years and older   (Adult, Senior)","","84","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","14-114","July 2014","September 2016","null","September 2016","July 7, 2014","July 10, 2014","null","null","September 26, 2016","September 27, 2016","Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States|Memoral Sloan Kettering Cancer Center at Phelps, Sleepy Hollow, New York, United States|Memorial Sloan Kettering West Harrison, West Harrison, New York, United States","https://ClinicalTrials.gov/show/NCT02186236"
507,"NCT01343849","Blood Test for Breast Cancer Associated Auto Antibodies","null","Unknown status","No Results Available","Breast Cancer","","","Eventus Diagnostics Ltd","Female","18 Years and older   (Adult, Senior)","","1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","EventusDx_breast_2011ver2","September 2011","null","September 2012","November 2011","April 27, 2011","April 28, 2011","null","null","November 20, 2011","November 22, 2011","Eventus Diagnostics, Ora, Jerusalem, Israel","https://ClinicalTrials.gov/show/NCT01343849"
508,"NCT02624271","Diagnosis of Gastric Precancerous Lesions by a Blood Test GastroPanel in Patients With Increased Gastric Cancer Risk","GASTRO-PRA","Not yet recruiting","No Results Available","Gastric Cancer|Gastric Precancerous Lesions","Other: blood samples analysis","Sensitivity of GastroPanel blood test","Nantes University Hospital","All","18 Years and older   (Adult, Senior)","","2000","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RC14_0371","April 2016","April 2016","April 2018","December 2015","December 3, 2015","December 8, 2015","null","null","December 3, 2015","December 8, 2015","Nantes University Hospital, Nantes, France","https://ClinicalTrials.gov/show/NCT02624271"
509,"NCT01987193","Feasibility Study of Tumor Blood Flow Measurement by Detection of Positron Activation Post Proton Therapy (DS01)","null","Enrolling by invitation","No Results Available","Brain Cancer|Prostate Cancer|Lung Cancer","","Patients with hypoxic tumor identified by tumor blood flow measurement.","University of Florida","All","18 Years and older   (Adult, Senior)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UFPTI 1214 - DS01","July 2012","June 2018","June 2020","July 2017","October 24, 2013","November 19, 2013","null","null","July 27, 2017","July 28, 2017","University of Florida Proton Therapy Institute, Jacksonville, Florida, United States","https://ClinicalTrials.gov/show/NCT01987193"
510,"NCT00918008","A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer","null","Terminated","No Results Available","Bladder Cancer","Genetic: Blood draw","Assess the ability of a mononuclear-cell gene signature to predict the presence of metastatic cancer in the regional L.N. of patients with muscle-invasive bladder cancer at the time of cystectomy with PLND for presumed localized muscle-invasive disease.|Assess the ability of a mononuclear-cell gene signature, alone or in combination with pathological staging, to predict any metastatic disease w/i 2 yrs of cystectomy with PLND in pts. with clinical organ-confined muscle-invasive bladder cancer staging.","Memorial Sloan Kettering Cancer Center|New York Presbyterian Hospital|Weill Medical College of Cornell University","Male","18 Years and older   (Adult, Senior)","","12","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","09-054","June 2009","May 2011","May 2011","March 2015","June 10, 2009","June 11, 2009","null","null","March 4, 2015","March 6, 2015","Memorial Sloan Kettering Cancer Center, New York, New York, United States|New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00918008"
511,"NCT01251666","Comparison of Hemoccult, Magstream and OC-Sensor Faecal Occult Blood Tests in Colorectal Cancer Screening","HeMO","Completed","No Results Available","Colorectal Cancer","Other: Colonoscopy","Ratio of sensitivities (RSN) for detection of advanced neoplasias|Ratio of False Positives (RFP) for detection of invasive cancers|RFP for detection of advanced neoplasias|Relative Receiver Operating Characteristics(ROC) curves|Detection rate of invasive cancer|Detection rate of advanced neoplasias|Cost-effectiveness analysis|Predictive positive value for detection of invasive cancers|Predictive value for detection of advanced neoplasias|Positivity rate","University Hospital, Caen|National Cancer Institute, France|Ligue contre le cancer, France","All","50 Years to 74 Years   (Adult, Senior)","Phase 3","19797","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Screening","2008-A01463-52","June 2008","June 2012","August 2012","August 2012","November 29, 2010","December 2, 2010","null","null","August 31, 2012","September 3, 2012","ADECA, Moulins, France|Adoc18 - Irsa, St Doulchard, France","https://ClinicalTrials.gov/show/NCT01251666"
512,"NCT00355316","A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients","null","Completed","No Results Available","Breast Neoplasms","Other: Blood draw","The prevalence of breast cancer cells in the peripheral blood|Evaluate the prognostic significance of molecular detection of breast cancer cells in peripheral blood after initiation of systemic therapy.|Quantify baseline molecular marker expression levels in the peripheral blood of healthy volunteers|Compare molecular analyses to the results of the CellSeach assay","Washington University School of Medicine|National Institutes of Health (NIH)","Female","18 Years and older   (Adult, Senior)","","224","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","05-0435 / 201109033","November 2005","November 2012","February 2013","June 2013","July 19, 2006","July 21, 2006","null","null","June 19, 2013","June 21, 2013","Washington University School of Medicine, St. Louis, Missouri, United States|Medical University of South Carolina, Charleston, South Carolina, United States","https://ClinicalTrials.gov/show/NCT00355316"
513,"NCT00579462","Methylated Genes in Blood as Biomarkers for Advanced Lung Cancer","null","Completed","No Results Available","Lung Cancer","Other: Blood and Tissue studies","To measure the proportion of patients with advanced (stage IIIB/IV) lung cancer with methylated genes in their blood and determine if response to chemotherapy (CR or PR radiologic response) renders methylated genes undetectable in blood.|To collect data regarding time to disease progression in order to explore whether pretreatment and/or posttreatment blood levels of methylated genes are associated with an increased chance of disease progression.","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|University of Southern California","All","Child, Adult, Senior","","281","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","02-111","January 2003","November 2010","November 2010","November 2010","December 19, 2007","December 24, 2007","null","null","November 30, 2010","December 1, 2010","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00579462"
514,"NCT01586520","Diagnosing Thyroid Cancer Using a Blood Test","null","Completed","No Results Available","Differentiated Thyroid Cancer","","Proteomic markers of differentiated thyroid cancer|Genetic markers of diffferentiated thyroid cancer","Newcastle-upon-Tyne Hospitals NHS Trust","All","18 Years and older   (Adult, Senior)","","400","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","5559","April 2011","October 2014","December 2016","September 2017","April 25, 2012","April 26, 2012","null","null","September 14, 2017","September 15, 2017","Sir Bobby Robson Cancer Researhc Unit, Newcastle upon Tyne, Tyne and Wear, United Kingdom|Sir Bobby Robson Cancer Research Unit, Northern Centre for cancer care, Newcastle upon Tyne, United Kingdom","https://ClinicalTrials.gov/show/NCT01586520"
515,"NCT00210197","Hypercoagulability After Breast Cancer Surgery","EHC","Completed","No Results Available","Breast Cancer|Blood Coagulation Disorders","Procedure: Blood collection (pre and postoperative): plasma coagulation parameters","","Institut Bergonié","Female","18 Years and older   (Adult, Senior)","","48","Other","Observational","Time Perspective: Prospective","IB2005-06|EHC","January 2005","null","January 2006","October 2007","September 13, 2005","September 21, 2005","null","null","July 25, 2013","July 26, 2013","Institut Bergonié - Centre Régional de Luttre Contre le Cancer de Bordeaux et du Sud Ouest, Bordeaux, France","https://ClinicalTrials.gov/show/NCT00210197"
516,"NCT00514579","Adult Double Cord Blood Transplant Study","null","Completed","No Results Available","Cord Blood Stem Cell Transplantation|Hematologic Malignancies","Procedure: Cord blood transplantation","Measure overall survival of double unit UCBT in adult patients with hematologic malignancies|Measure incidence of donor-derived neutrophil and platelet recovery|Measure contribution of each unit to initial and sustained engraftment|Measure incidence and severity of acute graft-versus-host disease|Measure incidence and severity of chronic GVHD|Measure incidence of transplant-related mortality|Measure incidence of malignant relapse|Measure incidence of serious infectious complications|Measure incidence of immune reconstitution|Measure probability of overall and disease-free survival","Center for International Blood and Marrow Transplant Research","All","22 Years to 50 Years   (Adult)","Phase 2","56","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05-DCB","August 2007","August 2013","August 2013","March 2014","August 8, 2007","August 10, 2007","null","null","March 7, 2014","March 10, 2014","City of Hope, Duarte, California, United States|University of California at Los Angeles, Los Angeles, California, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|University of Wisconsin-Madison, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT00514579"
517,"NCT00899405","Studying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer","null","Recruiting","No Results Available","Lung Cancer","","Mutational status of the EGFR pathway","University of California, Davis","All","18 Years and older   (Adult, Senior)","","800","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CDR0000583056|UCD-155|UCD-200412410","May 2005","December 2017","December 2018","January 2017","May 9, 2009","May 12, 2009","null","null","January 19, 2017","January 23, 2017","University of California Davis Cancer Center, Sacramento, California, United States","https://ClinicalTrials.gov/show/NCT00899405"
518,"NCT03343691","Blood Test for Early Detection of Breast Cancer Using Todos Medical -Breast 1(TM-B1) Assay","TM-B1","Not yet recruiting","No Results Available","Breast Cancer","Diagnostic Test: Screening Population|Diagnostic Test: Breast Cancer Population","This study is intended to evaluate the sensitivity and specificity of the TM-B1 test compared to the Gold Standard diagnostic methods and clinical evaluations based on Digital X-Ray Mammography (XRM), and / or ultrasound, and / or MRI and / or pathology.|For asymptomatic women who have dense breast tissue (parenchymal density > 50% on XRM), evaluate the performance, in terms of sensitivity and specificity, of the TM-B1 test and XRM together as a breast cancer screening procedure compared to the XRM alone","Todos Medical, Ltd.","Female","25 Years and older   (Adult, Senior)","","200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IL-TM-B1-01","December 2017","June 2018","July 2018","November 2017","November 12, 2017","November 17, 2017","null","null","November 29, 2017","November 30, 2017","","https://ClinicalTrials.gov/show/NCT03343691"
519,"NCT00531778","NYU Ovarian Cancer Early Detection Program Blood and Genetics","null","Terminated","No Results Available","Ovarian Cancer","","identification and development of highly sensitive and specific tumor markers for ovarian cancer","New York University School of Medicine","Female","18 Years and older   (Adult, Senior)","","890","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NYU 04-30 H11938","June 2004","null","November 2010","January 2011","September 18, 2007","September 19, 2007","null","null","January 10, 2011","January 11, 2011","NYUCancer Institute Clinical Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00531778"
520,"NCT02304978","Prognostic Value of Tissue Factor (TF) in Blood t in Colorectal Cancer in Adults","TF","Recruiting","No Results Available","Colorectal Cancer","Biological: Group CRC|Biological: Group control","TNM primary colorectal tumor stage|TF (blood levels of soluble TF)|TF intratumoral (blood levels of TF intratumoral)|E- selectin and CRP|ACE|Interaction plate / tumor cell","University Hospital, Lille","All","18 Years and older   (Adult, Senior)","Early Phase 1","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2008-09/0908|2009-A00264-53","June 22, 2009","June 2018","June 2020","November 2017","June 24, 2014","December 2, 2014","null","null","November 8, 2017","November 9, 2017","Service de Chirurgie Digestive et de transplantation Hôpital Claude HURIEZ, Lille, France","https://ClinicalTrials.gov/show/NCT02304978"
521,"NCT00264095","An Observational Study of Blood Management Techniques in Oncology Surgical Treatment","null","Completed","No Results Available","Anemia|Blood Loss, Surgical|Neoplasms","Procedure: Oncological surgery","Patients' medical history; tumor stage; type/site of operation; anticipated vs. actual blood loss; hemoglobin/hematocrit values prior to surgery, blood-saving techniques used; number of units and types of blood transfusions up to 24 hours after surgery|Frequency of use of different blood-saving techniques for the various types of operations performed from each of the centers participating in the study","Janssen-Cilag B.V.","All","18 Years and older   (Adult, Senior)","Phase 4","488","Industry","Observational","Time Perspective: Cross-Sectional","CR003460|EPOSUR4001","July 2004","February 2006","February 2006","April 2014","December 9, 2005","December 12, 2005","null","null","April 25, 2014","April 28, 2014","Alkmaar, Netherlands|Amersfoort, Netherlands|Apeldoorn, Netherlands|Deventer, Netherlands|Dordrecht, Netherlands|Drachten, Netherlands|Nieuwegein, Netherlands|Nijmegen, Netherlands|Roosendaal, Netherlands|Sneek, Netherlands|Zwolle, Netherlands","https://ClinicalTrials.gov/show/NCT00264095"
522,"NCT02758678","Analysis of P-Selectin Expression on Platelets of Blood From Lung Cancer Patients","null","Completed","No Results Available","Lung Cancer","Biological: A single 2 ml heparinised peripheral blood sample","Assessment of the concentration of P-selectin in 3 groups in lung cancer patients and compared to the healthy participants.","Science and Technology Park, Center of Innovation Technologies for Human Health|University in Zielona Góra","All","40 Years to 80 Years   (Adult, Senior)","","40","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Science and Technology Park,|2/07/2015","November 2015","October 2016","October 2016","October 2016","April 18, 2016","May 2, 2016","null","null","October 17, 2016","October 19, 2016","Park Naukowo-Technologiczny Uniwersytetu Zielonogórskiego Sp. z o.o., Zielona Góra, Lubuskie, Poland","https://ClinicalTrials.gov/show/NCT02758678"
523,"NCT02479230","Pilot Trial of Type I-Polarized Autologous Dendritic Cell Vaccine Incorporating Tumor Blood Vessel Antigen-Derived Peptides in Patients With Metastatic Breast Cancer","null","Recruiting","No Results Available","Breast Cancer|Metastatic Breast Cancer","Biological: tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine|Drug: gemcitabine hydrochloride","Number of toxicities|mean change in Type-1 immune function|Number of patients with clinical response","Joseph Baar, MD, PhD|Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE3113|NCI-2014-00265","July 17, 2015","June 30, 2018","June 30, 2018","April 2017","June 19, 2015","June 24, 2015","null","null","April 17, 2017","April 18, 2017","University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT02479230"
524,"NCT00428896","A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer","null","Completed","No Results Available","Breast Cancer","Drug: ZD1839","Efficacy of ZD1839 by quantitative analysis of CK-19 mRNA CTCs|To assess duration of response by means of CK-19 mRNA detection|To assess Progression Free Survival by means of CK-19 mRNA detection|To assess the safety of ZD1839 administration in this patient population","University Hospital of Crete","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MICRO","April 2005","March 2008","March 2008","July 2008","January 29, 2007","January 30, 2007","null","null","July 18, 2008","July 21, 2008","University Hospital of Crete, Heraklion, Crete, Greece","https://ClinicalTrials.gov/show/NCT00428896"
525,"NCT01141218","Internet-Based Clinical Information and Blood Sample Collection From Patients With Non-Small Cell Lung Cancer Who Never Smoked Cigarettes","null","Terminated","No Results Available","Lung Cancer","Other: internet-based protocol and physician referral","Feasibility of an internet-based protocol to collect clinical information and biological specimens|Identification of alleles that predispose to lung cancer via genome-wide association studies","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","88","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","VICC THO 0938|P30CA068485|VU-VICC-THO-0938|IRB# 090568","July 2009","August 2012","September 2012","April 2017","June 9, 2010","June 10, 2010","null","null","April 21, 2017","April 25, 2017","Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT01141218"
526,"NCT01712971","Reduced Intra-operative Blood Loss in Pancreaticoduodenectomy for Pancreatic or Peri-ampullary Tumors; Monocentric Trial on Standard Open Versus Minimally Invasive Surgery","null","Withdrawn","No Results Available","Surgery|Pancreatic Tumour|Peri-ampullary Tumour|Blood Loss","","intra-operative blood loss|Surgical resection margin|length of hospital stay after surgery|hospital costs","Baki Topal|University Hospital, Gasthuisberg","All","18 Years to 80 Years   (Adult, Senior)","","0","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","LPD","November 2012","January 2014","June 2014","September 2013","October 18, 2012","October 24, 2012","null","null","September 16, 2013","September 17, 2013","University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium","https://ClinicalTrials.gov/show/NCT01712971"
527,"NCT02502656","RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer","RASANC","Recruiting","No Results Available","Colorectal Cancer","","Concordance regarding the mutation of RAS (yes vs no, dichotomous variable) between the two methods|Concordance regarding the mutation of RAS (yes vs no, dichotomous variable) between the two methods in patients for whom circulating tumor DNA has been identified in the avalaible plasma sample.|Comparison of the timelines to obtain results between the two methods|Comparisons of the costs between the two methods","Association des Gastroentérologues Oncologues","All","18 Years and older   (Adult, Senior)","","425","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RASANC","July 2015","August 2017","August 2017","November 2016","July 16, 2015","July 20, 2015","null","null","November 16, 2016","November 17, 2016","Hôpital Avicenne, Bobigny, France|Hopital Béclère, Clamart, France|Hopital Henri Mondor, Creteil, France|Hopital Kremlin-Bicêtre, Kremlin-Bicêtre, France|CH Longjumeau et Sud, Longjumeau, France|Hopital Mermoz, Lyon, France|Hopital Cochin, Paris, France|Hopital Saint-Antoine, Paris, France|Hopital Saint-Louis, Paris, France|Hôpital Européen Georges Pompidou, Paris, France|Hôpital Pitié Salpêtrière, Paris, France|CHU Poitiers, Poitiers, France|CHU Robert Debré, Reims, France|Hôpital Trousseau, Tours, France","https://ClinicalTrials.gov/show/NCT02502656"
528,"NCT01707758","Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence","null","Withdrawn","No Results Available","Pancreatic Cancer","","","University of Kansas|University of Kansas Medical Center","All","18 Years and older   (Adult, Senior)","","0","Other","Observational","Time Perspective: Prospective","13421","October 2012","February 2013","February 2013","May 2013","October 12, 2012","October 16, 2012","null","null","May 15, 2013","May 16, 2013","","https://ClinicalTrials.gov/show/NCT01707758"
529,"NCT00906997","Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy","null","Active, not recruiting","No Results Available","Colorectal Cancer|Colorectal Neoplasm","Procedure: Immunochemical fecal occult blood test|Procedure: Colonoscopy","Colorectal cancer-related mortality|Compliance rate|Complication rate|Colorectal cancer incidence|Adherence rate|Advanced colorectal neoplasm detection rate","Hospital Clinic of Barcelona|Grupo Cooperativo para el Cribado del Cancer Colorrectal en España.|Gastrointestinal Oncology Group of the Spanish Gastroenterological Association|Fundacion Cientifica de la Asociacion Española contra el Cancer|Instituto de Salud Carlos III","All","50 Years to 69 Years   (Adult, Senior)","Phase 3","55498","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","COLONPREV","November 2008","November 2021","November 2021","March 2015","May 19, 2009","May 21, 2009","null","null","March 31, 2015","April 1, 2015","Hospital del Mar, Barcelona, Spain|Hospital Clínico, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Meixoeiro, Ourense, Spain|Hospital de Donosti, San Sebastián, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Comunidad Valencia, Valencia, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT00906997"
530,"NCT01704664","Perioperative Immunonutrition, Phagocytic and Bactericidal Activity of Blood Platelets in Gastric Cancer Patients","null","Recruiting","No Results Available","Gastric Cancer","Dietary Supplement: Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb)|Drug: glutamine|Dietary Supplement: oral diet enriched with arginine (Cubitan)|Drug: Perioperative parenteral immunonutrition (Dipeptiven, Omegaven)","Phagocytic activity of blood platelets in gastric cancer patients.","Medical University of Bialystok","All","18 Years and older   (Adult, Senior)","","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","3-37878 L","March 2007","December 2017","March 2018","September 2017","September 26, 2012","October 11, 2012","null","null","September 4, 2017","September 6, 2017","Medical University of Bialystok, Bialystok, Podlaskie, Poland","https://ClinicalTrials.gov/show/NCT01704664"
531,"NCT01240681","Blood Oxygen Level Dependent Magnetic Resonance Imaging (BOLD MRI) and Fluorothymidine Positron Emission Tomography (FLT PET) in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy","IMPACT","Completed","No Results Available","Locally Advanced Breast Cancer (LABC)","Procedure: FLT PET and BOLD MRI scan","Clinical response (partial and complete)|Pathologic response|Imaging Quantification","Ontario Clinical Oncology Group (OCOG)","Female","18 Years and older   (Adult, Senior)","","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","OCOG-2010-IMPACT","April 2011","January 2015","January 2015","March 2015","November 1, 2010","November 15, 2010","null","null","March 10, 2015","March 11, 2015","Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Health Sciences Centres - London Regional Cancer Program, London, Ontario, Canada|Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada|Sunnybrook Odette Health Sciences Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT01240681"
532,"NCT00429572","Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer","null","Completed","Has Results","Breast Cancer","Drug: Fludarabine|Drug: Melphalan|Procedure: Stem Cell Infusion","Number of Participants With Tumor Response|Overall Survival|Time to Progressive Disease|Grade II-IV Toxicity|Number of Participants With Acute or Chronic GVHD And Response to Therapy","M.D. Anderson Cancer Center","All","18 Years to 60 Years   (Adult)","Phase 2","19","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DM97-268","January 1998","May 2008","May 2008","August 2012","January 29, 2007","January 31, 2007","September 25, 2009","July 13, 2011","August 1, 2012","August 7, 2012","U.T.M.D. Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00429572"
533,"NCT00898482","Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants","null","Completed","No Results Available","Pancreatic Cancer","Other: This is a non-intervention study for all groups.|Other: study of socioeconomic and demographic variables","Establishment of a central pancreatic cancer specimen repository|Utilization of the clinical database to perform clinicopathologic correlation with the results of current or future scientific studies|Test new hypotheses as they emerge","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","","88","Other|NIH","Observational","Observational Model: Case-Only","JHOC-J0533 CDR0000452792|P30CA006973|JHOC-J0533|JHOC-05042601","May 2005","June 2011","June 2011","November 2015","May 9, 2009","May 12, 2009","null","null","November 17, 2015","November 20, 2015","","https://ClinicalTrials.gov/show/NCT00898482"
534,"NCT03235765","Cancer Panel From Blood of Lung Cancer Patients","CAPABLE","Recruiting","No Results Available","Non Small Cell Lung Cancer Metastatic|Non Small Cell Lung Cancer Recurrent","Diagnostic Test: MACROGEN Pan Cancer Panel (Tier 2)","Concordance rate|Overall survival|Frequency of actionable genomic change|Overall survival by treatment","Seoul National University Hospital|MACROGEN","All","20 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SNUBH-17-01","March 10, 2017","March 10, 2018","March 10, 2020","July 2017","July 28, 2017","August 1, 2017","null","null","July 28, 2017","August 1, 2017","Seoul National University Bundang Hospital, Seongnam, Korea, Republic of","https://ClinicalTrials.gov/show/NCT03235765"
535,"NCT01015820","Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer","null","Completed","Has Results","Pancreatic Cancer","Procedure: EGD with EUS|Device: 4D-ELF","Deoxyhemoglobin Concentration (DHb)|Mean Blood Vessel Radius (BVR)","Mayo Clinic|Northwestern University|National Cancer Institute (NCI)|National Institute for Biomedical Imaging and Bioengineering (NIBIB)","All","18 Years and older   (Adult, Senior)","","37","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","09-002596|R01CA128641|R01CA156186|R01EB003682|U01CA111257|CBET-1240416","June 2010","October 2012","October 2012","July 2014","November 12, 2009","November 18, 2009","May 29, 2014","July 2, 2014","July 3, 2014","July 16, 2014","Mayo Clinic Florida, Jacksonville, Florida, United States","https://ClinicalTrials.gov/show/NCT01015820"
536,"NCT02113852","Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients","CHOICE","Completed","No Results Available","Non Small Cell Lung Cancer","","whole genome copy number variation in NSCLC patients|Establish more effective therapy for lung cancer treatment in the future","Guangdong Association of Clinical Trials","All","18 Years and older   (Adult, Senior)","","250","Other","Observational","Observational Model: Other|Time Perspective: Other","CTONG 1308","August 2013","May 2016","December 2016","February 2017","March 24, 2014","April 15, 2014","null","null","February 28, 2017","March 1, 2017","","https://ClinicalTrials.gov/show/NCT02113852"
537,"NCT01966510","Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies","LYMPHCORD","Completed","No Results Available","Patients With Advanced Lymphoid Malignancies in the Absence of an HLA Identical or Mismatch Donor","Other: Cord Blood Transplantation","Overall survival|Engraftment|Chimerism|Acute Graft versus host disease (GvHD)|Chronic graft versus host disease (GVHD)|Immunologic reconstitution|Incidence of severe infectious complications|Relapse rate|Relapse free survival|toxicity","Assistance Publique - Hôpitaux de Paris","All","18 Years to 65 Years   (Adult)","Phase 2","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P110145","March 2013","March 2015","December 2017","December 2017","October 17, 2013","October 21, 2013","null","null","December 7, 2017","December 8, 2017","Saint Louis hospital, Paris, France","https://ClinicalTrials.gov/show/NCT01966510"
538,"NCT02423785","Ocular Blood Flow in Colorectal Cancer Patients","null","Recruiting","No Results Available","Metastatic Colorectal Cancer","","Correlation between ocular blood flow (retinal blood flow) and treatment response|Correlation between retinal vessel diameter and treatment response|Changes in retinal surface before and after therapy as measured by optical coherence tomography","Medical University of Vienna","All","18 Years to 99 Years   (Adult, Senior)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","OBF-13","May 2014","May 2018","null","September 2016","July 31, 2014","April 22, 2015","null","null","September 12, 2016","September 14, 2016","Medical University of Vienna, Vienna, Austria","https://ClinicalTrials.gov/show/NCT02423785"
539,"NCT01313442","Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer","null","Recruiting","No Results Available","Non-GI Cancers|Cancer of Gastrointestinal Tract|Gastrointestinal Cancer","","Collected blood, normal tissue, tumor samples from patients withgastrointestinal (GI) cancers being reviewed by Medical OncologyBranch and to perform immune studies","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","","500","NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","110112|11-C-0112","March 10, 2011","null","null","August 1, 2017","March 10, 2011","March 11, 2011","null","null","October 18, 2017","October 19, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT01313442"
540,"NCT00580203","Collection Of Tissue, Blood, and Other Specimens From Patients With Head and Neck Tumors To Study the Causes, Diagnosis, Prevention and Treatment of Cancers","null","Active, not recruiting","No Results Available","Head and Neck Cancers","","Collect tissues, blood, and other specimens from patients with malignant or nonmalignant diseases of the head and neck. Specimens will be used to investigate growth, development, and transformation of normal and abnormal cells in the future.","Memorial Sloan Kettering Cancer Center|American Cancer Society, Inc.","All","Child, Adult, Senior","","1307","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","04-017","February 2004","December 2018","December 2018","November 2017","December 19, 2007","December 24, 2007","null","null","November 6, 2017","November 8, 2017","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00580203"
541,"NCT00899756","Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer","null","Unknown status","No Results Available","Lung Cancer","Genetic: molecular diagnostic method|Genetic: mutation analysis","Existence of epidermal growth factor receptor (EGFR) mutations in peripheral blood|Frequency of EGFR mutation|Correlation of the presence of EGFR mutation in blood with EFGR mutation in primary or metastatic tumor tissue","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","50","Other|NIH","Observational","","CDR0000491609|JHOC-JS0538|JHOC-06-03-07-01","June 2006","null","null","July 2009","May 9, 2009","May 12, 2009","null","null","July 7, 2009","July 8, 2009","Johns Hopkins Singapore International Medical Centre, Singapore, Singapore","https://ClinicalTrials.gov/show/NCT00899756"
542,"NCT00745160","Survey and Blood Sample Collection for Patients With Lung Cancer Who Never Smoked Cigarettes","null","Completed","No Results Available","Lung Cancer","Other: blood sample and questionnaire","To assess the feasibility of an internet-based protocol to collect clinical information and biological specimens from 2,000 never smokers with lung cancer.","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Senior)","","115","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","08-104","August 2008","August 2010","August 2010","March 2011","September 2, 2008","September 3, 2008","null","null","March 29, 2011","March 30, 2011","Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States|Memoral Sloan Kettering Cancer Center@Phelps, Sleepy Hollow, New York, United States","https://ClinicalTrials.gov/show/NCT00745160"
543,"NCT00437879","Pilot Investigation of Ultrasound Imaging and Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Locally-Advanced Breast Cancer Response to Neoadjuvant Treatment","null","Recruiting","No Results Available","Locally Advanced Breast Cancer","","","Sunnybrook Health Sciences Centre","Female","Child, Adult, Senior","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","185-2006","January 2007","January 2019","January 2019","May 2017","February 20, 2007","February 21, 2007","null","null","May 1, 2017","May 3, 2017","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT00437879"
544,"NCT02390739","Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer","null","Withdrawn","No Results Available","Metastatic Thyroid Cancer","Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-Thyroglobulin mTCR PBL","Determine a safe dose of administration and determine if this approach will result in an objective tumor regression.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","0","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","150090|15-C-0090","March 2, 2015","March 22, 2017","March 22, 2017","March 22, 2017","March 17, 2015","March 18, 2015","null","null","July 26, 2017","July 27, 2017","","https://ClinicalTrials.gov/show/NCT02390739"
545,"NCT02869269","A Study of Circulating Immune Cell Activity Changes in Blood of Colorectal Cancer Patients","null","Recruiting","No Results Available","Colorectal Cancer","Device: Early stage|Device: Late stage","Circulating helper T cell activity|Cytotoxic T cell and natural killer cell activity","Konkuk University Medical Center","All","20 Years and older   (Adult, Senior)","","300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","KUH1160096","October 2015","October 2018","October 2018","August 2016","July 15, 2016","August 16, 2016","null","null","August 11, 2016","August 16, 2016","Konkuk University Medical Center, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT02869269"
546,"NCT01075633","Colorectal Cancer Screening in Familiar-Risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy","COLONFAM","Completed","No Results Available","Colorectal Cancer","Procedure: Immunochemical fecal occult blood test And colonoscopy if test is positive|Procedure: Colonoscopy with sedation","Advanced colorectal neoplasm detection rate [Time Frame: 2 years] [Designated as safety issue: No]|Complications rate","Enrique Quintero|Fundación Canaria Rafael Clavijo para la Investigación Biomédica","All","40 Years to 75 Years   (Adult, Senior)","Phase 3","1501","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","COLONFAM","January 2006","December 2011","June 2013","January 2014","February 24, 2010","February 25, 2010","null","null","January 7, 2014","January 8, 2014","Hospital Universitario de Canarias, Tenerife, Spain","https://ClinicalTrials.gov/show/NCT01075633"
547,"NCT03195569","To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer","null","Recruiting","No Results Available","Non Small Cell Lung Cancer","Drug: QL1101|Drug: Avastin®|Drug: Paclitaxel|Drug: Carboplatin","Objective response rate|Number of circulating endothelial cell subsets|The strength of intratumoral blood perfusion index(BV,BF,PS and MTT)|Disease control rate|Treatment-emergent adverse events","Qilu Pharmaceutical Co., Ltd.|Tianjin Medical University Cancer Institute and Hospital","All","18 Years to 75 Years   (Adult, Senior)","","15","Industry|Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","QL1101","March 1, 2017","June 12, 2018","December 10, 2018","June 2017","June 20, 2017","June 22, 2017","null","null","June 21, 2017","June 22, 2017","Tianjin Medical University Cancer Institute and Hospital, Tainjin, China","https://ClinicalTrials.gov/show/NCT03195569"
548,"NCT03256630","Evaluation of Urine and Blood Biomarkers to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer","null","Not yet recruiting","No Results Available","Prostate Cancer","","Characterize the distribution of clinical/pathological factors of the samples by the Gleason Grade Group and to characterize the distribution of the signal of each biomarker by the Gleason Grade Group or combination of groups.","Genomic Health®, Inc.|Global Robotics Institute","Male","Child, Adult, Senior","","240","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","09-048","September 2017","May 2018","May 2018","August 2017","August 16, 2017","August 22, 2017","null","null","August 17, 2017","August 22, 2017","","https://ClinicalTrials.gov/show/NCT03256630"
549,"NCT01802970","Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients","null","Unknown status","No Results Available","Metastatic Breast Cancer","Drug: Anakinra plus Standard of Care","Safety - Adverse Events in participants|To determine investigator-assessed objective response rate, clinical benefit rate, progression-free survival, and rates of chemotherapy or cancer-related anemia (HgB<10), and an anakinra-induced anti-IL-1 blood transcriptional signatures","Baylor Research Institute","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","012-099","December 2012","December 2016","December 2016","January 2016","February 28, 2013","March 4, 2013","null","null","January 13, 2016","January 14, 2016","Baylor University Medical Center, Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT01802970"
550,"NCT02063464","Blood Collection From People With Ovarian Cancer","null","Completed","No Results Available","Ovarian Cancer|Cancer of the Ovary|Ovarian Neoplasms","","To obtain blood samples from patients with ovarian cancer","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Female","18 Years to 100 Years   (Adult, Senior)","","85","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","140056|14-C-0056","February 13, 2014","November 16, 2016","November 16, 2016","October 30, 2017","February 13, 2014","February 14, 2014","null","null","November 7, 2017","November 8, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT02063464"
551,"NCT00625625","Lymphatic Mapping, Sentinel Lymph Node Analysis, and Blood Tests in Detecting and Predicting Early Micrometastases in Patients With Colorectal Cancer","null","Unknown status","No Results Available","Colorectal Cancer","Drug: isosulfan blue|Genetic: polymerase chain reaction|Other: diagnostic laboratory biomarker analysis|Other: immunohistochemistry staining method|Procedure: diagnostic lymphadenectomy|Procedure: therapeutic conventional surgery|Procedure: therapeutic lymphadenectomy","Sensitivity and accuracy of lymphatic mapping in colorectal cancer|Overall survival|Disease-free survival","John Wayne Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","225","Other|NIH","Interventional","Primary Purpose: Diagnostic","CDR0000586464|JWCI-GULS-CRCSLN-0104","March 2004","November 2007","null","February 2008","February 27, 2008","February 28, 2008","null","null","September 16, 2013","September 17, 2013","","https://ClinicalTrials.gov/show/NCT00625625"
552,"NCT00588029","Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer","null","Active, not recruiting","No Results Available","Breast Cancer","","None. This is a tissue banking study.","Memorial Sloan Kettering Cancer Center|Memorial University Medical Center","All","18 Years and older   (Adult, Senior)","","7000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","99-030","July 1999","December 2018","December 2018","October 2017","December 24, 2007","January 8, 2008","null","null","October 3, 2017","October 4, 2017","Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan-Kettering Cancer, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00588029"
553,"NCT01514669","Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer","null","Active, not recruiting","No Results Available","Prostate Cancer","","Tear Sample","University of Arkansas","Male","35 Years to 80 Years   (Adult, Senior)","","75","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","133719","January 2012","February 2019","February 2019","March 2017","January 17, 2012","January 23, 2012","null","null","March 6, 2017","March 7, 2017","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States","https://ClinicalTrials.gov/show/NCT01514669"
554,"NCT00652691","Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer","null","Active, not recruiting","No Results Available","Ovarian Cancer|Peritoneal Cavity Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: topotecan hydrochloride|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Maximum tolerated dose of topotecan hydrochloride|Toxicity according to NCI criteria","Mayo Clinic|National Cancer Institute (NCI)","Female","18 Years to 70 Years   (Adult, Senior)","Phase 1","48","Other|NIH","Interventional","Primary Purpose: Treatment","976101|P30CA015083|1056-98","August 1998","December 2017","December 2017","April 2016","April 3, 2008","April 4, 2008","null","null","March 21, 2017","March 22, 2017","","https://ClinicalTrials.gov/show/NCT00652691"
555,"NCT00812942","Participation to Colorectal Cancer Screening With Fecal Occult Blood Test and Colonoscopy","null","Completed","No Results Available","Colorectal Cancer","Procedure: colonoscopy|Procedure: faecal test","Participation to colorectal cancer screening","Istituto Superiore di Sanità","All","55 Years to 64 Years   (Adult)","","9889","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1","November 2003","November 2005","November 2008","December 2008","December 18, 2008","December 22, 2008","null","null","December 19, 2008","December 22, 2008","IIstituto Nazionale Tumori Regina Elena, Rome, Italy","https://ClinicalTrials.gov/show/NCT00812942"
556,"NCT00306137","Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer","null","Terminated","No Results Available","Blood Loss, Surgical","Drug: Trasylol (Aprotinin, BAYA0128)|Drug: Placebo","Percent of patients requiring a blood transfusion anytime in the intra-operative or post-operative period|Number of units of blood or packed red cells transfused|Number of units transfused per patient|Intra-operative blood loss|Drainage volume|Transfusion of platelets, colloids and plasma|Change from pre-operative to post-operative hemoglobin concentration|Surgeon's assessment of obscurement of operative field by bleeding|Blood markers of inflammation and coagulation|Time to discontinuation of mechanical ventilation|Health related quality of life measurements","Bayer","All","18 Years and older   (Adult, Senior)","Phase 3","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","11800|EudraCT: 2005-004689-18","December 2005","null","March 2007","December 2014","March 21, 2006","March 23, 2006","null","null","December 8, 2014","December 9, 2014","Atlanta, Georgia, United States|Augusta, Georgia, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Boston, Massachusetts, United States|St. Louis, Missouri, United States|Durham, North Carolina, United States|Cleveland, Ohio, United States|Pittsburgh, Pennsylvania, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|ask Contact, Australia|ask Contact, Austria|ask Contact, Belgium|ask Contact, Canada|ask Contact, Denmark|ask Contact, France|ask Contact, Germany|ask Contact, Spain|ask Contact, United Kingdom","https://ClinicalTrials.gov/show/NCT00306137"
557,"NCT02349347","A Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles in Patients With Castration-resistant Prostate Cancer (CRPC)","MEL-CAP","Unknown status","No Results Available","Prostate Cancer","Drug: Melphalan|Drug: Lenograstim","Progression free survival (PFS) rate at 6 months according to PCWG2 criteria","Queen Mary University of London","Male","18 Years and older   (Adult, Senior)","Phase 2","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEL-CAP","December 2012","November 2017","null","January 2015","January 23, 2015","January 28, 2015","null","null","January 27, 2015","January 28, 2015","St Bartholomews Hospital, London, United Kingdom","https://ClinicalTrials.gov/show/NCT02349347"
558,"NCT01899391","Periperal Blood Lymphocytes During Prostate RT","null","Withdrawn","No Results Available","Prostate Cancer","","Gamma H2AX in peripheral blood lymphocytes.|Gamma H2AX following RT planning (CT scan).|Gamma H2AX during RT","University Health Network, Toronto","Male","18 Years and older   (Adult, Senior)","","0","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UHN REB 09-0136-CE","August 2009","March 2013","March 2013","July 2013","June 11, 2013","July 15, 2013","null","null","July 10, 2013","July 15, 2013","","https://ClinicalTrials.gov/show/NCT01899391"
559,"NCT02284633","Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer","null","Recruiting","No Results Available","Lung Neoplasms","","Progression Free Survival","Aarhus University Hospital|Odense University Hospital|Aalborg Universitetshospital|Herning Hospital|Roche Pharma AG","All","18 Years and older   (Adult, Senior)","","200","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","1-10-72-83-14|1-16-02-431-14","September 2014","September 2019","September 2019","March 2017","November 4, 2014","November 6, 2014","null","null","March 20, 2017","March 21, 2017","Aarhus University Hospital, Aarhus, DK, Denmark","https://ClinicalTrials.gov/show/NCT02284633"
560,"NCT01173458","Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)","null","Completed","No Results Available","Small Cell Lung Cancer","","Subject samples will be used to determine the correlation between CTCs in SCLC patients, detected by CellSearch, with treatment outcomes, including response to chemotherapy, relapse, and survival|Blood samples will be used to examine the genomic profiles of CTCs and compare them to the original tumor specimen.","University of Kansas Medical Center|VA Office of Research and Development|University of Nebraska","All","18 Years and older   (Adult, Senior)","","25","Other|U.S. Fed","Observational","Observational Model: Case-Only|Time Perspective: Prospective","12216","July 2010","November 2012","March 2015","January 2017","July 27, 2010","August 2, 2010","null","null","January 6, 2017","January 10, 2017","University of Kansas Medical Centner, Kansas City, Kansas, United States|University of Nebraska & Omaha VA, Omaha, Nebraska, United States","https://ClinicalTrials.gov/show/NCT01173458"
561,"NCT00274885","Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer","null","Unknown status","No Results Available","Cancer","Drug: oxaliplatin|Procedure: management of therapy complications","Relationship between residual platinum levels in the blood and persistent neurotoxicity|Pharmacokinetics","GERCOR - Multidisciplinary Oncology Cooperative Group|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 4","58","Other","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000454401|GERCOR-TAUROX|SANOFI-GERCOR-TAUROX|EU-20573","October 2005","null","null","May 2007","January 10, 2006","January 11, 2006","null","null","December 2, 2011","December 5, 2011","CHU de Grenoble - Hopital Michallon, Grenoble, France|Centre Hospital Universitaire Hop Huriez, Lille, France|Clinique Saint Jean, Lyon, France|Hopital Saint Antoine, Paris, France|CHU Pitie-Salpetriere, Paris, France|Hopital Tenon, Paris, France","https://ClinicalTrials.gov/show/NCT00274885"
562,"NCT00429507","Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases","null","Completed","Has Results","Breast Cancer|Bone Metastases","Drug: 153 Sm-EDTMP|Behavioral: Questionnaire|Procedure: Stem Cell Transplant","Time to Progression","M.D. Anderson Cancer Center|Cytogen Corporation","All","18 Years to 65 Years   (Adult)","Phase 2","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-0349|NCI-2010-00573","March 2007","November 2014","November 2014","October 2015","January 29, 2007","January 31, 2007","October 22, 2015","November 24, 2015","October 22, 2015","November 24, 2015","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00429507"
563,"NCT02288754","Detection of Tumor DNA in Blood Samples From Cancer Patients","null","Recruiting","No Results Available","Cancer|Tumors","Diagnostic Test: Blood test","Correlation between the tumor load score and patient response to therapies.|Determination of particular mutation events which underlie the basis of any established correlation with therapy response.","Lexent Bio, Inc.","All","18 Years and older   (Adult, Senior)","","500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Tumor DNA","December 2014","November 2018","November 2020","September 2017","November 7, 2014","November 11, 2014","null","null","September 25, 2017","September 27, 2017","James Sinclair, MD, La Jolla, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Cancer Care Associates, Torrance, California, United States","https://ClinicalTrials.gov/show/NCT02288754"
564,"NCT01084785","Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer","Biobank","Recruiting","No Results Available","Cancer","","","Maastricht Radiation Oncology|Maastricht University Medical Center","All","18 Years and older   (Adult, Senior)","","10000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","08-06-23/01","January 2003","January 2025","January 2025","May 2016","March 10, 2010","March 11, 2010","null","null","May 23, 2016","May 24, 2016","Maastricht Radiation Oncology, Maastricht, Limburg, Netherlands","https://ClinicalTrials.gov/show/NCT01084785"
565,"NCT01943500","Collection of Blood Specimens for Circulating Tumor Cell Analysis","null","Completed","No Results Available","Breast Cancer|Prostate Cancer|Colorectal Cancer","","The number of circulating tumor cells (CTCs) per milliliter of whole blood. Reported unit of measure will be the number of CTCs/milliliter.","Viatar LLC|Commonwealth Hematology-Oncology, P.C.","All","18 Years and older   (Adult, Senior)","","14","Industry|Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","T30-0001","September 30, 2013","January 28, 2014","August 26, 2016","February 2017","September 10, 2013","September 17, 2013","null","null","February 13, 2017","February 15, 2017","Commonwealth Hematology-Oncology, P.C., Lawrence, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT01943500"
566,"NCT01405638","Faith-based Approaches to Treating Hypertension and Colon Cancer Prevention","FAITH-CRC","Completed","No Results Available","Blood Pressure|Colorectal Cancer","Behavioral: Motivational Interviewing|Behavioral: Patient Navigation","Blood Pressure|Colorectal Cancer Screening","New York University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI)","Male","50 Years and older   (Adult, Senior)","","451","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","10-00427|1R01HL096946-01A2","March 2011","June 2015","June 2015","November 2015","July 27, 2011","July 29, 2011","null","null","November 11, 2015","November 13, 2015","New York University School of Medicine, New York, New York, United States","https://ClinicalTrials.gov/show/NCT01405638"
567,"NCT03205735","The Enzymatic Activity of Lymphocyte Dihydropyrimidine Dehydrogenase DPD in the Blood as a Predictive and Prognostic Factor in Patients With Digestive Cancer in the First or Second Metastatic Line","DPD DIG","Recruiting","No Results Available","Metastatic or Locally-advanced Digestive Cancer","Diagnostic Test: lymphocyte DPD dosage","progression free survival|overall survival|treatment response|toxicities evaluation","Centre Antoine Lacassagne","All","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2017/25","June 29, 2017","June 29, 2019","September 29, 2019","June 2017","June 29, 2017","July 2, 2017","null","null","July 5, 2017","July 6, 2017","Centre Antoine Lacassagne, Nice, France","https://ClinicalTrials.gov/show/NCT03205735"
568,"NCT00568282","Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients","null","Unknown status","No Results Available","Lung Cancer","Procedure: phlebotomy","to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells.","Stanford University","All","18 Years and older   (Adult, Senior)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LUN0017|96710|4086","February 2007","July 2014","July 2014","October 2013","December 4, 2007","December 6, 2007","null","null","October 23, 2013","October 25, 2013","Stanford University School of Medicine, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT00568282"
569,"NCT01907009","A PHASEII STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT)OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (MEL-CAP).","MEL-CAP","Unknown status","No Results Available","Castrate Resistant Prostate Cancer","Drug: Melphalan|Drug: Lenograstim","To determine the efficacy of intensified intravenous Melphalan with autologous whole blood stem cell transplantation in patients with castration resistant prostate cancer using progression free survival.|To determine weather early falls (two weeks)in circulating tumor cells (CTC)predict the progression free survival|To assess the changes in prostate specific antigen pre and post treament|To study progression free survival and overall survival|To assess the effect of this schedule in reintroduction of hormone senstivity|To study the Quality of life.","Barts & The London NHS Trust","Male","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","39","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEL-CAP","January 2013","January 2016","September 2017","July 2013","July 22, 2013","July 24, 2013","null","null","September 7, 2015","September 9, 2015","St Batholowmew's Hospital NHS, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01907009"
570,"NCT01543126","IL-6 and IL-8 Level of Blood and Pleural Effusion During Chemotherapy in Metastatic Breast Cancer","null","Terminated","No Results Available","Metastatic Breast Cancer","","level of IL-6 and IL-8","Fudan University","Female","18 Years to 70 Years   (Adult, Senior)","","9","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Fudan BR2011-06","February 2011","February 2013","February 2013","July 2013","February 27, 2012","March 2, 2012","null","null","July 24, 2013","July 26, 2013","Fudan University Cancer Hospital, Shanghai, China","https://ClinicalTrials.gov/show/NCT01543126"
571,"NCT00197405","Comparison of Fecal Ribonucleic Acid (RNA) Test With Fecal Occult Blood Test (FOBT) for Detecting Colorectal Cancer and Adenoma","null","Unknown status","No Results Available","Colorectal Cancer","","","Hamamatsu University","All","18 Years and older   (Adult, Senior)","","400","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","CRC-FRT-001","August 1999","null","December 2010","August 2009","September 12, 2005","September 20, 2005","null","null","August 3, 2009","August 4, 2009","Hamamatsu University School of Medicine, Hamamatsu, Japan","https://ClinicalTrials.gov/show/NCT00197405"
572,"NCT00180869","Unmodified Versus Leuko-Reduced Allogeneic Red Blood Cells Transfusion in Cancer Patients","null","Completed","No Results Available","Cancer|Surgery","Procedure: transfusion of allogeneic red blood cell concentrate|Procedure: transfusion of leuko-reduced red blood cell concentrate","Polarization of lymphocyte responses towards a Th2 response following transfusion during surgery as assessed by the IL-4/IFN-γ ratio|Peripheral blood mononuclear cell phenotyping|Cytokine production|Microchimerism at day 3 after transfusion during surgery|Alteration of T cell repertoire|Incidence of nosocomial infection|Survival","Gustave Roussy, Cancer Campus, Grand Paris","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TRANSFUGE","September 1997","null","null","September 2005","September 12, 2005","September 16, 2005","null","null","September 12, 2005","September 16, 2005","Institut Gustave Roussy, Villejuif, France","https://ClinicalTrials.gov/show/NCT00180869"
573,"NCT03289988","Novel Blood-based Colorectal Cancer Screening Method Using Natural Killer Cell Activity and Gene Panel Expression","null","Recruiting","No Results Available","Colorectal Adenoma|Colorectal Cancer","Other: blood sampling","Diagnostic Power for prediction of advanced colorectal neoplasms","Yonsei University","All","40 Years and older   (Adult, Senior)","","964","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","4-2017-0148","June 1, 2017","June 2019","August 2019","September 2017","September 18, 2017","September 21, 2017","null","null","September 18, 2017","September 21, 2017","Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT03289988"
574,"NCT01650922","Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples","null","Completed","No Results Available","Brain Cancer","Procedure: phlebotomy|Procedure: biopsy","","Stanford University","All","up to 24 Years   (Child, Adult)","","4","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PEDSBRN0004|96447","September 2005","September 2008","September 2008","July 2012","July 24, 2012","July 26, 2012","null","null","July 25, 2012","July 26, 2012","Stanford University School of Medicine, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT01650922"
575,"NCT00001498","A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer","null","Completed","No Results Available","Breast Cancer|Breast Neoplasms","Drug: methotrexate|Drug: leucovorin|Drug: 5-fluorouracil|Drug: cyclophosphamide|Procedure: peripheral blood progenitor cell|Drug: paclitaxel|Drug: doxorubicin","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","55","NIH","Interventional","Primary Purpose: Treatment","960032|96-C-0032","February 1996","null","December 2000","January 2000","November 3, 1999","December 10, 2002","null","null","March 3, 2008","March 4, 2008","National Cancer Institute (NCI), Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00001498"
576,"NCT00717002","Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study","null","Completed","No Results Available","Non Small Cell Lung Cancer","","","National University Hospital, Singapore","All","18 Years and older   (Adult, Senior)","","null","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","NS02/21/05","February 2008","April 2013","April 2013","December 2013","July 14, 2008","July 16, 2008","null","null","December 10, 2013","December 11, 2013","National University Hospital, Singapore, Singapore","https://ClinicalTrials.gov/show/NCT00717002"
577,"NCT01800058","Prognostic Value of the Levels of CTCs in Peripheral Blood in Patients With Prostate Cancer at High Risk (Clinical Stages IIB-III) Treated Radically With Radiotherapy and Hormone Therapy.","null","Unknown status","No Results Available","Patients With High-risk Prostate Cancer","","expression of circulating tumor cells in the peripheral blood in the peripheral blood of patients with high-risk prostate cancer (NCCN 2011)|Radiation dose|Duration and type of hormone therapy|Gleason sum;|Pretreatment PSA;|Clinical T stage|Biochemical failure-free survival;|Overall Survival defined as death due to any cause;|Metastasis-free survival","Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","Male","18 Years and older   (Adult, Senior)","","65","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CaPr-RTCTC-01/PI 197","March 2013","April 2014","April 2016","February 2013","February 18, 2013","February 27, 2013","null","null","February 25, 2013","February 27, 2013","Hospital Universitario de Santiago de Compostela, Santiago de Compostela, La Coruña, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01800058"
578,"NCT02657863","Cancer DNA in Blood and Urine","null","Active, not recruiting","No Results Available","Prostate Cancer","Procedure: Urine collection and blood draw","Healthy volunteer baseline|DNA alterations in blood and urine during radiation therapy","Sidney Kimmel Comprehensive Cancer Center","Male","18 Years to 100 Years   (Adult, Senior)","","45","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","J14106|IRB00043215","November 2014","December 2017","December 2017","May 2017","September 9, 2015","January 18, 2016","null","null","May 10, 2017","May 11, 2017","Johns Hopkins SKCCC, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT02657863"
579,"NCT02959541","PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer","null","Enrolling by invitation","No Results Available","Colon Cancer|Chemotherapy","Drug: Leucovorin","Tissue concentration of [6R] 5,10-methylene-THF in the tumor|Tissue concentration of [6R] 5,10-methylene-THF in adjacent mucosa|Tissue concentration of 5-formyl-THF in the tumor|Tissue concentration of 5-formyl-THFin the adjacent mucosa|Tissue concentration of 5-methyl-THF in the tumor|Tissue concentration of 5-methyl-THF in the adjacent mucosa|Tissue concentration of THF in the tumor|Tissue concentration of THF in the adjacent mucosa|AUC(0-24h) calculated from plasma concentration of [6R] 5,10-methylene-THF|AUC(0-24h) calculated from plasma concentration of 5-formyl-THF (if data permits)|AUC(0-24h) calculated from plasma concentration of 5-methyl-THF (if data permits)|AUC(0-24h) calculated from plasma concentration of THF (if data permits)|Correlation between AUC calculated from blood concentration and tissue concentration in the tumor and adjacent mucosa|Gene expression in the tumor and correlation to tissue concentration of the reduced folates|Gene expression in the adjacent mucosa and correlation to tissue concentration of the reduced folates","Vastra Gotaland Region","All","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","00068128","September 2016","December 2017","null","October 2016","October 20, 2016","November 9, 2016","null","null","November 8, 2016","November 9, 2016","","https://ClinicalTrials.gov/show/NCT02959541"
580,"NCT01687439","Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)","null","Completed","No Results Available","Non-small Cell Lung Cancer","Drug: Endostar|Drug: Vinorelbine|Drug: Cisplatin|Radiation: Radiotherapy","Tumor blood volume|Tumor blood flow|Permeability-surface area product|18-FDG PET SUV values|The incidence of adverse events","Fudan University","All","18 Years and older   (Adult, Senior)","Phase 2","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSCLC0901","December 2008","October 2009","October 2009","September 2012","August 16, 2012","September 19, 2012","null","null","September 18, 2012","September 19, 2012","Fudan University Shanghai Cancer Center, Shanghai, China","https://ClinicalTrials.gov/show/NCT01687439"
581,"NCT00611000","Effect of Folate on DNA in Colon Tissue and Blood Samples From Patients at Increased Risk of Developing Colorectal Neoplasia","null","Completed","No Results Available","Colorectal Cancer","Dietary Supplement: folic acid|Genetic: DNA methylation analysis|Genetic: gene expression analysis|Genetic: microarray analysis|Genetic: polymorphism analysis|Other: laboratory biomarker analysis","DNA uracil incorporation in peripheral blood mononuclear cells (PBMCs)|Strand breaks in the coding region of p53 in PBMCs and rectal biopsy cells|DNA methylation (overall, p53 coding, p16 promoter, MLH1 promoter) in PBMCs and rectal biopsy cells|Differential gene expression in colonic and PBMCs by microarray analysis","Rockefeller University|National Cancer Institute (NCI)","All","40 Years to 72 Years   (Adult, Senior)","Phase 1","20","Other|NIH","Interventional","Masking: Single|Primary Purpose: Prevention","CDR0000582113|RUH-PHO-0514-0306","June 2003","January 2006","null","February 2008","February 7, 2008","February 8, 2008","null","null","February 14, 2009","February 17, 2009","","https://ClinicalTrials.gov/show/NCT00611000"
582,"NCT01063283","Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC","AVF4759","Completed","No Results Available","Advanced Non-squamous Non-Small Cell Lung Cancer","Drug: Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg|Drug: Carboplatin and Pemetrexed with Bevacizumab 15 mg/kg","Does a higher dose of bevacizumab have any effect on changes in blood pressure|Response rate|Change in tumor size|Progression free survival","University of Chicago|Genentech, Inc.","All","18 Years to 89 Years   (Adult, Senior)","","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-014-B","March 2010","June 2016","June 2016","May 2017","February 3, 2010","February 5, 2010","null","null","May 30, 2017","June 1, 2017","The University of Chicago Medical Center, Chicago, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States","https://ClinicalTrials.gov/show/NCT01063283"
583,"NCT00900432","Immune Response in Peripheral Blood of Patients With Colon Cancer","null","Completed","No Results Available","Colorectal Cancer","Other: immunoenzyme technique|Other: laboratory biomarker analysis","Quantitation of T cells specific for tumor peptides (carcinoembryonic antigen and MUC1)","University of Arizona|National Cancer Institute (NCI)","All","Child, Adult, Senior","","67","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","04-0331-01|P50CA095060|P30CA023074|UARIZ-04-81","July 2004","December 2008","December 2008","August 2012","May 9, 2009","May 12, 2009","null","null","December 2, 2015","December 3, 2015","Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States","https://ClinicalTrials.gov/show/NCT00900432"
584,"NCT02950350","Clinical Trial of Laparoscopic Pelvic and Para-aortic Lymphadenectomy and Uterine Blood Vessel Blocking for Precision Diagnosis and Treatment in Advanced Cervical Cancer","null","Not yet recruiting","No Results Available","Cervical Cancer, Stage IIB|Cervical Cancer Stage IIIA|Cervical Cancer Stage IIIB|Cervical Cancer, Stage IVA","","The recurrence rate|The transfer rate|mortality","Shanghai First Maternity and Infant Hospital","Female","Child, Adult, Senior","","50","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","Guo Xiaoqing","December 2016","December 2016","December 2023","October 2016","October 28, 2016","November 1, 2016","null","null","October 31, 2016","November 1, 2016","","https://ClinicalTrials.gov/show/NCT02950350"
585,"NCT02199041","Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen","null","Terminated","No Results Available","Hematological Malignancies","Drug: Cyclophosphamide|Drug: Thiotepa|Drug: Fludarabine|Drug: Melphalan|Drug: Mesna|Biological: G-CSF|Drug: Mycophenolate mofetil|Drug: Tacrolimus|Drug: Methylprednisolone|Radiation: Total lymphoid irradiation|Biological: Lymphocyte infusions|Device: CliniMACS","Rate of neutrophil engraftment|Incidence of malignant relapse|Event-free survival|Overall survival|Incidence by severity of acute and chronic graft versus host disease (GVHD) in the first 100 days after HCT|Incidence of transplant-related mortality (TRM)|Incidence of transplant-related morbidity|Incidence of secondary graft failure","St. Jude Children's Research Hospital","All","up to 21 Years   (Child, Adult)","Phase 2","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HAPCORD|NCI-2014-00526","July 11, 2014","May 23, 2017","May 23, 2017","August 2016","July 9, 2014","July 24, 2014","null","null","May 26, 2017","May 31, 2017","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","https://ClinicalTrials.gov/show/NCT02199041"
586,"NCT02866149","Analysis of Circulating Tumor Markers in the Blood (ALCINA)","ALCINA","Recruiting","No Results Available","Cancer","Biological: Blood sampling|Procedure: Tumor sampling|Other: Stool sampling","Feasibility of the analysis of different blood-borne tumor biomarkers|Correlation with biological and clinical data","Institut Curie","All","18 Years and older   (Adult, Senior)","","620","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IC 2015-02","July 2015","July 2018","July 2024","February 2017","July 28, 2016","August 15, 2016","null","null","February 10, 2017","February 13, 2017","Centre Georges François Leclerc, Dijon, France|Institut du Cancer de Montpellier, Montpellier, France|Institut Curie (Paris hospital), Paris, France|Institut Mutualiste Montsouris, Paris, France|Institut Curie (St Cloud hospital), Saint-cloud, France","https://ClinicalTrials.gov/show/NCT02866149"
587,"NCT02658513","Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer","null","Recruiting","No Results Available","Cancer of the Thyroid|Cancer of Thyroid|Thyroid Cancer|Thyroid Carcinoma","Other: Lancet blood sampling|Other: Standard intravenous blood sampling","Quantify the bone marrow doses (in Gray) for each of the two blood sampling techniques.|Quantify the radiation exposure (in milli-Sieverts) to staff for each of the two blood sampling techniques.","Royal Surrey County Hospital NHS Foundation Trust","All","18 Years and older   (Adult, Senior)","","35","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","14OncN0013","September 2016","September 2018","September 2018","October 2016","December 24, 2015","January 20, 2016","null","null","October 3, 2016","October 4, 2016","Royal Surrey County Hospital NHS Foundation Trust, Guildford, Surrey, United Kingdom","https://ClinicalTrials.gov/show/NCT02658513"
588,"NCT00432094","Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors","null","Recruiting","No Results Available","Childhood Germ Cell Tumor|Ovarian Cancer|Teratoma","Drug: carboplatin|Drug: etoposide|Drug: ifosfamide|Drug: paclitaxel|Drug: thiotepa|Procedure: autologous hematopoietic stem cell transplantation|Drug: Mesna|Biological: filgrastim","Overall survival (OS)|Disease-free survival (DFS)|Engraftment of platelets|Numbers of Patients Unable to Mobilize Peripheral Blood Stem Cells|Engraftment of neutrophils","Masonic Cancer Center, University of Minnesota","All","10 Years to 69 Years   (Child, Adult, Senior)","Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006LS032|UMN-MT2005-21|UMN-0608M90586","December 19, 2006","January 2018","January 2018","November 2017","February 5, 2007","February 7, 2007","null","null","November 29, 2017","December 1, 2017","Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00432094"
589,"NCT02758314","Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients","null","Not yet recruiting","No Results Available","Non-Small Cell Lung Cancer","Other: Evaluation of PD-1/PDL-1 expression.","Immunolocalization of PD-1, PD-L1 in lung tumor tissue of patients with NSCLC. Immunohistochemical staining (IHC)|Evaluation of PD-1, PD-L1 by flow cytometry.","Instituto Nacional de Cancerologia de Mexico","All","18 Years to 80 Years   (Adult, Senior)","","150","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","INCAN/CI/498/13","March 2017","December 2017","December 2018","November 2016","April 6, 2016","May 2, 2016","null","null","November 23, 2016","November 25, 2016","Instituto National de Cancerologia, Mexico, Mexico","https://ClinicalTrials.gov/show/NCT02758314"
590,"NCT00745381","A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors","null","Recruiting","No Results Available","Gastric Cancer|Pancreatic Cancer","Other: questionnaire, Blood specimens","To develop a tissue, serum, plasma and DNA bank from individuals with NET. This bank will be combined with epidemiologic and clinical information to create a NET database.","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Senior)","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","08-105","August 2008","August 2018","August 2018","August 2017","September 2, 2008","September 3, 2008","null","null","August 2, 2017","August 3, 2017","Memorial Sloan-Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00745381"
591,"NCT02904135","Collection of Circulating Tumor Cells From the Peripheral Blood of Metastatic Breast Cancer Patients","null","Completed","No Results Available","Circulating Tumor Cells (CTCs)","","Overall survival(OS)","MiCareo Taiwan Co., Ltd.","Female","20 Years and older   (Adult, Senior)","","141","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MBC 2.7","February 2014","December 2016","December 2016","March 2017","September 13, 2016","September 16, 2016","null","null","March 21, 2017","March 23, 2017","Keelung Chang Gung Memorial Hospital, Keelung City, Taiwan","https://ClinicalTrials.gov/show/NCT02904135"
592,"NCT01247701","Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies","UCAML","Recruiting","No Results Available","Myeloid Hematological Malignancies","Drug: Busulfan|Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: Cord Blood Stem Cell Infusion","Overall survival at 1 year after UCB transplant in pediatric patients.|Number of participants with severe acute GVHD Grade III-IV as an assessment of safety.|Number of participants with chronic GvHD as an assessment of safety.|Assess relapse rate after transplant.|To evaluate donor engraftment after transplant.|Assessment of platelet count recovery.|Assessment of neutrophil count recovery.","Baylor College of Medicine|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine","All","up to 17 Years   (Child)","","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","26558-UCAML","November 2010","November 2024","November 2027","September 2017","November 22, 2010","November 24, 2010","null","null","September 22, 2017","September 25, 2017","Texas Children's Hospital, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT01247701"
593,"NCT00966498","Peripheral Blood Stem Cell Transplant (PBSCT) in Children With High Risk or Recurrent Solid Tumors","null","Terminated","No Results Available","High Risk Solid Tumors|Recurrent Solid Tumors","Procedure: Peripheral Blood Stem Cell Transplant","To determine the feasibility and toxicity of tandem high dose chemotherapy and peripheral blood stem cells rescue in patients with high-risk or recurrent solid tumors.","Emory University","All","up to 35 Years   (Child, Adult)","","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1023-2003|PBSCT for ST","May 2003","July 2011","July 2011","December 2013","August 11, 2009","August 27, 2009","null","null","December 9, 2013","December 11, 2013","Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States","https://ClinicalTrials.gov/show/NCT00966498"
594,"NCT01274572","Blood for Immune Response to Provenge® in HRPC","null","Withdrawn","No Results Available","Prostate Cancer","","Immune Response","Mary Crowley Medical Research Center","All","Child, Adult, Senior","","0","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MC 10-11","January 2011","January 2011","June 2011","April 2015","January 10, 2011","January 11, 2011","null","null","April 6, 2015","April 7, 2015","","https://ClinicalTrials.gov/show/NCT01274572"
595,"NCT00806650","Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer","null","Completed","No Results Available","Kidney Cancer","Genetic: gene expression analysis|Genetic: protein expression analysis|Diagnostic Test: diagnostic laboratory biomarker analysis|Other: immunoenzyme technique|Other: immunohistochemistry staining method","Presence of primary and/or metastatic renal cell carcinoma by IMP3 autoantibody|Presence of primary and/or metastatic renal cell carcinoma by miRNA/snRNA signature","City of Hope Medical Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","","155","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","07241|CHNMC-07241|CDR0000628796|NCI-2015-01327","July 2008","November 15, 2017","November 15, 2017","December 2017","December 10, 2008","December 11, 2008","null","null","December 6, 2017","December 8, 2017","City of Hope Medical Center, Duarte, California, United States","https://ClinicalTrials.gov/show/NCT00806650"
596,"NCT02830724","Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","null","Recruiting","No Results Available","Pancreatic Cancer|Renal Cell Cancer|Breast Cancer|Melanoma|Ovarian Cancer","Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin|Biological: Anti-hCD70 CAR PBL","Maximum tolerated cell dose (MTD)|Response to treatment|Engineered cell survival|Frequency of treatment related adverse events","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","113","NIH","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","160131|16-C-0131","July 12, 2016","July 1, 2020","July 1, 2021","December 20, 2017","July 12, 2016","July 13, 2016","null","null","December 22, 2017","December 25, 2017","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT02830724"
597,"NCT02809404","Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study)","SPOT","Completed","No Results Available","Breast Cancer|Renal Cell Carcinoma","Drug: Everolimus","Correlation everolimus concentration DBS with whole blood|Correlation everolimus concentration whole blood with saliva","Radboud University","All","18 Years and older   (Adult, Senior)","","75","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MOMAM15-SPOT","June 2015","January 2016","January 2017","May 2016","June 1, 2016","June 22, 2016","null","null","October 13, 2017","October 16, 2017","Radboud university medical center, Nijmegen, Netherlands","https://ClinicalTrials.gov/show/NCT02809404"
598,"NCT02979470","Study of Blood Components as Probable Prognostic and Predictive Markers of Response to Treatment in Advanced Colon and Rectal Cancers","BMACR","Recruiting","No Results Available","Colon Cancer Stage IIb|Rectum Cancer, Adenocarcinoma|Colon Cancer Stage IIIa|Colon Cancer Stage IIIc|Colon Cancer Stage IIIb","","progression free survival","AC Camargo Cancer Center","All","18 Years to 70 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CEP2141/15","September 2016","September 2018","September 2019","September 2016","November 29, 2016","December 1, 2016","null","null","November 30, 2016","December 1, 2016","ACCamargo Cancer Center, Sao Paulo, SP, Brazil","https://ClinicalTrials.gov/show/NCT02979470"
599,"NCT03242265","Measurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biopsy","ANKA-PCA","Recruiting","No Results Available","Immunity, Innate|Prostatic Neoplasm","Diagnostic Test: IVDD for NK cell activity in whole blood","The ability of NK cell activity to predict prostate cancer (yes/no) on biopsy|The ability of NK cell activity to predict tumor grade (Gleason 2-6 vs. no cancer; Gleason 7-10 vs. no cancer)|Test performance metrics of NK Vue and PSA (each alone)|Impact of combination of NK Vue and PSA on the test performance of PSA","ATGen Canada Inc","Male","18 Years and older   (Adult, Senior)","","200","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening","ANKA-PCA","April 4, 2017","July 2018","December 2018","August 2017","August 3, 2017","August 8, 2017","null","null","August 3, 2017","August 8, 2017","Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT03242265"
600,"NCT00005941","Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer","null","Completed","No Results Available","Cervical Cancer|Vaginal Cancer","Biological: therapeutic allogeneic lymphocytes|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Partial or complete response|Toxicity|Engraftment and donor chimerism|HPV-E6 and E7-specific T cell responses","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","Female","up to 64 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","1477.00|FHCRC-1477.00|NCI-G00-1784|CDR0000067816","November 1999","June 2005","June 2005","March 2010","July 5, 2000","January 27, 2003","null","null","March 31, 2010","April 2, 2010","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00005941"
601,"NCT02853097","Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients","null","Recruiting","No Results Available","Hormone-Resistant Prostate Cancer|Metastatic Prostate Carcinoma|Prostate Adenocarcinoma","Other: Cytology Specimen Collection Procedure|Other: Laboratory Biomarker Analysis","Change in AR-V7 presence|Expression level of AR-V7 in serum cfRNA assessed by quantitative RT-PCR|Time to start of another treatment|Expression levels of AR-Vs (other than AR-V7) in serum cfRNA assessed by quantitative RT-PCR|Tumor response as measured by Prostate Cancer Working Group","University of Southern California|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Senior)","","300","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","4P-15-4|NCI-2016-00958|P30CA014089","June 14, 2016","June 14, 2019","June 14, 2020","August 2017","July 29, 2016","August 2, 2016","null","null","August 19, 2017","August 22, 2017","Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Keck Medical Center of USC Pasadena, Pasadena, California, United States","https://ClinicalTrials.gov/show/NCT02853097"
602,"NCT02681120","Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast Cancer","null","Recruiting","No Results Available","Breast Neoplasms|Obesity","Procedure: Biopsy|Procedure: Blood draw|Procedure: Mammogram|Procedure: MRI","Change in breast density via MRI from baseline|Change in breast density via mammography from baseline|Comparison of obesity immune markers (B cells, cytotoxic T cells helper T cells, dendritic cells, leukocytes, monocytes/macrophages) in normal weight breast tissue with obese breast tissue|Change in obesity immune markers (B cells, cytotoxic T cells helper T cells, dendritic cells, leukocytes, monocytes/macrophages) in obese breast tissue from baseline|Comparison of number of crown-like structures in obese breast tissue and normal breast tissue|Change in aromatase expression markers in obese tissue from baseline|Comparison of aromatase expression markers in normal weight breast tissue with obese breast tissue|Change in other correlative blood markers (inflammatory, insulin, hormonal) from baseline","Anna Maria Storniolo|Indiana University","Female","18 Years to 75 Years   (Adult, Senior)","","40","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","IUSCC-0556","October 2016","February 2018","null","December 2016","February 9, 2016","February 12, 2016","null","null","December 7, 2016","December 8, 2016","Indiana University Health North Hospital, Carmel, Indiana, United States|Indiana University Health Hospital, Indianapolis, Indiana, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States","https://ClinicalTrials.gov/show/NCT02681120"
603,"NCT01471067","Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies","null","Completed","No Results Available","Blood And Marrow Transplantation|Leukemia|Lymphoma|Transplantation Infection|Transplantation, Bone Marrow","Drug: Melphalan|Drug: Fludarabine|Drug: Mycophenolate mofetil|Drug: Tacrolimus|Procedure: Cord Blood Infusion|Drug: Rituximab|Drug: ATG|Drug: Busulfan|Drug: Clofarabine|Radiation: Total Body Irradiation (TBI)","Number of Participants with engraftment within 42 days|Mean Time to Engraftment","M.D. Anderson Cancer Center|American Stem Cell, Inc.|National Cancer Institute (NCI)","All","1 Year to 80 Years   (Child, Adult, Senior)","Phase 1","33","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-0658|NCI-2011-03742|2R01CA06158|5P01CA148600","July 13, 2012","April 25, 2017","April 25, 2017","April 2017","November 9, 2011","November 11, 2011","null","null","April 27, 2017","April 28, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT01471067"
604,"NCT03058809","Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood","null","Not yet recruiting","No Results Available","Metastatic Cancer","Device: Oncopheresis","Change in Circulating Tumor Cells|Immune system activation","Viatar LLC","All","18 Years to 80 Years   (Adult, Senior)","","150","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","T30-0002","September 2017","December 2017","March 2018","February 2017","February 16, 2017","February 23, 2017","null","null","February 20, 2017","February 23, 2017","","https://ClinicalTrials.gov/show/NCT03058809"
605,"NCT00186680","CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant","null","Completed","No Results Available","Breast Cancer","Procedure: high dose chemo then auto hematopoietic cell transplant","Feasibility and safety|efficiency of mobilization|tumor contamination","Stanford University","All","19 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","99","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BMT86","September 1996","June 2005","June 2005","February 2010","September 14, 2005","September 16, 2005","null","null","February 26, 2010","March 2, 2010","Stanford University School of Medicine, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT00186680"
606,"NCT02153593","Postoperative Bleeding Prevention in Massive Bone Tumour Resection","TRANEXTUM","Terminated","No Results Available","Blood Loss|Bone Tumour","Drug: Tranexamic Acid|Drug: Fibrin glue|Procedure: Electrocauterization","Total blood loss (mL) in the postoperative period|Proportion of patients requiring blood transfusion|Units of blood transfused|Proportion of patients with wound infection|Proportion of patients with wound dehiscence|Proportion of patients with reoperation for wound complications|Deep venous thrombosis|Proportion of patients with seroma|Postoperative pain related with the surgery|Tumoral local relapse rate|Tumoral systemic dissemination rate|Mortality|Proportion of patients in which chemotherapy is delayed for wound complications|Proportion of patients in which radiotherapy is delayed for wound complications.|Length of hospital stay","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","All","18 Years and older   (Adult, Senior)","Phase 3","56","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIBSP-EVI-2011-138|EC11-340|2011-006276-40","March 2013","March 2015","May 2015","September 2016","May 27, 2014","June 3, 2014","null","null","September 19, 2016","September 20, 2016","Hospital Universitario de Cruces, Barakaldo,, Vizcaya, Spain|Hospital Universitario de San Juan de Alicante, Alicante, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT02153593"
607,"NCT02662621","Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors","EXODIAG","Recruiting","No Results Available","Cancer","Other: blood samples|Other: Urine samples","concentration of HSP70 exosomes in the blood and urine","Centre Georges Francois Leclerc","All","18 Years and older   (Adult, Senior)","","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2014-A01638-39","December 2015","May 2018","May 2019","August 2017","January 20, 2016","January 25, 2016","null","null","August 30, 2017","August 31, 2017","CGFL, Dijon, France","https://ClinicalTrials.gov/show/NCT02662621"
608,"NCT00003068","High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer","null","Completed","No Results Available","Breast Cancer|Drug/Agent Toxicity by Tissue/Organ","Drug: amifostine trihydrate|Drug: cyclophosphamide|Drug: mitoxantrone hydrochloride|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation","","University of Arizona|National Cancer Institute (NCI)","All","16 Years to 70 Years   (Child, Adult, Senior)","Phase 2","30","Other","Interventional","Primary Purpose: Treatment","CDR0000065742|UARIZ-HSC-9728|ALZA-UARIZ-HSC-9728|NCI-V97-1329","June 1997","null","November 2002","May 2006","November 1, 1999","August 2, 2004","null","null","January 30, 2013","January 31, 2013","Arizona Cancer Center, Tucson, Arizona, United States","https://ClinicalTrials.gov/show/NCT00003068"
609,"NCT00149006","Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors","null","Unknown status","No Results Available","Tumors","Procedure: Cell therapy","Study the feasibility, toxicity, and response rate of allogeneic cell therapy induced by selective intra-lesional and systemic administration of mismatched alloreactive lymphocytes in patients with metastatic cancer|Study the feasibility, toxicity, and response to treatment with allogeneic mini-transplant using sibling donors in patients with metastatic cancer","Hadassah Medical Organization","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","271296-HMO-CTIL","December 1996","null","null","September 2005","September 7, 2005","September 8, 2005","null","null","March 13, 2007","March 14, 2007","Hadassah Medical Organization, Jerusalem, Israel","https://ClinicalTrials.gov/show/NCT00149006"
610,"NCT01190644","Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors","null","Terminated","No Results Available","Solid Tumors","Drug: ACE 011","Red Blood Cell Mass|Plasma Volume|Absolute Reticulocyte Increase|Changes in Hemoglobin|Number of patients with adverse events","Celgene Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","4","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","ACE-011-ST-001","June 2010","September 2012","September 2012","May 2016","July 21, 2010","August 27, 2010","null","null","May 25, 2016","June 6, 2016","Saint Agnes Healthcare, Baltimore, Maryland, United States|Weinberg Cancer Institution at Franklin Square, Baltimore, Maryland, United States|Pennsylvania Oncology, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT01190644"
611,"NCT02024321","Study on Blood Glucose Variations in Tumor Patients Before and After Total Parenteral Nutrition","TPN","Completed","No Results Available","Cancer|Surgery|Nutrition Related Cancer","","Glycemic Variations during TPN","Chinese Academy of Medical Sciences","All","Child, Adult, Senior","","86","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","TPN-tumor","January 2013","December 2013","December 2013","December 2013","December 18, 2013","December 31, 2013","null","null","December 27, 2013","December 31, 2013","Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT02024321"
612,"NCT02967341","Blood Draw Validation for Ciprofloxacin Pharmacokinetic Research in Pediatric Cancer Patients","null","Recruiting","No Results Available","Childhood Cancer|Neutropenia","Other: Ciprofloxacin administration","Correlation between ciprofloxacin concentration drawn via Port a Cath (PAC) versus capillary/venous punction","Universitair Ziekenhuis Brussel","All","1 Month to 17 Years   (Child)","Phase 4","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Safepedrug-02","March 2016","March 2017","March 2017","June 2016","July 27, 2016","November 18, 2016","null","null","November 15, 2016","November 18, 2016","Universitair Ziekenhuis Brussel, Brussels, Belgium","https://ClinicalTrials.gov/show/NCT02967341"
613,"NCT01622556","Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies","null","Terminated","No Results Available","Hematologic Malignancies","Drug: Fludarabine|Drug: Busulfan|Drug: Thymoglobulin|Radiation: Total Body Irradiation|Biological: Umbilical Cord Blood","Event Free Survival|Transplant Engraftment|Incidence of Graft-versus-host disease (GVHD)|Time course for peripheral blood chimerism.|Incidence of secondary lymphoproliferative diseases|Incidence of disease recurrence|Incidence of serious infectious complications|Overall Survivals","University of Virginia","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15954 UCB-2011","January 2012","February 2014","January 2017","February 2014","June 8, 2012","June 19, 2012","null","null","February 10, 2014","February 11, 2014","University of Virginia, Charlottesville, Virginia, United States","https://ClinicalTrials.gov/show/NCT01622556"
614,"NCT01883388","NovellusDx Cancer Early Detection Blood Test- Clinical Trial","null","Suspended","No Results Available","Lung Cancer","","Number of Participants with a significant cancer fingerprint as measured by NovellusDX Cancer Early Detection test","NovellusDx","All","18 Years and older   (Adult, Senior)","","500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","RAM-NOVEL-211-2012","June 2013","December 2016","null","October 2014","June 17, 2013","June 21, 2013","null","null","October 6, 2014","October 7, 2014","Rambam MC, Haifa, Israel","https://ClinicalTrials.gov/show/NCT01883388"
615,"NCT01936571","Usefulness of Blood Biomarkers for Overall Survival in NSCLC","null","Completed","No Results Available","Non-small Cell Lung Cancer","Other: Blood samples","Correlation of blood biomarkers to overall survival","Maastricht Radiation Oncology","All","Child, Adult, Senior","","250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Blood Biomarkers","September 2013","February 2014","March 2014","April 2014","September 3, 2013","September 6, 2013","null","null","April 10, 2014","April 11, 2014","MAASTRO clinic, Maastricht, Limburg, Netherlands","https://ClinicalTrials.gov/show/NCT01936571"
616,"NCT02838836","Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers","null","Recruiting","No Results Available","Non-small Cell Lung Cancer|Esophageal Cancer|Gastric Cancer|Pancreatic Cancer|Hepatocellular Cancer|Colorectal Cancer","Procedure: Study sample collection","CTC/DTC numbers measured in blood, urine and bone marrow samples will be correlated with patient outcome|ctDNA characteristics will be correlated with survival data","University of Missouri-Columbia","All","18 Years and older   (Adult, Senior)","","110","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2004401","June 2016","June 2019","June 2021","October 2016","July 9, 2016","July 20, 2016","null","null","October 3, 2016","October 5, 2016","Ellis Fischel Cancer Center, University of Missouri, Columbia, Missouri, United States","https://ClinicalTrials.gov/show/NCT02838836"
617,"NCT01949181","Blood, Hair and Lung Concentrations of Metals and Metalloids in Patients With Lung Cancer or Chronic Obstructive Pulmonary Disease","Métaux/Poumons","Completed","No Results Available","Lung Cancer|Chronic Obstructive Pulmonary Disease|Emphysema|Lung Surgery","Procedure: Lung surgery","Metals/metalloids concentration","Hopital Foch","All","18 Years to 75 Years   (Adult, Senior)","","251","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2010/37","August 2011","March 2014","March 2014","May 2016","September 19, 2013","September 24, 2013","null","null","May 2, 2016","May 3, 2016","Hopital Foch, Suresnes, Ile de France, France|CHU de Poitiers, Chirurgie Cardiaque et Thoracique, Poitiers, France","https://ClinicalTrials.gov/show/NCT01949181"
618,"NCT03189108","Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors","null","Recruiting","No Results Available","Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Cancer","","To obtain blood samples, ascites, and pleural effusion samples from patients with solid tumor malignancies, with the intent of performing translational studies related to cancer|Develop the malignant fluid as a culture model to replicate intraperitoneal growth of ovarian cancers.|Characterize malignant effusion composition through immunohistochemistry and flow cytometry.|Compare immune cell phenotype in ascites and blood from the patient.|Study in vivo characteristics of matched sets of samples from the same patient to evaluate both for treatment response|Establish a bank of clinically annotated samples for translational science.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","","500","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","170100|17-C-0100","May 22, 2017","January 4, 2027","January 4, 2028","June 5, 2017","June 15, 2017","June 16, 2017","null","null","July 12, 2017","July 13, 2017","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT03189108"
619,"NCT00534053","Impact of a Mailed Educational Reminder on Fecal Occult Blood Testing (FOBT): A Randomized Controlled Trial","null","Unknown status","No Results Available","Colon Cancer","Other: Mailed Educational Reminder","Our primary outcome is FOBT card return rate|Predictors of Non-compliance to fecal occult blood testing","University of California, San Diego","All","50 Years and older   (Adult, Senior)","","800","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Screening","070504","June 2007","null","October 2007","September 2007","September 20, 2007","September 24, 2007","null","null","September 20, 2007","September 24, 2007","Veteran Affairs Medical Center San Diego, San Diego, California, United States","https://ClinicalTrials.gov/show/NCT00534053"
620,"NCT00533975","A Prospective Study of a New Immunochemical Fecal Occult Blood Test in U.S. Veteran Patients Undergoing Colonoscopy","null","Unknown status","No Results Available","Colon Cancer","","","University of California, San Diego","All","18 Years and older   (Adult, Senior)","","500","Other","Observational","Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Longitudinal|Time Perspective: Prospective","071015","September 2007","null","December 2008","June 2007","September 20, 2007","September 24, 2007","null","null","September 20, 2007","September 24, 2007","Veteran Affairs Medical Center San Diego, San Diego, California, United States","https://ClinicalTrials.gov/show/NCT00533975"
621,"NCT03071809","Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and ""Healthy Controls""","null","Recruiting","No Results Available","Neoplasms, Non-hematologic - Stage I-III","","Detection of signal in the presence of active neoplasm|Determine change in signal after surgery","Lexent Bio, Inc.","All","18 Years and older   (Adult, Senior)","","400","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","LB-2017-03-01","June 30, 2017","April 2019","April 2022","June 2017","March 1, 2017","March 7, 2017","null","null","September 25, 2017","September 27, 2017","La Jolla Surgery, La Jolla, California, United States","https://ClinicalTrials.gov/show/NCT03071809"
622,"NCT00900497","A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers","null","Enrolling by invitation","No Results Available","Solid Tumors","Biological: White Blood Cells/Granulocytes","The trial will observe the subject's cancer status for 3 months after the granulocyte infusions are completed. Response at 90 days will be based on comparison of tumor measurements at baseline.|The trial will evaluate the safety and dose tolerance of the transfusion of non-irradiated granulocytes (approximately 4 to 6 donors to reach a level of 2 x 10 to the 11th cells) from HLA-mismatched donors","Dipnarine Maharaj|South Florida Bone Marrow/Stem Cell Transplant Institute","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","29","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08001-BMSCTI","April 2009","December 2018","December 2018","October 2017","May 11, 2009","May 12, 2009","null","null","October 7, 2017","October 10, 2017","South Florida Bone Marrow / Stem Cell Transplant Institute, Boynton Beach, Florida, United States","https://ClinicalTrials.gov/show/NCT00900497"
623,"NCT01538264","Blood Flow MRI for Monitoring Brain Tumors","Glioma","Recruiting","No Results Available","Brain Tumors","","","Beth Israel Deaconess Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","125","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","2006P000116|R01CA115745-05","June 2006","June 2018","December 2018","March 2017","February 20, 2012","February 24, 2012","null","null","March 10, 2017","March 14, 2017","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT01538264"
624,"NCT00652678","Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients","null","Unknown status","No Results Available","Abnormalities, Radiation-Induced","","correlation of the results obtained from the three blood tests with the clinical assessments of cosmetic outcome for each subject","State University of New York - Upstate Medical University|Carol M. Baldwin Breast Cancer Research Fund, Inc.","Female","48 Years and older   (Adult, Senior)","","45","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Project # 1050425","August 2006","null","August 2012","July 2011","April 1, 2008","April 4, 2008","null","null","July 8, 2011","July 12, 2011","SUNY Upstate Medical University, Syracuse, New York, United States","https://ClinicalTrials.gov/show/NCT00652678"
625,"NCT02747563","Evaluation of PSA Blood Levels Prior to and After Digital Rectal Examination","null","Not yet recruiting","No Results Available","Prostate Cancer","Other: Blood test (PSA)","Percentage of PSA elevation after DRE","Kaplan Medical Center","Male","18 Years to 99 Years   (Adult, Senior)","Phase 1","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","0210-15-KMC","May 2016","May 2017","May 2017","April 2016","April 19, 2016","April 21, 2016","null","null","April 20, 2016","April 21, 2016","Kaplan Medical Center, Rehovot, Israel","https://ClinicalTrials.gov/show/NCT02747563"
626,"NCT00043615","Collection of Blood, Bone Marrow, Tumor or Tissue Samples","null","Completed","No Results Available","Neoplasms|Precancerous Conditions","","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","","74","NIH","Observational","","020258|02-C-0258","July 29, 2002","null","April 10, 2012","April 10, 2012","August 9, 2002","August 12, 2002","null","null","June 30, 2017","July 2, 2017","National Naval Medical Center, Bethesda, Maryland, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00043615"
627,"NCT03257735","A Study of the Gene Mutation Status in Cerebrospinal Fluid, Blood and Tumor Tissue of Non-small Cell Lung Cancer Patients With Brain Metastases","null","Recruiting","No Results Available","Lung Cancer|Brain Metastases|Cerebrospinal Fluid|Next-generation Sequencing","Diagnostic Test: next-generation sequencing","Change from baseline gene mutation status at 2 months|Change from second line gene mutation status at 6 months|PFS|OS","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Senior)","","50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","A2017-003","May 1, 2017","December 31, 2018","May 31, 2019","August 2017","August 5, 2017","August 22, 2017","null","null","August 21, 2017","August 22, 2017","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT03257735"
628,"NCT00579163","Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers","null","Recruiting","No Results Available","Breast Neoplasms|Ovarian Neoplasms|Colonic Neoplasms|Prostatic Neoplasms|Uterine Cervical Neoplasms|Leukemia|Lymphoma, Non-Hodgkin","","To establish a bank of DNA and frozen lymphoblastoid cell lines for the purpose of facilitating genetic epidemiology investigations of familial cancers.|A related goal is to provide patients with cancer and their living relatives the opportunity to preserve DNA samples so that they may be used for future genetic counseling regarding inherited cancer risk.","Memorial Sloan Kettering Cancer Center","All","Child, Adult, Senior","","1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","93-102","December 1994","December 2018","December 2018","August 2017","December 19, 2007","December 21, 2007","null","null","August 23, 2017","August 24, 2017","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00579163"
629,"NCT02848872","Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer","TOP 1502","Recruiting","No Results Available","Non-small Cell Lung Carcinoma","","Quantity of functional tumor infiltrating lymphocytes (TILs) to determine tumor antigen-specific T cell re-activities.","Duke University","All","18 Years and older   (Adult, Senior)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00069742","May 2016","February 2018","February 2021","April 2017","May 26, 2016","July 29, 2016","null","null","April 20, 2017","April 21, 2017","Duke University Medical Center, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT02848872"
630,"NCT01914263","Safety Study of Cord Blood-derived Cytokine-induced Killer Cells in Patients With Solid Tumor After Radical Resection","null","Unknown status","No Results Available","Hepatocellular Carcinoma|Renal Cell Carcinoma|Lung Cancer","Biological: cytokine induced killer cell","The incidence of adverse events following infusion of cord blood-derived cytokine-induced killer cells.|Haematology|Serological analysis","Alliancells-PuRui Biocience Co., Ltd.|Zhongyuan Union Stem Cell Bio-engineering Corporation","All","18 Years to 60 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AlliancellsPuRui-01","March 2014","April 2016","June 2016","July 2014","July 29, 2013","August 2, 2013","null","null","April 15, 2015","April 16, 2015","Hannan BOAO Life infinity international anti-aging medical center, Qionghai, Hainan, China|The 210 Hospital of Chinese People's Liberation Army, Dalian, Liaoning, China|The 323 Hospital of Chinese People's Liberation Army, Xi'an, Shaanxi, China","https://ClinicalTrials.gov/show/NCT01914263"
631,"NCT03337711","Explore Intra-tumor Heterogeneity and Prognostic Value of Postoperative Blood ctDNA of ⅡA - ⅢA Stage Non-squamous NSCLC Based on the Capture-based Sequencing and UMI Technology of Burning Rock","null","Recruiting","No Results Available","Non-small Cell Lung Cancer","","recurrence or metastasis","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","A2017-001","May 24, 2017","May 31, 2020","May 31, 2020","November 2017","November 6, 2017","November 9, 2017","null","null","November 7, 2017","November 9, 2017","Sun Yat-Sen university cancer center, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT03337711"
632,"NCT02401100","Anastomotic Leakage After Anterior Resection for Rectal Cancer - Predictive Biomarkers and Rectal Blood Flow","null","Recruiting","No Results Available","Anastomotic Leak","","Blood flow measurements|Anastomotic leakage","Umeå University","All","Child, Adult, Senior","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UmU-AL-01","May 2015","May 2018","September 2018","October 2017","March 24, 2015","March 27, 2015","null","null","October 25, 2017","October 27, 2017","Umeå University Hospital, Umeå, Sweden","https://ClinicalTrials.gov/show/NCT02401100"
633,"NCT01516489","Improving Fecal Occult Blood Test Completion Rates Among Veterans","null","Completed","No Results Available","Colorectal Cancer","Behavioral: Stage 1|Behavioral: Stage 2","FOBT completion and return|FOBT completion rate among previously non-adherent patients and FOBT kit return time by arm","Corporal Michael J. Crescenz VA Medical Center|VA Pittsburgh Healthcare System","Male","Child, Adult, Senior","Phase 1|Phase 2","1549","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","01334","February 2012","October 2013","June 2015","October 2015","January 19, 2012","January 25, 2012","null","null","October 23, 2015","October 26, 2015","Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT01516489"
634,"NCT00890500","Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.","null","Completed","No Results Available","Hematologic Malignancies|Allogeneic Stem Cell Transplantation","Drug: Fludarabine|Drug: Melphalan|Drug: Antithymocyte Globulin|Drug: Sirolimus|Drug: Tacrolimus","Determine the safety of ProHema modulated umbilical cord blood units when used for transplantation in a reduced intensity, sequential umbilical cord blood transplantation model.|Time to engraftment of umbilical cord blood units|Fractional chimerism of transplanted cord blood units|Rates of acute and chronic GVHD|30- and 100-day treatment related mortality|Measures of immune reconstitution and relapse-free and overall survival at 1 and 2 years after transplantation","Fate Therapeutics|Dana-Farber Cancer Institute","All","18 Years to 65 Years   (Adult)","Phase 1","12","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FT1050-01","January 2011","May 2013","October 2013","October 2013","April 28, 2009","April 29, 2009","null","null","October 7, 2013","October 8, 2013","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT00890500"
635,"NCT01343121","Measurement of Gemcitabine Metabolites in Blood and Urine as Predictors of Response to GemX Bladder Radiotherapy","Gemtrans","Unknown status","No Results Available","Bladder Cancer","Other: sample collection|Other: Sample Collection","Does response at Cystoscopy correlate with results of sample analysis|cause-specific and overall survival rates|acute and late toxicities as assessed by RTOG and LENT SOM scales","The Christie NHS Foundation Trust|University of Oxford","All","18 Years and older   (Adult, Senior)","","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","10_DOG04_124","January 2012","September 2015","January 2018","January 2016","April 7, 2011","April 27, 2011","null","null","January 26, 2016","January 27, 2016","The Christie NHS Foundation Trust, Manchester, Gtr Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01343121"
636,"NCT01495572","Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells","null","Terminated","Has Results","Metastatic Melanoma|Skin Cancer","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Aldesleukin|Drug: MART-1 Reactive CD8+ PBL","Clinical Tumor Response|Number of Participants With Adverse Events","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","5","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","120045|12-C-0045","December 2011","February 2014","February 2014","October 2015","December 16, 2011","December 20, 2011","May 8, 2014","June 10, 2014","October 13, 2015","October 15, 2015","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT01495572"
637,"NCT01441089","Collection of Blood From Cancer Patients for Genetic Analysis","null","Recruiting","No Results Available","Prostate Cancer|Breast Cancer|Lung Cancer|Ovarian Cancer|Lymphoma","","Obtain and analyze the genomic DNA from patients with cancer on a therapeutic clinical trial.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","","1000","NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","110242|11-C-0242","August 25, 2011","null","null","October 6, 2017","September 24, 2011","September 27, 2011","null","null","December 19, 2017","December 20, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT01441089"
638,"NCT02718651","Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer","null","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","","Progression-free survival","University of Aarhus|Aarhus University Hospital|Aalborg Universitetshospital|Odense University Hospital","All","18 Years and older   (Adult, Senior)","","70","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2015-1881-2|1-10-72-266-15|1-16-02-56-16","March 2016","December 2018","December 2018","October 2016","March 18, 2016","March 24, 2016","null","null","October 27, 2016","October 28, 2016","Aarhus University Hospital, Aarhus, Denmark","https://ClinicalTrials.gov/show/NCT02718651"
639,"NCT02291198","Measurement of NK Cell Activity in Whole Blood in Subjects Being Screened for Colorectal Cancer Using Colonoscopy","null","Completed","No Results Available","Natural Killer Cell Cytokine Production","Device: NK Vue: NK cell activity in stimulated whole blood","NK cell activity","ATGen Canada Inc|Maisonneuve-Rosemont Hospital","All","40 Years and older   (Adult, Senior)","","1081","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","ATG-001","October 2014","January 2016","March 2017","August 2017","November 10, 2014","November 14, 2014","null","null","August 11, 2017","August 14, 2017","Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT02291198"
640,"NCT02373735","Effect of SVV Guided Fluid Therapy on Blood Loss and Postoperative Outcomes","null","Completed","No Results Available","Bladder Cancer","Other: crystalloid|Other: colloid|Other: mannitol|Other: lasix","Intraoperative blood loss|Postoperative complications (cardiovascular complications, gastrointestinal complications, pulmonary complications, renal complications, infection, death)|Length of hospital stay/ICU stay","Asan Medical Center","All","20 Years to 80 Years   (Adult, Senior)","","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Supportive Care","S2014-2192","March 2015","November 2015","December 2015","December 2015","February 12, 2015","February 27, 2015","null","null","December 28, 2015","December 30, 2015","Asan Medical Center, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT02373735"
641,"NCT00001493","Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer","null","Completed","No Results Available","Breast Neoplasms|Neoplasm Metastasis","Genetic: peripheral blood progenitor cells carrying MDR1","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","42","NIH","Interventional","Primary Purpose: Treatment","960007|96-C-0007","October 1995","null","June 2000","August 1999","November 3, 1999","December 10, 2002","null","null","March 3, 2008","March 4, 2008","National Cancer Institute (NCI), Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00001493"
642,"NCT02343991","Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound","null","Recruiting","No Results Available","Brain Tumor","Device: Transcranial ExABlate","Number of Device and Procedure related adverse events|Severity of Device and Procedure related adverse events","InSightec","All","18 Years to 70 Years   (Adult, Senior)","","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BBB001|215600","October 2014","December 2017","December 2017","December 2016","January 12, 2015","January 22, 2015","null","null","December 9, 2016","December 13, 2016","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT02343991"
643,"NCT03071913","Blood Brain Barrier Differences in Patients With Brain Tumors Undergoing Surgery","null","Recruiting","No Results Available","Central Nervous System Neoplasm|Metastatic Malignant Neoplasm in the Brain|Primary Brain Neoplasm|Recurrent Brain Neoplasm","Procedure: Biospecimen Collection|Other: Laboratory Biomarker Analysis","BBB permeability as measured by the ratio of drugs in blood and tissue samples taken during surgery|Radiographic appearance at each tissue sample location","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","81","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","MC1671|NCI-2017-00299|P30CA015083","September 5, 2017","March 2021","March 2021","February 2017","February 27, 2017","March 7, 2017","null","null","September 6, 2017","September 7, 2017","Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT03071913"
644,"NCT00216541","A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy","null","Completed","No Results Available","Anemia|Neoplasms","Drug: epoetin alfa","Change in hemoglobin from the start of the study to 3 or 4, 8 or 9, and 12 weeks, and at the end of the treatment period|Number of patients who receive an allogenic blood transfusion during the study","Janssen-Cilag B.V.","All","18 Years and older   (Adult, Senior)","Phase 4","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR003541","August 2003","null","September 2006","June 2010","September 13, 2005","September 22, 2005","null","null","May 18, 2011","May 19, 2011","","https://ClinicalTrials.gov/show/NCT00216541"
645,"NCT02491593","Quantitative Immunochemical Fecal Occult Blood Test in Symptomatic Patients","FIKA","Enrolling by invitation","No Results Available","Colorectal Neoplasms","Device: fecal occult blood test","Number of patients with high fecal blood output in relation to colorectal cancer|Number of patients with low fecal blood output in relation to colorectal polyps","Uppsala University","All","18 Years and older   (Adult, Senior)","","500","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","QFecalBlood 2013/2:7","April 2014","December 2016","December 2016","March 2016","June 30, 2015","July 8, 2015","null","null","March 9, 2016","March 10, 2016","Unit of Endoscopy, Eskilstuna, Sweden","https://ClinicalTrials.gov/show/NCT02491593"
646,"NCT00580463","Collection of Tumor Tissue, Blood and Spinal Fluid From Patients With Brain or Spine Tumors","null","Completed","No Results Available","Primary or Metastatic Central Nervous System (CNS) Tumor","","To establish a repository of CNS tumors or metastases to the CNS and related tissues for current or future studies.","Memorial Sloan Kettering Cancer Center|Rockefeller University","All","Child, Adult, Senior","","1128","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","99-125","January 2000","March 2009","March 2009","March 2009","December 20, 2007","December 24, 2007","null","null","March 18, 2009","March 19, 2009","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00580463"
647,"NCT02700776","1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer","1380GCC","Terminated","No Results Available","Healthy Volunteers","Other: Phlebotomy - Blood sampling for GP88 at MM|Procedure: SOC Tissue biopsy","Determine the GP-88 blood levels in healthy female volunteers who are undergoing routine screening mammography","University of Maryland|A&G Pharmaceutical","Female","40 Years to 64 Years   (Adult)","","417","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HP-00058144 1380GCC","April 2014","February 27, 2017","February 27, 2017","May 2017","March 1, 2016","March 7, 2016","null","null","May 1, 2017","May 2, 2017","University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States|Baltimore Washington Medical Center, Glen Burnie, Maryland, United States","https://ClinicalTrials.gov/show/NCT02700776"
648,"NCT02951273","Cerebral Blood Flow During Propofol Anaesthesia","null","Completed","Has Results","Gastrointestinal Neoplasms","Other: Study of cerebral blood flow","Changes in Internal Carotid Artery Blood Flow by Treatment of Anaesthesia-induced Hypotension|Changes in Internal Carotid Artery Blood Flow by Induction of Anaesthesia.|Association Between Changes in Internal Carotid Artery Blood Flow, Mean Arterial Pressure and Cardiac Output by Treatment of Anaesthesia-induced Hypotension.|Changes in Frontal Lobe Oxygenation by Development of Mesenteric Traction Syndrome.|Changes in Forehead Skin Blood Flow by Development of Mesenteric Traction Syndrome.|Changes in Forehead Skin Oxygenation by Development of Mesenteric Traction Syndrome.|Changes in Internal Carotid Artery Blood Flow by Development of Mesenteric Traction Syndrome.|Changes in the CO2 Reactivity of the Internal Carotid Artery From Before to After Induction of Anaesthesia.|Changes in Heart Rate From Baseline Before Induction of Anaesthesia.|Changes in Mean Arterial Pressure From Baseline Before Induction of Anaesthesia.|Changes in Cardiac Output From Baseline Before Induction of Anaesthesia.|Changes in Stroke Volume From Baseline Before Induction of Anaesthesia.","Rigshospitalet, Denmark","All","18 Years and older   (Adult, Senior)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-16036250","December 8, 2016","July 6, 2017","July 6, 2017","November 2017","October 26, 2016","November 1, 2016","October 6, 2017","November 17, 2017","November 19, 2017","December 14, 2017","Department of Anaesthesia, Rigshospitalet 2043, Copenhagen, Denmark","https://ClinicalTrials.gov/show/NCT02951273"
649,"NCT01682252","Analysis of Blood During Surgery for Musculoskeletal Tumors","null","Terminated","No Results Available","Musculoskeletal Tumors","","presence of tumor cells in the operative field","Rutgers, The State University of New Jersey","All","18 Years to 90 Years   (Adult, Senior)","","34","Other","Observational","Time Perspective: Prospective","01201000247","May 2012","November 2015","February 2016","February 2016","September 5, 2012","September 10, 2012","null","null","February 8, 2016","February 9, 2016","University Hospital, Newark, New Jersey, United States","https://ClinicalTrials.gov/show/NCT01682252"
650,"NCT00436761","Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors","null","Unknown status","No Results Available","Unspecified Childhood Solid Tumor, Protocol Specific","Biological: anti-thymocyte globulin|Biological: graft-versus-tumor induction therapy|Biological: sargramostim|Drug: busulfan|Drug: cyclosporine|Drug: melphalan|Drug: methylprednisolone|Other: flow cytometry|Other: immunologic technique|Other: laboratory biomarker analysis|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation","Safety|Incidence of graft-versus-host disease|Donor/host chimerism status|Immune function post-transplant","Milton S. Hershey Medical Center|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 1","20","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000529361|PSCI-18589","May 2004","null","null","June 2007","February 15, 2007","February 19, 2007","null","null","December 17, 2013","December 18, 2013","Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00436761"
651,"NCT01862770","Effect of Lung Cancer Diagnoses on Family Behaviors","null","Completed","No Results Available","Lung Cancer|Blood Relatives of Patient w/Lung Cancer|Cigarette Smokers","","The primary aim of the analyses is to identify for whom genetic testing for lung cancer susceptibility may be a teachable moment to promote behavior change.","National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","","600","NIH","Observational","Time Perspective: Prospective","999913050|13-HG-N050","December 18, 2012","November 25, 2013","February 25, 2016","February 25, 2016","May 23, 2013","May 24, 2013","null","null","June 30, 2017","July 2, 2017","Moffitt Cancer Center, Tampa, Florida, United States|Duke University Medical Center, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT01862770"
652,"NCT00696345","Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay","null","Completed","No Results Available","Colorectal Cancer","","","Epigenomics, Inc","All","40 Years and older   (Adult, Senior)","","700","Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","Septin-9-2006","January 2005","October 2006","February 2007","June 2008","June 10, 2008","June 12, 2008","null","null","June 13, 2008","June 17, 2008","Department of Surgery and Surgical Oncology, Charité Campus Berlin Buch, Berlin, Germany|Department of Visceral-, Thoracic- and Vascular Surgery, University Hospital Carl Gustav Carus, Dresden, Germany|Department of Surgery, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany|Völklingen Clinic, Völklingen, Germany|Semmelweis University, Budapest, Hungary","https://ClinicalTrials.gov/show/NCT00696345"
653,"NCT02534142","Colonoscopy Followup After Positive Fecal Occult Blood Test- Understanding Barriers to Adherence","null","Recruiting","No Results Available","Colorectal Cancer","","Variables related to non-completion of colonoscopy following a positive fecal occult blood test","Meuhedet. Healthcare Organization|Bar-Ilan University, Israel","All","51 Years to 74 Years   (Adult, Senior)","","2000","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","01-20-05-15","October 2015","February 2017","December 2018","November 2016","July 28, 2015","August 27, 2015","null","null","December 8, 2016","December 9, 2016","Meuhedet, Tel Aviv, Israel","https://ClinicalTrials.gov/show/NCT02534142"
654,"NCT00897962","Blood Glycan Biomarkers in Women With Stage IV Breast Cancer","null","Active, not recruiting","No Results Available","Breast Cancer","Other: Healthy Controls|Other: Metastatic Breast Cancer|Other: Non-cancer medical illness","Profiling serum glycan biomarkers in patients with metastatic breast cancer, healthy controls, and patients with noncancer medical illness|Predictability of serial serum biomarkers in determining disease response and/or progression","University of California, Davis","Female","18 Years and older   (Adult, Senior)","","200","Other","Observational","","CDR0000583066|UCD-186|UCD-200614601","September 2006","February 2011","December 2017","January 2017","May 9, 2009","May 12, 2009","null","null","January 3, 2017","January 4, 2017","University of California Davis Cancer Center, Sacramento, California, United States","https://ClinicalTrials.gov/show/NCT00897962"
655,"NCT02385955","Phase II Study of Myeloablative Double Unit Umbilical Cord Blood Transplantation in Adult Patients","null","Not yet recruiting","No Results Available","Hematologic Malignancy","Procedure: Myeloablative double unit cord blood transplantation","Overall survival|Progression-free survival|Time to relapse or progression|Time to engraftment|Acute graft-versus-host disease|Chronic graft-versus-host disease|Non-relapse mortality|Other transplant-related serious adverse events","Seoul National University Hospital|The Korean Society of Blood and Marrow Transplantation","All","18 Years to 65 Years   (Adult)","Phase 2","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSBMT200809","April 2015","April 2017","April 2019","March 2015","January 20, 2015","March 11, 2015","null","null","March 10, 2015","March 11, 2015","","https://ClinicalTrials.gov/show/NCT02385955"
656,"NCT01763125","Tumor Bank for Blood Samples","null","Unknown status","No Results Available","Ovarian Neoplasms|Breast Neoplasms|Colorectal Neoplasms|Neoplasms of the Female Genitalia|Lung Neoplasms|Endocrine Gland Neoplasms","Other: Blood collection","Establishment of blood/tissue bank consisting of oncological samples from cancer patients and benign and healthy controls.","Medical University of Vienna","All","18 Years and older   (Adult, Senior)","","10000","Other","Observational","Observational Model: Case Control","EK 366/2003","November 2003","January 2017","January 2017","September 2015","January 4, 2013","January 8, 2013","null","null","September 28, 2015","September 30, 2015","Innsbruck Medical University, Innsbruck, Austria|University Hospitals Leuven - Department of Obstetrics and Gynaecology, Leuven, Belgium|University Hospital Motol, Charles University, Dpt of Obstet. & Gynaec., Praha, Czech Republic|Charité University - Campus Virchow Chlinic, Berlin, Germany|University Medical Center Freiburg, Freiburg, Germany|University Clinic of Ruhr University Bochum, Herne, Germany|European Institute of Oncology, Division of Gynecologic Oncology, Unit of Preventive Gynecology, Milan, Italy|Imperial College London - Faculty of Medicine, Dpt. of Surgery & Cancer, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01763125"
657,"NCT00576563","Rectal Study: Value of Repeated FDG-PET-CT Scans in Rectal Cancer","null","Completed","No Results Available","Rectum Cancer","Drug: FDG","The metabolic tumour response by PET scan will be determined according to the EORTC criteria (appendix 1)61. The pathological tumour response will be determined according to Dworak and Wheeler.62,63|Clinical examination(weight, performance status including the CTCv3.0 scale for acute and late reactions)","Maastricht Radiation Oncology","All","18 Years and older   (Adult, Senior)","","103","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-02","March 2007","January 2015","December 2015","April 2016","December 18, 2007","December 19, 2007","null","null","April 20, 2016","April 21, 2016","Maastricht Radiation Oncology, Maastricht, Limburg, Netherlands","https://ClinicalTrials.gov/show/NCT00576563"
658,"NCT00005851","Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer","null","Active, not recruiting","No Results Available","Recurrent Renal Cell Cancer|Stage IV Renal Cell Cancer","Drug: fludarabine phosphate|Radiation: total-body irradiation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Drug: cyclosporine|Drug: mycophenolate mofetil|Procedure: peripheral blood stem cell transplantation|Biological: therapeutic allogeneic lymphocytes|Other: laboratory biomarker analysis","True response rate (complete response [CR] or partial response [PR]) greater than the 15% achievable with standard therapy|Transplant-related mortality|Rate of grade IV acute GVHD|Survival|Incidence of relapse|Incidence of myelosuppression after initial PBSC infusion|Incidence of aplasia after DLI|Incidence of grades 2-4 acute GVHD after DLI|Incidence of grades chronic extensive GVHD after DLI","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 74 Years   (Child, Adult, Senior)","Phase 1|Phase 2","11","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1495.00|NCI-2012-00581|P30CA015704","February 2000","July 2004","null","July 2017","June 2, 2000","January 27, 2003","null","null","July 3, 2017","July 5, 2017","University of Arizona Health Sciences Center, Tucson, Arizona, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|Baylor University Medical Center, Dallas, Texas, United States|VA Puget Sound Health Care System, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT00005851"
659,"NCT00898703","Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer","null","Completed","No Results Available","Breast Cancer","Other: flow cytometry|Other: immunoenzyme technique|Other: laboratory biomarker analysis","Comparison of levels of peripheral blood (PB) circulating endothelial cells (CEC) and plasma angiogenic factors between patients with active, measurable breast cancer vs prior history of breast cancer with no evidence of active disease|Correlation of CEC and plasma angiogenic factors with response to tumor to a chemotherapy regimen","University of Arizona|National Cancer Institute (NCI)","Female","Child, Adult, Senior","","50","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CDR0000597587|P30CA023074|UARIZ-HSCA01134","August 2001","March 2007","March 2007","December 2012","May 9, 2009","May 12, 2009","null","null","December 13, 2012","December 17, 2012","Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States","https://ClinicalTrials.gov/show/NCT00898703"
660,"NCT02476162","Assessing Blood Pressure Remotely in Childhood Cancer Survivors","null","Completed","No Results Available","Hypertension","Device: iHealth Wireless Blood Pressure Monitor","Proportion of participants who meet or exceed defined minimum use of HBPM device by group|Compliance rate for the use of the HBPM device by group measurement frequency|Proportion of participants who comply with the use of HBPM device by cell phone status|Number of participants who fail to record any blood pressure measurements over the course of a month|Proportion of participants by group who recorded at least 80% of scheduled measurements","St. Jude Children's Research Hospital","All","18 Years and older   (Adult, Senior)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FABRIC|NCI-2015-02265","June 2015","January 2016","January 2016","September 2016","June 16, 2015","June 19, 2015","null","null","September 13, 2016","September 15, 2016","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","https://ClinicalTrials.gov/show/NCT02476162"
661,"NCT00766454","Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer","null","Completed","No Results Available","Breast Cancer","Genetic: DNA analysis|Genetic: mutation analysis|Genetic: polymorphism analysis|Other: laboratory biomarker analysis|Other: medical chart review|Other: questionnaire administration|Procedure: evaluation of cancer risk factors","Association between the genotype for 4 metabolic enzymes (e.g., CYP1A1, GSTM, GSTT, and GSTP) that play key roles in the metabolism of environmental human carcinogens and the risk of breast cancer development","Wake Forest University Health Sciences|National Cancer Institute (NCI)","Female","up to 120 Years   (Child, Adult, Senior)","","1104","Other|NIH","Observational","Observational Model: Other|Time Perspective: Prospective","CDR0000573065|P30CA012197|CCCWFU-98298|CCCWFU-BG98-278","November 1998","January 2010","January 2010","October 2015","October 3, 2008","October 6, 2008","null","null","July 27, 2017","August 1, 2017","Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00766454"
662,"NCT01410760","PERfusion CT in the FOXFIRE Trial to Study Blood Flow to Liver Metastases","PERFORM","Unknown status","No Results Available","Metastatic Colorectal Cancer","Other: Perfusion CT scan","Recruitment rate to this voluntary study and acquisition of sufficient data for perfusion analysis|Correlation between the tumour perfusion pattern on perfusion CT studies at baseline and shortly after the start of therapy and morphological response by RECIST criteria on CT scan 3 months post therapy in both arms of the FOXFIRE trial.","University of Oxford|Oxford University Hospitals NHS Trust|University Hospitals, Leicester","All","18 Years and older   (Adult, Senior)","Early Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","10/H0505/95","April 2011","April 2013","null","June 2012","August 3, 2011","August 5, 2011","null","null","June 19, 2012","June 20, 2012","Oxford Radcliffe Hospitals NHS Trust, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT01410760"
663,"NCT00898014","Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast Cancer","null","Completed","No Results Available","Breast Cancer","Genetic: fluorescence in situ hybridization|Other: immunologic technique|Other: laboratory biomarker analysis","Correlation of circulating tumor cells (CTC) with overall survival|Correlation of CTC with progression-free survival|Correlation of circulating tumor cells with tumor markers, clinical response, and radiological response|Change in HER-2 status in patients receiving trastuzumab (Herceptin®)","Institut Curie|National Cancer Institute (NCI)","All","Child, Adult, Senior","","216","Other","Observational","","CDR0000574195|CLCC-IC-2006-04|INCA-RECF0474","May 2007","April 2010","null","July 2009","May 9, 2009","May 12, 2009","null","null","May 12, 2011","May 13, 2011","Institut Curie Hopital, Paris, France","https://ClinicalTrials.gov/show/NCT00898014"
664,"NCT01034033","Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples","null","Recruiting","No Results Available","Breast Cancer|Ovarian Cancer|Gynecologic Cancers|Ovarian/Peritoneal/Fallopian Cancer","","","Stanford University|United States Department of Defense","Female","18 Years and older   (Adult, Senior)","","1500","Other|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","BRSNSTU0020|76102|SU-11022007-786","August 2001","January 2099","January 2099","July 2016","December 16, 2009","December 17, 2009","null","null","July 12, 2016","July 14, 2016","Stanford University School of Medicine, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT01034033"
665,"NCT02239575","Collection of Retrospective (Archival) Samples and Prospective Collection of Surplus Tissue and Blood Samples","GBCPRT0009","Enrolling by invitation","No Results Available","Cancer","","Identification and validation of cancer biomarkers in archival formalin fixed and paraffin embedded tumor samples","Global BioClinical","All","18 Years and older   (Adult, Senior)","","800","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","GBC PRT0009","March 2014","December 2018","December 2018","December 2017","July 16, 2014","September 15, 2014","null","null","December 4, 2017","December 6, 2017","Global BioClinical, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT02239575"
666,"NCT00026663","Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance","null","Recruiting","No Results Available","Renal Cell Carcinoma|Lung Carcinoma|Cervical Carcinoma","","Obtain specimens to develop assays","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult)","","100","NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","000078|00-C-0078","February 17, 2000","null","null","December 18, 2017","November 14, 2001","November 15, 2001","null","null","December 27, 2017","December 28, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00026663"
667,"NCT00327925","Blood Test for Ovarian Cancer Associated Antibodies (CAAb)","null","Unknown status","No Results Available","Ovarian Cancer","Procedure: Find Cancer Associated Antibodies","","Lab Discoveries Ltd.","Female","18 Years and older   (Adult, Senior)","","60","Industry","Observational","Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Cross-Sectional|Time Perspective: Retrospective/Prospective","LD-OC-CAAb","July 2006","null","June 2008","May 2006","May 18, 2006","May 19, 2006","null","null","March 1, 2007","March 2, 2007","Shiba Hospital, Tel Hashomer, Tel Aviv, Israel|Soroka, Beer-Sheva, Israel|Carmel Hospital, Haifa, Israel|Hadassah Hospital, Ein Karem Campus, Jerusalem, Israel|Hadassah Hospital, Mt. Scopus Campus, Jerusalem, Israel","https://ClinicalTrials.gov/show/NCT00327925"
668,"NCT01530581","Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation","null","Completed","No Results Available","Transplantation for Hematologic Malignancies","Procedure: G-PB Transplant|Procedure: G-BM Transplant","Efficacy","King Faisal Specialist Hospital & Research Center","All","16 Years to 65 Years   (Child, Adult)","Phase 3","230","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2081-076","November 2008","June 2012","June 2014","January 2016","January 23, 2012","February 10, 2012","null","null","January 4, 2016","January 5, 2016","King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia","https://ClinicalTrials.gov/show/NCT01530581"
669,"NCT00147862","Does Tranexamic Acid Administration Reduce Blood Loss During Head and Neck Surgery?","null","Completed","No Results Available","Head and Neck Neoplasms","Drug: Tranexamic Acid","Administration of tranexamic acid reduces perioperative blood loss and thus,|Requirement for replacement of blood in head and neck surgeries|To observe procoagulant effects leading to complications, if any.|Cost effectiveness of the drug in terms of savings on blood transfusion requirements.","Tata Memorial Hospital","All","Child, Adult, Senior","Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","TMH/185/IM-2004","May 2005","null","January 2007","February 2007","September 2, 2005","September 7, 2005","null","null","February 6, 2007","February 7, 2007","Tata Memorial Hospital, Mumbai, Maharashtra, India","https://ClinicalTrials.gov/show/NCT00147862"
670,"NCT00471978","DNA Analysis of Blood and Tissue From Patients With Lung Cancer","null","Recruiting","No Results Available","Lung Cancer","","Metabolic polymorphisms","Massachusetts General Hospital|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","","6800","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CDR0000450128|MGH-1999-P-004935/26","September 2005","June 2022","September 2022","August 2017","May 8, 2007","May 10, 2007","null","null","August 31, 2017","September 1, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States|Harvard School of Public Health, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT00471978"
671,"NCT01171235","Study of Biomarker From Blood and Tissue of Head and Neck Carcinoma","null","Unknown status","No Results Available","Laryngeal Neoplasms|Pharyngeal Neoplasms","","","Southern Medical University, China","All","15 Years to 75 Years   (Child, Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NFYY-H&N-1","July 2010","December 2011","December 2012","March 2009","July 27, 2010","July 28, 2010","null","null","July 27, 2010","July 28, 2010","","https://ClinicalTrials.gov/show/NCT01171235"
672,"NCT01138345","Biomarkers in Blood Samples From Older Breast Cancer Survivors","null","Completed","No Results Available","Breast Cancer","Genetic: gene expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: laboratory biomarker analysis|Other: medical chart review|Other: questionnaire administration","p16INK4a expression between cohort 2 vs cohort 3|p16INK4a expression between cohort 1 vs cohort 2|p16INK4a expression between cohorts 1, 2, and 3 vs cohort 4","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","50 Years and older   (Adult, Senior)","Phase 1","246","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","LCCC 0924|P30CA016086|CDR0000674103","January 2010","January 2013","February 2014","February 2014","June 4, 2010","June 7, 2010","null","null","February 26, 2014","February 27, 2014","Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States","https://ClinicalTrials.gov/show/NCT01138345"
673,"NCT02153151","Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy","null","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Other: Cytology specimen|Other: Laboratory biomarker analysis","Change in peripheral blood T cell proliferation (stimulation) and cytokine production in vitro","Sidney Kimmel Cancer Center at Thomas Jefferson University|MedImmune LLC|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","","21","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13D.374|2013-021","November 11, 2013","February 23, 2016","July 14, 2016","September 2017","May 29, 2014","June 2, 2014","null","null","September 5, 2017","September 6, 2017","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT02153151"
674,"NCT01120262","S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin","null","Completed","No Results Available","Prostate Cancer","Genetic: gene expression analysis|Genetic: polymorphism analysis|Other: laboratory biomarker analysis","Serum PSA values at 7 months|Role of genetic variation in response to therapy","Southwest Oncology Group|National Cancer Institute (NCI)","Male","18 Years to 120 Years   (Adult, Senior)","","545","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CDR0000669307|SWOG-S9346A","February 2010","July 2010","July 2010","October 2016","May 7, 2010","May 10, 2010","null","null","October 6, 2016","October 7, 2016","","https://ClinicalTrials.gov/show/NCT01120262"
675,"NCT00897728","Study of Tumor and Blood Samples From Women With Breast Cancer","null","Unknown status","No Results Available","Breast Cancer","Other: laboratory biomarker analysis","Local or remote relapse as assessed by biomarkers in tissue and blood samples collected during the first 2 years after diagnosis","Institut Curie|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","","180","Other","Observational","","CDR0000599189|CLCC-IC-COBRED-SEIN|CLCC-IC-2007-11|CLCC-RECF0632","February 2008","February 2010","null","July 2009","May 9, 2009","May 12, 2009","null","null","November 30, 2010","December 1, 2010","Institut Curie Hopital, Paris, France","https://ClinicalTrials.gov/show/NCT00897728"
676,"NCT00967889","Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer","null","Unknown status","No Results Available","Prostate Cancer","Genetic: gene expression analysis|Genetic: protein analysis|Other: biologic sample preservation procedure|Other: laboratory biomarker analysis","Molecular pathology and mechanisms of disease progression|Development of novel treatment strategies for patients with advanced prostate cancer|Evaluation of novel markers and treatment and epidemiological approaches","Cancer Research UK|National Cancer Institute (NCI)","Male","Child, Adult, Senior","","null","Other","Observational","","CRUK-ProMPT|CDR0000638974|EU-20919","January 2002","June 2011","null","August 2009","August 27, 2009","August 28, 2009","null","null","August 9, 2013","August 12, 2013","Cancer Research UK at Cambridge Research Institute, Cambridge, England, United Kingdom","https://ClinicalTrials.gov/show/NCT00967889"
677,"NCT00382018","S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo","null","Completed","Has Results","Breast Cancer","Drug: chemotherapy","Overall Survival|Progression-free Survival|Progression Free Survival|Number of Patients With Adverse Events That Are Related to Study Drugs","Southwest Oncology Group|National Cancer Institute (NCI)|Cancer and Leukemia Group B","Female","18 Years and older   (Adult, Senior)","Phase 3","624","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CDR0000504319|S0500|U10CA032102","October 2006","December 2015","July 11, 2017","October 2017","September 26, 2006","September 28, 2006","December 16, 2016","April 4, 2017","October 3, 2017","November 6, 2017","Regional Medical Center, Anniston, Alabama, United States|Alaska Regional Hospital Cancer Center, Anchorage, Alaska, United States|Providence Cancer Center, Anchorage, Alaska, United States|NEA Medical Center - Stadium Boulevard, Jonesboro, Arkansas, United States|Glendale Memorial Hospital Comprehensive Cancer Center, Glendale, California, United States|California Cancer Care, Incorporated - Greenbrae, Greenbrae, California, United States|Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|Camino Medical Group - Treatment Center, Mountain View, California, United States|Palo Alto Medical Foundation, Palo Alto, California, United States|Stanford Cancer Center, Stanford, California, United States|San Luis Valley Regional Medical Center, Alamosa, Colorado, United States|University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, United States|Veterans Affairs Medical Center - Denver, Denver, Colorado, United States|Shaw Regional Cancer Center, Edwards, Colorado, United States|Valley View Hospital Cancer Center, Glenwood Springs, Colorado, United States|St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center, Grand Junction, Colorado, United States|Montrose Memorial Hospital Cancer Center, Montrose, Colorado, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|Yale Cancer Center, New Haven, Connecticut, United States|Florida Hospital Cancer Institute at Florida Hospital Orlando, Orlando, Florida, United States|Pearlman Comprehensive Cancer Center at South Georgia Medical Center, Valdosta, Georgia, United States|Kapiolani Medical Center at Pali Momi, 'Aiea, Hawaii, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|OnCare Hawaii, Incorporated - Lusitana, Honolulu, Hawaii, United States|Queen's Cancer Institute at Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Incorporated, Honolulu, Hawaii, United States|Hawaii Medical Center - East, Honolulu, Hawaii, United States|OnCare Hawaii, Incorporated - Kuakini, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Maui Memorial Medical Center, Wailuku, Hawaii, United States|Pacific Cancer Institute - Maui, Wailuku, Hawaii, United States|Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, United States|Resurrection Medical Center, Chicago, Illinois, United States|Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States|Elmhurst Memorial Hospital, Elmhurst, Illinois, United States|Ingalls Cancer Care Center at Ingalls Memorial Hospital, Harvey, Illinois, United States|Swedish-American Regional Cancer Center, Rockford, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Michiana Hematology-Oncology, PC - Elkhart, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Community Regional Cancer Care at Community Hospital North, Indianapolis, Indiana, United States|St. Vincent Indianapolis Hospital, Indianapolis, Indiana, United States|Howard Community Hospital, Kokomo, Indiana, United States|Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, United States|Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States|Michiana Hematology-Oncology, PC - South Bend, Mishawaka, Indiana, United States|Saint Joseph Regional Medical Center, Mishawaka, Indiana, United States|Cancer Center at Ball Memorial Hospital, Muncie, Indiana, United States|Michiana Hematology Oncology PC - Plymouth, Plymouth, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology Oncology PC - La Porte, Westville, Indiana, United States|McFarland Clinic, PC, Ames, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Covenant Cancer Treatment Center, Waterloo, Iowa, United States|Tammy Walker Cancer Center at Salina Regional Health Center, Salina, Kansas, United States|Cotton-O'Neil Cancer Center, Topeka, Kansas, United States|Mercy Hospital, Portland, Maine, United States|Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States|Saint Vincent Hospital at Worcester Medical Center, Worcester, Massachusetts, United States|Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Battle Creek Health System Cancer Care Center, Battle Creek, Michigan, United States|Bay Regional Medical Center, Bay City, Michigan, United States|Mecosta County Medical Center, Big Rapids, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Green Bay Oncology, Limited - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Butterworth Hospital at Spectrum Health, Grand Rapids, Michigan, United States|CCOP - Grand Rapids, Grand Rapids, Michigan, United States|Lacks Cancer Center at Saint Mary's Health Care, Grand Rapids, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Dickinson County Healthcare System, Iron Mountain, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Breslin Cancer Center at Ingham Regional Medical Center, Lansing, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|Community Cancer Center of Monroe, Monroe, Michigan, United States|Mercy Memorial Hospital - Monroe, Monroe, Michigan, United States|Clemens Regional Medical Center, Mount Clemens, Michigan, United States|Mercy General Health Partners, Muskegon, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|Lakeland Regional Cancer Care Center - St. Joseph, Saint Joseph, Michigan, United States|Lakeside Cancer Specialists, PLLC, Saint Joseph, Michigan, United States|Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|Alexandria, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology Hematology, PA - Maplewood, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|CentraCare Clinic - River Campus, Saint Cloud, Minnesota, United States|Coborn Cancer Center, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States|Regions Hospital Cancer Care Center, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|St. Francis Cancer Center at St. Francis Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Willmar Cancer Center at Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States|University of Mississippi Cancer Clinic, Jackson, Mississippi, United States|Regional Cancer Center at Singing River Hospital, Pascagoula, Mississippi, United States|Central Care Cancer Center at Carrie J. Babb Cancer Center, Bolivar, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Goldschmidt Cancer Center, Jefferson City, Missouri, United States|Missouri Baptist Cancer Center, Saint Louis, Missouri, United States|Comprehensive Cancer Care, PC, Saint Louis, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Big Sky Oncology, Great Falls, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Good Samaritan Cancer Center at Good Samaritan Hospital, Kearney, Nebraska, United States|Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|UMDNJ University Hospital, Newark, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States|Lovelace Medical Center - Downtown, Albuquerque, New Mexico, United States|Hematology Oncology Associates, PC, Albuquerque, New Mexico, United States|Presbyterian Cancer Treatment Center at Presbyterian Kaseman Hospital, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|University of New Mexico Cancer Center - South, Las Cruces, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|CCOP - Hematology-Oncology Associates of Central New York, East Syracuse, New York, United States|Albert Einstein Cancer Center at Albert Einstein College of Medicine, The Bronx, New York, United States|Faxton Regional Cancer Center, Utica, New York, United States|Dickstein Cancer Treatment Center at White Plains Hospital Center, White Plains, New York, United States|Duke Cancer Institute, Durham, North Carolina, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States|Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Kinston Medical Specialists, Kinston, North Carolina, United States|Southeastern Regional Medical Center, Lumberton, North Carolina, United States|Granville Medical Center, Oxford, North Carolina, United States|Duke Health Raleigh Hospital, Raleigh, North Carolina, United States|Person Memorial Hospital, Roxboro, North Carolina, United States|Bismarck Cancer Center, Bismarck, North Dakota, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States|Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States|Cleveland Clinic Beachwood Family Health and Surgery Center, Beachwood, Ohio, United States|Wood County Oncology Center, Bowling Green, Ohio, United States|Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Community Cancer Center, Elyria, Ohio, United States|Hematology Oncology Center, Elyria, Ohio, United States|Cleveland Clinic Cancer Center, Independence, Ohio, United States|St. Rita's Medical Center, Lima, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Northwest Ohio Oncology Center, Maumee, Ohio, United States|Hillcrest Cancer Center at Hillcrest Hospital, Mayfield Heights, Ohio, United States|Fisher-Titus Medical Center, Norwalk, Ohio, United States|St. Charles Mercy Hospital, Oregon, Ohio, United States|Toledo Clinic - Oregon, Oregon, Ohio, United States|Parma Community General Hospital, Parma, Ohio, United States|North Coast Cancer Care, Incorporated, Sandusky, Ohio, United States|Cleveland Clinic Foundation - Strongsville, Strongsville, Ohio, United States|Flower Hospital Cancer Center, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|Toledo Hospital, Toledo, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Medical University of Ohio Cancer Center, Toledo, Ohio, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|St. Anne Mercy Hospital, Toledo, Ohio, United States|Toledo Clinic, Incorporated - Main Clinic, Toledo, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Cleveland Clinic - Wooster, Wooster, Ohio, United States|Natalie Warren Bryant Cancer Center at St. Francis Hospital, Tulsa, Oklahoma, United States|St. Charles Medical Center - Bend, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Three Rivers Community Hospital, Grants Pass, Oregon, United States|Dubs Cancer Center at Rogue Valley Medical Center, Medford, Oregon, United States|Providence Cancer Center at PMCC, Medford, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Willamette Falls Hospital, Oregon City, Oregon, United States|Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, United States|CCOP - Columbia River Oncology Program, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Ephrata Cancer Center at Ephrata Community Hospital, Ephrata, Pennsylvania, United States|Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States|Cancer Center at Phoenixville Hospital, Phoenixville, Pennsylvania, United States|UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States|McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading, Pennsylvania, United States|Guthrie Cancer Center at Guthrie Clinic Sayre, Sayre, Pennsylvania, United States|Hematology and Oncology Associates of Northeastern Pennsylvania, Scranton, Pennsylvania, United States|Roper St. Francis Cancer Center at Roper Hospital, Charleston, South Carolina, United States|Cancer Centers of the Carolinas - Easley, Easley, South Carolina, United States|Cancer Centers of the Carolinas - Faris Road, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Grove Commons, Greenville, South Carolina, United States|Greenville Hospital Cancer Center, Greenville, South Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|Cancer Centers of the Carolinas - Greer Medical Oncology, Greer, South Carolina, United States|Cancer Centers of the Carolinas - Seneca, Seneca, South Carolina, United States|Cancer Centers of the Carolinas - Spartanburg, Spartanburg, South Carolina, United States|West Tennessee Cancer Center at Jackson-Madison County General Hospital, Jackson, Tennessee, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|Veterans Affairs Medical Center - San Antonio (Murphy), San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Cancer Therapy and Research Center, San Antonio, Texas, United States|University Hospital - San Antonio, San Antonio, Texas, United States|CCOP - Scott and White Hospital, Temple, Texas, United States|American Fork Hospital, American Fork, Utah, United States|Sandra L. Maxwell Cancer Center, Cedar City, Utah, United States|Logan Regional Hospital, Logan, Utah, United States|Jon and Karen Huntsman Cancer Center at Intermountain Medical Center, Murray, Utah, United States|Val and Ann Browning Cancer Center at McKay-Dee Hospital Center, Ogden, Utah, United States|Utah Valley Regional Medical Center - Provo, Provo, Utah, United States|Dixie Regional Medical Center - East Campus, Saint George, Utah, United States|Utah Cancer Specialists at UCS Cancer Center, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|Danville Regional Medical Center, Danville, Virginia, United States|Fredericksburg Oncology, Incorporated, Fredericksburg, Virginia, United States|Virginia Cancer Institute - West End, Richmond, Virginia, United States|Island Hospital Cancer Care Center at Island Hospital, Anacortes, Washington, United States|St. Joseph Cancer Center, Bellingham, Washington, United States|Olympic Hematology and Oncology, Bremerton, Washington, United States|Highline Medical Center Cancer Center, Burien, Washington, United States|Providence Centralia Hospital, Centralia, Washington, United States|St. Francis Hospital, Federal Way, Washington, United States|Columbia Basin Hematology, Kennewick, Washington, United States|Skagit Valley Hospital Cancer Care Center, Mount Vernon, Washington, United States|Providence St. Peter Hospital Regional Cancer Center, Olympia, Washington, United States|Harrison Poulsbo Hematology and Onocology, Poulsbo, Washington, United States|Good Samaritan Cancer Center, Puyallup, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Minor and James Medical, PLLC, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Group Health Central Hospital, Seattle, Washington, United States|Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle, Washington, United States|University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States|North Puget Oncology at United General Hospital, Sedro-Woolley, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|Evergreen Hematology and Oncology, PS, Spokane, Washington, United States|Franciscan Cancer Center at St. Joseph Medical Center, Tacoma, Washington, United States|Allenmore Hospital, Tacoma, Washington, United States|CCOP - Northwest, Tacoma, Washington, United States|MultiCare Regional Cancer Center at Tacoma General Hospital, Tacoma, Washington, United States|St. Clare Hospital, Tacoma, Washington, United States|Southwest Washington Medical Center Cancer Center, Vancouver, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Gundersen Lutheran Center for Cancer and Blood, La Crosse, Wisconsin, United States|Holy Family Memorial Medical Center Cancer Care Center, Manitowoc, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States|St. Nicholas Hospital, Sheboygan, Wisconsin, United States|Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Oncology Alliance, SC - Milwaukee - West, Wauwatosa, Wisconsin, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States","https://ClinicalTrials.gov/show/NCT00382018"
678,"NCT00445562","Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters","null","Unknown status","No Results Available","Breast Cancer","Other: biologic sample preservation procedure|Other: informational intervention","Collection of blood samples and medical and background information","GenBasix Incorporated|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","1000","Industry","Observational","","GENBASIX-00127|CDR0000529353|GENBASIX-1024122","January 2001","December 2004","null","July 2009","March 7, 2007","March 9, 2007","null","null","July 9, 2013","July 10, 2013","GenBasix Incorporated, Duarte, California, United States","https://ClinicalTrials.gov/show/NCT00445562"
679,"NCT00898911","Blood Sample Analysis in Predicting Overall Survival in Patients With Recurrent or Metastatic Head and Neck Cancer","null","Completed","No Results Available","Head and Neck Cancer","Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry","Overall survival measured in weeks","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years to 120 Years   (Adult, Senior)","","30","Other|NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","CDR0000600560|ECOG-E3301T1","July 8, 2008","April 8, 2012","April 8, 2012","May 2017","May 9, 2009","May 12, 2009","null","null","May 16, 2017","May 17, 2017","","https://ClinicalTrials.gov/show/NCT00898911"
680,"NCT00179816","Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors","null","Unknown status","No Results Available","Ewing's Sarcoma|Soft Tissue Sarcoma|Hepatoblastoma|Hodgkin's Disease|Germ Cell Tumor","Drug: High-Dose Chemotherapy with Tandem PBSC Rescue.","Determine the feasibility and toxicity of tandem PBSC rescue following high dose chemotherapy as consolidation in pediatric patients with high risk solid tumors.|Evaluate length of remission and long term disease free survival in chemotherapy responsive high-risk pediatric solid tumor patients treated using this approach.|Evaluate correlation between cell dose and time to engraftment in high-risk pediatric solid tumor patients treated using this approach.","Ann & Robert H Lurie Children's Hospital of Chicago","All","up to 21 Years   (Child, Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BMT 0499 Solid","April 1999","September 2012","September 2012","October 2010","September 10, 2005","September 16, 2005","null","null","October 7, 2010","October 11, 2010","Children's Memorial Hospital, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT00179816"
681,"NCT02234453","Home Testing of Blood Counts in Chemotherapy Patients","null","Not yet recruiting","No Results Available","Cancer","Device: Minicare H-2000","Proportion of home tested blood count results transferred to the hospital team on the day of the venous blood test performed prior to the subsequent SACT cycle|Proportion of home tested temperature and questionnaire responses transferred to the hospital after (i) initial home training (TP1), (ii) forty-eight hours (TP2) and (iii) on the day of venous blood test pre subsequent SACT cycle (TP3).|Patient feedback on willingness to use and ease of use of Minicare H-2000.|Assess proportion of successful tests performed with subsequent cycles.|Health-care professional feedback on server clinical interface.|Correlation of capillary granulocyte count with venous laboratory measured neutrophil count pre subsequent SACT cycle.|Proportion of home tested blood count results transferred to the hospital team after (i) initial home training (TP1), (ii) forty-eight hours (TP2)","University of Leeds|Philips Healthcare","All","18 Years and older   (Adult, Senior)","","80","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","MO14/11295","October 2016","April 2017","April 2017","June 2016","August 26, 2014","September 9, 2014","null","null","June 16, 2016","June 17, 2016","St James's Teaching Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, United Kingdom","https://ClinicalTrials.gov/show/NCT02234453"
682,"NCT00959023","Study of Blood and Tumor Samples From Men With an Inherited Risk of Prostate Cancer","null","Unknown status","No Results Available","Prostate Cancer","Other: laboratory biomarker analysis|Other: medical chart review|Other: questionnaire administration","Prostate cancer (PC) predisposition (PCP) genes|Association of PCP genes with disease and treatment parameters|Association of PCP with environmental factors|Family history of PC|Relative risk of developing PC|Increased risk relatives of PC patients are to develop cancers other than PC|Markers of PC that are associated with PCP genes|Specific tumor genetic profile correlated with PCP genes","Institute of Cancer Research, United Kingdom|National Cancer Institute (NCI)","Male","Child, Adult, Senior","","21000","Other","Observational","","CDR0000636371|ICR-UKGPCS|EU-20909","June 1993","null","null","August 2009","August 13, 2009","August 14, 2009","null","null","August 23, 2013","August 26, 2013","William Harvey Hospital, Ashford-Kent, England, United Kingdom|Tameside General Hospital, Ashton-Under-Lyne, England, United Kingdom|Stoke Mandeville Hospital, Aylesbury-Buckinghamshire, England, United Kingdom|North Devon District Hospital, Barnstaple, England, United Kingdom|Furness General Hospital, Barrow in Furness, England, United Kingdom|Basildon University Hospital, Basildon, England, United Kingdom|Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, England, United Kingdom|Royal United Hospital, Bath, England, United Kingdom|Primrose Centre at Bedford Hospitals NHS Trust, Bedford, England, United Kingdom|Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom|City Hospital - Birmingham, Birmingham, England, United Kingdom|Good Hope Hospital, Birmingham, England, United Kingdom|Birmingham Heartlands Hospital, Birmingham, England, United Kingdom|Royal Blackburn Hospital, Blackburn, England, United Kingdom|Blackpool Victoria Hospital, Blackpool, England, United Kingdom|Pilgrim Hospital, Boston, England, United Kingdom|Royal Bournemouth Hospital, Bournemouth, England, United Kingdom|Sussex Cancer Centre at Royal Sussex County Hospital, Brighton, England, United Kingdom|Southmead Hospital, Bristol, England, United Kingdom|Frenchay Hospital, Bristol, England, United Kingdom|Bristol Royal Infirmary, Bristol, England, United Kingdom|Broomfield Hospital, Broomfield, England, United Kingdom|Burnley General Hospital, Burnley, England, United Kingdom|Queen's Hospital, Burton-upon-Trent, England, United Kingdom|Addenbrooke's Hospital, Cambridge, England, United Kingdom|Kent and Canterbury Hospital, Canterbury, England, United Kingdom|St. Helier Hospital, Carshalton, England, United Kingdom|Countess of Chester Hospital, Chester, England, United Kingdom|Colchester General Hospital, Colchester, England, United Kingdom|Castle Hill Hospital, Cottingham, England, United Kingdom|Walsgrave Hospital, Coventry, England, United Kingdom|Mid Cheshire Hospitals Trust- Leighton Hopsital, Crewe, England, United Kingdom|Mayday University Hospital, Croydon, England, United Kingdom|Darent Valley Hospital, Dartford Kent, England, United Kingdom|Derbyshire Royal Infirmary, Derby, England, United Kingdom|Royal Derby Hospital, Derby, England, United Kingdom|Dorset County Hospital, Dorchester, England, United Kingdom|Russells Hall Hospital, Dudley, England, United Kingdom|Eastbourne District General Hospital, Eastbourne, England, United Kingdom|Birmingham Women's Hospital, Edgbaston, England, United Kingdom|Epsom General Hospital, Epsom, Surrey, England, United Kingdom|Royal Devon and Exeter Hospital, Exeter, England, United Kingdom|Royal Bolton Hospital, Farnworth, England, United Kingdom|Frimley Park Hospital, Frimley, England, United Kingdom|Grantham and District Hospital, Grantham, Lincolnshire, England, United Kingdom|Diana Princess of Wales Hospital, Grimsby, England, United Kingdom|Harrogate District Hospital, Harrogate, England, United Kingdom|Wycombe General Hospital, High Wycombe, England, United Kingdom|Princess Royal Hospital at Hull and East Yorkshire NHS Trust, Hull, England, United Kingdom|Ipswich Hospital, Ipswich, England, United Kingdom|Kidderminster Hospital, Kidderminster Worcestershire, England, United Kingdom|Royal Albert Edward Infirmary, Lancanshire, England, United Kingdom|Royal Lancaster Infirmary, Lancaster, England, United Kingdom|Leeds General Infirmary, Leeds, England, United Kingdom|Cookridge Hospital, Leeds, England, United Kingdom|Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom|Leicester Royal Infirmary, Leicester, England, United Kingdom|Leicester General Hospital, Leicester, England, United Kingdom|Lincoln County Hospital, Lincoln, England, United Kingdom|Royal Liverpool University Hospital, Liverpool, England, United Kingdom|Royal London Hospital, London, England, United Kingdom|Whipps Cross Hospital, London, England, United Kingdom|Saint Bartholomew's Hospital, London, England, United Kingdom|Guy's Hospital, London, England, United Kingdom|Hammersmith Hospital, London, England, United Kingdom|Middlesex Hospital, London, England, United Kingdom|St. Mary's Hospital, London, England, United Kingdom|Charing Cross Hospital, London, England, United Kingdom|Macclesfield District General Hospital, Macclesfield, England, United Kingdom|Maidstone Hospital, Maidstone, England, United Kingdom|Christie Hospital, Manchester, England, United Kingdom|Clatterbridge Centre for Oncology, Merseyside, England, United Kingdom|James Cook University Hospital, Middlesbrough, England, United Kingdom|Milton Keynes General Hospital, Milton Keynes, England, United Kingdom|Newcastle Upon Tyne Hospitals NHS Trust, Newcastle-Upon-Tyne, England, United Kingdom|Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, England, United Kingdom|Norfolk and Norwich University Hospital, Norwich, England, United Kingdom|Kings Mill Hospital, Nottinghamshire, England, United Kingdom|Nottingham City Hospital, Nottingham, England, United Kingdom|George Eliot Hospital, Nuneaton, England, United Kingdom|Churchill Hospital, Oxford, England, United Kingdom|Peterborough Hospitals Trust, Peterborough, England, United Kingdom|Derriford Hospital, Plymouth, England, United Kingdom|Dorset Cancer Centre, Poole Dorset, England, United Kingdom|Rosemere Cancer Centre at Royal Preston Hospital, Preston, England, United Kingdom|Berkshire Cancer Centre at Royal Berkshire Hospital, Reading, England, United Kingdom|Alexandra Healthcare NHS, Redditch, Worcestershire, England, United Kingdom|Queens Hospital, Romford, England, United Kingdom|Conquest Hospital, Saint Leonards-on-Sea, England, United Kingdom|Hope Hospital, Salford, England, United Kingdom|Salisbury District Hospital, Salisbury, England, United Kingdom|Scarborough General Hospital, Scarborough, England, United Kingdom|Scunthorpe General Hospital, Scunthorpe, England, United Kingdom|Royal Shrewsbury Hospital, Shrewsbury, England, United Kingdom|Wexham Park Hospital, Slough, Berkshire, England, United Kingdom|Solihull Hospital, Solihull, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom|Southport and Formby District General Hospital, Southport, England, United Kingdom|Staffordshire General Hospital, Stafford, England, United Kingdom|Lister Hospital, Stevenage, England, United Kingdom|Stirling Royal Infirmary, Stirling, England, United Kingdom|Stepping Hill Hospital, Stockport, England, United Kingdom|Kingston Hospital, Surrey, England, United Kingdom|East Surrey Hospital, Surrey, England, United Kingdom|Royal Marsden - Surrey, Sutton, England, United Kingdom|Great Western Hospital, Swindon, England, United Kingdom|Taunton and Somerset Hospital, Taunton, England, United Kingdom|Torbay Hospital, Torquay, England, United Kingdom|Hillingdon Hospital, Uxbridge, England, United Kingdom|Warwick Hospital, Warwick, England, United Kingdom|Sandwell General Hospital, West Bromwich, England, United Kingdom|Southend University Hospital NHS Foundation Trust, Westcliff-On-Sea, England, United Kingdom|New Cross Hospital, Wolverhampton, England, United Kingdom|Worthing Hospital, Worthing, England, United Kingdom|Yeovil District Hospital, Yeovil, England, United Kingdom|Cancer Care Centre at York Hospital, York, England, United Kingdom|Belfast City Hospital Trust Incorporating Belvoir Park Hospital, Belfast, Northern Ireland, United Kingdom|Downe Hospital, Downpatrick, Northern Ireland, United Kingdom|Altnagelvin Area Hospital, Londonderry, Northern Ireland, United Kingdom|Craigavon Area Hospital, Portadown, Craigavon, Northern Ireland, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom|Ayr Hospital, Ayr, Scotland, United Kingdom|Falkirk and District Royal Infirmary, Falkirk, Scotland, United Kingdom|Western Infirmary, Glasgow, Scotland, United Kingdom|Pinderfields General Hospital, Wakefield, Scotland, United Kingdom|Princess of Wales Hospital, Bridgend, Wales, United Kingdom|Velindre Cancer Center at Velindre Hospital, Cardiff, Wales, United Kingdom|University Hospital of Wales, Cardiff, Wales, United Kingdom|Royal Gwent Hospital, Newport Gwent, Wales, United Kingdom|Glan Clwyd Hospital, Rhyl, Denbighshire, Wales, United Kingdom|Singleton Hospital, Swansea, Wales, United Kingdom|Queen Victoria Hospital, Morecambe, United Kingdom|Edith Cavell Hospital, Peterborough, United Kingdom|Southlands Hospital, Shoreham-by-Sea, United Kingdom|Princess Anne Hospital, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT00959023"
683,"NCT00699907","Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer","null","Completed","No Results Available","Ovarian Cancer","Drug: flutamide","Effect of of flutamide in ovarian tissue|Comparison of the results of this pilot study in patients at high risk for ovarian cancer who are undergoing prophylactic oophorectomy and are interested in taking flutamide vs patients at high risk for ovarian cancer who are undergoing prophylactic ...","University of Arizona|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","127","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","04-0707-04|P30CA023074|UARIZ-04-0707-04|UARIZ-HSC04184|UARIZ-SRC17834","January 2005","November 2012","November 2014","April 2014","June 17, 2008","June 18, 2008","null","null","December 11, 2014","December 12, 2014","Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States","https://ClinicalTrials.gov/show/NCT00699907"
684,"NCT01275651","Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole","null","Active, not recruiting","No Results Available","Prostate Cancer","Other: laboratory biomarker analysis","Progression-free survival (PFS)|Equal to or greater than 30% decline in PSA|Overall survival","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Male","Child, Adult, Senior","","48","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","CALGB-151004|CDR0000688286|NCI-2011-02835","December 2010","January 2100","null","August 2017","January 11, 2011","January 12, 2011","null","null","August 7, 2017","August 8, 2017","Alliance for Clinical Trials in Oncology, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT01275651"
685,"NCT01700257","Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker","null","Recruiting","No Results Available","High Risk of Developing Lung Cancer","Radiation: CT scan & Early CDT Lung test|Other: CT scan & Early CDT Lung test","CT alone vs. both Early CDT-Lung test and CT scan.|Value of Early CDT-lung test in detecting cancer","National Jewish Health","All","50 Years to 75 Years   (Adult, Senior)","Phase 2","1600","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Oncimmune-2550","May 2012","January 2018","January 2018","September 2016","October 2, 2012","October 4, 2012","null","null","September 12, 2016","September 14, 2016","National Jewish Health, Denver, Colorado, United States","https://ClinicalTrials.gov/show/NCT01700257"
686,"NCT00967954","Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer","null","Unknown status","No Results Available","Prostate Cancer","Drug: antiandrogen therapy|Drug: releasing hormone agonist therapy|Genetic: DNA analysis|Genetic: RNA analysis|Genetic: comparative genomic hybridization|Genetic: gene expression analysis|Other: laboratory biomarker analysis|Procedure: diffusion-weighted magnetic resonance imaging|Procedure: magnetic resonance spectroscopic imaging","Identification of molecular and pathophysiological changes|Functional imaging as a non-invasive tool to measure treatment response|Development of clinical models to predict tumor response","Cancer Research UK|National Cancer Institute (NCI)","Male","Child, Adult, Senior","","120","Other","Interventional","Allocation: Non-Randomized|Primary Purpose: Treatment","CDR0000639017|CRUK-CHIRRP|EU-20920","September 2008","August 2013","null","August 2009","August 27, 2009","August 28, 2009","null","null","January 9, 2014","January 10, 2014","Cancer Research UK at Cambridge Research Institute, Cambridge, England, United Kingdom","https://ClinicalTrials.gov/show/NCT00967954"
687,"NCT01327794","Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer","null","Completed","No Results Available","Pancreatic Cancer","Genetic: polymorphism analysis|Other: immunologic technique|Other: laboratory biomarker analysis|Other: medical chart review","Association between 25(OH)D level and OS|Association between 25(OH)D level and PFS","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","265","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CALGB-151006|U10CA031946|CDR0000698059","June 2011","August 2014","August 2014","June 2016","March 31, 2011","April 4, 2011","null","null","June 28, 2016","June 29, 2016","Charles R. Wood Cancer Center at Glens Falls Hospital, Glens Falls, New York, United States","https://ClinicalTrials.gov/show/NCT01327794"
688,"NCT00673114","Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies","null","Completed","Has Results","Hematologic Malignancy|Myelodysplastic Syndrome (MDS)|Aplastic Anemia","Biological: haplo/cord transplant","The Number of Participants Reaching Primary Endpoint of Absolute Neutrophil Count (ANC) of 500/uL (Engraftment).|180 Day Survival|Non-Relapse Mortality at 180 Days Post Transplant|Platelet Engraftment (Untransfused and Platelet Count > 50,000)|Incidence of Primary and Secondary Graft Failure|Number of Participants With Acute or Chronic Graft-versus-host Disease (GVHD)|Rates of Leukemic Relapse|Number of Participants With Donor Cells at 100 Days Post-transplant","Joanne Kurtzberg, MD|Miltenyi Biotec GmbH|Duke University","All","up to 55 Years   (Child, Adult)","Phase 1|Phase 2","3","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00008292|8717","August 2007","April 2012","April 2012","March 2015","December 27, 2007","May 7, 2008","May 8, 2013","December 24, 2013","March 16, 2015","April 3, 2015","Duke University Medical Center Pediatric Blood and Marrow Transplant, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00673114"
689,"NCT01124669","Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate","null","Completed","No Results Available","Lung Cancer","Genetic: DNA analysis|Genetic: mutation analysis|Other: laboratory biomarker analysis","Mutation rate of sorafenib tosylate-target gene BRAF, and its upstream proteins KRAS and EGFR|Association between BRAF, KRAS, and EGFR mutation status and clinical benefits (stable disease or partial response)","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years to 120 Years   (Adult, Senior)","","80","Other|NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","CDR0000670998|ECOG-E2501T2","June 13, 2010","July 13, 2010","July 13, 2010","May 2017","May 14, 2010","May 17, 2010","null","null","May 16, 2017","May 17, 2017","","https://ClinicalTrials.gov/show/NCT01124669"
690,"NCT00897234","Blood Samples From Patients With Non-Small Cell Lung Cancer and From Healthy Volunteers","null","Completed","No Results Available","Lung Cancer","Other: Mass Spectrometry","Levels of cathepsin D|Levels of fatty acid synthase (FAS)|Global microRNA expression","University of Minnesota - Clinical and Translational Science Institute","All","18 Years and older   (Adult, Senior)","","84","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2008NTLS094|0809M47482","December 2008","August 2010","October 2010","August 2014","May 9, 2009","May 12, 2009","null","null","August 21, 2014","August 22, 2014","Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00897234"
691,"NCT00991315","Collecting and Storing Blood and Tumor Tissue Samples From Patients Undergoing Prostatectomy or Transurethral Resection of the Prostate","null","Active, not recruiting","No Results Available","Prostate Cancer","","Collection and freezing of tumor samples","Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey","Male","18 Years and older   (Adult, Senior)","","126","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","080809|P30CA072720|0220080275","December 2008","May 2019","May 2019","November 2017","October 7, 2009","October 8, 2009","null","null","November 15, 2017","November 17, 2017","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States","https://ClinicalTrials.gov/show/NCT00991315"
692,"NCT02622815","Hypercoagulation Screening in Cancer","HYPERCAN","Unknown status","No Results Available","Healthy Blood Donors|Moli-sani Subjects|Cancer Patients","","Number of blood donors with a diagnosis of cancer|Incidence of Thrombotic events among enrolled cancer patients|Incidence of Cancer progression among enrolled cancer patients","A.O. Ospedale Papa Giovanni XXIII|Associazione Italiana per la Ricerca sul Cancro|Istituto Neurologico Mediterraneo Neuromed S. R. L|Fondazione Humanitas per la Ricerca|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|Azienda Sanitaria Locale Roma E|Istituti Ospedalieri Bergamaschi Srl|Azienda Ospedaliera Treviglio - Caravaggio","All","Child, Adult, Senior","","16000","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","AIRC5xmille - 12237","April 2012","April 2017","April 2017","December 2015","November 24, 2015","December 7, 2015","null","null","December 4, 2015","December 7, 2015","Istituti Ospedalieri Bergamaschi S.r.l. - Policlinico San Marco, Osio Sotto, Bergamo, Italy|Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, Bergamo, Italy|I.R.C.C.S. Istituto Neurologico Mediterraneo NEUROMED, Pozzilli, Isernia, Italy|Fondazione Humanitas per la Ricerca, Rozzano, Milan, Italy|A.O. Papa Giovanni XXIII - Oncology Unit, Bergamo, Italy|A.O. Papa Giovanni XXIII - S.I.M.T., Bergamo, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|ASL Roma E - ACO San Filippo Neri, Rome, Italy","https://ClinicalTrials.gov/show/NCT02622815"
693,"NCT00897403","Blood and Tissue Sample Collection for Future Colon Cancer Biomarker Studies in Patients Undergoing Colonoscopy","null","Completed","No Results Available","Colorectal Cancer|Health Status Unknown","Other: biologic sample preservation procedure|Procedure: diagnostic colonoscopy","Collection of blood and tissue","Vanderbilt University|National Cancer Institute (NCI)","All","25 Years to 75 Years   (Adult, Senior)","","6446","Other|NIH","Observational","Time Perspective: Prospective","CDR0000546530|P30CA068485|VU-VICC-GI-0661|VU-VICC-IRB-061096","December 2006","August 2015","April 2016","April 2017","May 9, 2009","May 12, 2009","null","null","April 5, 2017","April 7, 2017","Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States|Dan Rudy Cancer Center at Saint Thomas Hospital, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT00897403"
694,"NCT03056339","Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies","null","Recruiting","No Results Available","B-Lymphoid Malignancies|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Non-hodgkin Lymphoma","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Mesna|Biological: iC9/CAR.19/IL15-Transduced CB-NK Cells|Drug: AP1903","Optimal NK Cell Dose Level of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Killer (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies|Toxicity of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Liller (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies|Efficacy of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Killer (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies|Response of Chimeric Antigen Receptors (CAR).CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood Natural Killer (CB-NK) Cells in Patients with Relapsed/Refractory CD19+ B Lymphoid Malignancies","M.D. Anderson Cancer Center|Bellicum Pharmaceuticals","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","36","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0641","June 21, 2017","June 2022","June 2022","December 2017","February 14, 2017","February 17, 2017","null","null","December 27, 2017","December 29, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03056339"
695,"NCT01074424","Studying Biomarkers in Blood Samples From Patients With Invasive Cervical Cancer","null","Unknown status","No Results Available","Cervical Cancer","Genetic: proteomic profiling|Other: laboratory biomarker analysis","Generation of a serum proteomic profile using banked pre-treatment serum specimens that may have potential utility for cervical cancer prognosis (overall survival and progression-free survival [PFS])|Generation of a serum proteomic profile using banked post-treatment serum specimens that may have potential utility for cervical cancer prognosis (overall survival and PFS)","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","","84","Other|NIH","Observational","","CDR0000665346|GOG-8006","February 2010","March 2010","null","February 2010","February 23, 2010","February 24, 2010","null","null","February 23, 2010","February 24, 2010","","https://ClinicalTrials.gov/show/NCT01074424"
696,"NCT00166985","The Role of Functional MRI and Doppler Sonography in Assessing Blood Vessel Formation Within the Tumors of Endometrial Cancer Patients","null","Unknown status","No Results Available","Endometrial Cancer","","","National Taiwan University Hospital","Female","18 Years to 80 Years   (Adult, Senior)","","200","Other","Observational","Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Cross-Sectional|Time Perspective: Prospective","9361701182","September 2004","null","December 2008","August 2004","September 12, 2005","September 14, 2005","null","null","December 26, 2006","December 27, 2006","National Taiwan University Hospital, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT00166985"
697,"NCT01562288","Studying Blood and DNA Samples From Patients With Breast Cancer Treated With Chemotherapy With or Without Trastuzumab","null","Active, not recruiting","No Results Available","Breast Cancer","Genetic: DNA analysis|Genetic: gene expression analysis|Genetic: polymerase chain reaction|Other: enzyme-linked immunosorbent assay|Other: laboratory biomarker analysis","disease-free survival|overall survival","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","","1576","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","NCCTG-N9831D-NCCTG-ICSC|NCI-2012-00687|CDR0000726841","February 2012","January 2100","null","August 2017","March 21, 2012","March 23, 2012","null","null","August 7, 2017","August 8, 2017","","https://ClinicalTrials.gov/show/NCT01562288"
698,"NCT01139944","Biomarkers in Tissue and Blood Samples From Patients With Early-Stage Non-Small Cell Lung Cancer","null","Completed","No Results Available","Lung Cancer","Genetic: DNA methylation analysis|Genetic: polymerase chain reaction|Other: laboratory biomarker analysis","disease specific survival|overall survival","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","99","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","ACOSOG-Z4102|CDR0000671680","July 2010","January 2014","January 2014","July 2016","June 8, 2010","June 9, 2010","null","null","July 1, 2016","July 6, 2016","","https://ClinicalTrials.gov/show/NCT01139944"
699,"NCT01476670","Cerebral Blood Circulation in Patients With Posterior Fossa Brain Tumor","null","Unknown status","No Results Available","Brain Tumor","Other: Monitoring","","All India Institute of Medical Sciences, New Delhi","All","18 Years to 60 Years   (Adult)","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CA-CO2-TCD|Posterior fossa tumor - TCD","July 2012","null","null","November 2011","November 18, 2011","November 22, 2011","null","null","November 21, 2011","November 22, 2011","All India Institute of Medical Sciences, New Delhi, Delhi, India","https://ClinicalTrials.gov/show/NCT01476670"
700,"NCT00984919","Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers","null","Completed","No Results Available","Prostate Cancer","Other: high performance liquid chromatography|Other: laboratory biomarker analysis|Other: mass spectrometry","Identification of 11-dh-TXB2 in the blood and urine","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","Male","40 Years to 120 Years   (Adult, Senior)","","10","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","CDR0000654093|P30CA022453|WSU-2009-058","November 2009","January 2011","February 2011","February 2016","September 24, 2009","September 25, 2009","null","null","February 12, 2016","February 15, 2016","Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States","https://ClinicalTrials.gov/show/NCT00984919"
701,"NCT00719849","Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease","null","Terminated","Has Results","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Radiation: total body irradiation","Probability of Survival at 1 Year|Probability of Survival at 2 Years|Incidence of Non-relapse Mortality at 6 Months|Chimerism|Incidence of Neutrophil Engraftment at Day 42|Incidence of Platelet Engraftment at 6 Months|Incidence of Grade II-IV Acute Graft-versus-host-disease (GVHD) at Day 100|Incidence of Grade III-IV Acute Graft-versus-host-disease (GVHD) at Day 100|Incidence of Chronic Graft-versus-host-disease (GVHD) at 1 Year|Incidence of Clinically Significant Infections at 6 Months|Incidence of Clinically Significant Infections at 1 Year|Incidence of Clinically Significant Infections at 2 Years|Probability of Progression-free Survival at 1 Year|Probability of Progression-free Survival at 2 Years|Incidence of Relapse at 1 Year|Incidence of Relapse at 2 Years","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 69 Years   (Child, Adult, Senior)","Phase 2","13","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012.00|FHCRC-2012.00|CDR0000597623|T32CA009515","November 2005","November 2008","December 2009","May 2017","July 19, 2008","July 22, 2008","April 5, 2017","June 14, 2017","May 19, 2017","June 14, 2017","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00719849"
702,"NCT00960427","Studying Biomarkers in Tumor Tissue and Blood Samples From Patients Undergoing Chemotherapy and Radiation Therapy for Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery","null","Withdrawn","No Results Available","Colorectal Cancer","Drug: systemic chemotherapy|Genetic: RNA analysis|Genetic: gene expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: endoscopic biopsy|Procedure: neoadjuvant therapy|Procedure: sigmoidoscopy|Radiation: radiation therapy","Estimation of stem cell markers with stated precision|Correlation of disease-free survival with post-treatment value and change in expression of colorectal cancer stem cell markers after neoadjuvant chemoradiotherapy","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","0","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000649658|WSU-2009-041","June 2009","April 2010","April 2010","April 2013","August 14, 2009","August 17, 2009","null","null","April 12, 2013","April 16, 2013","","https://ClinicalTrials.gov/show/NCT00960427"
703,"NCT00989690","Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer","null","Unknown status","No Results Available","Lung Cancer","Drug: docetaxel|Drug: erlotinib hydrochloride|Drug: pemetrexed disodium|Genetic: fluorescence in situ hybridization|Genetic: mutation analysis|Genetic: proteomic profiling|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry|Procedure: breath test","Overall survival|Progression-free survival|Overall response rate according to RECIST criteria","Istituto Scientifico H. San Raffaele|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","275","Other","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","SRSI-HSRL-02-2007|CDR0000652115|2007-006299-13|EU-20975","February 2008","null","null","October 2009","October 2, 2009","October 5, 2009","null","null","August 9, 2013","August 12, 2013","Istituto Scientifico H. San Raffaele, Milan, Italy","https://ClinicalTrials.gov/show/NCT00989690"
704,"NCT00719966","Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer","null","Active, not recruiting","No Results Available","Breast Cancer","Drug: anastrozole|Drug: exemestane|Drug: letrozole|Procedure: assessment of therapy complications","Endothelial dysfunction as a result of aromatase inhibitor therapy","Mayo Clinic|National Cancer Institute (NCI)","Female","40 Years to 80 Years   (Adult, Senior)","","150","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","MC0834|P30CA015083|06-004006","June 2008","September 2017","null","April 2016","July 19, 2008","July 22, 2008","null","null","December 20, 2016","December 21, 2016","Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00719966"
705,"NCT00968214","Study of Tumor and Blood Samples From Postmenopausal Women With Primary Breast Cancer Enrolled on Clinical Trial CAN-NCIC-MA27","null","Active, not recruiting","No Results Available","Breast Cancer","Genetic: polymorphism analysis|Other: laboratory biomarker analysis","Genetic variation associated with musculoskeletal adverse events","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Female","45 Years and older   (Adult, Senior)","","364","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NCCTG-TBCI-MA.27A|CDR0000600225|NCI-2009-00694","September 2008","January 2100","null","August 2017","August 27, 2009","August 28, 2009","null","null","August 7, 2017","August 8, 2017","","https://ClinicalTrials.gov/show/NCT00968214"
706,"NCT01554254","Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation","null","Withdrawn","No Results Available","Cord Blood Transplant|Hematologic Malignancy|Inherited Metabolic Disease","Drug: TXA127","Safety of TXA127 in subjects undergoing cord blood transplantation|Effect of TXA127 on incidence, severity and duration of aGVHD|Effect of TXA127 on incidence, severity and duration of mucositis|Effect of TXA127 on neutrophil engraftment|Effect of TXA127 on platelet recovery|Effect of TXA127 on immune reconstitution","Tarix Pharmaceuticals","All","6 Months to 20 Years   (Child, Adult)","Phase 2","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TXA127-2010-002","March 2012","December 2013","null","August 2016","March 12, 2012","March 14, 2012","null","null","August 29, 2016","August 31, 2016","Pediatric Bone and Cord Blood, Duke Univ. Med. Center, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT01554254"
707,"NCT03249727","Analysis of Natural Killer Cell Activity (NKA) in Whole Blood in High Risk Subjects Undergoing Colonoscopy","ANKA-HR","Recruiting","No Results Available","Immunity, Innate|Colorectal Cancer","Diagnostic Test: IVDD for NK cell activity in whole blood","Test performance of NK Vue (ability of NK Vue to detect CRC in those subjects in risk categories P3 or P4)|Test performance of FIT, to be determined at different cut-offs reflective of the various Canadian provincial cut-offs.|Test performance of NK Vue in combination with FIT","ATGen Canada Inc","All","40 Years and older   (Adult, Senior)","","1200","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening","ANKA-HR","July 5, 2017","July 2018","December 2018","August 2017","August 10, 2017","August 15, 2017","null","null","November 7, 2017","November 9, 2017","CIUSSS de l'Est-de-l'île-de-Montréal, Installation Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada|McGill University and the McGill University Health Centre, Montreal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT03249727"
708,"NCT03128866","Reducing Blood Loss in Hemipelvectomy Surgery With the Use Tranexamic Acid (TXA)","null","Recruiting","No Results Available","Malignant Neoplasms of Bone and Articular Cartilage|Pelvic Tumor","Drug: Tranexamic Acid","Total Perioperative Blood Loss","M.D. Anderson Cancer Center","All","Child, Adult, Senior","Early Phase 1","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0650","May 19, 2017","May 2021","May 2021","May 2017","April 21, 2017","April 25, 2017","null","null","May 19, 2017","May 22, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03128866"
709,"NCT00963326","Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer","null","Unknown status","No Results Available","Head and Neck Cancer","Other: laboratory biomarker analysis","Tumor response rate by RECIST criteria","Centre Oscar Lambret|National Cancer Institute (NCI)","All","15 Years and older   (Child, Adult, Senior)","","60","Other","Observational","","CDR0000635996|COL-CARIO|2007-11|INCA-RECF0897|ID-RCB-2008-A00300-55","June 2008","July 2010","null","February 2011","August 20, 2009","August 21, 2009","null","null","February 25, 2011","February 28, 2011","Centre Oscar Lambret, Lille, France","https://ClinicalTrials.gov/show/NCT00963326"
710,"NCT00522639","Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation","FDG-PET lung","Terminated","No Results Available","Lung Cancer|SCLC|NSCLC","Other: 18F-deoxyglucose (FDG)","Tumour response, measured with FDG-PET-CT scans 3 months post-radiation. as a function of delta FDG uptake the first week during radiotherapy|- Incidence of acute radiation-induced oesophagitis - Incidence of radiation-induced pulmonary toxicity 3 and 9 months post-radiation","Maastricht Radiation Oncology|Academisch Ziekenhuis Maastricht","All","18 Years and older   (Adult, Senior)","Phase 3","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","06-02-117|TACIR","October 2008","null","June 2009","June 2009","August 29, 2007","August 30, 2007","null","null","June 29, 2009","June 30, 2009","Maastricht Radiation Oncology, MAASTRO, Maastricht, Limburg, Netherlands","https://ClinicalTrials.gov/show/NCT00522639"
711,"NCT00898274","Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants","null","Completed","No Results Available","Precancerous Condition|Prostate Cancer","Other: immunoenzyme technique|Other: laboratory biomarker analysis","Plasma levels of antioxidant enzymes as assessed by antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay|Oxidative DNA damage as assessed by antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","Male","45 Years to 65 Years   (Adult)","","40","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","CASE11807|P30CA043703","January 2008","May 2011","May 2011","March 2016","May 9, 2009","May 12, 2009","null","null","March 8, 2016","March 9, 2016","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|University Suburban Health Center, Cleveland, Ohio, United States|UHHS Chagrin Highlands Medical Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT00898274"
712,"NCT00967239","Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2","null","Unknown status","No Results Available","Breast Cancer","Genetic: DNA analysis|Genetic: polymorphism analysis|Other: laboratory biomarker analysis|Other: pharmacogenomic studies","Identification of genes, as measured by single-nucleotide polymorphisms (SNPs), that are associated with breast events|Impact of CYP2D6 metabolizer status on breast cancer events|Exploration of whether SNPs within a region are independently associated with a breast event|Exploration of whether interactions among SNPs increase the risk for a breast event|Exploration of whether SNPs have an effect on treatment","NSABP Foundation Inc|National Cancer Institute (NCI)","Female","35 Years and older   (Adult, Senior)","","1881","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Retrospective","NSABP MCO831|NSABP-MC083I","April 2009","December 2015","null","May 2015","August 26, 2009","August 27, 2009","null","null","May 6, 2015","May 8, 2015","","https://ClinicalTrials.gov/show/NCT00967239"
713,"NCT03145961","A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients","c-TRAK-TN","Not yet recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Pembrolizumab","Positive ctDNA detection by 12 months|Positive ctDNA detection by 24 months|Absence of detectable ctDNA or disease recurrence 12 months after commencing pembrolizumab|Time to ctDNA detection|Detection of overt metastatic disease at time of first ctDNA detection in patients allocated to pembrolizumab|Lead time between ctDNA detection and disease recurrence in the pembrolizumab treatment and observation groups|Absence of detectable ctDNA or disease recurrence after 12 months in the observation group|Safety and tolerability of pembrolizumab assessed using NCI CTCAE v4.0, and the proportion of patients reporting dose reductions or delays.|Commencement of treatment in patients randomised to receive pembrolizumab","Institute of Cancer Research, United Kingdom|National Institute for Health Research Biomedical Research Centre at the Royal Marsden / Institute of Cancer Research UK|Merck Sharp & Dohme Ltd","All","16 Years and older   (Child, Adult, Senior)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","ICR-CTSU/2016/10058|2017-000508-92","July 1, 2017","December 1, 2020","December 1, 2021","May 2017","April 28, 2017","May 9, 2017","null","null","May 5, 2017","May 9, 2017","Royal Marsden Hospital, Chelsea, Chelsea, London, United Kingdom|Royal Marsden Hospital, Sutton, Sutton, Surrey, United Kingdom","https://ClinicalTrials.gov/show/NCT03145961"
714,"NCT00025025","Screening Tests in Detecting Colorectal Cancer","null","Completed","No Results Available","Colorectal Cancer","Other: sample testing","","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Mayo Clinic","All","65 Years to 80 Years   (Adult, Senior)","","4482","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NCCTG-MC9944|P30CA015083|MAYO-MC9944|NCI-P01-0185","October 2001","June 2009","June 2009","July 2016","October 11, 2001","January 27, 2003","null","null","July 1, 2016","July 4, 2016","Arizona Cancer Center at University of Arizona Health Sciences Center, Tuscon, Arizona, United States|Kaiser Permanente Medical Center - Oakland, Oakland, California, United States|University of Colorado Cancer Center at University of Colorado Health Sciences Center, Aurora, Colorado, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital, Canton, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Eureka Hospital, Eureka, Illinois, United States|Galesburg Clinic, Galesburg, Illinois, United States|Galesburg Cottage Hospital, Galesburg, Illinois, United States|InterCommunity Cancer Center of Western Illinois, Galesburg, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hopedale Medical Complex, Hopedale, Illinois, United States|Joliet Oncology Hematology Associates, Limited - West, Joliet, Illinois, United States|Kewanee Hospital, Kewanee, Illinois, United States|McDonough District Hospital, Macomb, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|St. Margaret's Hospital, Spring Valley, Illinois, United States|Valley Cancer Center, Spring Valley, Illinois, United States|Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States|St. Luke's Hospital, Cedar Rapids, Iowa, United States|Cedar Rapids Oncology Associates, Cedar Rapids, Iowa, United States|Mercy Cancer Center at Mercy Medical Center, Cedar Rapids, Iowa, United States|Mercy Capitol Hospital, Des Moines, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates - West Des Moines, West Des Moines, Iowa, United States|Ochsner Cancer Institute at Ochsner Clinic Foundation, New Orleans, Louisiana, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|St. Joseph Mercy Cancer Center at St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|Seton Cancer Institute - Saginaw, Saginaw, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|MeritCare Clinic - Bemidji, Bemidji, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CentraCare Clinic - River Campus, St. Cloud, Minnesota, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|MeritCare Medical Group, Fargo, North Dakota, United States|Veterans Affairs Medical Center - Portland, Portland, Oregon, United States|Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States|Sioux Valley Hospital and University of South Dakota Medical Center, Sioux Falls, South Dakota, United States|Avera McKennan Hospital and University Health Center, Sioux Falls, South Dakota, United States|Medical X-Ray Center, Sioux Falls, South Dakota, United States","https://ClinicalTrials.gov/show/NCT00025025"
715,"NCT02031237","MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy","null","Completed","No Results Available","Brain Metastases","Radiation: Single Fraction Stereotactic Radiosurgery (SRS)|Radiation: Fractionated Whole Brain Radiation Therapy (WBRT)|Radiation: Fractionated Stereotactic Radiation Therapy (FSRT)|Device: Magnetic Resonance Imaging (MRI) Assessments","Change in Blood Brain Barrier (BBB)/Blood Tumor Barrier (BTB) permeability (per minute) in patients with brain metastases undergoing radiation therapy.|Change in magnitude and regional variability of Blood Tumor Barrier (BTB)/Blood Brain Barrier (BBB) permeability (per minute) in tumor, tumor margin, normal brain and brain metastases|Effect of radiation dose on vascular permeability (per minute) of the Blood Tumor Barrier (BTB)/Blood Brain Barrier (BBB)|Investigate whether changes in Magnetic Resonance Imaging (MRI) parameters can be used as a marker for early prediction of treatment response in brain metastases.","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","","52","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","UMCC 2005.003|HUM00043426","April 2005","May 2014","December 2014","April 2015","November 13, 2013","January 9, 2014","null","null","April 6, 2015","April 7, 2015","University of Michigan Hospital, Ann Arbor, Michigan, United States","https://ClinicalTrials.gov/show/NCT02031237"
716,"NCT00772083","Caring for Those Who Share: Improving the Health of Wisconsin Blood Donors","null","Completed","No Results Available","Anemia|Colorectal Cancer","Behavioral: Educational brochure|Behavioral: Standard pamphlet","self-reported seeking of medical care for diagnosis of anemia found at time of blood donation","Medical College of Wisconsin|Healthier Wisconsin Partnership Program|Blood Center of Wisconsin|National Anemia Action Council","All","18 Years and older   (Adult, Senior)","","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","PRO00008944","November 2008","June 2009","June 2009","August 2010","October 13, 2008","October 15, 2008","null","null","August 10, 2010","August 11, 2010","BloodCenter of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT00772083"
717,"NCT01933022","A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease","EFFECT","Terminated","No Results Available","Metastatic Prostate Cancer","Drug: Eligard","Changes from baseline of Testosterone levels in serum|Changes from baseline of PSA level in serum|Changes from baseline of PCA3 score in urine|Changes from baseline of Number of PSA mRNA copies in blood/PBMC|Changes from baseline of Number of PCA3 mRNA copies in blood/PBMC|Changes from baseline of Number of TMPRSS2-ERG mRNA copies in blood/PBMC|Number of Adverse Events from screening to the end of study visit (as reported by the investigator based on Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.3)","Astellas Pharma Europe Ltd.|Astellas Pharma Inc","Male","18 Years and older   (Adult, Senior)","Phase 4","1","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","EGD-EC-005|2012-000101-69","August 2014","August 2015","August 2015","March 2017","August 28, 2013","August 30, 2013","null","null","March 7, 2017","March 9, 2017","Site NL31005 St. Antonius ziekenhuis, Nieuwegein, Netherlands|Site NL31004 Radboudumc, Nijmegen, Netherlands|Site NL31001 Canisius-Wilhelmina Ziekenhuis, Nijmegen, Netherlands","https://ClinicalTrials.gov/show/NCT01933022"
718,"NCT02058953","CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases","13-052","Recruiting","No Results Available","Melanoma|Brain Metastases","Procedure: Craniotomy scheduled|Procedure: Collection for non-craniotomy","Collection of blood, tumor tissue samples and adjacent uninvolved tissue and Cerebrospinal Fluid","University of Pittsburgh|GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","","50","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","UPCI 13-052 (IMWG-01)","August 2014","August 31, 2018","August 31, 2019","September 2017","February 6, 2014","February 11, 2014","null","null","September 8, 2017","September 11, 2017","University of Pittsburgh Medical Center- Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|The University of Texas- MD Anderson Cancer Center, Houston, Texas, United States|Melanoma Institute Australia- Westmead Institute for Cancer Research, Sydney, Australia","https://ClinicalTrials.gov/show/NCT02058953"
719,"NCT00959231","Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease","null","Unknown status","No Results Available","Hematopoietic/Lymphoid Cancer","Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Other: laboratory biomarker analysis|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation","Non-relapse mortality at day 100|Incidence of grades II-IV and III-IV acute graft-vs-host disease (GVHD) at day 100 and chronic GVHD at 1 year|Mixed chimerism|Hemopoietic recovery","Cancer Research UK|National Cancer Institute (NCI)","All","2 Years to 60 Years   (Child, Adult)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000643641|CRUK-UCL-RIC-UCBT|EUDRACT-2004-003845-41|EU-20946","January 2009","August 2012","null","April 2010","August 13, 2009","August 14, 2009","null","null","August 23, 2013","August 26, 2013","Bristol Royal Hospital for Children, Bristol, England, United Kingdom|Cancer Research UK Clinical Centre at St. James's University Hospital, Leeds, England, United Kingdom|University College of London Hospitals, London, England, United Kingdom|UCL Cancer Institute, London, England, United Kingdom|Great Ormond Street Hospital for Children, London, England, United Kingdom|University of Newcastle-Upon-Tyne Northern Institute for Cancer Research, Newcastle-Upon-Tyne, England, United Kingdom","https://ClinicalTrials.gov/show/NCT00959231"
720,"NCT01893957","Effects of Electrical Stimulation on Blood Circulation and Sensibility Tactil in Lymphadenectomy","null","Unknown status","No Results Available","Breast Cancer","Procedure: high voltage electrical stimulation - axillary lymphadenectomy|Procedure: High voltage electrical stimulation - ( healthy women )|Device: Neurodyn High Volt Model (IBRAMED)","Tactile sensitivity|Blood flow velocity","University of Sao Paulo","Female","40 Years to 60 Years   (Adult)","","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","U1111-1143-1024","August 2012","July 2013","September 2013","July 2013","June 21, 2013","July 9, 2013","null","null","July 15, 2013","July 16, 2013","Medical School of Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil","https://ClinicalTrials.gov/show/NCT01893957"
721,"NCT01988675","MRI Study of Radiation-Induced Damage to White Matter and Blood-Brain-Barrier","null","Recruiting","No Results Available","Brain Neoplasms","Radiation: Whole Brain Irradiation|Radiation: Partial Brain Irradiation|Behavioral: Neuropsychological Testing|Behavioral: Quality of Life Questionnaire|Device: Magnetic Resonance Imaging (MRI) Assessments","Change in Magnetic Resonance Imagining (MRI) with different radiation dose at different timepoints.|Associate changes in Magnetic Resonance Imagining (MRI) assessments with changes in neurocognitive function and clinical symptoms, from baseline, and at different timepoints.","University of Michigan Cancer Center","All","18 Years and older   (Adult, Senior)","","90","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UMCC 2003.083|HUM00040138","July 2004","May 2018","May 2019","August 2017","November 13, 2013","November 20, 2013","null","null","August 3, 2017","August 7, 2017","University of Michigan Hosptial, Ann Arbor, Michigan, United States","https://ClinicalTrials.gov/show/NCT01988675"
722,"NCT00955435","Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15","null","Active, not recruiting","No Results Available","Prostate Cancer","Drug: bicalutamide|Drug: releasing hormone agonist therapy|Genetic: protein expression analysis|Genetic: proteomic profiling|Other: laboratory biomarker analysis|Radiation: radiation therapy","Changes in serum and urine proteomic profiles|Prognostic and biochemical markers of early disease progression|Protein expression and temporal alterations|Molecular targets","Cancer Trials Ireland","Male","18 Years and older   (Adult, Senior)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CTRIAL-IE (ICORG) 06-15|EU-20921","September 2005","October 2012","null","May 2017","August 7, 2009","August 10, 2009","null","null","May 23, 2017","May 24, 2017","Beacon Hospital, Dublin, Ireland|Saint Luke's Radiation Oncology Network, Dublin, Ireland","https://ClinicalTrials.gov/show/NCT00955435"
723,"NCT01556178","Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research","null","Completed","No Results Available","Hydrocephalus","","levels of miRNAs in the blood and CSF|Survivin and biologic markers levels in the CSF and blood","Ann & Robert H Lurie Children's Hospital of Chicago","All","1 Year to 21 Years   (Child, Adult)","","5","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2011-14612","July 2011","April 2012","April 2012","February 2016","February 24, 2012","March 16, 2012","null","null","February 3, 2016","February 5, 2016","Children's Memorial Hospital, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT01556178"
724,"NCT00448266","Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD","null","Terminated","No Results Available","Breast Cancer","Drug: Intensified Cyclophophamide, Carboplatin and Thiotepa|Drug: dose dense adriamycine and cyclophosphamide","Percentage of tumors with HRD (phase II part)|pCR rate|Comparison of extramedullary toxicity between the treatment arms.|Need for hospitalization.|Recurrence-free survival and overall survival (phase III part).","The Netherlands Cancer Institute","Female","18 Years to 59 Years   (Adult)","Phase 2|Phase 3","237","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","N06IAA","May 2007","February 2010","null","October 2010","March 14, 2007","March 16, 2007","null","null","October 25, 2010","October 26, 2010","NKI-AVL, Amsterdam, Netherlands","https://ClinicalTrials.gov/show/NCT00448266"
725,"NCT00993486","Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor","null","Completed","No Results Available","Hematologic Diseases|Hematologic Malignancies","Biological: Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)","Dose limiting toxicity, defined as acute graft-versus-host disease grade III or IV|Immune reconstitution|Rate of disease relapse|Occurrence and severity of graft-versus-host disease|Occurrence of adverse drug reactions|Incidence and severity of infections","Kiadis Pharma","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CR-GVH-001","January 2005","October 2008","April 2013","June 2013","October 9, 2009","October 12, 2009","null","null","June 19, 2013","June 20, 2013","Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT00993486"
726,"NCT00559598","Blood Proteins in Finding Pancreatic Cancer and Extrahepatic Biliary Tract Cancer","null","Completed","No Results Available","Extrahepatic Bile Duct Cancer|Pancreatic Cancer","Genetic: proteomic profiling|Other: medical chart review","Utility of the serum proteome pattern for early detection and diagnosis of pancreatic cancer and extrahepatic biliary tract cancer|Contact participants (recruited to the PANKRAS-II study 10 years ago) who were diagnosed with benign biliary-pancreatic disease in order to discern if they subsequently developed a malignant biliary-pancreatic tumor|Gather information about clinical factors surrounding the date of blood extraction that may influence the proteomic patterns of the blood samples by reviewing clinical records of participants","National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","Child, Adult, Senior","","502","NIH","Observational","","999904272|04-C-N272|CDR0000573190","August 2004","null","April 2009","March 2012","November 15, 2007","November 16, 2007","null","null","March 7, 2012","March 8, 2012","","https://ClinicalTrials.gov/show/NCT00559598"
727,"NCT00096590","Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery","null","Completed","No Results Available","Thromboembolism|Unspecified Adult Solid Tumor, Protocol Specific","Other: coagulation study|Other: immunoenzyme technique|Other: laboratory biomarker analysis|Other: physiologic testing|Procedure: study of high risk factors","Incidence of hypercoagulability|Comparison of the results of whole blood thrombin generation assay tests in patients who develop venous thromboembolism with those who do not","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","60","NIH","Observational","","CDR0000440092|NCI-05-CC-0033","November 2004","null","null","June 2007","November 11, 2004","November 12, 2004","null","null","May 9, 2009","May 12, 2009","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00096590"
728,"NCT00003838","Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow","null","Recruiting","No Results Available","Hematologic Disease|Lymphoma|Multiple Myeloma|Myelodysplastic Syndrome|Myeloproliferative Disorder","Procedure: Stem cell transplantation","To evaluate engraftment by bone marrow chimerism analysis.|To determine the incidence and severity of acute and chronic graft-versus-host disease (GVHD).","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","2 Years to 80 Years   (Child, Adult, Senior)","Phase 2","214","NIH","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","990050|99-H-0050","February 23, 1999","December 1, 2019","December 1, 2019","November 27, 2017","November 1, 1999","January 27, 2003","null","null","November 28, 2017","November 29, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00003838"
729,"NCT00607802","Donor White Blood Cell Infusion in Treating Patients With Metastatic or Unresectable Cancer","null","Withdrawn","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific","Biological: leukocyte therapy|Genetic: polymerase chain reaction","Safety|Response (complete response, partial response, stable disease, or disease progression)","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","up to 120 Years   (Child, Adult, Senior)","","0","Other|NIH","Interventional","Primary Purpose: Treatment","CCCWFU-99107|CDR0000584624|IRB00002178","null","null","null","June 2013","January 30, 2008","February 6, 2008","null","null","January 17, 2017","January 19, 2017","","https://ClinicalTrials.gov/show/NCT00607802"
730,"NCT00582647","Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract","null","Active, not recruiting","No Results Available","Esophageal Cancer|Bile Duct Neoplasms|Gastric Cancer|Liver Cancer|Melanoma|Pancreatic Cancer|Sarcoma","","To obtain & store tissues, blood, peritoneal, pleural, cyst & other gastrointestinal fluid from patients with benign or malignant tumors in order to carry out future laboratory studies on the causes, prevention, diagnosis & treatment of certain cancers.","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","6000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","00-032","March 2000","December 2018","December 2018","September 2017","December 21, 2007","December 28, 2007","null","null","September 7, 2017","September 8, 2017","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00582647"
731,"NCT00140036","Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).","null","Completed","No Results Available","Colorectal Neoplasms","Procedure: Blood draw","Correlation of genotype with safety and efficacy measures.","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 4","137","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPTAIV-0020-366|A5961020","September 2002","null","August 2005","February 2008","August 29, 2005","August 31, 2005","null","null","February 28, 2008","March 3, 2008","Pfizer Investigational Site, Mobile, Alabama, United States|Pfizer Investigational Site, Tucson, Arizona, United States|Pfizer Investigational Site, Fresno, California, United States|Pfizer Investigational Site, Stamford, Connecticut, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, New Port Richey, Florida, United States|Pfizer Investigational Site, Tamarac, Florida, United States|Pfizer Investigational Site, Rockford, Illinois, United States|Pfizer Investigational Site, Terre Haute, Indiana, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Annapolis, Maryland, United States|Pfizer Investigational Site, Pittsfield, Massachusetts, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, Columbia, Missouri, United States|Pfizer Investigational Site, Billings, Montana, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Hooksett, New Hampshire, United States|Pfizer Investigational Site, Lebanon, New Hampshire, United States|Pfizer Investigational Site, Rockville Centre, New York, United States|Pfizer Investigational Site, Greenville, North Carolina, United States|Pfizer Investigational Site, Hendersonville, North Carolina, United States|Pfizer Investigational Site, Hickory, North Carolina, United States|Pfizer Investigational Site, Winston - Salem, North Carolina, United States|Pfizer Investigational Site, Zanesville, Ohio, United States|Pfizer Investigational Site, Charleston, South Carolina, United States|Pfizer Investigational Site, Temple, Texas, United States|Pfizer Investigational Site, Newport News, Virginia, United States|Pfizer Investigational Site, Milwaukee, Wisconsin, United States|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Kingston, Ontario, Canada|Pfizer Investigational Site, Kitchener, Ontario, Canada|Pfizer Investigational Site, Windsor, Ontario, Canada|Pfizer Investigational Site, Fleurimont, Quebec, Canada","https://ClinicalTrials.gov/show/NCT00140036"
732,"NCT02150746","Circulating Tumor Cells in Operative Blood","null","Completed","No Results Available","Carcinoma, Pancreatic Ductal","Procedure: Peripheral/Central Venous Blood Draw|Procedure: Peritoneal Wash","Percentage of patients with isolated circulating tumor cells|Percentage of patients with successful in vivo animal engraftment of isolated circulating tumor cells","University of Florida","All","18 Years to 85 Years   (Adult, Senior)","","3","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2014-00271","February 2015","February 2016","February 2016","February 2016","May 27, 2014","May 30, 2014","null","null","February 22, 2016","February 23, 2016","Shands Hospital at the University of Florida, Gainesville, Florida, United States","https://ClinicalTrials.gov/show/NCT02150746"
733,"NCT01655641","Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery","TMGS","Unknown status","No Results Available","Gastric Cancer|Pancreatic Cancer|Hepatocellular Cancer|Colon Cancer","Drug: Tranexamic acid|Other: Standard of care","Primary objective of the study is to compare transfusion requirements and Mortality in patients receiving Tranexamic acid (Cyklokapron®) and those not receiving it.|Secondary outcome measure|Secondary Outcome measure","Tribhuvan University Teaching Hospital, Institute Of Medicine.|Pfizer","All","16 Years and older   (Child, Adult, Senior)","Phase 2|Phase 3","118","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","# WS2017115","July 2012","June 2013","July 2014","October 2012","July 23, 2012","August 2, 2012","null","null","October 14, 2012","October 16, 2012","Tribhuvan University Teaching Hospital, Kathmandu, Kathmandy, Nepal","https://ClinicalTrials.gov/show/NCT01655641"
734,"NCT00148226","ICIBS Trial - Improving Patient Information About Bowel Cancer Screening - a Decision Aid Trial","null","Completed","No Results Available","Colorectal Cancer Screening","Behavioral: Decision Aid","","University of Sydney","All","50 Years to 74 Years   (Adult, Senior)","Phase 2","null","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Educational/Counseling/Training","211205","November 2003","null","September 2005","September 2005","September 5, 2005","September 7, 2005","null","null","January 3, 2006","January 4, 2006","University of Sydney, Sydney, New South Wales, Australia","https://ClinicalTrials.gov/show/NCT00148226"
735,"NCT02220231","Echocardiographic Evaluation of the Change on Pulmonary Blood Flow and Cardiac Function Induced by Capnothorax During One Lung Ventilation","null","Completed","No Results Available","Mediastinal Tumors","Procedure: capnothorax","The changes of the echocardiographic indices|The changes of the oxygenation and respiratory dynamic parameters","Yonsei University","All","20 Years to 80 Years   (Adult, Senior)","","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","4-2014-0492","August 2014","March 2015","March 2015","April 2015","August 6, 2014","August 19, 2014","null","null","April 16, 2015","April 17, 2015","","https://ClinicalTrials.gov/show/NCT02220231"
736,"NCT02567045","Uptake to Colorectal Cancer Screening in Familial-risk Population","null","Recruiting","No Results Available","Colorectal Cancer|Screening Uptake of Colonoscopy and FIT","Procedure: annual FIT and colonoscopy in case of a positive test|Procedure: colonoscopy with sedation","Proportion of patients who participate in each screening arm|Efficacy measure: QALYs (Quality adjusted life years).|Costs measure: cost (euros) of the procedures associated with each screening strategy and treatment of advanced neoplastic lesions","Hospital Universitario de Canarias","All","18 Years to 40 Years   (Adult)","","1076","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Colorectal cancer screening","February 25, 2016","December 2018","March 2019","March 2017","September 29, 2015","October 2, 2015","null","null","March 6, 2017","March 7, 2017","Federico Sopeña Biarge, Zaragoza, Aragón, Spain|Cristina Alvarez Urturi, MD, Barcelona, Cataluña, Spain|Maria Teresa Ocaña Bombardo, Barcelona, Cataluña, Spain|Inés Castro Novo, Ourense, Galicia, Spain|Patricia Muñoz Garrrido, San Sebastián, País Vasco, Gipuzcoa, Spain|Digestive Service, Huc, La Laguna, S/c de Tenerife, Spain|María Rodriguez Soler, Alicante, Spain","https://ClinicalTrials.gov/show/NCT02567045"
737,"NCT02109913","Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane","null","Active, not recruiting","No Results Available","Hormone Receptor Positive Malignant Neoplasm of Breast|Metastatic Breast Cancer","Drug: Everolimus plus Exemestane","Biomarker Evaluation from Primary Tumor Tissue, New Tumor Biopsies and Blood Samples|Progression-free survival|Number of Participants with Adverse Events as a Measure of Safety and Tolerability","VU University Medical Center|Borstkanker Onderzoek Groep|Novartis","Female","18 Years and older   (Adult, Senior)","","175","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","EudraCT 2013-004120-11|BOOG 2013-06","March 2014","September 2017","March 2018","March 2017","April 2, 2014","April 10, 2014","null","null","March 30, 2017","March 31, 2017","VU University Medical Center, Amsterdam, Noord-Holland, Netherlands|Flevoziekenhuis, Almere, Netherlands|BovenIJ Ziekenhuis, Amsterdam, Netherlands|The Netherlands Cancer Institute, Amsterdam, Netherlands|Gelre, Apeldoorn, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Reinier de Graaf Groep, Delft, Netherlands|Haga, Den Haag, Netherlands|MC Haaglanden, Den Haag, Netherlands|Gemini, Den Helder, Netherlands|Deventer Ziekenhuis, Deventer, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|Tergooi ziekenhuizen, Hilversum, Netherlands|Spaarne Ziekenuis, Hoofddorp, Netherlands|MC Leeuwarden, Leeuwarden, Netherlands|LUMC, Leiden, Netherlands|Canisius Ziekenhuis, Nijmegen, Netherlands|Bravis, Roosendaal and Bergen op Zoom, Netherlands|Erasmus University Medical Center, Rotterdam, Netherlands|Ikazia, Rotterdam, Netherlands|Vlietland, Schiedam, Netherlands|Orbis MC, Sittard, Netherlands|Elisabeth - Tweesteden, Tilburg, Netherlands|UMC Utrecht, Utrecht, Netherlands|VieCuri, Venray, Netherlands|Isala, Zwolle, Netherlands","https://ClinicalTrials.gov/show/NCT02109913"
738,"NCT00897208","Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer","null","Active, not recruiting","No Results Available","Breast Cancer","Other: high performance liquid chromatography|Other: laboratory biomarker analysis|Other: mass spectrometry|Other: medical chart review|Procedure: evaluation of cancer risk factors","Comparison of the levels of estrogens, catechol estrogen (CE) metabolites, CE-glutathione conjugates, and CE-DNA adducts (N3Ade and N7Gua) among healthy women, high-risk women, and women with breast cancer","Mayo Clinic","Female","19 Years to 80 Years   (Adult, Senior)","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","19-2005|06-008665","May 2005","September 2017","null","April 2016","May 9, 2009","May 12, 2009","null","null","December 20, 2016","December 21, 2016","Mayo Clinic Cancer Center, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00897208"
739,"NCT00523471","Blood Test to Measure DNA Damage in Blood","null","Terminated","No Results Available","Prostate Cancer","Procedure: Blood test","","AHS Cancer Control Alberta","Male","Child, Adult, Senior","","40","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","GU-6-0076/ethics 23586","July 2007","June 2010","June 2010","April 2012","August 30, 2007","August 31, 2007","null","null","February 24, 2016","February 26, 2016","Cross Cancer Institute, Edmonton, Alberta, Canada","https://ClinicalTrials.gov/show/NCT00523471"
740,"NCT00020722","Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer","null","Terminated","Has Results","Breast Cancer","Biological: therapeutic autologous lymphocytes|Drug: Ifosfamide, carboplatin, and etoposide (ICE) regimen|Drug: Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)|Procedure: Leukapheresis|Procedure: peripheral blood stem cell transplantation (PBSCT)","Disease-free Survival|Overall Survival","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","Female","18 Years to 120 Years   (Adult, Senior)","Phase 2","7","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000068707|P30CA022453|WSU-2007-033|RWMC-0634246","August 2007","March 2013","March 2013","February 2016","July 11, 2001","January 27, 2003","February 9, 2015","March 30, 2015","February 15, 2016","February 17, 2016","Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States","https://ClinicalTrials.gov/show/NCT00020722"
741,"NCT02273336","Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer","null","Recruiting","No Results Available","Non-small Cell Lung Cancer|Small Cell Lung Cancer","Other: cytology specimen collection procedure|Other: laboratory biomarker analysis","Prevalence of targetable mutations, defined as any alteration in a drive oncogene for which Food and Drug Administration-approved therapy exists, for which an off-label therapy exists, or for which a clinical trial exists|Proportion of young lung cancer patients that enroll onto clinical trials|Proportion of patients that received targeted therapies based on their clinical genotyping results|Acquired deactivating mutations","University of Southern California|Foundation Medicine|Addario Lung Cancer Medical Institute|National Cancer Institute (NCI)","All","up to 39 Years   (Child, Adult)","","60","Other|Industry|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ALCMI-003|NCI-2014-02098|2L-14-1|P30CA014089","July 22, 2014","July 22, 2018","July 22, 2019","April 2017","October 21, 2014","October 23, 2014","null","null","April 11, 2017","April 13, 2017","USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT02273336"
742,"NCT00003392","High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer","null","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: melphalan|Drug: paclitaxel|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","61","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 9727|UNC-LCCC-970135|NCI-G98-1446","September 1997","August 2002","January 2003","February 2012","November 1, 1999","July 22, 2004","null","null","February 19, 2012","February 22, 2012","Scripps Clinic, La Jolla, California, United States|University of California San Diego, La Jolla, California, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|Bone Marrow Stem Cell Transplant Institute of Florida, Fort Lauderdale, Florida, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Lutheran General Cancer Care Center, Park Ridge, Illinois, United States|Stem Cell Sciences, New York, New York, United States|University of Rochester School of Medicine, Rochester, New York, United States|New York Medical College, Valhalla, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Temple University Cancer Center, Philadelphia, Pennsylvania, United States|Methodist Hospital-Central Unit, Memphis, Tennessee, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT00003392"
743,"NCT00002755","Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer","null","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: CMF regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: fluorouracil|Drug: methotrexate|Drug: tamoxifen citrate|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy","","Scottish Cancer Therapy Network|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 3","600","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000064692|SCTN-BR9405|EU-95048","November 1995","null","June 1999","May 2007","November 1, 1999","August 24, 2004","null","null","November 5, 2013","November 6, 2013","St. Vincent's Hospital, Dublin, Ireland|Addenbrooke's NHS Trust, Cambridge, England, United Kingdom|Cheltenham General Hospital, Cheltenham, England, United Kingdom|Royal Devon and Exeter Hospital, Exeter, England, United Kingdom|Royal Free Hospital, Hampstead, London, England, United Kingdom|Northwick Park Hospital, Harrow, England, United Kingdom|Huddersfield Royal Infirmary, Huddersfield, West Yorks, England, United Kingdom|St. James's Hospital, Leeds, England, United Kingdom|St. George's Hospital, London, England, United Kingdom|Middlesex Hospital- Meyerstein Institute, London, England, United Kingdom|Newcastle General Hospital, Newcastle Upon Tyne, England, United Kingdom|Nottingham City Hospital NHS Trust, Nottingham, England, United Kingdom|Derriford Hospital, Plymouth, England, United Kingdom|Weston Park Hospital, Sheffield, England, United Kingdom|Royal South Hants Hospital, Southampton, England, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom|Royal Infirmary, Edinburgh, Scotland, United Kingdom|Western General Hospital, Edinburgh, Scotland, United Kingdom|Beatson Oncology Centre, Glasgow, Scotland, United Kingdom|Royal Infirmary, Glasgow, Scotland, United Kingdom|Velindre Hospital, Cardiff, Wales, United Kingdom","https://ClinicalTrials.gov/show/NCT00002755"
744,"NCT00074269","Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer","null","Terminated","Has Results","Breast Cancer","Biological: anti-thymocyte globulin|Biological: filgrastim|Biological: graft-versus-tumor induction therapy|Biological: therapeutic allogeneic lymphocytes|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: melphalan|Drug: methotrexate|Procedure: peripheral blood stem cell transplantation","Adverse Events Rate|Facilitation of Long-term Engraftment|Incidence and Severity of Acute and Chronic Graft-versus-host Disease (GVHD)|Progression-free Survival|Overall Survival|Response (Partial and Complete) as Measured at 1, 3, 6, and 12 Months Post Allografting and Within 1 Week After the Onset of Documented GVHD if > 1 Month Separates Any of the Response Evaluation Timepoints|Frequency and Durability of the Induction of Full Donor Chimerism of Lymphocytes as Measured at 1, 3, 6, and 12 Months Post Allografting","University of California, San Diego|National Cancer Institute (NCI)","Female","18 Years to 60 Years   (Adult)","Phase 2","5","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCSD-020815|CDR0000343758","July 2003","March 2008","March 2008","November 2014","December 10, 2003","December 11, 2003","May 29, 2014","November 24, 2014","December 2, 2014","December 10, 2014","Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States","https://ClinicalTrials.gov/show/NCT00074269"
745,"NCT00691730","Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer","null","Active, not recruiting","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Other: laboratory biomarker analysis|Other: pharmacological study","Renal and blood pressure changes|Physiological mechanism behind proteinuria and hypertension induced by antiangiogenic therapies|Predictive value of soluble factors in the development of proteinuria or hypertension|Predictive value of steady state drug concentrations in the development of proteinuria or hypertension","University Health Network, Toronto|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PHL-064|NCI-2009-00277|PMH-PHL-064|CDR0000588665","February 2008","June 2012","December 2018","November 2017","June 4, 2008","June 5, 2008","null","null","November 6, 2017","November 8, 2017","Tom Baker Cancer Centre, Calgary, Alberta, Canada|London Regional Cancer Program, London, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT00691730"
746,"NCT00519805","Dalteparin in Preventing Blood Clots in Patients With Lung Cancer","null","Unknown status","No Results Available","Lung Cancer|Thromboembolism","Drug: dalteparin|Procedure: quality-of-life assessment","Overall survival|Venous thrombotic event-free survival|Serious adverse events|Metastasis-free survival|Toxicity|Quality of life as measured by EQ-5D|Breathlessness (dyspnea) as measured by the Cancer Dyspnea Scale|Anxiety and depression as measured by the Hospital Anxiety and Depression Scale|Cost effectiveness|Cost utility","Velindre NHS Trust|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","2200","Other","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Supportive Care","CDR0000561532|WCTU-FRAGMATIC|Velindre-FRAGMATIC|WCTU-02|EU-20753|PFIZER-WCTU-02|EUDRACT-2005-002438-37|ISRCTN80812769","August 2007","August 2012","null","March 2008","August 21, 2007","August 23, 2007","null","null","August 5, 2011","August 8, 2011","Stoke Mandeville Hospital, Aylesbury-Buckinghamshire, England, United Kingdom|Furness General Hospital, Barrow in Furness, England, United Kingdom|Royal Blackburn Hospital, Blackburn, England, United Kingdom|Blackpool Victoria Hospital, Blackpool, England, United Kingdom|Royal Bournemouth Hospital, Bournemouth, England, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom|Burnley General Hospital, Burnley, England, United Kingdom|Queen's Hospital, Burton-upon-Trent, England, United Kingdom|West Suffolk Hospital, Bury St. Edmunds, England, United Kingdom|Walsgrave Hospital, Coventry, England, United Kingdom|Darlington Memorial, Darlington, England, United Kingdom|Derbyshire Royal Infirmary, Derby, England, United Kingdom|Doncaster Royal Infirmary, Doncaster, England, United Kingdom|Dorset County Hospital, Dorchester, England, United Kingdom|Russells Hall Hospital, Dudley, England, United Kingdom|Queen Elizabeth Hospital, Gateshead, England, United Kingdom|Wycombe General Hospital, High Wycombe, England, United Kingdom|Kidderminster Hospital, Kidderminster Worcestershire, England, United Kingdom|Royal Lancaster Infirmary, Lancaster, England, United Kingdom|Whipps Cross Hospital, London, England, United Kingdom|Saint Bartholomew's Hospital, London, England, United Kingdom|Helen Rollason Cancer Care Centre at North Middlesex Hospital, London, England, United Kingdom|Whittington Hospital, London, England, United Kingdom|University College Hospital, London, England, United Kingdom|UCL Cancer Institute, London, England, United Kingdom|Luton and Dunstable Hospital, Luton, England, United Kingdom|James Cook University Hospital, Middlesbrough, England, United Kingdom|Milton Keynes General Hospital, Milton Keynes, England, United Kingdom|Newcastle Upon Tyne Hospitals NHS Trust, Newcastle-Upon-Tyne, England, United Kingdom|James Paget Hospital, Norfolk, England, United Kingdom|North Tyneside Hospital, North Shields, England, United Kingdom|Friarage Hospital, North Yorkshire, England, United Kingdom|Northampton General Hospital, Northampton, England, United Kingdom|Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, England, United Kingdom|Norfolk and Norwich University Hospital, Norwich, England, United Kingdom|Nottingham City Hospital, Nottingham, England, United Kingdom|George Eliot Hospital, Nuneaton, England, United Kingdom|Derriford Hospital, Plymouth, England, United Kingdom|Dorset Cancer Centre, Poole Dorset, England, United Kingdom|Rosemere Cancer Centre at Royal Preston Hospital, Preston, England, United Kingdom|Berkshire Cancer Centre at Royal Berkshire Hospital, Reading, England, United Kingdom|Alexandra Healthcare NHS, Redditch, Worcestershire, England, United Kingdom|Scarborough General Hospital, Scarborough, England, United Kingdom|Cancer Research Centre at Weston Park Hospital, Sheffield, England, United Kingdom|Wexham Park Hospital, Slough, Berkshire, England, United Kingdom|South Tyneside District Hospital, South Shields, England, United Kingdom|Staffordshire General Hospital, Stafford, England, United Kingdom|University Hospital of North Staffordshire, Stoke-On-Trent, England, United Kingdom|Royal Marsden - Surrey, Sutton, England, United Kingdom|South Warwickshire Hospital, Warwick, Warwickshire, England, United Kingdom|Weston General Hospital, Weston-super-Mare, England, United Kingdom|New Cross Hospital, Wolverhampton, England, United Kingdom|Yeovil District Hospital, Yeovil, England, United Kingdom|Ysbyty Gwynedd, Bangor, Wales, United Kingdom|Velindre Cancer Center at Velindre Hospital, Cardiff, Wales, United Kingdom|Llandough Hospital, Llandough, Wales, United Kingdom|Royal Glamorgan Hospital, Llantrisant, Wales, United Kingdom|Prince Charles Hospital, Mid Glamorgan, Wales, United Kingdom|Royal Gwent Hospital, Newport Gwent, Wales, United Kingdom|Glan Clwyd Hospital, Rhyl, Denbighshire, Wales, United Kingdom","https://ClinicalTrials.gov/show/NCT00519805"
747,"NCT00436137","Improving Followup of Abnormal Colon Cancer Screening Tests","null","Completed","No Results Available","Colorectal Cancer","Behavioral: Patient mailing","Performance of colonoscopy","Harvard Vanguard Medical Associates|Brigham and Women's Hospital","All","18 Years to 80 Years   (Adult, Senior)","","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Sequist Colorectal Cancer","June 2007","March 2008","March 2008","November 2008","February 14, 2007","February 16, 2007","null","null","November 5, 2008","November 6, 2008","Harvard Vanguard Medical Associates, Newton, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT00436137"
748,"NCT00956878","Cancer Pain Single Nucleotide Polymorphisms (SNPs)","null","Completed","No Results Available","Cancer|Pain","","correlation between pain SNPs and equianalgesic opioid requirement","Erasmus Medical Center","All","18 Years and older   (Adult, Senior)","","243","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MEC2008-166","September 2008","December 2012","December 2012","December 2014","August 10, 2009","August 11, 2009","null","null","December 23, 2014","December 24, 2014","Erasmus MC, Centrumlocatie en Daniel den Hoed, Rotterdam, Zuid-Holland, Netherlands","https://ClinicalTrials.gov/show/NCT00956878"
749,"NCT00002628","Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer","null","Unknown status","No Results Available","Breast Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: mesna|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation","","St. Louis University|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","50","Other","Interventional","Primary Purpose: Treatment","CDR0000064017|SLUMC-7915|NCI-V95-0608","November 1994","null","null","April 2000","November 1, 1999","August 31, 2004","null","null","January 9, 2014","January 10, 2014","Indiana University Cancer Center, Indianapolis, Indiana, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, United States|Methodist Hospital-Central Unit, Memphis, Tennessee, United States","https://ClinicalTrials.gov/show/NCT00002628"
750,"NCT03309917","The Effect of Blood Pressure on Cerebral Blood Flow During Propofol Anesthesia","CA","Recruiting","No Results Available","Gastrointestinal Neoplasms|Anesthesia, General","Other: MAP set at 80-85 mmHg for 5 min|Other: MAP set at 70-75 mmHg for 5 min|Other: MAP set at 60-65 mmHg for 5 min","Change in internal carotid artery blood flow when mean arterial pressure (MAP) is set to 80-85 and 60-65 mmHg|Change in internal carotid artery blood flow when MAP is set to 70-75 and 60-65 mmHg|Change in internal carotid artery blood flow when MAP is set to 80-85 and 70-75 mmHg|Comparison of the slope of linear regression of MAP and internal carotid artery blood flow for the evaluations when MAP is set to 80-85 and 70-75 mmHg and that of the evaluations when MAP is set to 70-75 and 60-65 mmHg","Rigshospitalet, Denmark","All","19 Years and older   (Adult, Senior)","","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","H-17021598-61256","December 27, 2017","April 15, 2018","April 15, 2018","December 2017","October 9, 2017","October 16, 2017","null","null","December 22, 2017","December 25, 2017","Department of Anaesthesia, Copenhagen, Denmark","https://ClinicalTrials.gov/show/NCT03309917"
751,"NCT00102011","Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer","00-046","Active, not recruiting","No Results Available","Colorectal Cancer","Procedure: annual screening|Procedure: fecal occult blood test|Procedure: screening colonoscopy|Procedure: standard follow-up care","Neoplastic findings as assessed by screening colonoscopy vs annual fecal occult blood test (FOBT)-directed colonoscopy|Burden on endoscopic and clinical resources|Harms associated with screening colonoscopy vs annual FOBT-directed colonoscopy|Benefit-to-harm ration for screening colonoscopy vs annual FOBT-directed colonoscopy|Level of participation in screening with FOBT-directed colonoscopy vs a single colonoscopy","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","40 Years to 69 Years   (Adult, Senior)","Phase 3","4952","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","00-046|MSKCC-00046A|UMN-2003NT062","May 2000","May 2018","May 2018","September 2017","January 18, 2005","January 19, 2005","null","null","September 13, 2017","September 14, 2017","Feist-Weiller Cancer Center at Louisiana State University Health Sciences, Shreveport, Louisiana, United States|Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Group Health Central Hospital, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00102011"
752,"NCT00959556","Study of Blood Samples in Patients With Breast Cancer","null","Unknown status","No Results Available","Breast Cancer","Other: laboratory biomarker analysis","Histologic complete response (Chevallier and Sataloff) or tumor response (RECIST)","Centre Oscar Lambret|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","","900","Other","Observational","","CDR0000633531|COL-GENEOM|COL-IDRCB-2007-A00908-45|COL-2007-08|INCA-RECF0635","November 2007","December 2011","null","August 2009","August 13, 2009","August 14, 2009","null","null","January 7, 2011","January 10, 2011","Centre Oscar Lambret, Lille, France","https://ClinicalTrials.gov/show/NCT00959556"
753,"NCT00003860","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer","null","Unknown status","No Results Available","Lung Cancer","Biological: filgrastim|Drug: carboplatin|Drug: etoposide|Drug: ifosfamide|Procedure: in vitro-treated peripheral blood stem cell transplantation","","UNICANCER|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","36","Other","Interventional","Primary Purpose: Treatment","CDR0000067023|FRE-FNCLCC-98003-CLEO|EU-98072|FRE-FNCLCC-CLEOPATRE03","September 1998","null","null","December 1999","November 1, 1999","June 16, 2004","null","null","February 6, 2009","February 9, 2009","CHR de Besancon - Hopital Saint-Jacques, Besancon, France|Institut Bergonie, Bordeaux, France|CMC Bligny, Briis Sous Forges, France|Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France|CHR de Grenoble - La Tronche, Grenoble, France|Centre Leon Berard, Lyon, France|Hopital Louis Pradel, Lyon, France|Institut J. Paoli and I. Calmettes, Marseille, France|Hopital Arnaud de Villeneuve, Montpellier, France|Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Institut Curie - Section Medicale, Paris, France|Hopital Saint Antoine, Paris, France|Hopital Tenon, Paris, France|Hopital Jules Courmont - Centre Hospitalier Lyon Sud, Pierre Benite, France|Hopital Rene Dubos, Pontoise, France|Institut Jean Godinot, Reims, France|Centre Rene Huguenin, Saint Cloud, France|Hopitaux Universitaire de Strasbourg, Strasbourg, France|Institut Claudius Regaud, Toulouse, France|CHRU de Nancy - Hopitaux de Brabois, Vandoeuvre-Les-Nancy, France|Institut Gustave Roussy, Villejuif, France","https://ClinicalTrials.gov/show/NCT00003860"
754,"NCT00003877","Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer","null","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: paclitaxel|Drug: thiotepa|Procedure: in vitro-treated bone marrow transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation","","Roswell Park Cancer Institute|National Cancer Institute (NCI)","Female","18 Years to 64 Years   (Adult)","Phase 1|Phase 2","30","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000067043|P30CA016056|RPCI-DS-9828|CWRU-OSIR-1198|OSIRIS-101|NCI-G99-1516","September 1998","February 2000","December 2000","March 2011","November 1, 1999","July 16, 2004","null","null","March 3, 2011","March 7, 2011","Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Ireland Cancer Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT00003877"
755,"NCT00002837","High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer","null","Completed","No Results Available","Breast Cancer","Biological: Filgrastim (G-CSF)|Drug: Cyclophosphamide|Drug: Doxorubicin Hydrochloride|Drug: Paclitaxel|Procedure: Peripheral Blood Stem Cell Transplantation","Maximum Tolerated Doses (MTD) of 4 courses Doxorubicin, Paclitaxel, + Cyclophosphamide followed by PBSC and G-CSF Support","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb","All","15 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","21","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DM95-156|P30CA016672|MDA-DM-95156|NCI-V96-1017|CDR0000065052","September 1995","January 2002","January 2002","July 2012","November 1, 1999","July 1, 2004","null","null","July 27, 2012","July 31, 2012","University of Texas - MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00002837"
756,"NCT00963092","Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer","null","Unknown status","No Results Available","Adenocarcinoma of the Gastroesophageal Junction|Esophageal Cancer|Gastric Cancer","Genetic: DNA analysis|Genetic: RNA analysis|Genetic: microarray analysis|Genetic: protein analysis|Other: cytology specimen collection procedure|Other: laboratory biomarker analysis|Other: questionnaire administration","Creation of repository of blood, saliva, and tumor samples","Cancer Research UK|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","","4000","Other","Observational","","CRUK-UC-SOCS-03-5-064|CDR0000636974|EU-20911","August 2002","December 2010","null","July 2011","August 20, 2009","August 21, 2009","null","null","August 9, 2013","August 12, 2013","Cancer Research UK at Cambridge Research Institute, Cambridge, England, United Kingdom","https://ClinicalTrials.gov/show/NCT00963092"
757,"NCT00897351","Study of Tissue and Blood Samples From Patients With Recurrent Prostate Cancer Who Received Lapatinib on Clinical Trial ECOG-E5803","null","Completed","No Results Available","Prostate Cancer","Genetic: mutation analysis|Genetic: polymorphism analysis|Genetic: protein expression analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis","Polymorphisms associated with toxicity|Association between mutations in EGFR, HER-2 and Kras; protein expression of HER2, EGFR, MAPK and AKT; polymorphism controlling androgen synthesis; and progression-free survival","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","Male","18 Years to 120 Years   (Adult, Senior)","","37","Other|NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","CDR0000600985|ECOG-E5803T1","July 10, 2008","February 10, 2009","February 10, 2009","May 2017","May 9, 2009","May 12, 2009","null","null","May 16, 2017","May 17, 2017","","https://ClinicalTrials.gov/show/NCT00897351"
758,"NCT00270881","Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies","null","Completed","No Results Available","Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome","Procedure: Cord blood transplantation|Radiation: TBI|Drug: cyclophosphamide|Drug: cytarabine","Non-relapse mortality at 1 year|Engraftment|Disease free survival|Overall survival|Incidence of acute and chronic graft-versus-host disease|Incidence of infectious complication|Duration of hospitalization|Immune reconstitution after transplantation","Keio University","All","20 Years to 55 Years   (Adult)","Phase 1|Phase 2","33","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSGCT-CB2005","January 2006","January 2009","January 2011","April 2012","December 28, 2005","December 29, 2005","null","null","April 5, 2012","April 6, 2012","Keio University School of Medicine, Tokyo, Japan","https://ClinicalTrials.gov/show/NCT00270881"
759,"NCT00020176","Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer","null","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation","","National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","null","NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000067899|NCI-00-C-0119|NCI-1027","June 2000","null","August 2007","November 2004","July 11, 2001","January 27, 2003","null","null","June 18, 2013","June 20, 2013","Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States|NCI - Center for Cancer Research, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00020176"
760,"NCT01286064","Colorectal Cancer Detection by Means of Optical Fluoroscopy","null","Unknown status","No Results Available","Colorectal Cancer","Device: Optical Fluoroscopy","Colorectal cancer detection by means of optical fluoroscopy","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","All","18 Years to 75 Years   (Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Screening","INT-D178768","October 2010","December 2010","April 2011","September 2010","January 27, 2011","January 31, 2011","null","null","January 28, 2011","January 31, 2011","Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy","https://ClinicalTrials.gov/show/NCT01286064"
761,"NCT00002780","Biological Therapy in Treating Women With Metastatic Breast Cancer","null","Unknown status","No Results Available","Breast Cancer","Biological: aldesleukin|Biological: cytokine therapy|Biological: sargramostim|Drug: carboplatin|Drug: cyclophosphamide|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation","","St. Luke's Medical Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","60","Other","Interventional","Primary Purpose: Treatment","CDR0000064792|STLMC-BRM-9503|NCI-V96-0902","May 1996","null","null","February 2001","November 1, 1999","May 24, 2004","null","null","December 18, 2013","December 19, 2013","St. Luke's Medical Center, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT00002780"
762,"NCT00693927","Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC)","null","Completed","No Results Available","Hematologic Malignancies","Procedure: Unmanipulated PBSC after nonmyeloablative conditioning|Procedure: CD8-depleted PBSC after nonmyeloablative conditioning","Incidence of acute GVHD in CD8-depleted versus unmanipulated groups|Incidence of chronic GVHD (overall and extensive) in CD8-depleted versus unmanipulated groups.|Incidence of graft rejection [according to the risk of transplant rejection (see table 1 above)] in CD8-depleted versus unmanipulated groups.|T cell (CD3) and myeloid (CD13) chimerism in CD8-depleted versus unmanipulated groups.|Quality and timing of immune reconstitution in CD8-depleted versus unmanipulated groups.","University Hospital of Liege","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Minitransplant - random","March 2002","May 2005","May 2008","September 2011","May 29, 2008","June 9, 2008","null","null","September 1, 2011","September 2, 2011","CHU Sart Tilman, Liege, Belgium","https://ClinicalTrials.gov/show/NCT00693927"
763,"NCT00283465","A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy","null","Completed","No Results Available","Anemia|Neoplasm","Drug: Epoetin alfa","Number of patients who receive an allogenic red blood cell transfusion during the study, during each chemotherapy cycle, and at 4 weeks after the last administration of chemotherapy|Number of units transfused during each chemotherapy cycle; change in quality of life; change in hemoglobin level; relationship between change in hemoglobin and quality of life; tumor response; patient survival up to 12 months after the end of treatment","Janssen-Cilag B.V.","All","18 Years and older   (Adult, Senior)","Phase 4","316","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR002047","November 1999","null","April 2004","January 2011","January 27, 2006","January 30, 2006","null","null","January 13, 2011","January 14, 2011","","https://ClinicalTrials.gov/show/NCT00283465"
764,"NCT01985113","Correlation Research of Thioredoxin Reductase in Lung Cancer","TRCRLC","Completed","No Results Available","Non-small Cell Lung Cancer|Benign Neoplasm of Lung","","measure the thioredoxin reductase activity in blood, tumor and pericarcinomatous tissue|Measure the difference of thioredoxin reductase activity between lung cancer tissue and lung benign mass|Measure the thioredoxin reductase mRNA and protein expression in tumor and pericarcimomatous tissue","Hunan Province Tumor Hospital","All","18 Years to 80 Years   (Adult, Senior)","","165","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TR001|TRRFLC1","May 2013","February 2016","February 2016","February 2016","November 4, 2013","November 15, 2013","null","null","February 14, 2016","February 17, 2016","Hunan Provincal Tumor Hospital, Changsha, Hunan, China","https://ClinicalTrials.gov/show/NCT01985113"
765,"NCT00200187","A Randomized Study of the Efficacy of Low Venous Pressure General Anesthesia Versus Combined Spinal-Epidural Anesthesia in Decreasing Blood Loss During Prostate Surgery","null","Completed","No Results Available","Prostate Cancer","Procedure: low venous pressure general anesthesia|Procedure: combined spinal-epidural anesthesia","Aim #1: To determine whether LVPGA reduces blood loss by >= 300 ml versus CSE in patients undergoing open RRP|Aim #2: To compare transfusion rates of autologous and allogenic blood between the two anesthesia groups|Aim #3: To identify differences in pattern of blood loss in the two groups according to different surgical stages|Stage I: Pelvic Lymph node dissection: From skin incision to completion of pelvic node dissection|Stage II: Prostatectomy: From endopelvic fascia opening to completion of prostatic bed hemostasis after the prostate is removed|Stage II a: Dorsal venous complex control: From endopelvic fascia opening to beginning of nerve bundles dissection (or ligature in case they were not preserved)|Stage II b: Nerve bundles dissection and prostate removal: From the beginning of nerve bundles dissection to completion of prostatic bed hemostasis after the prostate is removed|Stage III: Urinary tract reconstruction: From bladder neck reconstruction to completion of skin closure|To compare postoperative complication type, incidence and grade experienced by the two groups. The current MSKCC morbidity and mortality definitions and grading system will be utilized|To compare the efficacy of pain control postoperatively in the two groups (epidural PCA versus intravenous PCA+ NSAID’s)|To compare length of hospital stay for the two groups|To prospectively evaluate the relationship of pelvimetry, urethral length and prostatic veins size on MRI 1 to intraoperative blood loss and complications","Memorial Sloan Kettering Cancer Center","Male","18 Years and older   (Adult, Senior)","Phase 2","246","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","05-003","February 2005","null","January 2007","January 2007","September 12, 2005","September 20, 2005","null","null","January 25, 2007","January 26, 2007","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00200187"
766,"NCT02688517","Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer","null","Recruiting","No Results Available","Malignant Neoplasm","Other: Cytology Specimen Collection Procedure|Other: Laboratory Biomarker Analysis","Frequencies of individual specific mutations and combinations of mutations of related pathway genes|Rate of actionable mutations in rare and/or poor prognosis cancers","Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey","All","1 Year and older   (Child, Adult, Senior)","","1100","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","001209|NCI-2015-01812|CINJ # 001209|P30CA072720","February 2013","February 2020","February 2020","November 2017","February 17, 2016","February 23, 2016","null","null","November 15, 2017","November 17, 2017","Ocean Medical Center, Brick, New Jersey, United States|Bayshore Community Hospital, Holmdel, New Jersey, United States|Southern Ocean County Medical Center, Manahawkin, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Jersey Shore Medical Center, Neptune, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Riverview Medical Center/Booker Cancer Center, Red Bank, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT02688517"
767,"NCT01925625","Early Cancer Detection Test - Lung Cancer Scotland","ECLS","Recruiting","No Results Available","Lung Cancer","Biological: Early CDT Lung blood test","to assess the effectiveness of EarlyCDT-Lung test in reducing the incidence of patients with late-stage lung cancer at diagnosis, compared with standard clinical practice;","Cheryl Hume|University of Dundee","All","50 Years to 75 Years   (Adult, Senior)","","10000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2013ON07","August 2013","August 2016","August 2018","December 2014","August 15, 2013","August 20, 2013","null","null","December 3, 2014","December 4, 2014","NHS Tayside, Dundee, Tayside, United Kingdom|NHS Greater Glasgow & Clyde, Glasgow, United Kingdom","https://ClinicalTrials.gov/show/NCT01925625"
768,"NCT00003920","Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer","null","Unknown status","No Results Available","Breast Cancer","Biological: filgrastim|Drug: cyclosporine|Procedure: peripheral blood stem cell transplantation|Radiation: indium In 111 monoclonal antibody m170|Radiation: yttrium Y 90 monoclonal antibody m170","","University of California, Davis|National Cancer Institute (NCI)","All","18 Years to 55 Years   (Adult)","Phase 1","18","Other","Interventional","Primary Purpose: Treatment","UCD-986545|CDR0000067105|NCI-V99-1549","April 1996","null","null","November 2000","November 1, 1999","June 17, 2004","null","null","August 6, 2013","August 7, 2013","University of California Davis Medical Center, Sacramento, California, United States","https://ClinicalTrials.gov/show/NCT00003920"
769,"NCT00002836","Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer","null","Completed","No Results Available","Breast Cancer","Biological: Filgrastim (G-CSF)|Drug: Carmustine|Drug: Cisplatin|Drug: Cyclophosphamide (CTX)|Drug: Etoposide|Drug: Thiotepa|Procedure: Peripheral Blood Stem Cell Transplantation","Compare Effectiveness of Chemotherapy + Filgrastim to Filgrastim Alone","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 3","184","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DM95-047|P30CA016672|MDA-DM-95047|NCI-G96-1014|CDR0000065048","May 1995","March 2006","March 2006","July 2012","November 1, 1999","November 24, 2003","null","null","July 27, 2012","July 31, 2012","University of Texas - MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00002836"
770,"NCT02840578","NK Cell Activity in Smokers Screened for Lung Cancer","null","Recruiting","No Results Available","Lung Cancer","","The association between NK cell activity and presence of lung nodule and smoking exposure (pack-years),","University of Southern California|ATGen Global","All","50 Years to 80 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NK Cell Activity","May 2016","May 2017","May 2018","July 2016","July 14, 2016","July 21, 2016","null","null","July 18, 2016","July 21, 2016","USC Department of Radiology, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT02840578"
771,"NCT01651624","Screening for Colorectal Cancer With FOBT, Virtual Colonoscopy and Optical Colonoscopy. A Randomized Clinical Trial in the Florence District","SAVE","Active, not recruiting","No Results Available","Colorectal Cancer","Other: Invitation to screening","Participation rate to faecal occult blood test (FOBT), computed tomographic colonography (CTC) and colonoscopy|Detection rate for cancer or advanced adenomas of CTC versus three rounds of FOBT every second year|Referral rate for colonoscopy induced by primary CTC versus three rounds of FOBT every second year|Costs of the three different screening strategies proposed|Expected and perceived burden of colonoscopy and CTC|Number and type of complications in all groups","Cancer Prevention and Research Institute, Italy|University of Florence","All","55 Years to 64 Years   (Adult)","","14000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","D65C09002710007|432/10","December 2012","December 2018","December 2018","July 2017","July 20, 2012","July 27, 2012","null","null","July 31, 2017","August 1, 2017","Cancer Prevention and Research Institute, ISPO, Firenze, FI, Italy","https://ClinicalTrials.gov/show/NCT01651624"
772,"NCT02087787","Medical-legal Partnership (MLP) to Support Bone Marrow Transplant","null","Withdrawn","No Results Available","Blood or Marrow Transplant","Behavioral: BMT Legal Clinic","Difference between Concern and Well-being score|Proportion of patients with specific legal concerns|Mean cost of legal services|Proportion of patients satisfied|Average PSS-10 score|Number of hours on legal service","University of Minnesota - Clinical and Translational Science Institute","All","18 Years and older   (Adult, Senior)","","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2013NTLS112","March 2014","October 2015","February 2016","November 2017","March 12, 2014","March 14, 2014","null","null","November 1, 2017","November 6, 2017","University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT02087787"
773,"NCT00896675","Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer","null","Completed","No Results Available","Head and Neck Cancer","Other: proteomic profiles","Identification of patients who will benefit from treatment with EGFR and/or VEGF inhibitors based on serum proteomic profiles","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","","352","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","VICC HN 0744|P30CA068485|VU-VICC-HN-0744|VU-VICC-070359","June 2007","December 2008","December 2009","March 2013","May 9, 2009","May 12, 2009","null","null","March 29, 2013","April 2, 2013","Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT00896675"
774,"NCT02527889","The Effect of Resistive Exercise on Forearm Blood Flow and Tissue Oxygenation Among Breast Cancer Survivors With or at Risk for Breast Cancer-related Lymphoedema (BCRL)","null","Unknown status","No Results Available","Lymphedema|Breast Cancer","Other: Exercise training","Brachial artery blood flow|Tissue oxygenation|Arm circumference measurement|Extent of lymphoedema|Self-reported lymphoedema symptoms survey|Hand grip strength|Upper limb range of motion measurement|Quality of life measures","The Hong Kong Polytechnic University|Queen Elizabeth Hospital, Hong Kong","Female","18 Years to 70 Years   (Adult, Senior)","","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","BCRL-1","July 2015","December 2016","March 2017","August 2015","July 16, 2015","August 19, 2015","null","null","August 19, 2015","August 20, 2015","The Hong Kong Polytechnic University, Hong Kong, Hong Kong","https://ClinicalTrials.gov/show/NCT02527889"
775,"NCT00694252","Lapatinib and Circulating Tumor Cells in Breast Cancer","null","Completed","No Results Available","Metastatic Breast Cancer","Drug: Lapatinib","Efficacy of lapatinib by quantitative analysis of circulating tumour cells in the blood.The efficacy will be measured before, during and after the completion of treatment|Correlation of the levels of CTCs with the PFS of the patients|Assessment of the safety of lapatinib administration in this patient population.","University Hospital of Crete","Female","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT/07.15","July 2008","November 2011","November 2011","September 2015","June 6, 2008","June 10, 2008","null","null","September 25, 2015","September 28, 2015","University Hospital of Crete, Heraklion, Greece","https://ClinicalTrials.gov/show/NCT00694252"
776,"NCT00004177","Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer","null","Completed","No Results Available","Ovarian Cancer","Biological: filgrastim|Procedure: peripheral blood stem cell transplantation|Radiation: indium In 111 monoclonal antibody MN-14|Radiation: yttrium Y 90 monoclonal antibody MN-14","maximum tolerated dose","Garden State Cancer Center at the Center for Molecular Medicine and Immunology|National Cancer Institute (NCI)","Female","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000067299|R03CA077146|CMMI-C-039A-98|NCI-H99-0044|NCI-V99-1570","August 1999","May 2002","null","June 2011","January 21, 2000","April 16, 2004","null","null","June 21, 2011","June 22, 2011","Garden State Cancer Center, Belleville, New Jersey, United States|St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00004177"
777,"NCT02364154","Colorectal Cancer Detected by 1H-NMR Spectroscopy","BIOCOR","Unknown status","No Results Available","Colorectal Cancer","Other: Blood sampling","metabolic phenotype of colorectal cancer|tumor histology|tumor stage","Hasselt University|Ziekenhuis Oost-Limburg","All","40 Years to 90 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","14/070U","December 2014","June 2015","September 2015","February 2015","February 10, 2015","February 16, 2015","null","null","February 16, 2015","February 18, 2015","Ziekenhuis Oost-Limburg, Genk, Belgium","https://ClinicalTrials.gov/show/NCT02364154"
778,"NCT02280161","Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer","null","Recruiting","No Results Available","Malignant Neoplasm","Other: cytology specimen collection procedure","Prevalence of germ-line variants|Overall genotype frequencies|Response to treatment|Cancer development","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","2000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","14-001115|NCI-2014-02065|IRB00000173|JCCCID488|P30CA016042","September 16, 2014","September 16, 2024","September 16, 2025","September 2017","October 29, 2014","October 31, 2014","null","null","September 12, 2017","September 13, 2017","Jonsson Comprehensive Cancer Center, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT02280161"
779,"NCT01955915","Blood Vessel Patterns in Small Choroidal Tumors","null","Active, not recruiting","No Results Available","Small Posterior Choroidal Tumors","","Blood vessel patterns in small choroidal tumors","OHSU Knight Cancer Institute","All","18 Years and older   (Adult, Senior)","","15","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00009475|IRB#00009475","October 2013","April 2015","October 2017","April 2017","September 30, 2013","October 8, 2013","null","null","April 25, 2017","April 27, 2017","OHSU Knight Cancer Institute, Portland, Oregon, United States","https://ClinicalTrials.gov/show/NCT01955915"
780,"NCT00569712","Studying Genes in Blood and Lung Fluid Samples From Patients With Chronic Obstructive Pulmonary Disease With or Without a Previous Diagnosis of Lung Cancer or With Asthma Treated With Budesonide and Formoterol","null","Completed","No Results Available","Lung Cancer|Precancerous Condition","Drug: budesonide/formoterol fumarate dihydrate inhalation aerosol|Genetic: DNA methylation analysis|Genetic: comparative genomic hybridization|Genetic: microarray analysis|Other: bronchoalveolar lavage|Other: immunoenzyme technique|Other: laboratory biomarker analysis|Procedure: bronchoscopy","Changes in the concentrations of cytokines in plasma and bronchoalveolar lavage fluid as well as gene expression profiles before and after treatment with budesonide/formoterol fumarate dihydrate inhalation aerosol (Symbicort Turbuhaler)|Determination of DNA alterations in bronchial cells|Correlation of molecular features (e.g., methylation or gene expression changes) with biological features","British Columbia Cancer Agency|AstraZeneca","All","45 Years to 74 Years   (Adult, Senior)","Phase 1","30","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000577434|BCCA-H06-00209|ZENECA-BCCA-H06-00209","January 2007","December 2008","December 2008","March 2012","December 6, 2007","December 7, 2007","null","null","March 7, 2012","March 9, 2012","British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada","https://ClinicalTrials.gov/show/NCT00569712"
781,"NCT00891137","Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma|Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: human myeloid progenitor cells","Safety and tolerability|Neutrophil and platelet recovery|Persistence of CLT-008 derived cells|Graft-versus-host disease (GVHD)|Non-relapse mortality|Infections","Cellerant Therapeutics|Department of Health and Human Services","All","12 Years to 65 Years   (Child, Adult)","Phase 1","30","Industry|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","MT 2008-38","April 2009","June 2014","June 2014","October 2014","April 30, 2009","May 1, 2009","null","null","October 23, 2014","October 27, 2014","Children's Hospital of Orange County, Orange, California, United States|Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States|University of Minnesota: Masonic Cancer Center, BMT Clinic, and Fairview Medical Center, Minneapolis, Minnesota, United States|Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT00891137"
782,"NCT01503619","Studying Biomarkers in Tumor Tissue and Blood Samples From Patients With Small Cell Lung Cancer Registered on CALGB-140202","null","Active, not recruiting","No Results Available","Lung Cancer","Other: laboratory biomarker analysis","Identification of genetic alterations in human SCLC (driver or passenger mutations)|Gene expression between samples with or without mutations","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","23","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CALGB-151111|CDR0000721552|NCI-2012-00104","January 2012","January 2100","null","June 2017","January 3, 2012","January 4, 2012","null","null","June 26, 2017","June 27, 2017","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT01503619"
783,"NCT02672774","Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers","IM-ANG","Unknown status","No Results Available","Gastric Cancer|Colorectal Cancer|Gastrointestinal Neoplasms","Procedure: Magnification endoscopy with narrow band imaging|Device: Probe based confocal laser endomicroscopy","Real-time imaging of angiogenesis in gastric and colorectal tumors by using M-NBI and pCLE examinations|Validation of endoscopic imaging findings from immunohistochemical analysis with MVD calculations","University of Medicine and Pharmacy Craiova","All","18 Years to 90 Years   (Adult, Senior)","","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PN-II-RU-TE-2014-4-2289","October 2015","February 2017","September 2017","January 2016","January 25, 2016","February 3, 2016","null","null","January 31, 2016","February 3, 2016","Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy, Craiova, Romania","https://ClinicalTrials.gov/show/NCT02672774"
784,"NCT00865527","Pilot Study of Colon Cancer Screening Tests","null","Terminated","No Results Available","Colorectal Cancer|Colon Cancer|Adenomatous Polyps","Other: Fecal occult blood test|Procedure: Virtual colonoscopy|Procedure: Optical colonoscopy","Proportion of enrolled patients who attend for their assigned screening test|Proportion of non-responders to mailed invitations, who respond to telephone or mail reminders.|Proportion of patients requiring polypectomy after virtual colonoscopy who receive same or next day optical colonoscopy for polypectomy|Proportion of subjects who cross over to another arm of the study|Proportion of patients found to have an advanced adenoma|Proportion of patients found to have invasive colorectal carcinoma","Hamilton Health Sciences Corporation|McMaster University","All","50 Years to 70 Years   (Adult, Senior)","","198","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CTC1.0","March 2010","March 2011","September 2011","March 2016","March 18, 2009","March 19, 2009","null","null","March 29, 2016","March 31, 2016","Hamilton Health Sciences, Hamilton, Ontario, Canada","https://ClinicalTrials.gov/show/NCT00865527"
785,"NCT02474160","Collection and Storage of Tissue and Blood Samples From Patients With Cancer","null","Recruiting","No Results Available","Malignant Neoplasm","Other: Cytology Specimen Collection Procedure","Procurement of tissue and blood specimens for research purposes","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","5000","NIH","Observational","","NCI-2015-00863|P9846|P9846_R02PAPPHOLD01|9846|UM1CA186689|UM1CA186691|UM1CA186704|UM1CA186709|UM1CA186717|ZIABC011078","May 15, 2015","May 4, 2020","null","November 2017","June 15, 2015","June 17, 2015","null","null","November 29, 2017","December 1, 2017","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|PCR Oncology, Pismo Beach, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Delaware Clinical and Laboratory Physicians PA, Newark, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Medical Oncology Hematology Consultants PA, Newark, Delaware, United States|Regional Hematology and Oncology PA, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Christiana Care Health System-Wilmington Hospital, Wilmington, Delaware, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Cancer Care Center of Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Radiation Oncology of Northern Illinois, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|OSF Saint Francis Radiation Oncology at Peoria Cancer Center, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Central Illinois Hematology Oncology Center, Springfield, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Cancer Center of Kansas - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas-Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas-Liberal, Liberal, Kansas, United States|Cancer Center of Kansas-Manhattan, Manhattan, Kansas, United States|Cancer Center of Kansas - Newton, Newton, Kansas, United States|Cancer Center of Kansas - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas - Salina, Salina, Kansas, United States|Cancer Center of Kansas - Wellington, Wellington, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Via Christi Regional Medical Center, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas - Winfield, Winfield, Kansas, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Community Hospital, Niles, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Lakeland Hospital, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Central Care Cancer Center-Carrie J Babb Cancer Center, Bolivar, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|CoxHealth Cancer Center, Branson, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Capital Region Medical Center-Goldschmidt Cancer Center, Jefferson City, Missouri, United States|Freeman Health System, Joplin, Missouri, United States|Mercy Hospital-Joplin, Joplin, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|Saint John's Clinic-Rolla-Cancer and Hematology, Rolla, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CoxHealth South Hospital, Springfield, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Cancer and Blood Specialists-Henderson, Henderson, Nevada, United States|Cancer and Blood Specialists-Shadow, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas, Nevada, United States|Cancer Therapy and Integrative Medicine, Las Vegas, Nevada, United States|Cancer and Blood Specialists-Tenaya, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Nevada Cancer Specialists-Fort Apache, Las Vegas, Nevada, United States|HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center-Weiler Hospital, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee, United States|M D Anderson Cancer Center, Houston, Texas, United States|MultiCare Auburn Medical Center, Auburn, Washington, United States|Virginia Mason Bainbridge Island Medical Center, Bainbridge Island, Washington, United States|Virginia Mason Federal Way Medical Center, Federal Way, Washington, United States|MultiCare Gig Harbor Medical Park, Gig Harbor, Washington, United States|Virginia Mason Lynnwood Medical Center, Lynnwood, Washington, United States|MultiCare Good Samaritan Hospital, Puyallup, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|Marshfield Clinic-Chippewa Center, Chippewa Falls, Wisconsin, United States|Marshfield Clinic Cancer Center at Sacred Heart, Eau Claire, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Marshfield Clinic-Rice Lake Center, Rice Lake, Wisconsin, United States|Marshfield Clinic Cancer Care at Saint Michael's Hospital, Stevens Point, Wisconsin, United States|Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT02474160"
786,"NCT00019136","Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer","null","Completed","No Results Available","Ovarian Cancer","Biological: MOv-gamma chimeric receptor gene|Biological: aldesleukin|Biological: therapeutic allogeneic lymphocytes","","National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 1","null","NIH","Interventional","Primary Purpose: Treatment","CDR0000064488|NCI-96-C-0011|NCI-T95-0040N","February 1997","null","null","December 2003","July 11, 2001","January 27, 2003","null","null","April 28, 2015","April 29, 2015","Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00019136"
787,"NCT02024113","LC-NMR Study Biomarkers to Detect Lung Cancer","null","Completed","No Results Available","Lung Cancer","Other: Venous blood sample","Metabolic phenotype of lung cancer|Overall survival|Progression-free survival|Histology|Stage","Hasselt University|Ziekenhuis Oost-Limburg|Algemeen Ziekenhuis Vesalius|Ziekenhuis Maas en Kempen|Mariaziekenhuis Noord-Limburg","All","18 Years and older   (Adult, Senior)","","646","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","12/081U","February 2013","December 2014","January 2015","February 2015","December 10, 2013","December 31, 2013","null","null","February 9, 2015","February 10, 2015","Ziekenhuis Oost-Limburg, Genk, Limburg, Belgium|Hasselt University, Hasselt, Limburg, Belgium","https://ClinicalTrials.gov/show/NCT02024113"
788,"NCT00516698","Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer","null","Completed","No Results Available","Breast Cancer","Genetic: polymorphism analysis|Other: high performance liquid chromatography|Other: laboratory biomarker analysis|Procedure: radiomammography","Changes in percent breast density in response to 1 year of aromatase inhibitor therapy|Changes in dense area in response to 1 year of aromatase inhibitor therapy|Correlation of changes in percent breast density with changes in plasma hormone levels and drug levels|Correlation of changes in dense area with changes in plasma hormone levels and drug levels|Comparison of percent breast density in women with high pre-treatment percent density vs women with low pre-treatment percent density|Comparison of dense area in women with high pre-treatment dense area vs women with low pre-treatment dense area|Associations of haplotype-tagged single nucleotide polymorphisms in genes in the aromatase pathway with changes in percent and area density, plasma hormone levels, and drug levels after 1 year of aromatase inhibitor therapy","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","","140","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NCCTG-N063I|NCI-2012-02719|CDR0000560200","September 2007","December 2009","December 2009","July 2016","August 14, 2007","August 15, 2007","null","null","July 12, 2016","July 13, 2016","MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital, Canton, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|St. Anthony's Memorial Hospital, Effingham, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Galesburg Clinic, PC, Galesburg, Illinois, United States|Galesburg Cottage Hospital, Galesburg, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hopedale Medical Complex, Hopedale, Illinois, United States|Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois, United States|McDonough District Hospital, Macomb, Illinois, United States|Trinity Cancer Center at Trinity Medical Center - 7th Street Campus, Moline, Illinois, United States|Moline, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|St. Margaret's Hospital, Spring Valley, Illinois, United States|Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|St. Francis Hospital and Health Centers - Beech Grove Campus, Beech Grove, Indiana, United States|Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States|Reid Hospital & Health Care Services, Richmond, Indiana, United States|McFarland Clinic, PC, Ames, Iowa, United States|Bettendorf, Iowa, United States|Mercy Capitol Hospital, Des Moines, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - North Iowa, Mason City, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Southwest Medical Center, Liberal, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan, United States|Haematology-Oncology Associates of Ohio and Michigan, PC, Lambertville, Michigan, United States|Community Cancer Center of Monroe, Monroe, Michigan, United States|Mercy Memorial Hospital - Monroe, Monroe, Michigan, United States|MeritCare Bemidji, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Meeker County Memorial Hospital, Lichfield, Minnesota, United States|Immanuel St. Joseph's, Mankato, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology Hematology, PA - Maplewood, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States|HealthEast Cancer Care at St. Joseph's Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|St. Francis Cancer Center at St. Francis Medical Center, Shakopee, Minnesota, United States|Regions Hospital Cancer Care Center, St. Paul, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|HealthEast Cancer Care at Woodwinds Health Campus, Woodbury, Minnesota, United States|Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States|Missouri Baptist Cancer Center, Saint Louis, Missouri, United States|Arch Medical Services, Incorporated at Center for Cancer Care and Research, Saint Louis, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Great Falls, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Center, Missoula, Montana, United States|Guardian Oncology and Center for Wellness, Missoula, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Bismarck Cancer Center, Bismarck, North Dakota, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|MeritCare Broadway, Fargo, North Dakota, United States|Mary Rutan Hospital, Bellefontaine, Ohio, United States|Wood County Oncology Center, Bowling Green, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Medical Center Cancer Care, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital, Dayton, Ohio, United States|Samaritan North Cancer Care Center, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Hematology Oncology Center, Elyria, Ohio, United States|Blanchard Valley Medical Associates, Findlay, Ohio, United States|Middletown Regional Hospital, Franklin, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Northwest Ohio Oncology Center, Maumee, Ohio, United States|St. Luke's Hospital, Maumee, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|St. Charles Mercy Hospital, Oregon, Ohio, United States|Toledo Clinic - Oregon, Oregon, Ohio, United States|Firelands Regional Medical Center, Sandusky, Ohio, United States|North Coast Cancer Care, Incorporated, Sandusky, Ohio, United States|Mercy Medical Center, Springfield, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|Flower Hospital Cancer Center, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|Toledo Hospital, Toledo, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Medical University of Ohio Cancer Center, Toledo, Ohio, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|Toledo Clinic, Incorporated - Main Clinic, Toledo, Ohio, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Mount Carmel St. Ann's Cancer Center, Westerville, Ohio, United States|Clinton Memorial Hospital, Wilmington, Ohio, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|Natalie Warren Bryant Cancer Center at St. Francis Hospital, Tulsa, Oklahoma, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Geisinger Hazleton Cancer Center, Hazleton, Pennsylvania, United States|Geisinger Medical Group - Scenery Park, State College, Pennsylvania, United States|Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States|Mercy Hospital at Wilkes-Barre, Wilkes-Barre, Pennsylvania, United States|AnMed Cancer Center, Anderson, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Medical X-Ray Center, PC, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Fredericksburg Oncology, Incorporated, Fredericksburg, Virginia, United States|Cascade Cancer Center at Evergreen Hospital Medical Center, Kirkland, Washington, United States|Olympic Medical Center, Port Angeles, Washington, United States|Southlake Clinic, Renton, Washington, United States|CCOP - Virginia Mason Research Center, Seattle, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States","https://ClinicalTrials.gov/show/NCT00516698"
789,"NCT00907699","Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507","null","Withdrawn","No Results Available","Lung Cancer","Genetic: DNA analysis|Genetic: RNA analysis|Genetic: fluorescence in situ hybridization|Genetic: gene expression analysis|Genetic: mutation analysis|Genetic: polymerase chain reaction|Genetic: reverse transcriptase-polymerase chain reaction|Other: laboratory biomarker analysis","Predictive value of T790M mutation status of the second biopsy (before maintenance therapy on CASE-2507) on progression-free survival (PFS)|Difference of PFS between those with and without T790M mutation|Difference of clinical response rate between T790M mutation statuses|Predictive value of mutation status on clinical response|Association between T790M mutation and baseline clinical-pathological factors and smoking status","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","0","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","CASE9507|P30CA043703","August 2008","February 2013","null","July 2014","May 21, 2009","May 22, 2009","null","null","July 23, 2014","July 24, 2014","","https://ClinicalTrials.gov/show/NCT00907699"
790,"NCT00003136","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer","null","Completed","No Results Available","Ovarian Cancer|Primary Peritoneal Cavity Cancer","Biological: filgrastim|Drug: amifostine trihydrate|Drug: carboplatin|Drug: cyclophosphamide|Procedure: peripheral blood stem cell transplantation","Maximum tolerated dose","University of Chicago","Female","up to 65 Years   (Child, Adult)","Phase 1|Phase 2","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8433|UCCRC-8433|ALZA-97-005-ii|NCI-V97-1357","December 1996","December 2000","October 2001","February 2013","November 1, 1999","August 24, 2004","null","null","February 8, 2013","February 11, 2013","University of Chicago Cancer Research Center, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT00003136"
791,"NCT00002627","Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer","null","Unknown status","No Results Available","Breast Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: mesna|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation","","St. Louis University|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","30","Other","Interventional","Primary Purpose: Treatment","CDR0000064016|SLUMC-8038|NCI-V95-0607","November 1994","null","null","July 2000","November 1, 1999","July 29, 2004","null","null","January 9, 2014","January 10, 2014","St. Louis University Health Sciences Center, Saint Louis, Missouri, United States","https://ClinicalTrials.gov/show/NCT00002627"
792,"NCT00027820","Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer","null","Active, not recruiting","No Results Available","Adult Acute Myeloid Leukemia in Remission|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Myelodysplastic Syndrome|Childhood Renal Cell Carcinoma|Chronic Myelomonocytic Leukemia|Clear Cell Renal Cell Carcinoma|de Novo Myelodysplastic Syndrome|Metastatic Renal Cell Cancer|Previously Treated Myelodysplastic Syndrome|Progression of Multiple Myeloma or Plasma Cell Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult Non-Hodgkin Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Non-Hodgkin Lymphoma|Refractory Anemia|Refractory Anemia With Ringed Sideroblasts|Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Renal Medullary Carcinoma|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia","Drug: Fludarabine Phosphate|Radiation: Total-Body Irradiation|Procedure: Peripheral Blood Stem Cell Transplantation|Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclosporine|Drug: Mycophenolate Mofetil","Risk of true graft rejection in patients with and without preceding chemotherapy|Risk of grades II-IV acute GVHD in those patients with sustained engraftment|Incidence of reversing impending graft rejection (less than 40% donor cluster of differentiation [CD]3+ T cell chimerism)|Overall survival|Progression-free survival","Fred Hutchinson Cancer Research Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 1|Phase 2","106","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1641.00|NCI-2012-00591|P30CA015704|P01CA018029","August 2001","September 2004","null","December 2017","December 7, 2001","January 27, 2003","null","null","December 11, 2017","December 13, 2017","University of Arizona Health Sciences Center, Tucson, Arizona, United States|Stanford University Hospitals and Clinics, Stanford, California, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States|Baylor Medical Center at Garland, Garland, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Universitaet Leipzig, Leipzig, Germany|University of Torino, Torino, Italy","https://ClinicalTrials.gov/show/NCT00027820"
793,"NCT00009750","Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","null","Unknown status","No Results Available","Prostate Cancer","Biological: filgrastim|Biological: monoclonal antibody m170|Drug: cyclosporine|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation|Radiation: indium In 111 monoclonal antibody m170|Radiation: yttrium Y 90 monoclonal antibody m170","","University of California, Davis|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Senior)","Phase 1","null","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000068364|UCD-992126|NCI-V00-1639","March 2001","null","null","November 2003","February 2, 2001","January 27, 2003","null","null","September 19, 2013","September 20, 2013","University of California Davis Cancer Center, Sacramento, California, United States","https://ClinicalTrials.gov/show/NCT00009750"
794,"NCT02416726","Comparison of Gene Mutations in Matched Samples in Advanced Nonsquamous NSCLC Using NGS","null","Completed","No Results Available","Lung Cancer","Device: Nextseq500 sequencer","Gene mutations in matched samples","Jiayuan Sun|Shanghai Chest Hospital","All","18 Years to 80 Years   (Adult, Senior)","","35","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SHCHE201501","March 2015","July 2016","July 2016","January 2017","March 25, 2015","April 15, 2015","null","null","January 5, 2017","January 6, 2017","Shanghai Chest Hospital, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT02416726"
795,"NCT00891592","Umbilical Cord Blood Transplant for Hematological Malignancies","UCB","Completed","No Results Available","CML|AML|MDS|ALL|NHL|Multiple Myeloma|Hodgkin's Disease","Biological: Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells|Other: Observation Arm","Dose limiting toxicity (DLT) is defined as grade 4 acute GVHD within the first 90 days following infusion.","University of Pennsylvania","All","21 Years to 50 Years   (Adult)","Phase 1","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UPCC 02707","January 2009","November 2011","May 2016","August 2016","April 29, 2009","May 1, 2009","null","null","August 17, 2016","August 19, 2016","University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00891592"
796,"NCT02090166","Lung Cancer Detection by Measuring Monocyte Activity","EDLC","Not yet recruiting","No Results Available","Lung Cancer","Other: Blood test","Positive and negative diagnosis (scored 0/1 dichotomously) of lung cancer","Carmel Medical Center|Tel Aviv University","All","18 Years to 90 Years   (Adult, Senior)","","950","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CMC-13-0105-CTIL","April 2014","January 2020","January 2021","March 2014","March 10, 2014","March 18, 2014","null","null","March 16, 2014","March 18, 2014","Carmel Medical Center, Haifa, Israel","https://ClinicalTrials.gov/show/NCT02090166"
797,"NCT00003080","Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer","null","Completed","No Results Available","Ovarian Cancer","Drug: endocrine-modulating drug therapy|Drug: melphalan|Drug: mitoxantrone hydrochloride|Drug: tamoxifen citrate|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","Female","18 Years to 60 Years   (Adult)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","1144.00|FHCRC-1144.00|NCI-G97-1329|CDR0000065775","September 1996","May 2001","May 2001","September 2010","November 1, 1999","April 14, 2004","null","null","September 13, 2010","September 15, 2010","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00003080"
798,"NCT02548910","Phlebotomy to Prevent Blood Loss in Major Hepatic Resections","PRICE","Recruiting","No Results Available","Liver Neoplasms|Hepatectomy","Procedure: Phlebotomy|Device: Citrated whole blood collection bag","Total intraoperative blood loss, by measurement of change in hemoglobin levels|Blood product transfusion rates|Perioperative morbidity (Dindo-Clavien grade 3b of higher) and mortality|Changes in physiologic parameters (CVP)|Change in physiologic parameters (cardiac index)","Ottawa Hospital Research Institute","All","18 Years and older   (Adult, Senior)","","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","3588","April 2016","January 2018","January 2018","September 2017","July 23, 2015","September 14, 2015","null","null","September 26, 2017","September 28, 2017","The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada","https://ClinicalTrials.gov/show/NCT02548910"
799,"NCT01762813","Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer","ACROBATICC","Recruiting","No Results Available","Colorectal Cancer","Procedure: open and laparoscopic surgery","Cancer-specific survival|Recurrence-free survival","Helse Stavanger HF","All","18 Years and older   (Adult, Senior)","","850","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","29034/2012","August 2012","December 2027","December 2027","March 2017","January 3, 2013","January 8, 2013","null","null","March 30, 2017","March 31, 2017","Stavanger University Hospital, Stavanger, Norway","https://ClinicalTrials.gov/show/NCT01762813"
800,"NCT00002784","High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer","15-95","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: CMF regimen|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: fluorouracil|Drug: mesna|Drug: methotrexate|Drug: tamoxifen citrate|Procedure: peripheral blood stem cell transplantation|Radiation: low-LET electron therapy|Radiation: low-LET photon therapy","Disease-free survival.|Overall survival.|Toxicity.|Quality of life.","International Breast Cancer Study Group","Female","16 Years to 65 Years   (Child, Adult)","Phase 3","344","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000064834|IBCSG-15-95|EU-96021","June 1996","August 2011","December 2011","July 2012","November 1, 1999","July 29, 2004","null","null","April 3, 2013","April 4, 2013","Newcastle Mater Misericordiae Hospital, Newcastle, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, Sydney, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Swiss Institute for Applied Cancer Research, Bern, Switzerland|Inselspital, Bern, Bern, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Istituto Oncologico della Svizzera Italiana, Lugano, Switzerland|Kantonsspital - Saint Gallen, Saint Gallen, Switzerland|Universitaetsspital, Zurich, Switzerland","https://ClinicalTrials.gov/show/NCT00002784"
801,"NCT00002616","Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer","null","Unknown status","No Results Available","Breast Cancer","Biological: aldesleukin|Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation","","University of Illinois at Chicago|National Cancer Institute (NCI)","All","up to 64 Years   (Child, Adult)","Phase 1","36","Other","Interventional","Primary Purpose: Treatment","CDR0000063925|UIC-95-1011|LUMC-6728|NCI-V94-0573","February 1995","null","null","September 2000","November 1, 1999","August 31, 2004","null","null","September 19, 2013","September 20, 2013","University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT00002616"
802,"NCT00873236","MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer","null","Unknown status","No Results Available","Kidney Cancer","Biological: bevacizumab|Biological: recombinant interferon alpha-2a","Dynamic contrast-enhanced MRI defined changes in K-trans after 6 weeks of bevacizumab monotherapy or bevacizumab and low- or standard-dose recombinant interferon alpha-2a|Change in vascular permeability (K-trans) and tumor hypoxia at 2 and 6 weeks post-commencement of treatment|Best overall response|Progression-free survival|Time to progression|Treatment duration of bevacizumab and recombinant interferon alpha-2a|Treatment withdrawal|Dose modification|Incidence of adverse events|Number of circulating endothelial cells, circulating endothelial progenitors, and proangiogenic monocytic cells|Angiogenic factors (e.g., VEGF) and hypoxia-regulated markers|Correlation of DCE-MRI defined changes in K-trans with clinical response|Correlation of DCE-MRI defined changes in K-trans with surrogate biomarkers|Analysis of diffusion MRI and blood oxygen-level dependent MRI changes and comparison with other pharmacodynamic markers","Mount Vernon Cancer Centre at Mount Vernon Hospital|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Diagnostic","MTVERNHOSP-RD2007-114|CDR0000637812|ENH-RD2007-114|EUDRACT-2008-006414-19|EU-20917","April 2008","null","null","March 2009","March 31, 2009","April 1, 2009","null","null","August 9, 2013","August 12, 2013","Addenbrooke's Hospital, Cambridge, England, United Kingdom|Royal Marsden - London, London, England, United Kingdom|Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, England, United Kingdom|Churchill Hospital, Oxford, England, United Kingdom|Royal Marsden - Surrey, Sutton, England, United Kingdom","https://ClinicalTrials.gov/show/NCT00873236"
803,"NCT00002942","Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer","null","Completed","No Results Available","Breast Cancer","Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 3","136","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000065391|CCCWFU-95496|NCI-G97-1145","June 1996","January 2000","December 2003","July 2012","November 1, 1999","September 3, 2004","null","null","January 18, 2017","January 19, 2017","Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00002942"
804,"NCT01093586","Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","null","Completed","No Results Available","Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Erythroleukemia (M6a)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Adult Pure Erythroid Leukemia (M6b)|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Burkitt Lymphoma|Childhood Acute Erythroleukemia (M6)|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Juvenile Myelomonocytic Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Secondary Myelofibrosis|Splenic Marginal Zone Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia|T-cell Large Granular Lymphocyte Leukemia|Waldenstrom Macroglobulinemia","Procedure: double-unit umbilical cord blood transplantation|Other: cytogenetic analysis|Procedure: bone marrow aspiration|Other: fluorescence in situ hybridization|Drug: busulfan|Drug: cyclophosphamide|Drug: anti-thymocyte globulin|Drug: methylprednisolone|Drug: cyclosporine|Drug: mycophenolate mofetil|Other: flow cytometry|Procedure: allogeneic hematopoietic stem cell transplantation","Overall survival|Hematologic engraftment|Disease-free and overall survival|Duration of response|Transplant related mortality|Recurrence or relapse|Occurrence of serious infections|Immune reconstitution|Toxicity related to UCB transplantation and cytoreduction as assessed by CTC v3.0|Incidence of acute graft-versus-host disease (GVHD)|Incidence of chronic GVHD","Case Comprehensive Cancer Center","All","12 Years to 64 Years   (Child, Adult)","Phase 2","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE3Z07|NCI-2009-01319","March 2009","December 2015","December 2015","December 2015","March 24, 2010","March 26, 2010","null","null","December 18, 2015","December 21, 2015","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT01093586"
805,"NCT02370355","Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer","null","Terminated","No Results Available","Hormone-Resistant Prostate Cancer|Metastatic Prostate Carcinoma","Other: Cytology Specimen Collection Procedure|Other: Laboratory Biomarker Analysis","Proportion of patients with elevated CTCs|Expression of individual markers according to clinical stage, serum PSA, and pathologic grade","University of Southern California|National Cancer Institute (NCI)","Male","19 Years and older   (Adult, Senior)","","24","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Other","4P-14-6|NCI-2014-02682|HS-14-00861|P30CA014089","December 23, 2014","June 8, 2016","June 8, 2016","April 2017","February 17, 2015","February 24, 2015","null","null","April 13, 2017","April 17, 2017","USC Norris Comprehensive Cancer Center, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT02370355"
806,"NCT01637350","Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes","null","Unknown status","No Results Available","Gastric Cancer","Procedure: digestive tract reconstruction","","Tianjin Medical University Cancer Institute and Hospital","All","18 Years to 75 Years   (Adult, Senior)","","60","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","CIH-WXN-201205001","August 2012","October 2016","December 2016","August 2012","July 6, 2012","July 11, 2012","null","null","February 14, 2016","February 17, 2016","Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China","https://ClinicalTrials.gov/show/NCT01637350"
807,"NCT01445327","Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers","null","Terminated","No Results Available","Esophageal Cancer|Stomach Cancer|Pancreatic Cancer","","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","","9","NIH","Observational","Time Perspective: Prospective","070111|07-C-0111","February 20, 2007","null","January 20, 2015","January 20, 2015","September 30, 2011","October 3, 2011","null","null","October 5, 2017","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT01445327"
808,"NCT02997709","Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients","COMBINE","Recruiting","No Results Available","Prostate Cancer","Procedure: Blood Specimen Collection|Behavioral: Memorial Anxiety Scale for Prostate Cancer patients|Behavioral: Expanded Prostate Cancer Index Composite-SF-12|Behavioral: International Prostate Symptom Score|Device: MRI-US fusion guided biopsy|Device: Multiparametric MRI","Comparison of Pre- and Post-Treatment Quantitative Imaging Parameters to Changes in Circulating Tumor Cells Over Time in Prostate Cancer Patients Receiving Radiation Therapy (RT) with or without Androgen Deprivation Therapy per standard of care.|Relationship of CTC changes and/or quantitative imaging parameter changes to patient outcome (biochemical and clinical disease failure).|Relationship of Androgen Deprivation Therapy (ADT) status to quantitative imaging features and/or CTC levels in patients receiving radiation therapy.|Relationship of quantitative imaging characteristics and/or CTC changes with other tissue biomarkers (e.g., gene expression signatures) obtained from the pre-treatment MRI ultrasound (US) fusion guided prostate.|Comparison of changes in CTCs to endpoint prostate research biopsy status.|Comparison of changes in quantitative imaging characteristics to endpoint prostate research biopsy status.|Comparison of changes in gene expression patterns to endpoint prostate research biopsy status.","University of Miami","Male","35 Years to 85 Years   (Adult, Senior)","","300","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20150452","June 24, 2016","June 2021","June 2026","October 2017","December 15, 2016","December 20, 2016","null","null","October 3, 2017","October 6, 2017","University of Miami, Miami, Florida, United States","https://ClinicalTrials.gov/show/NCT02997709"
809,"NCT00002509","High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer","null","Completed","No Results Available","Breast Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: mesna|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","","Temple University|Fox Chase Cancer Center","Female","15 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000078064|TUHSC-1992|NCI-V92-0205","November 1991","December 2003","December 2003","September 2010","November 1, 1999","August 31, 2004","null","null","September 30, 2010","October 1, 2010","Temple University Cancer Center, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00002509"
810,"NCT00571389","Isolation and Culture of Immune Cells and Circulating Tumor Cells From Peripheral Blood and Leukopaks","null","Recruiting","No Results Available","Metastatic Cancer","","","BioCytics, Inc.|Carolina BioOncology Institute","All","18 Years and older   (Adult, Senior)","","500","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Biocytics0001|WIRB Protocol # 20070969","November 2007","January 2019","January 2019","May 2017","December 10, 2007","December 12, 2007","null","null","May 30, 2017","May 31, 2017","Carolina BioOncology Institute, Huntersville, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00571389"
811,"NCT01457131","Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer","null","Terminated","No Results Available","Metastatic Cancer|Metastatic Melanoma|Metastatic Renal Cancer","Drug: Fludarabine|Drug: Cyclophosphamide|Other: IL-12 &amp; Anti-NY ESO1 TCR PBL","To evaluate the safety of the IL-12 and anti-NY-ESO-1 engineered PBL in patients receiving a non-myeloablative conditioning regimen, and to determine if patients with metastatic cancer will have clinical tumor regression following this regimen.|To determine the in vivo survival of cotransduced gene-engineered cells.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","Phase 1","2","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","120006|12-C-0006","October 6, 2011","August 7, 2013","August 7, 2013","August 2, 2013","October 12, 2011","October 21, 2011","null","null","June 30, 2017","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT01457131"
812,"NCT02017834","Does the Harmonic Scalpel Reduce Blood Loss and OR Time in Major Head and Neck Cancer Surgery Undergoing Major Surgery for Oral Cavity Squamous Cell Carcinoma?","HS2","Completed","No Results Available","Oral Cavity Squamous Cell Carcinoma, Treated With Surgery","Procedure: surgical resection","blood loss|operating time","University of Calgary","All","18 Years and older   (Adult, Senior)","","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","UCENT005","February 2012","November 2014","November 2014","December 2013","January 31, 2012","December 23, 2013","null","null","December 1, 2014","December 3, 2014","Foothills Hospital, Calgary, Alberta, Canada","https://ClinicalTrials.gov/show/NCT02017834"
813,"NCT00003284","High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer","null","Unknown status","No Results Available","Lung Cancer","Biological: filgrastim|Drug: carboplatin|Drug: etoposide|Drug: ifosfamide|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","","Herbert Irving Comprehensive Cancer Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","30","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066206|CPMC-IRB-7836|CU-CAMP-017|NCI-G98-1408","January 1998","null","null","June 2000","November 1, 1999","August 13, 2004","null","null","January 3, 2014","January 6, 2014","Herbert Irving Comprehensive Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00003284"
814,"NCT00482365","National Registry and Blood Bank of Patients With Liver Cancer","null","Completed","No Results Available","Liver Cancer","Other: biologic sample preservation procedure|Other: medical chart review|Other: Patient interview","Etiologic factors associated with hepatocellular carcinoma in different ethnic groups across the US|Serum repository for registry patients","Vanderbilt-Ingram Cancer Center","All","18 Years and older   (Adult, Senior)","","151","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","VICC GI 0224|VU-VICC-GI-0224|VU-VICC-IRB-020116","April 2002","April 2009","August 2009","May 2013","June 4, 2007","June 5, 2007","null","null","August 16, 2013","August 19, 2013","Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT00482365"
815,"NCT00899782","Collection and Storage of Blood and Tissue Samples From Patients Who Are Undergoing Surgery For Lung Cancer","null","Active, not recruiting","No Results Available","Lung Carcinoma|Lung Neoplasm|Malignant Lung Neoplasm","Other: cytology specimen collection procedure","Collection and storage of frozen tissue samples for molecular analysisor resection of lung cancer|Collection and storage of frozen blood samples for the assessment of somatic mutations and levels of circulating markersto assess levels of circulating markers","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","500","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CALGB-140202|CDR0000271323|U10CA031946|U10CA180821","July 2004","January 2100","null","August 2017","May 9, 2009","May 12, 2009","null","null","August 7, 2017","August 8, 2017","Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States|CCOP - Christiana Care Health Services, Newark, Delaware, United States|Union Hospital of Cecil County, Elkton, Maryland, United States|Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States|Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States|Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|Veterans Affairs Medical Center - Asheville, Asheville, North Carolina, United States|Duke Cancer Institute, Durham, North Carolina, United States|Forbes Regional Hospital, Monroeville, Pennsylvania, United States|Alle-Kiski Medical Center, Natrona Heights, Pennsylvania, United States|Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital Comprehensive Cancer Center, Providence, Rhode Island, United States|Miriam Hospital, Providence, Rhode Island, United States|Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont, United States","https://ClinicalTrials.gov/show/NCT00899782"
816,"NCT01774643","A Study of Pancreatic Cancer in Xenografts From Liver Metastases","null","Active, not recruiting","No Results Available","Pancreatic Cancer|Liver Metastases|Tumor Tissue Biopsy|Blood Samples","","Number of patients with adverse events due to biopsies|Number of successful xenografts|Number of similiarities and differences between original patient tumor sample with xenograft sample|Engraftment rate compared to clinical data (response to treatment, disease-free survival, overall survival)","University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","","31","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","XENO-METPANC","January 2013","April 2015","June 2018","December 2017","January 22, 2013","January 24, 2013","null","null","December 29, 2017","January 3, 2018","Princess Margaret Cancer Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT01774643"
817,"NCT00445952","Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant","null","Unknown status","No Results Available","Cancer","Other: clinical observation|Procedure: management of therapy complications","Relative incidence of fungemia|Fungal species distribution|Survival in patients with fungemia|Mortality at 2, 4, and 12 weeks after diagnosis of fungemia","European Organisation for Research and Treatment of Cancer - EORTC|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","300","Other","Observational","","CDR0000423221|EORTC-65031","February 2005","null","null","July 2009","March 7, 2007","March 9, 2007","null","null","May 14, 2011","May 17, 2011","Institut Jules Bordet, Brussels, Belgium|CHU de Grenoble - Hopital de la Tronche, Grenoble, France|German Hodgkin's Lymphoma Study Group, Cologne, Germany|Ospedale San Martino, Genoa, Italy|Hopital Cantonal Universitaire de Geneve, Geneva, Switzerland","https://ClinicalTrials.gov/show/NCT00445952"
818,"NCT01979029","Study of the Preservation of the Left Colic Artery on Rectum Cancer Surgery","POTLCAORCS","Completed","Has Results","Rectum Cancer","Procedure: preserving the left colic artery|Procedure: not preserving the left colic artery","The Blood Pressure of the Arterial Arcade|Distal Colon Length","Jian Suo|First Hospital of Jilin University","All","18 Years to 85 Years   (Adult, Senior)","","57","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Left Colic Artery","February 2013","September 2014","October 2014","April 2016","October 25, 2013","November 8, 2013","March 2, 2016","June 6, 2016","April 28, 2016","June 6, 2016","First Hospital of Jilin University, Changchun, Jilin, China","https://ClinicalTrials.gov/show/NCT01979029"
819,"NCT00798330","Dental Study in Cancer Patients With Central Venous Catheters","null","Completed","No Results Available","Cancer","","To determine the incidence of transient bacteremia and established blood-stream infections (BSIs) by oral microorganisms in cancer patients with CVCs after an invasive dental procedure","Rajesh Lalla|UConn Health","All","18 Years and older   (Adult, Senior)","","27","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","09-059-2|786-001","September 2012","December 2012","December 2012","November 2013","November 25, 2008","November 26, 2008","null","null","November 19, 2013","November 21, 2013","University of Connecticut Health Center, Farmington, Connecticut, United States","https://ClinicalTrials.gov/show/NCT00798330"
820,"NCT00004087","Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Colorectal Cancer or Pancreatic Cancer","null","Completed","No Results Available","Colorectal Cancer|Pancreatic Cancer","Biological: filgrastim|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: indium In 111 monoclonal antibody MN-14|Radiation: yttrium Y 90 monoclonal antibody MN-14","maximum tolerated dose","Garden State Cancer Center at the Center for Molecular Medicine and Immunology|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000067300|P01CA054425|CMMI-C-033-98|NCI-H99-0042|NCI-V99-1571","March 1997","May 2001","null","June 2011","December 10, 1999","April 16, 2004","null","null","June 21, 2011","June 22, 2011","Garden State Cancer Center, Belleville, New Jersey, United States|St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00004087"
821,"NCT00003780","Chemotherapy Compared to Biological Therapy in Treating Patients With Cancer of the Pancreas","null","Unknown status","No Results Available","Pancreatic Cancer","Biological: tumor infiltrating lymphocyte therapy|Drug: gemcitabine hydrochloride","","Meyer Pharmaceuticals|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","150","Industry","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000066912|MEYER-AIT-PAN-201","December 1998","null","null","May 2007","November 1, 1999","September 14, 2004","null","null","December 18, 2013","December 19, 2013","Meyer Pharmaceuticals, LLC, Irvine, California, United States","https://ClinicalTrials.gov/show/NCT00003780"
822,"NCT00607529","Clinical Evaluation of an Investigational Blood Creatinine Point-of-Care Test Device","null","Completed","No Results Available","Cancer","Other: hand-held POC creatinine analyzer-blood test","The primary outcomes would be, reduced wait time and increased patient satisfaction.|reduced blood loss","Memorial Sloan Kettering Cancer Center|Nova Biomedical Corporation","All","18 Years and older   (Adult, Senior)","","99","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","07-023","August 2007","May 2010","May 2010","June 2010","January 22, 2008","February 5, 2008","null","null","June 3, 2010","June 4, 2010","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00607529"
823,"NCT00146055","Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood","null","Completed","No Results Available","Myeloma, Plasma-Cell|Lymphoma, Malignant|Myeloproliferative Disorders|Myelodysplastic Syndromes|Waldenstrom's Macroglobulinemia","Procedure: Reduced intensity conditioning with allogeneic transplant","- To evaluate the toxicity of low-intensity regimen for allogeneic stem cell transplantation from an unrelated donor.|- To evaluate the engraftment, and chimerism.|- To estimate the rate of acute GVHD, relapse and survival.","University of Michigan Cancer Center","All","Child, Adult, Senior","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMCC 9970","March 2000","November 2004","October 2007","August 2012","September 1, 2005","September 5, 2005","null","null","August 7, 2012","August 9, 2012","The University of Michigan, Ann Arbor, Michigan, United States","https://ClinicalTrials.gov/show/NCT00146055"
824,"NCT02163733","Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer","null","Active, not recruiting","Has Results","Advanced Non Small Cell Lung Cancer|Advanced (Inoperable) Non Small Cell Lung Cancer","Drug: AZD9291 tablets|Procedure: Pharmacokinetic sampling - AZD9291|Other: Dietary Fasted|Other: Dietary High Fat|Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550","AUC(0-72) of AZD9291|Cmax of AZD9291|AUC of AZD9291|AUC(0-t) of AZD9291|AUC(0-120) of AZD9291|Tmax of AZD9291|t1/2 of AZD9291|CL/F of AZD9291|Vz/F of AZD9291|AUC(0-72) of AZ5104 and AZ7550|Cmax of AZ5104 and AZ7550|AUC(0-t) of AZ5104 and AZ7550|AUC(0-120) of AZ5104 and AZ7550|Tmax of AZ5104 and AZ7550|t1/2 of AZ5104 and AZ7550","AstraZeneca","All","18 Years to 99 Years   (Adult, Senior)","Phase 1","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","D5160C00009|2014-001556-37","November 14, 2014","March 24, 2015","January 4, 2018","September 2017","May 29, 2014","June 16, 2014","March 3, 2016","April 5, 2016","September 14, 2017","September 15, 2017","Research Site, Dijon cedex, France|Research Site, Lyon Cedex 08, France|Research Site, Saint Herblain, France|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Manchester, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom|Research Site, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT02163733"
825,"NCT00776295","Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer","null","Terminated","Has Results","Small Cell Lung Cancer","Biological: Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes","Number of Subjects Meeting 1-year Overall Survival|3 Year Progression-free Survival","H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Senior)","Phase 2","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC 14955","May 2007","June 2010","August 2010","January 2013","October 20, 2008","October 21, 2008","October 4, 2011","June 21, 2012","January 16, 2013","January 24, 2013","HLeeMoffitt, Tampa, Florida, United States","https://ClinicalTrials.gov/show/NCT00776295"
826,"NCT00793650","Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study","null","Terminated","Has Results","Cancer|Multiple Myeloma","Drug: Bortezomib|Drug: Melphalan|Procedure: Autologous PBSC Transplant","Safety and Engraftment|Response Rate Using EBMT(European Group for Blood and Bone Marrow Transplan) Criteria at Day +100 After Transplant.","Emory University|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","39","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","080-2005","May 2005","October 2009","September 2011","August 2012","November 17, 2008","November 19, 2008","March 14, 2012","June 18, 2012","August 17, 2012","August 30, 2012","Emory University Winship Cancer Institute, Atlanta, Georgia, United States","https://ClinicalTrials.gov/show/NCT00793650"
827,"NCT02948985","Evaluation of CTCs Combined With Tumor Marker Detection of Efficacy of Chemotherapy in mCRC","null","Not yet recruiting","No Results Available","Colorectal Cancer Metastatic","Other: treated with FOLFIRI±cetuximab","Correlation of RAS status on CTCs with clinical outcomes|Correlation of mutant gene in ctDNA with cetuximab resistance.","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","All","18 Years to 75 Years   (Adult, Senior)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Shanghai1stQli01","January 2017","July 2019","December 2019","October 2016","October 27, 2016","October 31, 2016","null","null","October 31, 2016","November 1, 2016","","https://ClinicalTrials.gov/show/NCT02948985"
828,"NCT00814034","Coagulation Parameters in Postmenopausal Breast Cancer Patients Under Adjuvant Hormonal Therapy","COPA","Completed","No Results Available","Breast Cancer","","Percentage change (%) from baseline of the blood coagulation parameters (fibrinogen, PT, aPTT) at 6, 12, 18, and 24 months of treatment.","Hellenic Breast Surgeons Society","Female","18 Years to 80 Years   (Adult, Senior)","","306","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COPA-HBSS0801","February 2008","December 2009","December 2011","September 2015","December 22, 2008","December 23, 2008","null","null","September 4, 2015","September 7, 2015","Hellenic Breast Surgeons Society, Athens, Attica, Greece|Hellenic Breast Surgeons Society, Athens, Greece","https://ClinicalTrials.gov/show/NCT00814034"
829,"NCT01194635","Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy","null","Completed","No Results Available","Head and Neck Cancer","Genetic: fluorescence in situ hybridization|Genetic: gene expression analysis|Genetic: polymerase chain reaction|Genetic: protein analysis|Genetic: protein expression analysis|Other: enzyme-linked immunosorbent assay|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis","Correlation of biomarkers and clinical outcome","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years to 120 Years   (Adult, Senior)","","69","Other|NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","CDR0000683306|ECOG-E3303T1","August 5, 2010","September 5, 2010","September 5, 2010","May 2017","September 2, 2010","September 3, 2010","null","null","May 16, 2017","May 17, 2017","","https://ClinicalTrials.gov/show/NCT01194635"
830,"NCT00122005","GVAX in Advanced Prostate Cancer Patients Made Lymphopenic","null","Unknown status","No Results Available","Prostate Cancer","Biological: GM-CSF gene transduced allogeneic vaccine GVAX","To evaluate the safety of combined CG1940 & CG8711, chemotherapy with cyclophosphamide +/- fludarabine and hematopoietic reconstitution in patients with advanced hormone-refractory prostate cancer (HRPC)|To explore the effects of different chemotherapy regimens on the immune response of CG1940 & CG8711 vaccinated and reconstituted lymphopenic patients with HRPC|To compare the frequency of tumor vaccine-specific, PSMA-specific T cells, and the titer of vaccine-specific antibodies in Cohorts A-C, compare in Cohorts A-C|To evaluate in vitro sensitization (IVS) methods for their capacity to expand tumor vaccine-specific CD4+ and CD8+ T cells from the peripheral blood|To determine whether the degree of lymphopenia inversely correlates with the expansion of tumor-specific CD4 and CD8 T cells|To evaluate the effects of these procedures on serum PSA levels and tumor response","Providence Health & Services|Providence Cancer Center, Earle A. Chiles Research Institute|Cell Genesys","Male","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","18","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPMC-EACRI-IRB-02-119|DOD Grant #DAMD17-03-1-0097","July 2005","null","July 2005","February 2009","July 18, 2005","July 21, 2005","null","null","February 23, 2009","February 24, 2009","Providence Portland Medical Center, Portland, Oregon, United States","https://ClinicalTrials.gov/show/NCT00122005"
831,"NCT01230905","Study to Monitor the Effects of Androgen Suppression Treatment on the Heart","AST","Completed","No Results Available","Prostate Cancer","Radiation: PET scan and ultrasound","myocardial flow reserve|Regional myocardial perfusion","Ottawa Heart Institute Research Corporation","Male","40 Years to 80 Years   (Adult, Senior)","Phase 4","181","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2008341-01H","July 2008","September 2011","September 2011","April 2017","October 28, 2010","October 29, 2010","null","null","April 21, 2017","April 24, 2017","University of Ottawa Heart Institute, Ottawa, Ontario, Canada","https://ClinicalTrials.gov/show/NCT01230905"
832,"NCT00602329","MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer","null","Unknown status","No Results Available","Colorectal Cancer","Biological: bevacizumab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin","Analysis of tumor blood flow, assessed by DCE-MRI as percentage change in Ktrans, after 2 courses of FOLFOX and bevacizumab or FOLFOX alone compared to baseline value|Analysis of tumor markers of angiogenesis and apoptosis, and the effect of treatment|Correlation of tumor blood flow with time to progression|Correlation of markers of apoptosis in tumor cells with response to therapy, time to progression, and overall survival","University of Pennsylvania|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","120","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Diagnostic","CDR0000580810|UPCC-09205|GENENTECH-UPCC-09205|UPCC-804021","February 2006","December 2009","null","July 2009","January 19, 2008","January 28, 2008","null","null","July 7, 2009","July 8, 2009","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00602329"
833,"NCT00898378","Study of Biomarkers in Blood & Tissue Samples From Patients With Colorectal Cancer or Polyps & Patients Without Polyps","null","Completed","No Results Available","Colorectal Cancer|Healthy, no Evidence of Disease|Precancerous Condition","Genetic: gene expression analysis|Genetic: polymerase chain reaction|Genetic: polymorphism analysis|Genetic: protein expression analysis|Genetic: proteomic profiling|Other: gas chromatography|Other: laboratory biomarker analysis|Other: liquid chromatography|Other: mass spectrometry|Other: questionnaire administration","Metabolomic, lipidomic, glycoproteomic, proteomic, and genomic (OMIC) profiling|Creation of an OMIC profile to predict the risk of colorectal cancer (CRC)|Creation of an OMIC profile to predict response and toxicity to specific therapies for CRC|Identification of interactive molecular pathways that underlie the development and progression of CRC","Indiana University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","551","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","0808-24; IUCRO-0221|P30CA082709|IUCRO-0221","January 2009","March 2014","March 2014","September 2014","May 9, 2009","May 12, 2009","null","null","September 17, 2014","September 18, 2014","Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States","https://ClinicalTrials.gov/show/NCT00898378"
834,"NCT00002977","Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission","null","Completed","No Results Available","Ovarian Cancer","Biological: filgrastim|Drug: melphalan|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","Female","18 Years to 60 Years   (Adult)","Phase 1","45","Other|NIH","Interventional","Primary Purpose: Treatment","1181.00|NCI-G97-1229|CDR0000065499","January 1997","November 2001","null","September 2010","November 1, 1999","April 29, 2004","null","null","September 13, 2010","September 15, 2010","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00002977"
835,"NCT01847794","HER2 Positive CTC in Advanced Gastric Cancer","AGC-HER2CTC","Unknown status","No Results Available","HER2 Positive Advanced Gastric Cancer","Device: Cell Search® CTC epithelial kit","HER2 positive CTC|clinical significance of HER 2 positive CTC","Peking University","All","18 Years and older   (Adult, Senior)","","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CGOG5002","June 2013","June 2015","June 2016","May 2013","April 29, 2013","May 7, 2013","null","null","May 2, 2013","May 7, 2013","Peking cancer hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT01847794"
836,"NCT01731587","Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer","FINGERPRINT","Withdrawn","No Results Available","Non-small Cell Lung Cancer (NSCLC) Stage III","Other: Biological: MUC1 peptide specific immunotherapy|Drug: Cyclophosphamide (CPA)","Immune response defined as change from baseline in serum cytokine levels after L-BLP25 administration at Week 1, 4 and 8|Evaluation of a cellular immune response following treatment with L-BLP25|Change from baseline in alternative immune or inflammatory serum soluble immune mediators such as interferon alpha (IFNα), transforming growth factor beta (TGFβ), or C-reactive protein (CRP) at 6, 12, and 24 hours after L-BLP25 administration.|Number of subjects with adverse events (AEs)","Merck KGaA","All","18 Years and older   (Adult, Senior)","Phase 1","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","EMR 63325-019|2012-001435-31","January 2001","null","null","February 2017","October 11, 2012","November 22, 2012","null","null","February 27, 2017","February 28, 2017","","https://ClinicalTrials.gov/show/NCT01731587"
837,"NCT00429247","Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients","null","Completed","No Results Available","Breast Cancer","Drug: Trastuzumab","Compare the disease-free interval of patients with early-stage breast cancer|Elimination of CK-19 mRNA-positive CTCs.","University Hospital of Crete","Female","18 Years to 75 Years   (Adult, Senior)","Phase 2","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT/01.60","February 2003","December 2007","December 2007","January 2008","January 30, 2007","January 31, 2007","null","null","July 20, 2011","July 21, 2011","University Hospital of Crete, Heraklion, Crete, Greece","https://ClinicalTrials.gov/show/NCT00429247"
838,"NCT00898417","Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab","null","Completed","No Results Available","Lung Cancer","Biological: bevacizumab|Drug: carboplatin|Drug: paclitaxel|Genetic: proteomic profiling|Other: laboratory biomarker analysis|Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry","Survival","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years to 120 Years   (Adult, Senior)","","90","Other|NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","CDR0000592948|ECOG-E4599T2","March 14, 2008","April 14, 2008","April 14, 2008","May 2017","May 9, 2009","May 12, 2009","null","null","May 17, 2017","May 19, 2017","","https://ClinicalTrials.gov/show/NCT00898417"
839,"NCT00900172","Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel","null","Completed","No Results Available","Lung Cancer","Biological: bevacizumab|Drug: carboplatin|Drug: paclitaxel|Genetic: gene expression analysis|Genetic: polymerase chain reaction|Genetic: polymorphism analysis|Other: laboratory biomarker analysis","Correlation of results to response and toxicity","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","18 Years to 120 Years   (Adult, Senior)","","180","Other|NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","CDR0000592945|ECOG-E4599T1","March 15, 2008","April 15, 2009","April 15, 2009","May 2017","May 9, 2009","May 12, 2009","null","null","May 17, 2017","May 19, 2017","","https://ClinicalTrials.gov/show/NCT00900172"
840,"NCT02125617","Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer","uPARCRPC","Terminated","No Results Available","Prostatic Neoplasms","Drug: Abiraterone|Drug: Prednisolone","Impact of baseline uPAR cleavage products on response.|Impact of baseline plasma concentration of uPAR cleavage products on overall survival (OS).|Impact of baseline plasma concentration of uPAR cleavage products on progression free survival (PFS).|Impact of baseline plasma concentration of uPAR cleavage products on pain relief rate.|Impact of baseline plasma concentration of uPAR cleavage products on disease control rate (DCR).|Impact of baseline plasma concentration of uPAR cleavage products on serious adverse events (SAE).","Kristoffer Staal Rohrberg|Janssen-Cilag Ltd.|Rigshospitalet, Denmark","Male","18 Years to 120 Years   (Adult, Senior)","","3","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","uPARCRPC","January 2014","July 2016","February 2017","November 2015","April 25, 2014","April 29, 2014","null","null","November 18, 2015","November 20, 2015","University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark","https://ClinicalTrials.gov/show/NCT02125617"
841,"NCT03073902","The Correlation of PD-L1 Expression in Non-small Lung Cancer Tissue and Peripheral Blood T Cell and Serum.","null","Not yet recruiting","No Results Available","NSCLC","Other: Liquid biopsy","The match rate of PD-L1 protein expression in non-small lung cancer tissue and peripheral blood T cell .|The match rate of PD-L1 protein expression in non-small lung cancer tissue and serum.","Xinqiao Hospital of Chongqing","All","Child, Adult, Senior","","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XQonc-006","March 20, 2017","December 31, 2018","June 30, 2019","March 2017","February 26, 2017","March 8, 2017","null","null","March 2, 2017","March 8, 2017","Xinqiao Hospital of Chongqing, Chongqing, China","https://ClinicalTrials.gov/show/NCT03073902"
842,"NCT01543841","Laboratory Testing for Tie-2 Expressing Monocytes (TEMs) in Blood","null","Completed","No Results Available","Advanced Cancer|Healthy","","Characterize the in vitro response of circulating myeloid cells to angiopoeitins-1 and 2 (ANG1 and 2) in the presence or absence of pharmacologic inhibitors|Develop and optimize flow cytometry analyses","University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","TEMs-DC-001","August 2012","January 2014","January 2014","April 2015","January 19, 2012","March 5, 2012","null","null","April 16, 2015","April 17, 2015","Princess Margaret Hospital, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT01543841"
843,"NCT01898533","Feasibility of Blood Oxygenation Level-Dependent Contrast (BOLD) Breast MRI Induced by Breath- Holding","BOLD","Completed","No Results Available","Breast Cancer","","The change in BOLD contrast of the breasts and / or chest wall tissue will be measured by comparing breath hold sequences to normal breathing.|Feasibility as measured by a BOLD contrast signal in at least 30% of subjects","Duke University","Female","18 Years and older   (Adult, Senior)","","11","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Pro00046072","September 2013","April 2014","April 2014","July 2017","July 9, 2013","July 12, 2013","null","null","July 7, 2017","July 11, 2017","Duke University Medical Center, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT01898533"
844,"NCT01314391","Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor","null","Completed","No Results Available","Kidney Cancer|Renal Failure","Genetic: mutation analysis|Genetic: polymerase chain reaction|Other: laboratory biomarker analysis","Higher incidence of ESRD in non-syndromic WT patients with germline WT1 mutations than WT patients without WT1 mutations","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 15 Years   (Child)","","20","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Retrospective","AREN11B1|COG-AREN11B1|NCI-2011-02850","August 2011","May 2016","null","May 2016","March 11, 2011","March 14, 2011","null","null","May 17, 2016","May 18, 2016","","https://ClinicalTrials.gov/show/NCT01314391"
845,"NCT00900536","DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE","null","Completed","No Results Available","Kidney Cancer","Genetic: mutation analysis|Genetic: polymorphism analysis|Genetic: protein expression analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis","Relationship between tumor genotype, expression, and patient outcome|Relationship between constitutional genotype and patient outcome","Medical Research Council|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","null","Other","Observational","","MRC-RE05-TRANSORCE|CDR0000601175|EU-20867|EUDRACT-2006-006079-19|ISRCTN38934710","July 2007","null","June 2012","November 2008","May 9, 2009","May 12, 2009","null","null","August 9, 2013","August 12, 2013","Addenbrooke's Hospital, Cambridge, England, United Kingdom","https://ClinicalTrials.gov/show/NCT00900536"
846,"NCT03096782","Cord Blood (CB) Ex-vivo Mesenchymal Stem Cell (MSC) Expansion + Fucosylation","null","Recruiting","No Results Available","Hematopoietic/Lymphoid Cancer","Drug: Busulfan|Drug: Rituximab|Drug: ATG|Drug: Fludarabine|Drug: Clofarabine|Radiation: Total Body Irradiation|Procedure: Cord Blood Transplant|Drug: Mycofenolate mofetil|Drug: Tacrolimus|Drug: G-CSF|Drug: Melphalan|Drug: Cyclophosphamide|Drug: Mesna","Feasibility of Cord Blood Infusion Expanded in Mesenchymal Stem Cells (MSC) with Fucosylation|Time to Engraftment|Disease Free Survival","M.D. Anderson Cancer Center|Mesoblast, Inc.","All","12 Years to 65 Years   (Child, Adult)","Phase 2","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0051","October 13, 2017","October 2020","October 2020","October 2017","March 21, 2017","March 30, 2017","null","null","October 16, 2017","October 18, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03096782"
847,"NCT00579618","Ascertainment of Saliva or Blood Samples For Genetic Epidemiology Studies of Cancer and Aging","null","Completed","No Results Available","Non-cancer Affected Volunteers","Other: Saliva or Blood samples","obtain saliva or blood from non-cancer volunteers, 60 years or older to carry out anonymous genetic epidemiology studies related to resistance to cancer in elderly.|samples perform high density genomic scans & candid gene studies carriers specif BRCA found mutat who haven't been affect by breast cancer & old than 60 find genetic cofactor may modify a predispo breast ca confer by germline mutation in BRCA1 & BRCA2.","Memorial Sloan Kettering Cancer Center|Susan G. Komen Breast Cancer Foundation|Beth Abraham|Gurwin Jewish Nursing & Rehabilitation Center|Hebrew Home at Riverdale|Jewish Home & Hospital Lifecare System|Margaret Tietz Center|Metropolitan Jewish Health System|Northern Services Group|Parker Jewish Institute|Lenox Hill Neighborhood House|JASA at Temple Emanuel of Parkchester Senior Center|Van Cortlandt Village Senior Center","All","60 Years and older   (Adult, Senior)","","53","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","06-102","September 2006","July 2017","July 2017","July 2017","December 20, 2007","December 24, 2007","null","null","July 28, 2017","July 31, 2017","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00579618"
848,"NCT01576211","Studying Genes Using Cord Blood and Placenta Samples From Relatively Healthy Newborns and Samples From Younger Patients With Wilms Tumor","null","Completed","No Results Available","Kidney Cancer","Genetic: DNA methylation analysis|Genetic: RNA analysis|Genetic: allele-specific oligonucleotide real-time quantitative polymerase chain reaction|Genetic: gene expression analysis|Genetic: nucleic acid sequencing|Genetic: polymorphism analysis|Other: laboratory biomarker analysis","Frequency of loss of imprinting at birth|Association between methylation levels and gene expression","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","","40","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Retrospective","AREN12B6|COG-AREN12B6|CDR0000730596|NCI-2012-00726","April 2012","May 2016","null","May 2016","April 11, 2012","April 12, 2012","null","null","May 17, 2016","May 18, 2016","","https://ClinicalTrials.gov/show/NCT01576211"
849,"NCT01426074","DCE-MRI PET Bevacizumab Study in Rectal Cancer","null","Active, not recruiting","No Results Available","Rectal Cancer Patients","Drug: Bevacizumab 5 mg/kg","Pathologic Complete Response (pCR)","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Senior)","Phase 2","30","Other","Interventional","Primary Purpose: Treatment","UPCC 05209","August 2011","August 2014","null","September 2016","August 29, 2011","August 31, 2011","null","null","September 23, 2016","September 26, 2016","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT01426074"
850,"NCT01608919","Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection","null","Terminated","No Results Available","Venous Thromboembolism","Other: blood tests","Venous thromboembolism free survival after surgery for gastrointestinal or urologic cancer","University of Colorado, Denver","All","18 Years to 80 Years   (Adult, Senior)","","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-1295","November 2012","January 2014","January 2014","August 2015","May 29, 2012","May 31, 2012","null","null","August 7, 2015","August 10, 2015","University of Colorado Hospital, Aurora, Colorado, United States","https://ClinicalTrials.gov/show/NCT01608919"
851,"NCT00003943","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.","null","Completed","No Results Available","Carcinoma of Unknown Primary|Lung Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: paclitaxel|Drug: topotecan hydrochloride|Procedure: peripheral blood stem cell transplantation","Determine the one year progression-free survival|Overall survival; safety of regimen; CR rate; lab correlates; pharmacokinetics","Fox Chase Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","3","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000067136|FCCC-98039|NCI-G99-1535","September 1998","November 2000","February 2003","April 2013","November 1, 1999","May 3, 2004","null","null","April 16, 2013","April 17, 2013","Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00003943"
852,"NCT01625702","Clinical Significance of Circulating Tumor Cells (CTCs) in Blood of Patients With Advanced/Metastatic Gastric Cancer","null","Completed","No Results Available","Gastric Cancer","Device: CellSearch® CTC kit","circulating tumor cells in blood","Peking University","All","18 Years and older   (Adult, Senior)","","138","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CGOG5001","June 2012","July 2014","December 2015","May 2017","June 13, 2012","June 21, 2012","null","null","May 7, 2017","May 9, 2017","Department of GI Oncology, Peking University Cancer Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT01625702"
853,"NCT00436189","Assess Cancer in Ovarian Tumors With Biomarkers.","null","Completed","No Results Available","Ovarian Tumor","Procedure: Blood Draw","Proportion of actual ovarian cancer cases among OvaRl positive patients is higher than the proportion of actual ovarian cancer cases among referred patients.|Evaluate OvaRl assay plus standard clinical practice.","Ciphergen Biosystems","Female","18 Years and older   (Adult, Senior)","","1000","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","OVA-001-C01","February 2007","April 2008","April 2008","April 2008","February 13, 2007","February 16, 2007","null","null","April 25, 2008","April 30, 2008","Clinical Research Consultants, Hoover, Alabama, United States|Women's Health Research, Phoenix, Arizona, United States|Precision Trials, Phoenix, Arizona, United States|Gynecologic Oncology Associates, Newport Beach, California, United States|North Coast Women's Care Medical Group Inc, Vista, California, United States|Farmington Obstetrics and Gynecology Group, Avon, Connecticut, United States|The GYN Center for Women's Health, Waterbury, Connecticut, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|OB/GYN Specialists of the Palm Beaches, West Palm Beach, Florida, United States|University of Kentucky - Whitney Facility, Lexington, Kentucky, United States|Maine Medical Center, Scarborough, Maine, United States|Eastern Carolina Women's Center, New Bern, North Carolina, United States|HWC Women's Research Center, Miamisburg, Ohio, United States|Advanced Clinical Research, Medford, Oregon, United States|Chattanooga Gyn-Oncology, Chattanooga, Tennessee, United States|SWRCC, Austin, Texas, United States|UT South Western Medical Center at Dallas, Dallas, Texas, United States|Tacoma Women's Specialists, Tacoma, Washington, United States","https://ClinicalTrials.gov/show/NCT00436189"
854,"NCT02848651","A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer","B-F1RST","Active, not recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Atezolizumab","Percentage of Participants With Objective Response per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Determined by Investigator|Progression-Free Survival (PFS) per RECIST v1.1 as Determined by Investigator, by Positive Versus Negative bTMB Groups|PFS per RECIST v1.1 as Determined by Investigator|Duration of Response (DOR) per RECIST v1.1 as Determined by Investigator|Overall Survival (OS)|Percentage of Participants With Adverse Events|Percentage of Participants Who Are Alive and Progression-Free (per RECIST v1.1) at 6, 9, and 12 Months by Various bTMB Quantiles|Percentage of Participants Who Are Alive (OS) at 6, 9, and 12 Months by Various bTMB Quantiles|Percentage of Participants with Objective Response (per RECIST v1.1) by Various bTMB Quantiles","Genentech, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","150","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML39237","September 23, 2016","June 28, 2019","June 28, 2019","December 2017","July 26, 2016","July 28, 2016","null","null","December 4, 2017","December 6, 2017","Veterans Affairs Central California Health Care System, Fresno, California, United States|Loma Linda Cancer Center, Loma Linda, California, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Florida Hospital, Orlando, Florida, United States|St. Alexius Medical Center, Hoffman Estates, Illinois, United States|Quincy Medical Group; Canc Ctr at Blessing Hosp, Quincy, Illinois, United States|Franciscan St. Francis Health; Research Services, Indianapolis, Indiana, United States|Investigative Clin Rsch of IN, Indianapolis, Indiana, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Michigan Cancer Rsch Cons, Ypsilanti, Michigan, United States|Virginia Piper Cancer Inst, Minneapolis, Minnesota, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Eastchester Center for Cancer Care, Bronx, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Levine Cancer Institute-Carolinas Medical Center; Levine Cancer Institute-Carolinas Medical Center, Charlotte, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Cancer Treatment Centers of America - Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|Univ of Texas SW Medical Ctr, Dallas, Texas, United States|Inova Health Care Services, Falls Church, Virginia, United States|Western WA Oncology Inc PS, Lacey, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT02848651"
855,"NCT00835133","Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma","null","Recruiting","No Results Available","Familial Pancreatic Cancer","Other: biologic sample preservation procedure|Other: medical chart review|Other: survey administration","Collection of familial data and biospecimens in a data and tissue repository for familial pancreas research","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","","4000","Other|NIH","Observational","Observational Model: Family-Based|Time Perspective: Prospective","355-06|R01CA097075-08|CDR0000613097","August 2002","September 2022","September 2022","September 2017","January 31, 2009","February 3, 2009","null","null","September 8, 2017","September 11, 2017","Mayo Clinic Cancer Center, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00835133"
856,"NCT03367611","Use of iFOBT in Patients Presenting With Alarm Symptoms of Colorectal Cancer","null","Not yet recruiting","No Results Available","Colorectal Neoplasms|Colorectal Cancer|Colorectal Carcinoma|Colorectal Adenoma|Colorectal Adenocarcinoma","Diagnostic Test: Immunochemical faecal occult blood test (iFOBT)","Faecal occult haemoglobin.|Colonic lesion.","University of Aarhus|Regionshospitalet Horsens|Randers Regional Hospital|Central Denmark Region","All","40 Years and older   (Adult, Senior)","","1100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1234","January 1, 2018","March 1, 2019","March 1, 2019","November 2017","November 21, 2017","December 11, 2017","null","null","December 8, 2017","December 11, 2017","","https://ClinicalTrials.gov/show/NCT03367611"
857,"NCT02887612","ctDNA for Prediction of Relapse in Gastric Cancer","null","Recruiting","No Results Available","Stomach Neoplasms","Other: ctDNA test","Positive Predictive Value|prognostic molecular markers","Sun Yat-sen University","All","18 Years to 80 Years   (Adult, Senior)","","200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ctDNA001","September 2016","December 2017","December 2019","June 2017","May 14, 2016","September 2, 2016","null","null","June 12, 2017","June 14, 2017","Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT02887612"
858,"NCT01523808","Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer","null","Completed","No Results Available","Pancreatic Cancer","Drug: GRASPA","limiting toxicity|Immunogenicity : Titers of anti-L-asparaginase antibodies|Tumor response Evaluation by one or several tumor (bio)markers evolution|Serum concentrations of asparagine, aspartate, glutamine, glutamate, and asparaginase","ERYtech Pharma","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GRASPANC2008-02","June 2009","March 2011","March 2011","March 2013","January 16, 2012","February 1, 2012","null","null","March 7, 2013","March 8, 2013","","https://ClinicalTrials.gov/show/NCT01523808"
859,"NCT00546039","Synthetic Genistein (BONISTEIN™) in Patients Who Are Undergoing Surgery for Prostate Cancer","null","Unknown status","No Results Available","Prostatic Neoplasms","Drug: Genistein|Drug: Placebo","Modulation of biomarkers: PSA, Testosterone, STAMP1, STAMP2, NKX3A and KLK4, p21, p27, p53, bcl-2, bax, Ki67, CgA and NSE in blood and/or prostate tissue.|Modulation of prostate cancer grade, volume and Gleason score. Safety parameters (blood, electrolytes, liver, pancreas, lipids, thyroid and sexual hormones). Plasma and tissue concentrations of BONISTEIN™.","University Hospital, Aker","Male","18 Years and older   (Adult, Senior)","Phase 2","47","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","P2BV10","April 2007","August 2008","January 2009","September 2008","October 17, 2007","October 18, 2007","null","null","September 29, 2008","September 30, 2008","Aker University Hospital, Oslo, Norway","https://ClinicalTrials.gov/show/NCT00546039"
860,"NCT01881334","Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants","null","Available","No Results Available","Hematologic Malignancies|Inborn Errors of Metabolism Disorders|Immune Deficiencies","Biological: CliniMACS CD34 Reagent System","","Joanne Kurtzberg, MD|Duke University|Miltenyi Biotec, Inc.","All","up to 65 Years   (Child, Adult)","","null","Other|Industry","Expanded Access","","Pro00045700","null","null","null","June 2017","June 17, 2013","June 19, 2013","null","null","June 27, 2017","June 29, 2017","Duke University Medical Center, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT01881334"
861,"NCT01497470","A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen","null","Completed","No Results Available","Cancer","Drug: Custirsen, paclitaxel and carboplatin","To evaluate the impact of custirsen on paclitaxel pharmacokinetics|To evaluate the safety and tolerability of adding custirsen to standard paclitaxel/carboplatin chemotherapy","Achieve Life Sciences|Teva Pharmaceutical Industries","All","18 Years and older   (Adult, Senior)","Phase 1","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","TV1011-DDI-105","April 2012","July 2013","October 2013","October 2016","December 9, 2011","December 22, 2011","null","null","October 7, 2016","October 10, 2016","Teva Investigational Site 002, Detroit, Michigan, United States|Teva Investigational Site 001, Dallas, Texas, United States|Teva Investigational Site 003, San Antonio, Texas, United States|Teva Investigational Site 004, Tacoma, Washington, United States","https://ClinicalTrials.gov/show/NCT01497470"
862,"NCT00004048","Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer","null","Completed","No Results Available","Head and Neck Cancer","Biological: filgrastim|Drug: doxorubicin hydrochloride|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: indium In 111 monoclonal antibody MN-14|Radiation: yttrium Y 90 monoclonal antibody MN-14","","Garden State Cancer Center at the Center for Molecular Medicine and Immunology","All","16 Years to 80 Years   (Child, Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Primary Purpose: Treatment","CDR0000067172|CMMI-C-040A-98|CMMI-FDR001555|NCI-V99-1564","September 1998","May 2002","May 2002","June 2011","December 10, 1999","April 15, 2004","null","null","June 21, 2011","June 22, 2011","Garden State Cancer Center, Belleville, New Jersey, United States|St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States","https://ClinicalTrials.gov/show/NCT00004048"
863,"NCT00034216","Collection of Blood From Patients With Cancer","null","Recruiting","No Results Available","Prostate Cancer|Breast Cancer|Colon Cancer|Lung Cancer|Liver Cancer","","Analyze tissue, urine, saliva, and blood components, which include serum, leukocytes, peripheral blood mononuclear cells (PBMC), and circulating tumor cells (cTC), of human subjects.|Correlate analysis results with clinical parameters such as demographics, toxicities, and treatment outcomes.|Undertake genetic analysis of both prokaryotic and eukaryoticsamples for advanced mutational analysis.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Senior)","","1000","NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","020179|02-C-0179","April 19, 2002","null","null","June 6, 2017","April 24, 2002","April 24, 2002","null","null","October 18, 2017","October 19, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00034216"
864,"NCT02892786","Detection in Peripheral Blood of Circulating Tumor Cells in Patient With Head and Neck Squamous Cell Carcinoma","CTCVADS","Active, not recruiting","No Results Available","Head and Neck Cancer","Other: Circulating Tumor Cells","Circulating tumor cells in peripheral blood during head and neck surgery|Comparison between RT-PCR and CellSearch™ method|Prognostic marker of relapse","Institut de Cancérologie de Lorraine","All","18 Years and older   (Adult, Senior)","","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2010-A00586-33","December 2010","December 2017","December 2018","October 2017","September 2, 2016","September 8, 2016","null","null","October 9, 2017","October 10, 2017","Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France","https://ClinicalTrials.gov/show/NCT02892786"
865,"NCT02571530","Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer","null","Recruiting","No Results Available","Neoplasm Metastasis","Drug: Intra-arterial Cerebral Infusion of Trastuzumab","Maximum tolerated dose (MTD)|Adverse events and dose-limiting toxicities|Response Evaluation Criteria in Solid Tumors (RECIST)|Overall Survival (OS)|Intracranial Time to Progression","Northwell Health","All","18 Years and older   (Adult, Senior)","Phase 1","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-312","September 2015","September 2020","null","November 2017","September 16, 2015","October 8, 2015","null","null","November 29, 2017","December 1, 2017","Lenox Hill Brain Tumor Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT02571530"
866,"NCT00009763","Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer","null","Unknown status","No Results Available","Breast Cancer","Biological: filgrastim|Biological: monoclonal antibody m170|Drug: cyclosporine|Drug: paclitaxel|Procedure: peripheral blood stem cell transplantation|Radiation: yttrium Y 90 monoclonal antibody m170","","University of California, Davis|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other","Interventional","Primary Purpose: Treatment","CDR0000068369|UCD-992080|NCI-V00-1640","March 2001","null","null","November 2003","February 2, 2001","January 27, 2003","null","null","September 19, 2013","September 20, 2013","University of California Davis Cancer Center, Sacramento, California, United States","https://ClinicalTrials.gov/show/NCT00009763"
867,"NCT03194542","A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence","null","Recruiting","No Results Available","Primary Myelofibrosis|Anemia","Drug: Luspatercept","Anemia response as it relates to hemoglobin (Hgb)increase|Anemia response as it relates to increased red blood cell (RBC)- transfusion independence|Time to anemia response|Duration of anemia response|Frequency of RBC transfusions|Frequency of RBC transfusion dependence|Proportion of subjects who achieve ≥ 50% reduction in fatigue symptom as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)|The proportion of subjects who achieve ≥ 50% reduction in total symptom score (TSS)|Health-related quality of life (HRQoL)|Functional Assessment of Cancer Therapy - Anemia (FACT-An)|EQ-5D-5L questionnaires|Adverse Events (AEs)|Frequency of Antidrug Antibodies (ADA)|Pharmacokinetic - AUC|Pharmacokinetic - Cmax","Celgene","All","18 Years and older   (Adult, Senior)","Phase 2","70","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACE-536-MF-001|2017-000322-35|U1111-1197-1202","November 15, 2017","June 8, 2019","June 29, 2019","December 2017","June 15, 2017","June 21, 2017","null","null","December 21, 2017","December 25, 2017","Mayo Clinic - Arizona, Phoenix, Arizona, United States|Stanford Cancer Center, Stanford, California, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Mid Florida Hematology and Oncology Centers, PA, Orange City, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Mount Sinai Medical Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|MD Anderson Cancer Center The University of Texas, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|CHRU de Brest - Hopital Morvan, Brest Cedex, France|Centre Hospitalier de Lens, Lens Cedex, France|Hopital Saint Louis, Paris, France|Institut Gustave Roussy, Villejuif, France|Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Ospedale di Circolo di Varese, Varese, Italy|Belfast Health and Social Care Trust, Belfast Northern Ireland, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|University of Oxford, Headington, Oxford, United Kingdom|Guys Hospital, London, United Kingdom|Imperial College London, London, United Kingdom","https://ClinicalTrials.gov/show/NCT03194542"
868,"NCT02600208","Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device","null","Recruiting","No Results Available","Hematologic Malignancies","Biological: CliniMACs","Evaluate the engraftment of patients receiving unrelated donor or partially matched related donor peripheral stem cells that have T cell depleted and CD19+ B cell depleted using the CliniMACS device.|Assess the probability of one year leukemia free survival (LFS).|Estimate the incidence and extent of acute and chronic graft vs. host disease.|Assess the incidence treatment-related mortality (TRM).","Julie-An M. Talano|Miltenyi Biotec, Inc.|Medical College of Wisconsin","Female","up to 23 Years   (Child, Adult)","Phase 2|Phase 3","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BT13BTθ51","October 2015","December 2019","December 2022","October 2016","October 28, 2015","November 9, 2015","null","null","October 18, 2016","October 19, 2016","Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT02600208"
869,"NCT02317016","Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer","null","Active, not recruiting","Has Results","Non Small Cell Lung Cancer","Procedure: Pharmacokinetic sampling - AZD9291|Drug: AZD9291 tablet dosing|Drug: Rosuvastatin|Procedure: Pharmacokinetic sampling - rosuvastatin|Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550","Assessment of Maximum Plasma Concentration (Cmax) for Rosuvastatin After a Single Dose Alone and in Combination With AZD9291|Assessment of AUC From Time Zero Extrapolated to Infinity for Rosuvastatin After a Single Dose Alone and in Combination With AZD9291|Assessment of Time to Maximum Plasma Concentration (Tmax) for Rosuvastatin After a Single Dose Alone and in Combination With AZD9291|Assessment of Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration at Time ""t"" (AUC0-t) for Rosuvastatin After a Single Dose Alone and in Combination With AZD9291|Assessment of Apparent Plasma Clearance (CL/F) for Rosuvastatin After a Single Dose Alone and in Combination With AZD9291|Assessment of Apparent Volume of Distribution (Vz/F) for Rosuvastatin After a Single Dose Alone and in Combination With AZD9291|Assessment of Terminal Elimination Half-life (t1/2[lambda_z]) for Rosuvastatin After a Single Dose Alone and in Combination With AZD9291|Assessment of Area Under the Plasma Concentration-time Curve During the Dosing Interval (AUCtau) for AZD9291, and AZ5104 and AZ7550 (Metabolites) Following Administration of AZD9291 and Rosuvastatin Together|Assessment of Maximum Plasma Concentration at Steady State (Css,Max) for AZD9291, and AZ5104 and AZ7550 (Metabolites) Following Administration of AZD9291 and Rosuvastatin Together|Assessment of Time to Reach Maximum Plasma Concentration at Steady State (Tss,Max) for AZD9291, and AZ5104 and AZ7550 (Metabolites) Following Administration of AZD9291 and Rosuvastatin Together|Assessment of Minimum Plasma Concentration at Steady State (Css,Min) for AZD9291, and AZ5104 and AZ7550 (Metabolites) Following Administration of AZD9291 and Rosuvastatin Together|Assessment of Apparent Plasma Clearance at Steady State (CLss/F) for AZD9291 Following Administration of AZD9291 and Rosuvastatin Together|Assessment of the Metabolite to Parent Ratios of Css,Max (MRCss,Max) for AZ5104 and AZ7550 Following Administration of AZD9291 and Rosuvastatin Together|Assessment of the Metabolite to Parent Ratios of AUCtau (MRAUCtau) for AZ5104 and AZ7550 Following Administration of AZD9291 and Rosuvastatin Together","AstraZeneca","All","18 Years to 99 Years   (Adult, Senior)","Phase 1","44","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5160C00019","March 10, 2015","July 11, 2015","January 4, 2018","October 2017","December 11, 2014","December 15, 2014","June 6, 2016","July 14, 2016","October 19, 2017","October 20, 2017","Research Site, Fairfax, Virginia, United States|Research Site, Bordeaux Cedex, France|Research Site, Bordeaux Cedex, France|Research Site, Montpellier, France|Research Site, Rennes, France|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT02317016"
870,"NCT03178552","A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","B-FAST","Recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Alectinib|Drug: Atezolizumab|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin|Drug: Gemcitabine","Cohort A: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1|Cohort B: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on the RECIST v1.1|Cohort C: Progression Free Survival (PFS) as Assessed by the Investigator Based on the RECIST v1.1|All Cohorts: Duration of Response as Assessed by the Investigator Based on the RECIST v1.1|Cohorts A and B: Percentage of Participants with Clinical Benefit Response as Assessed by the Investigator Based on the RECIST v1.1|Cohorts A and B: PFS as Assessed by the Investigator Based on the RECIST v1.1|All Cohorts: Duration of Response as Assessed by the Independent Review Facility (IRF) Based on the RECIST v1.1|Cohorts A and B: Percentage of Participants with Clinical Benefit Response as Assessed by IRF Based on the RECIST v1.1|All Cohorts: PFS as Assessed by IRF Based on the RECIST v1.1|All Cohorts: Percentage of Participants with Confirmed Objective Response as Assessed by IRF Based on the RECIST v1.1|All Cohorts: Overall Survival|All Cohorts: Percentage of Participants with Adverse Events|Cohorts A and B: Percentage of Participants who Have Shown Improvement Compared with Baseline in Total Severity Symptom Score as Measured by Symptoms in Lung Cancer (SILC) Scale in Patient-Reported Lung Cancer Symptoms (Cough, Dyspnea and Chest Pain)|All Cohorts: Time to Deterioration in Patient-Reported Lung Cancer Symptoms (Cough, Dyspnea and Chest Pain) as Measured by SILC Scale|Cohort C: Change from Baseline in Patient-Reported Lung Cancer Symptom (Cough, Dyspnea, Chest pain) Score as Measured by the SILC Scale|All Cohorts: Change from Baseline in Health Related Quality of Life (HRQoL) Scores as Measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - C30 (EORTC QLQ-C30)|Cohorts A and B: Change from Baseline in HRQoL Scores as Measured by the SILC Scale|All Cohorts: Change from Baseline in Patient Functioning and Symptoms Score as Measured by the EORTC QLQ-C30|Cohorts A and B: Change from Baseline in Patient Functioning and Symptoms Score as Measured by the SILC Scale|All Cohorts: Health Status Assessed as an Index Score Using the European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Questionnaire|Cohort B: Percentage of Participants with Dose-Limiting Toxicities (DLTs)|Cohort B: Maximum Plasma Concentration (Cmax) of Alectinib|Cohort B: Area Under the Concentration-Time Curve from Time Zero to the Last Measurable Concentration (AUC0-last) of Alectinib|Cohort B: Time to Reach Cmax (Tmax) of Alectinib|Cohort B: Half-Life (t1/2) of Alectinib|Cohort B: Metabolite to Parent Exposure Ratio for AUC0-last|Cohort B: Metabolite to Parent Exposure Ratio for Cmax|Cohort C: Percentage of Participants with Objective Response as Assessed by the Investigator Based on the RECIST v1.1|Cohort C: Percentage of Participants Free from Disease Progression as Assessed by the Investigator Based on the RECIST v1.1 at Months 6 and 12","Hoffmann-La Roche","All","18 Years and older   (Adult, Senior)","Phase 2|Phase 3","580","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BO29554|2017-000076-28","September 22, 2017","March 5, 2020","January 2, 2022","November 2017","June 5, 2017","June 7, 2017","null","null","November 16, 2017","November 20, 2017","University of California San Diego, La Jolla, California, United States|UC Davis; Comprehensive Cancer Center, Sacramento, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Eastern Connecticut Hematology and Oncology Associates; (ECHO), Norwich, Connecticut, United States|SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States|Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States|University Cancer & Blood Center, LLC, Athens, Georgia, United States|Illinois Cancer Care, Peoria, Illinois, United States|University of Kentucky; Markey Cancer Center, Lexington, Kentucky, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cancer Inst. of New Jersey, New Brunswick, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Oregon HSU, Portland, Oregon, United States|St. Luke's Cancer Care Associates, Bethlehem, Pennsylvania, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Tennessee Oncology PLLC - Nashville (20th Ave), Nashville, Tennessee, United States|Texas Oncology - South Austin, Austin, Texas, United States|Oncology Consultants PA, Houston, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|University of Washington Seattle Cancer Care Alliance, Seattle, Washington, United States|Royal North Shore Hospital; Department of Medical Oncology, St Leonards, New South Wales, Australia|The Prince Charles Hospital; Oncology Dept., Chermside, Queensland, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|Austin Hospital; Medical Oncology, Heidelberg, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|UZ Brussel, Brussel, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|CancerCare Manitoba; Department of Medical Oncology, Winnipeg, Manitoba, Canada|Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials, Barrie, Ontario, Canada|William Osler Health System Brampton Civic Hospital, Brampton, Ontario, Canada|London Health Sciences Centre · Victoria Hospital; Department of Medicine, London, Ontario, Canada|Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center, Oshawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|Jewish General Hospital; Sir Mortimer B. Davis, Montreal, Quebec, Canada|IUCPQ (Hôpital Laval), Quebec City, Quebec, Canada|Saskatoon Cancer Agency, Saskatoon, Saskatchewan, Canada|Centro Internacional de Estudios Clínicos (CIEC), Santiago, Chile|Centre Francois Baclesse; Radiologie, Caen, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hopital Caremeau; Pneumologie, Nimes, France|Hopital Bichat Claude Bernard; Oncologie Serv., Paris, France|Hôpital Européen Georges Pompidou, Paris, France|CHRU Poitiers, Poitiers, France|Hopital Pontchaillou, Rennes, France|CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique, Toulouse Cedex 9, France|Hopital Bretonneau; Pneumologie Oncologie, Tours, France|Hopital Robert Schuman; Pneumologie, Vantoux, France|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Heinrich-Heine Universitätsklinik Düsseldorf, Düsseldorf, Germany|Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen, Germany|Asklepios-Fachklinik Muenchen-Gauting; Klinik Für Pneumologie, Gauting, Germany|Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie, Gerlingen, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Queen Mary Hospital; Medicine & Respiratory, Hong Kong, Hong Kong|Prince of Wales Hospital; Department of Clinical Onocology, Sha Tin, Hong Kong|Soroka Medical Center; Oncology Dept, Beer Sheva, Israel|Rambam Health Care Campus; Oncology, Haifa, Israel|Meir Medical Center; Oncology, Kfar-Saba, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Israel|Sourasky / Ichilov Hospital; Dept. of Oncology, Tel Aviv, Israel|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|Irccs Istituto Europeo di Oncologia (IEO); Divisione di Oncologia, Milano, Lombardia, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga; S.C.D.U. di Oncologia Toracica, Orbassano (TO), Piemonte, Italy|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Bunkyo-ku, Japan|Shikoku Cancer Center, Ehime, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Kanazawa University Hospital, Ishikawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Kyoto University Hospital, Kyoto, Japan|Tohoku University Hospital, Miyagi, Japan|Niigata Cancer Center Hospital, Niigata-shi, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Saga University Hospital, Saga, Japan|Juntendo University Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Kyorin University Hospital, Tokyo, Japan|Fujita Health University Hospital, Toyoake-shi, Japan|National Cancer Center, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Health Pharma Professional Research, CD Mexico, Mexico CITY (federal District), Mexico|Oncologico Potosino, San Luis Potosí, SAN LUIS Potosi, Mexico|AVIX Investigación Clínica S.C, Monterrey, Mexico|Hospital Angeles Tijuana, Tijuana, Mexico|Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdańsk, Poland|Krakowski Szpital Specjalistyczny im.Jana Pawla II, Krakow, Poland|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu, Poznan, Poland|Centrum Onkologii Instytut im.Marii Sklodowskiej-Curie; Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Insititut Catala D'Oncologia, Hospitalet de Llobregat, Barcelona, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital Universitari Vall d'Hebron; Oncology, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal; Servicio de Oncología, Madrid, Spain|Hospital Quiron de Madrid; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clínico Universitario de Valencia; Servicio de Oncología, Valencia, Spain|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand","https://ClinicalTrials.gov/show/NCT03178552"
871,"NCT02948946","Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors","null","Recruiting","No Results Available","Gastroenteropancreatic Neuroendocrine Tumor|Lung Neuroendocrine Neoplasm","Procedure: NETest","Rate of Successful Test Results Per Cohort","H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MCC-18756","January 9, 2017","November 2018","December 2019","December 2017","October 27, 2016","October 31, 2016","null","null","December 13, 2017","December 15, 2017","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","https://ClinicalTrials.gov/show/NCT02948946"
872,"NCT00942968","Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer","null","Completed","Has Results","Cancer","Drug: dalteparin","Number of Participants With Major Bleeding Events Adjudicated by Central Adjudication Committee|Number of Participants With New or Recurrent Venous Thromboembolism (VTE) Adjudicated by Central Adjudication Committee|Number of Participants With Investigator Identified Major Bleeding Events|Number of Participants With Any Bleeding Event (Major or Minor) Adjudicated by Central Adjudication Committee|Number of Participants With Fatal Bleeding Events|Time to First Occurrence of Major Bleeding Event Adjudicated by Central Adjudication Committee|Time to First Occurrence of Any Bleeding Event (Major or Minor) Adjudicated by Central Adjudication Committee|Number of Participants With Investigator Identified New or Recurrent Venous Thromboembolism (VTEs)|Number of Participants With New or Recurrent Venous Thromboembolism (VTE) or Central Venous Thrombosis (CVT) Adjudicated by Central Adjudication Committee|Number of Participants With Investigator Identified New or Recurrent Venous Thromboembolism (VTE) or Central Venous Thrombosis (CVT)|Time to First Occurrence of New or Recurrent Venous Thromboembolism (VTE) Adjudicated by Central Adjudication Committee|Time to First Occurrence of New or Recurrent VTE or CVT Adjudicated by Central Adjudication Committee","Pfizer","All","18 Years and older   (Adult, Senior)","Phase 4","338","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FRAG-A001-401|A6301095","June 2009","March 2012","June 2013","January 2017","July 16, 2009","July 21, 2009","January 4, 2017","February 24, 2017","January 4, 2017","February 24, 2017","Arizona Cancer Center, Tuscon, Arizona, United States|Bay Area Cancer Research Group, Pleasant Hill, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|University of CT Health Center, Farmington, Connecticut, United States|Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut, United States|Georgetown University Hospital-Lombardi Cancer Ctr, Washington, District of Columbia, United States|Halifax Health, Daytona Beach, Florida, United States|Atlanta Institute for Medical Research, Decatur, Georgia, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Bringham and Women's Hospital, Boston, Massachusetts, United States|Henry Ford Hospital K-15, Detroit, Michigan, United States|University of Rochester Medical Center, Rochester, New York, United States|Stony Brook University, Medical Center, Stony Brook, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|MidDakota Clinic, Bismarck, North Dakota, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Vermont Cancer Center at Fletcher Allen Health Care, Burlington, Vermont, United States|University of Virginia, Charlottesville, Virginia, United States|LKH Graz Univrsitatstklinik fur Innere Medizin, Graz, Austria|Medizinische Universitat Innsbruck Studienambulanz Hamatologie, Innsbruck, Austria|KH d. Elizabethinen Linz GmbH Servicestelle fur klin. Studien und Universitare Angelegenheiten, Linz, Austria|KH der Barmherzigen Schwestern, Linz, Austria|Dialysestation Landesklinkum St.Poelten, St. Poelten, Austria|Medizinische Universitat Wien, Vienna, Austria|University of Alberta, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|London Health Sciences Centre, London, Ontario, Canada|Ottawa Health Research Institute, Ottawa, Ontario, Canada|University Health Network-Toronto General Hospital, Toronto, Ontario, Canada|Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada|Gelre Ziekenhuizen-Locatie Apeldoorn, Apeldoorn, Netherlands|Orbis Medisch Centrum, Sittard-Geleen, Sittard-Geleen, Netherlands|Hospital clinic i Provincial de Agencia de Ensayos Clinicos, Barcelona, Spain|Hospital General Santa Maria del Rosell, Caragena (Murcia), Spain|Hospital Virgen de la Arrixaca, El Palmar (Murcia), Spain|Hospital Universitari Dr Josep Trueta, Girona, Spain|Clinica Universitaria de Navarra, Pamplona, Spain","https://ClinicalTrials.gov/show/NCT00942968"
873,"NCT00016029","Comparison of Barium Enema, Computed Tomographic Colonography, and Colonoscopy in Detecting Colon Cancer","null","Terminated","No Results Available","Colorectal Cancer","Other: screening questionnaire administration|Procedure: barium enema injection|Procedure: computed tomography|Procedure: computed tomography colonography|Procedure: diagnostic colonoscopy|Procedure: screening colonoscopy","","Duke University","All","18 Years and older   (Adult, Senior)","","775","Other","Interventional","Primary Purpose: Diagnostic","0866|DUMC-000866-00-5R|DUMC-CA14326|NCI-V01-1655|CDR0000068587","August 2000","null","August 2005","September 2003","May 6, 2001","January 27, 2003","null","null","March 20, 2013","March 22, 2013","Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|California Pacific Medical Center - Pacific Campus, San Francisco, California, United States|California Pacific Medical Center - California Campus, San Francisco, California, United States|Veterans Affairs Medical Center - San Francisco, San Francisco, California, United States|Indian River Radiology, Vero Beach, Florida, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Troy Internal Medicine, P.C., Troy, Michigan, United States|Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States|Veterans Affairs Medical Center - Durham, Durham, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Massey Cancer Center, Richmond, Virginia, United States","https://ClinicalTrials.gov/show/NCT00016029"
874,"NCT00117442","A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood","null","Completed","No Results Available","Breast Cancer|Lung Cancer|Ovarian Cancer","Drug: carboplatin|Drug: paclitaxel|Drug: pegfilgrastim","PBPC mobilization profiles and success rate of achieving planned chemotherapy administration on time.|PBPC kinetics and response to chemotherapy treatment","Amgen","All","18 Years to 65 Years   (Adult)","Phase 2","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20010191","August 2002","August 2004","December 2004","May 2013","June 30, 2005","July 7, 2005","null","null","May 9, 2013","May 13, 2013","","https://ClinicalTrials.gov/show/NCT00117442"
875,"NCT00262886","Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer","null","Completed","No Results Available","Kidney Cancer","Biological: anti-thymocyte globulin|Biological: graft-versus-tumor induction therapy|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Response rate based on tumor measurements at 1 year|Toxicity as measured by NCI CTC at days 0, 7, 14, 21 and 28 after transplantation and monthly for 11 months|Overall and disease-free survival at day 100 and 1 year after transplantation","University of Rochester","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","35","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000449939|URCC-U1801|URCC-RSRB-09084","August 2001","July 2007","null","June 2013","December 6, 2005","December 7, 2005","null","null","June 5, 2013","June 6, 2013","James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States","https://ClinicalTrials.gov/show/NCT00262886"
876,"NCT01793207","Peripheral Blood DNA Methylation Markers for the Early Detection of Colorectal Carcinoma in the Egyptian Population","null","Completed","No Results Available","Colorectal Neoplasms|Adenoma|Colorectal Tumors","","Methylation markers present in peripheral blood of patients with colorectal cancer(Sept 9, CDKN2B-p15, CDH4, SFRP2, ALX4, Neurog1 and CDH13)in comparison to their presence in other subjects|Methylation markers present in peripheral blood of patients with colorectal adenomas (Sept 9, CDKN2B-p15, CDH4, SFRP2, ALX4, Neurog1 and CDH13)in comparison to their presence in other subjects|Methylation markers present in peripheral blood of patients with hyperplastic polyps(Sept 9, CDKN2B-p15, CDH4, SFRP2, ALX4, Neurog1 and CDH13)in comparison to their presence in other subjects","Cairo University|National Cancer Institute (NCI)|science and technology development fund, Egypt","All","18 Years to 85 Years   (Adult, Senior)","","316","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","CRCS001|3023","December 2012","March 2015","March 2015","May 2015","February 13, 2013","February 15, 2013","null","null","May 4, 2015","May 6, 2015","Kar-Alaini hospital (Cairo Univeristy hospital), Cairo, Egypt|National cancer institute, Cairo, Egypt","https://ClinicalTrials.gov/show/NCT01793207"
877,"NCT03052335","The Efficiency of Colon Capsule Endoscopy in Colon Cancer Screening","null","Recruiting","No Results Available","Colon Cancer","Device: Pillcam® COLON 2 Capsule|Procedure: Colonoscopy","Negative predictive value (NPV) of the CCE2 for large polyps (≥ 10 mm)|CCE2 accuracy for detection of advanced adenomas|CCE2 accuracy for detection of colon cancer|CCE2 and optical colonoscopy acceptance (special questionnaire)|Cost-effectiveness analyses: cost reduction of preventive colonoscopies spared","Military University Hospital, Prague|Masaryk University|Institute for Clinical and Experimental Medicine|University Hospital Hradec Kralove","All","50 Years to 75 Years   (Adult, Senior)","","230","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","16-29614A","March 1, 2017","December 31, 2019","December 31, 2019","September 2017","January 31, 2017","February 14, 2017","null","null","September 3, 2017","September 7, 2017","Military University Hospital, Prague, Czechia","https://ClinicalTrials.gov/show/NCT03052335"
878,"NCT02735512","MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer","null","Recruiting","No Results Available","No Evidence of Disease|Stage II Bladder Cancer|Stage III Bladder Cancer|Stage IVA Bladder Cancer|Stage IVB Bladder Cancer","Other: Cytology Specimen Collection Procedure|Other: Laboratory Biomarker Analysis","Change in MDSC level in patients with known localized, muscle-invasive bladder cancer who undergo surgical treatment|Change in MDSC level in patients with known metastatic bladder cancer who undergo systemic treatment|Change in MDSC level in patients with no history of cancer|Change in tumor burden evaluated by radiographic imaging|Change in urine cytology analysis","University of Southern California|National Cancer Institute (NCI)","All","Child, Adult, Senior","","63","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","4B-15-2|NCI-2016-00265|P30CA014089","March 1, 2016","March 1, 2018","March 1, 2019","March 2017","March 15, 2016","April 12, 2016","null","null","March 24, 2017","March 28, 2017","USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT02735512"
879,"NCT01287104","A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias","null","Active, not recruiting","No Results Available","Leukemia|Lymphoma","Biological: NK Cell Infusion|Biological: Stem Cell Infusion","Feasibility &amp; Toxicity|Efficacy|Incidence of cGVHD in allogeneic PBSCT followed by NK-DLI|Compare disease-free and overall survival|Incidence of viral infection and/or reactivation in allogeneic PBSCT followed by NK-DLI|Correlate post-transplant cell numbers with select immunologic parameters|Impact of KIR expression and KIR reactivity on PFS","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","4 Years to 35 Years   (Child, Adult)","Phase 1","34","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110073|11-C-0073","January 29, 2011","October 1, 2019","October 1, 2019","November 6, 2017","January 29, 2011","February 1, 2011","null","null","November 15, 2017","November 17, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT01287104"
880,"NCT02216149","Effects of S-1 and Capecitabine on Coronary Artery Blood Flow","FluoHeart","Recruiting","No Results Available","Esophagus Cancer|Stomach Cancer|Small Bowel Cancer|Colon Cancer|Rectum Cancer","Drug: S-1|Drug: Capecitabine","Frequency of coronary artery dysfunction|Coronary artery blood flow rate|Cardiac arrythmias during 24-hour electrocardiogram registration|Adverse events between the allocation groups|Response to chemotherapy","Heikki Joensuu|Helsinki University Central Hospital","All","18 Years to 100 Years   (Adult, Senior)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HUS-01/2013|2013-003976-11","January 2015","August 2018","August 2019","March 2016","August 7, 2014","August 13, 2014","null","null","March 4, 2016","March 7, 2016","Helsinki University Central Hospital, Helsinki, Finland","https://ClinicalTrials.gov/show/NCT02216149"
881,"NCT02955173","Significance of Circulating Tumor Cells in the Treatment of Gastric and Rectal Cancer","null","Recruiting","No Results Available","Circulating Tumor Cells|Colorectal Cancer|Gastric Cancer","Procedure: Surgery","Disease-free survival|Circulating tumor cell (CTC) test","Qilu Hospital of Shandong University|Peking University People's Hospital","All","18 Years to 80 Years   (Adult, Senior)","","600","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening","2016YFC0106003","December 2016","December 2018","December 2019","February 2017","November 2, 2016","November 4, 2016","null","null","February 8, 2017","February 9, 2017","Qilu Hospital of Shandong University, Jinan, Shandong, China","https://ClinicalTrials.gov/show/NCT02955173"
882,"NCT00764322","Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen","NRR","Completed","Has Results","Breast Cancer|Menopausal Symptoms","Drug: tamoxifen citrate|Genetic: gene expression analysis|Other: pharmacogenomic studies|Other: questionnaire administration|Procedure: quality-of-life assessment","Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes|Number of Participants With Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), Stroke, and/or Endometrial Cancer|Change in Median Endoxifen Concentrations to Determine Feasibility of Obtaining Pharmacogenomic Information From Patients in the Clinical Setting and Using it to Guide Changes in Therapy|CYP2D6 Allele Frequencies and Endoxifen Levels Among African-American Women Taking Tamoxifen Citrate|Change in Plasma Endoxifen Levels After an Increase in Tamoxifen Citrate Dose From 20 mg to 40 mg Daily in Patients With Poor-metabolizing Genotypes|Patient Understanding of Pharmacogenomics","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","21 Years to 120 Years   (Adult, Senior)","Phase 2","501","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LCCC 0801|P30CA016086|08-0483","June 18, 2008","September 28, 2010","July 1, 2011","July 2017","October 1, 2008","October 2, 2008","March 31, 2017","July 2, 2017","July 3, 2017","August 1, 2017","Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Moses Cone Regional Cancer Center at Wesley Long Community Hospital, Greensboro, North Carolina, United States|Leo W. Jenkins Cancer Center at ECU Medical School, Greenville, North Carolina, United States|Rex Cancer Center at Rex Hospital, Raleigh, North Carolina, United States|Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States","https://ClinicalTrials.gov/show/NCT00764322"
883,"NCT00038883","Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies","null","Completed","No Results Available","Leukemia, Lymphocytic, Chronic|Leukemia, Lymphocytic, Acute|Lymphoma, Low-Grade|Lymphoma, T-Cell|Lymphoma, B-Cell","Drug: Campath-1H","CAMPATH 2-year event-free survival rate","M.D. Anderson Cancer Center|Leudosite","All","15 Years to 60 Years   (Child, Adult)","","19","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID99-410","April 2001","May 2006","May 2006","July 2012","June 5, 2002","June 7, 2002","null","null","July 27, 2012","July 31, 2012","UT MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00038883"
884,"NCT00003553","Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer","null","Unknown status","No Results Available","Kidney Cancer","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: methotrexate|Drug: mycophenolate mofetil","Graft vs tumor effect as measured by CT scan at days 30, 60, and 100 following transplant|Disease-free survival as measured by CT scan at 6 months and 1 year","National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","80","NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000066610|NHLBI-97-H-0196","January 1999","December 2009","null","June 2009","November 1, 1999","January 27, 2003","null","null","June 23, 2009","June 24, 2009","NIH - Warren Grant Magnuson Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00003553"
885,"NCT02774291","Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1","null","Not yet recruiting","No Results Available","HLA-A2 Positive Cells Present|Metastatic Malignant Neoplasm|Metastatic Malignant Neoplasm in the Brain","Biological: Aldesleukin|Biological: Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes|Drug: Cyclophosphamide|Biological: Filgrastim|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis","Incidence of toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|In vivo survival of TCR gene-engineered cells|Objective response rate, graded according to RECIST criteria","Albert Einstein College of Medicine, Inc.|National Cancer Institute (NCI)","All","18 Years to 66 Years   (Adult, Senior)","","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-5254|NCI-2015-01781|P30CA013330","August 2016","January 2018","January 2018","August 2016","May 13, 2016","May 17, 2016","null","null","August 15, 2016","August 17, 2016","Albert Einstein College of Medicine, Bronx, New York, United States","https://ClinicalTrials.gov/show/NCT02774291"
886,"NCT00005790","Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors","null","Withdrawn","No Results Available","Brain and Central Nervous System Tumors","Other: laboratory biomarker analysis|Procedure: biopsy|Procedure: magnetic resonance imaging|Radiation: gadopentetate dimeglumine","","Northwestern University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","0","Other|NIH","Interventional","Primary Purpose: Diagnostic","NU 95C1|NU-95C1|NCI-G00-1738","April 1996","May 1999","May 1999","June 2012","June 2, 2000","June 9, 2004","null","null","June 8, 2012","June 11, 2012","","https://ClinicalTrials.gov/show/NCT00005790"
887,"NCT01983761","Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation","null","Unknown status","No Results Available","Blood And Marrow Transplantation|Leukemia|Lymphoma|Transplantation Infection|Myelodysplastic Syndrome (MDS)|Non-Hodgkin's Lymphoma (NHL)|Hodgkin's Lymphoma","Drug: Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)|Drug: Fludarabine, Melphalan, ATG (Reduced Intensity)","Safety and tolerability in patients who receive ASC-101-treated dual-cord UCBT|Preliminary efficacy of ASC-101-treated dual-cord UCBT, as assessed by the rate of reconstitution of neutrophils and platelets as compared to historical controls receiving an unmanipulated dual-cord UCBT","Targazyme, Inc.","All","1 Year to 80 Years   (Child, Adult, Senior)","Phase 1|Phase 2","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASC-101-001","November 2013","March 2014","null","November 2013","November 2, 2013","November 14, 2013","null","null","November 14, 2013","November 18, 2013","Scripps Green Hospital, La Jolla, California, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|Texas Transplant Institute, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT01983761"
888,"NCT00467961","Stem Cell Transplantation for Patients With Cancers of the Blood","null","Completed","Has Results","CML (Chronic Myelogenous Leukemia)|CLL (Chronic Lymphocytic Leukemia)|AML (Acute Myelogenous Leukemia)|Acute Lymphocytic Leukemia|MDS (Myelodysplastic Syndrome)","Device: Miltenyi system","To Determine if Selective T Cell Depletion Using the Photodepletion Procedure Can Substantially Reduce the Rate of Severe Acute GVHD (Grade III/IV) After Matched Sibling Transplantation Followed by Low-dose or no Immunosuppression.|Secondary Objectives Include Determining the Rate od Standard Transplant Outcome Variables: Toxicity, Relapse, Graft Rejection, Disease Free Survival.","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","61","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","070136|07-H-0136","April 2007","November 2012","November 2012","December 2014","April 28, 2007","May 1, 2007","December 22, 2014","January 6, 2015","December 22, 2014","January 6, 2015","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00467961"
889,"NCT00974610","Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.","null","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Lung Cancer|Melanoma (Skin)|Pancreatic Cancer","","Detection of peptide and protein markers in serum|Identification of the protein/peptide involved","Cancer Trials Ireland","All","Child, Adult, Senior","","803","Other","Observational","Observational Model: Other|Time Perspective: Prospective","CTRIAL-IE (ICORG) 07-12|EU-20949","August 2008","December 2015","January 2017","May 2017","September 9, 2009","September 10, 2009","null","null","May 23, 2017","May 24, 2017","Cork University Hospital, Cork, Ireland|Mercy University Hospital, Cork, Ireland|Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|Mater Misericordiae University Hospital, Dublin, Ireland|St. James's Hospital, Dublin, Ireland|Beaumont Hospital, Dublin, Ireland|Mater Private Hospital, Dublin, Ireland|St Luke's Hospital, Dublin, Ireland|University College Hospital, Galway, Ireland|Letterkenny General Hospital, Letterkenny, Ireland|Mid-Western Cancer Centre at Mid-Western Regional Hospital, Limerick, Ireland|Waterford Regional Hospital, Waterford, Ireland","https://ClinicalTrials.gov/show/NCT00974610"
890,"NCT00025519","Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer","null","Withdrawn","No Results Available","Kidney Cancer","Biological: therapeutic allogeneic lymphocytes|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Drug: tacrolimus|Drug: thalidomide|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","","Fox Chase Cancer Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","0","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","FCCC-01006|CDR0000068970|TUHSC-3721|NCI-G01-2021","June 2001","October 2006","October 2006","July 2013","October 11, 2001","January 27, 2003","null","null","July 10, 2013","July 11, 2013","","https://ClinicalTrials.gov/show/NCT00025519"
891,"NCT01028716","Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","null","Recruiting","No Results Available","Acute Biphenotypic Leukemia|Acute Erythroid Leukemia in Remission|Acute Leukemia in Remission|Acute Megakaryoblastic Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia in Remission|Acute Myeloid Leukemia With FLT3/ITD Mutation|Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM|Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM|Acute Myeloid Leukemia With Multilineage Dysplasia|Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Complete Remission|B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Burkitt Lymphoma|Childhood Acute Lymphoblastic Leukemia in Complete Remission|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Myelodysplastic Syndrome|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|Secondary Acute Myeloid Leukemia|T Lymphoblastic Lymphoma","Drug: Cyclophosphamide|Biological: Filgrastim|Drug: Fludarabine Phosphate|Procedure: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Tacrolimus|Radiation: Total-Body Irradiation","Cumulative incidence of non-relapse mortality, defined as death without evidence of disease progression|Incidence of chronic graft versus host disease|Incidence of grades III/IV acute graft versus host disease|Relapse of malignancy after transplantation|Donor cell engraftment|Infections|Neutrophil recovery|Platelet recovery|Primary graft failure|Progression-free survival|Secondary graft failure|Toxicity of treatment regimen","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2372.00|NCI-2009-01433|2372|P30CA015704","February 8, 2010","August 1, 2018","null","December 2017","December 8, 2009","December 9, 2009","null","null","December 11, 2017","December 13, 2017","VA Puget Sound Health Care System, Seattle, Washington, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT01028716"
892,"NCT01418118","Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery","Free4Flow","Completed","No Results Available","Oral Cancer|Head and Neck Cancer|Free Flap|Hypotension","Drug: Epinephrine|Drug: Norepinephrine|Drug: Dobutamine|Drug: Dopexamine","Absolute change in transfer function (flap vascular resistance) after pressor infusion.|Relative change in transfer function after pressor infusion compared with ""normal"" tissue.|Change in flap flow after pressor infusion|Differences in frequency spectrum of skin blood flow between flaps and ""normal"" tissue before and after pressor infusion.","Oxford University Hospitals NHS Trust","All","17 Years and older   (Child, Adult, Senior)","Phase 4","25","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2008-000073-37 5579|2008 000073 37|08/H0606/31","October 2008","February 2010","February 2010","August 2011","August 15, 2011","August 16, 2011","null","null","August 15, 2011","August 16, 2011","John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom","https://ClinicalTrials.gov/show/NCT01418118"
893,"NCT01359254","Cord Blood Transplantation for Patients With Cancer","null","Terminated","Has Results","Hematological Disease","Drug: Melphalan|Drug: Fludarabine|Drug: Antithymocyte Globulin (ATG)|Drug: Busulfan|Drug: Total Body Irradiation (TBI)","Cord Blood Engraftment by Day 100|Survival at Day 100","University of Chicago","All","18 Years and older   (Adult, Senior)","Phase 2","1","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-020-B","April 2010","September 2011","June 2012","April 2015","May 20, 2011","May 24, 2011","April 10, 2015","April 30, 2015","April 10, 2015","April 30, 2015","University of Chicago, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT01359254"
894,"NCT03281902","Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy","null","Recruiting","No Results Available","Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer","Procedure: Biopsy|Procedure: Biospecimen Collection|Other: Laboratory Biomarker Analysis","Bioinformatics analysis","Mayo Clinic|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","","250","Other|NIH","Observational","Observational Model: Other|Time Perspective: Prospective","MC1634|NCI-2017-01479|P30CA015083","November 13, 2017","September 7, 2019","September 7, 2019","September 2017","September 7, 2017","September 13, 2017","null","null","November 16, 2017","November 20, 2017","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT03281902"
895,"NCT01221324","Diagnostic Value of C-reactive Protein and White Blood Cell Counts for Early Detection of Inflammatory Complications After Open Resection of Colorectal Cancer","null","Completed","No Results Available","Given Indication for Open Resection of Colorectal Cancer","","postoperative inflammatory complications|Anastomotic leakage","Cantonal Hospital of St. Gallen","All","18 Years and older   (Adult, Senior)","","1200","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","EKSG10/126","November 2010","November 2010","November 2010","February 2012","October 14, 2010","October 15, 2010","null","null","February 10, 2012","February 13, 2012","","https://ClinicalTrials.gov/show/NCT01221324"
896,"NCT03152071","Comparison of Robot Assisted Thoracic Surgery With Video Assisted Thoracic Surgery in Case of Lung Cancer","null","Recruiting","No Results Available","Lung Cancer|Postoperative Pain|Blood Loss|Inflammatory Response","Procedure: Robot assited thoracic surgery|Procedure: Video assited thoracic surgery","Postoperative pain|blood loss|operative time|conversion to spreading of the ribs/thoracotomy|lymph node dissection|prolonged air leak|chest tube drainage|length of stay|pulmonary function|Inflammatory reaction","Universitair Ziekenhuis Brussel","All","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","RATS vs VATS","August 15, 2017","June 1, 2018","July 1, 2018","October 2017","May 9, 2017","May 12, 2017","null","null","October 6, 2017","October 9, 2017","Universitair Ziekenhuis Brussel, Jette, Brussel, Belgium","https://ClinicalTrials.gov/show/NCT03152071"
897,"NCT00796068","Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant","null","Recruiting","No Results Available","Acute Biphenotypic Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Myelodysplastic Syndrome|Blasts Under 5 Percent of Bone Marrow Nucleated Cells|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Childhood Myelodysplastic Syndrome|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Myelodysplastic Syndrome With Excess Blasts-2","Drug: Cyclosporine|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Radiation: Total-Body Irradiation|Drug: Treosulfan|Procedure: Umbilical Cord Blood Transplantation","Incidence of graft failure/rejection|Incidence of non-relapse mortality|Incidence of secondary graft failure|Incidence of acute graft-versus-host disease (GVHD)|Incidence of acute or chronic graft-versus-host disease (GVHD)|Incidence of clinically significant infections|Incidence of platelet engraftment|Incidence of relapse or disease progression|Non-relapse mortality|One year survival|Overall survival|Progression-free survival","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","130","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2275.00|NCI-2010-00299|2275|P30CA015704","October 29, 2008","June 30, 2018","null","October 2017","November 21, 2008","November 24, 2008","null","null","October 16, 2017","October 18, 2017","University of Colorado Hospital, Aurora, Colorado, United States|Oregon Health and Science University, Portland, Oregon, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00796068"
898,"NCT00900120","Collecting and Storing Blood Samples From Patients With Cancer","null","Withdrawn","No Results Available","Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Nonmalignant Neoplasm|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific","","DNA repository for long-term storage of DNA obtained from patients treated at the Cancer Institute of New Jersey|Investigative mechanism to allow correlations between genetic polymorphisms and clinical outcomes","University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey","All","Child, Adult, Senior","","0","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CDR0000592848|P30CA072720|CINJ-000402|CINJ-IRB-4856","March 2004","May 2011","May 2011","December 2011","May 9, 2009","May 12, 2009","null","null","December 8, 2011","December 12, 2011","","https://ClinicalTrials.gov/show/NCT00900120"
899,"NCT00653068","Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System","null","Active, not recruiting","Has Results","Childhood Atypical Teratoid/Rhabdoid Tumor","Procedure: autologous hematopoietic stem cell transplantation|Radiation: 3-dimensional conformal radiation therapy|Drug: methotrexate|Drug: leucovorin calcium|Drug: etoposide|Drug: cyclophosphamide|Drug: cisplatin|Biological: filgrastim|Drug: carboplatin|Drug: thiotepa|Drug: vincristine sulfate|Other: laboratory biomarker analysis","Event-free Survival|Overall Survival (OS)|Toxic Death|Non-hematological Toxicity Associated With Chemotherapy: Grade 3 or Higher During Protocol Therapy","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 3","70","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACNS0333|NCI-2009-00337|COG-ACNS0333|U10CA098543","December 2008","April 2015","null","February 2017","April 3, 2008","April 4, 2008","December 20, 2016","February 13, 2017","February 13, 2017","March 20, 2017","Children's Hospital of Alabama, Birmingham, Alabama, United States|Southern California Permanente Medical Group, Downey, California, United States|Miller Children's Hospital, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital Central California, Madera, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Childrens Hospital of Orange County, Orange, California, United States|University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|University of Florida, Gainesville, Florida, United States|Nemours Children's Clinic - Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Florida Hospital, Orlando, Florida, United States|UF Cancer Center at Orlando Health, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Saint Joseph Children's Hospital of Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|University of Hawaii, Honolulu, Hawaii, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|University of Kentucky, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Children's Hospital-Main Campus, New Orleans, Louisiana, United States|Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|The Childrens Mercy Hospital, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|Saint Joseph's Regional Medical Center, Paterson, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|New York University Langone Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|New York Medical College, Valhalla, New York, United States|Mission Hospital-Memorial Campus, Asheville, North Carolina, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|Mercy Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Penn State Hershey Children's Hospital, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Palmetto Health Richland, Columbia, South Carolina, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|West Virginia University Charleston, Charleston, West Virginia, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada|McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada|Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT00653068"
900,"NCT03234309","Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors","null","Recruiting","No Results Available","Childhood Brain Neoplasm","Drug: Ferumoxytol|Procedure: Magnetic Resonance Imaging","Cerebral blood volume in small (< 1cm) enhancing lesions|Confidence in identifying the lesion corresponding areas on cerebral blood volume maps|Delineation of tumor from larger blood vessels|Overlay accuracy with 3-dimensional anatomical T1w post contrast scans|Ferumoxytol enhancement|Histology and genetic markers|Progression free survival|Relative cerebral blood volume value|Survival|Treatment response","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","5 Years to 18 Years   (Child, Adult)","Phase 2","100","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STUDY00016165|NCI-2017-00713|P30CA069533","October 20, 2017","April 14, 2021","April 14, 2022","October 2017","July 26, 2017","July 31, 2017","null","null","October 31, 2017","November 6, 2017","OHSU Knight Cancer Institute, Portland, Oregon, United States","https://ClinicalTrials.gov/show/NCT03234309"
901,"NCT02029209","To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer","null","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: Anlotinib|Drug: Placebo Capsule","Number of circulating endothelial cell subsets（ total CECs 、 aCECs、apopCECs, etc.)|The strength of intratumoral blood perfusion index (BV, BF, PS and MTT) .","Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd|Tianjin Medical University Cancer Institute and Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 2|Phase 3","110","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","ALTN-03-II 1.2-2","December 2013","March 2017","March 2017","December 2016","December 30, 2013","January 7, 2014","null","null","December 14, 2016","December 16, 2016","20th Floor, Block C, Lake Road, Hexi District, Tianjin Medical University Cancer Institute and Hospital ., Tianjin, Tianjin, China","https://ClinicalTrials.gov/show/NCT02029209"
902,"NCT01929603","Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours","null","Completed","No Results Available","Solid Tumours","Procedure: Pharmacokinetic sampling|Drug: Rifampicin|Drug: Olaparib tablet dosing","Pharmacokinetics of olaparib by assessment of maximum plasma olaparib concentration (Cmax)|Pharmacokinetics of olaparib by assessment of area under the plasma concentration time curve from zero to infinity (AUC)|Pharmacokinetics of olaparib by assessment of area under the plasma concentration time curve from zero to the last measurable time point, AUC0-t, if AUC is not adequately estimable.|Pharmacokinetics of olaparib by assessment of time to reach maximum plasma concentration for olaparib (tmax).|Pharmacokinetics of olaparib by assessment of olaparib area under the plasma concentration time curve from zero to the last measurable time point (AUC0-τ).|Pharmacokinetics of olaparib by assessment of olaparib apparent clearance (CL/F).|Pharmacokinetics of olaparib by assessment of olaparib apparent volume of distribution (Vz/F).|Pharmacokinetics of olaparib by assessment of olaparib terminal half-life (t1/2).|Pharmacokinetics of rifampicin by assessment of plasma concentrations of rifampicin during rifampicin dosing period.|Demonstration of induction of CYP by assessment of plasma concentrations of 4β-hydroxycholesterol during rifampicin dosing period.|Assessment of the safety and tolerability of olaparib by collection of adverse event reports|Determine safety and tolerability of olaparib by assessment of 12 lead electrocardiograms|Determine safety and tolerability of olaparib by physical examination|Determine safety and tolerability of olaparib by assessment of vital signs|Determine safety and tolerability of olaparib by assessment of clinical chemistry results|Determine safety and tolerability of olaparib by assessment of haematology results|Determine safety and tolerability of olaparib by assessment of urinalysis results","AstraZeneca","All","18 Years to 99 Years   (Adult, Senior)","Phase 1","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","D0816C00008","December 2013","May 2014","November 2016","January 2017","August 23, 2013","August 28, 2013","null","null","January 13, 2017","January 16, 2017","Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Wilrijk, Belgium|Research Site, Amsterdam, Netherlands|Research Site, Maastricht, Netherlands","https://ClinicalTrials.gov/show/NCT01929603"
903,"NCT00242723","Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining","null","Recruiting","No Results Available","Pulmonary Metastases From Cancers|Mediastinal or Chest Wall Neoplasms|Malignant Pleural Mesotheliomas NOS|Esophageal Cancers NOS|Lung Cancer NOS","","Permit evaluation of patients referred to the Thoracic Surgery Section, of the Thoracic and GI Malignancies Branch, NCI in order to identify individuals who will be suitable candidates for clinical research protocols|To obtain specimens for research","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","up to 100 Years   (Child, Adult, Senior)","","800","NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","060014|06-C-0014","October 18, 2005","null","null","July 25, 2017","October 20, 2005","October 20, 2005","null","null","November 21, 2017","November 22, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00242723"
904,"NCT02161770","Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment","null","Completed","No Results Available","Solid Tumours","Drug: AZD9291 tablet dosing|Procedure: Pharmacokinetic sampling - AZD9291|Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550","Pharmacokinetics of AZD9291 by assessment of maximum plasma AZD9291 concentration (Cmax)|Pharmacokinetics of AZD9291 by assessment of area under the plasma concentration time curve from zero to infinity (AUC)|Pharmacokinetics of AZD9291, AZ5104, and AZ7550 by assessment of AUC(0-t)|Pharmacokinetics of AZ5104 and AZ7550 by assessment of Cmax|Assessment of the safety and tolerability of AZD9291|Pharmacokinetics of AZD9291, AZ5104, and AZ7550 by assessment of tmax|Pharmacokinetics of AZD9291, AZ5104, and AZ7550 by assessment of AUC(0-24)|Pharmacokinetics of AZD9291, AZ5104, and AZ7550 by assessment of AUC(0-72)|Pharmacokinetics of AZD9291, AZ5104, and AZ7550 by assessment of AUC(0-168)|Pharmacokinetics of AZD9291, AZ5104, and AZ7550 by assessment of λz|Pharmacokinetics of AZD9291, AZ5104, and AZ7550 by assessment of t½|Pharmacokinetics of AZD9291, AZ5104, and AZ7550 by assessment of CL(R)|Pharmacokinetics of AZD9291 by assessment of CL/F|Pharmacokinetics of AZD9291 by assessment of Vz/F|Pharmacokinetics of AZ5104 and AZ7550 by assessment of AUC","AstraZeneca","All","18 Years to 99 Years   (Adult, Senior)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","D5160C00008|2014-001515-39","December 22, 2014","May 16, 2017","August 22, 2017","September 2017","May 29, 2014","June 12, 2014","null","null","September 25, 2017","September 26, 2017","Research Site, San Diego, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Detroit, Michigan, United States|Research Site, Cleveland, Ohio, United States|Research Site, San Antonio, Texas, United States|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Angers Cedex 9, France|Research Site, Marseille Cedex 20, France|Research Site, Pierre Benite Cedex, France|Research Site, Rennes, France|Research Site, Saint Herblain, France|Research Site, Toulouse, France|Research Site, Seoul, Korea, Republic of|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Newcastle Upon Tyne, United Kingdom","https://ClinicalTrials.gov/show/NCT02161770"
905,"NCT01212887","Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer","null","Terminated","No Results Available","Breast Cancer|Colorectal Cancer|Gastric Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Biological: MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes|Biological: aldesleukin|Drug: cyclophosphamide|Drug: fludarabine phosphate|Other: laboratory biomarker analysis|Other: pharmacological study","Percentage of patients (goal is 50%) who are evaluable for MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes survival|Adverse event according to CTCAE version 3 criteria|Dose of MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes that gives the highest frequency in the circulation as measured by the primary assays (recommended phase II dose)|Presence of cells with a functional chimeric immune receptor on bCEA binding assay|Partial response or complete response on CT scans at 6, 12, 24, and 52 weeks as defined by RECIST criteria|Long-term follow up for insertional mutagenesis","Cancer Research UK","All","18 Years and older   (Adult, Senior)","Phase 1","14","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000685060|CRUK-PH1/105|CRUK-MFEz|EUDRACT-2005-004085-16|EU-21070","August 2007","April 2010","April 2010","February 2012","September 30, 2010","October 1, 2010","null","null","February 27, 2012","February 28, 2012","Christie Hospital, Manchester, England, United Kingdom","https://ClinicalTrials.gov/show/NCT01212887"
906,"NCT00542048","A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases","null","Completed","No Results Available","Liver Cancer|Neoplasm Metastasis","Drug: EndoTAG®-1","Pharmacokinetic profile|Tumor response, Tumor perfusion, Soluble markers of angiogenesis, Pharmacodynamics, Safety","MediGene","All","18 Years and older   (Adult, Senior)","Phase 2","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CT 4003","November 2007","September 2009","September 2009","November 2009","October 9, 2007","October 10, 2007","null","null","February 8, 2010","February 9, 2010","Klinik für Internistische Onkologie in der KTB Klinik für Tumorbiologie an der Albert-Ludwigs-Universität Freiburg, Freiburg Im Breisgau, Baden-Würtemberg, Germany","https://ClinicalTrials.gov/show/NCT00542048"
907,"NCT00343798","A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies","null","Completed","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Prolymphocytic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma","Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: cyclosporine|Drug: mycophenolate mofetil|Other: ex-vivo umbilical cord blood expansion|Procedure: double-unit umbilical cord blood transplantation|Procedure: biopsy|Other: immunologic technique|Other: diagnostic laboratory biomarker analysis","Severe (grades 3 and 4) acute GVHD|Grade greater than or equal to 3 infusional toxicity|Graft failure as defined by failure to achieve ANC greater than or equal to 500/mm^3 of donor origin","Fred Hutchinson Cancer Research Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Damon Runyon Cancer Research Foundation","All","6 Months to 45 Years   (Child, Adult)","Phase 1","23","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2044.00|NCI-2010-00236|R43HL106868|R24HL074445|RC2HL101844","April 2006","July 2013","null","February 2015","June 22, 2006","June 23, 2006","null","null","February 10, 2015","February 11, 2015","City of Hope Medical Center, Duarte, California, United States|University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States|University of Colorado, Denver, Colorado, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00343798"
908,"NCT03190941","Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients","null","Recruiting","No Results Available","Pancreatic Cancer|Gastric Cancer|Gastrointestinal Cancer|Colon Cancer|Rectal Cancer","Drug: Cyclophosphamide|Drug: Fludarabine|Biological: anti-KRAS G12V mTCR|Drug: Aldesleukin","Response rate|Maximum Tolerated Dose|Survival and persistence of mTCR gene-engineered cells.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","110","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","170113|17-C-0113","January 9, 2018","December 1, 2022","December 29, 2023","November 16, 2017","June 16, 2017","June 19, 2017","null","null","January 3, 2018","January 4, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT03190941"
909,"NCT00348738","Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment Outcome","null","Unknown status","No Results Available","Cervix Cancer","Drug: Erythropoietin","remission rate 3 months after completion of the radiation therapy|local control rate|Disease specific survival|The extent of increase in hemoglobin levels during the treatment with erythropoietin.|The need of transfusion during the treatment.","Medical University of Vienna","Female","19 Years to 80 Years   (Adult, Senior)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OEGRO54","July 2000","null","July 2009","October 2007","July 5, 2006","July 6, 2006","null","null","October 31, 2007","November 2, 2007","Department of Radiotherapy-University Hospital of Innsbruck, Innsbruck, Austria|Department of Radiotherapy-University Hospital of Salzburg, Salzburg, Austria|Department of Radiotherapy and Radiobiology-Medical University of Vienna, Vienna, Austria|Department of Radiotherapy-Hospital of Hietzing, Vienna, Austria","https://ClinicalTrials.gov/show/NCT00348738"
910,"NCT00027326","Collection of Blood and Urine From Patients Undergoing Radiation Therapy","null","Recruiting","No Results Available","Carcinoma|Cancer|Tumor","","To acquire peripheral blood and/or urine samples from patients receiving radiation therapy in the Radiation Oncology Branch, NCI.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 90 Years   (Adult, Senior)","","450","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","020064|02-C-0064","December 6, 2001","null","null","October 5, 2017","July 13, 2006","December 3, 2001","null","null","October 18, 2017","October 19, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00027326"
911,"NCT00826683","Detection of Circulating Endothelial Progenitors Cells (EPCs) in Non-small Cell Lung Cancer (NSCLC)","CBNPC:PCE","Completed","No Results Available","Non-Small Cell Lung Cancer|Chronic Obstructive Pulmonary Disease","Biological: Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures","Number of EPCs in peripheral blood from NSCLC patients. Comparison with healthy non-smokers patients and smokers with COPD.|Characterization of EPCs by primary cultures. Correlation between initial EPCs and VEGF concentration in COPD and NSCLC patients Overall survival in NSCLC patients in relation to EPCs initial numeration","University Hospital, Limoges","All","18 Years and older   (Adult, Senior)","Phase 3","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","I08002","March 2009","December 2010","January 2011","October 2009","January 9, 2009","January 22, 2009","null","null","August 19, 2016","August 22, 2016","CHU limoges, Limoges, France","https://ClinicalTrials.gov/show/NCT00826683"
912,"NCT02372409","Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors","null","Recruiting","No Results Available","Glioma|Pilocytic Astrocytoma|Anaplastic Astrocytoma|Glioblastoma|Mixed Oligoastrocytoma|Mixed Glioma|Oligodendroglioma|Optic Glioma|Astrocytoma","Device: MRI-guided laser ablation|Drug: Doxorubicin|Drug: Etoposide|Device: Dynamic contrast-enhanced (DCE) MRI|Device: Dynamic susceptibility contrast (DSC) MRI","Arm A only: Progression-free survival (PFS)|Arm A only: Overall survival (OS)|Arm B only: Progression-free survival (PFS)|Arm B only: Quality of life (QOL)|Correlation of MR imaging with peritumoral BBB disruption|Serum biomarkers of peritumoral BBB disruption|Predictive value of the peritumoral permeability score for patient outcome as measured by PFS","Washington University School of Medicine","All","3 Years to 21 Years   (Child, Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201502062","August 14, 2015","October 30, 2019","October 30, 2019","September 2017","February 13, 2015","February 26, 2015","null","null","September 27, 2017","October 2, 2017","Washington University School of Medicine, Saint Louis, Missouri, United States","https://ClinicalTrials.gov/show/NCT02372409"
913,"NCT01119066","HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies","null","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Multiple Myeloma","Radiation: total body irradiation|Drug: Thiotepa|Drug: Cyclophosphamide|Drug: Busulfan|Drug: Melphalan|Drug: Fludarabine|Drug: Clofarabine|Procedure: (CliniMACS) T-cell depleted PBSC Transplant","To assess the incidence of durable hematopoietic engraftment for T-cell depleted transplants fractionated by the CliniMACS system administered after each of the four disease targeted cytoreduction regimens.|To assess the incidence and severity of acute and chronic GVHD following T-cell depleted, CD34+ progenitor cell enriched transplants fractionated by the CliniMACS system.|To assess the incidence of non-relapse mortality (transplant-related mortality) following each cytoreduction regimen and a transplant fractionated by the CliniMACS system.|To estimate the probability of survival and disease-free survival (DFS)|To determine the proportion of patients receiving optimal CD34+ (> 5x106/kg) and CD3+ (<1x105/kg) cell doses the proportion recurring suboptimal doses (< 2x106/kg) CD34+ cells; and the proportion of patients receiving CD3+ T-cell doses > 1x105/kg.|To correlate doses of CD34+ progenitors and CD3+ T cells with engraftment, graft vs. host disease and non-relapse mortality.","Memorial Sloan Kettering Cancer Center","All","up to 69 Years   (Child, Adult, Senior)","Phase 2","400","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-050","May 2010","May 2018","May 2018","January 2017","May 4, 2010","May 7, 2010","null","null","January 9, 2017","January 10, 2017","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT01119066"
914,"NCT02974764","Changes in Biomarkers From Blood Over Time in Patients With Pancreatic Adenocarcinoma","null","Recruiting","No Results Available","Neoplastic Cells, Circulating|Pancreatic Cancer|Biological Markers","Other: No intervention/exposures","Changes in Circulating Tumor Cells (CTCs) numbers after application of chemotherapy in patients with pancreatic adenocarcinoma.|Changes in Circulating Tumor Cells (CTCs) numbers after application of radiation therapy in patients with pancreatic adenocarcinoma.|Changes in Circulating Tumor Cells (CTCs) numbers after surgical resection of the primary tumor in patients with pancreatic adenocarcinoma.|Changes in Circulating Tumor Cells (CTCs) protein expression after application of chemotherapy in patients with pancreatic adenocarcinoma.|Changes in Circulating Tumor Cells (CTCs) protein expression after application of radiation therapy in patients with pancreatic adenocarcinoma.|Changes in Circulating Tumor Cells (CTCs) protein expression after surgical resection of the primary tumor in patients with pancreatic adenocarcinoma.|Driver gene mutations detection in CTCs in patients with pancreatic adenocarcinoma.|Changes in Circulating Tumor Cells (CTCs) numbers in response to disease progression from localized to metastatic disease.|Changes in Circulating Tumor Cells (CTCs) protein expression in response to disease progression from localized to metastatic disease.","Johns Hopkins University","All","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","00092443","March 2016","December 2018","December 2018","December 2017","November 23, 2016","November 28, 2016","null","null","December 5, 2017","December 7, 2017","Johns Hopkins University, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT02974764"
915,"NCT02586389","Specimen Collection From Patients With Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay","null","Recruiting","No Results Available","Non-hematologic Cancer","","biospecimen sample collection for liquid biopsy assay development","Sequenom, Inc.","All","18 Years and older   (Adult, Senior)","","3000","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","SQNM-CA-101","October 2015","October 2021","October 2021","May 2016","October 21, 2015","October 26, 2015","null","null","May 18, 2016","May 19, 2016","Compassionate Care Research Group, Inc., Riverside, California, United States","https://ClinicalTrials.gov/show/NCT02586389"
916,"NCT00578045","UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies","null","Withdrawn","No Results Available","Multiple Myeloma","Procedure: Transfusion","The researchers on this study want to find out if subjects treated on this study will achieve long term bone marrow recovery (engraftment) and if their tumors will respond to this treatment.|The researchers also want to find out what types of side effects, if any, subjects will experience with this treatment.","University of Arkansas","All","18 Years and older   (Adult, Senior)","Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","67363","July 2006","March 2011","March 2011","October 2015","December 18, 2007","December 20, 2007","null","null","October 23, 2015","October 26, 2015","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States","https://ClinicalTrials.gov/show/NCT00578045"
917,"NCT00079391","Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies","null","Completed","Has Results","Hematologic Malignancies|Bone Marrow Transplant Rejection","Device: allogeneic hematopoietic stem cell transplantation","The Proportion of Patients Who Develop Full Donor T Cell Chimerism at Day 30|Overall Survival|Non Relapse Mortality.|Cumulative Incidence of Relapse|Acute Graft Versus Host Disease (Before Day 60 T Cell Add Back)|Acute GVHD Overall","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","2 Years to 80 Years   (Child, Adult, Senior)","Phase 2","50","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","040112|04-H-0112","January 2004","December 2008","September 2011","June 2014","March 8, 2004","March 10, 2004","April 20, 2011","May 28, 2012","October 5, 2015","October 26, 2015","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00079391"
918,"NCT01141257","Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug","null","Completed","No Results Available","Solid Tumor","Drug: Angiocal® (PRS-050-PEG40)","Dose limiting toxicity|Pharmacokinetic analysis|Development of biomarkers in blood over time|Response of target lesions over time|ECOG performance status|Clinical laboratory measures|Anti-drug antibodies|Results of 12-lead Electrocardiogram by time point|Changes of vital signs from the baseline visit|Physical examination","Pieris Pharmaceuticals GmbH|FGK Clinical Research GmbH","All","18 Years and older   (Adult, Senior)","Phase 1","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pieris001","May 2010","September 2011","September 2011","October 2011","May 28, 2010","June 10, 2010","null","null","October 18, 2011","October 19, 2011","Breisgau, Baden-Württemberg, Germany|Ruhrgebiet, Nordrhein-Westfalen, Germany","https://ClinicalTrials.gov/show/NCT01141257"
919,"NCT00019357","Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy","null","Completed","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Biological: therapeutic tumor infiltrating lymphocytes","","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","NIH","Interventional","Primary Purpose: Treatment","CDR0000065811|NCI-97-C-0144|NCI-T97-0059","June 1998","null","null","August 2001","July 11, 2001","April 22, 2004","null","null","April 28, 2015","April 29, 2015","Medicine Branch, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00019357"
920,"NCT00328237","Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation","null","Unknown status","No Results Available","Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia|Non-Hodgkin Lymphoma|Myelodysplastic Syndromes","Procedure: Cord Blood Transplant","Evaluate the incidence of neutrophil engraftment after transplantation of one or two cord blood units|Evaluate safety as measured by day 100 treatment related mortality|Evaluate incidence of platelet engraftment|Evaluate incidences of acute and chronic graft-versus-host disease (GVHD)|Evaluate efficacy as measured by survival at 1 and 2 years after transplant|Evaluate chimerism from double cord transplants to determine source of long term engraftment","Colorado Blood Cancer Institute","All","18 Years to 49 Years   (Adult)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RMBMT-149","November 2005","null","null","November 2005","May 17, 2006","May 19, 2006","null","null","June 23, 2006","June 26, 2006","Rocky Mountain Blood and Marrow Transplant Program, Denver, Colorado, United States","https://ClinicalTrials.gov/show/NCT00328237"
921,"NCT01642147","Cerebral Blood Perfusion Changes After General Anesthesia for Craniotomy","null","Completed","Has Results","Brain Neoplasms|Surgery|Hyperemia","Device: Transcranial Doppler (TCD)|Procedure: jugular venous bulb catheterization|Procedure: Tumor removal surgery under general anesthesia|Procedure: Radial artery catheterization|Procedure: Abdominal surgery under general anesthesia","Mean Blood Flow Velocity in Middle Cerebral Artery|Oxygen Saturation of Jugular Venous Bulb","Huashan Hospital","All","25 Years to 60 Years   (Adult)","","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","KY2012-183","November 2012","January 2013","January 2013","May 2013","July 8, 2012","July 17, 2012","March 9, 2013","April 23, 2013","May 15, 2013","June 24, 2013","Huashan Hospital, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT01642147"
922,"NCT01682226","Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies","null","Recruiting","No Results Available","Leukemia|Myelodysplastic Syndrome|Lymphoma","Device: CliniMACS Fractionation system (Arm A)|Device: CliniMACS Fractionation system (Arm B)","number of days to neutrophil recovery|Overall survival","Memorial Sloan Kettering Cancer Center","All","2 Years to 70 Years   (Child, Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-153","September 2012","September 2018","September 2018","June 2017","September 6, 2012","September 10, 2012","null","null","June 20, 2017","June 21, 2017","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT01682226"
923,"NCT01236885","Computer-Guided Glucose Management Systems in Treating Patients With Hyperglycemia Who Have Undergone Blood and Bone Marrow Transplant","null","Completed","No Results Available","Hyperglycemia|Malignant Neoplasm","Other: computer-assisted intervention","Percentage of glucose values within target range (100-140) by using CGGMS|Percentage of patients who experience hypoglycemia (defined as at least one blood glucose value less than 70)|Percentage of patients who experience severe hypoglycemia (defined as at least one blood glucose value less than 40)|Mean time to target range (100-140)|Percentage of patients who experience hyperglycemia (defined as at least one blood glucose value greater than 200) 24 hours after initiation of infusion|Percentage of patients who experience severe hyperglycemia (defined as at least one blood glucose value greater than 300) 24 hours after initiation of infusion|Number of values greater than 200 or less than 70 per patient per day of treatment|Glucose variability (defined as standard deviation of individual blood glucose values)|Nursing satisfaction evaluated by the Glucose Monitoring Tool Trial Evaluation Form","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","19","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2425.00|NCI-2010-01102|P30CA015704","December 2012","February 2015","null","April 2015","November 4, 2010","November 9, 2010","null","null","April 21, 2015","April 23, 2015","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT01236885"
924,"NCT03084926","First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors","null","Active, not recruiting","No Results Available","Neoplasms","Drug: MP0274","Incidence and severity of adverse events|Pharmacokinetics of MP0274|Preliminary assessment of anti-tumor activity of MP0274|Incidence of anti-drug-antibodies","Molecular Partners AG","All","18 Years and older   (Adult, Senior)","Phase 1","46","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP0274-CP101|2016-004712-36","August 8, 2017","November 30, 2019","February 28, 2020","December 2017","March 6, 2017","March 21, 2017","null","null","December 20, 2017","December 21, 2017","Study Site Heidelberg, Heidelberg, Germany|Study Site St. Gallen, St. Gallen, Saint Gallen, Switzerland|Study Site Cambridge, Cambridge, United Kingdom","https://ClinicalTrials.gov/show/NCT03084926"
925,"NCT02194426","First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients","null","Recruiting","No Results Available","Neoplasms","Drug: MP0250","Proportion of patients with dose limiting toxicities|Vital signs|Frequency of adverse events|MP0250 plasma concentration-time profile|Nature of dose limiting toxicities|Nature of adverse events|Severity of adverse events|Blood chemistry values|Haematology values|Urine values|Electrocardiogram measurements|Pharmacokinetics parameters|Incidence of anti-drug-antibodies|Titre of anti-drug-antibodies","Molecular Partners AG","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","37","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP0250-CP101|2014-000366-21","July 2014","April 2018","April 2018","October 2017","June 12, 2014","July 18, 2014","null","null","October 17, 2017","October 18, 2017","Study Site Barcelona, Barcelona, Catalunya, Spain|Study Site St. Gallen, St. Gallen, Switzerland|Study Site Cambridge, Cambridge, Cambridgeshire, United Kingdom|Study Site Oxford, Oxford, Oxfordshire, United Kingdom","https://ClinicalTrials.gov/show/NCT02194426"
926,"NCT01075607","Lymph Fluid and Blood Collection for Identification of Novel Biomarkers","null","Terminated","No Results Available","Adenocarcinoma of the Breast","","Identification and Validation of Metastasis Protein Markers","Indiana University","Female","18 Years to 80 Years   (Adult, Senior)","","50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","0911-04","April 2010","April 2020","April 2022","March 2012","February 24, 2010","February 25, 2010","null","null","March 27, 2012","March 28, 2012","Indiana University Hospital, Indianapolis, Indiana, United States","https://ClinicalTrials.gov/show/NCT01075607"
927,"NCT01105533","A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors","null","Completed","Has Results","Neoplasm","Drug: PF-00337210","Number of Participants With Dose-limiting Toxicities (DLTs)|Maximum Tolerated Dose (MTD)|Maximum Administered Dose (MAD)|Recommended Phase-2 Dose (RP2D)|Maximum Observed Plasma Concentration (Cmax)|Plasma Decay Half-Life (t1/2)|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)]|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]|Apparent Volume of Distribution (Vss)|Systemic Clearance (CL)|Number of Participants With Objective Response of Complete Response or Partial Response|Change From Baseline in Biomarkers at Day 1 of Each Cycle up to Cycle 25","Pfizer|University of Wisconsin, Madison","All","18 Years and older   (Adult, Senior)","Phase 1","46","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A8051001","May 2006","October 2010","September 2011","February 2013","April 14, 2010","April 16, 2010","December 20, 2012","March 19, 2013","February 13, 2013","March 19, 2013","Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT01105533"
928,"NCT02066974","Circulating Tumor Cell Genome in Peripheral Blood From Hepatocellular Carcinoma Patients Under Radiotherapy","null","Unknown status","No Results Available","Circulating Neoplastic Cells|Adverse Effect of Radiation Therapy|Fatal Outcome","Genetic: hepatoma requiring radiotherapy","Response rate|Overall survival, relapse-free survival","China Medical University, China","All","21 Years to 79 Years   (Adult, Senior)","","45","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CMUH102-REC2-112","January 2014","February 2016","February 2016","February 2015","February 18, 2014","February 20, 2014","null","null","February 3, 2015","February 5, 2015","China Medical University Hospital, Taichung, Taiwan","https://ClinicalTrials.gov/show/NCT02066974"
929,"NCT03132259","Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach","null","Recruiting","No Results Available","Pituitary Tumor","Drug: high dose dexmedethomidine|Drug: low dose dexmedethomidine","Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach|Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor","Mahidol University","All","18 Years to 65 Years   (Adult)","Phase 4","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","116/2559","May 2016","May 2017","June 2018","May 2017","July 18, 2016","April 27, 2017","null","null","May 25, 2017","May 30, 2017","Faculy of Medicine Siriraj hospital Mahidol University, Bangkok, Thailand","https://ClinicalTrials.gov/show/NCT03132259"
930,"NCT00003199","Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer","null","Completed","Has Results","Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|Inflammatory Breast Cancer|Male Breast Cancer|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage IIIB Breast Cancer|Stage IV Breast Cancer","Drug: tamoxifen citrate|Drug: busulfan|Drug: thiotepa|Drug: melphalan|Biological: aldesleukin|Biological: sargramostim|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Event-free Survival|Overall Survival|Number of Participants With Toxicity of a Combination of Low-dose IL-2 and GM-CSF","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","19 Years to 65 Years   (Adult)","Phase 2","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PSOC 1605|NCI-2010-00728","November 1997","December 2009","December 2009","June 2017","November 1, 1999","January 27, 2003","April 10, 2017","May 17, 2017","June 16, 2017","July 12, 2017","Fred Hutchinson Cancer Research Center/Puget Sound Oncology Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00003199"
931,"NCT00253721","Melphalan With BBBD in Treating Patients With Brain Malignancies","null","Terminated","No Results Available","Brain and Central Nervous System Tumors|Lymphoma|Metastatic Cancer","Drug: Melphalan","Maximum tolerated dose (MTD)of Melphalan as measured by NCI common toxicity criteria (CTC) v2 toxicities|Efficacy of chemotherapy regimen as measured by clinical and radiographic response from first day of treatment","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1","21","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00001299|P30CA069533|1299|ONC-98018-L|4834","May 1998","December 2015","December 2016","April 2017","November 11, 2005","November 15, 2005","null","null","April 19, 2017","April 21, 2017","Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States","https://ClinicalTrials.gov/show/NCT00253721"
932,"NCT00964275","Standard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Cancer in Patients With a Blood Clot in a Vein","MVTEP","Completed","No Results Available","Thromboembolism|Unspecified Adult Solid Tumor, Protocol Specific","Procedure: diagnostic procedure|Radiation: fludeoxyglucose F 18","Number of cancers diagnosed","University Hospital, Brest","All","18 Years and older   (Adult, Senior)","","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CDR0000639720|HCB-MVTEP|RB 08-062|INCA-RECF0945|EUDRACT-2008-004135-38","March 2009","October 2014","October 2014","December 2014","August 21, 2009","August 24, 2009","null","null","December 5, 2014","December 8, 2014","CHU Brest - Hopital De La Cavale Blanche, Brest, France","https://ClinicalTrials.gov/show/NCT00964275"
933,"NCT00381888","Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer","null","Completed","Has Results","Cervical Cancer|Endometrial Cancer|Fallopian Tube Cancer|Ovarian Cancer|Sarcoma|Thromboembolism|Vaginal Cancer|Vulvar Cancer","Drug: fondaparinux sodium","Number of Patients With Venous Thromboembolism at Week 4|Number of Patients Who Achieved Thromboembolism Prophylaxis at Week 4.","Masonic Cancer Center, University of Minnesota","Female","18 Years and older   (Adult, Senior)","Phase 2","44","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000503985|UMN-2006LS009|UMN-0603M82707","January 2007","January 2009","January 2009","December 2017","September 26, 2006","September 28, 2006","October 29, 2009","January 27, 2010","December 3, 2017","December 28, 2017","Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States|Crozer-Chester Medical Center, Upland, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00381888"
934,"NCT00397501","BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain","null","Withdrawn","No Results Available","Brain and Central Nervous System Tumors|Breast Cancer|Cognitive/Functional Effects|Drug/Agent Toxicity by Tissue/Organ|Psychosocial Effects of Cancer and Its Treatment","Biological: trastuzumab|Drug: carboplatin|Drug: methotrexate|Drug: sodium thiosulfate","Overall survival exceeding 5 months in patients with Human Epidermal growth factor Receptor 2(HER2)-negative disease|Overall survival exceeding 5 months in patients with HER2-positive disease|Overall survival|Progression-free survival|Complete response rate|Time to best response|Quality of life","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","Female","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","0","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00002188|2188|SOL-06015|OHSU-2188","October 2013","October 2013","October 2013","April 2017","November 8, 2006","November 9, 2006","null","null","April 19, 2017","April 21, 2017","","https://ClinicalTrials.gov/show/NCT00397501"
935,"NCT01500161","Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match","null","Terminated","No Results Available","Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Hodgkins Disease|Non-Hodgkins Lymphoma|Aplastic Anemia|Multiple Myeloma|Myelodysplastic Syndrome","Drug: Busulfan|Drug: Clofarabine|Drug: Fludarabine|Drug: Melphalan|Drug: Carmustine|Drug: Etoposide|Drug: Cytarabine","evaluate the multi-lineage hematopoietic chimerism for unrelated UCB grafts pooled from two to three cord blood units|evaluate the antitumor responses of pooled UCB transplant|Number of participants that develop Graft Versus Host Disease after pooled UCB transplant|The Infection rate seen in the participants who received a pooled UCB transplant","Texas Oncology Cancer Center","All","18 Years to 65 Years   (Adult)","Phase 2","1","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1127920","November 2011","November 2013","November 2013","November 2013","November 18, 2011","December 28, 2011","null","null","November 21, 2013","November 25, 2013","Texas Oncology, Amarillo, Texas, United States","https://ClinicalTrials.gov/show/NCT01500161"
936,"NCT02354417","A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies","null","Terminated","No Results Available","Hematologic Malignancies","Biological: Biological: ProHema-CB","Safety Profile, primarily assessed by neutrophil engraftment","Fate Therapeutics","All","1 Year to 18 Years   (Child, Adult)","Phase 1","3","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FT1050-04","December 2014","December 2016","February 2017","June 2017","September 25, 2014","February 3, 2015","null","null","June 22, 2017","June 26, 2017","City of Hope, Duarte, California, United States|Boston Children's Hospital, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT02354417"
937,"NCT00189488","Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation","null","Completed","Has Results","Graft Versus Host Disease|Hematologic Malignancies","Drug: Palifermin|Drug: Placebo|Other: Conditioning Regimen|Procedure: Allogeneic stem cell transplant|Drug: Methotrexate","Number of Participants With Severe (Grade 3 and 4) Acute Graft Versus Host Disease (GVHD)|Number of Participants With Grade 2 to 4 Acute Graft Versus Host Disease (GVHD)|Number of Participants With Day 11 Methotrexate Graft Versus Host Disease Prophylaxis Administration|Number of Participants With Severe (Grade 3 or 4) Oral Mucositis|Duration of Severe Oral Mucositis (WHO Grade 3 and 4)|Number of Participants With Parenteral or Transdermal Opioid Analgesic Use|Duration of Hospitalization|Area Under the Curve (AUC) of Mouth and Throat Soreness Score","Swedish Orphan Biovitrum|Amgen","All","18 Years and older   (Adult, Senior)","Phase 2","155","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20040213","December 2005","November 2008","August 2013","September 2014","September 15, 2005","September 19, 2005","November 25, 2009","September 15, 2014","September 12, 2014","September 15, 2014","","https://ClinicalTrials.gov/show/NCT00189488"
938,"NCT01875601","NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors","null","Completed","No Results Available","Solid Tumors|Brain Tumors|Sarcoma|Pediatric Cancers|Neuroblastoma","Biological: Recombinant human interleukin-15 (rhIL-15)|Biological: NK Cell Infusion","Toxicity|Feasibility|Antitumor activity","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","2 Years to 25 Years   (Child, Adult)","Phase 1","16","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","130152|13-C-0152","June 11, 2013","September 8, 2015","September 8, 2015","December 15, 2017","June 11, 2013","June 12, 2013","null","null","December 19, 2017","December 20, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT01875601"
939,"NCT00002600","Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer","null","Completed","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cavity Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","Female","18 Years to 65 Years   (Adult)","Phase 1","18","Other","Interventional","Primary Purpose: Treatment","CDR0000063839|JHOC-9434|NCI-V94-0544","September 1994","null","null","September 2001","November 1, 1999","April 6, 2004","null","null","April 23, 2011","April 26, 2011","Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00002600"
940,"NCT01854567","P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies","null","Active, not recruiting","No Results Available","Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma|Hodgkin's Disease","Biological: Infusion of one MPC expanded cord unit and one unexpanded cord unit|Biological: Infusion of two unexpanded cord blood units.","Time to Neutrophil and Platelet Engraftment|Proportion of subjects with neutrophil recovery at day 26, platelet recovery at day 60 and subjects alive at day 100|Percentage of patients with primary graft failure","Mesoblast, Ltd.","All","up to 65 Years   (Child, Adult)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CB-AB006|2012-0166","February 2013","February 2018","July 2018","July 2016","May 13, 2013","May 15, 2013","null","null","July 21, 2016","July 25, 2016","University of Miami Health System Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell-New York Presbyterian Hospital, New York, New York, United States|Westchester Medical Center, Valhalla, New York, United States|Case Western, Cleveland, Ohio, United States|MD Anderson Cancer Center, Houston, Texas, United States|Texas Transplant Center at Methodist Healthcare System, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT01854567"
941,"NCT00689884","Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies","null","Terminated","Has Results","Hematologic Malignancies","Drug: Pegfilgrastim","Efficacy of Pegfilgrastim in the Mobilization of Autologous Peripheral Blood Stem Cells (PBSCs), Defined as Cell Yield ≥ 3 x 10e6 CD34+/kg|Assess the Per-patient Costs Related to Pegfilgrastim Use in the Mobilization of Autologous PBSCs in 16 Study Participants.","Dartmouth-Hitchcock Medical Center","All","18 Years and older   (Adult, Senior)","","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D0546","January 2007","January 2009","January 2009","October 2011","May 30, 2008","June 4, 2008","January 16, 2012","August 31, 2012","July 31, 2012","August 31, 2012","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States","https://ClinicalTrials.gov/show/NCT00689884"
942,"NCT00935233","Study of Biomarkers in Blood and/or Tumor Tissue Samples From Patients With Ductal Carcinoma in Situ and From Healthy Volunteers","null","Unknown status","No Results Available","Breast Cancer","Genetic: DNA analysis|Genetic: polymorphism analysis|Genetic: protein analysis|Other: laboratory biomarker analysis|Other: questionnaire administration|Other: survey administration","Collection of blood and/or tumor tissue|Frequency of genetic variants that predispose women to develop ductal carcinoma in situ (DCIS)|Effect of these variants on tumor risk|Benefit of testing for these variants|Analysis of acquired genetic changes within DCIS","Queen Mary University of London|National Cancer Institute (NCI)","Female","Child, Adult, Senior","","6000","Other","Observational","","CRUK-ICICLE|CDR0000629681|EU-20895","July 2008","July 2010","null","July 2009","July 7, 2009","July 8, 2009","null","null","August 9, 2013","August 12, 2013","North Devon District Hospital, Barnstaple, England, United Kingdom|Basildon University Hospital, Basildon, England, United Kingdom|Cumberland Infirmary, Cambridge, England, United Kingdom|Colchester General Hospital, Colchester, England, United Kingdom|Dartford & Gravesham NHS Trust, Joyce Green Hospital, Dartford Kent, England, United Kingdom|Dorset County Hospital, Dorchester, England, United Kingdom|Northwick Park Hospital, Harrow, England, United Kingdom|West Middlesex University Hospital, Isleworth, England, United Kingdom|Barts and the London School of Medicine, London, England, United Kingdom|Helen Rollason Cancer Care Centre at North Middlesex Hospital, London, England, United Kingdom|Cancer Research UK Clinical Groups at Guy's King's & St. Thomas' Hospitals, London, England, United Kingdom|King's College Hospital, London, England, United Kingdom|Charing Cross Hospital, London, England, United Kingdom|Mount Vernon Cancer Centre at Mount Vernon Hospital, Northwood, England, United Kingdom|Princess Royal University Hospital, Orpington, Kent, England, United Kingdom|Southend University Hospital NHS Foundation Trust, Westcliff-On-Sea, England, United Kingdom|Dumfries & Galloway Royal Infirmary, Dumfries, Scotland, United Kingdom|Bronglais District General Hospital, Aberystwyth, Wales, United Kingdom","https://ClinicalTrials.gov/show/NCT00935233"
943,"NCT02386332","A Randomized Multicenter Study to Compare Two Types of Transplant in Adult Patients With Hematologic Malignancies","null","Not yet recruiting","No Results Available","Hematologic Malignancies","Procedure: transplantation","Disease-Free Survival (DFS)","Instituto de Investigacion Sanitaria La Fe","All","18 Years to 55 Years   (Adult)","Phase 3","206","Other","Observational","Time Perspective: Prospective","TPH","March 2015","February 2020","March 2020","March 2015","February 26, 2015","March 11, 2015","null","null","March 5, 2015","March 11, 2015","","https://ClinicalTrials.gov/show/NCT02386332"
944,"NCT00588510","Detection of Circulating Osteosarcoma Tumor Cells in the Blood of Patients Using the Polymerase Chain Reaction","null","Completed","No Results Available","Osteosarcoma","Other: Blood draw","To determine if circulating osteosarcoma cells can be reliably detected and quantitated in the blood of patients with localized and advanced osteosarcoma.|To determine the frequency circulating osteosarcoma cells can be detected in the blood of patients at diagnosis, during therapy, at the completion of all planned therapy and at relapse.|To determine if the presence of circulating osteosarcoma tumor cells is associated with patient outcome.","Memorial Sloan Kettering Cancer Center","All","3 Years and older   (Child, Adult, Senior)","","59","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","99-120","January 2000","September 2011","September 2011","September 2011","December 24, 2007","January 8, 2008","null","null","September 1, 2011","September 2, 2011","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00588510"
945,"NCT00003852","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors","null","Terminated","No Results Available","Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Ovarian Cancer|Testicular Germ Cell Tumor","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: epirubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: paclitaxel|Drug: thiotepa|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","","UNICANCER","All","15 Years to 120 Years   (Child, Adult, Senior)","Phase 2","45","Other","Interventional","Primary Purpose: Treatment","CDR0000067015|FRE-FNCLCC-GETUG-04|EU-99004","March 1998","March 2000","March 2000","June 2016","November 1, 1999","January 27, 2004","null","null","June 22, 2016","June 23, 2016","Centre Paul Papin, Angers, France|CHR de Besancon - Hopital Jean Minjoz, Besancon, France|Institut Bergonie, Bordeaux, France|Centre Regional Francois Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France|CHR de Grenoble - La Tronche, Grenoble, France|Clinique Saint Michel, La Rochelle, France|Centre Leon Berard, Lyon, France|Institut J. Paoli and I. Calmettes, Marseille, France|Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hopital d'Instruction des Armees du Val de Grace, Paris, France|Institut Jean Godinot, Reims, France|Centre Henri Becquerel, Rouen, France|Centre Rene Huguenin, Saint Cloud, France|Hopitaux Universitaire de Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif, France","https://ClinicalTrials.gov/show/NCT00003852"
946,"NCT00739141","Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.","null","Recruiting","No Results Available","Leukemia|Myelodysplastic Syndrome|Non-Hodgkins Lymphoma|Chronic Myelogenous Leukemia|Hodgkins Lymphoma","Other: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft","To obtain a preliminary estimate of disease-free survival at 1 year post UCBT.|The speed of neutrophil and platelet recovery post allograft|The incidence and speed of donor-derived engraftment and contribution of each UCB unit to engraftment.","Memorial Sloan Kettering Cancer Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-087","August 2008","August 2018","August 2018","September 2017","August 19, 2008","August 21, 2008","null","null","September 6, 2017","September 7, 2017","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00739141"
947,"NCT01697527","Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies","null","Recruiting","No Results Available","Malignant Neoplasm","Biological: aldesleukin|Drug: fludarabine phosphate|Drug: cyclophosphamide|Other: laboratory biomarker analysis|Biological: NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Biological: dendritic cell vaccine therapy|Radiation: fludeoxyglucose F 18|Procedure: positron emission tomography","Clinical response|NY-ESO-1 TCR transgenic cell persistence, quantitated in PBMC samples|NY-ESO-1 TCR transgenic cell tumor trafficking","Jonsson Comprehensive Cancer Center","All","16 Years and older   (Child, Adult, Senior)","Phase 2","22","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-000153|NCI-2012-01548","November 2, 2012","November 2, 2018","November 2, 2019","September 2017","September 28, 2012","October 2, 2012","null","null","September 12, 2017","September 13, 2017","University of California at Los Angeles (UCLA ), Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT01697527"
948,"NCT00003944","Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","null","Completed","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: paclitaxel|Drug: topotecan hydrochloride|Procedure: peripheral blood stem cell transplantation","","Fox Chase Cancer Center|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","3","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000067137|FCCC-98030|NCI-G99-1536","August 1998","December 1999","February 2003","April 2013","November 1, 1999","May 25, 2004","null","null","April 16, 2013","April 17, 2013","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00003944"
949,"NCT01894256","Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function","null","Completed","Has Results","Solid Tumours","Drug: Olaparib tablet dosing","Cmax of Olaparib|AUC of Olaparib|AUC0-t of Olaparib|Tmax of Olaparib|Vz/F of Olaparib|CL/F of Olaparib|CLR of Olaparib|t1/2 of Olaparib","AstraZeneca","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","56","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","D0816C00006|2013-002225-30","November 2013","March 2015","February 2016","August 2016","July 4, 2013","July 10, 2013","March 18, 2016","April 19, 2016","August 19, 2016","October 13, 2016","Research Site, Brussels (Jette), Belgium|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Wilrijk, Belgium|Research Site, Herlev, Denmark|Research Site, København Ø, Denmark|Research Site, Bordeaux, France|Research Site, Dijon, France|Research Site, Amsterdam, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Newcastle Upon Tyne, United Kingdom|Research Site, Surrey, United Kingdom","https://ClinicalTrials.gov/show/NCT01894256"
950,"NCT01627314","The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.","null","Terminated","No Results Available","Hematologic Malignancies","Biological: ProHema-CB|Biological: Untreated CB","Neutrophil engraftment/chimerism|Neutrophil engraftment","Fate Therapeutics","All","15 Years to 65 Years   (Child, Adult)","Phase 2","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FT1050-03","July 2012","February 2017","May 2017","June 2017","June 21, 2012","June 25, 2012","null","null","August 17, 2017","August 22, 2017","City of Hope, Duarte, California, United States|Emory University-Winship Cancer Institute, Atlanta, Georgia, United States|Loyola University Medical Center, Maywood, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute- Hematopoietic Stem Cell Transplant Program, Boston, Massachusetts, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mount Sinai Hospital, New York, New York, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Oregon Health Sciences, Portland, Oregon, United States","https://ClinicalTrials.gov/show/NCT01627314"
951,"NCT03080883","Apixaban in Preventing Secondary Cancer Related Blood Clots in Cancer Patients Who Have Completed Anticoagulation Therapy","null","Recruiting","No Results Available","Deep Vein Thrombosis|Malignant Neoplasm|Metastatic Malignant Neoplasm|Pulmonary Embolism","Drug: Apixaban","Proportion of patients who experience at least one bleeding event|Proportion of patients who experienced at least one bleeding event|Venous thromboembolism recurrence","Academic and Community Cancer Research United|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","370","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","ACCRU-SC-1601|NCI-2017-00325|P30CA015083","July 14, 2017","May 1, 2020","May 1, 2020","December 2017","March 10, 2017","March 15, 2017","null","null","December 5, 2017","December 7, 2017","NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Mayo Clinic, Rochester, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|FirstHealth of the Carolinas-Moore Regional Hosiptal, Pinehurst, North Carolina, United States|Marshfield Clinic, Marshfield, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT03080883"
952,"NCT01894243","Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment","null","Completed","No Results Available","Solid Tumours","Drug: Olaparib tablet dosing","Pharmacokinetics of olaparib: maximum olaparib concentration (Cmax)|Pharmacokinetics of olaparib: time to maximum concentration (tmax)|Pharmacokinetics of olaparib: area under the plasma concentration-time curve from zero to the last measurable time point (AUC0-t)|Pharmacokinetics of olaparib: area under the plasma concentration-time curve from zero to infinity (AUC)|Pharmacokinetics of olaparib: apparent plasma clearance following oral administration (CL/F)|Pharmacokinetics of olaparib: terminal half-life (t½)|Pharmacokinetics of olaparib : apparent volume of distribution (Vz/F)|Pharmacokinetics of olaparib : terminal rate constant (λz)|Determine safety and tolerability of olaparib by recording adverse events|Determine safety and tolerability of olaparib by assessment of 12 lead Electrocardiograms|Determine safety and tolerability of olaparib by physical examination|Determine safety and tolerability of olaparib by assessment of vital signs|Determine safety and tolerability of olaparib by assessment of body temperature|Determine safety and tolerability of olaparib by assessment of clinical chemistry results|Determine safety and tolerability of olaparib by assessment of haematology results|Determine safety and tolerability of olaparib by assessment of urinalysis results","AstraZeneca","All","18 Years to 130 Years   (Adult, Senior)","Phase 1","53","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","D0816C00005|2013-002246-37","March 13, 2014","December 1, 2016","March 30, 2017","April 2017","July 4, 2013","July 10, 2013","null","null","April 13, 2017","April 14, 2017","Research Site, Brno, Czech Republic|Research Site, Bordeaux Cedex, France|Research Site, Bordeaux, France|Research Site, Dijon, France|Research Site, Grenoble cedex 9, France|Research Site, Lyon Cedex 8, France|Research Site, Paris Cedex 13, France|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Maastricht, Netherlands|Research Site, London, United Kingdom|Research Site, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01894243"
953,"NCT01745913","Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies","null","Terminated","Has Results","Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Acute Lymphocytic Leukemia|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma","Device: CliniMACS® CD34 Reagent System|Drug: Fludarabine|Drug: Melphalan|Drug: Rabbit ATG|Procedure: Double Umbilical Cord Blood Transplantation|Procedure: Haplo-Identical Cord Transplantation","Rate of Neutrophil Engraftment After Combined Haplo-identical Cord With That of Umbilical Cord Blood Transplantation.|Platelet Recovery After Transplant Regimens|Transfusion Requirements After Haplo-identical Umbilical Cord Blood Transplant Versus Double Umbilical Cord Blood Transplant|Transplant-related Mortality (TRM), Relapse Rate, Survival and Progression Free Survival|Incidence of Acute and Chronic GVHD|Severity of Opportunistic Infections","Weill Medical College of Cornell University","All","18 Years and older   (Adult, Senior)","Phase 2","2","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1205012374","October 26, 2012","April 29, 2015","April 29, 2015","August 2017","December 6, 2012","December 10, 2012","March 2, 2017","August 9, 2017","August 3, 2017","August 9, 2017","Weill Cornell Medical College, New York, New York, United States","https://ClinicalTrials.gov/show/NCT01745913"
954,"NCT01679847","Blood Brain Barrier Penetration and Pharmacokinetics of the Elemene in Malignant Patients.","null","Unknown status","No Results Available","Cancer","","blood and cerebrospinal fluid concentration","Dalian Holley Kingkong Pharmaceutical Co., Ltd","All","Child, Adult, Senior","Phase 1","8","Industry","Observational","Observational Model: Case-Only","HSZL201001","September 2012","April 2013","June 2013","September 2012","September 3, 2012","September 6, 2012","null","null","September 7, 2012","September 10, 2012","Huashan Hospital of Fudan University, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT01679847"
955,"NCT02512666","Non Invasive Optical Imaging of WBC Count","null","Completed","No Results Available","Hematologic Malignancy","Device: AM4113-N5UT Dino-Lite","Video of nail-fold imaging captured by capillaroscope","Massachusetts General Hospital","All","18 Years and older   (Adult, Senior)","","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","15-070","September 2015","September 2017","September 2017","September 2017","July 28, 2015","July 31, 2015","null","null","September 28, 2017","October 2, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT02512666"
956,"NCT02132858","Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation","null","Recruiting","No Results Available","Mucinous Adenocarcinoma of the Rectum|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Rectum|Stage IIA Rectal Cancer|Stage IIB Rectal Cancer|Stage IIC Rectal Cancer|Stage IIIA Rectal Cancer|Stage IIIB Rectal Cancer|Stage IIIC Rectal Cancer","Other: cytology specimen collection procedure|Other: laboratory biomarker analysis","Proportion of the randomly chosen samples that are successfully sequenced|Tumor response measured using the tumor regression grading system|Tumor heterogeneity in patients with partial response to radiation","Fox Chase Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","40","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CGI-066|NCI-2014-00719|P30CA006927","July 2014","July 2018","July 2020","September 2017","May 6, 2014","May 7, 2014","null","null","September 8, 2017","September 11, 2017","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT02132858"
957,"NCT00038779","Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States","null","Terminated","No Results Available","Leukemia|Non Hodgkin's Lymphoma|Aplastic Anemia","Procedure: Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation","","M.D. Anderson Cancer Center","All","up to 49 Years   (Child, Adult)","","7","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DM96-122","August 1996","September 2004","September 2004","August 2012","June 5, 2002","June 7, 2002","null","null","August 3, 2012","August 6, 2012","MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00038779"
958,"NCT01101412","Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies","null","Withdrawn","No Results Available","Chronic Myeloproliferative Disorders|Infection|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Unspecified Adult Solid Tumor, Protocol Specific","Drug: Edetate Calcium Disodium|Drug: Ethanol|Drug: Trimethoprim-sulfamethoxazole|Other: Hypertonic Saline","Incidence of occlusion as defined by the inability to infuse or withdraw 3 cc of saline from the catheter|Time to development of a catheter-related bloodstream infections during the period of lock therapy administration|Adverse events","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","2009-0237|MDA-2009-0237|CDR0000668850","null","null","null","February 2013","April 9, 2010","April 12, 2010","null","null","February 13, 2013","February 15, 2013","","https://ClinicalTrials.gov/show/NCT01101412"
959,"NCT00826384","Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion","null","Completed","No Results Available","Hepatocellular Carcinoma","Procedure: balloon catheter","Overall survival","Eastern Hepatobiliary Surgery Hospital","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","352","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","EHBH-RCT-2008-001","October 2008","December 2009","December 2010","March 2016","January 21, 2009","January 22, 2009","null","null","March 30, 2016","April 1, 2016","Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT00826384"
960,"NCT00763490","Trial Of Double Umbilical Cord Blood Transplantation","null","Completed","Has Results","Hematological Malignancies","Procedure: Full intensity, double umbilical cord, stem cell transplant|Drug: Flu/Bu4 conditioning regimen|Radiation: Total Lymphoid Irradiation (TLI)|Drug: Graft versus Host Disease prevention (GVHD prophylaxis)|Drug: Mycophenolate Mofetil","Percentage of Participants Alive at 1 Year After Transplant|Percentage of Patients Alive at the End of the Trial|Cumulative Incidence of Neutrophil and Platelet Engraftment|Incidence of Acute (Grade II-IV) and Chronic Graft-vs-host Disease(GVHD)","University of Michigan Cancer Center|Otsuka Pharmaceutical Development & Commercialization, Inc.","All","up to 65 Years   (Child, Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","umcc 2007.137|HUM00017515","December 2008","March 2013","October 2015","November 2016","September 30, 2008","October 1, 2008","January 5, 2015","January 12, 2015","November 3, 2016","December 23, 2016","University of Michigan Cancer Center, Ann Arbor, Michigan, United States","https://ClinicalTrials.gov/show/NCT00763490"
961,"NCT02804945","Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies","null","Recruiting","No Results Available","Blood And Marrow Transplantation|Adult Respiratory Distress Syndrome","Biological: Mesenchymal Stem Cells (MSCs)|Other: Standard of Care Treatment","Infusional Toxicity Between ARDs Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) Versus ARDs Participants Who Receive Standard of Care Treatment","M.D. Anderson Cancer Center|Katz Foundation","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2015-0327|NCI-2016-01184","February 24, 2017","February 2019","February 2019","September 2017","June 15, 2016","June 17, 2016","null","null","September 11, 2017","September 13, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT02804945"
962,"NCT01175785","Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies","null","Completed","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes","Procedure: umbilical cord blood transplantation|Drug: fludarabine phosphate|Drug: cyclophosphamide|Procedure: ex vivo-expanded cord blood progenitor cell infusion|Radiation: total-body irradiation|Drug: cyclosporine|Drug: mycophenolate mofetil|Other: laboratory biomarker analysis","Time to neutrophil engraftment|Time to platelet engraftment|Overall survival|Event-free survival|Incidence of severe (grades 3-4) acute GVHD|Incidence of grade greater than or equal to 3 infusional toxicity|Primary graft failure|Secondary graft failure","Fred Hutchinson Cancer Research Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)","All","6 Months to 45 Years   (Child, Adult)","Phase 2","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2378.00|NCI-2010-01426|2378|P30CA015704|RC2HL101844","August 2010","August 2014","null","April 2017","August 3, 2010","August 5, 2010","null","null","April 5, 2017","April 6, 2017","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT01175785"
963,"NCT00002948","High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer","null","Terminated","No Results Available","Unspecified Adult Solid Tumor, Protocol Specific","Biological: filgrastim|Drug: topotecan hydrochloride|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","","Yale University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000065416|YALE-HIC-9042|NCI-G97-1155","October 1996","January 2004","January 2004","July 2014","November 1, 1999","January 27, 2003","null","null","July 1, 2014","July 2, 2014","Yale Comprehensive Cancer Center, New Haven, Connecticut, United States","https://ClinicalTrials.gov/show/NCT00002948"
964,"NCT01728389","Intrabone Transplantation of Allogenic Peripheral Blood Stem Cells in Patients With Myeloid and Lymphoid Malignancies.","null","Unknown status","No Results Available","Leukemia|Lymphoma","Procedure: Intrabone transplantation","Neutrophil engraftment (ANC > 0,5 G/l)|Lineage chimerism of peripheral blood T-cell lymphocytes|Platelet engraftment (Plt > 20 G/l)|Adverse reactions related with intrabone transplantation procedure","Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBT-COI-01","November 2012","December 2013","April 2014","July 2013","November 13, 2012","November 19, 2012","null","null","July 23, 2013","July 24, 2013","MSC Memorial CAncer Center and Institute of Oncology, Gliwice, Poland","https://ClinicalTrials.gov/show/NCT01728389"
965,"NCT01052818","Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung Cancer","null","Unknown status","No Results Available","Circulating Tumor Cells","","Response rate, progression-free survival and over-all survival|Quantification of CTCs","National Institute of Cancerología","All","18 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","INCAN/OfCA204/SO151/CB451/09|87453","July 2007","August 2008","null","January 2010","January 18, 2010","January 20, 2010","null","null","January 18, 2010","January 20, 2010","National Institute of Cancerologia, Mexico City, Distrito Federal, Mexico","https://ClinicalTrials.gov/show/NCT01052818"
966,"NCT00248430","Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer","null","Completed","No Results Available","Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm","Biological: aldesleukin|Biological: therapeutic allogeneic lymphocytes|Drug: melphalan|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Feasibility|Toxicity|Extent, degree, and duration of donor chimerism|Complete response rate","Fred Hutchinson Cancer Research Center","All","18 Years to 69 Years   (Adult, Senior)","Phase 1|Phase 2","20","Other","Interventional","Primary Purpose: Treatment","1838.00|FHCRC-1838.00|CDR0000430694","August 2003","null","July 2007","September 2010","November 3, 2005","November 4, 2005","null","null","September 20, 2010","September 21, 2010","Seattle Cancer Care Alliance, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00248430"
967,"NCT01233479","Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy","null","Withdrawn","No Results Available","Brain and Central Nervous System Tumors","Drug: systemic chemotherapy|Other: laboratory biomarker analysis|Procedure: therapeutic surgical procedure|Radiation: radiation therapy","Peripherally circulating T-regulatory (T-reg) cells in patients with medulloblastoma or Chiari malformation|Longitudinal side effects of standard radiotherapy and chemotherapy regimens on the overall population of lymphocytes as well as the fraction of circulating T-reg cells|Effect of treatment on lymphocytes and T-reg cells|Baseline fraction of circulating T-reg cells","Pediatric Brain Tumor Consortium|National Cancer Institute (NCI)","All","4 Years to 21 Years   (Child, Adult)","","0","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Basic Science","CDR0000673892|PBTC-N11","May 2010","July 2011","null","October 2012","November 2, 2010","November 3, 2010","null","null","October 19, 2012","October 23, 2012","Childrens Hospital Los Angeles, Los Angeles, California, United States|Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|NCI - Pediatric Oncology Branch, Bethesda, Maryland, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Duke Cancer Institute, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT01233479"
968,"NCT00006126","Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery","null","Withdrawn","No Results Available","Breast Cancer|Kidney Cancer|Lung Cancer|Melanoma (Skin)|Testicular Germ Cell Tumor","Drug: busulfan|Drug: cyclophosphamide|Drug: etoposide|Drug: fludarabine phosphate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","","Northwestern University|National Cancer Institute (NCI)","All","up to 59 Years   (Child, Adult)","Phase 1","0","Other|NIH","Interventional","Primary Purpose: Treatment","NU 99H2|NU-99H2|NCI-G00-1838","September 1999","April 2001","April 2001","November 2015","August 3, 2000","March 8, 2004","null","null","November 10, 2015","November 13, 2015","","https://ClinicalTrials.gov/show/NCT00006126"
969,"NCT01816230","Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM","null","Active, not recruiting","No Results Available","Hematological Malignancies|Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS)","Drug: NiCord®","Engraftment","Gamida Cell ltd","All","12 Years to 65 Years   (Child, Adult)","Phase 1|Phase 2","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GC P#03.01.020","April 2013","June 2017","June 2018","August 2017","March 19, 2013","March 22, 2013","null","null","December 31, 2017","January 3, 2018","Cedars-Sinai Medical Center, Los Angeles, California, United States|Loyola University, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States|University of Minnesota, Minneapolis, Minnesota, United States|Steven and Alexandra Cohen Children's Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Vanderbilt, Nashville, Tennessee, United States|Children Hospital Gaslini Scientific Institute, Genoa, Italy|University of Turin, Turin, Italy|University Medical Center Utrecht, Utrecht, Netherlands|National University Cancer Institute, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|University Hospital Vall d´Hebron, Barcelona, Spain|Hospital Universitario La Fe, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01816230"
970,"NCT03240861","Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer","NYESO SCT","Recruiting","No Results Available","HLA-A*0201 Positive Cells Present|Locally Advanced Malignant Neoplasm|NY-ESO-1 Positive|Unresectable Malignant Neoplasm","Other: 18F-FHBG|Biological: Aldesleukin|Drug: Busulfan|Biological: Cellular Therapy|Procedure: Computed Tomography|Biological: Filgrastim|Drug: Fludarabine|Procedure: Leukapheresis|Drug: Plerixafor|Procedure: Positron Emission Tomography","Incidence of dose limiting toxicity|Detection of replication competent retrovirus and replication competent lentivirus|Duration of overall complete response|Duration of overall response|Persistence of transduced T cells|Engraftment and persistence of transduced progeny T cells|Engraftment and persistence of transduced T cells and progeny T cells|Feasibility of generation NY-ESO-1 TCR transgenic T cells and NY-ESO-1 TCR/sr39TK transgenic stem cells that meet the lot release criteria|Immunological monitoring will consist primarily of quantifying T cells bearing surface NY-ESO-1 TCR|Objective response|Persistence of TCR gene transduced cells|Time to disease progression","Jonsson Comprehensive Cancer Center|California Institute for Regenerative Medicine|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","Phase 1","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-000511|NCI-2017-00896|Ribas NYESO SCT Cancer|P30CA016042","July 26, 2017","September 1, 2021","September 1, 2022","June 2017","June 22, 2017","August 7, 2017","null","null","November 3, 2017","November 7, 2017","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT03240861"
971,"NCT01172912","High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy","null","Unknown status","No Results Available","Brain and Central Nervous System Tumors|Extragonadal Germ Cell Tumor|Testicular Germ Cell Tumor","Biological: filgrastim|Biological: pegfilgrastim|Drug: carboplatin|Drug: cisplatin|Drug: dexamethasone|Drug: etoposide|Drug: ifosfamide|Other: high-dose chemotherapy with autologous stem cell rescue|Other: laboratory biomarker analysis|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Efficacy|Toxicity|Biological correlates of outcome","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Senior)","Phase 2","47","Other","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","ITA-MIL-INT-38-10|CDR0000682204|EUDRACT-2010-021898-36|EU-21054","October 2010","October 2012","null","August 2011","July 29, 2010","July 30, 2010","null","null","August 9, 2013","August 12, 2013","Fondazione Istituto Nazionale dei Tumori, Milan, Italy","https://ClinicalTrials.gov/show/NCT01172912"
972,"NCT01930162","Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant","UCBT","Completed","Has Results","Single Umbilical Cord Blood Transplantation|Non-myeloablative Conditioning|Acute Lymphocytic Leukemia|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma|Multiple Myeloma|Chronic Lymphocytic Leukemia","Drug: HSC835","Absence of Graft Failure at Day 42|Incidence of Neutrophil Recovery Within 42 Days|Incidence of Non-relapse Mortality (NRM) Within 100 Days and One Year|Incidence of Overall Survival Within One Year|Incidence of Relapse-free Survival Within One Year","Novartis Pharmaceuticals|Novartis","All","Child, Adult, Senior","Phase 2","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CHSC835X2202","October 7, 2014","August 29, 2016","August 29, 2016","August 2017","August 23, 2013","August 28, 2013","July 12, 2017","August 10, 2017","August 31, 2017","September 29, 2017","Novartis Investigative Site, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT01930162"
973,"NCT00005796","Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors","null","Completed","No Results Available","Bone Marrow Suppression|Brain and Central Nervous System Tumors|Drug/Agent Toxicity by Tissue/Organ","Procedure: filgrastim|Biological: gene therapy|Drug: lomustine|Drug: procarbazine hydrochloride|Drug: vincristine sulfate|Procedure: in vitro-treated peripheral blood stem cell transplantation","Determine the toxicity (detection of replication competent retrovirus) associated with CD34+ cells transduced with a retroviral vector expressing human O6-methylguanine DNA methyltransferase in adult and pediatric patients with poor prognosis CNS tumors.","Indiana University|Indiana University Melvin and Bren Simon Cancer Center","All","5 Years and older   (Child, Adult, Senior)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9607-22|IUMC-9607-22|NCI-H00-0049","February 2000","June 2003","December 2011","March 2015","June 2, 2000","April 28, 2004","null","null","March 23, 2015","March 25, 2015","Indiana University Cancer Center, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT00005796"
974,"NCT01882374","Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation","null","Withdrawn","No Results Available","Hematologic Malignancies","Drug: TXA127","Incidence of Grade II-IV acute graft-vs-host disease (aGVHD)|Incidence, severity, and duration of mucositis|Neutrophil engraftment and platelet recovery|Platelet transfusion requirements|Immune reconstitution|Duration of corticosteroid use","Tarix Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","TXA127-2012-01","December 2013","December 2013","December 2013","August 2016","June 17, 2013","June 20, 2013","null","null","August 29, 2016","August 31, 2016","University of Virginia Cancer Center, Charlottesville, Virginia, United States","https://ClinicalTrials.gov/show/NCT01882374"
975,"NCT00977509","Gene Mutations in Non-Small Cell Lung Cancer Cells","null","Unknown status","No Results Available","Carcinoma, Non-Small-Cell Lung","","To determine the frequency of individual genetic abnormality in advanced non-small cell lung cancer (NSCLC) patients who will commence systemic therapy.|To determine the frequency with which molecular profiling of a NSCLC patient's tumor by DNA sequencing and/or FISH yields a target against which there is approved or investigational therapeutic regimen.|To determine the response rate according to RECIST, progression-free, and overall survival in patients with advanced NSCLC whose therapy is selected by molecular profile.","National Taiwan University Hospital","All","20 Years and older   (Adult, Senior)","","200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","200812092R","November 2009","December 2014","December 2014","November 2013","September 10, 2009","September 15, 2009","null","null","November 29, 2013","December 2, 2013","National Taiwan University Hospital, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT00977509"
976,"NCT01882387","Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation","null","Withdrawn","No Results Available","Hematologic Malignancies","Drug: TXA127","Incidence of Grade II-IV acute graft-vs-host disease (aGVHD)|Incidence, duration, and severity grade of mucositis|Neutrophil engraftment and platelet recovery|Platelet transfusion requirements|Immune reconstitution|Duration of corticosteroid use","Tarix Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","TXA127-2012-02","December 2013","December 2013","December 2013","August 2016","June 17, 2013","June 20, 2013","null","null","August 29, 2016","August 31, 2016","Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Siteman Cancer Center, St Louis, Missouri, United States","https://ClinicalTrials.gov/show/NCT01882387"
977,"NCT01408524","Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol and Diltiazem","null","Completed","No Results Available","Hypertension|Craniotomy","Drug: Diltiazem|Drug: Labetalol","The number of the patients who have systolic blood pressure below 140 mmHg|mean doses of the study drugs|the number of patients with Adverse Events as a Measure of Safety and Tolerability","Mahidol University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","184","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","594/2552(EC4)","February 2010","November 2012","December 2013","March 2014","July 11, 2011","August 3, 2011","null","null","March 31, 2014","April 1, 2014","","https://ClinicalTrials.gov/show/NCT01408524"
978,"NCT00897624","Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma","null","Completed","No Results Available","Intraocular Melanoma","Genetic: gene expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: laboratory biomarker analysis","Detection of micro-metastatic cells in 20 x 10^6 nucleated cells","Institut Curie|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","15","Other","Observational","","CDR0000633500|CLCC-IC-Micrometa-Melanome|CLCC-IC-2007-03|INCA-RECF0631","November 2007","May 2011","null","May 2011","May 9, 2009","May 12, 2009","null","null","May 12, 2011","May 13, 2011","","https://ClinicalTrials.gov/show/NCT00897624"
979,"NCT00891722","Tumor Tissue, Blood Samples, and Family History in Predicting Tumor Development and Response to Treatment in Young Patients With Low-Grade Glioma","null","Unknown status","No Results Available","Brain and Central Nervous System Tumors","Other: biologic sample preservation procedure|Other: laboratory biomarker analysis|Other: questionnaire administration","Identification of factors that could determine different patterns of tumor development, natural tumor behavior, and tumor sensitivity to therapies","Children's Cancer and Leukaemia Group|National Cancer Institute (NCI)","All","Child, Adult, Senior","","900","Other","Observational","","CDR0000614912|CCLG-CNS-2007-13-TRANSCAL|EU-20879","August 2008","null","null","June 2009","April 30, 2009","May 1, 2009","null","null","August 23, 2013","August 26, 2013","Queen's Medical Centre, Nottingham, England, United Kingdom","https://ClinicalTrials.gov/show/NCT00891722"
980,"NCT00838019","Intrabone Cord Blood Transplantation","null","Unknown status","No Results Available","Hematological Malignancies","Procedure: Intrabone administration of umbilical cord blood","Kinetics of hematopoietic engraftment|Dynamics and chimerism of hematological engraftment","Hospital Clinic of Barcelona","All","18 Years to 60 Years   (Adult)","Phase 4","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TPH/SCU-IMed 01/08","February 2009","February 2011","February 2011","February 2009","February 5, 2009","February 6, 2009","null","null","February 5, 2009","February 6, 2009","BMT Unit Hematology Department Hospital Clinic, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT00838019"
981,"NCT02668315","Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant","null","Recruiting","No Results Available","Hematologic Malignancy","Biological: Transplantation of cord blood expanded with UM171","Monitoring adverse events, toxicities and medical evolution|Feasibility of cord blood expansion using UM171 (transplant success)|Kinetics of hematopoietic recovery|Minimal cord blood cell dose that when expanded achieves prompt engraftment|Correlation between neutrophil and platelet engraftment and CD34+ and CD34+CD45RA- dose|Incidence of primary and late graft failure|Incidence of backup cord infusion and graft dominance|Incidence of acute and chronic GVHD|Incidence of severe infectious complications|T cell evaluation (Cluster of differentiation (CD) 4+ and CD8+)|B cell evaluation|Natural Killer (NK) cell evaluation|Transplant related mortality (TRM)|progression free survival|Overall survival|Incidence of engraftment syndrome requiring therapy","Maisonneuve-Rosemont Hospital|Canadian Cancer Society Research Institute (CCSRI)|Canadian Institutes of Health Research (CIHR)|Hopital de l'Enfant-Jesus|Vancouver General Hospital|St. Justine's Hospital|Stem Cell Network (SCN)","All","3 Years to 64 Years   (Child, Adult)","Phase 1|Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UM0128171","January 2016","June 2018","January 2021","May 2017","January 15, 2016","January 29, 2016","null","null","May 8, 2017","May 9, 2017","Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT02668315"
982,"NCT00028782","EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer","null","Terminated","No Results Available","Advanced Malignant Mesothelioma|Localized Malignant Mesothelioma|Malignant Ascites|Primary Peritoneal Cavity Cancer|Recurrent Malignant Mesothelioma","Drug: etanidazole|Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis","Level of hypoxia in tumor nodules|Inter- and intra-patient variability of hypoxia by EF5 binding|Levels of microvascular density by PECAM/CD31 staining|Relationships among levels of hypoxia, microvascular density, and photosensitizer levels|Associations between hypoxia and photosensitizer levels in tumor nodules with clinical outcome periodically until disease recurrence|Toxicity of EF5 administration","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","80","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NCI-2012-02438|UPCC# 05901|P01CA087971|CDR0000069134","October 2001","September 2007","null","January 2013","January 4, 2002","January 27, 2003","null","null","January 15, 2013","January 16, 2013","Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00028782"
983,"NCT00027937","Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma","null","Completed","No Results Available","Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific","Biological: aldesleukin|Biological: filgrastim|Biological: sargramostim|Drug: busulfan|Drug: cyclophosphamide|Drug: melphalan|Drug: paclitaxel|Drug: thiotepa|Procedure: bone marrow ablation with stem cell support|Procedure: in vitro-treated peripheral blood stem cell transplantation","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 56 Years   (Child, Adult)","Phase 2","null","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","1595.00|FHCRC-1595.00|IMMUNEX-FHCRC-1595.00|NCI-G01-2037|CDR0000069095","August 2001","null","November 2007","May 2010","December 7, 2001","January 27, 2003","null","null","May 12, 2010","May 14, 2010","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00027937"
984,"NCT00433602","Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors","null","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Gastric Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer|Thromboembolism","Other: clinical observation|Procedure: management of therapy complications|Procedure: ultrasound imaging","Incidence of asymptomatic proximal deep vein thrombosis (DVT) of the lower limbs as assessed by bilateral compression ultrasound at baseline and at 3 months|Incidence of symptomatic, proximal and/or distal DVT of the lower limbs as assessed by clinical diagnosis and compression ultrasound within 72 hours of detection of symptoms (during the 3-month observation period)|Incidence of symptomatic pulmonary embolism as assessed by ventilation/perfusion lung scan, pulmonary angiogram, or CT lung scan within 72 hours of detection of symptoms or during autopsy (during the 3-month observation period)","European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","","64","Other","Observational","","EORTC-90051|SANOFI-AVENTIS-EORTC-90051","November 2006","March 2007","null","June 2013","February 8, 2007","February 12, 2007","null","null","June 11, 2013","June 12, 2013","Slotervaart Ziekenhuis, Amsterdam, Netherlands","https://ClinicalTrials.gov/show/NCT00433602"
985,"NCT00897793","Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer","null","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Prostate Cancer","Procedure: venipuncture|Radiation: radiation therapy","TGF-beta levels","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","25","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","VICC RAD 0576|P30CA068485|VU-VICC-RAD-0576","January 2006","July 2010","July 2010","April 2013","May 9, 2009","May 12, 2009","null","null","April 10, 2013","April 12, 2013","Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT00897793"
986,"NCT01483859","Prediction of Intraoperative Blood Loss and Postoperative Recovery by Liver Stiffness Measurement (Fibroscan®) in Right Hepatectomy","null","Completed","No Results Available","Liver Malignancy","Other: preoperative liver stiffness measurement","The correlation between the value of liver stiffness measurement and intraoperative blood loss during right hepatectomy","Yonsei University","All","20 Years to 80 Years   (Adult, Senior)","","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","1-2011-0053","September 2011","December 2011","December 2012","July 2015","November 24, 2011","December 1, 2011","null","null","July 14, 2015","July 16, 2015","Severance Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT01483859"
987,"NCT00429416","Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation","null","Completed","Has Results","Hematologic Malignancies","Drug: L-leucyl-L-leucine Methyl Ester (LLME)|Drug: Fludarabine|Drug: Cytarabine|Drug: Cyclophosphamide|Drug: Tacrolimus|Drug: Mesna|Biological: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|Procedure: Hematopoietic stem cell transplantation (HSCT)","Safety of CD34+ Stem Cell Infusions Followed by LLME as Measured by 100-Day Mortality|Rate of Engraftment of Non-Myeloablative Transplants|Incidence of Grade II-IV Acute Graft-Versus-Host-Disease (GVHD)|Rate of Serious Infectious Complications|Number of Patients Who Achieve a CD4 Count > 200/Micro-liters","Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04U.115|2003-68","March 2004","December 2008","May 2009","October 2016","January 29, 2007","January 31, 2007","July 19, 2013","December 10, 2013","October 19, 2016","November 29, 2016","Thomas Jefferson University`, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00429416"
988,"NCT02904161","Detection of Circulating Tumor Cells in Peripheral Blood From Healthy Volunteers and Patients With Cancer","null","Completed","No Results Available","Circulating Tumor Cells (CTCs)","","Overall Survival","MiCareo Taiwan Co., Ltd.","All","20 Years and older   (Adult, Senior)","","137","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MCPZ12001J1","August 2012","November 2016","December 2016","September 2016","September 13, 2016","September 16, 2016","null","null","March 21, 2017","March 23, 2017","Mackay Memorial Hospital, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT02904161"
989,"NCT00253669","Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas","null","Completed","No Results Available","Brain and Central Nervous System Tumors|Thromboembolism","Other: laboratory biomarker analysis|Other: physiologic testing|Procedure: management of therapy complications","Thrombosis-free survival as assessed by objectively documented deep vein thrombosis or pulmonary embolism|ABO blood group association with venous thromboembolism (VTE) factor VIII activity and VTE as assessed by laboratory test result at study entry","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)|North American Brain Tumor Consortium","All","18 Years and older   (Adult, Senior)","","110","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","NABTT-0307 CDR0000441111|U01CA062475|NABTT-0307|JHOC-NABTT-0307","April 2005","August 2009","August 2009","May 2012","November 11, 2005","November 15, 2005","null","null","May 24, 2012","May 28, 2012","Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States|H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00253669"
990,"NCT00613652","A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients","null","Completed","No Results Available","Cancer|Tumors|Carcinoma","Drug: AZD4877","To evaluate the safety and tolerability of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies|To determine the PK profile of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies","AstraZeneca","All","20 Years to 75 Years   (Adult, Senior)","Phase 1","30","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D2782C00008","January 2008","June 2009","June 2009","July 2009","January 31, 2008","February 13, 2008","null","null","July 20, 2009","July 21, 2009","Research Site, Fukuoka, Japan","https://ClinicalTrials.gov/show/NCT00613652"
991,"NCT02079363","DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer","null","Unknown status","No Results Available","Pancreatic Diseases|Pancreatic Neoplasms|Pancreatitis","Other: No interventions, this is an observational study","Number of methylated genes for each participant.|Number of methylated genes for each participant related to prognosis","Aalborg Universitetshospital","All","18 Years and older   (Adult, Senior)","","330","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Hypmet","August 2013","August 2017","January 2018","July 2014","March 4, 2014","March 5, 2014","null","null","July 29, 2014","July 30, 2014","Research unit, Surgical Department of Gastroenterology, Aalborg University Hospital, Aalborg, Denmark","https://ClinicalTrials.gov/show/NCT02079363"
992,"NCT00275678","Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies","null","Completed","No Results Available","Blood Stem Cell Transplant","Procedure: Blood stem cell versus bone marrow transplant","Two-year survival|Neutrophil Engraftment > 500/mcl|Primary graft failure|Platelet engraftment > 20,000 and 50,000/mcl transfusion independent|Acute GVHD of grades II-IV and III-IV","Mayo Clinic|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|National Marrow Donor Program|University of Minnesota - Clinical and Translational Science Institute|University of Florida|Duke University|Ann & Robert H Lurie Children's Hospital of Chicago","All","18 Years to 66 Years   (Adult, Senior)","Phase 3","15","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2158-03","November 2003","September 2009","null","June 2010","January 10, 2006","January 12, 2006","null","null","June 2, 2010","June 3, 2010","Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00275678"
993,"NCT00460356","Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes","null","Completed","No Results Available","Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Small Cell Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Stage IB Cervical Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage III Cervical Cancer|Stage IVA Cervical Cancer","Other: Laboratory Biomarker Analysis|Procedure: Lymphadenectomy","Differences in 10 of the 300 carbohydrates under examination using the customized glycan array|Differences in approximately 50 of the 400 genes on the customized glycogene expression array|Level of immunohistochemical staining for Tn antigen and sialyl Tn antigen|Presence of T-synthase or Cosmc mutation|Local control|Lymph node metastasis|Overall survival|Progression-free survival (recurrence and disease progression)","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","","159","Other|NIH","Observational","","GOG-0221|NCI-2009-00592|CDR0000540243|U10CA180868|U10CA027469","April 2, 2007","July 16, 2016","July 16, 2016","August 2017","April 11, 2007","April 13, 2007","null","null","August 23, 2017","August 24, 2017","UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Olive View-University of California Los Angeles Medical Center, Sylmar, California, United States|Augusta University Medical Center, Augusta, Georgia, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|Women's Cancer Center of Nevada, Las Vegas, Nevada, United States|Montefiore Medical Center-Einstein Campus, The Bronx, New York, United States|Summa Akron City Hospital/Cooper Cancer Center, Akron, Ohio, United States|University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|Lake University Ireland Cancer Center, Mentor, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma, United States|Women and Infants Hospital, Providence, Rhode Island, United States","https://ClinicalTrials.gov/show/NCT00460356"
994,"NCT00611104","Studying the Effect of Freeze-Dried Table Grape Powder on Blood Estrogen Levels in Postmenopausal Women","null","Active, not recruiting","No Results Available","Breast Cancer","Dietary Supplement: standardized freeze-dried table grape powder|Other: laboratory biomarker analysis|Other: pharmacological study","Serum levels of plasma estrone (E1), estradiol, E1-conjugates, and E1-sulfates|Bioavailability of the freeze-dried table grape powder in humans","Mayo Clinic|National Cancer Institute (NCI)","Female","18 Years to 120 Years   (Adult, Senior)","","25","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CDR0000581219|P30CA015083|MC0536|06-002061","May 2008","December 2017","December 2017","April 2016","February 7, 2008","February 8, 2008","null","null","March 21, 2017","March 22, 2017","Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00611104"
995,"NCT00425334","Safety Study of Hemospan® in Prostatectomy Patients","null","Completed","No Results Available","Blood Loss, Surgical|Prostate Cancer|Surgery","Drug: Hemospan (MP4OX)|Drug: Ringer's lactate","Incidence of adverse events|Changes in oxygenation, perfusion and cardiovascular status|Number and type of cardiac rhythm disturbances|Number and duration of intraoperative hypotensive episodes|Incidence of pharmacologic interventions for cardiovascular support|Duration of supplemental oxygen use|Volume of intravenous fluid administered|Blood products administered","Sangart","Male","18 Years and older   (Adult, Senior)","Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","6012","July 2005","October 2007","November 2007","August 2013","January 18, 2007","January 22, 2007","null","null","August 15, 2013","August 19, 2013","Johns Hopkins Medical Institutions, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00425334"
996,"NCT02167958","Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source","null","Recruiting","No Results Available","Leukemia|MDS|Myelofibrosis|Lymphoma","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Mesna|Radiation: Total Body Irradiation|Other: Hematopoietic stem cell infusion|Drug: Tacrolimus|Drug: Mycophenolate|Drug: G-CSF","Acute GvHD|Chronic Graft-versus-Host Disease|Nonrelapse Mortality (NRM)|Relapse of Malignancy|Neutrophil Recovery|Primary graft failure|Secondary graft failure|Platelet recovery|Donor Cell Engraftment|Progression-free Survival|Infections","University of Pittsburgh","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-131","November 2014","July 2019","July 2020","May 2017","June 17, 2014","June 19, 2014","null","null","May 3, 2017","May 4, 2017","UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT02167958"
997,"NCT02464930","Evaluation of MicroRNA Expression in Blood and Cytology for Detecting Barrett's Esophagus and Associated Neoplasia","null","Recruiting","No Results Available","Barrett's Esophagus|Gastroesophageal Reflux|Esophageal Adenocarcinoma","","Sensitivity and specificity of tissue and serum microRNA expression by digital polymerase chain reaction for diagnosis of BE neoplasia|Differences in the microRNA expression of biliary exosomes between GERD, Barrett's esophagus and Cancer","Midwest Biomedical Research Foundation|Kansas City Veteran Affairs Medical Center|University of Kansas","All","18 Years and older   (Adult, Senior)","","220","Other|U.S. Fed","Observational","Observational Model: Case Control|Time Perspective: Prospective","AB0009","April 2015","April 2018","December 2018","June 2015","June 2, 2015","June 8, 2015","null","null","June 4, 2015","June 8, 2015","Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States","https://ClinicalTrials.gov/show/NCT02464930"
998,"NCT00897260","Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders","null","Unknown status","No Results Available","Hematological Malignancy|Bone Marrow Failure Syndrome","Drug: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|Radiation: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|Procedure: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders","To determine the safety and efficacy of multiple cord blood transplantation in patients with hematological malignancy.|To determine the 100-day treatment related mortality (TRM), complete remission rate and the 2-year progression free and overall survival rate for patients under going this treatment.|To determine the incidence of grades II-IV and grades III-IV acute GVHD and incidence of limited and extensive chronic GVHD.|To measure time to immunologic reconstitution as defined by normal numbers of T and B-cells and normal immunoglobulin synthesis|To determine rate of hematologic engraftment following umbilical cord blood transplantation with 1-2 cord blood units using total body irradiation & fludarabine as transplant conditioning regimen & cyclosporine/MMF as graft-vs-host disease prophylaxis","University of British Columbia","All","Child, Adult, Senior","","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H08-02813","May 2009","December 2012","December 2012","November 2011","May 8, 2009","May 12, 2009","null","null","November 21, 2011","November 22, 2011","Vancouver General Hospital, Leukemia/BMT Program of BC, Vancouver, British Columbia, Canada","https://ClinicalTrials.gov/show/NCT00897260"
999,"NCT00003194","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors","null","Unknown status","No Results Available","Unspecified Childhood Solid Tumor, Protocol Specific","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Drug: thiotepa|Drug: topotecan hydrochloride|Procedure: peripheral blood stem cell transplantation","","Seattle Children's Hospital|National Cancer Institute (NCI)","All","1 Year to 30 Years   (Child, Adult)","Phase 1","24","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000066029|CHMC-6006|FHCRC-1244.00|NCI-G98-1373","July 1997","null","null","March 2003","April 6, 2000","January 27, 2003","null","null","February 6, 2009","February 9, 2009","Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00003194"
1000,"NCT01050504","Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer","null","Recruiting","No Results Available","Healthy Control|Localized Urothelial Carcinoma of the Renal Pelvis and Ureter|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Neoplasm in the Soft Tissues|Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter|Recurrent Bladder Carcinoma|Recurrent Prostate Carcinoma|Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter|Stage IV Bladder Cancer|Stage IV Bladder Urothelial Carcinoma|Stage IV Prostate Cancer","Other: Cytology Specimen Collection Procedure|Other: Laboratory Biomarker Analysis","DNA genomic sequencing|Gene expression profile using microarray assays|Mutation mapping using the OncoMap and other genotyping techniques|Expression of androgen metabolic enzymes by quantitative real time-polymerase chain reaction|Proteomic profile","University of Washington|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Senior)","","300","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","6932|NCI-2014-01087|6932p|P30CA015704","August 2009","September 1, 2018","null","December 2017","September 30, 2009","January 15, 2010","null","null","December 4, 2017","December 6, 2017","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT01050504"
1001,"NCT02302885","Healthy Human Control Blood Collection for Validation of Biomarker Assay","null","Recruiting","No Results Available","Healthy","Other: Blood collection","blood count","Abramson Cancer Center of the University of Pennsylvania","All","18 Years to 60 Years   (Adult)","","70","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UPCC 42914","November 2014","November 2016","November 2016","April 2016","November 25, 2014","November 27, 2014","null","null","April 11, 2016","April 13, 2016","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT02302885"
1002,"NCT01585415","Vemurafenib and White Blood Cell Therapy for Advanced Melanoma","null","Terminated","No Results Available","Metastatic Cancer|Melanoma","Drug: Vemurafenib|Biological: Young TIL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin","Determine the safety of the administration of vemurafenib in conjunction with ACT consisting of autologous TIL infused along with high dose aldesleukin following a non-myeloablative lymphodepleting preparative regimen.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 66 Years   (Adult, Senior)","Phase 1","12","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","120114|12-C-0114","April 9, 2012","July 21, 2016","July 21, 2016","July 21, 2016","April 24, 2012","April 25, 2012","null","null","October 5, 2017","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT01585415"
1003,"NCT02585713","Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism","null","Active, not recruiting","No Results Available","Cerebral Vein Thrombosis|Deep Vein Thrombosis|Gonadal Thrombosis|Hepatic Thrombosis|Malignant Neoplasm|Mesenteric Thrombosis|Metastatic Malignant Neoplasm|Portal Vein Thrombosis|Pulmonary Embolism|Renal Vein Thrombosis|Splenic Thrombosis|Venous Thromboembolism","Drug: Apixaban|Drug: Dalteparin|Other: Questionnaire Administration","Episode of major bleeding including fatal bleeding|Incidence of bleeding event defined as a major bleed or a clinically relevant non-major bleed|Time to the first event of the composite deep vein thrombosis (DVT)/pulmonary embolism (PE)","Academic and Community Cancer Research United|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 3","315","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","RU221501I|NCI-2015-01573|CV185-444|P30CA015083","November 20, 2015","November 20, 2018","November 20, 2018","December 2017","October 22, 2015","October 23, 2015","null","null","December 28, 2017","December 29, 2017","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Cancer Research Consortium of West Michigan NCORP, Grand Rapids, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States|Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|New Hampshire Oncology Hematology PA-Hooksett, Hooksett, New Hampshire, United States|FirstHealth of the Carolinas-Moore Regional Hosiptal, Pinehurst, North Carolina, United States|Columbus NCI Community Oncology Research Program, Columbus, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Guthrie Medical Group PC-Robert Packer Hospital, Sayre, Pennsylvania, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States","https://ClinicalTrials.gov/show/NCT02585713"
1004,"NCT02118311","Treg Cells for AGVHD in Non-myeloablative UCB Transplant","null","Withdrawn","No Results Available","Hematologic Malignancies","Biological: T Regulatory cells|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total Body Irradiation","Incidence of grade II-IV acute graft-versus-host disease|Incidence of double and single unit chimerism|Incidence of grade III-IV acute graft-versus-host disease|Incidence of viral and fungal infections|Survival|Incidence of neutrophil recovery|Incidence of treatment related mortality|Incidence of platelet recovery|Incidence of chronic GVHD|Incidence of relapse","Masonic Cancer Center, University of Minnesota|National Institutes of Health (NIH)|National Cancer Institute (NCI)","All","18 Years to 69 Years   (Adult, Senior)","Phase 2","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2013LS091|MT2013-27|P01CA065493","June 2016","September 2018","September 2018","November 2017","March 26, 2014","April 21, 2014","null","null","November 29, 2017","December 1, 2017","University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT02118311"
1005,"NCT00180791","High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood","null","Unknown status","No Results Available","Medulloblastoma|Brain Tumors|Neuroectodermal Tumors, Primitive","Drug: Etoposide, carboplatin, melphalan, cisplatin, thiotepa","Response of medulloblastoma metastases to the chemotherapy regimen in children less than 5 years of age|Progression-free survival of children less than 10 years of age with brain PNET|Progression-free survival of children less than 5 years of age with metastatic medulloblastoma|Toxicity|Long term sequelae","Gustave Roussy, Cancer Campus, Grand Paris","All","up to 10 Years   (Child)","Phase 2","71","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PNET HR","July 2002","null","null","September 2006","September 9, 2005","September 16, 2005","null","null","September 17, 2007","September 18, 2007","Institut Gustave Roussy, Villejuif, France","https://ClinicalTrials.gov/show/NCT00180791"
1006,"NCT01344837","Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer","null","Not yet recruiting","No Results Available","Endometrial Serous Adenocarcinoma|Stage I Uterine Corpus Cancer|Stage II Uterine Corpus Cancer|Stage III Uterine Corpus Cancer|Stage IV Uterine Corpus Cancer","Other: Diagnostic Laboratory Biomarker Analysis|Other: Immunohistochemistry Staining Method|Other: Medical Chart Review|Genetic: Microarray Analysis|Other: Study of Socioeconomic and Demographic Variables|Genetic: Western Blotting","Overall survival|Presence of synchronous or metachronous breast cancer|Progression-free survival","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","Child, Adult, Senior","","360","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GOG-8023|NCI-2011-02872|CDR0000698458|R21CA135467|U10CA027469|U10CA037517","January 2100","January 2100","null","May 2015","April 28, 2011","April 29, 2011","null","null","May 27, 2015","May 29, 2015","Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT01344837"
1007,"NCT01652014","Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies","null","Withdrawn","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia","Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation|Procedure: double-unit umbilical cord blood transplantation|Radiation: total-body irradiation|Drug: tacrolimus|Procedure: peripheral blood stem cell transplantation","Engraftment of white blood cells (WBC) (absolute neutrophil count > 500/mm^3)|Non-relapse mortality|Platelet engraftment rate (non-transfusion dependent)|Transplant related mortality|Rates of infection requiring hospitalization or prolongation of hospitalization|Incidence of steroid-refractory acute GVHD|Incidence of extensive chronic GVHD|Total time on immunosuppressive therapy|Time to CD4 count > 200/mm^3","University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey","All","18 Years to 65 Years   (Adult)","Phase 2","0","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","021002|NCI-2011-03187|0220100266|P30CA072720","January 2014","January 2017","January 2017","July 2016","July 20, 2012","July 27, 2012","null","null","July 13, 2016","July 14, 2016","Cancer Institute of New Jersey, New Brunswick, New Jersey, United States","https://ClinicalTrials.gov/show/NCT01652014"
1008,"NCT01076270","Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","null","Terminated","Has Results","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma","Drug: plerixafor|Biological: filgrastim|Procedure: peripheral blood stem cell transplantation|Procedure: allogeneic hematopoietic stem cell transplantation","Successful Collection of Stem Cells|CD34-positive Cells Collected","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","","1","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2385.00|NCI-2010-00252","June 2010","January 2011","February 2011","June 2017","February 24, 2010","February 26, 2010","February 15, 2017","March 31, 2017","June 26, 2017","June 28, 2017","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT01076270"
1009,"NCT02197234","Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC","null","Active, not recruiting","Has Results","Non Small Cell Lung Cancer","Procedure: Pharmacokinetic sampling - AZD9291|Drug: Simvastatin|Drug: AZD9291 tablet dosing|Procedure: Pharmacokinetic sampling - simvastatin|Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550","Cmax of Simvastatin|AUC of Simvastatin|Tmax of Simvastatin and Simvastatin Acid|CL/F of Simvastatin|Cmax of Simvastatin Acid|AUC of Simvastatin Acid|AUC(0-t) of Simvastatin and Simvastatin Acid","AstraZeneca","All","18 Years to 130 Years   (Adult, Senior)","Phase 1","52","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5160C00014","December 22, 2014","April 30, 2015","January 4, 2018","September 2017","July 21, 2014","July 22, 2014","April 8, 2016","June 22, 2016","September 14, 2017","September 15, 2017","Research Site, Atlanta, Georgia, United States|Research Site, Leuven, Belgium|Research Site, Angers Cedex 9, France|Research Site, Dijon cedex, France|Research Site, Marseille, France|Research Site, Rennes, France|Research Site, Saint Herblain, France|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Badalona(Barcelona), Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT02197234"
1010,"NCT02517086","Vascular Changes Due to Different Treatments of Lymphedema Secondary to Postoperative Breast Cancer","null","Unknown status","No Results Available","Breast Cancer|Lymphedema","Other: therapeutic exercises|Other: elastic compression|Other: functional compressive bandaging","Doppler Ultrasound- velocity of blood flow","University of Sao Paulo","Female","45 Years to 60 Years   (Adult)","","3","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)","HC-FMRP nº 810616/2014","August 2015","August 2015","July 2016","August 2015","June 10, 2015","August 6, 2015","null","null","August 3, 2015","August 6, 2015","","https://ClinicalTrials.gov/show/NCT02517086"
1011,"NCT00003846","Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors","null","Completed","No Results Available","Brain and Central Nervous System Tumors|Neuroblastoma","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: thiotepa|Drug: vincristine sulfate|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Event Free Survival","Children's Oncology Group|National Cancer Institute (NCI)","All","3 Years to 21 Years   (Child, Adult)","Phase 2","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","99702|COG-99702|CCG-99702|CDR0000067006","July 1999","October 2004","March 2007","July 2014","November 1, 1999","May 25, 2004","null","null","July 25, 2014","July 28, 2014","Children's Hospital Los Angeles, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|Children's Hospital of Denver, Denver, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio, United States|Children's Hospital of Columbus, Columbus, Ohio, United States|Oregon Cancer Center at Oregon Health Sciences University, Portland, Oregon, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00003846"
1012,"NCT02197247","Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC","null","Active, not recruiting","Has Results","Non Small Cell Lung Cancer","Procedure: Pharmacokinetic sampling - AZD9291|Drug: Rifampicin|Drug: AZD9291 tablet dosing|Procedure: Pharmacokinetic sampling - rifampicin|Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550","Assessment of Maximum Plasma Concentration for AZD9291 After Dosing Alone and in Combination With Rifampicin (Css,Max)|Assessment of Area Under the Plasma Concentration-time Curve During the Dosing Interval for AZD9291 After Dosing Alone and in Combination With Rifampicin (AUCtau)|Assessment of Css,Max for AZD9291 Before and After Rifampicin|Assessment of Css,Max for AZ5104 (Metabolite)|Assessment of Css,Max for AZ7550 (Metabolite)|Assessment of Css,Max for Rifampicin|Assessment of AUCtau for AZD9291 Before and After Rifampicin|Assessment of AUCtau for AZ5104 (Metabolite)|Assessment of AUCtau for AZ7550 (Metabolite)|Assessment of AUCtau for Rifampicin|Assessment of Tss,Max for AZD9291, and AZ5104 and AZ7550 (Metabolites)|Assessment of Tss,Max for Rifampicin|Assessment of Css,Min for AZD9291, and AZ5104 and AZ7550 (Metabolites)|Assessment of Css,Min for Rifampicin|Assessment of CLss/F for AZD9291|Assessment of CLss/F for Rifampicin|Assessment of the Metabolic Ratios of Css,Max for AZ5104 and AZ7550 (MRCss,Max)|Assessment of the Metabolic Ratios of AUCtau for AZ5104 and AZ7550 (MRAUCtau)","AstraZeneca","All","18 Years to 130 Years   (Adult, Senior)","Phase 1","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","D5160C00013|2014-001525-32","December 4, 2014","July 9, 2015","January 4, 2018","September 2017","July 21, 2014","July 22, 2014","May 24, 2016","September 28, 2016","September 14, 2017","October 16, 2017","Research Site, Atlanta, Georgia, United States|Research Site, Detroit, Michigan, United States|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Barcelona, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Sevilla, Spain|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Cardiff, United Kingdom|Research Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT02197247"
1013,"NCT01479582","Providing Access to Cord Blood Units for Transplants","null","Withdrawn","No Results Available","Chronic Myelogous Leukemia/Other Leukemia|Acute Leukemias|MDS/MPS|Multiple Myeloma|Non-Hodgkin Lymphoma","Drug: Access to unlicensed cord blood units","The primary aim of this study is to examine the incidence of neutrophil recovery of greater than or equal to 500/mm3 after cord blood transplantation in a multi-institution setting using CBUs that are not Food and Drug Administration (FDA) licen...|Assess incidence of graft rejection.|Assess incidence of transmission of infection.|Assess incidence of serious infusion reaction.|Determine 1 year survival after cord blood transplantation.|Assess cumulative incidence of aGVHD vs cGVHD.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","up to 99 Years   (Child, Adult, Senior)","Phase 2","0","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","120027|12-C-0027","October 27, 2011","November 26, 2012","November 26, 2012","November 26, 2012","November 22, 2011","November 24, 2011","null","null","June 30, 2017","July 2, 2017","","https://ClinicalTrials.gov/show/NCT01479582"
1014,"NCT00520130","Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System","null","Active, not recruiting","Has Results","Myelodysplastic Syndrome|Hodgkin's Lymphoma|Non-Hodgkin's Disease|Acute Leukemia|Multiple Myeloma","Biological: Rituximab|Drug: Cyclosporine|Drug: Allogenic stem cell transplant (ASCT)|Drug: Conditioning Chemotherapy|Drug: TMS|Drug: FLAG|Drug: EPOCH-F|Biological: Alemtuzumab","Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD)|Percentage of Participants With Chronic Graft Versus Host Disease (cGVHD)|Recovery of Naïve Cluster of Differentiation 4 (CD4) T Cells|Recovery of Naïve Cluster of Differentiation 8 (CD8) T Cells|Changes in Cluster of Differentiation 4 (CD4) T Cell Receptor Vbeta Repertoire|Changes in CD8 T Cell Receptor Vbeta Repertoire|Percentage of Participants With Grade III-IV Acute Graft Versus Host Disease (GVHD)|Toxicities|Days to Engraftment of Neutrophils|Days to Engraftment of Platelets|Days to Engraftment of Lymphocytes|Overall Survival|Early Treatment Related Mortality|Percentage of Participants With Late Treatment Related Mortality|Decline in Homeostatic Cytokine Interleukin 7 (IL-7) Post-Transplant|Immune Reconstitution of Normal Killer (NK) Cells|Immune Reconstitution of Cluster of Differentiation 4 (CD4) T Cell Populations|Immune Reconstitution of Cluster of Differentiation 8 (CD8) T Cell Populations","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 74 Years   (Adult, Senior)","Phase 1|Phase 2","92","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","070195|07-C-0195","October 30, 2007","October 14, 2015","March 2018","August 2017","August 21, 2007","August 23, 2007","November 17, 2016","August 24, 2017","August 23, 2017","August 24, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00520130"
1015,"NCT00369226","Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation","null","Completed","Has Results","Hematologic Malignancies","Drug: Bortezomib (Velcade)|Drug: Tacrolimus|Drug: Methotrexate|Procedure: blood stem cell transplantation","The Maximally Tolerated Dose (MTD) of Bortezomib (Velcade) That Can be Administered With Tacrolimus and Methotrexate After Mismatched Allogeneic Non-myeloablative Peripheral Blood Stem Cell (PBSC) Transplantation|Successful Initial Engraftment by Day 45 Post Peripheral Blood Stem Cell (PBSC) Infusion and Administration of Bortezomib (Velcade), Tacrolimus and Methotrexate|Incidence of Grade II-IV Acute Graft Versus Host Disease (GVHD) by Day 100.|Sustained Engraftment Following Transplant.|Incidence of Chronic Graft Versus Host Disease (Chronic GVHD).|Overall Survival and Progression-free Survival.","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","45","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","06-065|X05175","August 2006","July 2010","September 2011","June 2013","August 24, 2006","August 29, 2006","August 8, 2012","July 25, 2013","June 19, 2013","July 25, 2013","Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT00369226"
1016,"NCT00306150","Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy","null","Terminated","No Results Available","Blood Loss, Surgical|Postoperative Hemorrhage","Drug: Trasylol (Aprotinin, BAYA0128)|Drug: Placebo","The primary criterion for efficacy is the percent of patients requiring a blood transfusion anytime in the intra-operative or post-operative period (up to the earlier of Day 7 or discharge)|The number of units of blood or packed red cells transfused. There will be an analysis for the combination of autologous and allogenic transfusion and for allogenic alone|The number of units of blood or packed red cells transfused per patient requiring transfusion|The intraoperative blood loss determined as follow: a) by surgeon estimate b) summing weight of the blood in gauze and other materials and the suction drainage volume|The drainage volume (in milliliters) from the operative site|Transfusion of platelets, colloids, plasma and number of patients requiring these products|The change from preoperative hemoglobin concentration to postoperative hemoglobin concentration|Surgeon s assessment of the degree to which bleeding obscures his/her view of the surgical field, relative to past, similar procedures|Changes in blood markers related to inflammation and blood coagulation; baseline until Discharge or day 7|Time to discontinuing of mechanical ventilation|Changes in FEV1|Changes in the patients health related quality of life (HRQoL) (at baseline and 6+-2 weeks post surgery) using the Functional Assessment Cancer Therapy for patients with Bladder cancer (FACT-Bl) questionnaire","Bayer","All","18 Years and older   (Adult, Senior)","Phase 3","57","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","12002|2005-004055-35","December 2005","null","March 2007","December 2014","March 21, 2006","March 23, 2006","null","null","December 16, 2014","December 17, 2014","Los Angeles, California, United States|Denver, Colorado, United States|Miami, Florida, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Portland, Maine, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Rochester, Minnesota, United States|Chapel Hill, North Carolina, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Burlington, Vermont, United States|Gent, Belgium|Leuven, Belgium|Nantes Cedex, France|Nice, France|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Fulda, Hessen, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Maastricht, Netherlands|Nijmegen, Netherlands|Linköping, Sweden|Lund, Sweden|Stockholm, Sweden|Uppsala, Sweden|Cambridge, Cambridgeshire, United Kingdom|Newcastle Upon Tyne, Tyne and Wear, United Kingdom","https://ClinicalTrials.gov/show/NCT00306150"
1017,"NCT03012789","Surgical Intervention and the NETest","NETest_Sx","Recruiting","No Results Available","Neuroendocrine Tumor|Gastroenteropancreatic","Procedure: Surgery","Biomarker prediction of tumor recurrence|Biomarkers and clinical symptomatology","Wren Laboratories LLC","All","18 Years and older   (Adult, Senior)","","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Surgery_NETest","May 15, 2017","December 2019","June 2020","May 2017","December 6, 2016","January 6, 2017","null","null","May 18, 2017","May 19, 2017","San Raffaele Hospital IRCCS, Milano, Italy","https://ClinicalTrials.gov/show/NCT03012789"
1018,"NCT00596999","A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders","HPDSC","Unknown status","No Results Available","Hematologic Malignancies","Procedure: UCB and HPDSC","Incidence of GVHD, time to engraftment and survival","Celgene Corporation|Celgene","All","up to 55 Years   (Child, Adult)","Phase 1","6","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CCT-HPDSC-001","May 2007","July 2013","December 2013","November 2007","January 8, 2008","January 17, 2008","null","null","April 9, 2012","April 10, 2012","Louisiana State University Children's Hospital, New Orleans, Louisiana, United States","https://ClinicalTrials.gov/show/NCT00596999"
1019,"NCT00296049","Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy","null","Withdrawn","No Results Available","Infection|Neutropenia|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific","Drug: daptomycin|Drug: vancomycin","determine the efficacy of daptomycin to treat gram positive infections|determine the safety of daptomycin in neutropenic patients","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","up to 120 Years   (Child, Adult, Senior)","","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CDR0000466308|CCCWFU-98804|CUBIST-CCCWFU-98804|CCCWFU-BG04-494","July 2005","March 2006","March 2006","July 2012","February 23, 2006","February 24, 2006","null","null","January 18, 2017","January 19, 2017","Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00296049"
1020,"NCT01004887","Study of Tissue and Blood Samples From Patients With High-Grade Glioma","null","Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors","Other: diagnostic laboratory biomarker analysis","time to progression|survival","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","200","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","NCCTG-94-72-52|NCCTG-947252|CDR0000406625|NCI-2009-00688","November 1995","December 2014","null","August 2017","October 29, 2009","October 30, 2009","null","null","August 7, 2017","August 8, 2017","Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Illinois CancerCare - Bloomington, Bloomington, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital, Canton, Illinois, United States|Illinois CancerCare - Canton, Canton, Illinois, United States|Illinois CancerCare - Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Illinois CancerCare - Eureka, Eureka, Illinois, United States|Galesburg Clinic, PC, Galesburg, Illinois, United States|Illinois CancerCare - Galesburg, Galesburg, Illinois, United States|Illinois CancerCare - Havana, Havana, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Illinois CancerCare - Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare - Macomb, Macomb, Illinois, United States|McDonough District Hospital, Macomb, Illinois, United States|Trinity Cancer Center at Trinity Medical Center - 7th Street Campus, Moline, Illinois, United States|Moline, Illinois, United States|Illinois CancerCare - Monmouth, Monmouth, Illinois, United States|OSF Holy Family Medical Center, Monmouth, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare - Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Illinois CancerCare - Pekin, Pekin, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare - Peru, Peru, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Illinois CancerCare - Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Illinois CancerCare - Spring Valley, Spring Valley, Illinois, United States|Bettendorf, Iowa, United States|Cedar Rapids Oncology Associates, Cedar Rapids, Iowa, United States|Mercy Regional Cancer Center at Mercy Medical Center, Cedar Rapids, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|Community Cancer Center of Monroe, Monroe, Michigan, United States|Mercy Memorial Hospital - Monroe, Monroe, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|MeritCare Bemidji, Bemidji, Minnesota, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CentraCare Clinic - River Campus, Saint Cloud, Minnesota, United States|Coborn Cancer Center, Saint Cloud, Minnesota, United States|Mount Sinai Medical Center, New York, New York, United States|Bismarck Cancer Center, Bismarck, North Dakota, United States|Medcenter One Hospital Cancer Care Center, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States|MeritCare Broadway, Fargo, North Dakota, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|Roger Maris Cancer Center at MeritCare Hospital, Fargo, North Dakota, United States|Wood County Oncology Center, Bowling Green, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Medical Center Cancer Care, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Community Cancer Center, Elyria, Ohio, United States|Hematology Oncology Center, Elyria, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Northwest Ohio Oncology Center, Maumee, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|St. Charles Mercy Hospital, Oregon, Ohio, United States|Toledo Clinic - Oregon, Oregon, Ohio, United States|Southern Ohio Medical Center Cancer Center, Portsmouth, Ohio, United States|North Coast Cancer Care, Incorporated, Sandusky, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|Flower Hospital Cancer Center, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|Toledo Hospital, Toledo, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Medical University of Ohio Cancer Center, Toledo, Ohio, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|St. Anne Mercy Hospital, Toledo, Ohio, United States|Toledo Clinic, Incorporated - Main Clinic, Toledo, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Mount Carmel St. Ann's Cancer Center, Westerville, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Fredericksburg Oncology, Incorporated, Fredericksburg, Virginia, United States","https://ClinicalTrials.gov/show/NCT01004887"
1021,"NCT01247129","Delaying the Superficial Inferior Epigastric Artery (SIEA) Flap and Determining the Change in SIEA Diameter and Blood Flow","null","Completed","No Results Available","Breast Neoplasms","Procedure: Delay procedure of SIEA flap.","","University Medical Centre Ljubljana|University Medical Centre Maribor","All","18 Years to 80 Years   (Adult, Senior)","Phase 2","26","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MG-2010","September 2009","May 2010","September 2010","November 2010","November 23, 2010","November 24, 2010","null","null","November 23, 2010","November 24, 2010","University Medical Centre Maribor, Maribor, Slovenia","https://ClinicalTrials.gov/show/NCT01247129"
1022,"NCT02308384","A Trial of the Implementation of iFOBT in General Practice","null","Completed","No Results Available","Colorectal Cancer","Behavioral: Intervention","The rate of positive iFOBTs|The number of CRCs diagnosed after a positive iFOBT|The stage distribution of CRCs for patients with a positive iFOBT|The positive predictive value for detecting colorectal cancer|The positive predictive value for detecting colorectal cancer in relation to cut-off value of iFOBT|The positive predictive value for detecting colorectal cancer in relation to indications of using iFOBT|The rate of general practices starting to use the iFOBT, stratified for participation in the CME.|The monthly rate of requested iFOBTs, stratified for participation in the CME.|The monthly rate of positive iFOBTs, stratified for participation in the CME.|Indications used for requesting iFOBT, stratified for participation in the CME.|The rate of referrals in the cancer patient pathway for colorectal cancer|The rate of performed colonoscopies","University of Aarhus","All","Child, Adult, Senior","","825","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Randomiseret iFOBT studie","September 2015","September 2016","September 2016","November 2015","November 26, 2014","December 4, 2014","null","null","April 25, 2017","April 27, 2017","Research Unit for General Practice, Aarhus C, Denmark","https://ClinicalTrials.gov/show/NCT02308384"
1023,"NCT01527838","Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit","null","Completed","No Results Available","Non-Hodgkin's Lymphoma (NHL)|Hodgkin's Disease|Chronic Lymphocytic Leukemia (CLL)|Acute Myelogenous Leukemia (AML)|Acute Lymphoblastic Leukemia (ALL)","Biological: Single FT1050 treated UCB unit","Neutrophil engraftment/chimerism|Safety|Immune reconstitution|Donor search","Fate Therapeutics","All","18 Years to 65 Years   (Adult)","Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FT1050-02","January 2012","October 2013","November 2013","January 2015","February 1, 2012","February 7, 2012","null","null","September 9, 2016","September 12, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program, Boston, Massachusetts, United States|Ohio State Univeristy Comprehensive Cancer Center, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT01527838"
1024,"NCT00597519","A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy","null","Completed","Has Results","Cancer|Leukemia|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma","Drug: Fludarabine, Cyclophosphamide|Procedure: Transplantation","Overall Response","Memorial Sloan Kettering Cancer Center","All","4 Years to 50 Years   (Child, Adult)","Phase 2","28","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-014|CA23766","March 2006","September 2015","September 2015","January 2016","December 26, 2007","January 18, 2008","January 14, 2016","February 12, 2016","January 14, 2016","February 12, 2016","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00597519"
1025,"NCT02991898","Treg Cell With IL-2 to Suppress aGVHD Umbilical Cord Blood Transplantation","null","Suspended","No Results Available","Acute Lymphoblastic Leukemia|Burkitt Lymphoma|Natural Killer Cell Malignancies|Chronic Myelogenous Leukemia|Myelodysplastic Syndromes|Large-cell Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Marginal Zone B-Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-Cell Lymphoma|Prolymphocytic Leukemia|Hodgkin Lymphoma|Multiple Myeloma|Acute Myelogenous Leukemia|Biphenotypic Leukemia|Undifferentiated Leukemia","Biological: Infusion of Treg","Efficacy of Intervention|Feasibility of this protocol in preparation for future larger scale studies|Grade II-IV aGVHD|Grade III-IV aGVHD|Treatment related mortality (TRM)|Relapse|Incidence of viral and fungal infections|Detectable Treg cells|Immune reconstitution|Toxicity|Treg Survival|Chimerism|Survival|Neutrophil Recovery|Platelet Recovery|Chronic GVHD","Masonic Cancer Center, University of Minnesota","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016LS107|MT2016-17","February 16, 2017","January 2025","January 2025","December 2017","December 7, 2016","December 14, 2016","null","null","December 1, 2017","December 5, 2017","Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT02991898"
1026,"NCT01484470","Umbilical Cord Transplantation for the Elderly Population","null","Active, not recruiting","No Results Available","Hematologic Malignancies","Biological: StemEx","Efficacy of StemEx|Time to engraftment","Loyola University|Gamida Cell ltd","All","55 Years to 73 Years   (Adult, Senior)","Phase 2","18","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202041","January 2010","January 14, 2014","March 2018","December 2017","November 30, 2011","December 2, 2011","null","null","December 14, 2017","December 18, 2017","Loyola University Medical Center, Maywood, Illinois, United States","https://ClinicalTrials.gov/show/NCT01484470"
1027,"NCT00427765","Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma","null","Completed","Has Results","Multiple Myeloma|Lymphoma","Drug: Busulfan|Drug: Melphalan","Average Overall Survival Time","M.D. Anderson Cancer Center","All","18 Years to 65 Years   (Adult)","Phase 2","168","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004-0190","December 2004","November 2010","November 2010","December 2011","January 25, 2007","January 29, 2007","November 14, 2011","January 19, 2012","December 15, 2011","January 19, 2012","UT MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00427765"
1028,"NCT02280525","Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma","null","Active, not recruiting","No Results Available","Leukemia","Drug: Lenalidomide|Drug: Rituximab|Drug: Fludarabine|Drug: Cyclophosphamide|Procedure: NK Cells|Drug: Cytarabine","Maximum Tolerated Dose (MTD) of Natural Killer (NK) Cells with Lenalidomide and Lymphodepleting Chemotherapy|Response Rate of Natural Killer (NK) Cells with Lenalidomide and Lymphodepleting Chemotherapy Determined by Bone Marrow Biopsy/Aspiration","M.D. Anderson Cancer Center|The Leukemia and Lymphoma Society|Celgene Corporation","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","8","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0297|P-TRP-1996-14|NCI-2014-02678","March 5, 2015","March 2021","March 2021","November 2017","October 29, 2014","October 31, 2014","null","null","November 27, 2017","November 29, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT02280525"
1029,"NCT00078858","Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant","null","Active, not recruiting","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Childhood Renal Cell Carcinoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Clear Cell Renal Cell Carcinoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Juvenile Myelomonocytic Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Renal Cell Cancer|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Anemia|Refractory Anemia With Ringed Sideroblasts|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Renal Cell Cancer|T-cell Large Granular Lymphocyte Leukemia|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies|Waldenström Macroglobulinemia","Drug: fludarabine phosphate|Radiation: total-body irradiation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Drug: cyclosporine|Drug: mycophenolate mofetil|Other: laboratory biomarker analysis","Incidence of life-threatening GVHD in patients undergoing a modified taper of post-grafting immunosuppression after undergoing nonmyeloablative HSCT from matched unrelated donors|Need for corticosteroid treatment, defined as more than 1 mg/kg or equivalent of prednisone for more than 3 days at any time after transplant|Graft rejection|Incidence of acute and chronic GVHD|Overall survival","Fred Hutchinson Cancer Research Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 1|Phase 2","37","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1668.00|NCI-2012-00668|P30CA015704|P01CA018029","September 2003","January 2006","null","February 2017","March 8, 2004","March 9, 2004","null","null","February 27, 2017","March 1, 2017","Stanford University Hospitals and Clinics, Stanford, California, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|Emory University/Winship Cancer Institute, Atlanta, Georgia, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States|Froedtert Memorial Lutheran Hospital, Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Universitaet Leipzig, Leipzig, Germany|University of Tuebingen-Germany, Tuebingen, Germany|University of Torino, Torino, Italy","https://ClinicalTrials.gov/show/NCT00078858"
1030,"NCT01757145","Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation","null","Unknown status","No Results Available","Hematological Malignancy|Bone Marrow Failure Syndrome","Drug: Eltrombopag","Platelet engraftment rate up to 50 days post transplantation, defined as the first of 7 consecutive days of an unsupported platelet count of at least 20,000/microliter.|Time to partial platelet engraftment, defined as the first of 7 consecutive days of an unsupported platelet count of at least 20,000/microliter.|Time to sustained complete platelet engraftment defined as the first of 7 consecutive days of an unsupported platelet count of at least 50,000/microliter.|Complete platelet engraftment rates up to 50 days post transplantation defined as the first of 7 consecutive days of an unsupported platelet count of at least 50,000/microliter.|Time to neutrophil engraftment defined as the first of 3 consecutive days to achieve an absolute neutrophil count ≥ 500/microliter.","Rabin Medical Center","All","18 Years and older   (Adult, Senior)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7114","January 2013","June 2016","June 2016","February 2013","December 6, 2012","December 28, 2012","null","null","June 18, 2015","June 19, 2015","Hadassah hospital, Jerusalem, Israel|Davidof Cancer Center, Beilinson hospital, Rabin medical center, Petach Tikva, Israel","https://ClinicalTrials.gov/show/NCT01757145"
1031,"NCT01486550","Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy","VONE","Terminated","No Results Available","Kidney Cancer","Drug: Voluven (Hydroxyethyl starch 130/0,4)|Drug: Sodium Chloride 9mg/ml","u-NGAL|u-Kim1 and u-LFABP|FENa, u-ENaCβ, CH2O, u-AQP2,u-NCC, u-NK2CC|PRC, p-Ang-II, p -Aldo, p-ANP,P-GDP, p-AVP, p-Endothelin|SBP, DBP, heartrate","Regional Hospital Holstebro","All","18 Years and older   (Adult, Senior)","Phase 4","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ASK-1-2011","December 2011","September 2014","September 2014","October 2014","December 4, 2011","December 6, 2011","null","null","October 8, 2014","October 9, 2014","Medicinck forskningsafsnit, Regionshospitalet Holstebro, Holstebro, Denmark","https://ClinicalTrials.gov/show/NCT01486550"
1032,"NCT01351545","A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)","null","Recruiting","No Results Available","Hematologic Malignancies|Inherited Disorders of Metabolism|Inherited Abnormalities of Platelets|Histiocytic Disorders|Acute Myelogenous Leukemia (AML or ANLL)|Acute Lymphoblastic Leukemia (ALL)|Other Acute Leukemia|Chronic Myelogenous Leukemia (CML)|Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases|Other Leukemia|Hodgkin Lymphoma|Non-hodgkin Lymphoma|Multiple Myeloma/ Plasma Cell Disorder (PCD)|Inherited Abnormalities of Erythrocyte Differentiation or Function|Disorders of the Immune System|Automimmune Diseases|Severe Aplastic Anemia","Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)","","Center for International Blood and Marrow Transplant Research|National Marrow Donor Program","All","Child, Adult, Senior","","99999","Other","Observational","Observational Model: Other|Time Perspective: Prospective","10-CBA","October 2011","October 2021","null","January 2018","May 9, 2011","May 11, 2011","null","null","January 2, 2018","January 4, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|Mayo Clinic Arizona (adults), Phoenix, Arizona, United States|Scottsdale Healthcare/Cancer Transplant Institute at Virginia G. Piper Cancer Center, Scottsdale, Arizona, United States|University of Arizona Medical Center - Tucson, Tucson, Arizona, United States|City of Hope, Duarte, California, United States|Children's Hospital of Los Angeles, Glendale, California, United States|Scripps Green Hospital, La Jolla, California, United States|University of California San Diego, La Jolla, California, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|Children's Hospital and Research Center of Oakland, Oakland, California, United States|Children's Hospital of Orange County (CHOC), Orange, California, United States|Sutter Medical Center, Sacramento, California, United States|UC Davis Cancer Center, Sacramento, California, United States|Rady Children's Hospital San Diego, San Diego, California, United States|UCSF (adults), San Francisco, California, United States|UCSF (peds), San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Presbyterian St. Luke's/Colorado Blood Cancer Institute, Denver, Colorado, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Nemours - Alfred I. duPont Hospital for Children, Brandywine, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Shands Medical Center, Gainesville, Florida, United States|Nemours Children's Hospital - Mayo Jacksonville, Jacksonville, Florida, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|University of Miami (adult), Miami, Florida, United States|University of Miami (peds), Miami, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|Florida Center for Cellular Therapy (adults only), Orlando, Florida, United States|Florida Center for Pediatric Cellular Therapy, Orlando, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Medical College of Georgia, Augusta, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Indiana Blood & Marrow Transplantation, Beech Grove, Illinois, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Indiana University/Riley Hospital for Children, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas, Westwood, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|University of Louisville Hospital - James Brown Cancer Center, Louisville, Kentucky, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Children's Hospital of New Orleans/LSUHSC, New Orleans, Louisiana, United States|Greenebaum Cancer Center - University of Maryland, Baltimore, Maryland, United States|Johns Hopkins, Baltimore, Maryland, United States|Nih/Niaid, Bethesda, Maryland, United States|NIH/NCI, Bethesda, Maryland, United States|Nih/Nhlbi, Bethesda, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States|Spectrum Health, Grand Rapids, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Univeristy of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|St. Louis University Medical Center, Saint Louis, Missouri, United States|Washington University St. Louis, Saint Louis, Missouri, United States|Washington University/St. Louis Children's Hospital, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson/Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Children's Hospital at Montefiore, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|North Shore University Hospital, Lake Success, New York, United States|Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|New York University Langone Medical Center, New York, New York, United States|New York Presbyterian Hospital at Cornell, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center - Morgan Stanley Children's Hospital, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Westchester Medical Center, New York, New York, United States|Strong Memorial Hospital/University of Rochester, Rochester, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Levine Children's Hospital, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University, Winston-Salem, North Carolina, United States|Childrens Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|The Jewish Hospital, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|The Arthur G. James Cancer Hospital/The Ohio State University Medical Center, Columbus, Ohio, United States|University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States|Oregon Health & Science University/Doernbecher Children's Hospital, Portland, Oregon, United States|Penn State Milton S. Hershey Cancer Center, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Western Penn Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Pennsylvania/Thomas Jefferson, Pittsburgh, Pennsylvania, United States|Roger Williams Medical Center, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Avera Transplant Institute, Sioux Falls, South Dakota, United States|Methodist Healthcare Blood and Marrow Transplant Center, Memphis, Tennessee, United States|St. Jude Childrens Research Hospital, Memphis, Tennessee, United States|VA Tennessee Valley Healthcare System, Nashville, Tennessee, United States|Vanderbilt University, Nashville, Tennessee, United States|Amarillo Blood and Marrow Transplant Program, Amarillo, Texas, United States|Medical City Dallas, Dallas, Texas, United States|Children's Medical Center Dallas, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Hospital, Fort Worth, Texas, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|Texas Children's Hospital - Baylor Medical Center, Houston, Texas, United States|Southwest Cancer Treatment & Research Center, Lubbock, Texas, United States|The Children's Hospital of San Antonio, San Antonio, Texas, United States|Methodist Healthcare System of San Antonio/Texas Transplant Institute, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Intermountain Blood and Marrow Transplant Program, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|VA Puget Sound HCS, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|University of Wisconsin - Madison, Madison, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT01351545"
1033,"NCT00006234","Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone","null","Completed","No Results Available","Metastatic Cancer|Sarcoma","Procedure: peripheral blood stem cell transplantation|Radiation: holmium Ho 166 DOTMP","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","12 Years and older   (Child, Adult, Senior)","Phase 1|Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","1474.00|FHCRC-1474.00|CHMC-S-6007|NCI-G00-1842|CDR0000068159","November 2001","null","March 2006","November 2011","September 11, 2000","January 27, 2003","null","null","November 30, 2011","December 1, 2011","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00006234"
1034,"NCT01312701","Study of Blood Immune Cells in Cancer Patients Compared to Controls","null","Unknown status","No Results Available","Solid Carcinoma","","changes in immune markers mainly cd247-zeta chain - levels in cancer patients undergoing therapy|levels of zeta chain -cd247 in cancer patients","Hadassah Medical Organization|Hebrew University of Jerusalem","All","16 Years and older   (Child, Adult, Senior)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","zeta-im-1","March 2011","March 2013","December 2013","March 2011","March 1, 2011","March 11, 2011","null","null","March 9, 2011","March 11, 2011","Oncology day care Oncology Dept Sharett Inst Hadassah Ein Kerem, Jerusalem, Israel","https://ClinicalTrials.gov/show/NCT01312701"
1035,"NCT00003211","Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor","null","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: filgrastim|Drug: amifostine trihydrate|Drug: cisplatin|Drug: cyclophosphamide|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","","St. Jude Children's Research Hospital|National Cancer Institute (NCI)","All","3 Years to 20 Years   (Child, Adult)","Phase 2","94","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CDR0000066069|SJCRH-MB-96|SJMB-96|NCI-G98-1387","October 1996","June 2007","June 2007","November 2012","November 1, 1999","July 9, 2003","null","null","November 6, 2012","November 7, 2012","St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Cancer Center, Houston, Texas, United States|Children's Hospital at Westmead, Westmead, New South Wales, Australia|Royal Children's Hospital, Parkville, Victoria, Australia","https://ClinicalTrials.gov/show/NCT00003211"
1036,"NCT00427557","Cellular Therapy With Cord Blood Cells","null","Completed","Has Results","Multiple Myeloma|Leukemia|Lymphoma","Drug: Fludarabine|Drug: Melphalan|Procedure: Umbilical Cord Blood|Drug: Rituximab|Other: Peripheral Blood Stem Cell Infusion","Number of Participants With Engraftment","M.D. Anderson Cancer Center","All","up to 80 Years   (Child, Adult, Senior)","Phase 2","31","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-0553","October 2006","November 2010","November 2010","May 2012","January 25, 2007","January 29, 2007","April 19, 2012","May 17, 2012","May 23, 2012","May 28, 2012","UT MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00427557"
1037,"NCT01177501","Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma","ITOV04","Terminated","No Results Available","Ovarian Cancer|Relapses","Drug: Topotecan","Identification of the maximum tolerated dose (MTD) of topotecan at 6 weeks|Pharmacokinetic of topotecan|Pharmacokinetic of carboplatin|The response to therapy|The duration of response and the overall survival","Assistance Publique - Hôpitaux de Paris","Female","18 Years to 65 Years   (Adult)","Phase 1","3","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P 050603","April 2009","March 2012","March 2012","November 2012","August 6, 2010","August 9, 2010","null","null","November 16, 2012","November 19, 2012","Frédéric Selle, Paris, France","https://ClinicalTrials.gov/show/NCT01177501"
1038,"NCT01255527","Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study","null","Unknown status","No Results Available","Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation","Drug: Bortezomib","Maximally tolerated dose (Phase 1)|CR and near CR (Phase 2)","Yonsei University","All","20 Years to 65 Years   (Adult)","Phase 1|Phase 2","53","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4-2010-0482","October 2010","December 2014","December 2014","June 2013","December 6, 2010","December 7, 2010","null","null","June 1, 2013","June 4, 2013","National Cancer Center, Goyang, Korea, Republic of|Gachon University Gill Hospital, Incheon, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|ASAN Medical Center, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT01255527"
1039,"NCT01163201","T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies","null","Withdrawn","No Results Available","Hematologic Malignancy|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia in Blast Crisis|Anemia, Refractory, With Excess of Blasts|Chronic Myeloproliferative Disease|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Marginal Zone B-cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-Cell Lymphoma|Prolymphocytic Lymphoma|Large Cell Non-Hodgkin's Lymphoma|Lymphoblastic Lymphoma|Burkitt's Lymphoma|High Grade Non-Hodgkin's Lymphoma","Biological: Treg cells|Biological: CD3+ Teff cells|Drug: Fludarabine|Drug: Cyclophosphamide|Radiation: Total body irradiation|Biological: Umbilical cord blood transplantation","Optimal Cell Dose Mixture|Determine incidence of infusional toxicity|Incidence of neutrophil recovery|Incidence of double and single chimerism|Incidence of Viral and Fungal Infections|1 Year Survival|Incidence of Grade III-IV Acute Graft-Versus-Host Disease|Incidence of Treatment Related Death|Incidence of Platelet Recovery|Incidence of Chronic Graft-Versus-Host Disease|Incidence of Relapse","Masonic Cancer Center, University of Minnesota","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009LS018|MT2009-03|0910M73595","January 2014","January 2015","January 2015","November 2017","May 26, 2010","July 15, 2010","null","null","November 29, 2017","December 1, 2017","Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT01163201"
1040,"NCT00919750","Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors","null","Active, not recruiting","No Results Available","Childhood Atypical Teratoid/Rhabdoid Tumor|Childhood Central Nervous System Germ Cell Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Oligodendroglioma|Childhood Supratentorial Ependymoma|Newly Diagnosed Childhood Ependymoma|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma|Recurrent Childhood Visual Pathway Glioma","Other: cytology specimen collection procedure","Collection of brain tumor tissue and an accompanying blood sample from pediatric patients with brain tumors treated at Children's Oncology Group institutions|Creation of a repository for long-term storage of these specimens|Making these specimens available to qualified researchers to understand the biology of pediatric brain tumors","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","","5000","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","ACNS02B3|NCI-2009-00334|COG-ACNS02B3|CDR0000352347|U10CA098543","March 2005","January 2100","January 2100","December 2017","June 11, 2009","June 12, 2009","null","null","December 11, 2017","December 13, 2017","Children's Hospital of Alabama, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Southern California Permanente Medical Group, Downey, California, United States|City of Hope Medical Center, Duarte, California, United States|City of Hope, Duarte, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's Hospital, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Children's Hospital Central California, Madera, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Childrens Hospital of Orange County, Orange, California, United States|Sutter General Hospital, Sacramento, California, United States|University of California at Davis Cancer Center, Sacramento, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|Memorial Healthcare System - Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Nemours Children's Clinic - Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Florida Hospital, Orlando, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Saint Joseph Children's Hospital of Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|University of Hawaii, Honolulu, Hawaii, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Advocate Lutheran General Hospital., Park Ridge, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Saint Vincent Hospital and Health Services, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Children's Hospital-Main Campus, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Floating Hospital for Children at Tufts Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Michigan State University Clinical Center, East Lansing, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Kalamazoo Center for Medical Studies, Kalamazoo, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Children's Hospital and Clinic-Saint Paul, Saint Paul, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Columbia Regional, Columbia, Missouri, United States|The Childrens Mercy Hospital, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|UMDNJ - Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Saint Joseph's Regional Medical Center, Paterson, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|University of New Mexico, Albuquerque, New Mexico, United States|Albany Medical Center, Albany, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|New York University Langone Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Medical Center-Fargo, Fargo, North Dakota, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Natalie Warren Bryant Cancer Center at Saint Francis, Tulsa, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center, Portland, Oregon, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Penn State Hershey Children's Hospital, Hershey, Pennsylvania, United States|Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Palmetto Health Richland, Columbia, South Carolina, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Greenville Cancer Treatment Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|T C Thompson Children's Hospital, Chattanooga, Tennessee, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Covenant Children's Hospital, Lubbock, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Vermont, Burlington, Vermont, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Childrens Hospital-King's Daughters, Norfolk, Virginia, United States|Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States|Carilion Clinic Children's Hospital, Roanoke, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|Saint Vincent Hospital, Green Bay, Wisconsin, United States|Gundersen Lutheran, La Crosse, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Childrens Hospital, Herston, Queensland, Australia|Women's and Children's Hospital-Adelaide, North Adelaide, South Australia, Australia|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada|Chedoke-McMaster Hospitals, Hamilton, Ontario, Canada|Children's Hospital, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke-Fleurimont, Sherbrooke, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Starship Children's Hospital, Grafton, Auckland, New Zealand|Swiss Pediatric Oncology Group - Geneva, Geneva, Switzerland","https://ClinicalTrials.gov/show/NCT00919750"
1041,"NCT00900094","UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer","IRB 2000-294","Completed","No Results Available","Breast Cancer|Colorectal Cancer|Esophageal Cancer|Liver Cancer|Lung Cancer|Ovarian Cancer|Pancreatic Cancer","Genetic: fluorescence in situ hybridization|Genetic: polymerase chain reaction|Genetic: protein expression analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Other: mass spectrometry","Identification of tumor antigens that induce a humoral response in cancer patients|Identification of tumor-secreted proteins by special analysis in culture|Tumor-secreted protein expression in tumors and preneoplastic lesions|Potential markers for early detection of cancer","University of Michigan Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","200","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CDR0000276589|U01CA084982|P30CA046592|CCUM-0003","June 2000","December 2006","October 2007","February 2012","May 9, 2009","May 12, 2009","null","null","February 5, 2012","February 7, 2012","","https://ClinicalTrials.gov/show/NCT00900094"
1042,"NCT01276665","Effects of Noradrenaline Administration Combined With Restrictive Intraoperative Fluid Substitution on Perioperative Outcome in Patients Undergoing Radical Cystectomy","null","Completed","No Results Available","Bladder Cancer|Urinary Diversion","Procedure: restrictive intraoperative fluid substitution|Procedure: assessment of the pelvic venous pressure","Complications (morbidity score)|Perioperative blood loss and quality of the surgical field|-Hospital stay|Correlation between pelvic venous pressure and bleeding","University Hospital Inselspital, Berne","All","18 Years and older   (Adult, Senior)","","190","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","154/08","November 2009","September 2012","December 2012","December 2012","January 12, 2011","January 13, 2011","null","null","December 17, 2012","December 18, 2012","Dep. of Anesthesiology and Pain Therapy, Bern University Hospital, Bern, Switzerland","https://ClinicalTrials.gov/show/NCT01276665"
1043,"NCT02156310","Mechanisms of Anti-VEGF Induced Hypertension","null","Completed","No Results Available","Renal Cancer","","Changes in systolic blood pressure with different anti-hypertensive drug classes in anti-VEGF induced hypertension|Number of patients developing hypertension, i.e. >140/90 mmHg, with anti-VEGF drugs","Arduino Mangoni|Flinders University","All","Child, Adult, Senior","","2000","Other","Observational","Time Perspective: Retrospective","AAMFUSA001","January 2009","December 2012","null","June 2014","May 29, 2014","June 5, 2014","null","null","June 3, 2014","June 5, 2014","Department of Clinical Pharmacology, Adelaide, South Australia, Australia","https://ClinicalTrials.gov/show/NCT02156310"
1044,"NCT01221857","Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies","null","Completed","No Results Available","Acute Lymphoblastic Leukemia (ALL)|Acute Myelogenous Leukemia (AML)|Myelodysplastic Syndrome (MDS)|Non-Hodgkin's Lymphoma|Hodgkin's Disease","Drug: NiCord®","Safety and Tolerability: will be measured by acute NiCord® infusional toxicity, and assessment of the proportion of patients with neutrophil engraftment|Proportion of non-relapse mortality, development of acute GvHD","Gamida Cell ltd","All","8 Years to 65 Years   (Child, Adult)","Phase 1|Phase 2","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GC P#01.01.020","November 2010","September 2012","May 2013","February 2014","October 14, 2010","October 15, 2010","null","null","February 24, 2014","February 25, 2014","Loyola University, Cardinal Bernardin Cancer Center, Maywood, Illinois, United States|Duke University Medical Center, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT01221857"
1045,"NCT03246906","Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","null","Recruiting","No Results Available","Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Aggressive Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Diffuse Large B-Cell Lymphoma|Hematopoietic Cell Transplantation Recipient|Loss of Chromosome 17p|Mantle Cell Lymphoma|Myelodysplastic Syndrome|Myelodysplastic/Myeloproliferative Neoplasm|Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Recurrent Waldenstrom Macroglobulinemia","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Cyclosporine|Drug: Mycophenolate Mofetil|Drug: Sirolimus","Chronic graft versus host disease (GVHD)-free, relapse-free survival (CRFS)|Grades II-IV and III-IV acute graft versus host disease (GVHD)|Late graft versus host disease (GVHD) not meeting National Institute of Health (NIH) consensus criteria for chronic GVHD|Moderate and severe chronic graft versus host disease|Non-relapse mortality|Overall survival|Progression or relapse-free survival|Relapse","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","160","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9816|NCI-2017-01311|P01CA078902|P30CA015704","November 2, 2017","August 15, 2022","August 15, 2022","December 2017","August 8, 2017","August 11, 2017","null","null","December 26, 2017","December 28, 2017","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT03246906"
1046,"NCT01570439","To Identify HLA-A1101-restricted Peptide Epitopes Derived From Novel Oncoantigens (URLC10, KIF20A, and CDCA1) Applicable for Cancer Vaccine in Singapore","null","Unknown status","No Results Available","Anonymous Donors at Blood Donation Center (NUH)","","To identify HLA-A1101-restricted peptide epitopes derived from novel Oncoantigens (URLC10, KIF20A, and CDCA1) applicable for Cancer Vaccine in Singapore.","National University Hospital, Singapore","All","22 Years to 80 Years   (Adult, Senior)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KK001","January 2012","December 2014","null","December 2013","April 2, 2012","April 4, 2012","null","null","December 10, 2013","December 11, 2013","Nationa University Hospital, Singapore, Singapore","https://ClinicalTrials.gov/show/NCT01570439"
1047,"NCT02285738","Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis","null","Recruiting","No Results Available","Solid Tumor|Cancer","Drug: Aspirin|Drug: Simvastatin|Other: Observation","Change in average sP-selectin levels|Frequency of major bleeding complications or clinically significant non-bleeding complications per patient|Change in average Platelet Factor 4|Change in average CD40 ligand|Change in average serum thromboxane B2|Change in average serum VEGF|Change in average serum angiopoietin-2|Change in average serum hepatocyte growth factor|Change in average serum PECAM|Change in average serum PDGF|Change in average plasma F1.2|Change in average plasma TAT complexes|Change in average plasma D-dimer|Change in the number of thrombotic events","Case Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","Early Phase 1","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CASE8Y14","December 30, 2014","October 1, 2017","October 1, 2017","March 2017","November 5, 2014","November 7, 2014","null","null","March 27, 2017","March 29, 2017","Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT02285738"
1048,"NCT02074436","PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)","PROBLEMA","Recruiting","No Results Available","Hematological Malignancies|Thrombocytopenia","Drug: EACA|Other: Platelet transfusion","Proportion of patients who develop major bleeding episodes (WHO grades 3-4)","Emory University|Akorn, Inc.","All","19 Years and older   (Adult, Senior)","Phase 2","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00066504|WINSHIP2429-13","May 2014","May 2018","May 2018","May 2017","February 26, 2014","February 28, 2014","null","null","May 22, 2017","May 24, 2017","Emory University Hospital, Atlanta, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States","https://ClinicalTrials.gov/show/NCT02074436"
1049,"NCT00078988","High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas","null","Completed","No Results Available","Brain Tumor|Central Nervous System Tumor","Biological: filgrastim|Drug: carboplatin|Drug: etoposide|Drug: isotretinoin|Drug: thiotepa|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","Event-free survival|Toxic death attributable to complications of treatment in the absence of tumor progression as assessed by NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0|Overall survival (OS)","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 20 Years   (Child, Adult)","Phase 3","1","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACNS0231|COG-ACNS0231|CDR0000353207|NCI-2012-02578|U10CA098543","October 2004","September 2006","September 2006","May 2015","March 8, 2004","March 9, 2004","null","null","May 6, 2015","May 7, 2015","Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Children's Hospital and Research Center - Oakland, Oakland, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|Children's Hospital and Health Center - San Diego, San Diego, California, United States|Children's Hospital Cancer Center, Denver, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Shands Cancer Center, Gainesville, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|All Children's Hospital, St. Petersburg, Florida, United States|St. Joseph's Cancer Institute at St. Joseph's Hospital, Tampa, Florida, United States|Kaplan Cancer Center at St. Mary's Medical Center, West Palm Beach, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|St. Vincent Indianapolis Hospital, Indianapolis, Indiana, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|CancerCare of Maine at Eastern Maine Medial Center, Bangor, Maine, United States|Floating Hospital for Children at Tufts - New England Medical Center, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Spectrum Health Cancer Care - Butterworth Campus, Grand Rapids, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Children's Hospital of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|Fairview University Medical Center - University Campus, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Siteman Cancer Center at Barnes-Jewish Hospital, St. Louis, Missouri, United States|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Cancer Institute at New York University Medical Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Columbus Children's Hospital, Columbus, Ohio, United States|Children's Medical Center - Dayton, Dayton, Ohio, United States|Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States|Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|Sioux Valley Hospital and University of South Dakota Medical Center, Sioux Falls, South Dakota, United States|Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States|Covenant Children's Hospital, Lubbock, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|INOVA Fairfax Hospital, Fairfax, Virginia, United States|Children's Hospital of the King's Daughters, Norfolk, Virginia, United States|Massey Cancer Center at Virginia Commonwealth University, Richmond, Virginia, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|Children's & Women's Hospital of British Columbia, Vancouver, British Columbia, Canada|McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|Montreal Children's Hospital at McGill University Health Center, Montreal, Quebec, Canada|Hopital Sainte Justine, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Quebec, Ste-Foy, Quebec, Canada","https://ClinicalTrials.gov/show/NCT00078988"
1050,"NCT01288573","A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone","null","Completed","No Results Available","Ewing's Sarcoma/Soft Tissue Sarcoma|Neuroblastoma|Brain Tumors","Drug: plerixafor","Proportion of patients achieving at least a doubling of peripheral blood CD34+ count during Stage 2|Number of days of apheresis required to reach ≥2 × 10^6 CD34+ cells/kg|Yield of CD34+ cells for each apheresis|Total CD34+ cell yield|Percentage of patients proceeding to transplant|Percentage of patients successfully engrafting|Percentage of patients with durable engraftment|Summary of adverse events (AEs)|Duration of hospitalizations (planned or unplanned)|Mobilization of tumor cells into peripheral blood|Relapse rates|Occurrence of secondary malignancies|Incidence of primary and secondary graft failure|Time to secondary graft failure|Survival rates","Genzyme, a Sanofi Company|Sanofi","All","1 Year to 18 Years   (Child, Adult)","Phase 1|Phase 2","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DFI12860|2010-019340-40|MOZ15609","March 3, 2014","May 9, 2017","May 9, 2017","May 2017","January 28, 2011","February 2, 2011","null","null","May 15, 2017","May 16, 2017","Investigational Site Number 51, Gent, Belgium|Investigational Site Number 81, Brno, Czechia|Investigational Site Number 82, Praha 5 - Motol, Czechia|Investigational Site Number 61, København Ø, Denmark|Investigational Site Number 42, Lyon, France|Investigational Site Number 43, Paris Cedex 05, France|Investigational Site Number 33, Frankfurt Am Main, Germany|Investigational Site Number 34, Freiburg, Germany|Investigational Site Number 35, Hamburg, Germany|Investigational Site Number 31, Hannover, Germany|Investigational Site Number 36, München, Germany|Investigational Site Number 83, Budapest, Hungary|Investigational Site Number 92, Petach Tikva, Israel|Investigational Site Number 91, Tel-Aviv, Israel|Investigational Site Number 21, Genova, Italy|Investigational Site Number 24, Milano, Italy|Investigational Site Number 23, Padova, Italy|Investigational Site Number 22, Roma, Italy|Investigational Site Number 26, Torino, Italy|Investigational Site Number 72, Amsterdam, Netherlands|Investigational Site Number 71, Rotterdam, Netherlands|Investigational Site Number 85, Krakow, Poland|Investigational Site Number 84, Wroclaw, Poland|Investigational Site Number 94, Barcelona, Spain|Investigational Site Number 93, Madrid, Spain|Investigational Site Number 11, Birmingham, United Kingdom|Investigational Site Number 13, Glasgow, United Kingdom","https://ClinicalTrials.gov/show/NCT01288573"
1051,"NCT01009307","Study of Blood and Cheek Cell Samples From Patients With Glioma","null","Completed","No Results Available","Brain and Central Nervous System Tumors","Genetic: polymorphism analysis|Other: laboratory biomarker analysis|Other: medical chart review","Factors related to glioma survival","University of California, San Francisco|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","1709","Other|NIH","Observational","","CDR0000437072|UCSF-H6539-04956-13A","October 2001","July 2006","null","May 2015","November 5, 2009","November 6, 2009","null","null","May 14, 2015","May 15, 2015","UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT01009307"
1052,"NCT01525407","Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation","null","Completed","Has Results","Malignant Neoplasm","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Atorvastatin Calcium|Procedure: Peripheral Blood Stem Cell Transplantation","Grade 3-4 Acute GVHD|Chronic Extensive GVHD|Disease-free Survival|Grades II-IV Acute GVHD|Non-relapse Mortality|Overall Survival|Proportion of Donors Who Have to Discontinue Atorvastatin Because of Toxicity|Proportion of Patients Requiring Secondary Systemic Immunosuppressive Therapy|Recurrent or Progressive Malignancy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Senior)","Phase 2","83","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2545.00|NCI-2011-03827|P30CA015704|R01HL108307","May 2012","September 2015","February 2016","July 2017","January 31, 2012","February 3, 2012","April 11, 2017","August 17, 2017","July 18, 2017","August 17, 2017","Stanford University Hospitals and Clinics, Stanford, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT01525407"
1053,"NCT00999622","Study of Blood Samples and Risk of Infection in Patients With Newly Diagnosed Malignant Supratentorial Astrocytoma","null","Completed","No Results Available","Brain and Central Nervous System Tumors|Infection","Other: laboratory biomarker analysis|Other: questionnaire administration","Frequency and severity of decreases in CD4 counts|Determination of decrease in CD4 counts as significant predictor of infections or adverse outcomes","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)|North American Brain Tumor Consortium","All","18 Years and older   (Adult, Senior)","","104","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","NABTT-0305 CDR0000363636|U01CA062475|NABTT-0305","July 2004","August 2009","null","May 2012","October 21, 2009","October 22, 2009","null","null","May 24, 2012","May 28, 2012","","https://ClinicalTrials.gov/show/NCT00999622"
1054,"NCT02908750","Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC","null","Active, not recruiting","No Results Available","Non Small Cell Lung Cancer","Drug: Fexofenadine tablet dosing|Drug: Osimertininb tablet dosing","Fexofenadine Cmax (alone and in combination with osimertinib)|Fexofenadine AUC (alone and in combination with osimertinib)|Fexofenadine tmax (alone and in combination with osimertinib)|Fexofenadine AUC0-t (alone and in combination with osimertinib)|Fexofenadine CL/F (alone and in combination with osimertinib)|Fexofenadine Vz/F (alone and in combination with osimertinib)|Fexofenadine λz (alone and in combination with osimertinib)|Fexofenadine t½λz (alone and in combination with osimertinib)|Osimertinib and metabolites (AZ5104 and AZ7550)|Osimertinib and metabolites (AZ5104 and AZ7550) single dose: AUC0-72|Osimertinib and metabolites (AZ5104 and AZ7550) single dose: Cmax|Osimertinib and metabolites (AZ5104 and AZ7550) single dose: tmax|Osimertinib and metabolites (AZ5104 and AZ7550) single dose: MRCmax|Osimertinib and metabolites (AZ5104 and AZ7550) multiple dose: AUCtau|Osimertinib and metabolites (AZ5104 and AZ7550) multiple dose Css,max|Osimertinib and metabolites (AZ5104 and AZ7550) multiple dose Css,min|Osimertinib and metabolites (AZ5104 and AZ7550) multiple dose: CLss/F (osimertinib only)|Osimertinib and metabolites (AZ5104 and AZ7550) multiple doses: MRAUCtau|Osimertinib and metabolites (AZ5104 and AZ7550) multiple dose: MRCss,max|Safety data collected using: Assessment of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v4.0|Safety data collected using: Assessment of serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) (Version 4)|Safety data collected using: vital signs (blood pressure, pulse, temperature, height, weight)|Safety data collected using: laboratory parameters (clinical chemistry, heamatology, urinalysis)|Safety data collected using: physical examination|Safety data collected using: standard 12-lead electrocardiograms (ECGS)","AstraZeneca|Quintiles, Inc.","All","18 Years to 130 Years   (Adult, Senior)","Phase 1","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5160C00036","March 2, 2017","July 31, 2017","March 13, 2019","October 2017","August 23, 2016","September 21, 2016","null","null","October 18, 2017","October 19, 2017","Research Site, Rennes Cedex 9, France|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT02908750"
1055,"NCT00507260","Nutritional Assessment Intervention to Improve Cancer-Related Fatigue","null","Completed","No Results Available","Leukemia|Lymphoma|Fatigue","Behavioral: Food Record|Other: Nutritional Consults","Patient Fatigue Scores <Brief Fatigue Inventory (BFI)>","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Senior)","","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006-0515","September 2006","December 2014","December 2014","December 2014","July 24, 2007","July 26, 2007","null","null","December 23, 2014","December 24, 2014","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00507260"
1056,"NCT00469729","Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy","ExCell","Completed","No Results Available","Hematologic Malignancies|Acute Myeloid Leukemia|Lymphoid Leukemia|Chronic Myeloid Leukemia|Hodgkin's Disease|Non-Hodgkin's Lymphoma|Myelodysplastic Syndromes","Drug: StemEx®","Overall 100-day mortality|180 day mortality, acute Graft versus Host Disease (GvHD) grades III-IV, engraftment failure|Safety and tolerability measures: The incidence and frequency of adverse experiences, acute toxicity, laboratory data and vital signs follow-up.|Proportion of overall mortality at 1 year|Proportion of overall mortality at 2 years","Gamida Cell -Teva Joint Venture Ltd.","All","12 Years to 55 Years   (Child, Adult)","Phase 2|Phase 3","101","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GC P#02.01.001","October 2007","February 2013","June 2015","March 2013","May 3, 2007","May 4, 2007","null","null","July 9, 2015","July 10, 2015","UCLA's Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|The Children's Hospital, B115, University of Colorado Health Sciences Center, Aurora, Colorado, United States|Northwestern University School of Medicine, Stem Cell Transplant Program, Children's Memorial Hospital, Chicago, Illinois, United States|Cardinal Bernardin Cancer Center, Loyola University Stritch School of Medicine, Maywood, Illinois, United States|The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Cornell University, Joan & Sanford I. Weill Medical College, New York, New York, United States|Steven and Alexandra Cohen Children's Medical Center of New York, New York, New York, United States|Mount Sinai Medical Center, One Gustave L Levy Place, BOX 1410, New York, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute/UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States|Texas Transplant Institute, San Antonio, Texas, United States|University of Virginia, Hematopoietic Stem Cell Transplant Program, West Complex 1300 Jefferson Park Av, Charlottesville, Virginia, United States|Medical College of Wisconsin Division of Neoplastic Diseases and Related Disorders, Milwaukee, Wisconsin, United States|Medical College of Wisconsin Pediatric Blood and Marrow Transplant Program, Milwaukee, Wisconsin, United States|Szent Laszlo & Szent Istvan Hospital, Budapest, Hungary|Hebrew University Hospital Ein-Karem, Department of Bone Marrow Transplantation And Cancer Immunotherapy, Jerusalem, Israel|Rambam Medical Center, PO Box 9602, Haifa, Israel|Chaim Sheba Medical Center, Tel Hashomer, Israel|Ospedale Pedriatrico Bambino Gesù, Roma, Italy|Universita di Roma Tor Vergata, via Oxford 81, Roma, Italy|Ospedale di Careggi BMT Unit Department of Haematology, Viale Morgagni, Florence, Italy|Hospital Clínico Universitario de Valencia, Avda. Blasco Ibañez, 17, Valencia, Comunidad Valenciana, Spain|Hospital Universitario La Fe, Av Campanar 21, Valencia, Spain|Hospital de la Santa Creu i Sant Pau, C/ Sant Antoni Maria Claret, Barselona, Spain|Hospital Germans Trias i Pujol, Carretera de Canyet s/n, Badalona, Spain|Hospital General Universitario Gregorio Marañón, Doctor Esquerdo 46 , Madrid, Spain|Hospital Universitario Vall d´Hebrón (Pediatrics), Passeig de la Vall d´Hebrón 119-129, Barcelona, Spain|Hospital Universitario Vall d´Hebrón, Passeig de la Vall d´Hebrón 119-129, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT00469729"
1057,"NCT00143884","Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood","null","Terminated","No Results Available","Leukemia|Lymphoma, Low-Grade|Lymphoma, Non-Hodgkin's|Multiple Myeloma|Myelodysplastic Syndromes","Procedure: Reduced intensity conditioning|Procedure: Prophylactic donor leukocyte infusions","To conduct a phase I-II trial of prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies|To evaluate both surrogate markers of GVHD (with a cytokine panel) and minimal residual disease and correlate these with clinical outcomes during the above trial","University of Michigan Cancer Center","All","Child, Adult, Senior","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training","UMCC 9979","March 2000","null","null","January 2007","August 31, 2005","September 2, 2005","null","null","April 20, 2007","April 23, 2007","The University of Michigan, Ann Arbor, Michigan, United States","https://ClinicalTrials.gov/show/NCT00143884"
1058,"NCT02511288","LIquid BIopsies in Lung Cancer (LIBIL)","LIBIL","Recruiting","No Results Available","Carcinoma, Non-small Cell Lung","","Evaluate the clinical utility of liquid biopsy in the setting of Advanced NSCLC|Concordance (pourcentage) between tissue and droplet digital PCR for detection of molecular alterations|Identification of resistance mechanisms in cDNA for patients under targeted therapies|Evaluate the role of liquid biopsies in the monitoring of treatment","Centre Leon Berard","All","18 Years and older   (Adult, Senior)","","900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ET15000076","July 2015","December 2019","December 2021","February 2017","July 16, 2015","July 30, 2015","null","null","September 14, 2017","September 15, 2017","Centre Hospitalier Annecy Genevois, Annecy, France|CH Fleyriat, Bourg-en-Bresse, France|Hôpital Louis Pradel, Bron, France|CHU Grenoble Alpes, Grenoble, France|Centre Léon Bérard, Lyon, France|Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France|Hôpital Nord Ouest, Villefranche-sur-Saône, France","https://ClinicalTrials.gov/show/NCT02511288"
1059,"NCT00996047","S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers","null","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Genetic: cytogenetic analysis|Genetic: fluorescence in situ hybridization","Maintain and expand a database of cytogenetic information on leukemia patients.","Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","All","Child, Adult, Senior","","3341","Other|NIH","Observational","","S9007|SWOG-9007|U10CA032102","July 1991","January 2012","January 2012","March 2015","October 15, 2009","October 16, 2009","null","null","March 5, 2015","March 6, 2015","Providence Cancer Center at Providence Hospital, Mobile, Alabama, United States|Providence Cancer Center, Anchorage, Alaska, United States|Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States|Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Ft. Smith, Arkansas, United States|Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States|Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center, Burbank, California, United States|Peninsula Medical Center, Burlingame, California, United States|Tibotec Therapeutics - Division of Ortho Biotech Products, LP, Marysville, California, United States|Sutter Health - Western Division Cancer Research Group, Novato, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|California Pacific Medical Center - California Campus, San Francisco, California, United States|Stanford Cancer Center, Stanford, California, United States|Sutter Solano Medical Center, Vallejo, California, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Front Range Cancer Specialists, Fort Collins, Colorado, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|M.D. Anderson Cancer Center at Orlando, Orlando, Florida, United States|Piedmont Hospital, Atlanta, Georgia, United States|Northside Hospital Cancer Center, Atlanta, Georgia, United States|Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|WellStar Cobb Hospital, Austell, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|Kennestone Cancer Center at Wellstar Kennestone Hospital, Marietta, Georgia, United States|Southern Regional Medical Center, Riverdale, Georgia, United States|Harbin Clinic Cancer Center - Medical Oncology, Rome, Georgia, United States|Kapiolani Medical Center at Pali Momi, Aiea, Hawaii, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|OnCare Hawaii, Incorporated - Lusitana, Honolulu, Hawaii, United States|Queen's Cancer Institute at Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Incorporated, Honolulu, Hawaii, United States|Hawaii Medical Center - East, Honolulu, Hawaii, United States|OnCare Hawaii, Incorporated - Kuakini, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Castle Medical Center, Kailua, Hawaii, United States|Kauai Medical Clinic, Lihue, Hawaii, United States|Maui Memorial Medical Center, Wailuku, Hawaii, United States|Pacific Cancer Institute - Maui, Wailuku, Hawaii, United States|Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Mountain States Tumor Institute at St. Luke's Regional Medical Center, Boise, Idaho, United States|Saint Anthony's Hospital at Saint Anthony's Health Center, Alton, Illinois, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States|Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States|Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States|Mid-Illinois Hematology-Oncology Associates at Community Cancer Center, Normal, Illinois, United States|Regional Cancer Center at Memorial Medical Center, Springfield, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|St. Francis Hospital and Health Centers - Beech Grove Campus, Beech Grove, Indiana, United States|Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States|Reid Hospital & Health Care Services, Richmond, Indiana, United States|McFarland Clinic, PC, Ames, Iowa, United States|Hematology Oncology Associates of the Quad Cities, Bettendorf, Iowa, United States|Medical Oncology and Hematology Associates - West Des Moines, Clive, Iowa, United States|Genesis Regional Cancer Center at Genesis Medical Center, Davenport, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas, PA - Liberal, Liberal, Kansas, United States|Cancer Center of Kansas, PA - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's Hospital - South, Overland Park, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|CCOP - Kansas City, Prairie Village, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Tammy Walker Cancer Center at Salina Regional Health Center, Salina, Kansas, United States|Cotton-O'Neil Cancer Center, Topeka, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Lucille P. Markey Cancer Center at University of Kentucky, Lexington, Kentucky, United States|Tulane Cancer Center Office of Clinical Research, Alexandria, Louisiana, United States|Louisiana State University Health Sciences Center - Monroe, Monroe, Louisiana, United States|Feist-Weiller Cancer Center at Louisiana State University Health Sciences, Shreveport, Louisiana, United States|CancerCare of Maine at Eastern Maine Medical Center, Bangor, Maine, United States|Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Battle Creek Health System Cancer Care Center, Battle Creek, Michigan, United States|Mecosta County Medical Center, Big Rapids, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center, Grand Blanc, Michigan, United States|Butterworth Hospital at Spectrum Health, Grand Rapids, Michigan, United States|CCOP - Grand Rapids, Grand Rapids, Michigan, United States|Lacks Cancer Center at Saint Mary's Health Care, Grand Rapids, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|Mercy General Health Partners, Muskegon, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|University of Mississippi Cancer Clinic, Jackson, Mississippi, United States|Keesler Air Force Base Medical Center, Kessler AFB, Mississippi, United States|Regional Cancer Center at Singing River Hospital, Pascagoula, Mississippi, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Truman Medical Center - Hospital Hill, Kansas City, Missouri, United States|Saint Luke's Cancer Institute at Saint Luke's Hospital, Kansas City, Missouri, United States|St. Joseph Medical Center, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Parvin Radiation Oncology, Kansas City, Missouri, United States|Heartland Hematology Oncology Associates, Incorporated, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Hospital, Liberty, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Joseph Oncology, Incorporated, Saint Joseph, Missouri, United States|Midwest Hematology Oncology Group, Incorporated, Saint Louis, Missouri, United States|Saint Louis University Cancer Center, Saint Louis, Missouri, United States|CCOP - St. Louis-Cape Girardeau, Saint Louis, Missouri, United States|David C. Pratt Cancer Center at St. John's Mercy, Saint Louis, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Big Sky Oncology, Great Falls, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Methodist Estabrook Cancer Center, Omaha, Nebraska, United States|CCOP - Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|New Mexico Cancer Care Associates, Santa Fe, New Mexico, United States|Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States|Presbyterian Cancer Center at Presbyterian Hospital, Charlotte, North Carolina, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States|Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Kinston Medical Specialists, Kinston, North Carolina, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Iredell Memorial Hospital, Statesville, North Carolina, United States|McDowell Cancer Center at Akron General Medical Center, Akron, Ohio, United States|Mary Rutan Hospital, Bellefontaine, Ohio, United States|Mercy Cancer Center at Mercy Medical Center, Canton, Ohio, United States|Aultman Cancer Center at Aultman Hospital, Canton, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Charles M. Barrett Cancer Center at University Hospital, Cincinnati, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Medical Center Cancer Care, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital, Dayton, Ohio, United States|David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Cancer Care Center, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Blanchard Valley Medical Associates, Findlay, Ohio, United States|Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|MedCentral - Mansfield Hospital, Mansfield, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States|Mount Carmel St. Ann's Cancer Center, Westerville, Ohio, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Willamette Falls Hospital, Oregon City, Oregon, United States|Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, United States|Adventist Medical Center, Portland, Oregon, United States|CCOP - Columbia River Oncology Program, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|AnMed Cancer Center, Anderson, South Carolina, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|McLeod Regional Medical Center, Florence, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Medical X-Ray Center, PC, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|U.T. Medical Center Cancer Institute, Knoxville, Tennessee, United States|Harrington Cancer Center, Amarillo, Texas, United States|Baylor University Medical Center - Dallas, Dallas, Texas, United States|Baylor University Medical Center - Houston, Houston, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital, Houston, Texas, United States|Veterans Affairs Medical Center - Houston, Houston, Texas, United States|Veterans Affairs Medical Center - San Antonio (Murphy), San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Cancer Therapy and Research Center, San Antonio, Texas, United States|University Hospital - San Antonio, San Antonio, Texas, United States|Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States|Danville Regional Medical Center, Danville, Virginia, United States|Island Hospital Cancer Care Center at Island Hospital, Anacortes, Washington, United States|St. Joseph Cancer Center, Bellingham, Washington, United States|Olympic Hematology and Oncology, Bremerton, Washington, United States|Highline Medical Center Cancer Center, Burien, Washington, United States|Providence Centralia Hospital, Centralia, Washington, United States|St. Francis Hospital, Federal Way, Washington, United States|Columbia Basin Hematology, Kennewick, Washington, United States|Skagit Valley Hospital Cancer Care Center, Mount Vernon, Washington, United States|Providence St. Peter Hospital Regional Cancer Center, Olympia, Washington, United States|Harrison Poulsbo Hematology and Onocology, Poulsbo, Washington, United States|Good Samaritan Cancer Center, Puyallup, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Minor and James Medical, PLLC, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Group Health Central Hospital, Seattle, Washington, United States|Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle, Washington, United States|University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States|North Puget Oncology at United General Hospital, Sedro-Woolley, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|Evergreen Hematology and Oncology, PS, Spokane, Washington, United States|Franciscan Cancer Center at St. Joseph Medical Center, Tacoma, Washington, United States|Allenmore Hospital, Tacoma, Washington, United States|CCOP - Northwest, Tacoma, Washington, United States|MultiCare Regional Cancer Center at Tacoma General Hospital, Tacoma, Washington, United States|Madigan Army Medical Center - Tacoma, Tacoma, Washington, United States|St. Clare Hospital, Tacoma, Washington, United States|Southwest Washington Medical Center Cancer Center, Vancouver, Washington, United States|Northwest Cancer Specialists at Vancouver Cancer Center, Vancouver, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States","https://ClinicalTrials.gov/show/NCT00996047"
1060,"NCT00899080","Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide","null","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Genetic: gene expression analysis|Genetic: reverse transcriptase-polymerase chain reaction|Other: immunoenzyme technique|Other: laboratory biomarker analysis|Other: platelet aggregation test","Proportion of patients with failed disease based on expectations for changes in cathepsin G (CG) levels|Mechanism of development of thalidomide/lenalidomide-induced venous thromboembolism (VTE)|Intensity, dynamics, and specificity of CG upregulation in response to thalidomide and lenalidomide treatment|Specificity and threshold levels of CG for induction of platelet aggregation in response to thalidomide and lenalidomide and the resulting risk for VTE development","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","up to 120 Years   (Child, Adult, Senior)","","33","Other|NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","CDR0000600320|ECOG-E4A03T2","July 4, 2008","August 4, 2008","August 4, 2008","May 2017","May 9, 2009","May 12, 2009","null","null","May 16, 2017","May 17, 2017","","https://ClinicalTrials.gov/show/NCT00899080"
1061,"NCT00665470","Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma","null","Completed","Has Results","Skin Cancer|Metastatic Melanoma","Drug: Aldesleukin","Response|Toxicity as Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V3.0","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","Phase 2","10","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","080104|08-C-0104","April 2008","April 2012","April 2012","September 2015","April 23, 2008","April 24, 2008","December 12, 2012","January 22, 2013","September 28, 2015","October 19, 2015","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00665470"
1062,"NCT00109031","Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)","null","Completed","Has Results","Cancer|Lymphoma|Leukemia","Drug: palifermin|Radiation: Total Body Irradiation|Drug: Cyclophosphamide|Drug: Etoposide|Drug: Placebo","Number of Participants With Severe Oral Mucositis (WHO Grade 3 and 4)|Duration of Severe Oral Mucositis (WHO Grade 3 and 4)|Area Under the Curve (AUC) of Mouth and Throat Soreness Score|Number of Participants With Parenteral or Transdermal Opioid Analgesic Use|Number of Participants With WHO Grades 2, 3 or 4 Oral Mucositis|Duration of WHO Grade 2, 3 or 4 Oral Mucositis|Number of Participants With WHO Grade 4 Oral Mucositis","Swedish Orphan Biovitrum|Amgen","All","18 Years and older   (Adult, Senior)","Phase 3","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","20040212","January 2005","February 2006","December 2010","September 2014","April 22, 2005","April 25, 2005","January 24, 2014","September 15, 2014","September 12, 2014","September 15, 2014","","https://ClinicalTrials.gov/show/NCT00109031"
1063,"NCT00007813","Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors","null","Unknown status","No Results Available","Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Liver Cancer|Neuroblastoma|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor","Biological: filgrastim|Drug: carboplatin|Drug: cyclophosphamide|Drug: etoposide|Procedure: autologous bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","up to 35 Years   (Child, Adult)","Phase 1","36","Other","Interventional","Primary Purpose: Treatment","CDR0000064263|JHOC-9512|NCI-V95-0688","May 1995","null","null","December 2007","January 6, 2001","April 2, 2004","null","null","February 6, 2009","February 9, 2009","Johns Hopkins Oncology Center, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00007813"
1064,"NCT00897910","Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma","null","Terminated","Has Results","Multiple Myeloma and Plasma Cell Neoplasm","Other: flow cytometry|Other: immunoenzyme technique|Other: laboratory biomarker analysis","Percentage of Myeloma-specific T Cells ex Vivo Expanded Using Flow Cytometry|Cell Counts of Myeloma-specific T Cells ex Vivo Expanded Before and After CD3/CD28 Stimulation","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","6","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CDR0000597015|P30CA022453|WSU-2007-070","April 2008","November 2009","September 2012","December 2015","May 9, 2009","May 12, 2009","October 22, 2013","December 12, 2013","December 9, 2015","January 11, 2016","Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States","https://ClinicalTrials.gov/show/NCT00897910"
1065,"NCT00923910","Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood","null","Completed","Has Results","Leukemia, Acute Myelogenous (AML)|Leukemia, Acute Lymphocytic (ALL)|Leukemia, Chronic Myelogenous (CML)|Myelodysplastic Syndrome (MDS)|Non-Hodgkin's Lymphoma (NHL)","Drug: WT1 Peptide-Pulsed Dendritic Cells|Drug: Donor Lymphocytes|Drug: IL-4|Drug: KLH|Drug: WT1 Peptides|Drug: Endotoxin|Drug: Diphenhydramine|Drug: Acetaminophen","Toxicity|Number of Participants With Graft Versus Host Disease (GVHD) Greater Than or Equal to Grade 3|Time to Immune Response|Wilm's Tumor 1 (WT1) Enzyme-Linked Immunospot (ELISpot)|Wilm's Tumor (WT1) Delayed-type Hypersensitivity (DTH)|Keyhole Limpet Hemocyanin (KLH) Delayed-type Hypersensitivity (DTH)|Number of Participants With Progressive Disease","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","1 Year to 74 Years   (Child, Adult, Senior)","Phase 1|Phase 2","10","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","080051|08-C-0051","February 22, 2008","October 18, 2013","November 15, 2016","March 2017","June 17, 2009","June 18, 2009","April 7, 2014","May 8, 2014","March 1, 2017","April 12, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00923910"
1066,"NCT00513916","Effect of Dietary Soy on Estrogens in Breast Fluid, Blood, and Urine Samples From Healthy Women","null","Completed","No Results Available","Breast Cancer|Healthy, no Evidence of Disease","Dietary Supplement: soy isoflavones","Effect of two daily servings of soy on estrogen levels in nipple aspirate fluid (NAF) and serum|Cytologic patterns of epithelial breast cells obtained from NAF|Effect of two daily servings of soy on cytochrome alterations of estrogen metabolism as expressed in the formation of urinary 2-, 16α-, and 4-hydroxy estrogen metabolites|Comparison of estrogen levels in NAF and serum measured at the same time during luteal phase","University of Hawaii Cancer Research Center|National Cancer Institute (NCI)","Female","30 Years to 45 Years   (Adult)","Phase 3","100","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Prevention","CDR0000560821|UHM-CHS-4116","July 2006","February 2011","February 2012","April 2009","August 8, 2007","August 9, 2007","null","null","December 18, 2013","December 19, 2013","Cancer Research Center of Hawaii, Honolulu, Hawaii, United States","https://ClinicalTrials.gov/show/NCT00513916"
1067,"NCT00566098","Activated White Blood Cells in Treating Patients Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Stage II or Stage III Multiple Myeloma","null","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: therapeutic autologous lymphocytes|Biological: therapeutic tumor infiltrating lymphocytes|Drug: melphalan|Procedure: autologous hematopoietic stem cell transplantation","Toxicity|Hematopoietic engraftment|Response rates utilizing the Blade criteria, including complete response (CR) rate, near complete response (nCR) rate, very good partial response (VGPR) rate, partial response (PR) rate, minimal response (MR) rate, overall response rate (CR, VGPR, ...|Generation of activated marrow infiltrating lymphocytes (aMILs)|T-cell reconstitution, including absolute lymphocyte counts, CD3+/ CD4+/ CD8+ T-cell counts|Progression-free survival and overall survival|Pneumococcal-specific vaccine responses|Anti-tumor immune responses|Delayed-type hypersensitivity (DTH) responses","Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","Phase 1|Phase 2","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J0770|P30CA006973|JHOC-J0770","November 2007","June 2014","June 2014","October 2015","November 30, 2007","December 3, 2007","null","null","October 30, 2015","November 2, 2015","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00566098"
1068,"NCT01474681","Safety and Tolerability of HSC835 in Patients With Hematological Malignancies","null","Completed","Has Results","Acute Myelocytic Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome|Chronic Lymphocytic Leukemia|Marginal Zone Lymphoma|Follicular Lymphomas|Large-cell Lymphoma|Lymphoblastic Lymphoma|Burkitt's Lymphoma|High Grade Lymphomas|Mantle-cell Lymphoma|Lymphoplasmacytic Lymphoma","Biological: HSC835","Safety and Tolerability of HSC835 for Clinical Use Were Measured by Infusional Toxicity (Within First 48 Hours After Transplant) and Absence of Graft Failure After 32 Days in Excess of That Currently Observed With UCBT.|Incidence of Neutrophil Recovery Within 42 Days|Incidence of Platelet Recovery Within Six Months|Frequency of Expanded Unit Predominance at Day 100 (DUCBT Recipients Only)|Incidence of Transplant Related Mortality (TRM) Within 100 Days and One Year|Incidence of Acute Graft Versus Host Disease (aGVHD) Within 100 Days and Chronic Graft Versus Host Disease (cGVHD) Within 1 Year|Incidence of Relapse Within One Year|Overall Survival (OS) Within One Year|Disease Free Survival (DFS) Within One Year","Novartis Pharmaceuticals|Novartis","All","10 Years to 55 Years   (Child, Adult)","Phase 1|Phase 2","27","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHSC835X2201","January 9, 2012","October 3, 2016","October 3, 2016","March 2017","November 15, 2011","November 18, 2011","April 3, 2017","May 12, 2017","April 3, 2017","May 12, 2017","Novartis Investigative Site, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT01474681"
1069,"NCT01651182","Tranexamic Acid Versus Placebo for Blood to Reduce Perioperative Bleeding Post-liver Resection","null","Completed","No Results Available","Cancer|Tumour|Surgery","Drug: No tranexamic acid|Drug: Tranexamic Acid","Receipt of blood transfusion(s)|Fibrinolytic Markers|Pharmacokinetic Study|Post-operative incidence of symptomatic venous thromboembolic event|Other post-operative complications","Sunnybrook Health Sciences Centre|University of Toronto|University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","Phase 3","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TXA Liver - PK","March 2014","February 2015","February 2015","September 2015","July 24, 2012","July 26, 2012","null","null","September 17, 2015","September 18, 2015","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT01651182"
1070,"NCT00253487","Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas","null","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: O6-benzylguanine|Drug: busulfan|Drug: temozolomide|Procedure: adjuvant therapy|Procedure: autologous bone marrow transplantation|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","","Children's Hospital Medical Center, Cincinnati|National Cancer Institute (NCI)","All","5 Years to 55 Years   (Child, Adult)","","null","Other|NIH","Interventional","Primary Purpose: Treatment","CCHMC-04660|CDR0000446082|NCI-7036","August 2005","August 2012","August 2012","January 2006","November 11, 2005","November 15, 2005","null","null","January 3, 2014","January 6, 2014","","https://ClinicalTrials.gov/show/NCT00253487"
1071,"NCT00897923","Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma","null","Completed","No Results Available","Lymphoma|Small Intestine Cancer","Procedure: radionuclide imaging|Radiation: indium In 111-labeled autologous peripheral blood mononuclear cells|Radiation: indium In 111-labeled autologous polymorphonuclear leukocytes","Number of baseline indium In 111-labeled peripheral blood mononuclear cells (PBMCs) trafficking into tumors|Number of baseline indium In 111-labeled polymorphonuclear leukocytes (PMNLs) trafficking into tumors|Number of PBMC and PMNL trafficking prior to vs after therapy|Cellular uptake of PBMCs and PMNLs as measured by reader/visual interpretation, semiquantitative grading system, and tumor-to-background uptake ratios","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","","17","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CDR0000529768|UIHC-LS0383|MAYO-IRB-1414-03","September 2003","February 10, 2012","February 10, 2012","April 2016","May 9, 2009","May 12, 2009","null","null","March 21, 2017","March 22, 2017","Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00897923"
1072,"NCT00657995","Tight Glycemic Control by Artificial Pancreas","null","Completed","No Results Available","Pancreatic Neoplasm","Device: Artificial Pancreas (STG-22)","the incidence of severe hypoglycemia (< 40 mg/dl) during the intensive care period following pancreatic resection in patients monitored using the artificial pancreas|the total amount of insulin required for glycemic control after pancreatic resection","Kochi University","All","Child, Adult, Senior","","32","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TGC-AP-01","April 2007","December 2007","December 2007","April 2008","April 4, 2008","April 14, 2008","null","null","April 8, 2008","April 14, 2008","Kochi Medical School, Kochi University, Nankoku-City, Kohasu-Okocho, Japan","https://ClinicalTrials.gov/show/NCT00657995"
1073,"NCT02046291","Safety of Romiplostim (Nplate®) Following UCBT","null","Recruiting","No Results Available","Hematologic Malignancies","Drug: Romiplostim","Maximum tolerated dose of romiplostim|Platelet recovery|Thrombocytopenia|Bone marrow fibrosis","Masonic Cancer Center, University of Minnesota","All","18 Years and older   (Adult, Senior)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2012LS089|MT2012-17R","April 10, 2015","March 2018","June 2018","December 2017","January 23, 2014","January 27, 2014","null","null","December 3, 2017","December 5, 2017","University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT02046291"
1074,"NCT02917759","Liver and Biliary Tumor Tissue Registry","null","Recruiting","No Results Available","Hepatocellular Carcinoma|Cholangiocarcinoma","","Number of successful xenografts established","Mayo Clinic","All","18 Years and older   (Adult, Senior)","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","13-006829","February 2014","February 2024","February 2024","October 2017","September 24, 2016","September 28, 2016","null","null","October 9, 2017","October 10, 2017","Mayo Clinic, Jacksonville, Florida, United States","https://ClinicalTrials.gov/show/NCT02917759"
1075,"NCT00179764","Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])","null","Recruiting","No Results Available","Tumors|Malignant Melanoma|Hematological Malignancies|Myelogenous Leukemia, Chronic|Leukemia, Lymphoblastic, Acute","Procedure: Immunoablative Hematopoietic PBSC Transplant|Procedure: Busulfan pharmacokinetics|Radiation: Central Nervous System (CNS) prophylaxis radiation","Evaluate the morbidity and mortality of matched related and unrelated hematopoietic progenitor cell (HPC) transplantation at Children's Memorial Hospital using high dose CD34+ HPCs after a reduced intensity conditioning regimen.|Determine the toxicity of a reduced intensity conditioning regimen consisting of Fludarabine and Busulfan.|Validate the pharmacokinetics of once-a-day dosing of intravenous Busulfan given as a 3-hour infusion, using a limited number of samples.|Assess chimeric engraftment utilizing this regimen in malignant and non-malignant disorders.|Assess the relapse rate of patients transplanted with this reduced intensity regimen.|Determine the incidence of acute and chronic Graft vs. Host Disease (GVHD) using prophylaxis with Cyclosporine A and mycophenolate mofetil following this reduced intensity regimen.","Ann & Robert H Lurie Children's Hospital of Chicago","All","up to 21 Years   (Child, Adult)","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BMT 0300 Mini","March 2000","December 2016","December 2016","July 2016","September 10, 2005","September 16, 2005","null","null","July 25, 2016","July 27, 2016","Children's Memorial Hospital, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT00179764"
1076,"NCT00288028","Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant","null","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: bortezomib","Maximum tolerated dose|Safety and tolerability|Overall response rate by Southwest Oncology Group (SWOG) criteria|Complete response rate by SWOG criteria|Response duration by SWOG criteria","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000455585|P30CA022453|WSU-D-2957|WSU-0506002467","July 2005","November 2010","June 2012","November 2013","February 6, 2006","February 7, 2006","null","null","November 18, 2013","November 19, 2013","Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States","https://ClinicalTrials.gov/show/NCT00288028"
1077,"NCT01427881","Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies","null","Completed","Has Results","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Myeloid Leukemia in Remission|Adult Erythroleukemia (M6a)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Adult Pure Erythroid Leukemia (M6b)|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Erythroleukemia (M6)|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Philadelphia Chromosome Negative Chronic Myelogenous Leukemia|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Multiple Myeloma|Testicular Lymphoma|Waldenström Macroglobulinemia","Drug: cyclophosphamide|Drug: cyclosporine|Procedure: peripheral blood stem cell transplantation|Radiation: total-body irradiation|Drug: fludarabine phosphate|Drug: busulfan|Procedure: allogeneic hematopoietic stem cell transplantation","Chronic GVHD Requiring Systemic Immunosuppressive Treatment|Donor Engraftment|Grades II-IV and III-IV Acute GVHD|Duration of Systemic Immunosuppressive Treatment|Persistent or Recurrent Malignancy After HCT|Non-relapse Mortality|Overall Survival|Disease-free Survival|Hematologic Recovery|Graft Failure","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","43","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2541.00|NCI-2011-02459|P30CA015704","September 2011","June 2014","July 2015","May 2017","August 31, 2011","September 2, 2011","April 11, 2017","May 19, 2017","May 17, 2017","May 19, 2017","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT01427881"
1078,"NCT01004523","Study of Tissue and Blood Samples From Patients With Low-Grade Glioma","null","Completed","No Results Available","Brain and Central Nervous System Tumors","Genetic: fluorescence in situ hybridization|Genetic: loss of heterozygosity analysis|Genetic: polymerase chain reaction|Other: flow cytometry|Other: immunohistochemistry staining method","Alterations in chromosomes 7, 9p, 10, 17, 19q, X, or Y as determined by FISH|Loss of chromosomal materials in chromosomes 9p, 10, 13, 17, or 22 by PCR analysis|Levels of PCNA, Ki-67 (MIB-1), or mutated p53 by immunostaining with monoclonal antibodies|DNA ploidy by FISH and flow cytometry|Percentage of cells in S-phase or G2M-phase as measured by flow cytometry","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","Child, Adult, Senior","","135","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","NCCTG-94-72-53|NCCTG-947253|CDR0000406626|NCI-2009-00689","December 1995","March 2013","March 2013","July 2016","October 29, 2009","October 30, 2009","null","null","July 15, 2016","July 18, 2016","Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Medical Oncology and Hematology Associates - West Des Moines, Clive, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Hickman Cancer Center at Bixby Medical Center, Adrian, Michigan, United States|Community Cancer Center of Monroe, Monroe, Michigan, United States|Mercy Memorial Hospital - Monroe, Monroe, Michigan, United States|MeritCare Bemidji, Bemidji, Minnesota, United States|Essentia Health - Duluth Clinic, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|St. Alexius Medical Center Cancer Center, Bismarck, North Dakota, United States|MeritCare Broadway, Fargo, North Dakota, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|Wood County Oncology Center, Bowling Green, Ohio, United States|Community Cancer Center, Elyria, Ohio, United States|Hematology Oncology Center, Elyria, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Northwest Ohio Oncology Center, Maumee, Ohio, United States|St. Charles Mercy Hospital, Oregon, Ohio, United States|Toledo Clinic - Oregon, Oregon, Ohio, United States|Flower Hospital Cancer Center, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|Toledo Hospital, Toledo, Ohio, United States|St. Vincent Mercy Medical Center, Toledo, Ohio, United States|Medical University of Ohio Cancer Center, Toledo, Ohio, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|St. Anne Mercy Hospital, Toledo, Ohio, United States|Toledo Clinic, Incorporated - Main Clinic, Toledo, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Fredericksburg Oncology, Incorporated, Fredericksburg, Virginia, United States","https://ClinicalTrials.gov/show/NCT01004523"
1079,"NCT00767234","Permission to Collect Blood Over Time for Research","null","Terminated","No Results Available","Pancreatic Cancer|Gastrointestinal Neoplasms|Colon Rectal Cancer Adenocarcinoma|Esophageal Cancer|Gall Bladder Cancer|Gastric (Stomach) Cancer|Gastrooesophageal Cancer|Gastrointestinal Stromal Tumor (GIST)|Hepatobiliary Neoplasm|Liver Carcinoma|Gallbladder Carcinoma|Bile Duct Carcinoma|Carcinoma of the Large Intestine|Anal Cancer","Procedure: Observation","Identify Biomarkers","Stanford University","All","18 Years and older   (Adult, Senior)","","104","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GI0003|8502","August 2008","October 2011","October 2011","July 2016","October 3, 2008","October 7, 2008","null","null","July 6, 2016","July 11, 2016","Stanford University School of Medicine, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT00767234"
1080,"NCT00048412","Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H","null","Completed","No Results Available","Myelodysplastic Disorders|Leukemia|Multiple Myeloma|Plasma Cell Dyscrasia|Lymphoproliferative Disorders","Drug: FLUDARABINE|Drug: CAMPATH 1H|Drug: FK50|Procedure: Stem Cell Collection and Infusion","","Baylor College of Medicine|The Methodist Hospital System|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine","All","up to 70 Years   (Child, Adult, Senior)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H8714|DIMSUM","June 2000","null","null","April 2007","October 30, 2002","November 1, 2002","null","null","April 9, 2007","April 11, 2007","Texas Children's Hospital, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00048412"
1081,"NCT00024297","Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters","null","Completed","No Results Available","Thromboembolism","Drug: warfarin","","Cancer Research Campaign Clinical Trials Centre|National Cancer Institute (NCI)","All","16 Years and older   (Child, Adult, Senior)","","null","Other","Interventional","Primary Purpose: Supportive Care","CRC-WARP|CDR0000068909|EU-20049|ISRCTN50312145","October 1999","null","February 2009","December 2002","September 13, 2001","January 27, 2003","null","null","August 6, 2013","August 7, 2013","Queen Elizabeth Hospital at University of Birmingham, Birmingham, England, United Kingdom|City Hospital - Birmingham, Birmingham, England, United Kingdom|Birmingham Heartlands and Solihull NHS Trust -Teaching, Birmingham, England, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom|Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom|Cumberland Infirmary, Carlisle, England, United Kingdom|Cheltenham General Hospital, Cheltenham, England, United Kingdom|Essex County Hospital, Colchester, England, United Kingdom|Royal Devon and Exeter Hospital, Exeter, England, United Kingdom|Diana Princess of Wales Hospital, Grimsby, England, United Kingdom|St. Luke's Cancer Centre at Royal Surrey County Hospital, Guildford, England, United Kingdom|Huddersfield Royal Infirmary, Huddersfield, West Yorks, England, United Kingdom|Princess Royal Hospital, Hull, England, United Kingdom|Ipswich Hospital NHS Trust, Ipswich, England, United Kingdom|Royal Lancaster Infirmary, Lancaster, England, United Kingdom|Cookridge Hospital at Leeds Teaching Hospital NHS Trust, Leeds, England, United Kingdom|Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom|Guy's and St. Thomas' Hospitals NHS Foundation Trust, London, England, United Kingdom|St. George's Hospital, London, England, United Kingdom|Charing Cross Hospital, London, England, United Kingdom|Clatterbridge Centre for Oncology NHS Trust, Merseyside, England, United Kingdom|South Tees Hospitals NHS Trust, Middlesbrough, Cleveland, England, United Kingdom|Northern Centre for Cancer Treatment at Newcastle General Hospital, Newcastle-Upon-Tyne, England, United Kingdom|Mount Vernon Hospital, Northwood, England, United Kingdom|Royal Preston Hospital, Preston, England, United Kingdom|Oldchurch Hospital, Romford, England, United Kingdom|Royal South Hants Hospital, Southampton, England, United Kingdom|Sandwell General Hospital, West Bromwich, England, United Kingdom|Good Hope Hospital Trust, West Midlands, England, United Kingdom|Airedale General Hospital, West Yorkshire, England, United Kingdom|Royal Hampshire County Hospital, Winchester, England, United Kingdom|New Cross Hospital, Wolverhampton, England, United Kingdom|Worcester Royal Hospital, Worcester, England, United Kingdom|Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom|Royal Infirmary - Castle, Glasgow, Scotland, United Kingdom|Velindre Cancer Center at Velinde Hospital, Cardiff, Wales, United Kingdom|Singleton Hospital, Swansea, Wales, United Kingdom|Plymouth Hospitals NHS Trust, Plymouth, United Kingdom","https://ClinicalTrials.gov/show/NCT00024297"
1082,"NCT02514408","Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer","null","Withdrawn","No Results Available","Stage II Bladder Urothelial Carcinoma","Procedure: Catheter Management|Other: Cytology Specimen Collection Procedure|Other: Laboratory Biomarker Analysis","Number of CTCs in the blood drawn from central line|Number of CTCs in the blood drawn from peripheral line|Incidence of complications during the cannulation of the femoral vein","University of Southern California|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","0","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","4B-15-7|NCI-2015-01063|P30CA014089","February 5, 2018","February 5, 2019","March 5, 2019","December 2017","July 30, 2015","August 3, 2015","null","null","December 28, 2017","January 1, 2018","","https://ClinicalTrials.gov/show/NCT02514408"
1083,"NCT00507702","Identification of Key Blood Molecular Markers for Immunotherapy","null","Suspended","No Results Available","Squamous Cell Carcinoma|Adenocarcinoma|Neoplasms","Procedure: phlebotomy","To identify and evaluate the presence of pre-existing immunity related markers in peripheral human blood, to identify patients who may respond to IL-12 immunotherapy","Stanford University","All","18 Years and older   (Adult, Senior)","","300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VAR0017|97125","July 2006","July 2012","July 2012","July 2012","July 24, 2007","July 26, 2007","null","null","July 5, 2012","July 9, 2012","Stanford University School of Medicine, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT00507702"
1084,"NCT01096381","Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor","null","Terminated","No Results Available","Breast Cancer|Cardiovascular Complications|Colorectal Cancer|Fallopian Tube Cancer|Head and Neck Cancer|Lung Cancer|Ovarian Cancer|Peritoneal Cavity Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Other: laboratory biomarker analysis|Other: questionnaire administration","Digital-pulse amplitude (DPA) measures|Relationship between hypertension and baseline DPA|Endothelial progenitor cell levels pre- and post-bevacizumab|Correlation between physical fitness level and cardiotoxicity","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","8","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","VICC BRE 0983|P30CA068485|VU-VICC-BRE-0983","March 2010","July 2011","August 2011","February 2012","March 30, 2010","March 31, 2010","null","null","February 23, 2012","February 27, 2012","Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT01096381"
1085,"NCT02752607","Reduction to Preventive Doses of Enoxaparin After 3 to 6 Months of Treatment With Blood Thinners for Cancer-associated Blood Clots","STEP-CAT","Not yet recruiting","No Results Available","Deep Vein Thrombosis","","Rate of recurrent VTE|Cumulative incidence of major bleeding events|Cumulative incidence of clinically relevant non-major bleeding events|Cumulative incidence of minor bleeding events|Overall survival","Dr. Vicky Tagalakis|Sanofi|Lady Davis Institute","All","18 Years and older   (Adult, Senior)","","150","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MM-JGH-16-003","May 2016","January 2018","May 2018","April 2016","April 25, 2016","April 27, 2016","null","null","April 26, 2016","April 27, 2016","","https://ClinicalTrials.gov/show/NCT02752607"
1086,"NCT03295695","PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient","null","Not yet recruiting","No Results Available","Breast Cancer|Breast Cancer, Female|Breast Cancer, Male|Breast Neoplasms","Diagnostic Test: Fluoro-D-glucose-positron Emission Tomography|Biological: 2-deoxy-2-[18F]fluoro-D-glucose (FDG)|Diagnostic Test: Echocardiogram","Cardiac Ejection Fraction (EF)|Concordance Between FDG-RBC PET-CT and Echocardiogram","H. Lee Moffitt Cancer Center and Research Institute","All","18 Years and older   (Adult, Senior)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","MCC-19220","February 2018","December 2019","December 2020","December 2017","September 25, 2017","September 28, 2017","null","null","December 1, 2017","December 5, 2017","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","https://ClinicalTrials.gov/show/NCT03295695"
1087,"NCT00006518","Specimen Collections From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer","null","Recruiting","No Results Available","HIV|Kaposi's Sarcoma|Lymphomas|Multicentric Castleman's Disease|Primary Effusion Lymphoma","","Acquisition of serum, circulating cells, bone marrow, and tumor or normal tissue samples from patients with HIV infection, KSHV infection, or with cancer.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Senior)","","9999","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","010038|01-C-0038","November 21, 2000","null","null","January 27, 2017","November 22, 2000","November 23, 2000","null","null","October 18, 2017","October 19, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00006518"
1088,"NCT00787761","Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer","null","Completed","Has Results","Myeloproliferative Disorders|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: nonmyeloablative allogeneic HSCT","Achievement of > 90% (Full) Donor Chimerism in the T-cell Lineage as Measured by PCR at Day 30 Post-transplantation|T-cell and Myeloid Chimerism at Days 90 Post-transplantation (>90% Chimerism)|T-cell and Myeloid Chimerism at Days 180 Post-transplantation (>90%)|Number of Patients Who Experience Severe (Grade 3 or 4) Acute Graft-versus-host Disease|Number of Patients Experiencing Extensive Chronic Graft Versus Host Disease (GVHD)|Non-relapse Mortality (NRM) at Day 180 Post-transplantation|Disease-free Survival (DFS) at 24 Months|Overall Survival (OS) at 24 Months","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000618483|BMTGG-NSH-807","April 2007","July 2010","May 2012","August 2012","November 7, 2008","November 10, 2008","July 9, 2012","October 1, 2012","August 29, 2012","October 1, 2012","Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States","https://ClinicalTrials.gov/show/NCT00787761"
1089,"NCT02743351","Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies","null","Recruiting","No Results Available","Hematologic Malignancies|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndromes|Chronic Myelogenous Leukemia","Biological: ProTmune|Biological: Control Arm","Number of patients with treatment related AEs as assessed by CTCAE grading scale v.4.0|Number of patients that experience Grade B-D acute Graft vs Host Disease (aGvHD)|For CMV positive subjects, incidence of subjects with CMV viremia or who have initiated anti-viral therapy for CMV","Fate Therapeutics","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PT-001","June 2016","September 2019","June 2020","October 2017","February 9, 2016","April 19, 2016","null","null","October 19, 2017","October 23, 2017","University of Alabama, Birmingham, Alabama, United States|City of Hope, Duarte, California, United States|University of California, San Diego (UCSD) Moores Cancer Center, San Diego, California, United States|University of Chicago, Chicago, Illinois, United States|Indiana Blood and Marrow Transplant, Indianapolis, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Weill Cornell Medicine, New York, New York, United States|Jewish Hospital, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Transplant Institute, San Antonio, Texas, United States|Huntsman Cancer Institute (University of Utah), Salt Lake City, Utah, United States|Virginia Commonwealth University, Richmond, Virginia, United States","https://ClinicalTrials.gov/show/NCT02743351"
1090,"NCT00003883","Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation","null","Completed","No Results Available","Cancer","Drug: fluconazole|Drug: itraconazole","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","13 Years and older   (Child, Adult, Senior)","Phase 3","578","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Supportive Care","1322.00|FHCRC-1322.00|NCI-H99-0030|CDR0000067050","October 1998","July 2002","July 2002","March 2010","November 1, 1999","March 31, 2004","null","null","March 31, 2010","April 2, 2010","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00003883"
1091,"NCT02136277","Vascular Changes During Colorectal Surgery","MaMiFlo","Unknown status","No Results Available","Patients Undergoing Open Resection of Colorectal Tumours","Drug: Hartmann's solution","Changes in microvascular blood flow during colorectal surgery","University of Nottingham","All","18 Years to 80 Years   (Adult, Senior)","","32","Other","Observational","Time Perspective: Prospective","13115","January 2015","January 2016","June 2016","January 2015","May 8, 2014","May 12, 2014","null","null","January 25, 2015","January 27, 2015","Royal Derby Hospital, Derby, Derbyshire, United Kingdom","https://ClinicalTrials.gov/show/NCT02136277"
1092,"NCT00286611","Determination of Amifostine Levels During Radiation Therapy","null","Completed","No Results Available","Cancer","Procedure: Blood and salivary sampling of amifostine","","University of Iowa","All","18 Years and older   (Adult, Senior)","","13","Other","Observational","Time Perspective: Prospective","200406002","October 2004","null","May 2008","June 2008","January 31, 2006","February 3, 2006","null","null","June 9, 2008","June 10, 2008","University of Iowa Department of Radiation Oncology, Iowa City, Iowa, United States","https://ClinicalTrials.gov/show/NCT00286611"
1093,"NCT00146614","Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation","null","Completed","No Results Available","Graft Versus Host Disease|Hematologic Malignancies","Drug: Sirolimus|Drug: Tacrolimus|Drug: Methotrexate|Procedure: Stem Cell Transplantation","To assess the effect on the incidence and severity of GVHD by adding sirolimus, tacrolimus and methotrexate to GVHD prophylaxis.","Dana-Farber Cancer Institute|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Massachusetts General Hospital","All","18 Years and older   (Adult, Senior)","Phase 2","105","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","02-057","July 2002","April 2003","April 2003","March 2012","September 6, 2005","September 7, 2005","null","null","March 6, 2012","March 8, 2012","Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT00146614"
1094,"NCT00819143","Collection of Blood and Bone Marrow Samples From Select Patients With CML to Measure Minimal Residual Disease","null","Completed","No Results Available","Leukemia","","","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Senior)","","3","NIH","Observational","Time Perspective: Prospective","090062|09-H-0062","December 29, 2008","null","July 13, 2011","July 13, 2011","January 7, 2009","January 8, 2009","null","null","June 30, 2017","July 2, 2017","National Heart, Lung and Blood Institute (NHLBI), 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00819143"
1095,"NCT00005813","Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme","null","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: bispecific antibody MDX447|Biological: lymphokine-activated killer cells|Procedure: conventional surgery","","Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 1","null","Other|NIH","Interventional","Primary Purpose: Treatment","D9705|P30CA023108|NCI-G00-1783","March 1997","January 2003","January 2003","October 2011","June 2, 2000","May 20, 2003","null","null","October 26, 2011","October 27, 2011","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States","https://ClinicalTrials.gov/show/NCT00005813"
1096,"NCT01742169","Improving Rates of Colorectal Cancer Screening Among Never Screened Patients","null","Completed","No Results Available","Colorectal Neoplasms","Behavioral: Outreach and Reminder Intervention","Completion of fecal occult blood test (FOBT)","Northwestern University|Agency for Healthcare Research and Quality (AHRQ)","All","50 Years to 75 Years   (Adult, Senior)","","420","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Screening","1P01HS021141-01-Project1B|1P01HS021141-01","January 2013","April 2014","June 2014","January 2015","December 3, 2012","December 5, 2012","null","null","January 6, 2015","January 7, 2015","Northwestern University, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT01742169"
1097,"NCT01453894","Improving Rates of Repeat Colorectal Cancer Screening","null","Completed","Has Results","Colorectal Neoplasms","Behavioral: Reminder and Outreach Intervention","Completion of a Fecal Occult Blood Test (FOBT)","Northwestern University|Agency for Healthcare Research and Quality (AHRQ)","All","51 Years to 75 Years   (Adult, Senior)","","450","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Screening","1P01HS021141-01-Project1|1P01HS021141-01","March 2012","August 2013","August 2013","July 2014","October 13, 2011","October 18, 2011","July 24, 2014","August 15, 2014","July 24, 2014","August 15, 2014","Northwestern University, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT01453894"
1098,"NCT00426205","GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies","null","Completed","No Results Available","Myelodysplastic Syndrome RAEB-I or RAEB-II|Refractory Acute Myeloid Leukemia|Refractory CML Myeloid Blast Crisis","Biological: GM-CSF secreting leukemia vaccine","Feasibility as measured by ability to generate sufficient vaccine, and ability for this patient population to initiate vaccination between day 30 to day 45 after transplant.|Safety of GVAX vaccination as measured by grade III-IV acute GVHD, and CTC grade 3 or higher non-hematologic toxicity|biologic activity of GVAX vaccination|disease free and overall survival.","Dana-Farber Cancer Institute|Brigham and Women's Hospital","All","18 Years and older   (Adult, Senior)","","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-023","June 2004","September 2007","September 2009","March 2014","January 23, 2007","January 24, 2007","null","null","March 3, 2014","March 4, 2014","Dana-Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT00426205"
1099,"NCT02129543","Immune Reconstitution in Stem Cell Transplant Recipients","null","Recruiting","No Results Available","Cancer","Procedure: Blood Draw","Number of study subjects experiencing immune reconstitution","University of Miami","All","18 Years to 75 Years   (Adult, Senior)","","200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20080899","August 15, 2012","June 2018","June 2019","August 2017","April 30, 2014","May 2, 2014","null","null","August 4, 2017","August 7, 2017","University of Miami, Miami, Florida, United States","https://ClinicalTrials.gov/show/NCT02129543"
1100,"NCT01896778","Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer","null","Recruiting","No Results Available","Adult Liver Carcinoma|Breast Carcinoma|Colon Carcinoma|Kidney Neoplasm|Lung Carcinoma|Malignant Head and Neck Neoplasm|Malignant Neoplasm|Melanoma|Ovarian Neoplasm|Soft Tissue Sarcoma","Procedure: Hyperthermia Treatment|Other: Laboratory Biomarker Analysis","Changes in tumor vascular (blood flow, blood volume)|Changes in tumor vascular measures|Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","20","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","I 229812|NCI-2013-01198|P30CA016056","October 4, 2013","April 11, 2018","April 11, 2019","September 2017","July 8, 2013","July 11, 2013","null","null","September 27, 2017","September 28, 2017","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT01896778"
1101,"NCT01056614","Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies","null","Completed","No Results Available","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Hematopoietic/Lymphoid Cancer|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia","Drug: fludarabine phosphate|Drug: busulfan|Biological: anti-thymocyte globulin|Drug: tacrolimus|Drug: methotrexate|Procedure: peripheral blood stem cell transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Other: laboratory biomarker analysis","Incidence of acute GvHD|Pharmacokinetics of IV busulfan including interdose variability and evaluation of a limited sampling strategy|Thymoglobulin pharmacokinetics|Incidence of donor cell engraftment|Incidence of system toxicities >= grade 3 as graded per CTCAE v.3|Incidence of chronic GvHD|Incidence of non-relapse mortality defined as death without history of post-transplant relapse|Incidence of relapse|Relapse-free survival|Incidence of EBV activation defined as an increase in plasma EBV DNA to >= 1000 copies/mL as determined by quantitative polymerase chain reaction (PCR)","Fred Hutchinson Cancer Research Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)","All","up to 60 Years   (Child, Adult)","Phase 2","23","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1913.00|NCI-2009-01785|P30CA015704|P01HL036444","September 2004","August 2005","April 2016","May 2016","January 22, 2010","January 26, 2010","null","null","May 4, 2016","May 6, 2016","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT01056614"
1102,"NCT00004157","Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors","null","Completed","No Results Available","Breast Cancer|Gestational Trophoblastic Tumor|Kidney Cancer|Lymphoma|Neuroblastoma|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor","Biological: filgrastim|Biological: recombinant interleukin-11","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","1365.00|FHCRC-1365.00|NCI-G99-1622|CDR0000067395","August 2000","April 2002","April 2002","March 2010","December 10, 1999","February 12, 2004","null","null","March 31, 2010","April 2, 2010","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00004157"
1103,"NCT02475174","Manual Lymphatic Drainage in the Superior Member in Women in Post-surgery for Breast Cancer","null","Unknown status","No Results Available","Lymphedema","Other: Without upper limb elevation|Other: Upper limb elevation to 30º","Blood flow velocity (Flow velocity in brachial artery and vein)|Volume upper limbs","University of Sao Paulo","Female","40 Years to 60 Years   (Adult)","","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HCRP nº 13408/2013","June 2015","June 2015","March 2016","June 2015","June 10, 2015","June 18, 2015","null","null","June 15, 2015","June 18, 2015","","https://ClinicalTrials.gov/show/NCT02475174"
1104,"NCT00983398","Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors","null","Recruiting","No Results Available","Adult Central Nervous System Germ Cell Tumor|Adult Embryonal Tumor With Multilayered Rosettes, C19MC-Altered|Adult Medulloblastoma|Adult Pineoblastoma|Adult Supratentorial Embryonal Tumor, Not Otherwise Specified|Atypical Teratoid/Rhabdoid Tumor|Childhood Atypical Teratoid/Rhabdoid Tumor|Childhood Central Nervous System Germ Cell Tumor|Childhood Embryonal Tumor With Multilayered Rosettes, C19MC-Altered|Medulloepithelioma|Ototoxicity|Recurrent Adult Brain Neoplasm|Recurrent Childhood Central Nervous System Embryonal Neoplasm|Recurrent Childhood Malignant Germ Cell Tumor|Recurrent Childhood Medulloblastoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified","Drug: Carboplatin|Drug: Mannitol|Drug: Melphalan|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Drug: Sodium Thiosulfate","Maximum tolerated dose based on the incidence of dose-limiting toxicity, graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase I)|Response rate (Phase II)|Change in neurocognitive assessment scores (Phase II)|Overall survival rate (Phase II)|Progression free survival rate (Phase II)|Proportion of patients with ototoxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase II)","OHSU Knight Cancer Institute|National Cancer Institute (NCI)|National Institute of Neurological Disorders and Stroke (NINDS)","All","1 Year to 45 Years   (Child, Adult)","Phase 1|Phase 2","55","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00005056|NCI-2013-00790|OHSU-5056|MR00042551|5056|P30CA069533|R01NS044687","September 17, 2009","December 31, 2019","December 31, 2020","October 2017","September 23, 2009","September 24, 2009","null","null","October 31, 2017","November 6, 2017","University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States","https://ClinicalTrials.gov/show/NCT00983398"
1105,"NCT00669812","High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma","null","Unknown status","No Results Available","Lymphoma|Small Intestine Cancer","Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: epirubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: melphalan|Drug: methotrexate|Drug: prednisolone|Drug: vincristine sulfate|Procedure: autologous hematopoietic stem cell transplantation|Procedure: biopsy|Procedure: peripheral blood stem cell transplantation","Survival at 1 year|Toxicity","Cancer Research UK|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","60","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000593564|CRUK-2005-003906-27|CRUK-BRD/05/93","February 2008","null","null","November 2008","April 30, 2008","May 1, 2008","null","null","August 23, 2013","August 26, 2013","Sir James Spence Institute of Child Health at Royal Victoria Infirmary, Newcastle-Upon-Tyne, England, United Kingdom","https://ClinicalTrials.gov/show/NCT00669812"
1106,"NCT01235468","Allogenic Transplantation of Ex-vivo Expanded Cord Blood (CB)","null","Withdrawn","No Results Available","Umbilical Cord Blood|Stem Cell Transplantation|Hematological Malignancies","Biological: ex vivo expansion","Safety|engraftment|treatment-related toxicity|GVHD|Immunological reconstruction|relapse","Dr. Avichai Shimoni MD|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Sheba Medical Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHEBA-10-7959-AN-CTIL","June 2012","November 2015","November 2015","December 2015","November 2, 2010","November 5, 2010","null","null","December 1, 2015","December 3, 2015","","https://ClinicalTrials.gov/show/NCT01235468"
1107,"NCT01139333","Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia","null","Completed","No Results Available","Leukemia","Genetic: gene expression analysis|Genetic: western blotting|Other: flow cytometry|Other: laboratory biomarker analysis","Expression of Mer and Axl|Association of abnormal expression of Mer and Axl with induction failure or relapse","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 17 Years   (Child)","","52","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","AAML10B4|COG-AAML10B4|CDR0000671452|NCI-2011-02222","September 2009","May 2016","null","May 2016","June 5, 2010","June 8, 2010","null","null","May 17, 2016","May 18, 2016","","https://ClinicalTrials.gov/show/NCT01139333"
1108,"NCT00109707","A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers","null","Completed","No Results Available","Chronic Myelogenous Leukemia|Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)|Hypereosinophilic Syndrome|Systemic Mastocytosis","Drug: Nilotinib","• To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of AMN107 as a single agent when administered as an oral once-daily and twice daily dose to adult patients with imatinib-resistant CML (phase l)|• To characterize the pharmacokinetic profile of AMN107 in serum and, where samples are available, in tumor cells and normal hematopoietic cells. (phase l)|• To evaluate the efficacy and safety of AMN107 in patients with imatinib-resistant or intolerant CML-BC, imatinib-resistant or intolerant CML-AP and imatinib-resistant or intolerant CML-CP. (phase ll)|• To evaluate safety and preliminary anticancer activity of AMN107 in relapsed/refractory patients with Ph+ ALL, HES/CEL and SM. (phase ll)|To assess changes during and after therapy in malignant cells taken from the bone marrow and/or blood.(phase ll)|To evaluate the population pharmacokinetics of AMN107 (all arms of the study) (phase ll)|To examine whether individual genetic variation in genes relating to drug metabolism, CML and the drug pathway confer differential response to AMN107 (phase ll)|To identify gene expression patterns in tumor cells that are associated with treatment response to AMN107 or that correlate with the severity or progression of CML. (phase ll)","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","942","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAMN107A2101","May 2004","September 2012","September 2012","April 2016","May 2, 2005","May 3, 2005","null","null","April 27, 2016","April 29, 2016","City of Hope National Medical Center, Duarte, California, United States|Stanford University Medical Center, Stanford, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|H. Lee Moffitt Cancer Center & Research Institute Dept.of H. Lee Moffitt, Tampa, Florida, United States|University of Chicago Medical Center Dept. of U. of Chicago Hosp(3), Chicago, Illinois, United States|University of Illinois at Chicago Divisionof Hematology/Oncology, Chicago, Illinois, United States|Indiana Blood and Marrow Institute Dept of Indiana Blood&Mar (2), Beach Grove, Indiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Div.of Hematologic Malignancie, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Health System Clinical Trials Office, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute Rosewell SC, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Oregon Health Sciences University, Portland, Oregon, United States|The Jones Clinic, Germantown, Tennessee, United States|Vanderbilt University Medical Center, Clinical Trials Center Investigational Drug Services, Nashville, Tennessee, United States|MD Anderson Cancer Center/University of Texas, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Novartis Investigative Site, St. Leonards, New South Wales, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Prahran, Victoria, Australia|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Haine-saint-Paul, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, HUS Helsinki, Finland|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Créteil, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Limoges cedex, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Poitiers, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, Vandoeuvre les Nancy, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Frankfurt/M, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Pokfulam, Hong Kong|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Pescara, PE, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Hwasun-gun, Jeollanam-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Taegu, Korea, Republic of|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Grafton, Auckland, New Zealand|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Katowice, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Göteborg, Sweden|Novartis Investigative Site, Linköping, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Genève, Switzerland|Novartis Investigative Site, Niaosong Township, Taiwan|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Cambridge, United Kingdom|Novartis Investigative Site, Glasgow - Scotland, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom","https://ClinicalTrials.gov/show/NCT00109707"
1109,"NCT00008268","Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma","null","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Drug: melphalan","","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","00-067|CDR0000068392|NCI-G00-1895","August 2000","June 2003","June 2003","June 2013","January 6, 2001","January 27, 2003","null","null","June 17, 2013","June 18, 2013","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00008268"
1110,"NCT00313625","Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma","null","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: busulfan|Drug: melphalan|Drug: methotrexate|Drug: tacrolimus|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Transplant-related mortality at 180 days|Disease response (complete response)|Progression-free survival|Overall survival at 1 year","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 60 Years   (Adult)","Phase 2","20","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","2018.00|FHCRC-2018.00|CDR0000467231","September 2005","July 2007","null","September 2010","April 11, 2006","April 12, 2006","null","null","September 20, 2010","September 21, 2010","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00313625"
1111,"NCT00002630","High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse","null","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Drug: cyclophosphamide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET photon therapy","","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","50","Other|NIH","Interventional","Primary Purpose: Treatment","CDR0000064030|P30CA015083|928003|V95-0613","June 1993","February 1999","May 2001","May 2011","November 1, 1999","July 29, 2004","null","null","May 10, 2011","May 11, 2011","Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00002630"
1112,"NCT00923780","Evaluation of Blood Vessel Formation in Endocrine Tumors","null","Completed","No Results Available","Lesions","","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","","400","NIH","Observational","Time Perspective: Prospective","070060|07-C-0060","January 5, 2007","September 28, 2009","null","September 28, 2009","June 17, 2009","June 18, 2009","null","null","June 30, 2017","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00923780"
1113,"NCT00004158","Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma","null","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: melphalan|Procedure: peripheral blood stem cell transplantation|Radiation: holmium Ho 166 DOTMP","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","1442.00|FHCRC-1442.00|NEORX-9804|NCI-G99-1623|CDR0000067396","June 1999","null","January 2006","September 2010","December 10, 1999","July 19, 2004","null","null","September 17, 2010","September 21, 2010","Sylvester Cancer Center, University of Miami, Miami, Florida, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|University of Washington School of Medicine, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00004158"
1114,"NCT01362452","Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells","null","Completed","No Results Available","Leukemia|Lymphoma","Genetic: T-Cell Infusion|Procedure: Cord Blood Infusion","Maximum Tolerated Dose (MTD) of T-Cell Infusions|Secondary Graft Failure of T-Cell Infusions","M.D. Anderson Cancer Center","All","1 Year to 75 Years   (Child, Adult, Senior)","Phase 1","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010-0835|FD-R-04369-01|NCI-2011-01046|RP130516","December 7, 2012","July 25, 2017","July 25, 2017","August 2017","May 26, 2011","May 30, 2011","null","null","August 2, 2017","August 3, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT01362452"
1115,"NCT00084747","Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma","null","Completed","Has Results","Multiple Myeloma and Plasma Cell Neoplasm","Drug: bortezomib","Progression-free Survival|Overall Survival","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 69 Years   (Adult, Senior)","Phase 1|Phase 2","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000365583|P30CA016042|UCLA-0306106|MILLENNIUM-MM2003","June 2004","January 2013","January 2013","February 2016","June 10, 2004","June 11, 2004","January 20, 2016","March 15, 2016","February 17, 2016","March 15, 2016","Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT00084747"
1116,"NCT02481635","A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer","null","Recruiting","No Results Available","Pancreatic Cancer","Drug: Gemcitabine|Drug: Nab-paclitaxel|Radiation: Radiation Therapy|Procedure: Surgical Resection","Type and the severity of side effects|Number of surviving patients at 1 year after treatment|Number of patients who disease has not progressed|Number of patients that are able to receive surgery after chemoradiation|Average length of hospital stay per patient|Number of surviving patients at 30-days after surgery|Number of surviving patients at 90-days after surgery|Number of patients who need to be re-admitted to the hospital at 90-days after surgery|Time to Progression","University Health Network, Toronto","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARCAP-GA","July 2016","July 2020","January 2021","January 2017","June 23, 2015","June 25, 2015","null","null","January 4, 2017","January 5, 2017","Princess Margaret Cancer Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT02481635"
1117,"NCT00526734","High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma","null","Unknown status","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Biological: pegfilgrastim|Drug: melphalan|Procedure: autologous hematopoietic stem cell transplantation","Number of patients with engraftment after induction chemotherapy|Number and proportion of patients from whom ≥ 2 x 10e6 CD34-positive cells/kg are harvested|Number and proportion of patients from whom ≥ 4 x 10e6 CD34-positive cells/kg are harvested|CD34-positive cells/kg yield in each leukapheresis|Number of leukaphereses to collect ≥ 2 x 10e6 CD34-positive cells/kg|Number of leukaphereses to collect ≥ 4 x 10e6 CD34-positive cells/kg|Proportion of patients with platelet recovery ≥ 20 x 10e9/L in the absence of transfusion for at least 7 days|Proportion of patients with ANC recovery of ≥ 0.5 x 10e9/L|Time to neutrophil recovery, defined as the time to neutrophil engraftment (i.e., ANC ≥ 0.5 x 10e9/L for 3 consecutive days)|Time to ANC ≥ 1.0 x 10e9/L|Time to platelet recovery, defined as the time to platelets ≥ 20 x 10e9/L in the absence of platelet transfusion support for at least 7 days|Incidence and duration of hospitalization during mobilization phase and during post-transplantation phase|Incidence and severity of adverse events during and after the use of pegfilgrastim 12 mg or pegfilgrastim 18 mg and filgrastim","Erasme University Hospital|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","100","Other","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","ERA-2006-001|CDR0000561733|ERA-NEUMOBIL|EUDRACT-2006-000891-34","February 2006","null","null","September 2007","September 5, 2007","September 10, 2007","null","null","August 9, 2013","August 12, 2013","Hopital Universitaire Erasme, Brussels, Belgium|Medical University of Gdansk, Gdansk, Poland|Silesian Medical Academy, Katowice, Poland|Institute of Haematology and Blood Transfusion, Warsaw, Poland","https://ClinicalTrials.gov/show/NCT00526734"
1118,"NCT00003146","Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma","null","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: busulfan|Drug: melphalan|Drug: thiotepa|Procedure: bone marrow transplantation|Procedure: peripheral blood stem cell transplantation","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","1204.00|FHCRC-1204.00|NCI-H97-0007|CDR0000065929","November 1997","June 2001","June 2001","June 2011","November 1, 1999","April 23, 2004","null","null","June 21, 2011","June 23, 2011","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00003146"
1119,"NCT01211990","An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States","null","Completed","No Results Available","Cancer|Allogeneic Peripheral Blood Stem Cell Transplant|Bone Marrow Transplantation","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Senior)","","22","NIH","Observational","Time Perspective: Prospective","100192|10-M-0192","August 31, 2010","null","May 13, 2013","May 13, 2013","September 29, 2010","September 30, 2010","null","null","October 5, 2017","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT01211990"
1120,"NCT00186641","High Dose Chemotherapy and Autologous Transplant for Breast Cancer","null","Unknown status","No Results Available","Graft vs Host Disease","Procedure: high dose chemo and auto hematopoietic cell transplant","Survival","Stanford University","All","18 Years to 65 Years   (Adult)","Phase 2","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BMT42","null","null","March 2005","July 2007","September 14, 2005","September 16, 2005","null","null","July 10, 2007","July 11, 2007","Stanford University Cancer Center, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT00186641"
1121,"NCT00004088","Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma","null","Active, not recruiting","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Biological: recombinant interferon alfa|Drug: busulfan|Drug: cyclophosphamide|Drug: melphalan|Drug: pamidronate disodium|Drug: thalidomide|Procedure: peripheral blood stem cell transplantation","Assess feasibility and toxicities of tandem cycle high-dose melphalan and busulfan/cyclophosphamide followed by autologous peripheral blood progenitor cell rescue.","City of Hope Medical Center|National Cancer Institute (NCI)","All","up to 65 Years   (Child, Adult)","Phase 2","70","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","99021|P30CA033572|CHNMC-IRB-99021|NCI-G99-1583|CDR0000067301","April 13, 1999","February 2018","February 2018","March 2017","December 10, 1999","January 27, 2003","null","null","March 1, 2017","March 3, 2017","Banner Good Samaritan Medical Center, Phoenix, Arizona, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States","https://ClinicalTrials.gov/show/NCT00004088"
1122,"NCT00003195","Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma","null","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: recombinant interferon alfa|Drug: busulfan|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","1272.00|FHCRC-1272.00|NCI-H98-0009|CDR0000066030","December 1997","null","November 2000","November 2011","November 1, 1999","May 24, 2004","null","null","November 15, 2011","November 17, 2011","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00003195"
1123,"NCT01135875","Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients","null","Completed","No Results Available","Glioblastoma Multiforme|Healthy Volunteers","Other: GBM Patients|Other: Normal Controls","Identification of Human GBM CD Antigen Signature.|Identification & Isolation of Human GBM Cells in Seeded Normal Control Human Blood.|Prospective Isolation of GBM Tumor Cells in GBM Patient Blood.|Prospective Evaluation of the Routine Medical History of GBM Patients.","University of Florida","All","18 Years to 89 Years   (Adult, Senior)","","130","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","CTC-01","October 2009","April 2013","April 2013","October 2013","May 24, 2010","June 3, 2010","null","null","October 15, 2013","October 17, 2013","University of Florida, Gainesville, Florida, United States","https://ClinicalTrials.gov/show/NCT01135875"
1124,"NCT00008229","Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma","null","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Drug: melphalan|Procedure: peripheral blood stem cell transplantation|Radiation: holmium Ho 166 DOTMP","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","null","Other|NIH","Interventional","Primary Purpose: Treatment","1542.00|FHCRC-1542.00|NEORX-9902|UCLA-0006110|NCI-G00-1892|CDR0000068389","August 2000","null","September 2001","September 2010","January 6, 2001","May 24, 2004","null","null","September 17, 2010","September 21, 2010","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00008229"
1125,"NCT00005987","Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma","null","Terminated","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Drug: carmustine|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Drug: filgrastim|Drug: mitoxantrone hydrochloride|Drug: recombinant interferon alfa|Drug: sargramostim|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Procedure: radiation therapy","","Masonic Cancer Center, University of Minnesota","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","87","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","1996LS137|UMN-MT-9216|UMN-MT-1992-16","August 2000","July 2003","July 2003","November 2017","July 5, 2000","January 27, 2003","null","null","November 27, 2017","November 29, 2017","University of Minnesota Cancer Center, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00005987"
1126,"NCT00963612","Non-invasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma by Blood-Oxygen-Level Dependent Magnetic Resonance Imaging (BOLD MRI)","null","Completed","No Results Available","Hepatocellular Carcinoma","Procedure: BOLD MRI test","To assess the ability of BOLD MRI to predict microvascular invasion in hepatocellular carcinoma via assessment of intratumoral oxygenation.|To identify a quantitative threshold tumor R2* value using BOLD MRI technique reasonably sensitive of predicting microvascular invasion in HCC pre-operatively.","University Health Network, Toronto","All","18 Years and older   (Adult, Senior)","","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UHN09-0426-CE","September 2009","December 2016","December 2016","September 2017","August 7, 2009","August 21, 2009","null","null","September 28, 2017","October 2, 2017","University Health Network, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT00963612"
1127,"NCT02744092","Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer","CANVAS","Recruiting","No Results Available","Cancer|Venous Thromboembolism|Deep Vein Thrombosis (DVT)|Pulmonary Embolism (PE)|Blood Clot","Drug: Rivaroxaban|Drug: Apixaban|Drug: Edoxaban|Drug: Dabigatran|Drug: Warfarin|Drug: Dalteparin|Drug: Enoxaparin|Drug: Fondaparinux","Cumulative VTE recurrence reported by participants (via study-specific questionnaire) or clinicians (via study-specific case report form)|Cumulative rates of major bleeding reported by participants (via study-specific questionnaire) or clinicians (via study-specific case report form)|Health related quality of life reported by participants via the Optum SF-12v2 Health Survey questionnaire|Burden of anticoagulation therapy reported by participants via the Anti-Clot Treatment Scale (ACTS) questionnaire|Mortality reported by participants' surrogates (via study-specific questionnaire) or clinicians (via study-specific case report form)","Alliance Foundation Trials, LLC.|Patient-Centered Outcomes Research Institute","All","21 Years and older   (Adult, Senior)","","940","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFT-28|CER-1503-29805","December 2016","September 2019","September 2019","October 2017","April 11, 2016","April 20, 2016","null","null","October 30, 2017","November 1, 2017","UCSF Medical Center - Mission Bay, San Francisco, California, United States|Middlesex Hospital, Middletown, Connecticut, United States|The Stamford Hospital, Stamford, Connecticut, United States|Morton Plant Hospital, Clearwater, Florida, United States|Breast Cancer Center at Memorial Regional Hospital, Hollywood, Florida, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Hollis Cancer Center, Lakeland, Florida, United States|Breast Cancer Center at Memorial Hospital West, Pembroke Pines, Florida, United States|Memorial Cancer Institute at Memorial Hospital West, Pembroke Pines, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|Kootenai Health, Post Falls, Idaho, United States|Carle on Vermillion, Danville, Illinois, United States|Carle - Effingham, Effingham, Illinois, United States|NorthShore University HealthSystem Evanston Hospital, Evanston, Illinois, United States|NorthShore University HealthSystem Glenbrook Hospital, Glenview, Illinois, United States|NorthShore University HealthSystem Highland Park Hospital, Highland Park, Illinois, United States|Carle - Mattoon/Charleston, Mattoon, Illinois, United States|NorthShore University HealthSystem Skokie ACC, Skokie, Illinois, United States|The Carle Foundation Hospital/Carle Cancer Center, Urbana, Illinois, United States|Reid Health, Richmond, Indiana, United States|Chandler Medical Center - University of Kentucky, Lexington, Kentucky, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Norton Hospital, Louisville, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|University of Louisville Physicians, PSC, Louisville, Kentucky, United States|University of Louisville, Division of Surgical Oncology, Louisville, Kentucky, United States|Eastern Maine Medical Center, Bangor, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|DF/BWCC at Milford Regional Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|St. Elizabeth's Medical Center, Brighton, Massachusetts, United States|Lowell General Hospital, Lowell, Massachusetts, United States|South Shore Hospital, South Weymouth, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Green Bay Oncology, Ltd./St. Francis Hospital, Escanaba, Michigan, United States|Veterans Administration/Harry S Truman Memorial Hospital, Columbia, Missouri, United States|Ellis Fischel Cancer Center University of Missouri Healthcare, Columbia, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center - South County, Saint Louis, Missouri, United States|Siteman Cancer Center - West County, Saint Louis, Missouri, United States|Siteman Cancer Center - St. Peters, Saint Peters, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic, Billings, Montana, United States|Montana Cancer Consortium, Billings, Montana, United States|Bozeman Health, Bozeman, Montana, United States|Benefis Sletten Cancer Institute, Great Falls, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Center, Missoula, Montana, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Dana-Farber/New Hampshire Oncology Hematology, Londonderry, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|SUNY Upstate Medical University, New York, New York, United States|Southeastern Medical Oncology Center, Clinton, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Southeastern Medical Oncology Center, Jacksonville, North Carolina, United States|Kenansville Medical Center, Kenansville, North Carolina, United States|Kinston Medical Specialists, P.A., Kinston, North Carolina, United States|Lenoir Memorial Hospital, Kinston, North Carolina, United States|Onslow Medical Center, Richlands, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Dayton Physicians LLC, Miami Valley South, Centerville, Ohio, United States|The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|Dayton Physicians LLC, Samaritan North, Dayton, Ohio, United States|Dayton Clincial Oncology Program, Dayton, Ohio, United States|Wright Patterson Medical Center, Dayton, Ohio, United States|Dayton Physicians LLC, Atrium, Franklin, Ohio, United States|Dayton Physicians, Wayne, Greenville, Ohio, United States|Greater Dayton Cancer Center, Kettering, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Toledo Clinic Cancer Center - Maumee, Maumee, Ohio, United States|Toledo Clinic Cancer Center - Toledo, Toledo, Ohio, United States|Dayton Physicians LLC, Upper valley, Troy, Ohio, United States|WellSpan Health Ephrata Cancer Center, Ephrata, Pennsylvania, United States|WellSpan Health Adams Cancer Center, Gettysburg, Pennsylvania, United States|WellSpan Health Sechler Family Cancer Center, Lebanon, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|WellSpan Health York Cancer Center, York, Pennsylvania, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Augusta Health Cancer Center, Fishersville, Virginia, United States|Bon Secours Cancer Institute Medical Oncology at Memorial Regional, Mechanicsville, Virginia, United States|Bon Secours Cancer Institute Medical Oncology at St. Francis, Midlothian, Virginia, United States|Bon Secours Cancer Institute Medical Oncology at St. Mary's, Richmond, Virginia, United States|MultiCare Regional Cancer Center - Auburn, Auburn, Washington, United States|MultiCare Regional Cancer Center - Gig Harbor Medical Park, Gig Harbor, Washington, United States|MultiCare Regional Cancer Center - Puyallup, Puyallup, Washington, United States|Multicare Institute for Research & Innovation, Tacoma, Washington, United States|MultiCare Regional Cancer Center - Tacoma, Tacoma, Washington, United States|Green Bay Oncology, Ltd./HSHS St. Vincent Hospital, Green Bay, Wisconsin, United States|HSHS St. Vincent Hospital, Green Bay, Wisconsin, United States|Green Bay Oncology, Ltd./HSHS St. Mary's Hospital Medical Center, Green Bay, Wisconsin, United States|HSHS St. Mary's Hospital Medical Center, Green Bay, Wisconsin, United States|University of Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Green Bay Oncology, Ltd./HSHS St. Clare Memorial Hospital, Oconto Falls, Wisconsin, United States|Green Bay Oncology, Ltd./Door County Memorial Hospital, Sturgeon Bay, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT02744092"
1128,"NCT00002810","High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis","null","Completed","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Drug: melphalan|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","Overall survival|Time to clinical progression of amyloid symptoms","Temple University","All","16 Years to 65 Years   (Child, Adult)","Phase 2","null","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000064938|TUHSC-2797|NCI-V96-0951","May 1996","May 2006","May 2006","September 2010","November 1, 1999","January 27, 2003","null","null","September 30, 2010","October 1, 2010","Fox Chase-Temple Cancer Center CCOP Research Base, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00002810"
1129,"NCT02211677","Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma","null","Recruiting","No Results Available","Nasopharyngeal Neoplasms|Blood Cell Count|Neoplasm Staging|Prognosis","","5-year overall survival|5-year disease-free survival|5-year recurrence-free survival|5-year distant-free survival","Sun Yat-sen University","All","18 Years to 75 Years   (Adult, Senior)","","500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","B2014-002-01","August 2014","December 2019","December 2024","July 2017","August 5, 2014","August 7, 2014","null","null","July 11, 2017","July 13, 2017","The Fisrt Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China|Anhui Province Hospital, Hefei, Anhui, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|The Central Hospital of Shaoyang, Shaoyang, Hunan, China|The Affiliated Hospital of Luzhou Medical College, Luzhou, Sichuan, China","https://ClinicalTrials.gov/show/NCT02211677"
1130,"NCT02261415","The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial","HeLiX","Recruiting","No Results Available","Cancer|Tumour|Surgery","Drug: Tranexamic acid (TXA)|Drug: Normal saline","Mean centre recruitment|Eligible patients who consent to participate|Ability to randomize patients and administer intervention|Ability to collect complete perioperative data to 90 days|Adherence with perioperative blood transfusion guidelines|Assessment of transfusion incidence","Sunnybrook Health Sciences Centre|HepatoPancreaticoBiliary (HPB) Concept Team","All","18 Years and older   (Adult, Senior)","Phase 2","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","244-2014","November 2014","January 2022","January 2027","November 2017","October 7, 2014","October 10, 2014","null","null","November 24, 2017","November 28, 2017","Foothills Hospital, Calgary, Alberta, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT02261415"
1131,"NCT01491308","Restrictive Versus Liberal Red Cell Transfusion Strategy in Orthopedic-Oncology Patients Undergoing Surgery - a Randomized Controlled Study","null","Unknown status","No Results Available","Red Blood Cells Transfusion.","Other: Red blood cells transfusion","Functional outcome|Mortality and morbidity|Admission to ICU|Hospital lengths of stay|RBC transfusions","Tel-Aviv Sourasky Medical Center","All","18 Years and older   (Adult, Senior)","","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TASMAC-11-IM-0449-11-CTIL","January 2012","January 2013","null","December 2011","December 8, 2011","December 13, 2011","null","null","December 12, 2011","December 13, 2011","Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel","https://ClinicalTrials.gov/show/NCT01491308"
1132,"NCT00899275","Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma","null","Active, not recruiting","No Results Available","Sarcoma","Other: biologic sample preservation procedure","Collect biological specimens from patients with osteosarcoma|Provide a repository for long-term storage of osteosarcoma-related biological materials|Make these specimens available to qualified researchers to understand the biology of osteosarcoma|Correlate these results with the patients' clinical data","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 120 Years   (Child, Adult, Senior)","","1000","Other|NIH","Observational","Observational Model: Other|Time Perspective: Retrospective","AOST06B1|COG-AOST06B1|NCI-2009-00410","February 2008","January 2100","null","December 2017","May 9, 2009","May 12, 2009","null","null","December 11, 2017","December 13, 2017","Children's Hospital of Alabama at University of Alabama at Birmingham, Birmingham, Alabama, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States|Jonathan Jaques Children's Cancer Center at Miller Children's Hospital, Long Beach, California, United States|Childrens Hospital Los Angeles, Los Angeles, California, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|Mattel Children's Hospital at UCLA, Los Angeles, California, United States|Children's Hospital Central California, Madera, California, United States|Children's Hospital and Research Center Oakland, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States|Kaiser Permanente Medical Center - Oakland, Sacramento, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Children's Hospital Colorado Center for Cancer and Blood Disorders, Aurora, Colorado, United States|Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Yale Cancer Center, New Haven, Connecticut, United States|Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States|Children's National Medical Center, Washington, District of Columbia, United States|Broward General Medical Center Cancer Center, Fort Lauderdale, Florida, United States|Lee Cancer Care of Lee Memorial Health System, Fort Myers, Florida, United States|Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Baptist-South Miami Regional Cancer Program, Miami, Florida, United States|Florida Hospital Cancer Institute at Florida Hospital Orlando, Orlando, Florida, United States|M.D. Anderson Cancer Center at Orlando, Orlando, Florida, United States|Nemours Children's Clinic - Orlando, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|St. Joseph's Cancer Institute at St. Joseph's Hospital, Tampa, Florida, United States|AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States|Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Mountain States Tumor Institute at St. Luke's Regional Medical Center, Boise, Idaho, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Keyser Family Cancer Center at Advocate Hope Children's Hospital, Oak Lawn, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Simmons Cooper Cancer Institute, Springfield, Illinois, United States|Riley's Children Cancer Center at Riley Hospital for Children, Indianapolis, Indiana, United States|St. Vincent Indianapolis Hospital, Indianapolis, Indiana, United States|Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States|Lucille P. Markey Cancer Center at University of Kentucky, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Tulane Cancer Center Office of Clinical Research, Alexandria, Louisiana, United States|Ochsner Cancer Institute at Ochsner Clinic Foundation, New Orleans, Louisiana, United States|CancerCare of Maine at Eastern Maine Medical Center, Bangor, Maine, United States|Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Floating Hospital for Children at Tufts - New England Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C.S. Mott Children's Hospital at University of Michigan Medical Center, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Breslin Cancer Center at Ingham Regional Medical Center, Lansing, Michigan, United States|Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|University of Mississippi Cancer Clinic, Jackson, Mississippi, United States|Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States|Children's Hospital, Omaha, Nebraska, United States|UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States|CCOP - Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Hackensack University Medical Center Cancer Center, Hackensack, New Jersey, United States|Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States|Carol G. Simon Cancer Center at Morristown Memorial Hospital, Summit, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States|Brooklyn Hospital Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Schneider Children's Hospital, New Hyde Park, New York, United States|NYU Cancer Institute at New York University Medical Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States|James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States|Stony Brook University Cancer Center, Stony Brook, New York, United States|SUNY Upstate Medical University Hospital, Syracuse, New York, United States|Mission Hospitals - Memorial Campus, Asheville, North Carolina, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, United States|Presbyterian Cancer Center at Presbyterian Hospital, Charlotte, North Carolina, United States|Duke Cancer Institute, Durham, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|Akron Children's Hospital, Akron, Ohio, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's - Dayton, Dayton, Ohio, United States|Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States|Penn State Children's Hospital, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|Palmetto Health South Carolina Cancer Center, Columbia, South Carolina, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|T.C. Thompson Children's Hospital, Chattanooga, Tennessee, United States|East Tennessee Children's Hospital, Knoxville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|CCOP - Scott and White Hospital, Temple, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Carilion Medical Center for Children at Roanoke Community Hospital, Roanoke, Virginia, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States|Providence Cancer Center at Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Tacoma, Tacoma, Washington, United States|West Virginia University Health Sciences Center - Charleston, Charleston, West Virginia, United States|Mary Babb Randolph Cancer Center at West Virginia University Hospitals, Morgantown, West Virginia, United States|Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States|Midwest Children's Cancer Center at Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Royal Children's Hospital, Brisbane, Queensland, Australia|Women's and Children's Hospital, North Adelaide, South Australia, Australia|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Children's and Women's Hospital of British Columbia, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada|Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|Montreal Children's Hospital at McGill University Health Center, Montreal, Quebec, Canada|Hopital Sainte Justine, Montreal, Quebec, Canada|Allan Blair Cancer Centre at Pasqua Hospital, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre at the University of Saskatchewan, Saskatoon, Saskatchewan, Canada|Starship Children's Health, Auckland, New Zealand|San Jorge Children's Hospital, Santurce, Puerto Rico","https://ClinicalTrials.gov/show/NCT00899275"
1133,"NCT00897182","Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia","null","Completed","No Results Available","Leukemia","Genetic: microarray analysis|Genetic: polymerase chain reaction","Correlation of increased or decreased expression of same transcripts with disease outcome|Minimum number of genes that can be used for precise diagnosis of each of the three subtypes of acute myeloid leukemia|Identification of individual genes that are differentially expressed between the subtypes of AMLs|Correlation of the patterns of expression of the translocation-specific transcripts with age, sex, race, response to treatment, survival, and with other known mutations","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","Child, Adult, Senior","","96","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CALGB-20801|CDR0000595708|NCI-2009-00462","May 2008","March 2014","March 2014","July 2016","May 9, 2009","May 12, 2009","null","null","July 1, 2016","July 4, 2016","Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00897182"
1134,"NCT02093325","A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia","null","Enrolling by invitation","No Results Available","Solid Tumor","Drug: Eltrombopag|Drug: Placebo","efficacy of eltrombopag (50mg once daily)|safety and feasibility of 7-day eltrombopag","Chang Gung Memorial Hospital|Novartis","All","18 Years and older   (Adult, Senior)","Phase 3","83","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","102-4363A3","March 2014","March 2019","August 2019","October 2017","March 17, 2014","March 21, 2014","null","null","October 22, 2017","October 24, 2017","Department of Obstetrics & Gynecology and Department of Oncology Chang Gung Memorial Hospital, Chiayi City, Taiwan|Department of Obstetrics & Gynecology Chang Gung Memorial Hospital, Kaohsiung, Taiwan|Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Division of Oncology Chang Gung Memorial Hospital, Linkou, Taiwan","https://ClinicalTrials.gov/show/NCT02093325"
1135,"NCT02130752","Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery","CGCT-01","Not yet recruiting","No Results Available","Gastric Cancer|Surgery|Ultrasonic Scalpel|Monopolar Electrocautery|Operation Time|Blood Loss, Surgical|Quality of Life|External Causes of Morbidity and Mortality","Device: Monopolar electrocautery|Device: Ultrasonic scalpel","Surgical duration|Blood loss|Number of harvested and positive lymph nodes|Intraoperative Mortality and Morbidity|Survival outcome|Postoperative Mortality and Morbidity","West China Hospital","All","18 Years to 75 Years   (Adult, Senior)","Phase 3","430","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CGCT-01","October 2014","October 2016","October 2019","September 2014","April 7, 2014","May 5, 2014","null","null","September 5, 2014","September 8, 2014","Peking University Cancer Hospital and Institute, Beijing, Beijing, China|Guangdong General Hospital, Guangzhou, Guangdong, China|The Third Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang, China|Union Hospital, Tongji Medical College, Wuhan, Hubei, China|The First Affiliated Hospital of China Medical University, Shengyang, Liaoning, China|Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China","https://ClinicalTrials.gov/show/NCT02130752"
1136,"NCT01875653","Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma","null","Terminated","No Results Available","Stage IV Melanoma|Stage III Melanoma","Biological: Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|Biological: Autologous PBMCs in GM-CSF (MC)","Overall survival|Adverse Events as a Measure of Safety and Tolerability","Caladrius Biosciences, Inc.","All","18 Years and older   (Adult, Senior)","Phase 3","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CL-CA-P01|2015-001984-38","October 2014","January 2017","June 2022","January 2016","June 7, 2013","June 12, 2013","null","null","April 25, 2016","April 27, 2016","Irvine, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|Orange, California, United States|Santa Monica, California, United States|Aurora, Colorado, United States|Goshen, Indiana, United States|Louisville, Kentucky, United States|Marrero, Louisiana, United States|Baltimore, Maryland, United States|Hackensack, New Jersey, United States|Cincinnati, Ohio, United States|Easton, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Knoxville, Tennessee, United States|Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT01875653"
1137,"NCT01517035","Improving Blood Stem Cell Collection and Transplant Procedures","null","Completed","No Results Available","Myelodysplastic Syndrome (MDS)|Chronic Myelogenous Leukemia|Acute Lymphoblastic Leukemia|CML (Chronic Myelogenous Leukemia|CLL (Chronic Lymphocytic Leukemia)","Procedure: Stem Cell Transplantation","The primary endpoint is all cause mortality at day 200, and the proportion of subjects who have survived at day 200 will be used to determine the sample size.|Cumulative incidence of relapse|Secondary Outcome Measure: Standard transplant outcome variables such as relapse, non-relapse mortality, neutrophil and platelet recovery kinetics, incidence and severity of acute GVHD and chronic GVHD. Technical success rates and the use of DLI...|Non Relapse Mortality|Days till ANC greater than 500/uL|Days till Platelet greater than 20 k/ul","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","2 Years to 80 Years   (Child, Adult, Senior)","Phase 1|Phase 2","43","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","120028|12-H-0028","January 13, 2012","March 29, 2017","March 29, 2017","March 29, 2017","January 24, 2012","January 25, 2012","null","null","June 30, 2017","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT01517035"
1138,"NCT02033616","Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas","null","Recruiting","No Results Available","Stage III Ovarian Carcinoma|Stage IV Ovarian Carcinoma|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma","Biological: AVOVA-1|Biological: MC","Primary Efficacy Endpoint: Overall Survival","Aivita Biomedical, Inc.","Female","18 Years and older   (Adult, Senior)","Phase 2","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CL-OVA-P01","November 18, 2017","December 2022","December 2022","December 2017","January 7, 2014","January 13, 2014","null","null","December 6, 2017","December 8, 2017","Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States","https://ClinicalTrials.gov/show/NCT02033616"
1139,"NCT03033186","Everolimus TDM to Predict Long Term Toxicity","Foresight","Recruiting","No Results Available","Breast Cancer|Renal Cell Carcinoma|Pancreatic Neuroendocrine Tumour|Gastrointestinal Neuroendocrine Tumour|Neuroendocrine Neoplasm of Lung","","Everolimus TDM to predict long-term toxicity|Everolimus TDM to predict short-term toxicity|Correlation everolimus concentration DBS from fingerprick with whole blood from venipuncture|Correlation everolimus concentration DBS from fingerprick with DBS spiked with whole blood from venipuncture|Everolimus TDM to predict dose reductions","Maastricht University Medical Center","All","18 Years and older   (Adult, Senior)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NL58486.068.16","May 16, 2017","September 1, 2018","December 31, 2018","May 2017","January 24, 2017","January 26, 2017","null","null","May 30, 2017","May 31, 2017","Maastricht University Medical Centre, Maastricht, Limburg, Netherlands","https://ClinicalTrials.gov/show/NCT03033186"
1140,"NCT01178281","Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence","RESUME","Active, not recruiting","Has Results","Primary Myelofibrosis","Drug: Pomalidomide 0.5 mg|Drug: Placebo","Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence|Duration of RBC-transfusion Independence|Time to Becoming RBC-transfusion-independent|Healthcare Resource Utilization|Euro QOL 5 Dimension Questionaire|FACT-Anemia Quality of Life Questionaire|Frequency of Adverse Events|Overall Survival","Celgene","All","18 Years and older   (Adult, Senior)","Phase 3","252","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CC-4047-MF-002|2010-018965-42","September 2010","January 2013","May 2018","February 2017","July 15, 2010","August 10, 2010","January 31, 2014","March 14, 2014","February 1, 2017","March 13, 2017","Mayo Clinic, Scottsdale, Arizona, United States|UCLA School of Medicine, Los Angeles, California, United States|University of Florida Shands Cancer Center, Gainesville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Mount Sinai School of Medicine Brookdale University Hospital, Brooklyn, New York, United States|Weill Medical College of Cornell University, New York, New York, United States|Ruttenberg Treatment Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Medicine Taussig Cancer Institute, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Avera Hematology and Transplant, Sioux Falls, South Dakota, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Fred Hutchinson Cancer Center, Seattle, Washington, United States|Gosford Hospital, Gosford, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Frankston Hospital, Frankston, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Medizinische Universitatklinik Graz, Graz, Austria|Medizinische Universitat Innsbruck, Innsbruck, Austria|Medizinische Universitat Wien, Vienna, Austria|Algemeen Ziekenhuis Sint-Jan, Brugge, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|Universitaire Ziekenhuis Leuven Gathuisberg, Leuven, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Centre Hospitalier de L'Universite de Montreal, Montreal,, Canada|Peking University People's Hospital, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Jiangsu Province Hospital, Jiangsu, China|Shanghai Ruijin Hospital, Shanghai, China|West China Hospital, Sichuan University, Sichuan, China|Hopital Albert Michallon, La Tronche, France|Hopital Saint Vincent de Paul, Lille, France|CHU Dupuytren, Limoges, France|Hopital Saint-Louis, Paris, France|CHRU - Hopital du Haut Leveque, Pessac, France|Hopitaux Universitaires de Strasbourg, CHU Haute-Pierre, Strasbourg, France|Hopital Purpan, Toulouse, France|Institut Gustave Roussy, Villejuif, France|Universitatsklinikum Aachen, Aachen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum Leipzig, Leipzig, Germany|Johannes Wesling Klinikum Minden, Minden, Germany|Universitatsklinikum Ulm, Ulm, Germany|Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari, Bari, Italy|Ospedali Riuniti di Bergamo, Bergamo, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Azienda Ospedaliera Universitaria Federico II di Napoli, Napoli, Italy|Azienda Ospedaliera San Luigi Gonzaga, Orbassano, Italy|IRCCS Fondazione Policlinico San Matteo, Universita di Pavia, Centro per lo Studio della Mielofibrosi, Pavia, Italy|IRCCS Fondazione Policlinico San Matteo, Universita di Pavia, Ematologia, Pavia, Italy|Ospedale di Circolo e Fondazione Macchi Varese, Varese, Italy|Juntendo University Hospital, Bunkyou-ku, Japan|Kyushu University Hospital, Fukuoka City, Japan|Tokai University Hospital, Isehara City, Japan|Kyoto University Hospital, Kyoto City, Japan|Nagasaki University Hospital, Nagasaki City, Japan|Tokyo Medical University Hospital, Shinjuku, Japan|VU University Medical Center, Amsterdam, Netherlands|Erasmus Medish Centrum, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Wojewodzki Szpital Specjalistyczny im. F.Chopina, Rzeszow, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 PAM, Szczecin, Poland|Centralny Szpital Kliniczny MSWiA, Warsaw, Poland|Russian Scientific Haematology Centre, Moscow, Russian Federation|Federal State Institution Russian Scientific-research Institute of Hematology and Transfusiology of Federal Medical-Biological Agency of Russia, Saint-Petersburg, Russian Federation|State Pavlov Medical University, Saint-Petersburg, Russian Federation|Federal State Institution ""Federal Centre of Heart, Blood and Endocrinology of Rosmedtechnologies named after V.A. Almazov"", Saint-Petersburg, Russian Federation|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital Universitario Puerta De Hierro Majadahonda, Majadahonda, Spain|Hospital Clinico de Salamanca, Salamanca, Spain|Hospital Clinico de Valencia, Valencia, Spain|Skane University Hospital, Lund, Sweden|Karolinska University Hospital Huddinge, Stockholm, Sweden|Belfast City Hospital, Belfast, United Kingdom|Beatson Oncology Centre, Glasgow, United Kingdom|John Radcliffe Hospital NHS Trust, Headington, United Kingdom|St. Thomas Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Freeman Hospital, Newcastle upon Tyne, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT01178281"
1141,"NCT00152139","Stem Cell Transplantation for Patients With Hematologic Malignancies","null","Completed","No Results Available","Acute Lymphoblastic Leukemias|Acute Myelocytic Leukemia|Chronic Myeloid Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndrome|Hemoglobinuria, Paroxysmal|Non-Hodgkin Lymphoma","Procedure: Allogeneic Stem Cell Transplantation|Drug: Chemotherapy and antibodies","To estimate the occurrence of acute graft versus host disease in patients who have received an unmanipulated hematopoietic stem cell transplant from a matched unrelated donor","St. Jude Children's Research Hospital","All","2 Years to 21 Years   (Child, Adult)","Phase 3","33","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MUDSCT","May 2002","June 2005","January 2009","January 2009","September 8, 2005","September 9, 2005","null","null","January 28, 2009","January 29, 2009","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","https://ClinicalTrials.gov/show/NCT00152139"
1142,"NCT03188497","Clinical Study of Concurrent Radiotherapy With Concurrent Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma","null","Recruiting","No Results Available","Gastrointestinal Toxicity|Blood / Bone Marrow Toxicity","Drug: Lobaplatin|Device: linear accelerator","Platelets|Leukocytes|Neutrophils|Hemoglobin|Nausea|Vomiting","Fifth Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 65 Years   (Adult)","Phase 1","18","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","zsu20170203","February 2, 2017","January 31, 2018","May 31, 2018","June 2017","May 22, 2017","June 15, 2017","null","null","June 13, 2017","June 15, 2017","the Fifth Hospital Affiliated to Sun Yat-Sen University, Zhuhai, Guangdong, China","https://ClinicalTrials.gov/show/NCT03188497"
1143,"NCT00305682","Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant","null","Active, not recruiting","No Results Available","Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: Fludarabine|Drug: mycophenolate mofetil|Procedure: umbilical cord blood transplantation|Radiation: total body irradiation|Drug: Sirolimus","Overall Survival|Incidence of Non-relapse mortality|Chimerism Values|Incidence of neutrophil engraftment|Incidence of platelet engraftment|Incidence of acute graft-versus-host disease (GVHD)|Incidence of Chronic Graft-Versus-Host Disease|Progression-free survival|Incidence of relapse","Masonic Cancer Center, University of Minnesota","All","up to 75 Years   (Child, Adult, Senior)","Phase 2","293","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2005LS036|UMN-MT-2005-02|UMN-0507M70121","June 2005","June 2018","June 2018","December 2017","March 21, 2006","March 22, 2006","null","null","December 3, 2017","December 5, 2017","Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00305682"
1144,"NCT00014235","Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies","null","Active, not recruiting","No Results Available","Acute Myeloid Leukemia/Transient Myeloproliferative Disorder|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Plasmacytoid Dendritic Cell Neoplasm|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Juvenile Myelomonocytic Leukemia|Mast Cell Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Systemic Amyloidosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage II Multiple Myeloma|Stage III Multiple Myeloma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies|Waldenström Macroglobulinemia","Drug: fludarabine phosphate|Radiation: total-body irradiation|Procedure: peripheral blood stem cell transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Drug: cyclosporine|Drug: mycophenolate mofetil|Other: laboratory biomarker analysis","Probability of severe (grade III/IV) GVHD in each arm|Incidence of graft rejection|Incidence of non-relapse mortality|Incidence of infectious complications|Severity of infectious complications","Fred Hutchinson Cancer Research Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)","All","up to 74 Years   (Child, Adult, Senior)","","160","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1596.00|NCI-2012-00671|P30CA015704","December 2000","February 2005","null","November 2017","April 10, 2001","January 27, 2003","null","null","November 20, 2017","November 22, 2017","University of Arizona Health Sciences Center, Tucson, Arizona, United States|City of Hope Medical Center, Duarte, California, United States|Stanford University Hospitals and Clinics, Stanford, California, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States|Baylor University Medical Center, Dallas, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States|Froedtert Hospital, Milwaukee, Wisconsin, United States|Universitaet Leipzig, Leipzig, Germany|University of Torino, Torino, Italy","https://ClinicalTrials.gov/show/NCT00014235"
1145,"NCT01823094","CTP Imaging of Lung Cancer","CTPLC","Completed","No Results Available","Non Small Cell Lung Cancer","","Yield of conducting CTP studies|Variability of CTP measurements|Magnitude of treatment induced changes in tumor blood flow","University of California, Davis|Radiological Society of North America","All","18 Years and older   (Adult, Senior)","","14","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","393991","March 2013","June 2015","June 2015","January 2016","March 22, 2013","April 4, 2013","null","null","January 22, 2016","January 26, 2016","University of California, Davis Medical Center, Sacramento, California, United States","https://ClinicalTrials.gov/show/NCT01823094"
1146,"NCT01174615","Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth","null","Recruiting","No Results Available","Leukemia","","The study is designed to collect blood and bone marrow from patients with various hematological diseases.|Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth in Patients With Malignancy or Hematologic Disorders","University of Massachusetts, Worcester","All","18 Years and older   (Adult, Senior)","","1000","Other","Observational","Time Perspective: Prospective","UM200901","September 2009","December 2099","December 2100","January 2017","May 24, 2010","August 3, 2010","null","null","January 10, 2017","January 11, 2017","University of Massachusetts Medical School, Worcester, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT01174615"
1147,"NCT00864227","Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)","null","Completed","Has Results","Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Myeloid, Acute|Burkitt Lymphoma|Lymphoma, B-Cell|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse","Biological: Hematopoietic Umbilical Cord Blood Stem Cell Transplantation|Biological: GVHD prophylaxis","Overall Survival at 180 Days From the Time of Transplant|Neutrophil Recovery|Primary Graft Failure|Secondary Graft Failure|Platelet Recovery to 20K|Donor Cell Engraftment|Acute Graft-versus-host Disease (GVHD)|Chronic GVHD|Progression-free Survival|Treatment-related Mortality (TRM)|Incidence of Infections|Platelet Recovery to 50K","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program","All","1 Year to 70 Years   (Child, Adult, Senior)","Phase 2","54","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BMTCTN0604|U01HL069294|5U24CA076518","December 2008","April 2011","November 2013","August 2016","March 17, 2009","March 18, 2009","May 20, 2015","August 28, 2015","September 27, 2017","October 27, 2017","City of Hope National Medical Center, Duarte, California, United States|University of Florida College of Medicine, Shands, Gainesville, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Hospital, Kansas City, Kansas, United States|Dana-Farber Cancer Institute (DFCI), Brigham & Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute (DFCI), Massachusetts General Hospital, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Barnes Jewish Hospital, Saint Louis, Missouri, United States|Weill Cornell Medical College, NY Presbyterian Hospital, New York, New York, United States|Ohio State, Arthur G. James Cancer Hospital, Columbus, Ohio, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Texas Transplant Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Medical College of Virginia (MCV) Hospital, Richmond, Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT00864227"
1148,"NCT00178308","Measuring Alterations of DNA in Human Blood","null","Completed","No Results Available","Neoplasms","","","University of Rochester|Litron Laboratories","All","21 Years to 70 Years   (Adult, Senior)","","24","Other|Industry","Observational","Observational Model: Defined Population|Time Perspective: Longitudinal|Time Perspective: Prospective","URCC 1702","null","null","null","September 2006","September 12, 2005","September 15, 2005","null","null","September 6, 2006","September 11, 2006","University of Rochester, Rochester, New York, United States","https://ClinicalTrials.gov/show/NCT00178308"
1149,"NCT00722683","Evaluate Breast Masses Using a New Method of Ultrasound Contrast to Detect Abnormal Blood Flow in Breasts","null","Withdrawn","No Results Available","Breast Cancer|Breast Abnormalities","Procedure: Ultrasound Imaging with Contrast","","University of Michigan","Female","18 Years and older   (Adult, Senior)","","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2001-0184","April 2001","August 2010","December 2010","October 2017","July 23, 2008","July 25, 2008","null","null","October 16, 2017","October 18, 2017","University of Michigan Health System, Ann Arbor, Michigan, United States","https://ClinicalTrials.gov/show/NCT00722683"
1150,"NCT01273766","Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies","null","Completed","Has Results","Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Grade III Lymphomatoid Granulomatosis|Adult Langerhans Cell Histiocytosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Mast Cell Leukemia|Myelodysplastic Syndrome With Isolated Del(5q)|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myeloid/NK-cell Acute Leukemia|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Anemia|Refractory Multiple Myeloma|Secondary Acute Myeloid Leukemia|Secondary Myelofibrosis|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Testicular Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Waldenstrom Macroglobulinemia","Drug: deferasirox|Other: laboratory biomarker analysis|Other: enzyme-linked immunosorbent assay","Changes in Mean Neutrophil Values (as Measured by Lab) for Arm 1 (Other Arms Were Used for Calibration Only)|Need for Hospitalization, Ventilator Support, Exchange Transfusion/Apheresis or Treatment With Antifungals or Antibiotics|Cumulative Incidence of Documented Bacterial, Fungal, and Viral Infections","Wake Forest University Health Sciences|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","16","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CCCWFU 97710|NCI-2010-02228","January 2011","March 2012","December 2014","December 2014","January 7, 2011","January 10, 2011","June 20, 2013","November 27, 2013","May 25, 2017","June 20, 2017","Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States","https://ClinicalTrials.gov/show/NCT01273766"
1151,"NCT02466828","qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.","null","Active, not recruiting","No Results Available","Glioblastoma|Hypoxia","Drug: Feraheme®","Oxygen saturation in GBM with qBOLD MRI and its correlation with histological markers of tissue hypoxia and angiogenesis|Oxygen saturation in GBM with qBOLD MRI and its correlation with targeted intraoperative oxygen measurement","Sunnybrook Health Sciences Centre|St. Michael's Hospital, Toronto","All","18 Years and older   (Adult, Senior)","Early Phase 1","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","127-2014","March 2015","December 2018","December 2018","October 2017","November 21, 2014","June 9, 2015","null","null","October 4, 2017","October 6, 2017","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT02466828"
1152,"NCT02955550","A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)","null","Recruiting","No Results Available","Multiple Myeloma","Drug: rhIL-2|Biological: PNK-007","Dose-Limiting Toxicity (DLT)|Maximum Tolerated Dose (MTD)|Dose Timing After Autologous Stem Cell Transplant|Adverse Events (AEs)|Response Rate","Celgene","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCT-PNK-007-MM-001","January 19, 2017","November 30, 2018","November 30, 2018","July 2017","November 2, 2016","November 4, 2016","null","null","July 21, 2017","July 24, 2017","University of Minnesota, Minneapolis, Minnesota, United States|Washington Univ School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Mt. Sinai School of Medicine, New York, New York, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT02955550"
1153,"NCT01866839","Preventing Stem Cell Transplant Complications With a Blood Separator Machine","null","Recruiting","No Results Available","MDS (Myelodysplastic Syndrome)|Myeloproliferative Disorder|Lymphoma, Non-Hodgkin|ALL (Acute B-Lymphoblastic Leukemia)|AML (Acute Meylogenous Leukemia","Device: Graft Manipulation (CD34+ Selection)","The primary outcome of this protocol is to determine the rate of overall survival at 200 day using the Miltenyi CliniMACS CD34 selection system.|Non Relapse Mortality|Relapse incidence|Disease free survival|Time to neutrophil and platelet recovery|Acute GVHD incidence|Acute GVHD severity|Chronic GVHD incidence|Chronic GVHD severity|GVHD free survival","National Heart, Lung, and Blood Institute (NHLBI)|Children's Research Institute|National Institutes of Health Clinical Center (CC)","All","2 Years to 80 Years   (Child, Adult, Senior)","Phase 1|Phase 2","192","NIH|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","130144|13-H-0144","May 29, 2013","February 3, 2018","February 3, 2018","December 19, 2017","May 29, 2013","June 3, 2013","null","null","December 20, 2017","December 21, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT01866839"
1154,"NCT00046852","Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma","null","Completed","No Results Available","Infection|Multiple Myeloma and Plasma Cell Neoplasm","Biological: filgrastim|Biological: pneumococcal polyvalent vaccine|Biological: therapeutic autologous lymphocytes|Biological: therapeutic tumor infiltrating lymphocytes|Drug: carmustine|Drug: cyclophosphamide|Drug: melphalan|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation","","University of Maryland|University of Maryland Greenebaum Cancer Center","All","18 Years to 80 Years   (Adult, Senior)","Phase 1|Phase 2","null","Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","CDR0000256870|MSGCC-0065|UPCC-6401|NCI-V02-1709","December 2001","November 2004","February 2008","September 2009","October 3, 2002","January 27, 2003","null","null","September 23, 2009","September 24, 2009","Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00046852"
1155,"NCT01015742","Unrelated Double Umbilical Cord Blood Units Transplantation","null","Unknown status","No Results Available","Leukemia, Myeloid, Acute|Leukemia, Lymphoblastic, Acute|Leukemia, Myeloid, Chronic","Drug: Stem cell Transplantation","To determine the Benefit and Side Effects of Double Umbilical Cord Blood Units Stem Cell Transplantation in Hematologic Malignancies|Neutrophil and platelet engraftment|Severity of acute graft-vs-host disease(GvHD|Early transplant related mortality|Overall and disease free survival at one years","Tehran University of Medical Sciences","All","1 Year to 50 Years   (Child, Adult)","Phase 2|Phase 3","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HORCSCT-0902","November 2009","December 2012","January 2013","May 2012","November 17, 2009","November 18, 2009","null","null","May 31, 2012","June 4, 2012","Hematology-Oncology & SCT Research Center, Tehran, Iran, Islamic Republic of","https://ClinicalTrials.gov/show/NCT01015742"
1156,"NCT00019097","Vaccine Therapy in Treating Patients With Multiple Myeloma","null","Completed","No Results Available","Stage II Multiple Myeloma|Stage III Multiple Myeloma|Refractory Plasma Cell Neoplasm","Drug: autologous tumor cell vaccine|Drug: keyhole limpet hemocyanin|Drug: melphalan|Drug: sargramostim","","National Cancer Institute (NCI)","null","18 Years and older   (Adult, Senior)","Phase 2","null","NIH","Interventional","Primary Purpose: Treatment","CDR0000064244|NCI-97-C-0033B|NCI-T94-0094N|CRB-9409","July 1995","null","March 2007","May 2006","March 1, 2007","March 5, 2007","null","null","June 19, 2013","June 20, 2013","Arkansas Cancer Research Center, Little Rock, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Medicine Branch, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00019097"
1157,"NCT00862719","Sitagliptin Umbilical Cord Blood Transplant Study","null","Completed","Has Results","Leukemia, Myeloid, Acute|Acute Lymphoblastic Leukemia|Myelodysplasia|Leukemia, Myelogenous, Chronic|Lymphoma, Non-Hodgkin","Drug: Sitagliptin","Cumulative Incidence of Patients With Engraftment by Day +30 Following Transplant|Time to Neutrophil Engraftment|Time to Platelet Engraftment|Treatment Related Adverse Events Grade 3 or Higher for Non-hematological Toxicity","Indiana University School of Medicine|Indiana University","All","18 Years to 59 Years   (Adult)","Phase 2","29","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0812-15; IUCRO-0223","March 2009","November 2012","February 2015","August 2016","March 16, 2009","March 17, 2009","June 22, 2016","August 4, 2016","August 25, 2016","October 7, 2016","IU Simon Cancer Center, Indianapolis, Indiana, United States","https://ClinicalTrials.gov/show/NCT00862719"
1158,"NCT00118339","Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma","null","Completed","No Results Available","Multiple Myeloma|Plasma Cell Neoplasm","Drug: chemoprotection|Procedure: complementary or alternative medicine procedure|Procedure: management of therapy complications","","Fred Hutchinson Cancer Research Center","All","18 Years and older   (Adult, Senior)","","41","Other","Interventional","Primary Purpose: Supportive Care","1845.00|FHCRC-1845.00|CDR0000430699","July 2003","May 2006","May 2006","August 2011","July 8, 2005","July 11, 2005","null","null","August 30, 2011","September 1, 2011","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00118339"
1159,"NCT02728167","Efficacy of HIFU-AR on Blood Loss Reduction in Patients With Liver Metastases Requiring Hepatectomy","HIFU-AR","Not yet recruiting","No Results Available","Liver Metastasis","Device: Pre-coagulation of the liver parenchyma with HIFU","Normalized blood loss (ml/cm2)|Total blood los (ml)|Transection time|Transection time/cm2 of liver area (min/cm2)|Hemostasis time|Clip density on the liver section area|Rate of Pringle manoeuvre|Rate of patients needing a blood transfusion|Length of hospital stay|Number of patients with postoperative complications assessed using Dindo-Clavien classification","Centre Leon Berard","All","18 Years and older   (Adult, Senior)","","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIFU-AR","April 2016","April 2018","October 2018","March 2016","March 22, 2016","April 5, 2016","null","null","March 30, 2016","April 5, 2016","","https://ClinicalTrials.gov/show/NCT02728167"
1160,"NCT00387959","Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma","null","Completed","Has Results","Leukemia|Lymphoma","Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation","Survival at 1 Year After Transplantation","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","17","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-066|MSKCC-06066","July 2006","April 2014","April 2014","December 2015","October 12, 2006","October 13, 2006","December 22, 2015","February 1, 2016","December 22, 2015","February 1, 2016","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00387959"
1161,"NCT00004221","Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer","null","Terminated","No Results Available","Malignant Ovarian Mixed Epithelial Tumor|Ovarian Clear Cell Cystadenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Mucinous Cystadenocarcinoma|Ovarian Serous Cystadenocarcinoma|Primary Peritoneal Carcinoma|Stage III Ovarian Cancer|Undifferentiated Ovarian Carcinoma","Drug: Carboplatin|Drug: Cyclophosphamide|Biological: Filgrastim|Drug: Paclitaxel|Procedure: Peripheral Blood Stem Cell Transplantation|Drug: Topotecan Hydrochloride","Complete response defined as complete disappearance of all measurable and evaluable tumor documented at second-look surgery|Indication of excessive toxicity defined as hospitalization > 14 days per course, delay of day 1 therapy > 14 days, or grade 3 (irreversible) or grade 4 vital organ toxicity (non-hematologic)|Overall survival|PFS","Gynecologic Oncology Group|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Senior)","Phase 2","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GOG-9903|NCI-2012-02312|CDR0000067462|U10CA027469","November 1999","February 6, 2002","null","August 2017","January 28, 2000","August 25, 2003","null","null","August 8, 2017","August 9, 2017","Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00004221"
1162,"NCT00303849","Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors","null","Recruiting","No Results Available","Adult Anaplastic Oligodendroglioma|Adult Mixed Glioma|Adult Oligodendroglioma|Oligoastrocytoma|Recurrent Adult Brain Neoplasm","Drug: Carboplatin|Drug: Etoposide Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mannitol|Drug: Melphalan|Other: Quality-of-Life Assessment|Drug: Sodium Thiosulfate","MTD of melphalan, defined as one dose level below the dose that produces grade 4 toxicity in 33% of patients, graded in accordance with National Cancer Institute Common Toxicity Criteria (NCI CTC) (version 3.0) (Phase I)|Overall survival|Progression free survival (Phase II)|Response rate|Time to best response|Functional outcomes|Incidence of severe neutropenia (specifically febrile neutropenia or sepsis) in accordance with NCI CTC (version 3.0)|Rates of 2YPFS for specific tumor types","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","43","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00002868|NCI-2013-00786|CR00002456|2868|P30CA069533","September 2005","December 2020","December 2021","October 2017","March 15, 2006","March 17, 2006","null","null","October 31, 2017","November 6, 2017","University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States","https://ClinicalTrials.gov/show/NCT00303849"
1163,"NCT03196869","the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer","null","Recruiting","No Results Available","Locally Advanced Head and Neck Squamous Cell Carcinoma","Device: Chrono-chemotherapy|Device: Routine intravenous drip|Drug: induction Chrono-chemotherapy|Drug: induction Routine-chemotherapy|Drug: cisplatin chrono-chemotherapy|Drug: cisplatin routine-chemotherapy|Radiation: intensity-modulated radiation therapy","Dendritic cell subgroup changes of Participants|Number of Participants with curative effect|Number of Participants with Adverse Events as a Measure of Safety","Guiyang Medical University","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201708112121","April 7, 2017","April 12, 2019","August 12, 2022","June 2017","June 21, 2017","June 23, 2017","null","null","June 21, 2017","June 23, 2017","Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China","https://ClinicalTrials.gov/show/NCT03196869"
1164,"NCT02909348","Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab","PASIP","Recruiting","No Results Available","Neoplasms|Melanoma","Drug: Pembrolizumab","Change in immune markers in blood following immunotherapy with pembrolizumab","Royal Free Hospital NHS Foundation Trust|Merck Sharp & Dohme Corp.|University College, London","All","18 Years and older   (Adult, Senior)","","50","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","9797","September 2016","March 2019","September 2020","September 2016","September 13, 2016","September 21, 2016","null","null","September 16, 2016","September 21, 2016","Royal Free London NHS Foundation Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT02909348"
1165,"NCT01576653","Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL","null","Recruiting","No Results Available","Invasive Fungal Infection|Hematological Malignancy|Receipt of Solid Organ Transplant","Other: Fungitell Assay in BAL","Fungitell Assay from BAL in patients with hematologic malignancy or ICU patients/patients after solid organ transplantation and suspected IFI","Robert Krause, MD|Medical University of Graz","All","18 Years to 95 Years   (Adult, Senior)","","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","23-343","June 2011","June 2018","September 2018","September 2017","April 10, 2012","April 12, 2012","null","null","September 20, 2017","September 25, 2017","Medical University of Graz, Graz, Styria, Austria","https://ClinicalTrials.gov/show/NCT01576653"
1166,"NCT00792142","Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma","null","Active, not recruiting","No Results Available","Multiple Myeloma and Plasma Cell Neoplasm|Neurotoxicity","Drug: bortezomib|Drug: dexamethasone|Drug: melphalan|Drug: thalidomide|Genetic: cytogenetic analysis|Genetic: fluorescence in situ hybridization|Other: laboratory biomarker analysis|Other: questionnaire administration|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Feasibility and toxicities of maintenance therapy|Overall survival|Complete response rate|Duration of response|3-year progression-free survival","City of Hope Medical Center|National Cancer Institute (NCI)","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","45","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06143|P30CA033572|CHNMC-06143|MILLENNIUM-06143|CDR0000624513","January 16, 2008","April 2018","April 2018","August 2017","November 14, 2008","November 17, 2008","null","null","August 9, 2017","August 11, 2017","City of Hope Medical Center, Duarte, California, United States","https://ClinicalTrials.gov/show/NCT00792142"
1167,"NCT00461955","Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation","Expansion","Completed","No Results Available","Multiple Myeloma","Procedure: autologous peripheral blood stem cell transplantation, ex vivo amplified","Hematopoietic reconstitution defined by a neutrophils number > 500/mm3 at day 7 after injection of in vitro amplified graft and by a platelets number > 20000/mm3, at day 15 after the injection of in vitro amplified graft, without transfusion.|Immediate Toxicity of the injection of the amplified graft ;|Quantitative immunological Reconstitution|Stability of the hematopoiesis in the long term|Absence of cytogenetics abnormalities not related to the multiple myeloma in the long term.","University Hospital, Bordeaux","All","18 Years to 65 Years   (Adult)","Phase 2","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHUBX 2000/04","August 2007","September 2008","August 2009","November 2010","April 17, 2007","April 18, 2007","null","null","November 3, 2010","November 4, 2010","CHU Haut-Leveque, Pessac, France","https://ClinicalTrials.gov/show/NCT00461955"
1168,"NCT02765997","StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies","null","Withdrawn","No Results Available","Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Myelodysplasia","Biological: Unmanipulated UCB|Biological: SR-1 UCB","Neutrophil Recovery|Secondary Graft Failure|Platelet Recovery|Transplant-Related Mortality","Masonic Cancer Center, University of Minnesota","All","2 Years to 35 Years   (Child, Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016LS006|MT2016-01","April 2017","June 2020","June 2022","December 2017","May 5, 2016","May 9, 2016","null","null","December 3, 2017","December 5, 2017","University of Minnesota Cancer Center, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT02765997"
1169,"NCT00001336","In Vitro Studies of Immunological and Stem Cell Function in Peripheral Blood Mononuclear Cells in Patients","null","Completed","No Results Available","Immunologic Deficiency Syndrome|Leukemia|Lymphoma|Neoplasm","","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","","1000","NIH","Observational","","930129|93-C-0129","April 1993","null","February 2003","February 2003","November 3, 1999","November 4, 1999","null","null","March 3, 2008","March 4, 2008","National Cancer Institute (NCI), Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00001336"
1170,"NCT01237639","Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation","TRIST","Completed","No Results Available","Hematologic Malignancies","Other: Red blood cell Transfusion","Quality of Life (QOL)/Function based on the FACT-BMT scale|Transplant Related Mortality|Red Cell Transfusion|Platelet Transfusion|Acute Graft Versus Host Disease|Bleeding|Serious Infections|Time to Non-relapse Mortality|Economic Evaluation/Quality of Life|NCI Toxicity Scale","Ottawa Hospital Research Institute|Canadian Blood Services|Canadian Institutes of Health Research (CIHR)|The Ottawa Hospital|Hamilton Health Sciences Corporation|London Health Sciences Centre|Saskatchewan Cancer Centre","All","18 Years and older   (Adult, Senior)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","20120673","March 2011","October 2016","October 2016","October 2016","October 13, 2010","November 9, 2010","null","null","October 11, 2016","October 12, 2016","Hamilton Health Sciences Centre, Hamilton, Ontario, Canada|London Health Sciences Centre, University Hospital, London, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Saskatchewan Cancer Centre, Saskatoon, Saskatchewan, Canada","https://ClinicalTrials.gov/show/NCT01237639"
1171,"NCT02730533","The Efficacy of Esomeprazole Premedication on Intraoperative Bleeding During Gastric ESD","null","Completed","No Results Available","Stomach Neoplasms","Drug: Esomeprazole|Drug: No PPI treatment","The total bleeding rate according to grading of intraoperative bleeding during ESD procedure|The frequency of coagrasper usage which reflects grade of major bleeding|Post-ESD ulcer quality as indicated in description|Intra-procedure injury to muscularis propria including perforation.|Mean haemoglobin reduction between intervention and control group.|Delayed bleeding rate as indicated by haematemesis and melaena|The mean percentage of mucosal defect reduction at follow-up endoscopy on 28 days after ESD procedure.","Xijing Hospital of Digestive Diseases","All","18 Years and older   (Adult, Senior)","","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","KY20162024-1","March 2016","March 2017","April 2017","July 2017","March 28, 2016","April 6, 2016","null","null","July 19, 2017","July 21, 2017","Xijing Hospital of Digestive Diseases, Xi'an, Shaanxi, China","https://ClinicalTrials.gov/show/NCT02730533"
1172,"NCT00539942","Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy","null","Terminated","Has Results","Venous Thrombosis","Drug: Arixtra (fondaparinux sodium)|Device: Intermittent compression devices (ICD)","Comparison of Deep Venous Thromboembolism (DVT) Using Intermittent Compression Devices With and Without Arixtra|Incidence of Untoward Effects With Arixtra","University of Alabama at Birmingham|GlaxoSmithKline","Female","19 Years to 85 Years   (Adult, Senior)","Phase 3","7","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","F070727009|UAB 0723","April 2007","June 2010","June 2010","February 2017","October 3, 2007","October 5, 2007","February 7, 2012","March 9, 2012","February 22, 2017","March 27, 2017","UAB, Women's and Infant Center, 1700 6th Avenue South, Birmingham, Alabama, United States","https://ClinicalTrials.gov/show/NCT00539942"
1173,"NCT01527045","Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies","null","Recruiting","No Results Available","Aggressive Non-Hodgkin Lymphoma|Blasts Under 5 Percent of Bone Marrow Nucleated Cells|Loss of Chromosome 17p|Myelodysplastic/Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Aggressive Adult Non-Hodgkin Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|T-Cell Chronic Lymphocytic Leukemia|Waldenstrom Macroglobulinemia","Drug: Atorvastatin Calcium|Drug: Cyclosporine|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Procedure: Peripheral Blood Stem Cell Transplantation|Radiation: Total-Body Irradiation","Proportion of patients who develop grade 3-4 acute graft-versus-host disease (GVHD) after transplant|Chronic extensive GVHD|Disease-free survival|Grades II-IV acute GVHD|Non-relapse mortality|Overall survival|Proportion of donors who have to discontinue atorvastatin because of toxicity|Proportion of patients requiring secondary systemic immunosuppressive therapy|Recurrent or progressive malignancy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)","All","Child, Adult, Senior","Phase 2","100","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2546.00|NCI-2011-03828|P01CA018029|P30CA015704","September 25, 2012","May 26, 2018","null","September 2017","January 31, 2012","February 6, 2012","null","null","September 12, 2017","September 14, 2017","Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT01527045"
1174,"NCT00968396","Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts","null","Withdrawn","No Results Available","Multiple Myeloma","Procedure: Apheresis|Procedure: Stem Cell Transplantation|Drug: Melphalan","Neutrophil Engraftment Rate","M.D. Anderson Cancer Center","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2007-0886","February 2013","February 2015","null","April 2013","August 27, 2009","August 31, 2009","null","null","April 4, 2013","April 5, 2013","","https://ClinicalTrials.gov/show/NCT00968396"
1175,"NCT01690520","Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes","null","Recruiting","No Results Available","Acute Biphenotypic Leukemia|Acute Erythroid Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Megakaryoblastic Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia in Remission|Blasts Under 10 Percent of Bone Marrow Nucleated Cells|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts|Pancytopenia|Refractory Anemia|Secondary Acute Myeloid Leukemia","Drug: Cyclophosphamide|Drug: Cyclosporine|Procedure: Double-Unit Umbilical Cord Blood Transplantation|Procedure: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Drug: Mycophenolate Mofetil|Drug: Thiotepa|Radiation: Total-Body Irradiation|Procedure: Umbilical Cord Blood Transplantation","Time to engraftment defined as the first 2 consecutive days in which absolute neutrophil count >= 500 in both arms (standard myeloablative cord blood transplantation with and without off-the-shelf expanded cord blood progenitors)|Incidence and severity of acute and chronic graft versus host disease|Incidence of infectious complications|Non-relapse mortality|Overall survival|Platelet engraftment (20k)","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)","All","6 Months to 65 Years   (Child, Adult)","Phase 2","160","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2603.00|NCI-2012-01572|2603|P30CA015704|P50HL110787","December 11, 2012","April 30, 2018","null","October 2017","September 19, 2012","September 21, 2012","null","null","October 24, 2017","October 26, 2017","City of Hope Comprehensive Cancer Center, Duarte, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|Stanford Cancer Institute Palo Alto, Palo Alto, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|University of Colorado, Denver, Colorado, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mount Sinai Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT01690520"
1176,"NCT01729091","Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma","null","Recruiting","No Results Available","Myeloma","Drug: Lenalidomide|Drug: Melphalan|Procedure: NK Cell Infusion|Procedure: Stem Cell Infusion|Drug: G-CSF|Drug: Elotuzumab|Drug: Dexamethasone","Maximum Tolerated Dose (MTD) of umbilical cord blood (UCB)-derived natural killer (NK) cells|Minimal Residual Disease (MRD) Negative r\Rate 100 days Post-Transplant","M.D. Anderson Cancer Center|Celgene|The Leukemia and Lymphoma Society","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-0379|NCI-2014-01096|6555-18","June 2013","June 2019","June 2019","December 2017","November 9, 2012","November 20, 2012","null","null","December 27, 2017","December 29, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT01729091"
1177,"NCT00816413","Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","null","Withdrawn","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes|Nonmalignant Neoplasm","Drug: cyclosporine|Drug: mycophenolate mofetil|Drug: pentostatin|Genetic: cytogenetic analysis|Genetic: fluorescence in situ hybridization|Genetic: protein analysis|Other: flow cytometry|Other: immunoenzyme technique|Other: laboratory biomarker analysis|Other: reduced-intensity transplant conditioning procedure|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation (PBSC)|Radiation: total-body irradiation","Severe transplant-related toxicity (grade III-IV adverse events) as assessed by NCI CTCAE v2.0|Stable donor engraftment|Mortality|Incidence of grade III-IV acute graft-versus-host disease","University of Nebraska|National Cancer Institute (NCI)","All","19 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","164-07|P30CA036727|UNMC-16407","September 2008","February 2010","February 2010","June 2013","December 31, 2008","January 1, 2009","null","null","June 17, 2013","June 19, 2013","UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States","https://ClinicalTrials.gov/show/NCT00816413"
1178,"NCT02792023","Usefulness of Fecal Immunochemical Test in Iron Deficiency Anemia (IDAFIT)","IDAFIT","Recruiting","No Results Available","Colorectal Cancer","Other: Immunochemical fecal occult blood test|Device: Colonoscopy|Device: Upper endoscopy","The number of patients with colorectal cancer among those with a positive immunochemical fecal test (Positive predictive value)|The number of patients with a significant lesion among those with a positive immunochemical fecal test (Positive predictive value) after the colonoscopy and after the upper endoscopy|The number of patients without a significant lesion among those with a negative immunochemical fecal test (negative predictive value) after the colonoscopy and after the upper endoscopy","Hospital Universitario de Canarias","All","18 Years and older   (Adult, Senior)","","550","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FIT-Iron deficiency anemia","June 30, 2016","August 2019","October 2019","August 2017","May 20, 2016","June 7, 2016","null","null","August 16, 2017","August 21, 2017","Digestive Service, Huc, La Laguna, S/c de Tenerife, Spain","https://ClinicalTrials.gov/show/NCT02792023"
1179,"NCT03049774","A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor","null","Not yet recruiting","No Results Available","Chemotherapy-induced Thrombocytopenia","","Days that platelet count firstly rebound to 75×10^9/L, 100×10^9/L, respectively, from the first time below 75×10^9/L at the chemotherapy cycle and the last chemotherapy cycle|Days that platelet count firstly rebound to 75×10^9/L, 100×10^9/L|the maximum and minimum platelet count at the chemotherapy cycle and the last chemotherapy cycle|the lasting days of platelet count below 50×10^9/L at the chemotherapy cycle and the last chemotherapy cycle|The number of platelet transfusions at the chemotherapy cycle and the last chemotherapy cycle|the percentage of patients whose platelet count firstly recovered above 75×10^9/L and 100×10^9/L|the maximum and minimum platelet count, the lasting days of platelet count below 50×10^9/L|The number of platelet transfusions","Angde Biotech Pharmaceutical Co., Ltd.","All","18 Years to 85 Years   (Adult, Senior)","","2000","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","EY201608","February 28, 2017","August 2017","December 2017","August 2016","January 23, 2017","February 10, 2017","null","null","February 8, 2017","February 10, 2017","Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03049774"
1180,"NCT01216267","Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples","null","Completed","No Results Available","Neuroendocrine Carcinoma (Carcinoid)","Drug: Lansoprazole|Drug: lansoprazole","chromogranin A concentration serum|Effect of PPI on chromogranin A concentration","University of Western Ontario, Canada","All","18 Years to 70 Years   (Adult, Senior)","","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HSREB16279","June 2010","January 2012","January 2012","January 2013","October 5, 2010","October 7, 2010","null","null","January 14, 2013","January 16, 2013","London Health Sciences Center and St. Joseph's Health Care, London, Ontario, Canada","https://ClinicalTrials.gov/show/NCT01216267"
1181,"NCT01382615","Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research","null","Terminated","No Results Available","Multiple Myeloma","","Cancer cell response to molecular testing of killing cell parts.","Dartmouth-Hitchcock Medical Center","All","18 Years and older   (Adult, Senior)","","75","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","D1029","August 2010","December 2014","December 2014","May 2016","April 12, 2010","June 27, 2011","null","null","May 23, 2016","May 24, 2016","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States","https://ClinicalTrials.gov/show/NCT01382615"
1182,"NCT02169791","Nonmyeloablative Haploidentical Transplant Followed by MLN9708","null","Recruiting","No Results Available","Acute Leukemia|Chronic Leukemia|Myelodysplastic Syndrome|Lymphomas|Multiple Myeloma","Drug: MLN9708","Incidence of Relapse and progression|Overall Survival|Event Free|Non-relapsed mortality|Graft-versus-host disease","Northside Hospital, Inc.|Millennium Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","25","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NSH 1074|X16035","September 2014","July 2018","July 2020","December 2017","June 19, 2014","June 23, 2014","null","null","December 12, 2017","December 14, 2017","Northside Hospital, Atlanta, Georgia, United States","https://ClinicalTrials.gov/show/NCT02169791"
1183,"NCT00967018","A Long Term Safety Study of Degarelix in Patients With Prostate Cancer","null","Completed","Has Results","Prostate Cancer","Drug: Degarelix","Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables|Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight","Ferring Pharmaceuticals","Male","18 Years and older   (Adult, Senior)","Phase 3","77","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FE200486 CS34|EudraCT No: 2008-006827-29","August 2009","November 2011","December 2011","January 2013","August 18, 2009","August 27, 2009","November 23, 2012","December 24, 2012","January 2, 2013","January 3, 2013","Institut Jules Bordet, Bruxelles, Belgium|St. Elisabethziekenhuis, Turnhout, Belgium|Hopital Jean Minjoz, Besancon, France|Institut Bergonié, Bordeaux Cedex, France|Centre Francois Baclesse, Caen, France|CHU Henri Mondor, Creteil, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Hopital de la Timone, Marseille, Cedex, France|CRLC Val d' Aurelle - Oncology Radiotherapy, Montpellier, France|Hôpital Saint Louis - Radiotherapy Departement, Paris, France|Hôpital Tenon, Paris, France|Clinique Francheville, Perigueux, France|CHU La Milétrie - Oncology Radiotherapy, Poitiers, France|Centre de Lutte Contre le Cancer Nantes-Atlantique Centre René Gauducheau, Saint Herblain Cedex, France|Institut de Cancérologie de la Loire, Saint Priest en Jarez, France|Clinique Saint Brieuc, St Brieuc Cedex, France|Centre Paul Strauss, Strassbourg, France|Centre de radiologie Saint Louis, Toulon, France|Clinique du Parc, Toulouse, France|IGR, Villejuif, France|Azienda Ospedaliero Universitaria Ospedali riuniti, Ancona, Italy|Policlinico S.Orsola Malpighi - Universita' degli Studi di Bologna, Bologna, Italy|Clinica Urologica 1 Universita Firenze, Firenze, Italy|Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy|Fondazione IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milano, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone dell'Universita' degli Studi di Palermo, Palermo, Italy|Clinica Urologica - Azienda Ospedaliera di Perugia, Perugia, Italy|Azienda Ospedaliera S. Andrea - Universita' la Sapienza di Roma, Roma, Italy|S.C. Di Urologia - IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Azienda Ospedaliero Universitaria S. Giovanni Battista - Molinette, Torino, Italy|Hospital Fernando da Fonseca, Amadora, Portugal|Hospitais Universidade Coimbra, Coimbra, Portugal|Centro Hospitalar Lisboa Norte, Hospital Santa Maria, Lisboa, Portugal|Hospital S.João, Porto, Portugal|Hospital Universitario Principe de Asturias, Alcalá de Henares-Madrid, Spain|Fundacion Hospital Alcorcón, Alcorcon, Spain|Fundación Puigvert, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d´Hebron, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital Clinico Universitario S. Carlos, Madrid, Spain|Hospital Doce de Octubre, Madrid, Spain|Hospital universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Hospital Manacor, Manacor, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Santiago de Compostela, Santiago de Compostela, Spain|Hospital Virgen Macarena, Sevilla, Spain|Fundación IVO, Valencia, Spain|Hospital Xeral de Vigo, Vigo, Spain|Investigational site, Göteborg, Sweden|SU/Sahlgrenska, Göteborg, Sweden|Helsingborgs Lasarett, Helsingborg, Sweden|Universitetssjukhuset MAS, Malmö, Sweden|Södertälje Sjukhus, Södertälje, Sweden|Uppsala/Akademiska sjukhuset, Uppsala, Sweden|Ankara University Faculty of Medicine - Sıhhıye, Ankara, Turkey|Cerrahpasa Faculty of Medicine - Kocamustafapasa, Istanbul, Turkey|Istanbul University Faculty of Medicine - ÇAPA, Istanbul, Turkey|Marmara University Faculty of Medicine - Altunizade, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT00967018"
1184,"NCT01889186","A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion","null","Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia|17 p Deletion|Cancer of the Blood and Bone Marrow","Drug: ABT-199","Efficacy will be measured by overall response rate (ORR) (Main Cohort)|Number of subjects with adverse events (Expanded Safety Cohort)|Change in physical exam findings, including vital signs (Expanded Safety Cohort)|Change in clinical laboratory test results (Expanded Safety Cohort)|Change in cardiac assessment findings (Expanded Safety Cohort)|Percentage of subjects with adverse events (Expanded Safety Cohort)|Complete Remission (CR) rate|Partial Remission (PR) rate|Duration of response|Progression-free survival|Time to progression|Overall survival|Percent of subjects who move on to stem cell transplant|Number of subjects with adverse events (Main Cohort)|Change in physical exam findings, including vital signs (Main Cohort)|Change in clinical laboratory test results (Main Cohort)|Change in cardiac assessment findings (Main Cohort)|Percentage of subjects with adverse events (Main Cohort)|Overall Response Rate (ORR) (Expanded Safety Cohort)|Event free survival|Time to first response|Time to 50% reduction in absolute lymphocyte count","AbbVie|Genentech, Inc.","All","18 Years to 99 Years   (Adult, Senior)","Phase 2","150","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-982|2012-004027-20","June 27, 2013","May 12, 2020","May 12, 2020","October 2017","June 26, 2013","June 28, 2013","null","null","October 9, 2017","October 11, 2017","University of Arizona Cancer Center /ID# 96748, Tucson, Arizona, United States|City of Hope National Medical Center /ID# 112875, Duarte, California, United States|UCSD Moores Cancer Center, US /ID# 91793, La Jolla, California, United States|Stanford University School of Medicine /ID# 105117, Stanford, California, United States|Medstar Georgetown University Medical Center /ID# 96954, Washington, D.C., District of Columbia, United States|Northwestern University /ID# 92499, Chicago, Illinois, United States|The University of Chicago Medical Center /ID# 96960, Chicago, Illinois, United States|Ingalls Memorial Hospital /ID# 92497, Harvey, Illinois, United States|Dana Farber Cancer Institute /ID# 92494, Boston, Massachusetts, United States|Henry Ford Health System /ID# 97795, Detroit, Michigan, United States|The Cancer Center at Hackensack University Medical Center /ID# 92500, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey /ID# 92513, New Brunswick, New Jersey, United States|Columbia University Medical Center /ID# 103835, New York, New York, United States|New York Presbyterian Hospital /ID# 94716, New York, New York, United States|Cleveland Clinic Foundation /ID# 92495, Cleveland, Ohio, United States|The University of Texas - MD Anderson Cancer Center /ID# 92521, Houston, Texas, United States|John Fawkner Hospital /ID# 98835, Coburg, Australia|Royal Melbourne Hospital /ID# 91794, Parkville, Melbourne, Australia|Peter MacCallum Cancer Centre /ID# 91795, Parkville, Australia|Royal North Shore Hospital /ID# 98836, St. Leonards, Australia|Jewish General Hospital, Sir Mortimer B. Davis /ID# 99476, Montreal, Canada|CHU-Hopital Avicenne /ID# 98840, Bobigny Cedex, France|Hopital Pitie Salpetriere /ID# 98842, Paris, Cedex 13, France|Centre Hospitalier Lyon Sud /ID# 98839, Pierre Benite, Cedex, France|Centre Henri Becquerel /ID# 98838, Rouen, Cedex 01, France|Uniklinik Koln /ID# 98847, Cologne, Germany|Universitaetklinikum Dresden /ID# 113256, Dresden, Germany|University Hospital Freiburg /ID# 113276, Freiburg, Germany|Universitaetsmedizin Goettingen /ID# 113258, Goettingen, Germany|Universitaetsklinikum Heidelberg Hautklinik /ID# 98845, Heidelberg, Germany|Universitaetsklinikum Schleswig-Holstein /ID# 113235, Kiel, Germany|Universitaetsmedizin der Johannes Gutenberg Mainz /ID# 113236, Mainz, Germany|Staedt. Klinikum Munich-Schwabing /ID# 113275, Munich, Germany|Universitaetsklinikum Ulm /ID# 92533, Ulm, Germany|Szpital Uniwersyteckiego Krakowie /ID# 98849, Krakow, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublin /ID# 98848, Lublin, Poland|Szpital Wojewodzki w Opolu /ID# 102855, Opole, Poland|The Royal Bournemouth Hospital /ID# 118975, Bournemouth, Dorset, United Kingdom|Cambridge University Hospitals NHS Foundation Trust /ID# 119977, Cambridge, Cambridgeshire, United Kingdom|St. James University Hospital /ID# 98863, Leeds, West Yorkshire, United Kingdom|Leicester Royal Infirmary, Univ Hosp of Leicester NHS /ID# 98865, Leicester, United Kingdom|Royal Liverpool and Broadgreen Univ Hospitals NHS Trust /ID# 98860, Liverpool, United Kingdom|St Bartholomew's Hospital /ID# 98862, London, United Kingdom|University College London Hospitals NHS Foundation Trust /ID# 119975, London, United Kingdom|The Christie NHS Foundation Trust /ID# 98864, Manchester, United Kingdom|Oxford University Hospitals NHS Trust /ID# 119976, Oxford, United Kingdom|Derriford Hospital /ID# 118335, Plymouth, Devon, United Kingdom|Royal Marsden Hospital /ID# 98861, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT01889186"
1185,"NCT00041665","Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy","null","Completed","No Results Available","Stomatitis","Drug: Recombinant Human Keratinocyte Growth Factor","","Amgen","All","18 Years and older   (Adult, Senior)","Phase 3","null","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","20000162|NLM Identifier NCT00020813|UCLA-0012064|MSKCC-01065|FHCRC-161200","null","null","null","May 2013","July 11, 2002","July 15, 2002","null","null","May 6, 2013","May 8, 2013","","https://ClinicalTrials.gov/show/NCT00041665"
1186,"NCT01352390","The Effect of a Coloring Prompt on Health Engagement","null","Completed","No Results Available","In Need of a Pap Smear (Cervical Cancer Screening)|In Need of a Blood Pressure Check (Hypertension Screening)|In Need of a Cholesterol Test (Lipid Disorder Screening)|In Need of a Fasting Plasma Glucose Test (Diabetes)","Behavioral: Planning Prompt|Behavioral: Control Condition","Number of Participants that schedule an appointment for receipt of a Pap smear.|Number of Participants that schedule an appointment for receipt of a Blood pressure check|Number of Participants that schedule an appointment for receipt of a Cholesterol test|Number of Participants that schedule an appointment for receipt of a Fasting plasma glucose test","University of Pennsylvania","All","18 Years and older   (Adult, Senior)","","8711","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","813606","May 2011","November 2012","November 2012","May 2017","May 6, 2011","May 11, 2011","null","null","May 3, 2017","May 4, 2017","University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT01352390"
1187,"NCT01339988","Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)","null","Not yet recruiting","No Results Available","Acute Leukemias|Chronic Leukemias|Myelodysplastic Syndrome|Juvenile Myelomonocytic Leukemia","Drug: Busulfan/Cyclophosphamide","Overall survival|Disease free survival","Tel-Aviv Sourasky Medical Center","Male","up to 21 Years   (Child, Adult)","Phase 4","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TASMC-11-MB-442-CTIL","June 2011","June 2014","June 2019","April 2011","April 20, 2011","April 21, 2011","null","null","April 20, 2011","April 21, 2011","","https://ClinicalTrials.gov/show/NCT01339988"
1188,"NCT00900068","Blood Samples From Patients on a Clinical Trial to CINV During HSCT","null","Terminated","No Results Available","Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Nausea and Vomiting|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor","Other: immunoenzyme technique|Other: laboratory biomarker analysis|Other: medical chart review","Average, median, and mode for substance P levels at different times|Correlation of substance P levels with patient response (emesis or not)","OHSU Knight Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Senior)","","9","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CDR0000617385|P30CA069533|OHSU-CPC-08055-L|OHSU-IRB 4517|MERCK-OHSU-CPC-08055-L","August 2008","August 2009","October 2009","May 2017","May 9, 2009","May 12, 2009","null","null","May 7, 2017","May 9, 2017","OHSU Knight Cancer Institute, Portland, Oregon, United States","https://ClinicalTrials.gov/show/NCT00900068"
1189,"NCT00608517","Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil","null","Terminated","Has Results","Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methylprednisolone|Radiation: total-body irradiation","Number of Participants With 100-day Non-relapse Mortality|Number of Participants With Sustained Donor Engraftment of Umbilical Cord Blood Stem Cells|Number of Participants With Acute Graft-versus-host Disease (GVHD)|Number of Participants Who Relapsed at 1 Year|Number of Subjects With All-cause Mortality|Overall Survival|Number of Participants With Chronic Graft Versus Host Disease (GVHD)","Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","","6","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VICC BMT 0552|VU-VICC-BMT-0552","September 2005","March 2008","May 2011","May 2012","January 31, 2008","February 6, 2008","October 11, 2010","November 10, 2010","May 12, 2014","May 20, 2014","Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States|Veterans Affairs Medical Center - Nashville, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT00608517"
1190,"NCT00504634","Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma","null","Completed","No Results Available","Multiple Myeloma","Drug: Bortezomib","Number of Participants with Complete Response (CR)","M.D. Anderson Cancer Center","All","up to 70 Years   (Child, Adult, Senior)","Phase 2","8","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2003-0751","January 2004","August 2007","May 2010","September 2011","July 18, 2007","July 20, 2007","null","null","September 14, 2011","September 15, 2011","UT MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00504634"
1191,"NCT01325896","Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)","null","Unknown status","No Results Available","Multiple Mieloma","Drug: PEG-Intron sc injection","Time to Progression (TTP) and WHO (World Health Organization) Toxicity scale|Increase of Response (anti-tumoral effect) and Dose Tolerance","Fundación de Investigación Biomédica - Hospital Universitario de La Princesa|Haematology Service,","All","18 Years to 65 Years   (Adult)","Phase 2","33","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PI-MM-01","September 2002","March 2012","March 2012","March 2011","March 11, 2011","March 30, 2011","null","null","March 30, 2011","March 31, 2011","Hospital Universitario de La Princesa, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01325896"
1192,"NCT00081055","OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies","null","Withdrawn","No Results Available","Graft Versus Host Disease|Leukemia|Myelodysplastic Syndromes","Biological: autologous expanded mesenchymal stem cells OTI-010|Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Incidence of acute GVHD grade II-IV of skin, liver and gut (stomach to rectum) through Day 84 post-PBSC transplantation|Safety as measured by infusional toxicity, relapse nd survival, formation of potential ectopic tissue foci","Mesoblast International Sàrl|National Cancer Institute (NCI)|Mesoblast, Ltd.","All","18 Years to 55 Years   (Adult)","Phase 2","0","Industry|NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Supportive Care","Mesoblast|UCLA-0303036|CDR0000358809","null","null","null","December 2014","April 7, 2004","April 8, 2004","null","null","December 3, 2014","December 4, 2014","Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT00081055"
1193,"NCT00439465","Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma","null","Active, not recruiting","No Results Available","Myeloma|Transplant-eligible Patients","Biological: Autologous ex-vivo expanded effector cells","To establish the safety (toxicity), time to engraftment and clinical outcomes of myeloma patients treated with high dose melphalan, APBSCT& adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.|Identify CD8+ effector cell-versus-myeloma effects in vivo by determining recovery,function& mechanism of tumor cell killing of PB CD8+ cells prior to& after completing therapy.","Dartmouth-Hitchcock Medical Center|The Leukemia and Lymphoma Society","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D0717|LLS-6061-06","January 2007","February 2018","December 2018","May 2016","February 21, 2007","February 23, 2007","null","null","May 23, 2016","May 24, 2016","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States","https://ClinicalTrials.gov/show/NCT00439465"
1194,"NCT01503242","90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma","null","Active, not recruiting","No Results Available","Plasma Cell Myeloma|Refractory Plasma Cell Myeloma","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclosporine|Drug: Fludarabine Phosphate|Drug: Mycophenolate Mofetil|Procedure: Peripheral Blood Stem Cell Transplantation|Radiation: Total-Body Irradiation|Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8","MTD of radiation delivered via 90 Y-BC8-DOTA|Tissue localization of 111In-BC8-DOTA Ab|Disease response|Disease-free survival|Duration of remission|Overall survival","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 1","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2450.00|NCI-2010-02041|2450|P30CA015704|R21CA155911","January 9, 2012","June 6, 2017","December 6, 2019","September 2017","December 30, 2011","January 2, 2012","null","null","September 20, 2017","September 25, 2017","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT01503242"
1195,"NCT02997813","Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies","MOZOBIL","Completed","No Results Available","Multiple Myeloma|Blood Stem Cell Transplant Failure","","Total cost of stem cell mobilization procedure (including remobilisation if applicable)|Number of visits for administration of mobilizing agents|Duration (days) of administration of mobilizing agents|Agents used as mobilizing agents|Attainment of CD34+ target (yes, no) (min 2.106 cells/kg, ideal >4.106cells/kg)|Number of days needed to meet CD34+ target level (min 2.106 cells/kg, ideal >4.106cells/kg)","Intergroupe Francophone du Myelome","All","18 Years and older   (Adult, Senior)","","112","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","IFM2014-05","June 2015","December 2015","December 2016","December 2016","December 16, 2016","December 20, 2016","null","null","December 16, 2016","December 20, 2016","CHRU Dijon, Dijon, France|Centre Hospitalier Universitaire (CHU) de Limoges, Limoges, France|Centre Hospitalier Lyon Sud, Lyon, France|CHRU Hôtel Dieu, Nantes, France|Institut Curie Centre de Lutte Contre le Cancer (CLCC), Paris, France|La Pitié Salpetriêre, Paris, France|Hôpital Saint-Antoine, Paris, France|Hôpital Robert Debré Hématologie, Reims, France|Centre Henri Becquerel, Rouen, France","https://ClinicalTrials.gov/show/NCT02997813"
1196,"NCT00898066","S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease","null","Completed","No Results Available","Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Precancerous/Nonmalignant Condition","Genetic: cytogenetic analysis|Genetic: fluorescence in situ hybridization","Frequency of deletion 13 as detected by fluorescence in situ hybridization (FISH) and conventional cytogenetics|Prognostic value of specific subsets of chromosome aberrations detected by conventional cytogenetics and FISH in relation to event-free and overall survival|Comparison of prognostic value of cytogenetics and FISH with other multiple myeloma and monoclonal gammopathy prognostic factors|Correlation between the presence of cytogenetic and FISH features and clinical pathophysiological, cellular, or other molecular characteristics","Southwest Oncology Group|National Cancer Institute (NCI)","All","Child, Adult, Senior","","37","Other|NIH","Observational","","S0334|U10CA032102","September 2005","June 2007","June 2007","March 2015","May 9, 2009","May 12, 2009","null","null","March 5, 2015","March 6, 2015","","https://ClinicalTrials.gov/show/NCT00898066"
1197,"NCT01998009","Study of In-home Tests for Colorectal Cancer","SIT","Completed","No Results Available","Colorectal Cancer","Other: fecal occult blood tests","The proportion of participants with a positive colonoscopy finding indicating an advanced colorectal neoplasia who also have a positive fecal occult blood test result|The proportion of participants with a negative colonoscopy finding who also have a negative fecal occult blood test result","Centers for Disease Control and Prevention|Battelle Memorial Institute|University of Minnesota - Clinical and Translational Science Institute|Indiana University|Park Nicollet Health Services","All","50 Years to 75 Years   (Adult, Senior)","","1382","U.S. Fed|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CDC-NCCDPHP-5985","May 2011","September 2014","September 2014","February 2015","November 6, 2013","November 28, 2013","null","null","February 4, 2015","February 5, 2015","Indiana University, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT01998009"
1198,"NCT01345214","A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia","null","Terminated","No Results Available","Chemotherapy-Induced Thrombocytopenia","Drug: ONO-7746","Safety and tolerability of ONO-7746 across ascending multiple doses using vital signs, physical examinations, ECGs, ECOG performance status, CT/MRI, laboratory tests|Characterization of PK profiles on ONO-7746 and exploration of the PD effect of ONO-7746, including changes in platelet counts and any potential effects on ECGs","Ono Pharma USA Inc|Ono Pharmaceutical Co. Ltd","All","18 Years and older   (Adult, Senior)","Phase 1","17","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ONO-7746POU003","May 2011","February 2014","null","March 2014","April 21, 2011","April 29, 2011","null","null","March 31, 2014","April 1, 2014","Fort Collins Clinical Site 13-01, Fort Collins, Colorado, United States|Augusta Clinical Site 01-01, Augusta, Georgia, United States|Ames Clinical Site 07-01, Ames, Iowa, United States|Deagu Clinical Site 18-01, Deagu, Korea, Republic of|Jeollanam-do Clinical Site 19-01, Jeollanam-do, Korea, Republic of|Seoul Clinical Site 20-01, Seoul, Korea, Republic of|Seoul Clinical Site 21-01, Seoul, Korea, Republic of|Arkhangelsk Clinical Site 10-01, Arkhangelsk, Russian Federation|Moscow Clinical Site 14-01, Moscow, Russian Federation|Samara Clinical Site 15-01, Samara, Russian Federation|St. Petersburg Clinical Site 11-01, St. Petersburg, Russian Federation|Tambov Clinical Site 16-01, Tambov, Russian Federation|Tula Clinical Site 12-01, Tula, Russian Federation|Ufa Clinical Site 17-01, Ufa, Russian Federation","https://ClinicalTrials.gov/show/NCT01345214"
1199,"NCT00914784","The Incidence of TRALI in Patients Undergoing Orthopedic-Oncology Surgery","null","Unknown status","No Results Available","Dyspnea|Pulmonary Edema","","The incidence of TRALI in patients undergoing orthopedic-oncology procedures, following blood product transfusion|The correlation between the incidence of TRALI and the age of blood product","Tel-Aviv Sourasky Medical Center","All","18 Years to 90 Years   (Adult, Senior)","","550","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","TASMC-09-IM-0295-CTIL","August 2009","August 2011","September 2011","June 2009","June 4, 2009","June 5, 2009","null","null","June 4, 2009","June 5, 2009","Tel Aviv Sourasky medical center, Tel Aviv, Israel","https://ClinicalTrials.gov/show/NCT00914784"
1200,"NCT02476682","Non-invasive Risk Stratification of CR AMN/SSP","FIT","Not yet recruiting","No Results Available","Adenomatous Polyps","Other: blood or stool samples will be collected","Demographics|Level of methylated DNA in circulation|Level of haemoglobin in stool","Professor Michael Bourke|Western Sydney Local Health District","All","18 Years and older   (Adult, Senior)","","1725","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HREC2014/9/4.4(4079)","July 2016","July 2020","July 2021","December 2015","June 10, 2015","June 19, 2015","null","null","December 15, 2015","December 17, 2015","Westmead Endoscopy Unit, Westmead, New South Wales, Australia","https://ClinicalTrials.gov/show/NCT02476682"
1201,"NCT02120157","Phase II Trial of Myeloablative Conditioning & Transplantation of Partially HLA-mismatched Marrow With Post-transplant Cyclophosphamide for Peds Pts w/ Hematologic Malignancies","null","Recruiting","No Results Available","Myeloablative Conditioning|HLA-mismatched Bone Marrow Transplantation|Graft Survival|Transplantion, Bone Marrow","Drug: Cyclophosphamide|Radiation: TBI|Drug: Busulfan|Other: Unmanipulated Bone Marrow|Drug: Tacrolimus|Drug: Mycophenolate mofetil","Incidence of Mortality|Donor Cell Engraftment","Sidney Kimmel Comprehensive Cancer Center","All","6 Months to 25 Years   (Child, Adult)","Phase 2","31","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J13161|NA_00091665","August 2014","May 2018","January 2019","November 2017","April 16, 2014","April 22, 2014","null","null","November 1, 2017","November 6, 2017","Children's Hospital of Colorado, Aurora, Colorado, United States|Nemours Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|All Children's Hospital Johns Hopkins Medicine, Saint Petersburg, Florida, United States|Emory/ Children's Hospital of Altanta, Atlanta, Georgia, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Levine Cancer Center, Charlotte, North Carolina, United States|Rainbow Babies Hospital/ University Hospital, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|Hospital for Sick Children, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT02120157"
1202,"NCT01980355","TXA Study in Major Oncologic Surgery","TXA","Active, not recruiting","No Results Available","Tranexamic Acid|Cancer|Major Surgery","Drug: Tranexamic Acid|Other: Placebo","Blood loss and transfusion rates|Cost-Effectiveness","Spectrum Health Hospitals","All","18 Years and older   (Adult, Senior)","","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2012-133","June 2012","December 2017","July 2018","October 2017","November 4, 2013","November 8, 2013","null","null","October 9, 2017","October 11, 2017","Spectrum Health Hospitals, Grand Rapids, Michigan, United States","https://ClinicalTrials.gov/show/NCT01980355"
1203,"NCT00310232","Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)","null","Terminated","No Results Available","Non-Small-Cell Lung Carcinoma|Lung Cancer|Anemia","Drug: Epoetin Alfa","Change in anemia and fatigue related QoL at 12 weeks following randomization|Overall QoL and domain-specific QoL scores|hemoglobin and hematocrit levels|number of transfusions","Ontario Clinical Oncology Group (OCOG)|Ortho Biotech Products, L.P.","All","18 Years and older   (Adult, Senior)","Phase 3","70","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CTA-Control-076080|HC File 9427-J0921-22C","February 2001","null","April 2004","March 2006","March 31, 2006","April 3, 2006","null","null","June 29, 2007","July 3, 2007","Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|St. John Regional Hospital, St. John, New Brunswick, Canada|Newfoundland Cancer Treatment & Research Foundation, St. John's, Newfoundland and Labrador, Canada|Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|Hamilton Regional Cancer Centre (Juravinski), Hamilton, Ontario, Canada|London Regional Cancer Centre, London, Ontario, Canada|Hotel Dieu Hospital, St. Catherines, Ontario, Canada|Northeastern Ontario Regional Cancer Centre, Sudbury, Ontario, Canada|Toronto East General Hospital, Toronto, Ontario, Canada|Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Windsor Regional Cancer Centre, Windsor, Ontario, Canada|McGill University Clinical Trials Operations, Montreal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT00310232"
1204,"NCT00102726","SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy","null","Completed","No Results Available","Thrombocytopaenia","Drug: SB497115|Other: Placebo","Change in baseline platelet count from the first day of the second cycle of chemotherapy to the lowest count observed (nadir) during the cycle(21 days)|Safety and tolerability, pharmacodynamics, changes in platelet count during cycle 1(21 days) and beyond cycle 2(21 days), population PK, and deliver intended doses of chemotherapy without thrombocytopenia related AEs|Safety and tolerability as indicated by physical exam, 12-lead ECGs, ophthalmologic examinations, clinical laboratory tests, clinical monitoring/observation, and AE reporting|Pharmacodynamic parameters including platelet count, grade of thrombocytopenia,serum thrombopoietin, and platelet aggregation/activation during the first and second cycles of carboplatin/paclitaxel|Change in platelet count from day 1 (baseline) to nadir during the first cycle and beyond the second cycle of carboplatin/paclitaxel|Population PK of SB-497115, including clearance (CL/F), absorption rate constant(ka), and volume of distribution (V/F) with assessment of demographic covariates influencing SB-497115 PK|The relationship between PK of SB-497115 andrelevant safety and efficacy endpoints will be explored|Dose intensity (percent of intended dose) of carboplatin/paclitaxel|Carboplatin/paclitaxel-associated thrombocytopenia-related AEs, as defined by NCI|Common Terminology Criteria for Adverse Events, CTCAE v3.0, to include the number of platelet transfusions, bleeding events (hematoma), hemorrhage/bleeding,petechiae/purpura), clinical laboratory tests, and clinical observations","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","183","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","497115/003","February 2005","February 2007","February 2007","March 2017","February 1, 2005","February 2, 2005","null","null","March 21, 2017","March 23, 2017","GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Jonesboro, Arkansas, United States|GSK Investigational Site, Greenbrae, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Colorado Springs, Colorado, United States|GSK Investigational Site, Newark, Delaware, United States|GSK Investigational Site, Boca Raton, Florida, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Tamarac, Florida, United States|GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Hattiesburg, Mississippi, United States|GSK Investigational Site, Tupelo, Mississippi, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Babylon, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Akron, Ohio, United States|GSK Investigational Site, Mayfield Heights, Ohio, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Bryan, Texas, United States|GSK Investigational Site, Ogden, Utah, United States|GSK Investigational Site, Salem, Virginia, United States|GSK Investigational Site, Capital Federal, Buenos Aires, Argentina|GSK Investigational Site, La Plata, Buenos Aires, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Plovdiv, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Brno, Czech Republic|GSK Investigational Site, Praha 8, Czech Republic|GSK Investigational Site, Freiburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Marburg, Hessen, Germany|GSK Investigational Site, Hemer, Nordrhein-Westfalen, Germany|GSK Investigational Site, Trier, Rheinland-Pfalz, Germany|GSK Investigational Site, Grosshansdorf, Schleswig-Holstein, Germany|GSK Investigational Site, Bad Berka, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Székesfehérvár, Hungary|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Hyderabad, Andhra Pradesh, India|GSK Investigational Site, Kolkatta, India|GSK Investigational Site, Vellore, India|GSK Investigational Site, Benevento, Campania, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Campobasso, Molise, Italy|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Merida, Yucatán, Mexico|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Szczecin, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Bucuresti, Romania|GSK Investigational Site, Moscow Region, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Cordoba, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Santa Cruz de Tenerife, Spain|GSK Investigational Site, Santander, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Tau-Yuan County, Taiwan|GSK Investigational Site, Dnepropetrovsk, Ukraine|GSK Investigational Site, Donetsk, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Lvov, Ukraine|GSK Investigational Site, Truro, Cornwall, United Kingdom|GSK Investigational Site, Chelmsford, Essex, United Kingdom|GSK Investigational Site, Colchester, United Kingdom|GSK Investigational Site, Dundee, United Kingdom|GSK Investigational Site, Leicester, United Kingdom","https://ClinicalTrials.gov/show/NCT00102726"
1205,"NCT00504361","Blood Collection From Individuals With Lung Disease for Genetic Studies (Qatar)","Q-BC","Completed","No Results Available","Asthma|COPD|Interstitial Lung Disease|Cystic Fibrosis|Lung Cancer","","Genomic DNA will be extracted, and genome wide SNP analysis and promoter sequences for genes will be obtained.","Weill Medical College of Cornell University|Weill Cornell Medical College in Qatar|Hamad Medical Corporation","All","18 Years to 90 Years   (Adult, Senior)","","600","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","0605008516|HMC RC#373/2006","May 2006","May 2012","May 2012","April 2016","July 19, 2007","July 20, 2007","null","null","April 29, 2016","May 2, 2016","Hamad Medical Corporation, Doha, Qatar","https://ClinicalTrials.gov/show/NCT00504361"
1206,"NCT03334708","A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma","null","Recruiting","No Results Available","Pancreatic Cancer|Pancreatic Diseases|Pancreatitis|Pancreatic Cyst","Diagnostic Test: Blood Draw|Diagnostic Test: Tumor Tissue Collection|Diagnostic Test: Cyst Fluid","Change in biomarkers to determine sensitivity and specificity of the assay to diagnose early stage pancreatic cancer","Memorial Sloan Kettering Cancer Center|Sha'are Zedek Medical Center|Sheba Medical Center|Weill Medical College of Cornell University|Weizmann Institute of Science","All","18 Years and older   (Adult, Senior)","","750","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","17-527","October 30, 2017","October 30, 2021","October 30, 2021","October 2017","November 1, 2017","November 7, 2017","null","null","November 2, 2017","November 7, 2017","Memorial Sloan - Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Sha'are Zedek Medical Center, Jerusalem, Israel|Weizmann Institute of Science, Reẖovot, Israel|Sheba Medical Center, Tel Hashomer, Israel","https://ClinicalTrials.gov/show/NCT03334708"
1207,"NCT02964325","Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia","MIPLATE","Recruiting","No Results Available","Hematologic Malignancies|Hypoproliferative Thrombocytopenia","Device: Mirasol platelets (MIR PLTs)|Device: Reference platelets (REF PLTs)","Number of days of grade 2 or higher bleeding|Human leukocyte antigen (HLA) alloimmunization|Proportion of subjects with ≥ grade 2 bleeding|Time to first ≥ grade 2 bleed|Proportion of subjects with ≥ grade 3 bleeding|Proportion of subjects with PLT refractoriness|Immune platelet refractoriness","Terumo BCTbio|Biomedical Advanced Research and Development Authority","All","Child, Adult, Senior","","556","Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","CTS-5030","May 5, 2017","March 2021","March 2021","August 2017","November 9, 2016","November 16, 2016","null","null","August 29, 2017","August 31, 2017","University of Florida Health Shands Hospital, Gainesville, Florida, United States|John Hopkins University School of Medicine/Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Robert Wood Johnson Medical School/RWJ University Hospital, New Brunswick, New Jersey, United States|University of Washington Medical Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT02964325"
1208,"NCT02095951","Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection","null","Completed","No Results Available","Leukemia|Lymphoma|Blood Disorders|Solid Tumors","Drug: Ethanol lock therapy (ELT)","Length of stay (LOS), Attributable Length of Stay (ALOS) and Hospital costs|Catheter sterilization rates|Catheter salvage rates|Adverse Events|Re-infection rates","Children's Hospital of Michigan|Blue Cross Blue Shield of Michigan Foundation","All","6 Months to 21 Years   (Child, Adult)","","35","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2024.11","June 2014","June 2016","June 2016","January 2017","March 17, 2014","March 26, 2014","null","null","January 4, 2017","January 5, 2017","Children's Hospital of Michigan, Detroit, Michigan, United States","https://ClinicalTrials.gov/show/NCT02095951"
1209,"NCT00001269","Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer","null","Completed","No Results Available","Breast Neoplasms|Neoplasm Metastasis","Drug: IL-3","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 1","100","NIH","Interventional","Primary Purpose: Treatment","910121|91-C-0121","May 1991","null","February 2001","April 2000","November 3, 1999","December 10, 2002","null","null","March 3, 2008","March 4, 2008","National Cancer Institute (NCI), Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00001269"
1210,"NCT02274506","Infusion of Allogeneic, 3rd Party CD19-specific T Cells","null","Withdrawn","No Results Available","Blood And Marrow Transplantation|Leukemia|Lymphoma","Drug: Cyclophosphamide|Drug: Fludarabine|Procedure: T-Cell Infusion","Maximum Tolerated Dose (MTD) of CD19-Specific T Cells","M.D. Anderson Cancer Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-0235","July 2014","July 2018","null","October 2014","October 22, 2014","October 24, 2014","null","null","October 22, 2014","October 24, 2014","","https://ClinicalTrials.gov/show/NCT02274506"
1211,"NCT00400686","Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma","null","Completed","Has Results","Anemia|Multiple Myeloma|Plasma Cell Neoplasm","Biological: epoetin alfa","Change From Baseline in Hemoglobin at Day 28|Number of Patients With an at Least 1gm/dL Increase in Hgb|Number of Patients With an at Least 2gm/dL Increase in Hgb","The Cleveland Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","31","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CASE-CCF-5497|P30CA043703|ORTHO-CASE-CCF-5497","September 2003","January 2009","August 2013","October 2016","November 16, 2006","November 17, 2006","June 3, 2015","December 9, 2016","October 18, 2016","December 9, 2016","Case Comprehensive Cancer Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT00400686"
1212,"NCT00943319","Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies","null","Active, not recruiting","No Results Available","Leukemia|Lymphoma|Myeloma","Drug: Busulfan|Drug: Fludarabine|Drug: Campath|Procedure: Stem Cell Transplant","Toxicity|Evaluate disease free and overall survival","University of Chicago","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","124","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-0132","March 2012","December 2017","December 2017","April 2017","July 20, 2009","July 22, 2009","null","null","April 18, 2017","April 19, 2017","The University of Chicago, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT00943319"
1213,"NCT01092026","Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells","null","Recruiting","No Results Available","Allogeneic Stem Cell Transplantation","Other: cord blood transplantation","treatment-related mortality|Hematopoietic recovery","Universitair Ziekenhuis Brussel","All","15 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BHS-UCB2009","November 2010","December 2017","December 2017","May 2016","March 23, 2010","March 24, 2010","null","null","June 3, 2016","June 6, 2016","UZ Brussel, Brussel, Belgium","https://ClinicalTrials.gov/show/NCT01092026"
1214,"NCT02300571","Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant","null","Recruiting","No Results Available","Hematological Malignancies","","Incidence of the observed GVHD rate and infections|Overall survival|Progression-free survival","Fondazione del Piemonte per l'Oncologia","All","18 Years to 65 Years   (Adult)","","60","Other","Observational","Observational Model: Case-Only|Time Perspective: Other","HDCTX 2013","September 2013","December 2017","January 2018","August 2017","November 21, 2014","November 25, 2014","null","null","September 1, 2017","September 5, 2017","Fondazione del Piemonte per l'Oncologia, Candiolo, Italy|Ospedale Regina Margherita, Torino, Italy","https://ClinicalTrials.gov/show/NCT02300571"
1215,"NCT00353860","Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances","null","Completed","No Results Available","Immunosuppression|Leukemia","Device: SOLEX 300i Stem Cell Selection","The proportion of patients with clinically significant acute GHVD (Grade II or higher) following the T depleted PBPC transplant.","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","10 Years to 80 Years   (Child, Adult, Senior)","Phase 2","70","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","020111|02-H-0111","January 23, 2002","November 29, 2007","November 29, 2007","November 21, 2016","July 18, 2006","July 19, 2006","null","null","October 5, 2017","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00353860"
1216,"NCT02329808","Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics","PROTECT","Recruiting","No Results Available","Hematologic Diseases|Oncology Problem|Kidney Diseases|Transplantation Infection","Procedure: blood drawing","drug concentration|Questionnaire|costs|Area under the curve","Radboud University|ZonMw: The Netherlands Organisation for Health Research and Development","All","2 Years to 18 Years   (Child, Adult)","","126","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","UMCN-AKF 14.02","June 2015","December 2018","December 2018","November 2017","December 19, 2014","January 1, 2015","null","null","November 14, 2017","November 17, 2017","Radboud University Medical Center, Nijmegen, Gelderland, Netherlands","https://ClinicalTrials.gov/show/NCT02329808"
1217,"NCT00507325","Sample Collection From Melanoma Patients","null","Active, not recruiting","No Results Available","Melanoma","Procedure: Blood Sample|Procedure: Tumor Sample","Collection and long-term collection of blood and tumor samples from patients with malignant melanoma for future biological and/or surrogate marker studies.","M.D. Anderson Cancer Center","All","Child, Adult, Senior","","200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2005-0466","June 2006","June 2019","June 2019","September 2017","July 24, 2007","July 26, 2007","null","null","September 12, 2017","September 13, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00507325"
1218,"NCT00070616","Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support","null","Completed","No Results Available","Leukemia|Lymphoma|Myeloma","Drug: Palifermin 6 x 60 μg/kg/day|Drug: Palifermin 2 x 180 μg/kg/day|Radiation: radiotherapy|Drug: Chemotherapy","To characterize the PK profile of 3 daily intravenous (IV) doses of rHuKGF before total body irradiation (TBI) / high-dose chemotherapy conditioning treatment and after PBPC transplantation|To assess the safety and tolerability of rHuKGF in subjects with hematologic malignancies undergoing TBI and high-dose chemotherapy followed by PBPC transplantation.|To assess oral mucositis in subjects receiving rHuKGF.","Swedish Orphan Biovitrum|Amgen","All","18 Years to 76 Years   (Adult, Senior)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20010182","December 2001","March 2005","March 2005","October 2014","October 6, 2003","October 8, 2003","null","null","October 23, 2014","October 24, 2014","","https://ClinicalTrials.gov/show/NCT00070616"
1219,"NCT00003898","Glutamine in Treating Side Effects in Children Who Are Undergoing Stem Cell Transplantation","null","Completed","No Results Available","Oral Complications|Unspecified Childhood Solid Tumor, Protocol Specific","Dietary Supplement: glutamine","","Roswell Park Cancer Institute","All","1 Year to 21 Years   (Child, Adult)","Phase 2","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CDR0000067069|RPCI-RP-9810","January 1999","June 2003","January 2004","February 2011","November 1, 1999","June 17, 2004","null","null","February 25, 2011","March 1, 2011","Roswell Park Cancer Institute, Buffalo, New York, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT00003898"
1220,"NCT00892502","Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?","Bismuth-PBH","Completed","No Results Available","Hematological Diseases|Hematological Malignancies|Blood Diseases|Malignant Lymphoma|Leukemia|Multiple Myeloma","Drug: Bismuth tablets|Drug: Placebo tablets","To evaluate a possible protective effect of bismuth on the mucous membranes during chemotherapy and radiotherapy|To identify the effect of bismuth on the regulation of metallothionein in tumour tissue and healthy tissue, respectively","Copenhagen University Hospital at Herlev","All","18 Years to 75 Years   (Adult, Senior)","","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2007-007652-34","May 2009","January 2012","February 2013","September 2013","May 1, 2009","May 4, 2009","null","null","September 9, 2013","September 10, 2013","Department of Haematology L, Herlev Hospital, Herlev Ringvej 75, Herlev, Denmark","https://ClinicalTrials.gov/show/NCT00892502"
1221,"NCT00074490","Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers","null","Completed","No Results Available","Lymphoma|Leukemia|Myeloproliferative Disorders|Multiple Myleoma|Myelodysplastic Syndrome","Drug: Rituximab|Drug: Fludarabine|Drug: Etoposide|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Procedure: PBSC transplantation|Genetic: T cell DLI with sirolimus generated donor TH-2 cells|Drug: Prednisone|Procedure: Allogeneic HSCT|Drug: Filgrastim|Genetic: T-Rapa cell DLI","Safety and feasibility|Graft-versus-host disease rate|Pattern of post-transplantation CD4+ and CD8+ T-cell production of Th1-Th2-type cytokines|Incidence of opportunistic infection","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","11 Years to 90 Years   (Child, Adult, Senior)","Phase 2","380","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","040055|04-C-0055","January 1, 2004","July 20, 2017","August 16, 2017","November 15, 2017","June 19, 2006","December 15, 2003","null","null","November 18, 2017","November 21, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States","https://ClinicalTrials.gov/show/NCT00074490"
1222,"NCT00003081","Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma","null","Completed","No Results Available","Sarcoma","Biological: filgrastim|Drug: busulfan|Drug: melphalan|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 49 Years   (Child, Adult)","Phase 1","16","Other|NIH","Interventional","Primary Purpose: Treatment","1205.00|NCI-G97-1331|CDR0000065777","March 1998","January 2002","January 2002","September 2010","November 1, 1999","April 27, 2004","null","null","September 16, 2010","September 20, 2010","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00003081"
1223,"NCT01544686","Antimicrobial Catheter Securement Dressings for the Prevention of Cvc-related Bloodstream Infections in Cancer Patients","COAT","Completed","No Results Available","Bloodstream Infection","Device: 3M™ Tegaderm™ CHG IV and 3M™ Tegaderm™ Advanced IV","Incidence of definite catheter-related bloodstream infection during the first 14 days after placement of the central venous catheter|Incidence of definite catheter related bloodstream infection-related severe sepsis during the first 14 days after placement of the central venous catheter|Definite catheter-related bloodstream infection-related mortality during the first 14 days after placement of the central venous catheter|Overall incidence of catheter-related bloodstream infection|Overall catheter-related bloodstream infection-related severe sepsis|Overall catheter-related bloodstream infection-related mortality|Overall mortality|Time to removal of central venous catheter|Time to central venous catheter-related blood stream infections|Time to first neutropenic fever|Rate of unplanned changes|Tolerability/safety","University of Cologne|3M","All","18 Years and older   (Adult, Senior)","","630","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","DRKS00003368","February 2012","October 2015","October 2015","December 2015","February 22, 2012","March 6, 2012","null","null","December 8, 2015","December 9, 2015","Klinikum Schwabing, Munich, Bavaria, Germany|Klinikum Neuperlach, Munich, Bavaria, Germany|Universitätsklinikum Aachen, Aachen, NRW, Germany|University Hospital Cologne, Cologne, NRW, Germany|Universitätsmedizin Berlin - Charité, Berlin, Germany","https://ClinicalTrials.gov/show/NCT01544686"
1224,"NCT00005606","Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation","null","Completed","No Results Available","Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm","Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|Biological: autologous Epstein-Barr virus-specific cytotoxic T lymphocytes","","Northwestern University|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","NU 98H1|NU-98H1|NCI-G00-1739","February 2000","September 2003","September 2003","May 2012","May 2, 2000","January 27, 2003","null","null","May 31, 2012","June 6, 2012","Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT00005606"
1225,"NCT00376519","Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases","null","Terminated","No Results Available","Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Secondary Myelofibrosis","Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: mycophenolate mofetil|Procedure: Treg cell infusion|Procedure: umbilical cord blood transplantation|Radiation: total-body irradiation","Maximum tolerated dose of T-regulatory cells|Incidence of neutrophil recovery|Incidence of double chimerism|Incidence of grades II-IV and III-IV acute graft-versus-host disease (GVHD)|Incidence of chronic graft-versus-host disease|Survival|Incidence of Platelet Recovery","Masonic Cancer Center, University of Minnesota","All","18 Years to 45 Years   (Adult)","Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UMN-2005LS011|UMN-0502M67473|UMN-MT2005-01","May 2007","March 2008","March 2008","November 2017","September 13, 2006","September 15, 2006","null","null","November 29, 2017","December 1, 2017","Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00376519"
1226,"NCT03372902","Use Of A Blood Test To Improve The Performance Of Imaging For Breast Cancer Screening","null","Recruiting","No Results Available","Breast Caner|Breast Benign","Device: Breast MRI|Device: Breast Mammogram|Other: Blood draw|Procedure: Breast Biopsy|Behavioral: online patient reported questionnaire","number of patients with malignant biopsy","Memorial Sloan Kettering Cancer Center|GRAIL, Inc.","Female","18 Years and older   (Adult, Senior)","","2347","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17-598","December 7, 2017","December 2019","December 2019","December 2017","December 11, 2017","December 14, 2017","null","null","December 11, 2017","December 14, 2017","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT03372902"
1227,"NCT02767609","Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging","null","Completed","No Results Available","Traumatic Brain Injury|Multiple Sclerosis|Alzheimer's Disease|Tumor","Device: Magnetic Resonance Imaging","Regional cerebral blood flow values of the brain measured using pseudo-continuous arterial spin labeling (pCASL) MRI.","Loma Linda University","All","18 Years to 90 Years   (Adult, Senior)","","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","5140083","May 2014","March 3, 2017","March 3, 2017","June 2017","May 6, 2016","May 10, 2016","null","null","June 13, 2017","June 14, 2017","","https://ClinicalTrials.gov/show/NCT02767609"
1228,"NCT01147809","Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag","null","Completed","Has Results","Thrombocytopaenia","Drug: Eltrombopag olamine|Other: Placebo","Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I|Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I|Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I|Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I|Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I|Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I|Mean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase II|Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I|Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I|Platelet Count Nadir for Each Chemotherapy Cycle in Phase I|Central Laboratory Average Daily Area Under the Curve Platelet-time Course Across Cycles 2 to 6 in Phase I|Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count|Maximum Duration of Thrombocytopenia Across Cycles 2 to 6 in Phase I, Estimated Using Central Laboratory Platelet Counts|Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I|Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts|Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I|Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase I|Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II|Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II|Number of Participants Requiring a Platelet Transfusion in Phase II|Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II|Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II|Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II|Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II|Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II|Number of Participants With Change From Baseline in Creatinine of >=26.5 UMOL/L in Phase II|Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II|Number of Participants With Electrocardiogram (ECG) Findings at Cycle 1 Day 4 (2 to 6 Hours Post-dose) in Phase II|Mean Day 8 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II|Mean Day 15 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II|Mean Within-subject Platelet Count Prior to Scheduled Chemotherapy Across Cycles 1 to 6 in Phase II|Platelet Count Nadir for Each Chemotherapy Cycle in Phase II|Average Daily Area Under the Platelet-time Course Across Cycles 1 to 6 in Phase II|Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II|Maximum Duration of Thrombocytopenia Across Cycles 1 to 6 in Phase II|Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II|Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II","GlaxoSmithKline","All","18 Years and older   (Adult, Senior)","Phase 2","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","112765","June 2010","January 2015","March 2015","March 2016","May 20, 2010","June 22, 2010","August 27, 2015","April 18, 2016","March 17, 2016","April 18, 2016","GSK Investigational Site, Sedona, Arizona, United States|GSK Investigational Site, Hot Springs, Arkansas, United States|GSK Investigational Site, Rancho Cucamonga, California, United States|GSK Investigational Site, Norwich, Connecticut, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, New Port Richey, Florida, United States|GSK Investigational Site, Rome, Georgia, United States|GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Wichita, Kansas, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Cherry Hill, New Jersey, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Greensboro, North Carolina, United States|GSK Investigational Site, Bend, Oregon, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Wynnewood, Pennsylvania, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Arlington, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Bedford, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Tyler, Texas, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Edmunds, Washington, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Vancouver, Washington, United States|GSK Investigational Site, Yakima, Washington, United States|GSK Investigational Site, Charleroi, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Libramont, Belgium|GSK Investigational Site, Namur, Belgium|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Olomouc, Czech Republic|GSK Investigational Site, Praha 10, Czech Republic|GSK Investigational Site, Praha 5, Czech Republic|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Tampere, Finland|GSK Investigational Site, Freiburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Augsburg, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Goslar, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Heraklion, Crete, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Kaposvár, Hungary|GSK Investigational Site, Törökbálint, Hungary|GSK Investigational Site, Zalaegerszeg, Hungary|GSK Investigational Site, Madurai, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Tallaght, Dublin, Ireland|GSK Investigational Site, Ashkelon, Israel|GSK Investigational Site, Haifa, Israel|GSK Investigational Site, Jerusalem, Israel|GSK Investigational Site, Kfar Saba, Israel|GSK Investigational Site, Tel Aviv, Israel|GSK Investigational Site, Zrifin, Israel|GSK Investigational Site, Modena, Emilia-Romagna, Italy|GSK Investigational Site, Aviano (PN), Friuli-Venezia-Giulia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Sassari, Sardegna, Italy|GSK Investigational Site, Pisa, Toscana, Italy|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Konin, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Poznan, Poland","https://ClinicalTrials.gov/show/NCT01147809"
1229,"NCT01517347","Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation","null","Terminated","No Results Available","Leukemia","Drug: Interleukin-2","To determine the feasibility and efficiency of administering 6 courses of subcutaneous IL-2 in these patients population.|To assess the immunologic impact of ultra-low dose subcutaneous IL-2 in patients after transplantation","Peking University People's Hospital","All","15 Years to 65 Years   (Child, Adult)","","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PUPH IRB [2012] (09）","January 2012","August 2015","August 2015","October 2016","January 10, 2012","January 25, 2012","null","null","October 20, 2016","October 24, 2016","Xiaosu Zhao, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT01517347"
1230,"NCT01749332","A Pilot Study of Perihepatic Phlebotomy During Hepatic Resections","null","Active, not recruiting","No Results Available","Liver Cancer","Other: Perihepatic Phlebotomy","ctDNA differences|collect preliminary data","Memorial Sloan Kettering Cancer Center|University of Michigan","All","Child, Adult, Senior","","117","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-236","December 2012","December 2018","December 2018","July 2017","December 11, 2012","December 13, 2012","null","null","July 17, 2017","July 18, 2017","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT01749332"
1231,"NCT00003196","Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma","null","Active, not recruiting","No Results Available","Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage II Multiple Myeloma|Stage III Multiple Myeloma|Testicular Lymphoma|Waldenström Macroglobulinemia","Drug: chemotherapy|Radiation: total-body irradiation|Procedure: peripheral blood stem cell transplantation|Drug: cyclosporine|Drug: mycophenolate mofetil|Procedure: allogeneic hematopoietic stem cell transplantation|Biological: therapeutic allogeneic lymphocytes","Incidence of GVHD, myelosuppression, and infections|Greater than 10% incidence of treatment-related mortality (TRM) after PBSC infusion, defined as death without evidence of disease progression|Greater than 20% incidence of TRM after DLI, defined as death without evidence of disease progression|Proportion of patients who successfully achieve mixed chimerism|Proportion of patients with mixed chimerism who successfully achieve full donor chimerism|Response of malignancy to DLI|Incidence of myelosuppression after initial PBSC transplant|Incidence of aplasia after DLI|Incidence of grades 2-4 acute GVHD after DLI|Incidence of grades 2-4 acute GVHD after PBSC infusion|Incidence of chronic extensive GVHD after DLI|Dose of cluster of differentiation (CD)3+ cells required to convert mixed to full lymphoid chimeras|Incidence of non-relapse mortality","Fred Hutchinson Cancer Research Center|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)","All","50 Years to 65 Years   (Adult)","","63","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1225.00|NCI-2012-00592|#1225.00A|P30CA015704","September 1997","April 2002","null","October 2017","November 1, 1999","July 19, 2004","null","null","October 23, 2017","October 25, 2017","City of Hope Medical Center, Duarte, California, United States|Stanford University Hospitals and Clinics, Stanford, California, United States|Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States|Universitaet Leipzig, Leipzig, Germany|University of Torino, Torino, Italy","https://ClinicalTrials.gov/show/NCT00003196"
1232,"NCT00001582","Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer","null","Recruiting","No Results Available","T-cell Lymphoma|B-Cell Lymphoma|ATL|Myeloma","","Create Biobank","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","1 Year to 99 Years   (Child, Adult, Senior)","","1000","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","970143|97-C-0143","July 10, 1997","null","null","December 10, 2017","November 3, 1999","November 4, 1999","null","null","December 19, 2017","December 20, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00001582"
1233,"NCT00887042","Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML","null","Unknown status","No Results Available","Acute Myeloid Leukemia","Drug: Fludarabine, Busulfan, Thymoglobulin","To evaluate the engraftment potential of fludarabine, busulfan plus thymoglobulin conditioning regimen for CBT in AML.|To evaluate the incidence and severity of toxicity and treatment related mortality.|To evaluate overall and event free survival rate.|To evaluate acute and chronic GVHD.|To evaluate immunologic recovery after CBT.","The Korean Society of Pediatric Hematology Oncology","All","1 Year to 21 Years   (Child, Adult)","Phase 1|Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSPHO-S0501","June 2006","May 2012","May 2012","March 2012","April 21, 2009","April 23, 2009","null","null","March 23, 2012","March 26, 2012","Seoul National University Hospital, Seoul, Chongno-gu, Korea, Republic of","https://ClinicalTrials.gov/show/NCT00887042"
1234,"NCT00740116","Tranexamic Acid in Surgery of Advanced Ovarian Cancer","null","Completed","No Results Available","Ovarian Cancer","Drug: Tranexamic acid|Drug: 0.9% NaCl solution","Perioperative bleeding volume|Number of patients receiving blood transfusions and number of transfusions|Number of patients with clinically or radiologically verified thromboembolic events within 5 week postoperatively","Preben Kjolhede|University Hospital, Linkoeping","Female","18 Years and older   (Adult, Senior)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EudraCT nr 2006-006714-14","March 2008","June 2012","June 2012","June 2012","August 21, 2008","August 22, 2008","null","null","June 26, 2012","June 28, 2012","Dept of Obstetric and Gynecology, Ryhov Central Hospital, Jönköping, Sweden|Department of Obstetrics and Gynecology, Kalmar Central Hospital, Kalmar, Sweden|University Hospital, Department of Obsterics and Gynecology,, Linköping, Sweden","https://ClinicalTrials.gov/show/NCT00740116"
1235,"NCT00339911","Collection and Distribution of Blood Samples From Healthy Donors for In Vitro Research at the NCI Frederick Cancer Research and Development Center","null","Enrolling by invitation","No Results Available","Healthy Donors","","Establish a centralized repository for the collection and distribution ofsamples","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Senior)","","1000","NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","999999046|OH99-C-N046","October 19, 1999","null","null","April 26, 2017","June 19, 2006","June 21, 2006","null","null","October 18, 2017","October 19, 2017","NCI Frederick Cancer Research Center, Frederick, Maryland, United States","https://ClinicalTrials.gov/show/NCT00339911"
1236,"NCT02379429","Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue","null","Recruiting","No Results Available","Bladder Cancer|Urinary Tract Cancer|Urothelial Cancer|Healthy Volunteers","","Collect samples for the purpose of studying the molecular mechanisms of carcinogenesis in urothelial cancer|Collect detailed history, pathologic data, perioperative findings, and treatment data to better characterize the natural and clinical histories of urothelial cancer when feasible.|Develop stable urothelial / bladder cancer cell lines from procured tissue when feasible.|Perform molecular profiling and analysis to better characterizeurothelial cancer and identify novel targets.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Senior)","","500","NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","150087|15-C-0087","February 20, 2015","January 1, 2025","January 1, 2025","December 15, 2017","March 4, 2015","March 5, 2015","null","null","December 27, 2017","December 28, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT02379429"
1237,"NCT02742701","Diabetes and Palliative Care","DIAPAL","Not yet recruiting","No Results Available","End-of-life|Diabetes|Terminal Cancer","Other: diagnosis","Predictive performance of glycosuria measured on urine collected between 10 am and 16 am on the blood glucose level at 6 pm|Relation between glycemia and glycosuria at different time points over 24 hours.|Intensity of pain caused by finger pricking|Type, frequency and intensity of symptoms in relation to the blood glucose level","Maison Médicale Jeanne Garnier","All","18 Years and older   (Adult, Senior)","","180","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MMJG/2014/SC/001","April 2016","October 2017","January 2018","April 2016","April 7, 2016","April 19, 2016","null","null","April 13, 2016","April 19, 2016","","https://ClinicalTrials.gov/show/NCT02742701"
1238,"NCT00362739","Blood Collection From Individuals With Lung Disease for Genetic Studies","null","Completed","No Results Available","Asthma|COPD|Interstitial Lung Disease|Cystic Fibrosis|Lung Cancer","","Establish a set of normal ranges for various parameters in healthy individual specimens and compare to specimens from individuals with lung disease to determine parameters resulting in disease susceptibility and severity.","Weill Medical College of Cornell University","All","18 Years and older   (Adult, Senior)","","3087","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","0508008095","September 2005","August 2015","August 2015","April 2016","August 8, 2006","August 10, 2006","null","null","April 28, 2016","April 29, 2016","New York Presbyterian Hospital -- Weill Cornell Medical College of Cornell University, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00362739"
1239,"NCT02835937","Red Blood Cell Transfusion in the Ambulatory Setting: Impact on Home Functional Status","null","Not yet recruiting","No Results Available","Red Blood Cell Transfusions|Anemia|Hematology|Oncology|Ambulatory Care","Other: No-Transfuse","Percent Change in Average Daily Physical Activity","Mayo Clinic|Project Honeybee -- The Biodesign Institute at Arizona State University","All","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-006487","August 2016","August 2017","December 2017","July 2016","July 14, 2016","July 18, 2016","null","null","July 15, 2016","July 18, 2016","Mayo Clinic in Arizona, Scottsdale, Arizona, United States","https://ClinicalTrials.gov/show/NCT02835937"
1240,"NCT00234169","A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone","null","Completed","No Results Available","Multiple Myeloma|Lymphoma","Drug: VTP195183","PB CD34+ kinetics using VTP195183 plus G-CSF|The toxicity of VTP195183 pretreatment when used with G-CSF","Peter MacCallum Cancer Centre, Australia|The Leukemia and Lymphoma Society","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","05/09","October 2005","January 2008","January 2008","May 2012","October 4, 2005","October 6, 2005","null","null","May 9, 2012","May 10, 2012","Peter MacCallum Cancer centre, Melbourne, Victoria, Australia","https://ClinicalTrials.gov/show/NCT00234169"
1241,"NCT02784561","Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation","null","Not yet recruiting","No Results Available","Leukemia","Drug: Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd)|Drug: Cytarabine(Actavis Italy S.p.A)|Drug: Fludarabine (Bayer)|Drug: granulocyte colony-stimulating factor (KirinKunpeng)|Drug: rabbit ATG（Sanofi/Genzyme）","Number of participants relapse as assessed by NCCN (National Comprehensive Cancer Network )criteria|Rate of Complete Remission as assessed by NCCN (National Comprehensive Cancer Network )criteria|DFS(disease-free survival )|TRM(treatment-related mortality )|Number of participants with aGVHD as assessed by acute graft versus host disease grading criteria (refer to Glucksberg criteria)|Number of participants with Regimen-related adverse events as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03","Chinese PLA General Hospital|309th Hospital of Chinese People's Liberation Army|Beijing Naval General Hospital|Space Center Hospital, Peking University","All","12 Years to 65 Years   (Child, Adult)","Phase 4","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","81370666-2","July 2016","July 2019","July 2020","May 2016","May 17, 2016","May 27, 2016","null","null","May 24, 2016","May 27, 2016","","https://ClinicalTrials.gov/show/NCT02784561"
1242,"NCT02845232","Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly","null","Completed","No Results Available","Acute Myeloid Leukemia","Other: Transfusion","Estimation of mean blood product transfusions costs (in euros) per patient according to overall survival|Complete remission (CR) rate|Number of blood product transfusions per patient","Hospices Civils de Lyon","All","70 Years and older   (Senior)","","214","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","69HCL16_0461","March 2013","December 2014","May 2015","July 2016","July 20, 2016","July 27, 2016","null","null","July 22, 2016","July 27, 2016","Hospices Civils de Lyon - Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet, Pierre-benite, France","https://ClinicalTrials.gov/show/NCT02845232"
1243,"NCT01279330","Does the Recall by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening?","Pagedocc2","Unknown status","No Results Available","Colorectal Cancer","Other: Co-signed Letter|Other: Control","Completion of Fecal Occult Blod Test|Delays from receipt of the letter and the completion of the test.|Proportion of uninterpretable test.","University of Paris 5 - Rene Descartes|Adeca 75|Société de Formation Thérapeutique du Généraliste|Hotel Dieu Hospital","All","50 Years to 74 Years   (Adult, Senior)","","1569","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","PAGEDOCC2","September 2010","April 2011","April 2011","September 2010","January 18, 2011","January 19, 2011","null","null","January 18, 2011","January 19, 2011","Université Paris Descartes, Paris, Ile de France, France","https://ClinicalTrials.gov/show/NCT01279330"
1244,"NCT01279278","Does the Invitation by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening?","Pagedocc1","Unknown status","No Results Available","Colorectal Cancer","Other: Co-signed letter|Other: Classical Letter","Completion of Fecal Occult Blod Test|Measure the impact of co-signing on deadline for completion of the test after the mailing.|Compare the proportion of uninterpretable tests.|Compare the rate of completion of colonoscopy after a positive test (information received by ADECA in the follow-up), according to the specifications.","University of Paris 5 - Rene Descartes|Adeca 75|Société de Formation Thérapeutique du Généraliste|Hotel Dieu Hospital","All","50 Years to 74 Years   (Adult, Senior)","","2700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","PAGEDOCC1","September 2010","April 2011","April 2011","September 2010","January 18, 2011","January 19, 2011","null","null","January 18, 2011","January 19, 2011","Université Paris Descartes, Paris, Ile de France, France","https://ClinicalTrials.gov/show/NCT01279278"
1245,"NCT01419509","DNA Tests in Detecting Disseminated Disease in Tumor, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma","null","Completed","No Results Available","Sarcoma","Genetic: DNA methylation analysis|Genetic: microarray analysis|Genetic: polymerase chain reaction|Other: laboratory biomarker analysis","Panel of hypermethylation assays for minimal disseminated RMS|Detection of RMS cells in bone marrow","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 18 Years   (Child, Adult)","","170","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","ARST11B1|COG-ARST11B1|NCI-2011-02985","August 2011","May 2016","May 2016","May 2016","August 17, 2011","August 18, 2011","null","null","May 13, 2016","May 17, 2016","","https://ClinicalTrials.gov/show/NCT01419509"
1246,"NCT01497184","Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood","null","Active, not recruiting","No Results Available","Leukemia|Lymphoma","Procedure: HSCT|Genetic: DLI","Maximum Tolerated dose (MTD) of Donor Lymphocyte Infusion (DLI)","M.D. Anderson Cancer Center|Intrexon Corporation|Ziopharm","All","1 Year to 65 Years   (Child, Adult)","Phase 1","140","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-0525|NCI-2012-00015","December 2011","December 2018","null","December 2016","December 20, 2011","December 22, 2011","null","null","December 27, 2016","December 28, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT01497184"
1247,"NCT02960646","Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation","null","Recruiting","No Results Available","Leukemia","Drug: Rituximab|Drug: Melphalan|Drug: Fludarabine|Radiation: Total body irradiation (TBI)|Procedure: Stem Cell Infusion|Drug: Cyclophosphamide|Drug: G-CSF","Treatment Failure of a Modified Peripheral Blood (PB) Graft for Haploidentical Transplantation","M.D. Anderson Cancer Center","All","18 Years to 60 Years   (Adult)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0738|NCI-2016-01915","January 18, 2017","January 1, 2020","January 1, 2020","December 2017","November 8, 2016","November 9, 2016","null","null","December 27, 2017","December 29, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT02960646"
1248,"NCT00926354","Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients","null","Terminated","No Results Available","Chemotherapy Induced Thrombocytopenia","Drug: AS101","Incidence of thrombocytopenia events (platelets <70,000) over the study period of the study groups|Evaluation of Safety and tolerability; Thrombocytopenia events that caused treatment delays and chemotherapy dose; reductions; Progression Free Survival (PFS); Response Rate (RR);","BioMAS Ltd","All","18 Years and older   (Adult, Senior)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#71 REV 00","August 2009","August 2010","August 2010","June 2011","June 17, 2009","June 23, 2009","null","null","June 19, 2011","June 21, 2011","Meir Medical Center, Kfar Saba, Israel","https://ClinicalTrials.gov/show/NCT00926354"
1249,"NCT01362985","Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor","null","Completed","No Results Available","Acute Leukemia|Chronic Leukemia|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Solid Tumors|Lymphoma|Plasma Cell Disorders","","Number of patients who received plerixafor outside of the label indication in Europe and the reason for administration","Genzyme, a Sanofi Company|European Group for Blood and Marrow Transplantation|Sanofi","All","up to 18 Years   (Child, Adult)","Phase 4","201","Industry|Other","Observational","Observational Model: Cohort","MOZ19310|OBS13612","July 2009","July 2014","July 2014","August 2015","May 27, 2011","June 1, 2011","null","null","August 12, 2015","August 13, 2015","","https://ClinicalTrials.gov/show/NCT01362985"
1250,"NCT01163110","Study to Investigate the Therapeutic Role of RNA Fragments in Platelet Production During Chemotherapy","null","Completed","No Results Available","Thrombocytopenia|Neoplasm|Cancer","Dietary Supplement: Realbuild","Determine whether E. coli or yeast ribosomal ribonucleic acid (rRNA) fragments prophylactically prevent the development of thrombocytopenia during chemotherapy.|Determine whether E. coli or yeast rRNA fragments accelerate the recovery of platelets in patients undergoing chemotherapy.","Midwestern Regional Medical Center","All","18 Years to 80 Years   (Adult, Senior)","Phase 1","32","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTCA04-04","March 2004","June 2007","June 2007","November 2013","July 13, 2010","July 15, 2010","null","null","November 14, 2013","November 15, 2013","Midwestern Regional Medical Center, Zion, Illinois, United States","https://ClinicalTrials.gov/show/NCT01163110"
1251,"NCT00273585","Study of Using Computerized Education to Increase Patients' Confidence in Their Ability to Be Screened for Colon Cancer","null","Completed","No Results Available","Colorectal Cancer Screening","Device: Personally-tailored educational software program","Colorectal cancer screening self-efficacy|Colorectal cancer screening intention|Colorectal cancer screening decisional conflict","University of California, Davis","All","50 Years and older   (Adult, Senior)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Prevention","200412524-2","August 2005","null","February 2006","September 2006","January 6, 2006","January 9, 2006","null","null","September 6, 2006","September 8, 2006","Department of Family & Community Medicine, UC Davis School of Medicine, Sacramento, California, United States","https://ClinicalTrials.gov/show/NCT00273585"
1252,"NCT00797758","Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid Leukemia","MINICORD","Completed","No Results Available","Acute Myeloid Leukemia","Other: Cord blood transplantation","Transplant related mortality|Clinical efficiency (overall survival, event free survival, relapse incidence, acute and chronic GVHD incidence, graft failure, venoocclusive disease, interstitial pneumonia, infections, comorbidity score, quality of life and medico-economic impact)","Assistance Publique - Hôpitaux de Paris","All","4 Years to 65 Years   (Child, Adult)","Phase 2","76","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P 060206","October 2007","July 2011","December 2011","March 2013","November 24, 2008","November 25, 2008","null","null","March 7, 2013","March 8, 2013","Département d'Hématologie et d'Oncologie Médicale, Hôtel-Dieu, Paris, France","https://ClinicalTrials.gov/show/NCT00797758"
1253,"NCT03124212","Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland","CASCADE","Recruiting","No Results Available","Hereditary Breast and Ovarian Cancer|Lynch Syndrome","Other: CASCADE genetic screening","Establishing the CASCADE Cohort|Quality of Life|Cancer Surveillance","University of Basel","All","18 Years and older   (Adult, Senior)","","700","Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","2016-02052","April 1, 2017","March 31, 2018","September 30, 2022","April 2017","April 10, 2017","April 21, 2017","null","null","April 18, 2017","April 21, 2017","University Hospital Basel, Basel, Switzerland|Istituto Oncologico della Zvizzera Italiana, Bellinzona, Switzerland|Bauch- und Tumorzentrum der Universitatsklinik fur Viszerale Chirurgie und Medicine, Inselspital, Bern, Switzerland|Universitatklinik fur Medizinische Onkologie, Inselspital, Bern, Switzerland|Unite d'Oncogenetique et de Prevention des Cancers, Geneva, Switzerland","https://ClinicalTrials.gov/show/NCT03124212"
1254,"NCT00867529","Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma","null","Completed","Has Results","B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia","Biological: rituximab|Procedure: peripheral blood stem cell transplantation|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Other: pharmacological study|Other: laboratory biomarker analysis","Disease Relapse Rate|Incidence and Severity of Acute and Chronic GVHD Evaluated Per an Adapted Version of Common Terminology Criteria for Adverse Events (CTCAE) Version 2.0|Overall Survival and Progression-free Survival|Rate of Graft Rejection and Graft Failure|Time to Engraftment","Fred Hutchinson Cancer Research Center|American Cancer Society, Inc.|National Cancer Institute (NCI)","All","Child, Adult, Senior","Phase 2","63","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2226.00|NCI-2010-00107|2226|P01CA078902|P30CA015704","February 2009","March 2015","March 26, 2015","December 2017","March 20, 2009","March 23, 2009","April 14, 2017","May 22, 2017","December 5, 2017","January 1, 2018","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00867529"
1255,"NCT02328885","Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation","null","Active, not recruiting","No Results Available","Leukemia","Other: DLI of the 20 fraction of the UCBT","Safety of this therapeutic approach as determined by clinical evaluation of the immediate effects of the infusion & Analysis of the GVHD post-DLI|Efficacy of this therapeutic approach as determinated by analysis of the speed and diversity of immune reconstitution|Efficacy of this therapeutic approach as determinated by analysis of the incidence and type of infections|Efficacy of this therapeutic approach as determinated by analysis of the incidence of relapse|Efficacy of this therapeutic approach as determinated by analysis of the therapeutic success of transplantation using survival curves","Banc de Sang i Teixits|Hospital Vall d'Hebron|Hospital de Sant Pau|Hospital Universitari de Bellvitge|Germans Trias i Pujol Hospital|Fundacion IMIM","All","up to 60 Years   (Child, Adult)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I.2013.004","July 2014","July 2017","July 2018","July 2017","December 16, 2014","December 31, 2014","null","null","July 7, 2017","July 11, 2017","Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Vall Hebron, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT02328885"
1256,"NCT00127543","Kid Cards: Teaching Kids About Medicines","null","Unknown status","No Results Available","Hemophilia|Sickle Cell Disease|Neoplasms|Blood Coagulation Disorders","Behavioral: Medication Education for Children","Develop medication cards appropriate for children|Develop a post-test to determine the effectiveness|Obtain data to support teaching children about medication|Assess the clinical implications of this research","Children's Mercy Hospital Kansas City","All","7 Years to 11 Years   (Child)","","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training","05 06-089E","August 2005","null","December 2005","December 2005","August 5, 2005","August 8, 2005","null","null","February 6, 2006","February 7, 2006","Childrens Mercy Hospitals and Clinics, Kansas City, Missouri, United States","https://ClinicalTrials.gov/show/NCT00127543"
1257,"NCT01617473","Randomized Trial of Mobilized Blood/Marrow Versus Blood Transplant","null","Withdrawn","No Results Available","Leukemia","Procedure: transplant with PBSCs","incidence of engraftment|incidence of non-relapse mortality","Peking University People's Hospital","All","2 Years to 60 Years   (Child, Adult)","","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","PUPH IRB [2012] (27)","October 2015","October 2016","October 2017","September 2016","June 8, 2012","June 12, 2012","null","null","September 27, 2016","September 29, 2016","Peking University People'S Hospital, Beijing, China","https://ClinicalTrials.gov/show/NCT01617473"
1258,"NCT00795769","Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","null","Completed","Has Results","Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Disseminated Neuroblastoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Poor Prognosis Metastatic Gestational Trophoblastic Tumor|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Neuroblastoma|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage II Ovarian Epithelial Cancer|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Ovarian Epithelial Cancer|Stage III Small Lymphocytic Lymphoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Breast Cancer|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Ovarian Epithelial Cancer|Stage IV Small Lymphocytic Lymphoma","Drug: ondansetron|Other: survey administration|Procedure: management of therapy complications","Reduction in Rates of Nausea or Vomiting After Ondansetron (Compared to FHCRC Historical Rates)","Fred Hutchinson Cancer Research Center","All","21 Years and older   (Adult, Senior)","Phase 2","49","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","2247.00|NCI-2010-00325","August 8, 2008","June 9, 2009","June 10, 2009","April 2017","November 20, 2008","November 21, 2008","March 6, 2017","May 23, 2017","April 20, 2017","May 23, 2017","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00795769"
1259,"NCT01562821","Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy","null","Completed","No Results Available","Acquired Bleeding Disorder|Cirrhosis","Drug: activated recombinant human factor VII|Drug: placebo","The RBC transfusion requirements|Number of transfusion product units|Change in coagulation-related parameters|Adverse events","Novo Nordisk A/S","All","21 Years to 70 Years   (Adult, Senior)","Phase 2","235","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","F7LIVER-1313","July 2001","December 2002","December 2002","January 2017","March 22, 2012","March 26, 2012","null","null","January 12, 2017","January 13, 2017","Novo Nordisk Investigational Site, Beijing, Beijing, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, China|Novo Nordisk Investigational Site, Beijing, China|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Taipei, Taiwan|Novo Nordisk Investigational Site, Bangkok, Thailand|Novo Nordisk Investigational Site, Bangkok, Thailand","https://ClinicalTrials.gov/show/NCT01562821"
1260,"NCT00571168","Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy","EmNa","Unknown status","No Results Available","Multiple Myeloma","Drug: Emend|Drug: Placebo","Overall complete response (no emesis and no rescue therapy)|Complete response acute/delayed phase|Vomiting event rate|No emesis (FLIE-Score)|No (significant) nausea (VAS < 5 mm;(< 25 mm))|No rescue therapy|Total control (no emesis, no nausea, no rescue therapy)|No impact on daily life|AEs","Heidelberg University|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Senior)","Phase 3","362","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EmNa (2001-004956-38)|EudraCT-No: 2004-004956-38","July 2005","December 2010","December 2010","January 2010","December 10, 2007","December 11, 2007","null","null","January 11, 2010","January 12, 2010","University Hospital of Heidelberg, Department V, Heidelberg, Germany","https://ClinicalTrials.gov/show/NCT00571168"
1261,"NCT00165139","Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas","null","Completed","No Results Available","Neuroblastoma|Ewings Sarcoma|Non-rhabdomyosarcoma Soft Tissue Sarcoma","Drug: Vincristine|Drug: Cyclophosphamide|Drug: Adriamycin|Drug: Etoposide (VP-16)|Drug: Cisplatin|Drug: Carboplatin|Drug: Melphalan|Drug: Ifosfamide|Drug: G-CSF (granulocyte-colony stimulating factor)|Drug: Mesna","To determine the toxicity and feasibility of double dose chemo-radiotherapy with blood progenitor cell rescue in this patient population.","Dana-Farber Cancer Institute|Boston Children’s Hospital|Children's Hospital of Philadelphia","All","up to 19 Years   (Child, Adult)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","94-131","January 1996","November 2000","February 2009","October 2009","September 9, 2005","September 14, 2005","null","null","October 30, 2009","November 2, 2009","Dana-Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT00165139"
1262,"NCT00188136","Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML)","null","Completed","No Results Available","Acute Myeloid Leukemia","Drug: Melphalan, ATG, Fludarabine","Total and relapse-free survival rate one year after the stem cell transplantation|Incidence of acute GvHD|Safety (evaluated after Common Terminology Criteria for Adverse Events [CTCAE] v 3.0)","University Hospital Carl Gustav Carus","All","16 Years to 75 Years   (Child, Adult, Senior)","Phase 2","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DDEATX","August 2002","July 2010","December 2010","December 2015","September 12, 2005","September 16, 2005","null","null","December 7, 2015","December 8, 2015","University hospital Carl Gustav Carus, Dresden, Germany","https://ClinicalTrials.gov/show/NCT00188136"
1263,"NCT01067300","A Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in the Young With Acute Leukemia Remission","null","Unknown status","No Results Available","Leukemia","Procedure: Transplantation of unrelated cord blood unit(s)","to compare the incidence of transplantation failure in the two treatment arms.|a cost-effectiveness study, the effectiveness criterion being a decrease in transplantation failure incidence.","Assistance Publique Hopitaux De Marseille","All","up to 35 Years   (Child, Adult)","Phase 3","198","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-17|2009-A00792-55","February 2010","January 2016","January 2016","September 2015","February 10, 2010","February 11, 2010","null","null","September 29, 2015","October 1, 2015","Assistance Publique - Hôpitaux de Marseille, Marseille, France","https://ClinicalTrials.gov/show/NCT01067300"
1264,"NCT03214562","Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML)","null","Recruiting","No Results Available","Other Diseases of Blood and Blood-forming Organs|Acute Myeloid Leukemia","Drug: Fludarabine|Drug: Cytarabine|Drug: Idarubicin|Drug: Filgrastim|Drug: Pegylated Filgrastim|Drug: Venetoclax","Maximum Tolerated Dose of FLAG-IDA + Venetoclax in Participants with Acute Myeloid Leukemia (AML)|Adverse Events of FLAG-IDA + Venetoclax in Participants with Acute Myeloid Leukemia (AML)|Overall Response Rate (ORR) of FLAG-IDA + Venetoclax in Participants with Acute Myeloid Leukemia (AML)","M.D. Anderson Cancer Center|AbbVie","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","56","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0979","September 26, 2017","September 2023","September 2023","September 2017","July 10, 2017","July 11, 2017","null","null","September 26, 2017","September 27, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03214562"
1265,"NCT02781467","A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)","null","Active, not recruiting","No Results Available","Leukemia, Myeloid, Acute","Biological: PNK-007|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Human recombinant Interleukin-2 (rhIL-2)","Dose-Limiting Toxicity (DLT)|Maximum Tolerated Dose (MTD)|Adverse Events (AEs)|Complete remission with incomplete platelet recovery (CRp)|Complete remission (CR)","Celgene","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CCT-PNK-007-AML-001","July 11, 2016","December 30, 2019","December 30, 2019","December 2017","May 20, 2016","May 24, 2016","null","null","December 21, 2017","December 25, 2017","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Center, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Vanderbilt Univ Medical Center, Nashville, Tennessee, United States|Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT02781467"
1266,"NCT01667952","Prospective Ascertainment for Late Effects Among Survivors of Cancer, Tumor, or a Related Illness","null","Recruiting","No Results Available","Pediatric or Young Adult Cancer Survivors","Genetic: Family History Questionnaire (FHQ)|Genetic: Salvia sample|Other: Blood sample","establish a registry of DNA","Memorial Sloan Kettering Cancer Center","All","Child, Adult, Senior","","2000","Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","12-143","August 2012","August 2022","August 2022","December 2017","August 15, 2012","August 17, 2012","null","null","December 19, 2017","December 21, 2017","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT01667952"
1267,"NCT01385579","Effectiveness of Direct-to-Patient Outreach on Colorectal Cancer Screening Within a Low Income and Diverse Population","null","Completed","Has Results","Malignant Neoplasm of Large Intestine","Other: Care manager outreach","Completion of a Colorectal Cancer Screening","Northwestern University","All","50 Years to 80 Years   (Adult, Senior)","","202","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STU00015652","January 2010","June 2010","June 2010","November 2013","June 28, 2011","June 30, 2011","November 18, 2013","January 6, 2014","November 18, 2013","January 6, 2014","Heartland International Health Center, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT01385579"
1268,"NCT01203033","Prospective Pilot Study of Bone Marrow and Peripheral Blood Samples From AML Patients to Characterize the Biologic Heterogeneity of the Disease Using Single Cell Network Profiling (SCNP)","null","Completed","No Results Available","Acute Myeloid Leukemia","","To characterize the biologic phenotypes of leukemic blast cells in bone marrow and peripheral blood samples collected from AML patients during the natural history of the disease.|To ""bridge"" assay performance between fresh and cryopreserved bone marrow and peripheral blood samples from AML patients.","West Virginia University","All","18 Years to 100 Years   (Adult, Senior)","","68","Other","Observational","Observational Model: Other|Time Perspective: Prospective","WVU 1910","September 2010","September 2012","October 2012","February 2017","September 14, 2010","September 16, 2010","null","null","February 6, 2017","February 7, 2017","MBRCC, West Virginia University, Morgantown, West Virginia, United States","https://ClinicalTrials.gov/show/NCT01203033"
1269,"NCT00084695","Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases","null","Unknown status","No Results Available","Childhood Langerhans Cell Histiocytosis|Fanconi Anemia|Leukemia|Lymphoma|Myelodysplastic Syndromes|Neuroblastoma|Sarcoma|Unspecified Childhood Solid Tumor, Protocol Specific","Biological: anti-thymocyte globulin|Drug: busulfan|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: melphalan|Drug: methylprednisolone|Radiation: radiation therapy","Impact of the use of umbilical cord blood as a source of hematopoietic stem cells|Comparison of the incidence of graft-vs-host disease with historical data|Comparison of the incidence of engraftment with historical data","Milton S. Hershey Medical Center|National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 2","25","Other","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","CDR0000365544|PSCI-2003-232","September 2003","December 2012","null","October 2008","June 10, 2004","June 11, 2004","null","null","January 9, 2014","January 10, 2014","Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00084695"
1270,"NCT02581007","RIC Transplant Using Haplo Donors","null","Recruiting","No Results Available","Chronic Myelogenous Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Myelofibrosis|CMML|Multiple Myeloma","Drug: Fludarabine|Drug: Melphalan|Drug: Cyclophosphamide|Procedure: peripheral blood stem cell transplant","Graft Rejection|Overall Survival|Overall survival|Relapse incidence|GVHD incidence","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSH 1132","November 2015","February 2018","February 2018","December 2017","October 16, 2015","October 20, 2015","null","null","December 12, 2017","December 14, 2017","Northside Hospital, Atlanta, Georgia, United States","https://ClinicalTrials.gov/show/NCT02581007"
1271,"NCT03041636","Administration of Jakafi (Ruxolitinib) to Patients With Previously Untreated High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","null","Recruiting","No Results Available","Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Other Diseases of Blood and Blood-Forming Organs|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma","Drug: Ruxolitinib","Clinical Response of Jakafi (Ruxolitinib) to Patients With High-Risk Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma|20% Reduction in Tumor Mass","M.D. Anderson Cancer Center|Incyte Corporation","All","18 Years and older   (Adult, Senior)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0570|NCI-2017-00478","March 8, 2017","March 2021","March 2021","October 2017","February 1, 2017","February 3, 2017","null","null","October 31, 2017","November 6, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03041636"
1272,"NCT01593696","Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma","null","Completed","No Results Available","ALL|B Cell Lymphoma|Leukemia|Large Cell Lymphoma|Non-Hodgkin Lymphoma","Biological: Anti-CD19- CAR","Safety|Feasibility|Persistence of Anti-CD19-CAR Tcells|Antitumor Effects|Ability to reduce grade 4 CRS to less than or equal to 10%","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","1 Year to 30 Years   (Child, Adult)","Phase 1","53","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","120112|12-C-0112","April 12, 2012","November 11, 2016","October 2, 2017","October 2, 2017","May 5, 2012","May 8, 2012","null","null","October 18, 2017","October 19, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT01593696"
1273,"NCT02195180","Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma","null","Completed","No Results Available","Pancreatic Adenocarcinoma Metastatic","Drug: ERY001|Drug: Gemcitabine|Drug: 5-fluoro-uracil/oxaliplatin/leucovorin (folfox)","Overall survival (OS)|Progression free survival (PFS)|Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)|Overall survival|Progression free survival|Objective response rate (ORR)|Disease control rate (DCR)|Duration of response (DoR)|Evaluate the relationship of clinical outcomes with tumor markers|Optical density reading|Quality of Life","ERYtech Pharma","All","18 Years and older   (Adult, Senior)","Phase 2","141","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GRASPANC 2013-03|2013-004262-34","July 2014","February 2017","October 2017","November 2017","July 16, 2014","July 21, 2014","null","null","November 3, 2017","November 7, 2017","Saint Catherine Institute, Avignon, France|Institut de Cancerologie, Brest, France|Hopital Beaujon, Clichy, France|Hospital Henri Mondor, Creteil, France|Groupe Hospitalier Mutualiste Grenoble, Grenoble, France|Centre Hospitalier Departemental Vendee - Les Oudairies, La Roche-sur-Yon, France|Centre Oscar Lambret, Lille, France|Cnetre Leon Berard, Lyon, France|Institut Regional du Cancer-Montpellier Val d'Aurelle, Montpellier, France|Institute Mutualiste Montsouris, Paris, France|Hospital Saint Antoine, Paris, France|Hospital Pitie Salpetriere, Paris, France|CHU de Poitiers, Poitiers, France|CHU Reims, Reims, France|CHU Toulouse - Rangueil, Toulouse, France|CHU de Tours, Tours, France","https://ClinicalTrials.gov/show/NCT02195180"
1274,"NCT00897325","Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma","null","Recruiting","No Results Available","Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Non-Hodgkin Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Non-Hodgkin Lymphoma","Other: Cytology Specimen Collection Procedure|Other: Laboratory Biomarker Analysis","Banking of tumor cells and germline DNA","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 30 Years   (Child, Adult)","","528","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","AALL05B1|NCI-2009-00310|COG-AALL05B1|CDR0000491159|U10CA098543","September 2006","January 2100","null","October 2017","May 9, 2009","May 12, 2009","null","null","October 19, 2017","October 23, 2017","Children's Hospital of Alabama, Birmingham, Alabama, United States|University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Southern California Permanente Medical Group, Downey, California, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Children's Hospital Central California, Madera, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|Sutter General Hospital, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|MedStar Georgetown University Hospital, Washington, D.C., District of Columbia, United States|Children's National Medical Center, Washington, D.C., District of Columbia, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|Lee Memorial Health System, Fort Myers, Florida, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States|University of Florida, Gainesville, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Florida Hospital Orlando, Orlando, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Clinic - Orlando, Orlando, Florida, United States|UF Cancer Center at Orlando Health, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Advocate Children's Hospital-Oak Lawn, Oak Lawn, Illinois, United States|Advocate Children's Hospital-Park Ridge, Park Ridge, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Michigan State University Clinical Center, East Lansing, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Kalamazoo Center for Medical Studies, Kalamazoo, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Columbia Regional, Columbia, Missouri, United States|University of Missouri - Ellis Fischel, Columbia, Missouri, United States|The Childrens Mercy Hospital, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States|Children's Specialty Center of Nevada II, Las Vegas, Nevada, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Saint Joseph's Regional Medical Center, Paterson, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Albany Medical Center, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Montefiore Medical Center - Moses Campus, The Bronx, New York, United States|New York Medical College, Valhalla, New York, United States|Mission Hospital-Memorial Campus, Asheville, North Carolina, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Medical Center-Fargo, Fargo, North Dakota, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Penn State Hershey Children's Hospital, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Childrens Oncology Group, Philadelphia, Pennsylvania, United States|Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Palmetto Health Richland, Columbia, South Carolina, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Greenville Cancer Treatment Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|T C Thompson Children's Hospital, Chattanooga, Tennessee, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Texas Tech University Health Science Center-Amarillo, Amarillo, Texas, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Covenant Children's Hospital, Lubbock, Texas, United States|Children's Hospital of San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Vermont College of Medicine, Burlington, Vermont, United States|Childrens Hospital-King's Daughters, Norfolk, Virginia, United States|Carilion Clinic Children's Hospital, Roanoke, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Mary Bridge Children's Hospital and Health Center, Tacoma, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University Charleston, Charleston, West Virginia, United States|Saint Vincent Hospital, Green Bay, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada|Children's Hospital, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|San Jorge Children's Hospital, San Juan, Puerto Rico|University Pediatric Hospital, San Juan, Puerto Rico|Swiss Pediatric Oncology Group - Bern, Bern, Switzerland","https://ClinicalTrials.gov/show/NCT00897325"
1275,"NCT03339804","Neurovascular Changes Induced by Chemotherapy","null","Completed","No Results Available","Breast Cancer|Chemotherapeutic Toxicity","Other: Chemotherapy","Neural change induced by chemoterapy|Vascular change induced by chemoterapy","University of Sao Paulo General Hospital","Female","35 Years to 65 Years   (Adult)","","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SDC 4227/15/054","February 22, 2016","December 1, 2016","October 1, 2017","September 2017","October 25, 2017","November 13, 2017","null","null","November 7, 2017","November 13, 2017","Heart Institute, São Paulo, Cerqueira Cesar, Brazil","https://ClinicalTrials.gov/show/NCT03339804"
1276,"NCT01597778","Double Cord Versus Haploidentical (BMT CTN 1101)","null","Recruiting","No Results Available","Acute Lymphocytic Leukemia|Acute Myelogenous Leukemia|Burkitt's Lymphoma|Follicular Lymphoma|Hodgkin Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin Lymphoma","Biological: Haploidentical Bone Marrow Transplant|Biological: Double Umbilical Cord Blood Transplant","Progression Free Survival (PFS)|Neutrophil Recovery|Primary Graft Failure|Secondary Graft Failure|Platelet Recovery|Donor Cell Engraftment|Acute Graft-versus-Host Disease (aGVHD)|Chronic Graft-versus-Host Disease (cGHVD)|Overall Survival|Treatment-related Mortality (TRM)|Infections","Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","410","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BMTCTN1101|2U10HL069294-11|5U24CA076518","June 2012","June 2018","June 2019","August 2017","May 10, 2012","May 14, 2012","null","null","August 29, 2017","August 30, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Cancer Center, Phoenix, Arizona, United States|Mayo Clinic Phoenix, Phoenix, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|University of California at Los Angeles, Los Angeles, California, United States|Stanford Hospital and Clinics, Stanford, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|University of Florida College of Medicine (Shands), Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|BMT Program at Northside Hospital, Atlanta, Georgia, United States|University of Kansas Hospital, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|DFCI Massachustts General Hospital, Boston, Massachusetts, United States|DFCI Brigham & Women's Hospital, Boston, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute/BMT, Detroit, Michigan, United States|Univeristy of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Mt. Sinai Medical Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|University of North Carolina Hospital at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Jewish Hospital BMT Program, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Case Western, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State / Arthur G. James Cancer Hospital, Columbus, Ohio, United States|University of Oklahoma Medical Center, Oklahoma City, Oklahoma, United States|Penn State College of Medicine - The Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Univesity of Texas, MD Anderson CRC, Houston, Texas, United States|Texas Transplant Institute, San Antonio, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT01597778"
1277,"NCT01685606","Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma","273","Terminated","Has Results","Mantle Cell Lymphoma|Diffuse Large Cell Lymphoma|Burkitts Lymphoma|T Cell Lymphomas|Acute Myeloid Leukemia/Acute Lymphoblastic Leukemia","Biological: cellular immunotherapy","Overall Response Rate of Cellular Immune Therapy With HLA Haploidentical Peripheral Blood Pheresed Cells in Patients With Relapsed/Refractory Hematological Malignancies.|To Evaluate the Rate of Dose Limiting Toxicities of HLA Haploidentical Peripheral Blood Pheresed Cellular Infusions.","Brown University","All","18 Years and older   (Adult, Senior)","Phase 2","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BrUOG 273","March 2013","June 2015","June 2015","July 2015","September 12, 2012","September 14, 2012","June 4, 2015","June 26, 2015","July 17, 2015","August 11, 2015","Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States","https://ClinicalTrials.gov/show/NCT01685606"
1278,"NCT03198234","Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders","T-allo10","Recruiting","No Results Available","AML - Acute Myeloid Leukemia|MDS (Myelodysplastic Syndrome)|Mixed Phenotype Acute Leukemia|NHL - Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|ALL","Biological: T-allo10","Incidence of treatment emergent adverse events (TEAE)|Severity of treatment emergent adverse events (TEAE)|Safety of T-allo10 will be measured by the time to stem cell engraftment after Hematopoietic Stem Cell Transplant.|Feasibility defined by the successful manufacture of the T-allo10 product|Incidence and severity of grade III and IV acute GvHD","Stanford University","All","3 Years to 30 Years   (Child, Adult)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SU-IRB-38734","August 30, 2017","July 2019","July 2020","September 2017","April 11, 2017","June 26, 2017","null","null","September 19, 2017","September 21, 2017","Lucile Packard Children's Hospital, Palo Alto, California, United States","https://ClinicalTrials.gov/show/NCT03198234"
1279,"NCT03145012","Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity","null","Not yet recruiting","No Results Available","Cancer","Drug: Ranitidine","Intra-individual frequency and function of immune cell subsets|Inter-individual frequency and function of immune cell subsets","Lisa Barrett|Nova Scotia Health Authority|Dalhousie University","All","20 Years to 50 Years   (Adult)","Phase 4","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SAIL-002","May 15, 2017","April 30, 2018","October 31, 2018","May 2017","April 26, 2017","May 9, 2017","null","null","May 4, 2017","May 9, 2017","Nova Scotia Health Authority, Halifax, Nova Scotia, Canada","https://ClinicalTrials.gov/show/NCT03145012"
1280,"NCT02253212","Safety of BBB Opening With the SonoCloud","SONOCLOUD","Recruiting","No Results Available","Glioblastoma|Glioma|Brain Tumor","Device: SonoCloud|Drug: Carboplatin","Safety of transient disruption of the blood-brain barrier using the SonoCloud system in patients with recurrent glioblastoma.|Maximum tolerated dose of ultrasound with the SonoCloud system for transient disruption of the BBB.|Quantification of the disruption of the BBB by the SonoCloud system using dynamic T1 contrast-enhanced MRI.|Progression-free survival in patients treated with the SonoCloud system in combination with carboplatin chemotherapy.|Overall survival in patients treated with the SonoCloud system in combination with carboplatin chemotherapy.","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","31","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P120905","July 2014","July 2018","December 2018","August 2017","September 29, 2014","October 1, 2014","null","null","August 28, 2017","August 29, 2017","Groupe Hospitalier Pitié Salpetriere - Neurosurgery Department, Paris, France","https://ClinicalTrials.gov/show/NCT02253212"
1281,"NCT00340405","Development of a Biologic Specimen Bank for the Study of Early Markers of Lung Cancer Among Tin Miners in Yunnan, China","null","Active, not recruiting","No Results Available","Lung Cancer","","Identification, validation and refinement of potential early markers of lung cancer","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","40 Years to 100 Years   (Adult, Senior)","","11000","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","9999920168|OH92-C-0168","April 23, 1992","null","null","December 14, 2017","June 19, 2006","June 21, 2006","null","null","December 19, 2017","December 20, 2017","Cancer Institute of the Chinese Academy of Medical Sciences, Beijing, China","https://ClinicalTrials.gov/show/NCT00340405"
1282,"NCT01598038","Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma","null","Terminated","No Results Available","Renal Cell Carcinoma","Other: Blood sample","Find a relationship between everolimus through blood level and treatment safety.","Centre Francois Baclesse|University Hospital, Caen","All","18 Years and older   (Adult, Senior)","","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PEVERENAL","April 2012","March 2015","December 2015","July 2017","May 10, 2012","May 15, 2012","null","null","July 27, 2017","July 28, 2017","Centre François Baclesse, Caen, France|Institut Gustave Roussy, Villejuif, France","https://ClinicalTrials.gov/show/NCT01598038"
1283,"NCT02863107","Young-Onset Microsatellite-Stable Colorectal Cancer","null","Recruiting","No Results Available","Colon Cancer|Rectal Cancer","Behavioral: Questionnaires|Procedure: Blood Draw","Genomes of Participants Diagnosed with Young-Onset Microsatellite Stable (MSS) Colorectal Cancers (CRCs) vs. Later Onset Microsatellite Stable (MSS) Colorectal Cancers (CRCs)|Polymorphism Variants and/or New Mutations of Participants Diagnosed with Young-Onset Microsatellite Stable (MSS) Colorectal Cancers (CRCs) vs. Later Onset Microsatellite Stable (MSS) Colorectal Cancers (CRCs)","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Senior)","","1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PA11-0566|2015-00051016-Y1|2016-00051406","June 2012","June 2022","June 2022","August 2017","August 8, 2016","August 11, 2016","null","null","August 17, 2017","August 22, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT02863107"
1284,"NCT03016806","Combined Cord Blood Transplant","Cord Tx","Recruiting","No Results Available","Acute Leukemia|Immune Deficiency Disorder|Congenital Hematological Disorder|Metabolism Disorder|Aplastic Anemia|Myelodysplastic Syndromes|Chronic Leukemia|Lymphoma|Multiple Myeloma|Solid Tumor","Radiation: Total Body Irradiation 1200 cGy|Radiation: Total Body Irradiation 200 cGy|Drug: Cyclophosphamide|Drug: Mesna|Procedure: Cord Blood Infusion|Drug: Busulfan|Drug: Fludarabine|Drug: Melphalan","Engraftment of ANC and Platelets|Rate of non-engraftment and of secondary graft failure|Incidence of acute graft-versus-host disease|Incidence of chronic graft-versus-host disease|Disease-free survival","University of Rochester","All","2 Months to 75 Years   (Child, Adult, Senior)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UBMT 15029","June 2015","June 2025","June 2026","January 2017","December 26, 2016","January 11, 2017","null","null","January 7, 2017","January 11, 2017","Wilmot Cancer Institute, Rochester, New York, United States","https://ClinicalTrials.gov/show/NCT03016806"
1285,"NCT00030550","Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome","null","Completed","No Results Available","Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Drug: thalidomide","","Roswell Park Cancer Institute|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","Phase 2","null","Other|NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","DS 01-16|RPCI-DS-0116|CELGENE-T-MDS-001|NCI-G01-2044","September 2001","June 2003","null","January 2013","February 14, 2002","January 27, 2003","null","null","January 30, 2013","January 31, 2013","PPD Development, Wilmington, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00030550"
1286,"NCT00048464","T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant","null","Unknown status","No Results Available","Multiple Myeloma","Procedure: Infusion of Activated & Expanded Autologous T Cells","","Xcyte Therapies","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XT003","October 2002","null","null","March 2005","October 31, 2002","November 4, 2002","null","null","November 6, 2006","November 7, 2006","Cedars Sinai Medical Center, Los Angeles, California, United States|University of California, San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Johns Hopkins Medical Institute, Baltimore, Maryland, United States|Washington University, St. Louis, Missouri, United States|Hackensack University, Hackensack, New Jersey, United States","https://ClinicalTrials.gov/show/NCT00048464"
1287,"NCT02405078","Pilot Project for Creation of the Diffuse Large B-cell Lymphoma (DLBCL) Response Prediction Model","null","Recruiting","No Results Available","Lymphoma","Drug: 18F-fluorodeoxyglucose|Procedure: FDG PET/CT Imaging|Procedure: Blood Draws","Response to Standard Immunochemotherapy","M.D. Anderson Cancer Center|Sequenta","All","18 Years and older   (Adult, Senior)","","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2015-0022|NCI-2015-01946","October 2015","October 2019","October 2019","August 2017","March 27, 2015","April 1, 2015","null","null","August 21, 2017","August 22, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT02405078"
1288,"NCT00272870","Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy","null","Terminated","No Results Available","Glioblastoma Multiforme (WHO Grade IV)|Anaplastic Astrocytoma (WHO Grade III)","Drug: 06Benzylguanine|Genetic: MGMT P140K|Device: Meltenyi CliniMacs","To assess the safety and feasibility of infusing autologous PBSC transduced with MSCV-MGMTP140K construct, using the fibronectin component CH-296 to assist gene transfer.|Assess the efficiency of gene transfer and durability of transgene expression in this clinical setting.|Assess the degree of chemotherapy resistance in transduced cells, and the ability to enrich the population of transduced stem cells with subsequent courses of chemotherapy.","Children's Hospital Medical Center, Cincinnati","All","5 Years to 55 Years   (Child, Adult)","Phase 1","1","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CCHMCEH003","December 2005","December 2008","August 2012","August 2012","January 4, 2006","January 9, 2006","null","null","August 28, 2012","August 29, 2012","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","https://ClinicalTrials.gov/show/NCT00272870"
1289,"NCT00207805","The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma","null","Completed","No Results Available","Multiple Myeloma","Procedure: autologous PBSC transplant","Overall survival (from randomistion) of the 2 groups at 5 years|Event-free-survival","Centre National de Greffe de Moelle Osseuse","All","up to 61 Years   (Child, Adult)","Phase 3","202","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MM01","May 2003","null","null","January 2009","September 13, 2005","September 21, 2005","null","null","January 26, 2009","January 27, 2009","Centre National de Greffe de Moelle Osseuse, Tunis, Tunisia","https://ClinicalTrials.gov/show/NCT00207805"
1290,"NCT01163357","Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma","null","Recruiting","No Results Available","Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma","Drug: bortezomib|Drug: fludarabine phosphate|Other: melphalan|Radiation: total marrow irradiation|Drug: tacrolimus|Drug: sirolimus|Procedure: peripheral blood stem cell transplantation|Other: laboratory biomarker analysis","Maximum tolerated dose of bortezomib as defined as the highest dose tested in which none or only one patient experiences dose limiting toxicity attributable to the study regimen|Feasibility of escalating doses of bortezomib with or without TMI in combination with FLU and MEL as preparative regimen for allogeneic hematopoietic stem cell transplant in patients with high risk multiple myeloma|Frequency of clinical response (i.e., complete, partial, or very good partial response)|Frequency of primary and secondary engraftment failure|Time to neutrophil and platelet engraftment|Progression-free survival|Incidence of acute and chronic graft-versus-host disease|Overall survival|Minimal residue disease","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1","27","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09171|NCI-2010-01610","January 28, 2011","September 2018","September 2018","July 2017","July 14, 2010","July 15, 2010","null","null","July 19, 2017","July 21, 2017","City of Hope, Duarte, California, United States","https://ClinicalTrials.gov/show/NCT01163357"
1291,"NCT00311337","VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)","null","Unknown status","No Results Available","Multiple Myeloma","Drug: bortezomib","Primary endpoints are to study the safety of four cycles of VELCADE in patients with multiple myeloma following high-dose chemotherapy and autologous PBSCT.|The secondary objectives of this study are to assess the efficacy of four cycles of VELCADE at two different dose levels as maintenance treatment in patients with multiple myeloma|and detectable residual disease following high-dose chemotherapy and autologous PBSCT|to assess the 2 year progression-free survival|and to assess the 2 year overall survival.","University of Wuerzburg","All","18 Years and older   (Adult, Senior)","Phase 2","61","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DSMM VIII","October 2005","null","October 2010","March 2006","April 3, 2006","April 5, 2006","null","null","April 4, 2006","April 5, 2006","Medizinische Univ.-Klinik Graz, Graz, Austria|Klin. Abt. für Onkologie, AKH Wien, Vienna, Austria|Dept. of Hematology/Oncology, Charité Berlin, Berlin, Germany|Dept. of Internal Medicine A, University Muenster, Muenster, Germany|Dept. of Internal Medicine, Ludwig-Maximilian-University Munich, Munich, Germany|Dept. of Internal Medicine III, University of Ulm, Ulm, Germany|Dept. of Internal Medicine II, University of Wuerzburg, Wuerzburg, Germany|Regionalkrankenhaus Bozen, Bozen, Italy","https://ClinicalTrials.gov/show/NCT00311337"
1292,"NCT00606437","Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants","null","Completed","No Results Available","Lymphoma|Myeloma|Leukemia|Myelodysplasia|Solid Tumors|Hodgkin's Disease|Myelofibrosis","Procedure: Total Body Irradiation with Fludarabine in UCB Transplants","The primary objective will be to measure the time to and rate of hematologic engraftment following transplant and the frequency of treatment-related mortality.|The secondary objective will be to estimate the proportion of patients developing acute and chronic graft-versus-host disease, 100 day treatment-related mortality, and to measure disease-free survival.|The tertiary objective will be to measure the time to immunologic reconstitution as defined by normal numbers of T and B cells, normal T-cell proliferative responses, normal natural killer (NK) cell function, and normal immunoglobulin synthesis.","Duke University","All","14 Years to 65 Years   (Child, Adult)","Phase 1","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00009529","September 2005","February 2014","February 2014","May 2014","January 7, 2008","February 4, 2008","null","null","May 15, 2014","May 16, 2014","Duke University Health System, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT00606437"
1293,"NCT01602432","Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients","null","Completed","No Results Available","Venous Thromboembolism|Deep-Vein Thrombosis|Pulmonary Embolism|Cancer","","Risk for Venous Thromboembolism|Timing to VTE detection|Study Feasibility|Physicians acceptance|Success of an IS/IT solution","Ottawa Hospital Research Institute|The Ottawa Hospital Academic Medical Association","All","18 Years and older   (Adult, Senior)","","143","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20120209-01H","November 2012","August 2013","August 2013","September 2014","May 16, 2012","May 21, 2012","null","null","September 8, 2014","September 10, 2014","Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada","https://ClinicalTrials.gov/show/NCT01602432"
1294,"NCT02295085","Fernald Community Cohort -18 Year Observational Study","FCC","Active, not recruiting","No Results Available","Cancer|Renal Failure|Diabetes|Cardiovascular Disease","","Incident cancer during the period of cohort follow-up|Incident renal disease during the period of cohort follow-up","University of Cincinnati|National Institute of Environmental Health Sciences (NIEHS)","All","8 Years and older   (Child, Adult, Senior)","","9782","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","UC2012-3745|P30ES006096","September 1990","December 2025","December 2025","January 2017","October 29, 2014","November 20, 2014","null","null","January 27, 2017","January 30, 2017","University of Cincinnati, Cincinnati, Ohio, United States","https://ClinicalTrials.gov/show/NCT02295085"
1295,"NCT00054353","Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma","null","Completed","Has Results","Refractory Multiple Myeloma","Drug: fludarabine phosphate|Drug: melphalan|Radiation: total-body irradiation|Drug: mycophenolate mofetil|Drug: cyclosporine|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Other: laboratory biomarker analysis","PFS|Non-relapse Mortality|Incidence of Acute GVHD (Grades III-IV)|Incidence of Chronic (Extensive) GVHD|OS|Engraftment|Relapse Rate|Response Rate","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 70 Years   (Adult, Senior)","Phase 1|Phase 2","16","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1743.00|NCI-2011-00386|P30CA015704","October 2002","October 2009","October 14, 2012","September 2017","February 5, 2003","February 6, 2003","April 11, 2017","October 16, 2017","September 14, 2017","October 16, 2017","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States|University of Torino, Torino, Italy","https://ClinicalTrials.gov/show/NCT00054353"
1296,"NCT00716911","Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Nonneoplastic Condition","Drug: ganciclovir|Genetic: polymerase chain reaction|Other: flow cytometry|Other: immunologic technique|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: assessment of therapy complications|Procedure: peripheral blood stem cell transplantation","Quantitative determination of HLA-peptide tetramer-binding assay (TBA) pp65 on days 40 and 90 after stem cell transplantation, with and without in vitro stimulation|Comparison of quantitative determination of TBApp65 with concomitant determination of in vitro CMV-specific cytotoxic T-lymphocyte function on days 40 and 90 after stem cell transplantation|Correlation of TBApp65 results with CMV viral loads|Correlation of TBApp65 results with CMV-associated complications|Correlation of TBApp65 results with clinical events, including acute graft-versus-host-disease (GVHD), chronic GVHD, ganciclovir exposure, and survival","City of Hope Medical Center|National Cancer Institute (NCI)|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Senior)","","100","Other|NIH","Interventional","Primary Purpose: Supportive Care","99061|R01AI058148|P30CA033572|CHNMC-99061|CDR0000600022","January 2000","July 2007","July 2007","June 2015","July 15, 2008","July 16, 2008","null","null","June 3, 2015","June 8, 2015","","https://ClinicalTrials.gov/show/NCT00716911"
1297,"NCT01253590","Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation","null","Terminated","No Results Available","Post-Operative Cancer Patients Experiencing Atrial|Fibrillation","Behavioral: questionnaire about the use of ECG device","Assess the feasibility and acceptance of continuous remote cardiac monitoring","Memorial Sloan Kettering Cancer Center","All","22 Years and older   (Adult, Senior)","","5","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","10-213","December 2010","November 2011","November 2011","March 2015","December 2, 2010","December 3, 2010","null","null","March 4, 2015","March 6, 2015","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT01253590"
1298,"NCT01602445","Pro-coagulant Markers and Anticoagulant Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism","REMARK","Completed","No Results Available","Venous Thromboembolism|Deep-Vein Thrombosis|Pulmonary Embolism|Cancer","","Relative changes on biochemical markers|Rates of treatment failure|Correlation between treatment failure and markers|Compliance to anticoagulation treatment","Ottawa Hospital Research Institute|Heart and Stroke Foundation of Ontario","All","18 Years and older   (Adult, Senior)","","700","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HSFO-000524|20120208-01H","July 2012","October 2016","October 2016","May 2017","May 16, 2012","May 21, 2012","null","null","May 9, 2017","May 11, 2017","Capital Health District Authority, Halifax, Nova Scotia, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|London Health Science Centre, London, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|CHUM-Notre-Dame Hospital, Montreal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT01602445"
1299,"NCT02863172","Molecular Basis for Variations in Hereditary Colorectal Cancer Syndromes","null","Recruiting","No Results Available","Hereditary Colorectal Cancer Syndrome","Behavioral: Questionnaires|Procedure: Blood Draw/Saliva Sample","Variations in Clinical Features Compared Between Proband Group and Family Member Group|Variations in the Overall Disease Phenotype Between Proband Group and Family Member Group","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Senior)","","2000","Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","PA11-0567|2015-00051016-Y1|2016-00051406","May 2012","May 2022","May 2022","August 2017","August 8, 2016","August 11, 2016","null","null","August 14, 2017","August 17, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT02863172"
1300,"NCT01617213","Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma","AMM-2011","Terminated","No Results Available","Multiple Myeloma","Drug: Melphalan|Drug: Lenalidomide","Event Free Survival|Disease Response|Overall survival|Grade > 2 toxicities|Incidence of infections|Treatment related Mortality","University of Virginia","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16043","April 2012","April 2015","null","June 2013","June 8, 2012","June 12, 2012","null","null","June 20, 2013","June 21, 2013","University of Virginia, Charlottesville, Virginia, United States","https://ClinicalTrials.gov/show/NCT01617213"
1301,"NCT00762801","Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects","null","Withdrawn","No Results Available","Healthy","","Expression of RLIP76 in red blood cells and white blood cells of 100 healthy human subjects.|To investigate the RLIP76 mediated transport of glutathione conjugates and chemotherapeutic drugs.","University of North Texas Health Science Center","All","18 Years and older   (Adult, Senior)","","0","Other","Observational","Time Perspective: Prospective","2008-32","September 2008","September 2011","September 2011","October 2016","September 26, 2008","September 30, 2008","null","null","October 24, 2016","October 26, 2016","University of North Texas Health Science Center, Fort Worth, Texas, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States","https://ClinicalTrials.gov/show/NCT00762801"
1302,"NCT00505895","FM 140 vs FM100 Study in Patients With Multiple Myeloma","null","Completed","Has Results","Multiple Myeloma","Drug: Melphalan|Drug: Fludarabine|Procedure: Stem Cell Infusion|Drug: Rituximab","Number of Participants With Successful Engraftment at Day 100|Acute Grade II-IV Graft Versus Host Disease (GVHD)","M.D. Anderson Cancer Center","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ID01-518","January 2002","May 2013","May 2013","October 2014","July 20, 2007","July 25, 2007","October 3, 2014","October 17, 2014","October 3, 2014","October 17, 2014","UT MD . Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00505895"
1303,"NCT00333190","CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation","null","Completed","No Results Available","Hematologic Malignancy|AML|ALL|CML|Multiple Myeloma|NHL|Hodgkin's Lymphoma","Device: CD+8 T cell depletion","To assess the initial engraftment of HLA matched unrelated donor mobilized peripheral blood stem cells depleted of CD+8 cells.|To assess sustained engraftment|to determine the incidence of GVHD|to assess disease relapse.","Dana-Farber Cancer Institute|Brigham and Women's Hospital","All","18 Years and older   (Adult, Senior)","","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","05-151","September 2005","March 2007","March 2009","March 2012","May 25, 2006","June 2, 2006","null","null","March 15, 2012","March 16, 2012","Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT00333190"
1304,"NCT00742729","Increasing Colorectal Cancer Screening Among Filipino Americans","null","Completed","No Results Available","Colorectal Cancer","Behavioral: Arm 1|Behavioral: Arm 2|Behavioral: Arm 3","Receipt of a colorectal cancer screening test|Knowledge and attitudes regarding CRC screening.","Jonsson Comprehensive Cancer Center|American Cancer Society, Inc.","All","50 Years to 70 Years   (Adult, Senior)","","906","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Screening","RSGT-04-210-01-CPPB","September 2004","June 2009","June 2009","November 2010","August 27, 2008","August 28, 2008","null","null","July 28, 2016","August 1, 2016","Division of Cancer Prevention and Control Research, Univ of California Los Angeles, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT00742729"
1305,"NCT00003874","Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia","null","Completed","No Results Available","Leukemia|Lymphoma","Biological: monoclonal antibody CD19|Biological: monoclonal antibody CD20|Procedure: in vitro-treated peripheral blood stem cell transplantation","","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","up to 70 Years   (Child, Adult, Senior)","Phase 1|Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","1345.00|FHCRC-1345.00|NCI-G99-1514|CDR0000067039","February 1999","null","September 2001","November 2011","November 1, 1999","July 16, 2004","null","null","November 28, 2011","November 29, 2011","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00003874"
1306,"NCT01876212","Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma","null","Recruiting","No Results Available","Metastatic Melanoma","Biological: DC vaccine|Drug: Dasatinib","Increase of CD8+ T cell response from addition of dasatinib|Number of participants with adverse events|Tumor response|PF and overall survival|Number of CD8+ T cells infiltrating into melanoma lesions|Number of suppressor cell populations and blood vessels in melanoma tumor biopsies|Number of suppressor cell populations in patients peripheral blood|Level of EphA2 protein expression in tumor biopsies|Serum concentration of the T cell-recruiting chemokine CXCL10/IP-10","Walter J. Storkus|National Cancer Institute (NCI)|University of Pittsburgh","All","18 Years and older   (Adult, Senior)","Phase 2","28","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-048|R01CA169118|UPCI 12-048","November 2013","October 2018","December 2018","October 2017","June 10, 2013","June 12, 2013","null","null","October 26, 2017","October 27, 2017","Hillman Cancer Center, Pittsburgh, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT01876212"
1307,"NCT01364454","General Practitioners (GP) Involvement in Colorectal Cancer (CRC) Screening","null","Completed","No Results Available","Colorectal Cancer","Other: Eligible patients' paper-based reminder","Patient's participation to colorectal cancer screening program","Paris 12 Val de Marne University","All","50 Years to 74 Years   (Adult, Senior)","Early Phase 1","8140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","DUERMG","June 2010","June 2011","June 2011","August 2016","May 31, 2011","June 2, 2011","null","null","August 18, 2016","August 19, 2016","Département Universitaire d'Enseignement et de Recherche en Médecine Générale, Créteil, France","https://ClinicalTrials.gov/show/NCT01364454"
1308,"NCT03118492","Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis","null","Recruiting","No Results Available","Secondary Myelofibrosis","Procedure: Allogeneic Hematopoietic Stem Cell Transplantation|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Glycosylated Recombinant Human G-CSF AVI-014|Other: Laboratory Biomarker Analysis|Drug: Melphalan|Drug: Mycophenolate Mofetil|Drug: Tacrolimus|Radiation: Total-Body Irradiation","Incidence of adverse events assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03|Incidence of unacceptable adverse event assessed by NCI CTCAE version 4.0|Cumulative incidence of acute GvHD assessed by Keystone Consensus criteria|Cumulative incidence of chronic GvHD assessed by NIH Consensus Criteria|Cumulative incidence of relapse/progression|Graft failure-free survival|Neutrophil recovery|Non-relapse mortality|Overall survival|Platelet recovery|Progression-free survival","City of Hope Medical Center|National Cancer Institute (NCI)","All","18 Years to 75 Years   (Adult, Senior)","Phase 1","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16420|NCI-2017-00613","June 21, 2017","October 2020","October 2020","December 2017","April 13, 2017","April 18, 2017","null","null","December 7, 2017","December 11, 2017","City of Hope Medical Center, Duarte, California, United States","https://ClinicalTrials.gov/show/NCT03118492"
1309,"NCT00378534","Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants","null","Completed","Has Results","Chronic Myelogenous Leukemia|Acute Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome","Device: Miltenyi reagent system|Drug: Fludarabine|Drug: Cyclosporine|Drug: Cyclophosphamide","Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System|Standard Transplant Outcome Variables Such as Non-hematologic Toxicity, Incidence and Severity of Acute and Chronic GVHD and Relapse of Disease.","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","10 Years to 75 Years   (Child, Adult, Senior)","Phase 2","115","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","060248|06-H-0248","September 2006","April 2014","April 2014","December 2014","September 19, 2006","September 20, 2006","December 22, 2014","January 6, 2015","October 5, 2015","October 28, 2015","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00378534"
1310,"NCT00003056","Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation","null","Terminated","No Results Available","Leukemia|Lymphoma|Graft Versus Host Disease","Drug: cyclosporine|Drug: cyclosporine and methotrexate","","Baxalta now part of Shire|Shire","All","18 Years to 55 Years   (Adult)","Phase 3","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care","BAXTER-302302|MCV-CCHR-9703-2A|CDR0000065709|NCI-G97-1311","April 1, 1997","June 1, 2003","June 1, 2003","December 2017","November 1, 1999","May 24, 2004","null","null","December 13, 2017","December 15, 2017","Los Angeles, California, United States|Jacksonville, Florida, United States|Atlanta, Georgia, United States|Indianapolis, Indiana, United States|Lawrence, Kansas, United States|Saint Paul, Minnesota, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Hackensack, New Jersey, United States|Pittsburgh, Pennsylvania, United States|San Antonio, Texas, United States|Richmond, Virginia, United States|Adelaide, South Australia, Australia","https://ClinicalTrials.gov/show/NCT00003056"
1311,"NCT01731886","Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma","null","Completed","No Results Available","Multiple Myeloma","Procedure: Autologous peripheral blood stem cell transplant|Drug: Lenalidomide|Drug: Dexamethasone|Procedure: Stem cell collection","Difference in complete response rate|Difference in overall survival rate","Columbia University","All","18 Years and older   (Adult, Senior)","Phase 4","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAJ2355","September 2012","April 11, 2017","April 11, 2017","June 2017","November 19, 2012","November 22, 2012","null","null","June 16, 2017","June 20, 2017","Columbia University, New York, New York, United States","https://ClinicalTrials.gov/show/NCT01731886"
1312,"NCT01142232","Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma","null","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Lenalidomide plus Melphalan during autologous stem cell transplantation|Drug: Lenalidomide maintenance","To determine the recommended phase II dosing and toxicity profile of lenalidomide when used in combination with high dose melphalan in the setting of autologous stem cell transplantation in patients with multiple myeloma|To evaluate the response rate of the regimen|To explore the biologic effect of the regimen.","Attaya Suvannasankha|Celgene|Indiana University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","60","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1005-06; IUCRO-0290","August 27, 2010","December 2017","December 2017","January 2017","June 10, 2010","June 11, 2010","null","null","January 26, 2017","January 27, 2017","IU Simon Cancer Center, Indianapolis, Indiana, United States","https://ClinicalTrials.gov/show/NCT01142232"
1313,"NCT00061581","Experimental Bone Marrow Transplant Protocol","null","Completed","No Results Available","Acute Lymphocytic Leukemia|Chronic Myeloid Leukemia|Acute Myelocytic Leukemia|Myelodysplastic Syndromes|Myeloproliferative Disorders","Device: Isolex 300i Stem Cell Selection","Acute and chronic graft-versus-host disease, transplant-related mortality (TRM), overall mortality, leukemic relapse, CMV reactivation and disease, and graft failure.","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","10 Years to 55 Years   (Child, Adult)","Phase 2","14","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","030192|03-H-0192","May 19, 2003","December 28, 2007","June 14, 2017","June 14, 2017","May 29, 2003","May 29, 2003","null","null","October 5, 2017","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00061581"
1314,"NCT01720264","Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant","null","Active, not recruiting","No Results Available","Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Hematopoetic Myelodysplasia|Leukemia, Myelogenous, Chronic|Lymphoma, Non-Hodgkin","Drug: Sitagliptin","The percent of subjects engrafting by day +30 after transplantation|Time to neutrophil engraftment|Time to platelet engraftment|Number of subjects with primary graft failure|Number of subjects with Grade 3 and 4 non-hematological toxicities|Number of subjects with acute GvHD at Day +100|Number of subjects with chronic GvHD at 1 year post transplant|Grade of acute GvHD at 1 year post transplantation.|Grade of chronic GvHD at Day +100|Grade of chronic GvHD at 1 year post transplantation|Number of subjects with acute GvHD at 1 year post transplantation|Number of subjects with chronic GVHD at Day 100.|Grade of acute GvHD at Day +100|Number of subjects with transplant-related mortality at 6 months post transplant|Time to disease relapse|Time until death|plasma levels of sitagliptin|Percent inhibition of DPP-IV relative to baseline","Sherif S. Farag|National Heart, Lung, and Blood Institute (NHLBI)|Indiana University","All","18 Years to 60 Years   (Adult)","Phase 2","19","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1208009261; HL112669|1R01HL112669-01","November 2, 2012","November 30, 2017","November 30, 2018","April 2017","October 30, 2012","November 2, 2012","null","null","April 10, 2017","April 11, 2017","Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|New York Medical College/Westchester Medical Center/Maria Fareri Children's Hosptial, Valhalla, New York, United States","https://ClinicalTrials.gov/show/NCT01720264"
1315,"NCT01303965","Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)","null","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Sirolimus|Drug: Tacrolimus|Drug: Lenalidomide","Number of Participants with Dose Limiting Toxicities as a Measure of Safety of the combination of sirolimus, tacrolimus and lenalidomide|Percent of patients alive and free of progression at 12 months.|Number of subjects with acute and chronic Graft versus Host Disease (GvHD)|Number of treatment-related deaths at 100 days and 1 year|Percentage of donor chimerism as assessed at days +30, +90, +180 and at 12 months post transplant|Number of toxicities, frequency and type of infections occurring within the first year|Time to engraftment of neutrophils and platelets|Time from day 0 to disease progression or death (regardless of cause of death), whichever comes first.|Number of patients with disease progression|Time from day 0 to death from any cause|Number of complete responses (CR), stringent complete responses (sCR), near complete responses (nCR), very good partial responses (VGPR), partial responses (PR) and minimal responses (MR).","Sherif S. Farag|Celgene Corporation|Indiana University","All","18 Years and older   (Adult, Senior)","Phase 1|Phase 2","53","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1012-24; IUCRO-0307","February 7, 2011","December 31, 2017","December 31, 2017","January 2017","February 18, 2011","February 25, 2011","null","null","January 30, 2017","February 1, 2017","Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States","https://ClinicalTrials.gov/show/NCT01303965"
1316,"NCT01629004","Increasing Uptake of Colorectal Cancer Screening in Ontario","null","Completed","No Results Available","Colorectal Disorders","Other: FOBT kit|Other: Mailed invitation","Uptake of appropriate CRC screening|Uptake of lower gastrointestinal investigations","Sunnybrook Health Sciences Centre","All","50 Years to 74 Years   (Adult, Senior)","","5155","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Screening","308-2010","April 2011","December 2013","December 2013","December 2014","June 25, 2012","June 27, 2012","null","null","December 19, 2014","December 23, 2014","Sunnybrook HSC, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT01629004"
1317,"NCT00396383","Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation","null","Terminated","Has Results","Multiple Myeloma","Drug: plerixafor","Number of Participants Who Achieved ≥4*10^6 CD34+ Cells/kg|Participant Counts of Summarized Adverse Events (AE) During Treatment|Number of Transplantations That Achieved Polymorphonuclear Leukocyte (PMN) Engraftment Grouped by Days to Engraftment|Number of Transplantations That Achieved Platelet (PLT) Engraftment Grouped by Days to Engraftment|Number of Participants With a Durable Graft at 12 Months Post Transplantation","Genzyme, a Sanofi Company|AnorMED|Sanofi","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMD3100-2108","November 2004","May 2007","May 2007","February 2014","November 2, 2006","November 6, 2006","February 11, 2009","October 21, 2010","February 10, 2014","March 13, 2014","Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00396383"
1318,"NCT00274794","VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL","null","Completed","No Results Available","Lymphoma","Biological: filgrastim|Biological: rituximab","Correlate CD34+ cell yields with the addition of rituximab|Acute toxicity of rituximab, etoposide, and filgrastim (G-CSF)","The Cleveland Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Senior)","","55","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CASE-CCF-3600|P30CA043703|CASE-CCF-0467","February 2000","May 2006","May 2006","March 2011","January 10, 2006","January 11, 2006","null","null","March 28, 2011","March 29, 2011","Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT00274794"
1319,"NCT02125318","A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders","null","Completed","No Results Available","Thrombocytosis|Myeloproliferative Neoplasms","Drug: Anagrelide CR","Platelet Response|Number of subjects with adverse events|Plasma concentrations of anagrelide","Galena Biopharma, Inc.","All","18 Years and older   (Adult, Senior)","Phase 2","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GALE-401-201","May 2014","May 2016","May 2016","February 2017","April 23, 2014","April 29, 2014","null","null","February 23, 2017","February 27, 2017","East Valley Hematology and Oncology Medical Group, Burbank, California, United States|California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States|California Cancer Associates for Research & Excellence (cCARE), Escondido, California, United States|California Cancer Associates For Research and Excellence, Fresno, California, United States|Innovative Medical Research of South Florida, Inc., Aventura, Florida, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Gettysburg Cancer Center, Gettysburgh, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Cancer Care Centers of South Texas, New Braunfels, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT02125318"
1320,"NCT00577096","Effects of Exercise in Combination With Epoetin Alfa","null","Completed","Has Results","Multiple Myeloma","Drug: Epoetin Alfa|Behavioral: Exercise|Biological: Autologous Peripheral Blood Stem Cell Transplantation|Biological: Red Blood Cell Transfusion|Drug: Thalidomide|Drug: Heparin, Low-Molecular-Weight|Biological: Platelet Transfusion|Drug: Melphalan|Drug: Total Therapy II","Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Short Term)|Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Long Term)|Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets.(Short Term)|Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets. (Long Term)|Number of Stem Cell Collection Attempts (Short Term)|Number of Stem Cell Collection Attempts (Long Term)|Total Number of Days of Stem Cell Collection (Short Term)|Total Number of Days of Stem Cell Collection (Long Term)|Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Short Term)|Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Long Term)","University of Arkansas|National Institutes of Health (NIH)|Ortho Biotech Clinical Affairs, L.L.C.","All","Child, Adult, Senior","","120","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","IRB # 29287|R01NR008937|Ortho Biotech Clinical Affairs","October 2001","June 2004","June 2004","April 2015","December 17, 2007","December 19, 2007","March 17, 2011","April 21, 2011","April 2, 2015","April 6, 2015","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States","https://ClinicalTrials.gov/show/NCT00577096"
1321,"NCT01336712","Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases","null","Completed","Has Results","Chronic Leukemia|Acute Leukemia|Hodgkin's Disease|Non-Hodgkin's Lymphoma|Myelodysplastic Syndrome","Procedure: Peripheral Blood Stem Cell Transplant","Percentage of Patients Experiencing Hemorrhagic Cystitis Post Transplant|Survival|Percentage of Participatns With Donor Chimerism Post-transplant|Disease Free Survival (DFS) Percentage|Non-relapsed Mortality (NRM) Percentage|Relapse Rate|Cumulative Incidence of Chronic Graft-versus-host Disease","Northside Hospital, Inc.|Blood and Marrow Transplant Group of Georgia","All","18 Years to 60 Years   (Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NSH 922","April 2011","December 2014","July 2015","December 2015","April 14, 2011","April 18, 2011","October 16, 2015","January 14, 2016","December 10, 2015","January 14, 2016","Northside Hospital, Atlanta, Georgia, United States","https://ClinicalTrials.gov/show/NCT01336712"
1322,"NCT00067639","Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma","null","Completed","No Results Available","Multiple Myeloma","Drug: Pegfilgrastim (Neulasta)|Procedure: Apheresis","Efficacy of pegfilgrastim in mobilizing progenitor cells","M.D. Anderson Cancer Center|Amgen","All","18 Years and older   (Adult, Senior)","Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ID03-0164","December 2003","April 2007","April 2007","July 2012","August 25, 2003","August 26, 2003","null","null","July 31, 2012","August 1, 2012","MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00067639"
1323,"NCT01242267","Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT","Thal/Mel/Vel","Completed","No Results Available","Multiple Myeloma","Drug: Thalidomide+Melphalan +Bortezomib+stem cell transplant","Determine the maximum tolerated dose of thalidomide used in conjunction with dose-intense melphalan, bortezomib and autologous (syngeneic) HSC support in the salvage therapy of patients who failed a prior treatment with dose-intense melphalan","Hackensack University Medical Center|Millennium Pharmaceuticals, Inc.","All","18 Years to 75 Years   (Adult, Senior)","Phase 1|Phase 2","29","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO-00001215","May 11, 2010","January 20, 2016","January 20, 2016","August 2017","November 15, 2010","November 16, 2010","null","null","August 8, 2017","August 10, 2017","John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States","https://ClinicalTrials.gov/show/NCT01242267"
1324,"NCT00784823","Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma","Mel-Vel","Completed","No Results Available","Multiple Myeloma","Drug: Bortezomib|Drug: Melphalan","Maximum Tolerated Dose The maximum tolerated dose of bortezomib (MTD) will be defined as the dose level prior to that resulting in two out of six patients experiencing a DLT","Hackensack University Medical Center","All","18 Years to 76 Years   (Adult, Senior)","Phase 1|Phase 2","32","Other","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06.05.109B","January 2007","December 2013","December 2013","February 2014","October 31, 2008","November 4, 2008","null","null","February 1, 2014","February 4, 2014","Hackensack University Medical Center, Hackensack, New Jersey, United States","https://ClinicalTrials.gov/show/NCT00784823"
1325,"NCT01932710","A Feasibility Study of Prophylactic White Blood Cell Transfusions","null","Active, not recruiting","No Results Available","Leukemia","Procedure: White Blood Cell Transfusion","Feasibility of Utilizing White Cell Transfusion as a Prophylactic Therapy|Infection Rate","M.D. Anderson Cancer Center","All","Child, Adult, Senior","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2012-1158|NCI-2013-02208","September 2013","September 2018","null","November 2016","August 27, 2013","August 30, 2013","null","null","November 4, 2016","November 7, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT01932710"
1326,"NCT00006244","Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma","null","Completed","Has Results","Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma","Drug: melphalan|Biological: recombinant interferon alfa|Biological: aldesleukin|Procedure: in vitro-treated peripheral blood stem cell transplantation","Overall Survival|Initial Response to Therapy|Time to Disease Progression|Proportion of Patients Alive and in Remission|Number of Patients <56 Years Old Experiencing Grade 3-4 Regimen Related Toxicity|Number of Patients ≥56 Years Old Experiencing Grade 3-4 Regimen Related Toxicity","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 69 Years   (Adult, Senior)","Phase 2","36","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1461.00|NCI-2011-01313","February 2000","April 2016","April 2016","June 2017","September 11, 2000","January 27, 2003","April 12, 2017","May 16, 2017","June 16, 2017","July 12, 2017","Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00006244"
1327,"NCT00899847","Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG","null","Completed","Has Results","Transplantation, Homologous|Transplantation, Autologous|Multiple Myeloma|Blood and Marrow Transplant (BMT)","Procedure: Autologous peripheral blood stem cells (auto-PBSC) transplantation|Procedure: Allogeneic peripheral blood stem cells (allo-PBSC) transplantation|Drug: Filgrastim|Drug: Cyclophosphamide|Drug: Melphalan|Drug: Cyclosporine|Radiation: Total lymphoid irradiation|Biological: Rabbit anti-thymocyte globulin|Drug: Mycophenolate Mofetil 250mg|Drug: Solumedrol|Drug: Diphenhydramine|Drug: Acetaminophen|Drug: Hydrocortisone","Incidence of Graft Versus Host Disease (GvHD)|Median Time to Engraftment After Auto-PBSC Transplant|Median Time to Engraftment After Allo-PBSC Transplant|Overall Response Rate (ORR)|Complete Response Rate (CRR)|Partial Response Rate (PRR)|Event-free Survival (EFS)|Overall Survival (OS)","Stanford University","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-15772|SU-04142009-2259|BMT201","May 2009","April 2014","December 2014","September 2017","May 8, 2009","May 12, 2009","August 24, 2017","October 20, 2017","September 19, 2017","October 20, 2017","Stanford University School of Medicine, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT00899847"
1328,"NCT02362776","Metabolic Changes as a Diagnostic Indicator for Cancer","null","Completed","No Results Available","Breast Cancer|Lung Cancer","Other: Venous blood sample","Metabolic phenotype of cancer","Hasselt University|Ziekenhuis Oost-Limburg|Algemeen Ziekenhuis Vesalius|Ziekenhuis Maas en Kempen|Mariaziekenhuis Noord-Limburg","All","Child, Adult, Senior","","426","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","09/046U","October 2009","July 2012","July 2012","February 2015","December 10, 2013","February 13, 2015","null","null","February 9, 2015","February 13, 2015","Ziekenhuis Oost-Limburg, Genk, Limburg, Belgium|Hasselt University, Hasselt, Limburg, Belgium","https://ClinicalTrials.gov/show/NCT02362776"
1329,"NCT02415413","Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma","null","Active, not recruiting","No Results Available","Smoldering Multiple Myeloma","Drug: carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Melphalan","Efficacy- Number of Immunophenotypic complete remission rate (Flow-CR) at day +100 after induction and HDT-ASCT|Efficacy - Number of Response rates after the different parts of the treatment, induction, HDT-ASCT, consolidation and maintenance|Efficacy- Months to progression free survival|Efficacy -Months to overall survival","PETHEMA Foundation|Celgene Corporation|Amgen","All","18 Years to 70 Years   (Adult, Senior)","Phase 2","90","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEM-CESAR","May 2015","August 2017","May 2020","November 2016","March 29, 2015","April 14, 2015","null","null","November 28, 2017","November 30, 2017","Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Morales Meseguer, Murcia, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Hospital de Son Llàtzer, Plama De Mallorca, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Universitario Reina Sofía, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT02415413"
1330,"NCT00112827","Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma","null","Active, not recruiting","No Results Available","Refractory Multiple Myeloma|Smoldering Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma","Radiation: total marrow irradiation|Drug: melphalan|Procedure: peripheral blood stem cell transplantation|Biological: filgrastim|Genetic: fluorescence in situ hybridization|Genetic: cytogenetic analysis|Drug: cyclophosphamide|Procedure: autologous-autologous tandem hematopoietic stem cell transplantation|Drug: lenalidomide","Feasibility|Response rate|Progression-free survival|Overall survival|Assessment of cell biology","City of Hope Medical Center","All","up to 70 Years   (Child, Adult, Senior)","Phase 1|Phase 2","86","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COH 04064|NCI-2009-01601|CDR0000428410","November 2004","November 2018","November 2018","November 2017","June 2, 2005","June 3, 2005","null","null","November 17, 2017","November 21, 2017","City of Hope Medical Center, Duarte, California, United States","https://ClinicalTrials.gov/show/NCT00112827"
1331,"NCT01754896","Pilot Evaluation of Fecal Immunologic Test (FIT) in Ontario","null","Completed","No Results Available","Colorectal Cancer","Other: mailing of FIT kit directly to patient|Other: mailed invitation to pick up lab requisition and then kit|Other: mailing completed kits in for processing|Other: dropping completed kits at lab for processing","FIT Kit uptake|Rejection rates","Sunnybrook Health Sciences Centre|Cancer Care Ontario","All","50 Years to 74 Years   (Adult, Senior)","","28","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","209-2011","April 2012","April 2013","April 2013","December 2014","December 18, 2012","December 21, 2012","null","null","December 19, 2014","December 23, 2014","Dr. Jill Tinmouth, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT01754896"
1332,"NCT02981862","CaptHPV : Validation of the Method ""CaptHPV"" for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas","CaptHPV","Recruiting","No Results Available","Cervical Cancer|Vulvar Cancer|Anal Cancer|Oropharynx Cancer","Other: CaptHPV method","Assessement of CaptHPV method","Institut de Cancérologie de Lorraine","All","18 Years and older   (Adult, Senior)","","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016-A01085-46","December 2016","December 2018","December 2018","October 2017","November 30, 2016","December 5, 2016","null","null","October 25, 2017","October 26, 2017","Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France","https://ClinicalTrials.gov/show/NCT02981862"
1333,"NCT00001750","Comparing Treatments for Multiple Myeloma","null","Completed","No Results Available","Multiple Myeloma","Drug: Stemgen","","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Senior","Phase 2","32","NIH","Interventional","Primary Purpose: Treatment","980154|98-H-0154","September 1998","null","August 2002","August 2002","November 3, 1999","November 4, 1999","null","null","March 3, 2008","March 4, 2008","National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00001750"
1334,"NCT00725634","A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma","P05538","Completed","No Results Available","Malignant Solid Tumor|Lymphomas|Multiple Myeloma","Biological: AV-299|Biological: AV-299 + erlotinib","Dose Limiting Toxicity and Recommended Phase 2 dose|Pharmacokinetic (PK) profile of AV-299, and erlotinib (for subjects enrolled in the Phase 1b only).|Evaluate the effects of AV-299 and combination of AV-299 and erlotinib on exploratory biomarkers in blood, body fluid, tumor tissue, and/or bone marrow.|Study the preliminary antineoplastic activity of AV-299 in subjects with advanced solid tumors, lymphoma, or multiple myeloma, and the preliminary antineoplastic activity of AV 299 in combination with erlotinib in subjects with advanced solid tumor.|Investigate the effect of AV-299 and of the combination of AV-299 and erlotinib on gene expression patterns in peripheral blood mononuclear cells and/or bone marrow.|Assess dosing schedules of AV-299 (e.g. every 2-week and every 3-week schedules).|Assess safety and tolerability of the RP2D of AV-299 in expansion cohort(s).","AVEO Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Senior)","Phase 1","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P05538","September 2008","December 2010","December 2013","January 2014","July 28, 2008","July 30, 2008","null","null","January 23, 2014","January 27, 2014","Investigational Site 2, Scottsdale, Arizona, United States|Investigational Site 3, Columbus, Ohio, United States|Investigational Site 1, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT00725634"
1335,"NCT00083564","Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma","null","Terminated","No Results Available","Multiple Myeloma","Drug: STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)","","Poniard Pharmaceuticals","All","18 Years to 70 Years   (Adult, Senior)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STR 0303","March 2004","null","null","March 2009","May 25, 2004","May 28, 2004","null","null","March 30, 2009","March 31, 2009","University of Alabama, Birmingham, Alabama, United States|Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|University of Miami, Miami, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Wayne State University, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Montefiore Medical Center, Bronx, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor University Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Princess Margaret Hospital, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT00083564"
1336,"NCT00049634","Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder","null","Completed","No Results Available","Chronic Myeloproliferative Disorders|Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases","Drug: busulfan|Drug: cyclophosphamide|Drug: cyclosporine|Drug: methotrexate|Procedure: in vitro-treated peripheral blood stem cell transplantation","Incidence of grade II, III, and IV graft-versus-host disease","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult)","Phase 1|Phase 2","30","Other|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","1628.00|FHCRC-1628.00|NCI-H02-0099|CDR0000258137","January 2002","February 2007","null","September 2010","November 12, 2002","January 27, 2003","null","null","September 14, 2010","September 16, 2010","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT00049634"
1337,"NCT00006184","Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma","null","Completed","Has Results","Multiple Myeloma","Drug: Myeloma Immunoglobulin Idiotype Vaccine|Drug: Bortezomib|Drug: Cyclophosphamide|Drug: Cyclosporine|Drug: Doxorubicin hydrochloride|Drug: Etoposide|Drug: Fludarabine phosphate|Drug: Prednisone|Drug: Vincristine Sulfate|Drug: Methotrexate|Biological: GMCSF (granulocyte macrophage colony stimulating factor)|Biological: GCSF (granulocyte colony stimulating factor)","Immune Response|Number of Participants With Adverse Events","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Senior)","Phase 2","20","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","000201|00-C-0201","February 8, 2001","January 12, 2008","January 12, 2008","September 2017","August 23, 2000","August 24, 2000","December 13, 2012","January 24, 2013","September 19, 2017","October 20, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00006184"
1338,"NCT00705731","Adherence and the Economics of Colon Cancer Screening","null","Completed","No Results Available","Colorectal Cancer Screening","","Adherence to colorectal cancer (CRC) screening, defined as completion of the screening strategy (the subject agrees to pursue/scheduled by the primary care provider).|Preventive Intention: Of those who agree to colonoscopy or FOBT, the proportion of patients who have colonoscopy scheduled or take home FOBT cards.|Preventive Behavior: Of the subjects with a positive FOBT result, determine the proportion adhering to the follow-up colonoscopy.|Identification of variables in the survey (based on the Health Belief Model) which are associated with non-adherence to screening.","University of California, San Francisco|National Cancer Institute (NCI)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","50 Years to 79 Years   (Adult, Senior)","","1000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","A105658|R01CA106773|K24DK080941|3R01CA106773-04S1","March 2007","November 2011","November 2011","June 2012","June 24, 2008","June 26, 2008","null","null","June 11, 2012","June 12, 2012","San Francisco General Hospital, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT00705731"
1339,"NCT01121120","Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients","TXA127-PBSC","Active, not recruiting","No Results Available","Lymphoma, Non-Hodgkin|Hodgkin Disease|Multiple Myeloma","Drug: TXA127|Drug: Placebo","Platelet recovery|Safety of TXA127|Initial neutrophil recovery|Mucositis|Febrile neutropenia|Platelet transfusions","Tarix Pharmaceuticals","All","18 Years and older   (Adult, Senior)","Phase 2","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","TXA127-2009-001","June 2010","June 2018","September 2018","October 2017","May 9, 2010","May 12, 2010","null","null","October 10, 2017","October 12, 2017","City of Hope Hospital, Duarte, California, United States|Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|IU Simon Cancer Center, Indianapolis, Indiana, United States|Washington University, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Stony Brook, Long Island City, New York, United States|Montefiori Medical Center, The Bronx, New York, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States","https://ClinicalTrials.gov/show/NCT01121120"
1340,"NCT00270166","The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy","null","Completed","No Results Available","Anemia|Multiple Myeloma|Lymphoma|Breast Cancer|Ovarian Cancer|Carcinoma, Small Cell Lung|Esophagus Cancer|Prostate Cancer|Neoplasm","Drug: epoetin alfa","Proportion of patients without transfusion after first month.|Proportion of responders, change of hemoglobin (not by transfusion), cumulative transfusion rate, proportion of patients transfused during the double-blind phase, excluding the first month; mean change score of baseline quality of life parameters; safety","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years to 80 Years   (Adult, Senior)","Phase 3","201","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","CR005923","February 1995","null","May 1998","February 2011","December 22, 2005","December 26, 2005","null","null","May 17, 2011","May 18, 2011","","https://ClinicalTrials.gov/show/NCT00270166"
1341,"NCT01305954","Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients","null","Active, not recruiting","No Results Available","Breast Cancer","","Determine if p16INK4a Expression at Baseline is Related to Nadir Neutrophil Counts in Women with Breast Cancer Receiving Chemotherapy|Define the Association Between p16INK4a Expression and Physical Activity, Smoking and Alcohol Consumption in Women with Breast Cancer Receiving Chemotherapy|Explore the Associations between p16INK4a Expression at Baseline and Other Chemotherapy-Related Toxicities including Nausea and Vomiting, Neuropathy, Fatigue and Other Grade 3 and 4 Toxicities|Explore Associations between p16INK4a Expression at Baseline, Chemotherapy Regimen, and its Effect on Patient Function","UNC Lineberger Comprehensive Cancer Center","All","18 Years and older   (Adult, Senior)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","LCCC1027|10-2121","December 2010","December 2013","December 2017","December 2016","February 17, 2011","March 1, 2011","null","null","December 22, 2016","December 23, 2016","University of North Carolina, Chapel Hill, North Carolina, United States","https://ClinicalTrials.gov/show/NCT01305954"
1342,"NCT01570582","A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer","null","Unknown status","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cancer","Drug: carboplatin and paclitaxel","24month progression free survival|Toxicity Profile","Korean Gynecologic Oncology Group","Female","18 Years to 70 Years   (Adult, Senior)","Phase 2","314","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KGOG3017","March 2010","March 2014","March 2014","April 2012","March 14, 2012","April 4, 2012","null","null","April 3, 2012","April 4, 2012","Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT01570582"
1343,"NCT00619814","Is Barium Enema an Adequate Diagnostic Test for Patients With Positive FOBT?","DCBE","Completed","No Results Available","Colorectal Cancer","Procedure: Double-contrast Barium enema, colonoscopy","","VA Caribbean Healthcare System","All","50 Years to 80 Years   (Adult, Senior)","","50","U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","00171","September 2003","October 2005","October 2005","February 2008","February 8, 2008","February 21, 2008","null","null","February 20, 2008","February 21, 2008","","https://ClinicalTrials.gov/show/NCT00619814"
1344,"NCT02874885","Circulating Tumor Cells in Patients With Rectal Cancer","null","Recruiting","No Results Available","Rectal Cancer","Procedure: Blood Draws","Change in Circulating Tumor Cell (CTC) Status","M.D. Anderson Cancer Center|American Society of Colon and Rectal Surgeons Research Foundation","All","18 Years and older   (Adult, Senior)","","520","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","PA13-0547","September 2013","September 2023","September 2023","August 2017","August 17, 2016","August 22, 2016","null","null","August 17, 2017","August 22, 2017","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT02874885"
1345,"NCT01692210","The Effect of Dexmedetomidine of the Immune System","null","Completed","No Results Available","Breast Cancer","Drug: Dexmedetomidine","Pre and Post Surgical Lymphocyte Counts","M.D. Anderson Cancer Center|Hospira, now a wholly owned subsidiary of Pfizer","Female","18 Years and older   (Adult, Senior)","","20","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PA12-0524","September 2012","February 2015","February 2015","January 2016","September 19, 2012","September 25, 2012","null","null","January 5, 2016","January 7, 2016","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT01692210"
1346,"NCT02982694","Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer","null","Recruiting","No Results Available","MSI|ColoRectal Cancer|Chemotherapy|Resistance, APC","Drug: Atezolizumab|Drug: Bevacizumab","Overall Response Rate|Immune-related tumor response|Progression Free Survival|Overall Survival|Safety and tolerability (adverse event assessment according to CTCAE v 4.0)","Vall d'Hebron Institute of Oncology|European Organisation for Research and Treatment of Cancer - EORTC","All","18 Years and older   (Adult, Senior)","Phase 2","58","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VHIO16001 - EORTC 1604|2016-002001-19","November 24, 2017","March 2019","March 2020","December 2017","December 1, 2016","December 5, 2016","null","null","December 1, 2017","December 5, 2017","KU Leuven, Leuven, Belgium|Ospedale Niguarda CA Granda, Milano, Italy|Second University of Naples, Naples, Italy|The Netherlands Cancer Institute, Amsterdam, Netherlands|Institut Català d'Oncologia, Barcelona, Spain|Vall d'Hebron Institute of Oncology, Barcelona, Spain|Fundación Investigación Clínico de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT02982694"
1347,"NCT00919269","Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma","null","Active, not recruiting","No Results Available","Adult Rhabdomyosarcoma|Childhood Desmoplastic Small Round Cell Tumor|Chordoma|Desmoid Tumor|Metastatic Childhood Soft Tissue Sarcoma|Nonmetastatic Childhood Soft Tissue Sarcoma|Previously Treated Childhood Rhabdomyosarcoma|Previously Untreated Childhood Rhabdomyosarcoma|Recurrent Adult Soft Tissue Sarcoma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Childhood Soft Tissue Sarcoma|Stage I Adult Soft Tissue Sarcoma|Stage II Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma","Other: biologic sample preservation procedure|Other: laboratory biomarker analysis","Collection of human tumor tissue and other biological specimens (blood, serum, and bone marrow) from patients with rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma|Collection of clinical data on patients who are not being treated on a COG therapeutic study","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 50 Years   (Child, Adult)","","1500","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","D9902|NCI-2009-00502|IRS-D9902|CCG-B904|COG-D9902|CDR0000078602|POG-9153|U10CA024507","March 1999","January 2100","January 2100","December 2017","June 11, 2009","June 12, 2009","null","null","December 11, 2017","December 13, 2017","Children's Hospital of Alabama, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|University of Arizona Health Sciences Center, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Children's Oncology Group, Arcadia, California, United States|Southern California Permanente Medical Group, Downey, California, United States|City of Hope Medical Center, Duarte, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's Hospital, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Mattel Children's Hospital UCLA, Los Angeles, California, United States|Children's Hospital Central California, Madera, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Childrens Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States|Santa Barbara Cottage Hospital, Santa Barbara, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|Lee Memorial Health System, Fort Myers, Florida, United States|University of Florida, Gainesville, Florida, United States|Memorial Healthcare System - Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Nemours Children's Clinic - Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Florida Hospital, Orlando, Florida, United States|M D Anderson Cancer Center- Orlando, Orlando, Florida, United States|Nemours Childrens Clinic - Orlando, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|All Children's Hospital, Saint Petersburg, Florida, United States|Saint Joseph Children's Hospital of Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|University of Hawaii, Honolulu, Hawaii, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|University of Illinois, Chicago, Illinois, United States|Childrens Memorial Hospital, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Advocate Hope Children's Hospital, Oak Lawn, Illinois, United States|Advocate Lutheran General Hospital, Park Ridge, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Services, Indianapolis, Indiana, United States|Raymond Blank Children's Hospital, Des Moines, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|Children's Hospital-Main Campus, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Floating Hospital for Children at Tufts Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Kalamazoo Center for Medical Studies, Kalamazoo, Michigan, United States|Michigan State University - Breslin Cancer Center, Lansing, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Missouri-Columbia, Columbia, Missouri, United States|The Childrens Mercy Hospital, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Saint John's Mercy Medical Center, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|UMDNJ - Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Saint Joseph's Regional Medical Center, Paterson, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Albany Medical Center, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Brooklyn Hospital Center, Brooklyn, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|New York University Langone Medical Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Mission Hospitals Inc, Asheville, North Carolina, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Presbyterian Hospital, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Sanford Medical Center-Fargo, Fargo, North Dakota, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|The Children's Medical Center of Dayton, Dayton, Ohio, United States|The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio, United States|Mercy Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Natalie W Bryant Cancer Center, Tulsa, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Penn State Hershey Children's Hospital, Hershey, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Palmetto Health Richland, Columbia, South Carolina, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Greenville Cancer Treatment Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|T C Thompson Children's Hospital, Chattanooga, Tennessee, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Tech University Health Science Center-Amarillo, Amarillo, Texas, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Covenant Children's Hospital, Lubbock, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|University of Vermont, Burlington, Vermont, United States|University of Virginia, Charlottesville, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Childrens Hospital-King's Daughters, Norfolk, Virginia, United States|Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Carilion Clinic Children's Hospital, Roanoke, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Mary Bridge Children's Hospital and Health Center, Tacoma, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University Charleston, Charleston, West Virginia, United States|Saint Vincent Hospital, Green Bay, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|Sydney Children's Hospital, Randwick, New South Wales, Australia|The Children's Hospital at Westmead, Sydney, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Childrens Hospital, Herston, Queensland, Australia|Women's and Children's Hospital-Adelaide, North Adelaide, South Australia, Australia|Royal Children's Hospital, Parkville, Victoria, Australia|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|Alberta Children's Hospital, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Janeway Child Health Centre, Saint John's, Newfoundland and Labrador, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada|Chedoke-McMaster Hospitals, Hamilton, Ontario, Canada|Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada|Children's Hospital, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|Hospital Sainte-Justine, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Quebec, Ste-Foy, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Starship Children's Hospital, Grafton, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|San Jorge Children's Hospital, Santurce, Puerto Rico|Swiss Pediatric Oncology Group - Bern, Bern, Switzerland|Swiss Pediatric Oncology Group - Geneva, Geneva, Switzerland|Swiss Pediatric Oncology Group - Lausanne, Lausanne, Switzerland","https://ClinicalTrials.gov/show/NCT00919269"
1348,"NCT00002718","T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia","null","Completed","No Results Available","Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms","Biological: anti-thymocyte globulin|Biological: filgrastim|Drug: cyclophosphamide|Drug: cytarabine|Drug: methylprednisolone|Drug: thiotepa|Procedure: in vitro-treated bone marrow transplantation|Procedure: in vitro-treated peripheral blood stem cell transplantation|Radiation: radiation therapy","overall disease survival|To correlate progenitor cell doses and doses of clonable T-cells","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","up to 49 Years   (Child, Adult)","Phase 2","31","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","95-084|P30CA008748|MSKCC-95084|NCI-V96-0809","November 1995","January 2004","October 2008","December 2015","November 1, 1999","January 27, 2003","null","null","December 21, 2015","December 23, 2015","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00002718"
